0001104659-21-044832.txt : 20210331 0001104659-21-044832.hdr.sgml : 20210331 20210331165443 ACCESSION NUMBER: 0001104659-21-044832 CONFORMED SUBMISSION TYPE: 10-K PUBLIC DOCUMENT COUNT: 91 CONFORMED PERIOD OF REPORT: 20201231 FILED AS OF DATE: 20210331 DATE AS OF CHANGE: 20210331 FILER: COMPANY DATA: COMPANY CONFORMED NAME: NORTHWEST BIOTHERAPEUTICS INC CENTRAL INDEX KEY: 0001072379 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 943306718 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 10-K SEC ACT: 1934 Act SEC FILE NUMBER: 001-35737 FILM NUMBER: 21794214 BUSINESS ADDRESS: STREET 1: 4800 MONTGOMERY LANE STREET 2: SUITE 800 CITY: BETHESDA STATE: MD ZIP: 20814 BUSINESS PHONE: (240) 497-9024 MAIL ADDRESS: STREET 1: 4800 MONTGOMERY LANE STREET 2: SUITE 800 CITY: BETHESDA STATE: MD ZIP: 20814 10-K 1 nwbo-20201231x10k.htm FORM 10-K
0001072379--12-312020FYfalseNORTHWEST BIOTHERAPEUTICS INCtrue82960000061430000000.37P2YP5YP8MP12M0.5P5YP2YP2YP30MP12MP3MP12MP12MP2Y6M43000006000000001072379us-gaap:SubsequentEventMember2021-02-280001072379nwbo:SubscriptionReceivableMember2020-01-012020-12-310001072379nwbo:AprilFinancingMember2020-04-012020-04-300001072379nwbo:FlaskworksMember2020-12-012020-12-010001072379us-gaap:RetainedEarningsMember2020-12-310001072379us-gaap:AdditionalPaidInCapitalMember2020-12-310001072379us-gaap:AccumulatedTranslationAdjustmentMember2020-12-310001072379nwbo:SubscriptionReceivableMember2020-12-310001072379us-gaap:RetainedEarningsMember2019-12-310001072379us-gaap:AdditionalPaidInCapitalMember2019-12-310001072379us-gaap:AccumulatedTranslationAdjustmentMember2019-12-310001072379nwbo:SubscriptionReceivableMember2019-12-310001072379us-gaap:RetainedEarningsMember2018-12-310001072379us-gaap:AdditionalPaidInCapitalMember2018-12-310001072379us-gaap:AccumulatedTranslationAdjustmentMember2018-12-310001072379nwbo:SubscriptionReceivableMember2018-12-3100010723792018-09-260001072379us-gaap:CommonStockMember2020-12-310001072379us-gaap:CommonStockMember2019-12-310001072379us-gaap:CommonStockMember2018-12-310001072379us-gaap:EmbeddedDerivativeFinancialInstrumentsMemberus-gaap:FairValueInputsLevel3Member2019-12-310001072379nwbo:WarrantLiabilityMemberus-gaap:FairValueInputsLevel3Member2019-12-310001072379srt:MinimumMembernwbo:CashlessOptionsExerciseMemberus-gaap:SubsequentEventMember2021-01-012021-03-310001072379srt:MaximumMembernwbo:CashlessOptionsExerciseMemberus-gaap:SubsequentEventMember2021-01-012021-03-310001072379us-gaap:EmployeeStockOptionMember2020-01-012020-12-3100010723792020-08-0500010723792020-08-052020-08-050001072379nwbo:PreModificationMember2020-08-052020-08-050001072379nwbo:PostModificationMember2020-08-052020-08-050001072379nwbo:PreModificationMember2020-01-012020-12-310001072379nwbo:PostModificationMember2020-01-012020-12-310001072379nwbo:PreModificationMember2020-12-310001072379nwbo:PostModificationMember2020-12-310001072379nwbo:PreModificationMember2020-08-050001072379nwbo:PostModificationMember2020-08-050001072379srt:MinimumMember2019-12-310001072379srt:MaximumMember2019-12-310001072379srt:CumulativeEffectPeriodOfAdoptionAdjustmentMemberus-gaap:RetainedEarningsMember2019-12-310001072379srt:CumulativeEffectPeriodOfAdoptionAdjustmentMember2019-12-310001072379nwbo:Mr.GoldmanMember2020-01-012020-12-310001072379nwbo:AdventBioServicesNotesMember2020-01-012020-12-310001072379us-gaap:ConvertibleDebtMemberus-gaap:SubsequentEventMember2021-03-012021-03-010001072379nwbo:GoldmanNoteMember2020-01-012020-12-3100010723792019-05-282019-05-280001072379nwbo:SawstonBuildoutMember2020-01-012020-12-310001072379nwbo:AdventBioservicesMember2020-01-012020-12-310001072379nwbo:SawstonBuildoutMember2019-01-012019-12-310001072379nwbo:AdventBioservicesMember2019-01-012019-12-310001072379srt:MinimumMemberus-gaap:PropertyPlantAndEquipmentOtherTypesMember2020-01-012020-12-310001072379srt:MinimumMemberus-gaap:FurnitureAndFixturesMember2020-01-012020-12-310001072379srt:MaximumMemberus-gaap:PropertyPlantAndEquipmentOtherTypesMember2020-01-012020-12-310001072379srt:MaximumMemberus-gaap:FurnitureAndFixturesMember2020-01-012020-12-310001072379us-gaap:GeographicDistributionDomesticMemberus-gaap:PropertyPlantAndEquipmentOtherTypesMember2020-12-310001072379us-gaap:GeographicDistributionDomesticMemberus-gaap:LeaseholdImprovementsMember2020-12-310001072379us-gaap:GeographicDistributionDomesticMemberus-gaap:FurnitureAndFixturesMember2020-12-310001072379country:GBus-gaap:LandMember2020-12-310001072379us-gaap:GeographicDistributionDomesticMemberus-gaap:PropertyPlantAndEquipmentOtherTypesMember2019-12-310001072379us-gaap:GeographicDistributionDomesticMemberus-gaap:LeaseholdImprovementsMember2019-12-310001072379us-gaap:GeographicDistributionDomesticMemberus-gaap:FurnitureAndFixturesMember2019-12-310001072379country:GBus-gaap:LandMember2019-12-310001072379nwbo:AprilNotesMemberus-gaap:ShortTermDebtMembernwbo:TenPercentUnsecuredMember2020-04-012020-04-3000010723792020-08-282020-08-280001072379nwbo:RegisteredDirectOfferingMember2020-01-012020-12-310001072379us-gaap:AccumulatedTranslationAdjustmentMember2020-01-012020-12-310001072379us-gaap:AccumulatedTranslationAdjustmentMember2019-01-012019-12-310001072379country:DEus-gaap:ForeignCountryMember2020-12-310001072379country:US2019-12-310001072379country:GB2019-12-310001072379country:US2019-03-0400010723792019-01-010001072379nwbo:SixPercentageNotePayableOneMember2020-12-310001072379nwbo:NoteDueIn2011Member2020-12-310001072379nwbo:SixPercentageNotePayableOneMember2019-12-310001072379nwbo:NoteDueIn2011Member2019-12-310001072379us-gaap:RetainedEarningsMember2020-01-012020-12-310001072379us-gaap:RetainedEarningsMember2019-01-012019-12-310001072379country:US2020-01-012020-12-310001072379country:GB2020-01-012020-12-310001072379country:US2019-01-012019-12-310001072379country:GB2019-01-012019-12-310001072379nwbo:RelatedPartyMemberus-gaap:NotesPayableOtherPayablesMember2020-01-012020-12-310001072379nwbo:RelatedPartyMemberus-gaap:ConvertibleNotesPayableMember2020-01-012020-12-310001072379us-gaap:ConvertibleNotesPayableMember2020-01-012020-12-310001072379nwbo:RelatedPartyMemberus-gaap:NotesPayableOtherPayablesMember2019-01-012019-12-310001072379nwbo:RelatedPartyMemberus-gaap:ConvertibleNotesPayableMember2019-01-012019-12-310001072379nwbo:ForbearanceOfDebtToRelatedPartiesMember2020-01-012020-12-310001072379us-gaap:EmbeddedDerivativeFinancialInstrumentsMember2020-12-310001072379nwbo:WarrantLiabilityMember2020-12-310001072379nwbo:ContingentPayableDerivativeLiabilityMember2020-12-310001072379nwbo:WarrantLiabilityMember2019-12-310001072379nwbo:ContingentPayableDerivativeLiabilityMember2019-12-310001072379us-gaap:EmbeddedDerivativeFinancialInstrumentsMember2018-12-310001072379nwbo:WarrantLiabilityMember2018-12-310001072379nwbo:WarrantLiabilityMember2019-01-012019-12-310001072379nwbo:ContingentPayableDerivativeLiabilityMember2019-01-012019-12-310001072379us-gaap:WarrantMembernwbo:RegisteredDirectOfferingMember2020-01-012020-12-310001072379nwbo:PlacementAgentMemberus-gaap:WarrantMember2020-01-012020-12-310001072379nwbo:DirectOfferingMember2020-01-012020-12-310001072379nwbo:DirectOfferingMember2019-01-012019-12-310001072379nwbo:PromissoryNoteMembernwbo:TenPercentUnsecuredMember2020-01-012020-12-310001072379nwbo:GoldmanNoteMember2020-12-310001072379country:NL2020-12-310001072379country:DE2020-12-310001072379nwbo:PaycheckProtectionProgramLoanCaresActMember2020-05-202020-05-200001072379srt:MinimumMembernwbo:TenPercentUnsecuredMember2020-01-012020-12-310001072379srt:MaximumMembernwbo:TenPercentUnsecuredMember2020-01-012020-12-310001072379nwbo:ForbearanceWarrantsMember2020-01-012020-12-310001072379nwbo:AdventBioServicesNotesMember2018-09-262018-09-260001072379us-gaap:ShortTermDebtMembernwbo:SixPercentUnsecurbleMember2020-01-012020-12-310001072379us-gaap:ShortTermDebtMembernwbo:EightPercentUnsecuredMember2020-01-012020-12-310001072379nwbo:ShortTermNotesPayableMembernwbo:TwelvePercentUnsecuredMember2020-01-012020-12-310001072379nwbo:ShortTermNotesPayableMembernwbo:TenPercentUnsecuredMember2020-01-012020-12-310001072379nwbo:ShortTermNotesPayableMembernwbo:EightPercentUnsecuredMember2020-01-012020-12-310001072379nwbo:LongTermNotesPayableMembernwbo:SixPercentSecuredMember2020-01-012020-12-310001072379nwbo:LongTermNotesPayableMembernwbo:EightPercentUnsecuredMember2020-01-012020-12-310001072379us-gaap:ShortTermDebtMembernwbo:TenPercentUnsecuredMember2019-01-012019-12-310001072379us-gaap:ShortTermDebtMembernwbo:SixPercentUnsecurbleMember2019-01-012019-12-310001072379nwbo:ShortTermNotesPayableRelatedPartiesMembernwbo:TenPercentUnsecuredMember2019-01-012019-12-310001072379nwbo:ShortTermNotesPayableMembernwbo:ZeroPercentUnsecuredMember2019-01-012019-12-310001072379nwbo:ShortTermNotesPayableMembernwbo:TwelvePercentUnsecuredMember2019-01-012019-12-310001072379nwbo:ShortTermNotesPayableMembernwbo:TenPercentUnsecuredMember2019-01-012019-12-310001072379nwbo:ShortTermNotesPayableMembernwbo:EightPercentUnsecuredMember2019-01-012019-12-310001072379nwbo:LongTermNotesPayableMembernwbo:EightPercentUnsecuredMember2019-01-012019-12-310001072379srt:ExecutiveOfficerMembernwbo:AdventBioServicesNotesMember2020-12-310001072379nwbo:SixPercentUnsecurbleMember2020-12-310001072379nwbo:PaycheckProtectionProgramLoanCaresActMember2020-05-200001072379nwbo:AdventBioServicesNotesMember2018-09-260001072379us-gaap:ConvertiblePreferredStockMember2019-12-310001072379us-gaap:ConvertibleDebtMemberus-gaap:SubsequentEventMember2021-03-010001072379nwbo:DebtInstrumentRedemptionMoreThanThreeAndLessThanFiveYearMembernwbo:LongTermNotesPayableMembernwbo:SixPercentSecuredMember2020-12-310001072379nwbo:DebtInstrumentRedemptionMoreThanOneAndLessThanTwoYearMembernwbo:LongTermNotesPayableMembernwbo:EightPercentUnsecuredMember2020-12-310001072379nwbo:DebtInstrumentRedemptionLessThanOneYearMembernwbo:ShortTermNotesPayableMembernwbo:TwelvePercentUnsecuredMember2020-12-310001072379nwbo:DebtInstrumentRedemptionLessThanOneYearMembernwbo:ShortTermNotesPayableMembernwbo:TenPercentUnsecuredMember2020-12-310001072379nwbo:DebtInstrumentRedemptionLessThanOneYearMembernwbo:ShortTermNotesPayableMembernwbo:EightPercentUnsecuredMember2020-12-310001072379nwbo:DebtInstrumentRedemptionLessThanOneYearMembernwbo:ShortTermConvertibleNoteMembernwbo:SixPercentUnsecuredMember2020-12-310001072379nwbo:DebtInstrumentRedemptionLessThanOneYearMembernwbo:ShortTermConvertibleNoteMembernwbo:EightPercentUnsecuredMember2020-12-310001072379nwbo:ShortTermNotesPayableMembernwbo:TwelvePercentUnsecuredMember2020-12-310001072379nwbo:ShortTermNotesPayableMembernwbo:TenPercentUnsecuredMember2020-12-310001072379nwbo:ShortTermNotesPayableMembernwbo:EightPercentUnsecuredMember2020-12-310001072379nwbo:ShortTermConvertibleNoteMembernwbo:SixPercentUnsecuredMember2020-12-310001072379nwbo:ShortTermConvertibleNoteMembernwbo:EightPercentUnsecuredMember2020-12-310001072379nwbo:PromissoryNoteMembernwbo:TenPercentUnsecuredMember2020-12-310001072379nwbo:LongTermNotesPayableMembernwbo:SixPercentSecuredMember2020-12-310001072379nwbo:LongTermNotesPayableMembernwbo:EightPercentUnsecuredMember2020-12-310001072379nwbo:TwelvePercentUnsecuredMember2020-12-310001072379nwbo:TenPercentUnsecuredMember2020-12-310001072379nwbo:ShortTermNotesPayableMember2020-12-310001072379nwbo:NotesMember2020-12-310001072379nwbo:LongTermNotesPayableMember2020-12-310001072379nwbo:DebtInstrumentRedemptionMoreThanThreeAndLessThanFiveYearMember2020-12-310001072379nwbo:DebtInstrumentRedemptionMoreThanOneAndLessThanTwoYearMember2020-12-310001072379nwbo:DebtInstrumentRedemptionLessThanOneYearMember2020-12-310001072379nwbo:AprilNotesMemberus-gaap:ShortTermDebtMembernwbo:TenPercentUnsecuredMember2020-04-300001072379nwbo:CambridgePeterboroughCombinedAuthorityMember2020-03-260001072379nwbo:ShortTermNotesPayableRelatedPartiesMembernwbo:TenPercentUnsecuredMember2019-12-310001072379nwbo:ShortTermNotesPayableMembernwbo:ZeroPercentUnsecuredMember2019-12-310001072379nwbo:ShortTermNotesPayableMembernwbo:TwelvePercentUnsecuredMember2019-12-310001072379nwbo:ShortTermNotesPayableMembernwbo:TenPercentUnsecuredMember2019-12-310001072379nwbo:ShortTermNotesPayableMembernwbo:EightPercentUnsecuredMember2019-12-310001072379nwbo:LongTermNotesPayableMembernwbo:EightPercentUnsecuredMember2019-12-310001072379us-gaap:ShortTermDebtMember2019-12-310001072379nwbo:TwelvePercentUnsecuredMember2019-12-310001072379nwbo:ShortTermNotesPayableRelatedPartiesMember2019-12-310001072379nwbo:ShortTermNotesPayableMember2019-12-310001072379nwbo:LongTermNotesPayableMember2019-12-310001072379us-gaap:ShortTermDebtMembernwbo:SixPercentUnsecurbleMember2020-12-310001072379nwbo:TenPercentUnsecuredMember2020-08-310001072379srt:MinimumMembernwbo:GoldmanNoteMember2020-05-310001072379srt:MaximumMembernwbo:GoldmanNoteMember2020-05-310001072379srt:MinimumMemberus-gaap:ShortTermDebtMembernwbo:TenPercentUnsecuredMember2020-04-300001072379srt:MaximumMemberus-gaap:ShortTermDebtMembernwbo:TenPercentUnsecuredMember2020-04-300001072379us-gaap:ShortTermDebtMembernwbo:TenPercentUnsecuredMember2019-12-310001072379us-gaap:ShortTermDebtMembernwbo:SixPercentUnsecurbleMember2019-12-310001072379nwbo:AugustFinancingMember2020-08-052020-08-050001072379nwbo:AfterAmendmentMembernwbo:TenPercentUnsecuredMember2020-01-012020-12-310001072379us-gaap:ConvertibleDebtSecuritiesMember2020-01-012020-12-310001072379us-gaap:ConvertiblePreferredStockMember2019-01-012019-12-310001072379us-gaap:ShortTermDebtMembernwbo:TenPercentUnsecuredMember2020-10-182020-10-180001072379nwbo:AugustNoteMember2020-09-292020-09-290001072379nwbo:TwelvePercentUnsecuredMember2020-01-012020-12-310001072379nwbo:TwelvePercentUnsecuredMember2019-01-012019-12-310001072379srt:ExecutiveOfficerMember2020-12-310001072379srt:ExecutiveOfficerMember2018-04-300001072379nwbo:AfterAmendmentMembernwbo:TenPercentUnsecuredMember2020-12-310001072379nwbo:EightPercentUnsecuredMember2020-12-310001072379nwbo:MayNoteMember2020-10-010001072379nwbo:AugustNoteMember2020-09-290001072379nwbo:AprilNotesMembernwbo:TenPercentUnsecuredMember2020-08-030001072379nwbo:TenPercentUnsecuredMember2020-05-310001072379nwbo:ShortTermNotesPayableRelatedPartiesMember2019-01-012019-12-310001072379srt:ScenarioPreviouslyReportedMember2019-01-012019-12-310001072379nwbo:RegisteredDirectOfferingMember2019-12-310001072379nwbo:MayFinancingMember2020-05-310001072379srt:MinimumMembernwbo:CashlessWarrantsExerciseMemberus-gaap:SubsequentEventMember2021-03-310001072379srt:MaximumMembernwbo:CashlessWarrantsExerciseMemberus-gaap:SubsequentEventMember2021-03-310001072379srt:MinimumMemberus-gaap:SubsequentEventMember2021-03-310001072379srt:MaximumMemberus-gaap:SubsequentEventMember2021-03-310001072379srt:MinimumMembernwbo:AfterAmendmentMembernwbo:TenPercentUnsecuredMember2020-12-310001072379srt:MaximumMembernwbo:AfterAmendmentMembernwbo:TenPercentUnsecuredMember2020-12-310001072379srt:MinimumMembernwbo:PlacementAgentMember2020-12-310001072379nwbo:RegisteredDirectOfferingMember2020-12-310001072379nwbo:PlacementAgentMember2020-12-310001072379nwbo:ForbearanceWarrantsMember2020-12-310001072379us-gaap:ConvertibleNotesPayableMembernwbo:OctoberFinancingMember2020-10-120001072379us-gaap:CommonStockMembernwbo:OctoberFinancingMember2020-10-120001072379us-gaap:ConvertibleNotesPayableMembernwbo:AugustFinancingMember2020-08-050001072379us-gaap:CommonStockMembernwbo:AugustFinancingMember2020-08-050001072379nwbo:WarrantsIssuedAsConsiderationForWarrantsSuspensionMembernwbo:AugustFinancingMember2020-08-050001072379srt:MinimumMembernwbo:MayFinancingMember2020-05-310001072379srt:MaximumMembernwbo:MayFinancingMember2020-05-310001072379nwbo:MayNoteMember2020-05-310001072379nwbo:GoldmanNoteMember2020-05-310001072379srt:MinimumMembernwbo:AprilNotesMembernwbo:TenPercentUnsecuredMember2020-04-300001072379srt:MaximumMembernwbo:AprilNotesMembernwbo:TenPercentUnsecuredMember2020-04-300001072379us-gaap:ShortTermDebtMembernwbo:TenPercentUnsecuredMember2020-04-300001072379nwbo:AprilNotesMembernwbo:TenPercentUnsecuredMember2020-04-300001072379nwbo:AprilFinancingMember2020-04-300001072379nwbo:FebruaryNotesMemberus-gaap:ShortTermDebtMembernwbo:TenPercentUnsecuredMember2020-02-290001072379nwbo:FlaskworksMember2020-10-012020-12-310001072379nwbo:FlaskworksMember2020-12-250001072379us-gaap:WarrantMember2020-01-012020-12-310001072379nwbo:ConvertibleNotesMember2020-01-012020-12-310001072379nwbo:CommonStockWarrantsLiabilityTreatmentMember2020-01-012020-12-310001072379nwbo:CommonStockOptionsMember2020-01-012020-12-310001072379us-gaap:WarrantMember2019-01-012019-12-310001072379nwbo:ConvertibleNotesMember2019-01-012019-12-310001072379nwbo:CommonStockWarrantsLiabilityTreatmentMember2019-01-012019-12-310001072379nwbo:CommonStockOptionsMember2019-01-012019-12-310001072379us-gaap:NotesPayableOtherPayablesMember2020-01-012020-12-310001072379us-gaap:NotesPayableOtherPayablesMember2019-01-012019-12-310001072379nwbo:ShortTermNotesPayableRelatedPartiesMember2020-01-012020-12-310001072379us-gaap:ResearchAndDevelopmentExpenseMember2020-12-012020-12-010001072379us-gaap:GeneralAndAdministrativeExpenseMember2020-12-012020-12-010001072379us-gaap:ResearchAndDevelopmentExpenseMember2020-01-012020-12-310001072379us-gaap:GeneralAndAdministrativeExpenseMember2020-01-012020-12-310001072379nwbo:FlaskworksMember2020-01-012020-12-310001072379us-gaap:ResearchAndDevelopmentExpenseMember2019-01-012019-12-310001072379us-gaap:GeneralAndAdministrativeExpenseMember2019-01-012019-12-310001072379nwbo:AncillaryServicesAgreementMember2020-12-310001072379nwbo:AdventBioServicesNotesMember2020-12-310001072379nwbo:AdventBioServicesAgreementMember2020-12-310001072379nwbo:AncillaryServicesAgreementMember2019-12-310001072379nwbo:AdventBioServicesNotesMember2019-12-310001072379nwbo:AdventBioServicesAgreementMember2019-12-310001072379nwbo:OctoberNoteMember2020-10-012020-10-310001072379nwbo:AugustNoteMember2020-08-012020-08-310001072379nwbo:MayNoteMember2020-05-012020-05-310001072379nwbo:GoldmanNoteMember2020-02-012020-05-310001072379nwbo:FebruaryNotesMemberus-gaap:ShortTermDebtMembernwbo:TenPercentUnsecuredMember2020-02-012020-02-290001072379us-gaap:ForeignCountryMember2021-02-122021-02-120001072379us-gaap:SubsequentEventMember2021-01-012021-03-310001072379nwbo:FlaskworksMember2020-08-0500010723792020-04-012020-04-300001072379nwbo:AdventBioserivicesMember2018-05-142018-05-140001072379nwbo:MayFinancingMember2020-05-012020-05-310001072379nwbo:AprilFinancingMember2020-01-012020-12-310001072379us-gaap:CommonStockMember2020-10-122020-10-120001072379srt:ExecutiveOfficerMember2020-01-012020-12-310001072379nwbo:CashlessWarrantsExerciseMemberus-gaap:SubsequentEventMember2021-01-012021-03-310001072379us-gaap:CommonStockMember2020-01-012020-12-310001072379nwbo:CashlessOptionsExerciseMemberus-gaap:SubsequentEventMember2021-01-012021-03-310001072379nwbo:AprilNotesMembernwbo:TenPercentUnsecuredMember2020-04-012020-04-300001072379us-gaap:ConvertibleDebtMemberus-gaap:SubsequentEventMember2021-11-012021-11-010001072379country:US2020-12-310001072379country:GB2020-12-310001072379us-gaap:LeaseholdImprovementsMember2020-01-012020-12-310001072379nwbo:ShareSettlementAgreementMember2019-01-012019-12-310001072379nwbo:FlaskworksMember2020-12-252020-12-250001072379us-gaap:ShortTermDebtMembernwbo:EightPercentUnsecuredMember2020-12-310001072379us-gaap:ShortTermDebtMember2020-12-310001072379us-gaap:EmbeddedDerivativeFinancialInstrumentsMember2019-01-012019-12-310001072379us-gaap:ShortTermDebtMembernwbo:TenPercentUnsecuredMember2020-04-012020-04-300001072379nwbo:WarrantLiabilityMember2020-01-012020-12-310001072379nwbo:ContingentPayableDerivativeLiabilityMember2020-01-012020-12-310001072379us-gaap:EmbeddedDerivativeFinancialInstrumentsMemberus-gaap:FairValueInputsLevel3Member2019-01-012019-12-310001072379nwbo:WarrantLiabilityMemberus-gaap:FairValueInputsLevel3Member2019-01-012019-12-310001072379nwbo:TenPercentUnsecuredMember2020-08-012020-08-310001072379nwbo:AncillaryServicesAgreementMember2020-01-012020-12-310001072379nwbo:AugustFinancingMember2020-08-012020-08-310001072379nwbo:CognateBioServicesNotesMembernwbo:ContingentNotePayableMember2020-12-310001072379nwbo:CambridgePeterboroughCombinedAuthorityMember2020-03-262020-03-260001072379nwbo:AprilNotesMemberus-gaap:ShortTermDebtMember2020-04-012020-04-300001072379us-gaap:InvestorMemberus-gaap:ConvertibleDebtMemberus-gaap:SubsequentEventMember2021-03-010001072379nwbo:OctoberNoteMember2020-10-310001072379nwbo:AugustNoteMember2020-08-310001072379us-gaap:InvestorMemberus-gaap:ConvertibleDebtMemberus-gaap:SubsequentEventMember2021-03-012021-03-010001072379nwbo:NotesMember2020-01-012020-12-310001072379nwbo:MayNoteMember2020-10-012020-10-010001072379nwbo:AprilNotesMembernwbo:TenPercentUnsecuredMember2020-08-032020-08-030001072379nwbo:TenPercentUnsecuredMember2020-05-012020-05-310001072379nwbo:FebruaryNotesMembernwbo:TenPercentUnsecuredMember2020-01-012020-12-310001072379nwbo:AprilNotesMembernwbo:TenPercentUnsecuredMember2020-01-012020-12-310001072379nwbo:TenPercentUnsecuredMember2020-01-012020-12-310001072379nwbo:EightPercentUnsecuredMember2020-01-012020-12-310001072379us-gaap:FairValueInputsLevel3Member2020-12-310001072379us-gaap:FairValueInputsLevel2Member2020-12-310001072379us-gaap:FairValueInputsLevel1Member2020-12-310001072379us-gaap:FairValueInputsLevel3Member2019-12-310001072379us-gaap:FairValueInputsLevel2Member2019-12-310001072379us-gaap:FairValueInputsLevel1Member2019-12-310001072379us-gaap:GeographicDistributionDomesticMember2020-12-310001072379us-gaap:GeographicDistributionDomesticMember2019-12-310001072379srt:MinimumMembernwbo:MayFinancingMember2020-05-012020-05-310001072379srt:MaximumMembernwbo:MayFinancingMember2020-05-012020-05-310001072379nwbo:PlacementAgentMember2020-01-012020-12-310001072379nwbo:ForbearanceWarrantsMember2020-07-022020-07-020001072379nwbo:WarrantsThroughDecemberFifteenTwoThousandAndTwentyMember2020-10-122020-10-120001072379nwbo:WarrantsOherNewSharePurchasesMember2020-10-122020-10-120001072379us-gaap:SubsequentEventMember2021-04-3000010723792020-12-1500010723792020-10-120001072379nwbo:AugustFinancingMember2020-08-050001072379us-gaap:ConvertibleNotesPayableMembernwbo:AugustFinancingMember2020-08-052020-08-0500010723792020-05-102020-05-1000010723792018-12-3100010723792018-01-012018-12-310001072379us-gaap:CommonStockMembernwbo:AugustFinancingMember2020-08-052020-08-050001072379us-gaap:SubsequentEventMember2021-02-282021-02-2800010723792020-10-312020-10-310001072379us-gaap:SubsequentEventMember2021-01-152021-01-150001072379us-gaap:ConvertibleNotesPayableMembernwbo:OctoberFinancingMember2020-10-122020-10-120001072379us-gaap:CommonStockMembernwbo:OctoberFinancingMember2020-10-122020-10-120001072379nwbo:OctoberFinancingMember2020-10-122020-10-120001072379srt:MinimumMemberus-gaap:CommonStockMembernwbo:AugustFinancingMember2020-08-052020-08-050001072379srt:MinimumMembernwbo:WarrantsIssuedAsConsiderationForWarrantsSuspensionMembernwbo:AugustFinancingMember2020-08-052020-08-050001072379srt:MaximumMemberus-gaap:CommonStockMembernwbo:AugustFinancingMember2020-08-052020-08-050001072379srt:MaximumMembernwbo:WarrantsIssuedAsConsiderationForWarrantsSuspensionMembernwbo:AugustFinancingMember2020-08-052020-08-0500010723792020-11-010001072379nwbo:WarrantsIssuedAsConsiderationForWarrantsSuspensionMember2020-10-3100010723792020-04-300001072379us-gaap:SubsequentEventMember2021-01-150001072379nwbo:OctoberFinancingMember2020-10-1200010723792020-05-100001072379srt:RevisionOfPriorPeriodErrorCorrectionAdjustmentMembernwbo:ErrorCorrectionAccrualAndCapitalizationErrorsMember2019-01-012019-12-310001072379nwbo:FlaskworksMember2020-08-282020-08-280001072379nwbo:FlaskworksMember2020-08-280001072379us-gaap:EmbeddedDerivativeFinancialInstrumentsMember2020-01-012020-12-310001072379nwbo:AncillaryServicesAgreementMember2019-11-082019-11-080001072379us-gaap:CommonStockMember2019-01-012019-12-310001072379us-gaap:AdditionalPaidInCapitalMember2020-01-012020-12-310001072379us-gaap:AdditionalPaidInCapitalMember2019-01-012019-12-3100010723792019-01-012019-12-3100010723792020-12-310001072379srt:RevisionOfPriorPeriodErrorCorrectionAdjustmentMembernwbo:ErrorCorrectionAccrualAndCapitalizationErrorsMember2019-12-310001072379srt:ScenarioPreviouslyReportedMember2019-12-310001072379srt:RevisionOfPriorPeriodErrorCorrectionAdjustmentMember2019-12-3100010723792019-12-3100010723792020-06-3000010723792021-03-2600010723792020-01-012020-12-31xbrli:sharesiso4217:USDxbrli:pureiso4217:USDxbrli:sharesnwbo:installmentiso4217:EURiso4217:GBPnwbo:segment

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

FORM 10-K

ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the fiscal year ended December 31, 2020

TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the transition period from ______to _______

Commission File Number: 001-35737

NORTHWEST BIOTHERAPEUTICS, INC.

(Exact name of registrant as specified in its charter)

Delaware

 

94-3306718

(State or Other Jurisdiction of Incorporation or Organization)

 

 (I.R.S. Employer Identification No.)

4800 Montgomery Lane, Suite 800, Bethesda, MD 20814

(Address of principal executive offices) (Zip Code)

(240497-9024

(Registrant’s telephone number)

N/A

(Former Name, Former Address and Former Fiscal Year, if changed since last report)

Securities registered pursuant to Section 12(b) of the Act:

Title of each class:

Trading Symbol(s):

Name of each exchange on which registered:

Common Stock, par value $0.001 per share

NWBO

OTCQB

Securities registered pursuant to Section 12(g) of the Act: None

Indicate by check mark if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Yes      No   

Indicate by check mark if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act. Yes      No   

Indicate by check mark whether the registrant: (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 (the “Exchange Act”) during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. Yes        No   

Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files). Yes       No   

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, or a smaller reporting company, or an emerging growth company. See definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company” and “emerging growth company” in Rule 12b-2 of the Exchange Act.:

Large accelerated filer

Accelerated filer

Non-accelerated filer

Smaller reporting company

 

 

Emerging growth company

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act). Yes   No 

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.    

The aggregate market value of the voting and non-voting common equity held by non-affiliates of the registrant was $234,821,000 on June 30, 2020. As of March 26, 2021, the registrant had 842,137,013 shares of common stock outstanding.

DOCUMENTS INCORPORATED BY REFERENCE

None.

NORTHWEST BIOTHERAPEUTICS, INC.

FORM 10-K

TABLE OF CONTENTS

PART I

Item 1.

Business

3

Item 1A.

Risk Factors

6

Item 1B.

Unresolved Staff Comments

21

Item 2.

Properties

21

Item 3.

Legal Proceedings

21

Item 4.

Mine Safety Disclosures

21

PART II

Item 5.

Market for the Registrant’s Common Equity, Related Stockholder Matters and Issuer Purchases of Equity Securities

21

Item 6.

Selected Financial Data

22

Item 7.

Management’s Discussion and Analysis of Financial Condition And Results of Operations

22

Item 7A.

Quantitative and Qualitative Disclosures About Market Risk

29

Item 8.

Financial Statements and Supplementary Data

29

Item 9.

Changes in and Disagreements with Accountants on Accounting and Financial Disclosures

29

Item 9A.

Controls and Procedures

29

Item 9B.

Other Information

30

PART III

Item 10.

Directors, Executive Officers and Corporate Governance

30

Item 11.

Executive Compensation

31

Item 12.

Security Ownership of Certain Beneficial Owners and Management and Related Stockholder Matters

31

Item 13.

Certain Relationships and Related Transactions, and Director Independence

31

Item 14.

Principal Accountant Fees and Services

31

PART IV

Item 15.

Exhibits and Financial Statement Schedules

31

SIGNATURES

34

2

PART I

This Report on Form 10-K for Northwest Biotherapeutics, Inc. may contain forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. Such forward-looking statements are characterized by future or conditional verbs such as “may,” “will,” “expect,” “intend,” “anticipate,” believe,” “estimate” and “continue” or similar words. You should read statements that contain these words carefully because they discuss future expectations and plans, which contain projections of future results of operations or financial condition or state other forward-looking information. Such statements are only predictions and our actual results may differ materially from those anticipated in these forward-looking statements. We believe that it is important to communicate future expectations to investors. However, there may be events in the future that we are not able to accurately predict or control. Factors that may cause such differences include, but are not limited to, those discussed under Item 1A of this Report, including the uncertainties associated with product development, the risk that products that appeared promising in early clinical trials do not demonstrate safety and efficacy in larger-scale clinical trials, the risk that we will not obtain approval to market our products, the risks associated with dependence upon key personnel and the need for additional financing. We do not assume any obligation to update forward-looking statements as circumstances change.

Unless the context otherwise requires, “Northwest Biotherapeutics,” the “Company,” “we,” “us,” “our” and similar names refer to Northwest Biotherapeutics, Inc. DCVax® is a registered trademark of the Company.

ITEM 1. BUSINESS.

Overview

We are a biotechnology company focused on developing personalized immune therapies for cancer. We have developed a platform technology, DCVax®, which uses activated dendritic cells to mobilize a patient’s own immune system to attack their cancer.

Our lead product, DCVax®-L, is designed to treat solid tumor cancers in which the tumor can be surgically removed. We have completed a 331-patient international Phase III trial of DCVax-L for Glioblastoma multiforme brain cancer (GBM). As previously reported, the data collection and confirmation process was conducted by the independent contract research organization (CRO) who managed the trial and by other independent service firms.  On October 5, 2020, the Company announced that Data Lock for the Phase III trial had been reached, and that a series of steps and processes would follow. These processes included data validation, analyses of the data by independent statisticians, preparations by the statisticians of summaries of the Trial results for review by the Company, the Principal Investigator, the Steering Committee of the Trial, the Scientific Advisory Board, and a panel of independent brain cancer experts, in preparation for publication in a scientific journal and public announcement.  This series of processes is under way.  It is anticipated that public announcement will follow these processes.

As also previously reported, coronavirus-related difficulties have impacted most aspects of the process, especially with the successive waves of COVID cases in many areas. The independent service firms have had limited capacity, and restrictions on operations. Key experts at certain specialized service providers have been unavailable for periods of time due to illness in their family.  Other experts have gone on extended leave due to restrictions on operations. Clinical trial site personnel have been unavailable due to being reassigned for COVID, and the limited site personnel have had to work under restrictions. Committee processes and regulatory processes have been similarly focused on COVID matters and delayed on other matters. Firms such as the ones storing the Phase III trial tissue samples that are needed for certain analyses, and the firms conducting the analyses, continue to have only limited operations. Even logistical matters such as the shipping of materials have been, and continue to be, subjected to substantial restrictions and delays.

On August 28, 2020, the Company acquired Flaskworks, LLC (“Flaskworks”), a company that has developed a system to close and automate the manufacturing of cell therapy products such as DCVax®. The Company acquired 100% of the ownership, and  Flaskworks became a wholly-owned subsidiary of the Company. Flaskworks was previously owned by its technical founders and Corning Inc. The technical team from Flaskworks joined the Company as part of the Acquisition. It is anticipated that the Flaskworks system will enable substantial scale-up of production volumes of DCVax products and substantial reduction of production costs. The Company’s buildout of the Sawston, UK facility has been designed to proceed in phases, as modules, both for efficiency in the timing of capital costs and to allow flexibility in operations and usage. The Company anticipates that implementation of the Flaskworks system will enable certain phases of the buildout to be simplified and streamlined.  For further details on the financial aspects of the acquisition, please see Item 8 Note 5 below.

3

Our second product, DCVax®-Direct, is designed to treat inoperable solid tumors. A 40-patient Phase I trial has been completed, and included treatment of a diverse range of more than a dozen types of cancers. The Company is working on preparations for Phase II trials of DCVax-Direct, as resources permit.

The DCVax Technology

Our platform technology, DCVax, is a personalized immune therapy that uses a patient’s own dendritic cells, or DCs, the master cells of the immune system, as the therapeutic agent. The patient’s DCs are obtained through a blood draw, or leukapheresis. The DCs are then activated and loaded with biomarkers (“antigens”) from the patient’s own tumor. For DCVax-L, the antigen loading process takes place during the manufacturing of the product. For DCVax-Direct, the antigen loading process takes place in situ in the tumor after the product is directly injected into the patient’s inoperable tumor. The loading of antigens into the DCs “educates” the DCs about what the immune system needs to target.

Manufacturing of DCVax

We use a batch manufacturing technology for our DCVax products, and we believe this manufacturing approach is a key part of the practicality of our product and its economic feasibility. Generally, we are able to produce enough doses for the patient’s treatment regimen through just one manufacturing process. When a batch of DCVax product has been made, we then cryopreserve it.

Both of these technologies, the personalized batch manufacturing for each patient and the cryopreservation, are essential elements of our manufacturing model and product economics. Together, they enable us to usually incur the high costs of manufacturing just one time for each patient, and then store the multi-year or multi-dose quantity of product, frozen, in single doses. This makes DCVax effectively an “off the shelf” product for the patient after the initial manufacturing, even though it is personalized, and we anticipate that this will enable the pricing of DCVax to be in line with other new cancer drugs. We also believe that both economies of scale and automation will further enhance the product economics. The manufacturing process today is also rapid: about 8 days for DCVax-L, and 7 days for DCVax-Direct, followed by quality control and release testing (including a sterility test that may take a couple of weeks).

As previously reported, we have been developing a manufacturing facility in Sawston, U.K. To date, the Company's production of dendritic cell vaccine products in the UK has been taking place in a GMP (clean room) facility in London, with a capacity of about 4 - 6 patients per month. The Sawston facility contains a total of 88,345 square feet on two floors. The initial production capacity comprises two manufacturing suites, occupying approximately 4,400 square feet on the ground floor. These two suites, together with some additional support and storage space, have anticipated potential capacity to produce dendritic cell vaccines for about 40 to 45 patients per month, or approximately 450 to 500 patients annually. The final stage of development of the initial production capacity (the Performance Qualification stage) is under way, and when that stage is completed it is anticipated that an application for certification of the facility will be submitted to the UK regulatory authority.

Since the initial production capacity will occupy only a small fraction of the total space in the Sawston facility, it is anticipated that additional capacity for third party production of other cell therapy products may be developed in some of the other space. GMP facilities are capital intensive both to develop and to operate. Third party production of other products will help support the Sawston facility costs and, in light of the growing demand for cell therapy manufacturing capacity, could substantially increase the asset value of the Sawston facility.

All of the development activities for the Sawston facility have been carried out by Advent BioServices, who is also the operator of the facility.

4

Intellectual Property and Orphan Drug Designation

We have an integrated strategy for protection of our technology through both patents and other mechanisms, such as Orphan Drug status. As of December 31, 2020, we have 202 issued patents and 63 pending patent applications worldwide, grouped into 11 patent families. Of these, 194 issued patents and 52 pending patent applications directly relate to our DCVax products. In the United States and Europe, some of our patents and applications relate to compositions and the use of products, while other patents and applications relate to other aspects such as manufacturing and quality control. For example, in the United States, we have four issued and seven pending patent applications that relate to the composition and/or use of our DCVax products. We also have other U.S patents and applications that cover, among other things, quality control for DCVax and an automated system which we believe will help enable the scale-up of production for large numbers of patients on a cost-effective basis. Similarly, in Europe, we have seven patents issued by and five pending patent applications with the European Patent Office ("EPO") that cover our DCVax products, and other patents and applications that cover aspects such as manufacturing and quality control, and the automated system. In Japan, we have seven issued patents and four pending patent applications relating to our DCVax products, as well as manufacturing related patents. Patents have been granted and are pending in other foreign jurisdictions which may be potential future markets for our DCVax products.

During 2020, three new patents were issued to us as part of our worldwide patent portfolio. The newly issued patents cover methods for manufacturing dendritic cells related to our DCVax products, as well as encompassing certain methods of use and compositions that may be potential future markets related DCVax products. Additionally, with the addition of Flaskworks, the Company gained one issued patent and eight pending patent applications.  In addition, the Company gained the rights to an another issued patent and 15 pending patent applications that Flaskworks had exclusively licensed from Northeastern University.  Collectively these patents and patent applications cover key aspects of the design and function of automated cell culture systems.

During 2019, six new patents were issued to us as part of our worldwide patent portfolio. The newly issued patents cover methods and devices for manufacturing dendritic cells related to our DCVax products, as well as encompassing certain methods and compositions that may be potential future markets related DCVax products.

The expiration dates of the issued U.S. patents involved in our current business range from 2022 to 2026. The expiration dates of the issued European patents involved in our current business range from 2022 to 2024. For some of the earlier dates, we plan to seek extensions of the patent life, and believe we have reasonable grounds for doing so.

In addition to our patent portfolio, we have obtained Orphan Drug designation for our lead product, DCVax-L for glioma brain cancers. Such designation brings with it a variety of benefits, including potential market exclusivity for seven years in the U.S. and ten years in Europe if our product is the first of its type to reach the market.

This market exclusivity applies regardless of patents, (i.e., even if the company that developed it has no patent coverage on the product). In addition, the time period for such market exclusivity does not begin to run until product sales begin. In contrast, the time period of a patent begins when the patent is filed and runs down during the years while the product is going through development and clinical trials.

Competition

The biotechnology and biopharmaceutical industries are characterized by rapidly advancing technologies, intense competition and a strong emphasis on proprietary products. A large and growing number of companies are actively involved in the research and development of immune therapies or cell-based therapies for cancer (including Juno, Kite, Bellicum, Agenus, Asterias, Dandrit, Immunicum, Sotio, AiVita and many others). In addition, many big pharma companies (including BMS, Merck, Pfizer, Astra Zeneca, Roche and others) are rapidly commercializing checkpoint inhibitor drugs to “take the brakes off” patients’ immune responses to cancer. Other novel technologies for cancer are also under development or have recently been approved, such as the Optune electro-therapy device developed by NovoCure and various oncolytic virus therapies and gene therapies. Additionally, many companies are actively involved in the research and development of monoclonal antibody-based and bi-specific or tri-specific antibody-based cancer therapies. Currently, a substantial number of antibody-based drugs are approved for commercial sale for cancer therapy, and a large number of additional ones are under development. Many other third parties compete with us in developing alternative therapies to treat cancer, including: biopharmaceutical companies; biotechnology companies; pharmaceutical companies; academic institutions; and other research organizations, as well as some medical device companies.

5

We face extensive competition from companies developing new treatments for brain cancer. These include a variety of immune therapies, as mentioned above, as well as a variety of small molecule drugs and biologics. There are also a number of existing drugs used for the treatment of brain cancer that may compete with our product, including, Avastin® (Roche Holding AG), Gliadel® (Eisai Co. Ltd.), and Temodar® (Merck & Co., Inc.), as well as the Optune electro-therapy device (Novocure) and oncolytic viruses. Both checkpoint inhibitor drugs and T cell-based therapies are pursuing clinical trials for solid tumors, including brain cancer, as well.

Most of our competitors have significantly greater financial resources and expertise in research and development, manufacturing, pre-clinical testing, conducting clinical trials, obtaining regulatory approvals and marketing and sales than we do. Smaller or early-stage companies may also prove to be significant competitors, particularly if they enter into collaborative arrangements with large and established companies. These third parties compete with us in recruiting and retaining qualified scientific and management personnel and collaborators, as well as in acquiring technologies complementary to our programs, and in obtaining sites for our clinical trials and enrolling patients.

Corporate Information

We were formed in 1996 and incorporated in Delaware in July 1998. Our principal executive offices are located in Bethesda, Maryland, and our telephone number is (240) 497-9024. Our website address is www.nwbio.com. The information on our website is not part of this report. We have included our website address as a factual reference and do not intend it to be an active link to our website.

Available Information

Our website address is www.nwbio.com. We make available, free of charge through our website, our annual report on Form 10-K, quarterly reports on Form 10-Q, current reports on Form 8-K and all amendments to those reports as soon as is reasonably practicable after such material is electronically filed with or furnished to the Securities and Exchange Commission (the “SEC”), but other information on our website is not incorporated into this report. The SEC maintains an Internet site that contains these reports at www.sec.gov.

Human Capital

The Company continues to operate with a lean staff, supplementing its full time employees with consultants with various expertise. The Company began the year with 17 full-time employees (FTEs) and ended the year on December 31, 2020 with 19 FTEs. With the acquisition of Flaskworks during FY2020, the Company gained additional experienced technical scientific management (1) and scientists (2). The Company's internal workforce is approximately gender equal. As in the past, the Company relied upon specialists in the areas of manufacturing, construction and construction management, clinical trial management, data validation and analysis, scientific advisory, legal, financial accounting and tax, and Information Technology. At the Company's international operations in the UK and Germany, the company relies on a contracted workforce. To attract and retain talent, the Company offers a competitive pay and benefits package.

ITEM 1A. RISK FACTORS

Our business, financial condition, operating results and prospects are subject to the following material risks. Additional risks and uncertainties not presently foreseeable to us may also impair our business operations. If any of the following risks actually occurs, our business, financial condition or operating results could be materially adversely affected. In such case, the trading price of our common stock could decline, and our stockholders may lose all or part of their investment in the shares of our common stock.

6

Risks Related to our Operations

We will need to raise substantial funds, on an ongoing basis, for general corporate purposes and operations, including our clinical trials. Such funding may not be available or may not be available on acceptable terms.

We will need substantial additional funding, on an ongoing basis, in order to continue execution of our clinical trials, to move our product candidates towards commercialization, to continue prosecution and maintenance of our large patent portfolio, to continue development and optimization of our manufacturing and distribution arrangements, and for other corporate purposes. Any financing, if available, may include restrictive covenants and provisions that could limit our ability to take certain actions, preference provisions for the investors, and/or discounts, warrants, anti-dilution rights, the provision of collateral, or other incentives. Any financing will involve issuance of equity and/or debt, and such issuances will be dilutive to existing shareholders. There can be no assurance that we will be able to complete any of the financings, or that the terms for such financings will be acceptable. If we are unable to obtain additional funds on a timely basis or on acceptable terms, we may be required to curtail or cease some or all of our operations at any time.

We are likely to continue to incur substantial losses, and may never achieve profitability.

As of December 31, 2020, we had net cash outflows (losses) from operations, since inception. We may never achieve or sustain profitability.

Our auditors have issued a “going concern” audit opinion.

Management has determined and our independent auditors have indicated in their report on our December 31, 2020 financial statements that there is substantial doubt about our ability to continue as a going concern. We have received such a “going concern” opinion each of the preceding years for more than a decade. A “going concern” opinion indicates that the financial statements have been prepared assuming we will continue as a going concern and do not include any adjustments to reflect the possible future effects on the recoverability and classification of assets, or the amounts and classification of liabilities that may result if we do not continue as a going concern. Therefore, you should not rely on our consolidated balance sheet as an indication of the amount of proceeds that would be available to satisfy claims of creditors, and potentially be available for distribution to stockholders, in the event of liquidation.

Our management and our independent auditors previously identified certain internal control deficiencies which, while now considered remediated, had been considered by our management and our independent auditor as material weaknesses.

In connection with the preparation of our financial statements for the year ended December 31, 2019, and prior years, our management and our independent auditor identified a certain internal control deficiency that, in the aggregate, represent material weaknesses, as described more fully in “Item 9A. Controls and Procedures” of Part I of this Form 10-K. Although we have undertaken and continue to undertake efforts to strengthen our internal controls and have remediated the material weaknesses, with no material weakness noted for the year ended December 31, 2020, maintaining a consistently strong control environment requires the ability to retain sufficient qualified personnel and other factors.

If we do not successfully maintain a strong controlled environment this could lead to heightened risk for financial reporting mistakes and irregularities, and/or lead to a loss of public confidence in our internal controls that could have a negative effect on the market price of our common stock. In addition, our ability to retain or attract qualified individuals to serve on our Board and to take on key management or other roles within our Company is uncertain.

As a company with a novel technology and unproven business strategy, an evaluation of our business and prospects is difficult.

We are still in the process of developing our product candidates through clinical trials. Our technology is novel and involves mobilizing the immune system to fight a patient’s cancer. Immune therapies have been pursued by many parties for decades, and have experienced many failures. In addition, our technology involves personalized treatment products, a new approach to medical products that involves new product economics and business strategies, which have not yet been shown to be commercially feasible or successful. We have not yet gone through scale-up of our operations to commercial scale. The novelty of our technology, product economics, and business strategy, and the limited scale of our operations to date, makes it difficult to assess our prospects for generating revenues commercially in the future.

7

We will need to expand our management and technical personnel as our operations progress, and we may not be able to recruit such additional personnel and/or retain existing personnel.

As of December 31, 2020, we had 18 full-time employees in the US, and one full-time employee in Europe. Of this group, only four employees are considered Management. Other personnel are retained on a consulting or contractor basis. Many biotech companies would typically have a larger number of employees by the time they reach late stage clinical trials. Such trials and other programs require extensive management capabilities, activities and skill sets, including scientific, medical, regulatory (for FDA and foreign regulatory counterparts), manufacturing, distribution and logistics, site management, reimbursement, business, financial, legal, public relations outreach to both the patient community and physician community, intellectual property, administrative, regulatory (SEC), investor relations and other.

In order to fully perform all these diverse functions, at many sites across the U.S. and in Europe, we may need to expand our management, technical and other personnel. However, with respect to management and technical personal, the pool of such personnel with expertise and experience with living cell products, such as our DCVax immune cell product, is very limited. In addition, we are a small company with limited resources, our business prospects are uncertain and our stock price is volatile. For some or all of such reasons, we may not be able to recruit all the management, technical and other personnel we need, and/or we may not be able to retain all of our existing personnel. In such event, we may have to continue our operations with a small team of personnel, and our business and financial results may suffer.

We rely at present on third-party contract manufacturers. As a result, we may be at risk for issues with manufacturing agreements, capacity limitations and/or supply disruptions, and/or issues with product equivalency.

We rely upon specialized contract manufacturers, operating in specialized GMP (clean room) manufacturing facilities, to produce all of our DCVax products. We have worked with several such manufacturers, in several different locations, during various periods of our clinical trials and our compassionate treatment programs, including Advent BioServices, Cognate BioServices and the Fraunhofer Institute.

We will need to enter into new contractual agreements for manufacturing at our Sawston, U.K. facility and new agreements for commercial production in any locations. We may encounter difficulties reaching such agreements, or the terms of such agreements may not be favorable. Following negotiations, if it is necessary or desirable to change our facility design and development arrangements or our manufacturing arrangements, that could involve increased facility costs and/or increased costs related to manufacturing of our products, and could result in delays in our programs or applications for various regulatory approvals. In addition, after such contracts are in place, the third party contractors may have capacity limitations and/or supply disruptions, and as a client we may not be able to prevent such limitations or disruptions, and not be able to control or mitigate the impact on our programs.

We have been in breach of the services agreements with our contract manufacturers on numerous occasions, primarily for untimely or non-payment. Our breaches of the services agreements may not be tolerated in the future as they have been in the past, and if we continue to breach the services agreements, for non-payment or otherwise, the contract manufacturers could cease providing services and/or terminate these agreements.

Our intention is for the U.K. facility to manufacture DCVax products for both the UK and other regions. However, this may not turn out to be feasible, for regulatory, operational and/or logistical reasons. It is also unclear whether or how Brexit will affect or interfere with these plans in regard to Europe.

8

Problems with the manufacturing facilities, processes or operations of our contract manufacturer(s) could result in a failure to produce, or a delay in producing adequate supplies of our DCVax product candidates. A number of factors could cause interruptions or delays, including the inability of a supplier to provide raw materials, equipment malfunctions or failures, damage to a facility due to natural disasters or otherwise, changes in FDA, U.K. or European regulatory requirements or standards that require modifications to our manufacturing processes, action by the FDA, U.K. or European regulators, or by us that results in the halting or slowdown of production of components or finished products due to regulatory issues, our manufacturers going out of business or failing to produce product as contractually required, insufficient technical personnel and/or specialized facilities to produce sufficient products, and/or other factors. A number of factors could also cause possible issues about the equivalency of DCVax product produced in different facilities or locations, which could make it necessary for us to perform additional studies and incur additional costs and delays. Because manufacturing processes for our DCVax product candidates are highly complex, require specialized facilities (dedicated exclusively to DCVax production) and personnel that are not widely available in the industry, involve equipment and training with long lead times, and are subject to lengthy regulatory approval processes, alternative qualified production capacity may not be available on a timely basis or at all. Also, as noted above, our contract manufacturer(s) could choose to terminate their agreements with us if we are in breach, or if we undergo a change of control. Difficulties, delays or interruptions in the manufacturing and supply and delivery of our DCVax product candidates could require us to stop enrolling new patients into clinical trials, and/or require us to stop the trials or other programs, stop the treatment of patients in the trials or other programs, increase our costs, damage our reputation and, if our product candidates are approved for sale, cause us to lose revenue or market share if our manufacturers are unable to timely meet market demands.

The manufacturing of our product candidates will have to be greatly scaled up for commercialization, and neither we nor our contract manufacturers have experience with such scale-up.

As is the case with any clinical trial, our Phase III clinical trial of DCVax-L for GBM involves a number of patients that is a small fraction of the number of potential patients for whom DCVax-L may be applicable in the commercial market. The same will be true of our other clinical programs with DCVax-L or other DCVax product candidates. If our DCVax-L and/or other DCVax product candidates are approved for commercial sale, it will be necessary to greatly scale up the volume of manufacturing, far above the level needed for clinical trials. Neither we nor our contract manufacturers have experience with such scale-up. In addition, there are likely only a few consultants or advisors in the industry who have such experience and can provide guidance or assistance, because active immune therapies such as DCVax are a fundamentally new category of product in two major ways: these active immune therapy products consist of living cells, not chemical or biologic compounds, and the products are personalized. To our knowledge, very few such products have successfully completed the necessary scale-up for commercialization. For example, Dendreon Corporation encountered substantial difficulties trying to scale up the manufacturing of its Provenge® product for commercialization. To our knowledge, even the CAR-T products which are being commercialized have so far only scaled up to moderate product volumes.

The necessary specialized facilities, equipment and personnel may not be available or obtainable for the scale-up of manufacturing of our product candidates.

The manufacture of living cells requires specialized facilities, equipment and personnel which are entirely different than what is required for the manufacturing of chemical or biologic compounds. Scaling up the manufacturing of living cell products to volume levels required for commercialization will require enormous amounts of these specialized facilities, equipment and personnel - especially where, as in the case of our DCVax product candidates, the product is personalized and must be made for each patient individually. Since living cell products are so new, and have barely begun to reach commercialization, the supply of the specialized facilities and personnel needed for them is not widely available and therefore is in the process of being developed. However, there has been a sharp increase in the demand for these specialized facilities and personnel, as large numbers of companies seek to develop T cell and other immune cell products. It may not be possible for us or our manufacturers to obtain all of the specialized facilities and personnel needed for commercialization of our DCVax product candidates, or even for further sizeable trials. This could delay or halt our commercialization and/or further substantial trials.

We are anticipating that the production systems developed by Flaskworks may play an important role in enabling scale-up of production and reducing the number of GMP (clean room) suites and personnel needed for scale-up.  However, the Flaskworks systems are still undergoing development and optimization, and have not been operated at commercial scale to date.  It could turn out that the Flaskworks systems are not capable of or suitable for substantial scale-up, or not acceptable to regulatory authorities for such scale-up.  It could also turn out that deployment the Flaskworks system does not reduce the number of GMP suites and personnel needed for DCVax production as anticipated.

9

Our technology is novel, involves complex immune system elements, and may not prove to be effective.

Data already obtained, or in the future obtained, from pre-clinical studies and clinical trials do not necessarily predict the results that will be obtained from later pre-clinical studies and clinical trials. Over the course of several decades, there have been many different immune therapy product designs - and many product failures and company failures. To our knowledge, to date, only a couple of active immune therapies have been approved by the FDA, including one dendritic cell therapy and a couple of CAR-T cell therapies. The human immune system is complex, with many diverse elements, and the state of scientific understanding of the immune system is still limited. Some immune therapies previously developed by other parties showed surprising and unexpected toxicity in clinical trials. Other immune therapies developed by other parties delivered promising results in early clinical trials, but failed in later stage clinical trials.

Although we believe the results from the small early stage clinical trials of DCVax-L for newly diagnosed GBM were quite positive, those results may not be achieved in our later stage clinical trials, such as the 331-patient Phase III trial for GBM that is nearing completion, and our product candidates may not ultimately be found to be effective. Similarly, although we believe the interim blinded data from the Phase III trial that we have collected and reported to date are encouraging, the results of this trial when the data are unblinded may not be as encouraging or may not be positive at all. Further, although the safety profile of our DCVax-L product was excellent in the early stage clinical trials, toxicity may be seen as we treat larger numbers of patients in late stage clinical trials. If such toxicity occurs, it could limit, delay or stop further clinical development or commercialization of our DCVax-L product.

We have only conducted the Phase I portion of our first-in-man Phase I/II clinical trial with our DCVax Direct product, after prior early stage trials with DCVax-L and DCVax-Prostate. Although the early results have not indicated any significant toxicity, we do not yet know what efficacy or toxicity DCVax-Direct may show in a larger sample of human patients. This product may not ultimately be found to be effective, and/or it may be found to be toxic, which could limit, delay or stop clinical development or commercialization of DCVax-Direct.

Clinical trials for our product candidates are expensive and time consuming, and their outcome is uncertain.

The process of obtaining and maintaining regulatory approvals for new therapeutic products is expensive, lengthy and uncertain. Costs and timing of clinical trials may vary significantly over the life of a project owing to any or all of the following non-exclusive reasons:

the duration of the clinical trial;
the number of sites included in the trials;
the countries in which the trial is conducted;
the length of time required and ability to enroll eligible patients;
the number of patients that participate in the trials;
the number of doses that patients receive;
the drop-out or discontinuation rates of patients;
per patient trial costs;
third party contractors failing to comply with regulatory requirements or meet their contractual obligations to us in a timely manner;
our final product candidates having different properties in humans than in laboratory testing;
the need to suspend or terminate our clinical trials;

10

insufficient or inadequate supply or quality of necessary materials to conduct our trials;
potential additional safety monitoring, or other conditions required by the FDA or comparable foreign regulatory authorities regarding the scope or design of our clinical trials, or other studies requested by regulatory agencies;
problems engaging independent review Boards, or IRBs, to oversee trials or in obtaining and maintaining IRB approval of studies;
the duration of patient follow-up;
the efficacy and safety profile of a product candidate;
the costs and timing of obtaining regulatory approvals; and
the costs involved in enforcing or defending patent claims or other intellectual property rights.

Late stage clinical trials, such as our Phase III clinical trial for GBM patients, are especially expensive, typically requiring tens or hundreds of millions of dollars, and take years to reach their outcomes. Such outcomes often fail to reproduce the results of earlier trials. It is often necessary to conduct multiple late stage trials (including multiple Phase III trials) in order to obtain sufficient results to support product approval, which further increases the expense and time involved. Sometimes trials are further complicated by changes in requirements while the trials are under way (for example, when the standard of care changes for the disease that is being studied in the trial, or when there are changes in the scientific understanding of the disease or the treatment, and/or changes in the competitive landscape.) For example, while the Company’s lead program, the Phase III clinical trial of DCVax-L for brain cancer, has been under way, there has been a very large proliferation of new treatments in various stages of development, as well as some new product approvals, for brain cancer. Any of our current or future product candidates could take a significantly longer time to gain regulatory approval than we expect, or may never gain approval, either of which could delay or stop the commercialization of our DCVax product candidates.

We have limited experience in conducting and managing clinical trials, or collecting, confirming and analyzing trial data, and we rely on third parties to conduct these activities.

We rely on third parties to assist us, on a contract services basis, in managing and monitoring all of our clinical trials as well as the collection, confirmation and analysis of the trial data. We do not have experience conducting late stage clinical trials, or collecting, validating and analyzing trial data by ourselves without third party service firms, nor do we have experience in supervising such third parties in managing late stage, multi-hundred patient clinical trials, and collecting, validating and analyzing the data, other than our current Phase III trial for GBM. Our lack of experience and/or our reliance on these third-party service firms may result in delays or failure to complete these trials and/or the data collection, validation and analyses successfully or on time. If the third parties fail to perform, we may not be able to find sufficient alternative suppliers of those services in a reasonable time period, or on commercially reasonable terms, if at all.

We may fail to comply with regulatory requirements.

Our success will be dependent upon our ability, and our collaborative partners’ abilities, to maintain compliance with regulatory requirements in multiple countries, including current good manufacturing practices, or cGMP, and safety reporting obligations. The failure to comply with applicable regulatory requirements can result in, among other things, fines, injunctions, civil penalties, total or partial suspension of regulatory approvals, refusal to approve pending applications, recalls or seizures of products, operating and production restrictions and criminal prosecutions.

11

Regulatory approval of our product candidates may be withdrawn at any time.

After any regulatory approval has been obtained for medicinal products (including any early or conditional approval), the product and the manufacturer are subject to continual review, including the review of adverse experiences and clinical results that are reported after our products are made available to patients, and there can be no assurance that such approval will not be withdrawn or restricted. Regulators may also subject approvals to restrictions or conditions, or impose post-approval obligations on the holders of these approvals, and the regulatory status of such products may be jeopardized if such obligations are not fulfilled. If post-approval studies are required, such studies may involve significant time and expense.

The manufacturer and manufacturing facilities we use to make any of our products will also be subject to periodic review and inspection by the FDA, MHRA, EMA or other regulator, as applicable. The discovery of any new or previously unknown problems with the product, manufacturer or facility may result in restrictions on the product or manufacturer or facility, including withdrawal of the product from the market. We will continue to be subject to the FDA, the U.K. Medicines and Healthcare Products Regulatory Agency, or MHRA, the European Medicines Agency, or EMA, and other regulatory requirements, as applicable, governing the labeling, packaging, storage, advertising, promotion, recordkeeping, and submission of safety and other post-market information for all of our product candidates, even those that the FDA, MHRA, EMA, or other regulator, as applicable, had approved. If we fail to comply with applicable continuing regulatory requirements, we may be subject to fines, restriction, suspension or withdrawal of regulatory approval, product recalls and seizures, operating restrictions and other adverse consequences.

Our Operations under early access programs may not be successful.

There is not much accumulated or available experience, information or precedents in regard to early access programs, especially for new types of treatments such as immune therapies. Establishing operations under an early access program will require us to establish and implement new operational, contractual, financial and other arrangements with physicians, hospitals, patients and others. We may not be successful in establishing and implementing such arrangements, and/or such arrangements may not be financially satisfactory or viable.

We may not be successful in negotiating reimbursement.

If our DCVax-L product obtains regulatory approval for commercialization, such commercialization will be difficult and may not be feasible unless we obtain coverage by health insurance and/or national health systems for reimbursement of our product price. Obtaining such coverage by health insurance and/or national health systems will be difficult and we do not have experience with such processes. Our DCVax-L product is a fully personalized, individual product and, as such, is expected to be expensive. In addition, our DCVax-L product involves a cost structure (with much of the costs upfront, in connection with the manufacturing of the personalized DCVax-L product for a patient) that is different than traditional drugs and may require different reimbursement arrangements. These factors may make our negotiations for reimbursement more difficult. We may not be successful in negotiating or obtaining reimbursement, or obtaining it on acceptable or viable terms.

Our product candidates will require a different distribution model than conventional therapeutic products, and this may impede commercialization of our product candidates.

Our DCVax product candidates consist of living human immune cells. Such products are entirely different from chemical or biologic drugs, and require different handling, distribution and delivery than chemical or biologic drugs. One crucial difference is that the biomaterial ingredients (immune cells and tumor tissue) from which we make DCVax products and the finished DCVax products themselves are subject to time constraints in the shipping and handling. The biomaterial ingredients come from the medical centers to the manufacturing facility fresh and not frozen, and must arrive within a certain window of time and in usable condition. Performance failures by the medical center or the courier company can result in biomaterials that are not usable, in which case it may not be possible to make DCVax product for the patient involved. The finished DCVax products are frozen, and must remain frozen throughout the process of distribution and delivery to the medical center or physician’s office, until the time of administration to the patient, and cannot be handled at room temperature until then or their viability will be lost. In addition, our DCVax product candidates are personalized and they involve ongoing treatment cycles over several years for each patient. Each product shipment for each patient must be tracked and managed individually. For all of these reasons, among others, we will not be able to simply use the distribution networks and processes that already exist for conventional drugs. It may take time for shipping companies, hospitals, pharmacies and physicians to adapt to the requirements for handling, distribution and delivery of these products, which may adversely affect our commercialization.

12

Our product candidates will require different marketing and sales methods and personnel than conventional therapeutic products. Also, we lack sales and marketing experience. These factors may result in significant difficulties in commercializing our product candidates.

The commercial success of any of our product candidates will depend upon the strength of our sales and marketing efforts. We do not have a marketing or sales force and have no experience in marketing or sales of products like our lead product, DCVax-L for GBM, or our additional product, DCVax-Direct. To fully commercialize our product candidates, we will need to recruit and train marketing staff and a sales force with technical expertise and ability to manage the distribution of our DCVax-L for GBM. As an alternative, we could seek assistance from a corporate partner or a third-party services firm with a large distribution system and a large direct sales force. However, since our DCVax products are living cell, immune therapy products, and these are a fundamentally new and different type of product than are on the market today, we would still have to train such partner’s or such services firm’s personnel about our products, and would have to make changes in their distribution processes and systems to handle our products. We may be unable to recruit and train effective sales and marketing forces or our own, or of a partner or a services firm, and/or doing so may be more costly and difficult than anticipated. Such factors may result in significant difficulties in commercializing our product candidates, and we may be unable to generate significant revenues.

The availability and amount of potential reimbursement for our product candidates by government and private payers is uncertain and may be delayed and/or inadequate.

The availability and extent of reimbursement by governmental and/or private payers is essential for most patients to be able to afford expensive treatments, such as cancer treatments. In the United States, the principal decisions about reimbursement for new medicines are typically made by the Centers for Medicare & Medicaid Services, or CMS, an agency within the U.S. Department of Health and Human Services, as CMS decides whether and to what extent a new medicine will be covered and reimbursed under Medicare. Private payers tend to follow CMS to a substantial degree. It is difficult to predict what CMS will decide with respect to reimbursement for fundamentally novel products such as ours, as there have been very few products similar to ours to date., We are aware of only a couple of active immune therapies that have reached the stage of reimbursement decision making processes, including one dendritic cell therapy and a couple of CAR-T cell therapies. Although CMS has approved coverage and reimbursement for a couple of these products, and private payers seem to be following suit in the US, there remain substantial questions and concerns about reimbursement for these products, especially outside the US.

Reimbursement agencies in Europe can be even more conservative than CMS in the U.S. A number of cancer drugs which have been approved for reimbursement in the U.S. have not been approved for reimbursement in certain European countries, and/or the level of reimbursement approved in Europe is lower than in the U.S. Reportedly, in Europe reimbursement for certain immune therapies was initially declined, and reportedly involved difficult negotiations. The same could happen with respect to our DCVax products.

Various factors could increase the difficulties for our DCVax products to obtain reimbursement. Costs and/or difficulties associated with the reimbursement of Provenge and/or T cell therapies could create an adverse environment for reimbursement of other immune therapies, such as our DCVax products. Approval of other competing products (drugs and/or devices) for the same disease indications could make the need for our products and the cost-benefit balance seem less compelling. The cost structure of our product is not a typical cost structure for medical products, as the majority of our costs are incurred up front, when the manufacturing of the personalized product is done. Our atypical cost structure may not be accommodated in any reimbursement for our products. If we are unable to obtain adequate levels of reimbursement, our ability to successfully market and sell our product candidates will be adversely affected.

The manner and level at which reimbursement is provided for services related to our product candidates (e.g., for administration of our product to patients) are also important. If the reimbursement for such services is inadequate, that may lead to physician resistance and adversely affect our ability to market or sell our products.

The methodology under which CMS makes coverage and reimbursement determinations is subject to change, particularly because of budgetary pressures facing the Medicare program. For example, the Medicare Prescription Drug, Improvement, and Modernization Act, or Medicare Modernization Act, enacted in 2003, provided for a change in reimbursement methodology that has reduced the Medicare reimbursement rates for many drugs, including oncology therapeutics. The Affordable Care Act may also result in changes in reimbursement arrangements that adversely affect the prospects for reimbursement of our products.

13

In markets outside the U.S., the prices of medical products are subject to direct price controls and/or to reimbursement with varying price control mechanisms, as part of national health systems. In general, the prices of medicines under such systems are substantially lower than in the U.S. Some jurisdictions operate positive and/or negative list systems under which products may only be marketed once a reimbursement price has been agreed. Other countries allow companies to fix their own prices for medicines, but monitor and control company profits. The downward pressure on health care costs in general, particularly prescription drugs, has become very intense. As a result, increasingly high barriers are being erected to the entry of new products. Accordingly, in markets outside the U.S., the reimbursement for our products may be reduced compared with the U.S. and may be insufficient to generate commercially reasonable revenues and profits.

Competition in the biotechnology and biopharmaceutical industry is intense, rapidly expanding and most of our competitors have substantially greater resources than we do.

The biotechnology and biopharmaceutical industries are characterized by rapidly advancing technologies, intense competition and a strong emphasis on proprietary products. A growing number of other companies, such as Juno, Kite Bellicum, Agenus, Asterias, Dandrit, Immunicum, Sotio, AiVita and many others, are actively involved in the research and development of immune therapies or cell-based therapies for cancer. In addition, other novel technologies for cancer are under development or commercialization, such as checkpoint inhibitor drugs (which are being rapidly developed by numerous big pharma companies including BMS, Merck, Pfizer, Astra Zeneca, Roche and others) and various T cell-based therapies (which are also being rapidly developed by numerous companies with extraordinary resource backing), as well as the electro-therapy device of NovoCure. Additionally, many companies are actively involved in the research and development of monoclonal antibody-based cancer therapies. Currently, a substantial number of antibody-based products are approved for commercial sale for cancer therapy, and a large number of additional ones are under development, including late stage trials. Many other third parties compete with us in developing alternative therapies to treat cancer, including: biopharmaceutical companies; biotechnology companies; pharmaceutical companies; academic institutions; and other research organizations, as well as some medical device companies (e.g., NovoCure and MagForce Nano Technologies AG).

We face extensive competition from companies developing new treatments for brain cancer. These include a variety of immune therapies, as mentioned above (including T cell-based therapies and checkpoint inhibitor drugs), as well as a variety of small molecule drugs and biologics drugs. There are also a number of existing drugs used for the treatment of brain cancer that may compete with our product, including, Avastin® (Roche Holding AG), Gliadel® (Eisai Co. Ltd.), and Temodar® (Merck& Co., Inc.), as well as NovoCure’s electrotherapy device.

Most of our competitors have significantly greater financial resources and expertise in research and development, manufacturing, pre-clinical testing, conducting clinical trials, obtaining regulatory approvals and marketing and sales than we do. Smaller or early-stage companies may also prove to be significant competitors, particularly if they enter into collaborative arrangements with large and established companies.

These third parties compete with us in recruiting and retaining qualified scientific and management personnel and collaborators, as well as in acquiring technologies complementary to our programs, and in obtaining sites for our clinical trials and enrolling patients.

Our competitors may complete their clinical development more rapidly than we and our products do, may develop more effective or affordable products, or may achieve earlier or longer patent protection or earlier product marketing and sales. Any products developed by us may be rendered obsolete and non-competitive.

Competing generic medicinal products may be approved.

In the E.U., there exists a process for approval of generic biological medicinal products once patent protection and other forms of data and market exclusivity have expired. Arrangements for approval of generic biologics products exist in the U.S. as well, and the FDA has begun approving bio-similar products. Jurisdictions may approve generic biologic medicinal products as well. If generic biologic medicinal products are approved, competition from such products may substantially reduce sales of our products.

14

We may be exposed to potential product liability claims, and our existing insurance may not cover these claims, in whole or in part. In addition, insurance against such claims may not be available to us on reasonable terms in the future, if at all.

Our business exposes us to potential product liability risks that are inherent in the testing, manufacturing, marketing, sale and use of therapeutic products. We have insurance coverage but this insurance may not cover any claims made. In the future, insurance coverage may not be available to us on commercially reasonable terms (including acceptable cost), if at all. Insurance that we obtain may not be adequate to cover claims against us. Regardless of whether they have any merit or not, and regardless of their eventual outcome, product liability claims may result in substantially decreased demand for our product candidates, injury to our reputation, withdrawal of clinical trial participants or physicians, and/or loss of revenues. Thus, whether or not we are insured, a product liability claim or product recall may result in losses that could be material.

We may be subject to environmental regulatory requirements, and could fail to meet such requirements, and we do not carry insurance against environmental damage or injury claims.

We may need to store, handle, use and dispose of controlled hazardous, radioactive and biological materials in our business. Our development activities may result in our becoming subject to regulatory requirements, and if we fail to comply with applicable requirements, we could be subject to substantial fines and other sanctions, delays in research and production, and increased operating costs. In addition, if regulated materials were improperly released at our current or former facilities or at locations to which we send materials for disposal, we could be liable for substantial damages and costs, including cleanup costs and personal injury or property damages, and we could incur delays in research and production and increased operating costs.

Insurance covering certain types of claims of environmental damage or injury resulting from the use of these materials is available but can be expensive and is limited in its coverage. We have no insurance specifically covering environmental risks or personal injury from the use of these materials and if such use results in liability, our business may be seriously harmed.

Collaborations play an important role in our business, and could be vulnerable to competition or termination.

We work with scientists and medical professionals at a variety of academic and other institutions, some of whom have conducted research for us or have assisted in developing our research and development strategy. These scientists and medical professionals are collaborators, not our employees. They may have commitments to, or contracts with, other institutions or businesses (including competitors) that limit the amount of time they have available to work with us. We have little control over these individuals. We can only expect that they devote time to us and our programs as required by any license, consulting or sponsored research agreements we may have with them. In addition, these individuals may have arrangements with other companies to assist in developing technologies that may compete with our products. If these individuals do not devote sufficient time and resources to our programs, or if they provide substantial assistance to our competitors, our business could be seriously harmed.

The success of our business strategy may partially depend upon our ability to develop and maintain our collaborations and to manage them effectively. Due to concerns regarding our ability to continue our operations or the commercial feasibility of our personalized DCVax product candidates, these third parties may decide not to conduct business with us or may conduct business with us on terms that are less favorable than those customarily extended by them. If either of these events occurs, our business could suffer significantly.

We may have disputes with our collaborators, which could be costly and time consuming. Failure to successfully defend our rights could seriously harm our business, financial condition and operating results. We intend to continue to enter into collaborations in the future. However, we may be unable to successfully negotiate any additional collaboration and any of these relationships, if established, may not be scientifically or commercially successful.

Our business could be adversely affected by new legislation and/or product related issues.

Changes in applicable legislation and/or regulatory policies or discovery of problems with the product, production process, site or manufacturer may result in delays in bringing products to market, the imposition of restrictions on the product’s sale or manufacture, including the possible withdrawal of the product from the market, or may otherwise have an adverse effect on our business.

15

Our business could be adversely affected by animal rights activists.

Our business activities have involved animal testing and could involve further such testing, as such testing is required before new medical products can be tested in clinical trials in human patients. Animal testing has been the subject of controversy and adverse publicity. Some organizations and individuals have attempted to stop animal testing by pressing for legislation and regulation in these areas. To the extent that the activities of such groups are successful, our business could be adversely affected. Negative publicity about us, our pre-clinical trials and our product candidates could also adversely affect our business.

Multiple late stage clinical trials of DCVax-L for GBM, our lead product, may be required before we can obtain regulatory approval.

Typically, companies conduct multiple late stage clinical trials of their product candidates before seeking product approval. Our current Phase III 331-patient clinical trial of DCVax-L for GBM is our first late stage trial. We may be required to conduct additional late stage trials with DCVax-L for GBM before we can obtain product approval. This would substantially delay our commercialization, and might not be possible to carry out, due to development and/or approval of competing products, lack of funding, and/or other factors. In addition, our Phase III trial of DCVax-L was placed on a partial clinical hold for new screening for enrollment in 2015. Although the FDA lifted its hold in February 2017 as previously reported by the Company, the Company had already closed enrollment with 331 of the planned 348 patients. Since we did not enroll the last 17 of the planned 348 patients, this could adversely affect the statistical and other analyses of our Phase III trial results, and could make it more difficult to seek product approval or more likely that further trials could be required. In addition, a rapidly growing number of products are under development for brain cancer, including immunotherapies such as checkpoint inhibitor drugs and T cell-based therapies, and some (e.g., NovoCure’s device) have been approved in the U.S. It is possible that the standard of care for brain cancer could change before we complete our Phase III trial and analysis of its results, or before we are able to seek approval for commercialization. This could necessitate further clinical trials with our DCVax-L product candidate for brain cancer, which may not be feasible.

Changes in manufacturing methods for DCVax-L could require us to conduct equivalency studies and/or additional clinical trials.

With biologics products, in some cases “the process is the product”: i.e., the manufacturing process is considered to be as integral to the product as is the composition of the product itself. If any changes are made in the manufacturing process, and such changes are considered material by the regulatory authorities, the company sponsor may be required to conduct equivalency studies to show that the product is equivalent under the changed manufacturing processes as under the original manufacturing processes, and/or the company sponsor may be required to conduct additional clinical trials. In addition, if there are multiple manufacturing locations, equivalency studies may be required to show that the products produced in the respective facilities are substantially the same. Our manufacturing processes have undergone some changes during or since the early clinical trials, and we have multiple manufacturing locations. Accordingly, we may be required to conduct equivalency studies, and/or additional clinical trials, before we can obtain product approval, unless the regulatory authorities are satisfied that the changes in processes do not affect the quality, efficacy or safety of the product, and satisfied that the products made in each manufacturing location are substantially the same.

We may not receive regulatory approvals for our product candidates or there may be a delay in obtaining such approvals.

Our products and our ongoing development activities are subject to regulation by regulatory authorities in the countries in which we and our collaborators and distributors wish to test, manufacture or market our products. For instance, the FDA will regulate our product in the U.S. and equivalent authorities, such as the MHRA and EMA will regulate in Europe and other jurisdictions. Regulatory approval by these authorities will be subject to the evaluation of data relating to the quality, efficacy and safety of the product for its proposed use, and there can be no assurance that the regulatory authorities will find our data sufficient to support product approval of DCVax-L or DCVax-Direct. In addition, the endpoint against which the data is measured must be acceptable to the regulatory authorities, and the statistical analysis plan for how the data will be evaluated must also be acceptable to the regulatory authorities. The statistical analysis plan that we submitted to regulators for the Phase III trial embodies a different primary endpoint and secondary endpoint than did the original Protocol for the trial. Under the Protocol the primary endpoint was progression free survival, or PFS, and the secondary endpoint was overall survival, or OS. Both of these endpoints were confounded: the PFS endpoint by pseudo-progression, and the OS endpoint by the “crossover” provision in the trial design, which allowed all of the patients in the trial to cross over to DCVax-L treatment after tumor recurrence (while remaining blinded as to which treatment they received before tumor recurrence).  The statistical analysis plan uses external control patients rather than within-study controls. There can be no assurance that regulatory authorities will allow a product approval to be based upon this approach.

16

The time period required to obtain regulatory approval varies between countries. In the U.S., for products without “Fast Track” status, it can take up to 18 months after submission of an application for product approval to receive the FDA’s decision. Even with Fast Track status, FDA review and decision can take up to 12 months. At present, we do not have Fast Track status for our lead product, DCVax-L for GBM. We plan to apply for Fast Track status, but there can be no assurance that FDA will grant us such status for DCVax-L.

Different regulators may impose their own requirements and may refuse to grant, or may require additional data before granting, an approval, notwithstanding that regulatory approval may have been granted by other regulators. Regulatory approval may be delayed, limited or denied for a number of reasons, including clinical data, the product not meeting safety or efficacy requirements or any relevant manufacturing processes or facilities not meeting applicable requirements as well as case load at the regulatory agency at the time.

We may not obtain or maintain the benefits associated with orphan drug status, including market exclusivity.

Although our lead product, DCVax-L for GBM, has been granted orphan drug status in both the U.S. and the E.U., we may not receive the benefits associated with orphan drug designation (including the benefit providing for market exclusivity for a number of years). This may result from a failure to maintain orphan drug status, or result from a competing product reaching the market that has an orphan designation for the same disease indication. Under U.S. and E.U. rules for orphan drugs, if such a competing product reaches the market before ours does, the competing product could potentially obtain a scope of market exclusivity that limits or precludes our product from being sold in the U.S. for seven years or from being sold in the E.U. for ten years. Also, in the E.U., even after orphan status has been granted, that status is re-examined shortly prior to the product receiving any regulatory approval. The EMA must be satisfied that there is evidence that the product offers a significant benefit relative to existing therapies, in order for the therapeutic product to maintain its orphan drug status. Accordingly, our product candidates will have to re-qualify for orphan drug status prior to any potential product approval in the E.U., and may have to do so elsewhere as well.

Our intellectual property rights may be overturned, narrowed or blocked, and may not provide sufficient commercial protection for our product candidates, or third parties may infringe upon our intellectual property.

The patent position of biotechnology and pharmaceutical companies generally is highly uncertain, involves complex legal and factual questions and has in recent years been the subject of much litigation. As a result, the issuance, scope, validity, enforceability and commercial value of our patent rights are highly uncertain. Patent laws afford only limited protection and may not protect our rights to the extent necessary to sustain any competitive advantage we may have. In addition, the laws of some foreign countries do not protect proprietary rights to the same extent as the laws of the United States, and we may encounter significant problems in protecting our proprietary rights in those countries. Moreover, patents and patent applications relating to living cell products are relatively new, involve complex factual and legal issues, and are largely untested in litigation - and as a result, are uncertain. Our pending and future patent applications may not result in patents being issued which adequately protect our technology or products or which effectively prevent others from commercializing the same or competitive technologies and products. As a result, we may not be able to obtain meaningful patent protection for our commercial products, and our business may suffer as a result. Third parties may challenge our existing patents, and such challenges could result in overturning or narrowing some of our patents. Even if our patents are not challenged, third parties could assert that their patents block our use of technology covered by some or all of our patents

As of December 31, 2020, we had over 204 issued patents and 86 pending patent applications worldwide relating to our product candidates and related matters such as manufacturing processes. The issued patents expire at various dates from 2022 to 2026. Our issued patents may be challenged, and such challenges may result in reductions in scope, cancellations or invalidations. Our pending patent applications may not result in issued patents. Moreover, our patents and patent applications may not be sufficiently broad to prevent others from using substantially similar technologies or from developing competing products. We also face the risk that others may independently develop similar or alternative technologies, or design around our patented technologies. As a result, no assurance can be given that any of our pending or future patent applications will be granted, that the scope of any patent protection currently granted or that may be granted in the future will exclude competitors or provide us with competitive advantages, that any of the patents that have been or may be issued to us will be held valid if subsequently challenged, or that other parties will not claim rights to or ownership of our patents or other proprietary rights that we hold.

We have taken security measures (including execution of confidentiality agreements) to protect our proprietary information, especially proprietary information that is not covered by patents or patent applications. These measures, however, may not provide adequate protection for our trade secrets or other proprietary information. In addition, others may independently develop substantially equivalent proprietary information or techniques or otherwise gain access to our trade secrets.

17

We may be exposed to claims or lawsuits that our products infringe patents or other proprietary rights of other parties.

Our commercial success depends upon our ability and the ability of our collaborators to develop, manufacture, market and sell our product candidates and use our proprietary technologies without infringing the proprietary rights of third parties. We have not conducted a comprehensive freedom-to-operate review to determine whether our proposed business activities or use of certain of the technology covered by patent rights owned by us would infringe patents issued to third parties.

There is a substantial amount of litigation involving patent and other intellectual property rights in the biotechnology and biopharmaceutical industries generally. The patent landscape is especially uncertain in regard to cell therapy products, as it involves complex legal and factual questions for which important legal principles remain unresolved. We may become party to, or be threatened with, future adversarial proceedings or litigation regarding intellectual property rights with respect to our products and technology, including interference proceedings, Inter Partes Reexamination, or Post Grant Review before the U.S. Patent and Trademark Office. Third parties may assert infringement claims against us based on existing patents or patents that may be granted in the future. If we are found to infringe a third party’s intellectual property rights, we could be required to obtain a license from such third party to continue developing and marketing our products and technology. However, we may not be able to obtain any required license on commercially reasonable terms or at all. Even if we were able to obtain a license, it could be non-exclusive, thereby giving our competitors access to the same technologies licensed to us. We could be forced, including by court order, to cease commercializing the infringing technology or product. In addition, we could be found liable for monetary damages. If the infringement is found to be willful, we could be liable for treble damages. A finding of infringement could prevent us from commercializing our product candidates or force us to cease some of our business operations, which could materially harm our business. Claims that we have misappropriated the confidential information or trade secrets of third parties could have a similar negative impact on our business.

We have already been exposed to one patent lawsuit by a large company, which we vigorously defended. Our defense resulted in the plaintiff withdrawing nearly all of the claims it filed, and in settlement of the last claims without our paying the plaintiff anything. However, the litigation was expensive and time consuming. In the past, we have also been exposed to claims (without a lawsuit) by a competitor asserting or implying (and commentaries by third parties based on the claims by our competitor) that a patent issued to our competitor covers our products. We obtained and publicly reported legal advice that those claims were without merit. However, in the future, we could again be exposed to claims by third parties - with or without merit - that our products infringe their intellectual property rights.

Even if resolved in our favor, litigation or other legal proceedings relating to intellectual property claims may cause us to incur significant expenses, and could distract our technical and management personnel from their normal responsibilities. In addition, there could be public announcements of the results of hearings, motions or other interim proceedings or developments and if securities analysts or investors perceive these results to be negative, it could have a substantial adverse effect on the price of our common stock. Such litigation or proceedings could substantially increase our operating losses and reduce the resources available for development activities or any future sales, marketing or distribution activities. We may not have sufficient financial or other resources to adequately conduct such litigation or proceedings. Some of our competitors may be able to sustain the costs of such litigation or proceedings more effectively than we can because of their greater financial resources. Uncertainties resulting from the initiation and continuation of patent litigation or other proceedings could have a material adverse effect on our ability to compete in the marketplace.

DCVax is our only technology in clinical development.

Unlike many pharmaceutical companies that have a number of products in development and which utilize many different technologies, we are dependent on the success of our DCVax platform technology. While the DCVax technology has a wide scope of potential use, and is embodied in several different product lines for different clinical situations, if the core DCVax technology is not effective or is toxic or is not commercially viable, our business could fail. We do not currently have other technologies that could provide alternative support for us.

18

Risks Related to our Common Stock

The market price of our common stock is volatile and can be adversely affected by several factors.

The share prices of publicly traded biotechnology and emerging pharmaceutical companies, particularly companies without consistent product revenues and earnings, can be highly volatile and are likely to remain highly volatile in the future. The price which investors may realize in sales of their shares of our common stock may be materially different than the price at which our common stock is quoted, and will be influenced by a large number of factors, some specific to us and our operations, and some unrelated to our operations. Such factors may cause the price of our stock to fluctuate frequently and substantially. Such factors may include large purchases or sales of our common stock, shorting of our stock, positive or negative events, commentaries or publicity relating to our company, management or products, or other companies, management or products, including other immune therapies for cancer or immune therapies or cancer therapies generally, positive or negative events relating to healthcare and the overall pharmaceutical and biotech sector, the publication of research by securities analysts and changes in recommendations of securities analysts, legislative or regulatory changes, and/or general economic conditions. In the past, shareholder litigation, including class action litigation, has been brought against other companies that experienced volatility in the market price of their shares and/or unexpected or adverse developments in their business. Whether or not meritorious, litigation brought against a company following such developments can result in substantial costs, divert management’s attention and resources, and harm the company’s financial condition and results of operations.

Our Common Stock is considered a “penny stock” and may be difficult to sell.

The Commission has adopted regulations which generally define “penny stock” to be an equity security that has a market price of less than $5.00 per share or an exercise price of less than $5.00 per share, subject to specific exemptions. Historically, the price of our Common Stock has fluctuated greatly. As of the date of this filing, the market price of our common stock is less than $5.00 per share, and therefore is a “penny stock” according to Commission rules. The “penny stock” rules impose additional sales practice requirements on broker-dealers who sell securities to persons other than established customers and accredited investors (generally those with assets in excess of $1,000,000 or annual income exceeding $200,000 or $300,000 together with their spouse). For transactions covered by these rules, the broker-dealer must make a special suitability determination for the purchase of securities and have received the purchaser’s written consent to the transaction before the purchase. Additionally, for any transaction involving a penny stock, unless exempt, the broker-dealer must deliver, before the transaction, a disclosure schedule prescribed by the Commission relating to the penny stock market. The broker-dealer also must disclose the commissions payable to both the broker-dealer and the registered representative and current quotations for the securities. Finally, monthly statements must be sent disclosing recent price information on the limited market in penny stocks. These additional burdens imposed on broker-dealers may restrict the ability or decrease the willingness of broker-dealers to sell our common stock, and may result in decreased liquidity for our common stock and increased transaction costs for sales and purchases of our common stock as compared to other securities.

The requirements of the Sarbanes-Oxley Act of 2002 and other U.S. securities laws impose substantial costs, and may drain our resources and distract our management.

We are subject to certain of the requirements of the Sarbanes-Oxley Act of 2002, as well as the reporting requirements under the Exchange Act. The Sarbanes-Oxley Act requires, among other things, that we maintain effective disclosure controls and procedures and internal controls over financial reporting. We have tested and concluded that we have remediated the identified material weaknesses in our internal controls that were reported over the years. The substantial efforts and resources the Company has invested achieved remediation of the previously identified weaknesses. However, requirements continue to become more stringent, requiring even more time and resources to be invested to maintain a controlled environment, which is difficult for a small company like ours. Continued additional investments and management time to meet these requirements will be necessary since control weaknesses raise the risk of future material errors in the company’s financial statements. We may not be able to maintain effective controls over time. If we have material weaknesses in the future, this may subject us to SEC enforcement action, which could include monetary fines or other equitable remedies that could be detrimental to the ongoing business of the Company.

19

We do not intend to pay any cash dividends in the foreseeable future and, therefore, any return on your investment in our common stock must come from increases in the market price of our common stock.

We have not paid any cash dividends on our common stock to date in our history, and we do not intend to pay cash dividends on our common stock in the foreseeable future. We intend to retain future earnings, if any, for reinvestment in the development and expansion of our business. Also, any credit agreements which we may enter into with institutional lenders may restrict our ability to pay dividends. Therefore, any return on your investment in our capital stock must come from increases in the fair market value and trading price of our common stock. Such increases in the trading price of our stock may not occur.

Our certificate of incorporation and bylaws and Delaware law, have provisions that could discourage, delay or prevent a change in control.

Our certificate of incorporation and bylaws and Delaware law contain provisions which could make it more difficult for a third party to acquire us, even if closing such a transaction would be beneficial to our stockholders. We are authorized to issue up to 100,000,000 shares of preferred stock. This preferred stock may be issued in one or more series, the terms of which may be determined at the time of issuance by our Board of Directors without further action by stockholders. The terms of any series of preferred stock may include voting rights (including the right to vote as a series on particular matters), preferences as to dividend, liquidation, conversion and redemption rights and sinking fund provisions. No preferred stock is currently outstanding. The issuance of any preferred stock could materially adversely affect the rights of the holders of our common stock, and therefore, reduce the value of our common stock. In particular, specific rights granted to future holders of preferred stock could be used to restrict our ability to merge with, or sell our assets to, a third party and thereby preserve control by the present management.

Provisions of our certificate of incorporation and bylaws and Delaware law also could have the effect of discouraging potential acquisition proposals or tender offers or delaying or preventing a change in control, including changes a stockholder might consider favorable. Such provisions may also prevent or frustrate attempts by our stockholders to replace or remove our management. In particular, the certificate of incorporation and bylaws and Delaware law, as applicable, among other things:

provide the Board of Directors with the ability to alter the bylaws without stockholder approval;
establish staggered terms for board members;
place limitations on the removal of directors; and
provide that vacancies on the Board of Directors may be filled by a majority of directors in office, although less than a quorum.

We are also subject to Section 203 of the Delaware General Corporation Law which, subject to certain exceptions, prohibits “business combinations” between a publicly-held Delaware corporation and an “interested stockholder,” which is generally defined as a stockholder who becomes a beneficial owner of 15% or more of a Delaware corporation’s voting stock for a three-year period following the date that such stockholder became an interested stockholder.

A substantial number of shares of common stock may be sold in the market, which may depress the market price for our common stock.

Sales of a substantial number of shares of our common stock in the public market could cause the market price of our common stock to decline. A substantial majority of the outstanding shares of our common stock are freely tradable without restriction or further registration under the Securities Act. As of December 31, 2020, 829.6 million shares of our common stock are issued and outstanding. In addition, as of December 31, 2020, 269 million shares of our common stock are issuable upon exercise of outstanding warrants and 18 million shares of our common stock are issuable upon exercise of outstanding options.

20

We may have claims and lawsuits against us that may result in adverse outcomes.

From time to time, we may be subject to a variety of claims and lawsuits. As described more fully in “Item 3. Legal Proceedings,” of Part I of this Form 10-K, in the past, we were engaged in responding to a shareholder demand for access to certain corporate books and records, and we were also engaged in several shareholder litigations. We believed that that the claims were without merit, fought them vigorously and settled them. We have also had several small litigations, for example relating to certain payables. However, litigation and claims are subject to inherent uncertainties, and adverse rulings or outcomes could occur, and/or could lead to further claims or litigation. Adverse outcomes or further litigation could result in significant monetary damages or injunctive relief that could adversely affect our business. A material adverse impact on our financial statements also could occur for the period in which an unfavorable final outcome becomes probable and its effect becomes reasonably estimable. In addition, litigation and claims may divert material amounts of management time and attention from our business, and/or involve significant legal costs and expenses.

ITEM 1B. UNRESOLVED STAFF COMMENTS

Not applicable.

ITEM 2. PROPERTIES

Our corporate headquarters are located at 4800 Montgomery Lane, Bethesda, Maryland, where we lease and occupy an aggregate of approximately 7,097 square feet of office space. The lease covering this property is currently scheduled to expire in August 2024.

Our research and development operations are mainly based in Sawston, U.K., where we lease and occupy an aggregate of approximately 87,000 square feet of building. The lease covering this property is currently scheduled to expire in December 2038.

We believe that our existing facilities are adequate for our immediate needs and that, should it be needed, additional space can be leased to accommodate any future growth.

ITEM 3. LEGAL PROCEEDINGS

Not Applicable.

ITEM 4. MINE SAFETY DISCLOSURES

Not Applicable.

PART II

ITEM 5. MARKET FOR THE REGISTRANT’S COMMON EQUITY, RELATED STOCKHOLDER MATTERS, AND ISSUERS PURCHASES OF EQUITY SECURITIES

Market for Common Equity and Related Stockholder Matters

Our common stock trade on OTCQB under the trading symbols “NWBO” effective December 19, 2016. No assurance can be given that an active market will exist for our common stock.

As of March 26, 2021, there were approximately 40,000 holders of record of our common stock. Such holders may include any broker or clearing agencies as holders of record, and in such cases exclude the individual stockholders whose shares are held by such brokers or clearing agencies.

Dividend Policy

We have never declared or paid cash dividends on our capital stock. We currently intend to retain all future earnings, if any, to fund the ongoing development and growth of our business. We do not currently anticipate paying any cash dividends in the foreseeable future.

21

Stock Performance Graph

Not Applicable

Recent Sales of Unregistered Securities

During the year ended December 31, 2020, the Company issued certain equity securities as set forth in footnote 11 (Stockholders’ Equity) to our financial statements, for the consideration described in such footnote, which disclosure is incorporated into this Item 5. Such securities were issued by the Company pursuant to Section 4(a)(2) of the Securities Act of 1933, as amended, or the provisions of Rule 506 of Regulation D promulgated under the Securities Act. Except as set forth in such footnote, the Company did not utilize an underwriter or a placement agent for any of these offerings of its securities.

ITEM 6. SELECTED CONSOLIDATED FINANCIAL DATA

Not Applicable

ITEM 7. MANAGEMENT’S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS

You should read this discussion together with the Financial Statements, related Notes and other financial information included elsewhere in this Form 10-K. The following discussion contains assumptions, estimates and other forward-looking statements that involve a number of risks and uncertainties, including those discussed under “Risk Factors,” and elsewhere in this Form 10-K. These risks could cause our actual results to differ materially from those anticipated in these forward-looking statements.

Overview

We are a biotechnology company focused on developing personalized immune therapies for cancer. We have developed a platform technology, DCVax®, which uses activated dendritic cells to mobilize a patient’s own immune system to attack their cancer.

Our lead product, DCVax®-L, is designed to treat solid tumor cancers in which the tumor can be surgically removed. We have completed a 331-patient international Phase III trial of DCVax-L for Glioblastoma multiforme brain cancer (GBM). As previously reported, the data collection and confirmation process was conducted by the independent contract research organization (CRO) who managed the trial and by other independent service firms.  On October 5, 2020, the Company announced that Data Lock for the Phase III trial had been reached, and that a series of steps and processes would follow. These processes included data validation, analyses of the data by independent statisticians, preparations by the statisticians of summaries of the Trial results for review by the Company, the Principal Investigator, the Steering Committee of the Trial, the Scientific Advisory Board, and a panel of independent brain cancer experts, in preparation for publication in a scientific journal and public announcement.  This series of processes is under way.  It is anticipated that public announcement will follow these processes.

As also previously reported, coronavirus-related difficulties have impacted most aspects of the process, especially with the waves of COVID cases in many areas. The independent service firms have had limited capacity, and restrictions on operations. Key experts at certain specialized service providers have been unavailable for periods of time due to illness in their family. Other experts have gone on extended leave due to restrictions on operations. Clinical trial site personnel have been unavailable due to being reassigned for COVID, and the limited site personnel have had to work under restrictions. Committee processes and regulatory processes have been similarly focused on COVID matters and delayed on other matters. Firms such as the ones storing the Phase III trial tissue samples that are needed for certain analyses, and the firms conducting the analyses, continue to have only limited operations. Even logistical matters such as the shipping of materials have been, and continue to be, subjected to substantial restrictions and delays.

22

On August 28, 2020, the Company acquired Flaskworks, LLC (“Flaskworks”), a company that has developed a system to close and automate the manufacturing of cell therapy products such as DCVax®. The Company acquired 100% of the ownership, and  Flaskworks became a wholly-owned subsidiary of the Company. Flaskworks was previously owned by its technical founders and Corning Inc. The technical team from Flaskworks joined the Company as part of the Acquisition. It is anticipated that the Flaskworks system will enable substantial scale-up of production volumes of DCVax products and substantial reduction of production costs. The Company’s buildout of the Sawston, UK facility has been designed to proceed in phases, as modules, both for efficiency in the timing of capital costs and to allow flexibility in operations and usage. The Company anticipates that implementation of the Flaskworks system will enable certain phases of the buildout to be simplified and streamlined.  For further details on the financial aspects of the acquisition, please see Item 8 Note 5 below.

Our second product, DCVax®-Direct, is designed to treat inoperable solid tumors. A 40-patient Phase I trial has been completed, and included treatment of a diverse range of more than a dozen types of cancers. The Company is working on preparations for Phase II trials of DCVax-Direct, as resources permit.

Critical Accounting Policies and Estimates

Our discussion and analysis of our financial condition and results of operations are based on our financial statements, which have been prepared in accordance with U.S. GAAP. The preparation of these financial statements requires us to make estimates and judgments that affect our reported amounts of assets, liabilities, revenues and expenses.

On an ongoing basis, we evaluate our estimates and judgments, including those related to derivative liabilities, accrued expenses and stock-based compensation. We based our estimates on historical experience and on various other assumptions that we believe to be reasonable under the circumstances, the results of which form the basis for making judgments about the carrying values of assets and liabilities and the reported amounts of revenues and expenses that are not readily apparent from other sources. Actual results could differ from those estimates, particularly given the significant social and economic disruptions and uncertainties associated with the ongoing coronavirus pandemic (“COVID-19”) and the COVID-19 control responses.

Fair Value Measurements

Fair value is defined as the price that would be received for sale of an asset or paid for transfer of a liability, in an orderly transaction between market participants at the measurement date. U.S. GAAP establishes a three-tier fair value hierarchy that prioritizes the inputs used in measuring fair value. The hierarchy gives the highest priority to unadjusted quoted prices in active markets for identical assets or liabilities (Level 1 measurements) and the lowest priority to unobservable inputs (Level 3 measurements). These tiers include:

Level 1 - defined as observable inputs such as quoted prices for identical instruments in active markets;
Level 2 - quoted prices for similar assets and liabilities in active markets or inputs that are observable
Level 3 - inputs that are unobservable (for example, cash flow modeling inputs based on assumptions)

We account for the issuance of common stock purchase warrants issued in connection with the equity offerings in accordance with the provisions of ASC 815, Derivatives and Hedging (“ASC 815”). We classify as equity any contracts that (i) require physical settlement or net-share settlement or (ii) gives the Company a choice of net-cash settlement or settlement in its own shares (physical settlement or net-share settlement). We account for certain common stock warrants outstanding as a liability at fair value and adjust the instruments to fair value at each reporting period. This liability is subject to re-measurement at each balance sheet date until exercised, and any change in fair value is recognized in our consolidated statements of operations. The fair value of the warrants issued by us has been estimated using Monte Carlo simulation and or a Black Scholes model. The warrant liabilities are valued using Level 3 valuation inputs.

Derivative Financial Instruments

The Company has derivative financial instruments that are not hedges and do not qualify for hedge accounting. Changes in the fair value of these instruments are recorded in other income (expense), net in the Consolidated Statements of Operations and Comprehensive Loss.

23

Impairment of Long-Lived Assets

The Company assesses its long-lived assets for impairment whenever facts and circumstances indicate that the carrying amounts may not be fully recoverable. To analyze recoverability, the Company projects undiscounted net future cash flows over the remaining lives of such assets. If these projected cash flows are less than the carrying amounts, an impairment loss would be recognized, resulting in a write-down of the assets with a corresponding charge to earnings. The impairment loss is measured based upon the difference between the carrying amounts and the fair values of the assets. Assets to be disposed of are reported at the lower of the carrying amounts or fair value less cost to sell. Management determines fair value using the discounted cash flow method or other accepted valuation techniques.

As of December 31, 2020 and 2019, the undiscounted net future cash flows of the U.K. property were greater than the carrying value. Therefore, no impairment loss was considered necessary.

Leases

We adopted ASC 842 on January 1, 2019, using the optional transition method to apply the new guidance as of January 1, 2019, rather than as of the earliest period presented, and elected the package of practical expedients. Leases with an initial term of 12 months or less are not recorded on the Consolidated Balance Sheets. We recognize these lease expenses on a straight-line basis over the lease term. Based on the analysis, on January 1, 2019, we recorded right of use (“ROU”) assets and lease liabilities of approximately $4.3 million, which represented operating lease entered prior to January 1, 2019. ROU assets represent our right to use an underlying asset for the lease term and lease liabilities represent our obligation to make lease payments arising from the lease. Operating lease ROU assets and liabilities are recognized at commencement date based on the present value of lease payments over the lease term. Additionally, we recorded an adjustment to opening accumulated deficit of $4.8 million related to the derecognition of deferred profit related to the U.K facility sales leaseback transaction.

Stock Based Compensation

Share-based compensation cost is recorded for all option grants and awards of non-vested stock based on the grant date fair value of the award using the Black-Scholes option-pricing model, and is recognized over the service period required for the award.

We estimate the fair value of stock option grants using the Black-Scholes option pricing model and the assumptions used in calculating the fair value of stock-based awards represent management’s best estimates and involve inherent uncertainties and the application of management’s judgment.

Expected Term - The expected term of options represents the period that the Company’s stock-based awards are expected to be outstanding based on the simplified method, which is the half-life from vesting to the end of its contractual term.

Expected Volatility - The Company computes stock price volatility over expected terms based on its historical common stock trading prices.

Risk-Free Interest Rate - The Company bases the risk-free interest rate on the implied yield available on U. S. Treasury zero-coupon issues with an equivalent remaining term.

Expected Dividend - The Company has never declared or paid any cash dividends on its common shares and does not plan to pay cash dividends in the foreseeable future, and, therefore, uses an expected dividend yield of zero in its valuation models.

We recognize forfeitures when they occur.

24

Recent Accounting Standards

Income Taxes

In December 2019, the FASB issued ASU No. 2019-12, “Income Taxes (Topic 740): Simplifying the Accounting for Income Taxes (“ASU 2019-12”), which is intended to simplify various aspects related to accounting for income taxes. ASU 2019-12 removes certain exceptions to the general principles in Topic 740 and also clarifies and amends existing guidance to improve consistent application. This guidance is effective for fiscal years, and interim periods within those fiscal years, beginning after December 15, 2020, with early adoption permitted. The Company is currently evaluating the impact of this standard on its consolidated financial statements and related disclosures.

Debt

In August 2020, the FASB issued ASU No. 2020-06, Debt—Debt with Conversion and Other Options (Subtopic 470-20) and Derivatives and Hedging—Contracts in Entity’s Own Equity (Subtopic 815-40): Accounting for Convertible Instruments and Contracts in an Entity’s Own Equity, which simplifies accounting for convertible instruments by removing major separation models required under current GAAP. The ASU removes certain settlement conditions that are required for equity contracts to qualify for the derivative scope exception and it also simplifies the diluted earnings per share calculation in certain areas. This ASU is effective for annual reporting periods beginning after December 15, 2021, including interim periods within those fiscal years. Early adoption is permitted, but no earlier than fiscal years beginning after December 15, 2020. This update permits the use of either the modified retrospective or fully retrospective method of transition. The Company is currently evaluating the impact this ASU will have on its consolidated financial statements and related disclosures.

Revision of Previously Issued Financial Statements

We have revised certain previously reported non-material financial information for the year ended December 31, 2019 in this Item 7, Management’s Discussion and Analysis of Financial Condition and Results of Operations, including but not limited to information within the Results of Operations section.

See Note 14, Revision to Prior Period Financial Statements, for additional information related to the revision, including descriptions of the misstatements and the non-material impact on our consolidated financial statements.

Results of Operations

Operating costs:

Operating costs and expenses consist primarily of research and development expenses, including clinical trial expenses, which increase when we are actively participating in clinical trials and especially when we are in a large ongoing international phase III trial or we are completing such a large international trial, and undertaking substantial one-time expenses such as for final site visits, query resolutions, statistical work for the Statistical Analysis Plan, preparations for data analyses and other activities related to completion and assessment of the trial and its results. The operating costs also include administrative expenses associated with trials, and increase as such operating activities grow.

In addition to clinical trial related costs, our operating costs may include ongoing work relating to our DCVax products, including R&D, product characterization, and related matters. Going forward, we are also incurring large amounts of costs to carry out and complete statistical analyses, process validation work, final data collection and validation, and other work associated with moving towards preparing for locking, unblinding and analyzing the trial results.

Following our acquisition of Flaskworks, our operating costs now include the costs for its ongoing operations and its intellectual property filings.

25

Our operating costs also include the costs of preparations for the launch of new or expanded clinical trial programs, such as our planned Phase II clinical trials. The preparation costs include payments to regulatory consultants, lawyers, statisticians, sites and others, evaluation of potential investigators, the clinical trial sites and the CROs managing the trials and other service providers, and expenses related to institutional approvals, clinical trial agreements (business contracts with sites), training of medical and other site personnel, trial supplies and other. Additional substantial costs relate to the maintenance and substantial expansion of manufacturing capacity, in both the US and Europe.

Our operating costs also include significant legal and accounting costs in operating the Company.

Research and development:

Discovery and preclinical research and development expenses include costs for substantial external scientific personnel, technical and regulatory advisers, and others, costs of laboratory supplies used in our internal research and development projects, travel, regulatory compliance, and expenditures for preclinical and clinical trial operation and management when we are actively engaged in clinical trials.

Because we are pre-revenue company, we do not allocate research and development costs on a project basis. We adopted this policy, in part, due to the unreasonable cost burden associated with accounting at such a level of detail and our limited number of financial and personnel resources.

General and administrative:

General and administrative expenses include personnel related salary and benefit expenses, cost of facilities, insurance, travel, legal services, property and equipment and amortization of stock options and warrants.

For the Years Ended December 31, 2020 and 2019

We recognized a net loss of $529.8 million and $20.8 million for the years ended December 31, 2020 and 2019, respectively. The net loss of $529.8 million for the year ended December 31, 2020 included a cash loss of $32 million and a non-cash loss of $497.8 million. The increase in net loss for the year ended December 31, 2020 was primarily due to the increased stock price, which resulted in significant non-cash loss from the change on the derivative liability.

Net cash used in operations was $32.1 million and $31.9 million for the years ended December 31, 2020 and 2019, respectively.

Research and development expense

For the years ended December 31, 2020 and 2019, research and development expense was $33.6 million and $14.1 million, respectively. Research and development expenses included activities and involvement of external consultants as the Phase 3 trial moved through final data collection and query resolution, independent data validation, and other preparations for Data Lock and analyses. The increase of $19.5 million was mainly due to the recognition of approximately $19.8 million stock-based compensation under research and development during the year ended December 31, 2020.

The following table summarizes expenses incurred (i.e., amounts invoiced, including those which have only been partly paid) to entities as related parties during the years ended December 31, 2020 and 2019 (amount in thousands):

For the year ended

December 31, 2020

    

2020

    

2019

(As Revised)

Advent BioServices

 

$

7,543

$

5,735

26

General and Administrative Expense

General and administrative expenses were $51.0 million and $12.5 million for the years ended December 31, 2020 and 2019, respectively. The increase was mainly related to a one-time cost of $30.8 million stock-based compensation that covered several years of such compensation and that was recognized in general and administrative.

Legal Expenses

Legal costs were $3.3 million and $3.7 million for the years ended December 31, 2020 and 2019, respectively. The decrease in legal costs reflects a reduction in the need for legal services.

Change in fair value of derivatives

We recognized a non-cash loss of $435.4 million and a non-cash gain of $11.8 million for the years ended December 31, 2020 and 2019, respectively. The non-cash loss was primarily due to the increase of our stock price as of December 31, 2020 ($1.53 per share) compared to December 31, 2019 ($0.21 per share). In the year ended December 31, 2019, the non-cash gain was primarily due to the decrease in stock price as of December 31, 2019 compared with December 31, 2018.

Loss from Extinguishment of Debt

During the year ended December 31, 2020, we converted debt of approximately $12.7 million principal and $1.2 million accrued interest into approximately 58.4 million shares of common stock and 6.2 million warrants. We also extinguished $6.6 million embedded derivative liabilities, wrote off $0.9 million unamortized debt discount and made some debt amendment upon the conversion. We recorded an approximate $1.6 million debt extinguishment loss from the conversion.

Our PPP Loan forgiveness application was approved on December 7, 2020. We recorded approximate $0.4 million debt extinguishment gain from the forgiveness of PPP Loan.

During the year ended December 31, 2019, we recorded loss from extinguishment of debt of $1.9 million. The debt extinguishment loss resulted from debt conversion, when the fair value of common stock exceeded the book value of the debt as of the conversion date. We also amended certain notes in 2019, which was treated as an extinguishment for accounting purposes.

Interest expense

During the years ended December 31, 2020 and 2019, we recorded interest expense of $8.5 million and $3.0 million, respectively.

Foreign currency transaction gain

During the years ended December 31, 2020 and 2019, we recognized foreign currency transaction gain of $2.3 million and $0.3 million, respectively. The gain was due to the weakening of the U.S. dollar relative to the British pound sterling.

Liquidity and Capital Resources

We have experienced recurring losses from operations since inception. We have not yet established an ongoing source of revenues and must cover our operating expenses through debt and equity financings to allow us to continue as a going concern. Our ability to continue as a going concern depends on the ability to obtain adequate capital to fund operating losses until we generate adequate cash flows from operations to fund our operating costs and obligations. If we are unable to obtain adequate capital, we could be forced to cease operations.

We depend upon our ability, and will continue to attempt, to secure equity and/or debt financing. We cannot be certain that additional funding will be available on acceptable terms, or at all. Our management determined that there was substantial doubt about our ability to continue as a going concern within one year after the consolidated financial statements were issued, and management’s concerns about our ability to continue as a going concern within the year following this report persist.

27

Contingent Contractual Payment

The following table summarizes our contractual obligations as of December 31, 2020 (amount in thousands):

Payment Due by Period

Less than

1 to 2

3 to 5

    

Total

    

1 Year

    

Years

Years

Short term convertible notes payable (1)

    

  

    

  

  

6% unsecured

 

$

226

$

226

$

$

8% unsecured

2,218

2,218

Short term notes payable (2)

 

  

  

  

8% unsecured

 

1,807

1,807

10% unsecured

 

329

329

12% unsecured

 

624

624

Long term notes payable (3)

 

  

  

  

8% unsecured

 

7,413

7,413

6% secured

2,202

262

1,940

Operating leases (4)

 

20,913

6,097

12,080

2,736

Purchase obligation (5)

 

Total

 

$

35,732

$

11,301

$

19,755

$

4,676

(1)The obligations related to short-term convertible notes were approximately $2.4 million as of December 31, 2020, which included remaining contractual unpaid interest of $0.2 million.
(2)The obligations related to short-term notes were approximately $2.8 million as of December 31, 2020, which included unpaid interest of $0.3 million.
(3)The obligations related to long-term notes were approximately $9.6 million as of December 31, 2020, which included unpaid interest for the next 5 years of approximately $0.6 million.
(4)The operating lease obligations during the next 2 years included approximately $468,000 and $9,000 for our offices in Maryland and Germany, respectively, and approximately $513,000 for our office in Maryland for the next 3-4 years. Approximately £1 million ($1.5 million) in lease obligations during the next 2 years and approximately £1.5 million ($2.2 million) for the next 3 to 5 years related to the Vision Centre in the U.K. that we leased back in December 2018. We also included approximately $10.3 million of anticipated payments to Advent BioServices, which represents the next 2 years’ obligation. The remaining contract term as of December 31, 2020 was approximately 2 years under the Manufacturing Services Agreement with Advent.
(5)We have possible contingent obligations to pay certain fees to contract manufacturers if we shut down or suspend programs.

For a shut down or suspension of the DCVax-L program at Advent, the Company must give 12 months’ advance notice. During the notice period services would still be provided. Minimum required payments for this notice period total approximately £3.8 million ($5 million).

As of December 31, 2020, no shut-down or suspension fees were triggered.

Operating Activities

We used $32.1 million and $31.9 million in cash for operating activities during the years ended December 31, 2020 and 2019, respectively. The increase in cash used in operating activities was primarily attributable to an increase in clinical trial related expenditures.

28

Investing Activities

During the year ended December 31, 2020, we spent approximately $6.6 million to purchase additional equipment in the UK and construction in progress.

During the year ended December 31, 2020, we spent approximately $1.5 million related to the Flaskworks acquisition.

During the year ended December 31, 2019, we spent approximately $360,000 to purchase additional equipment in the UK.

Financing Activities

We received approximately $26.8 million and $6.9 million in cash proceeds from issuance of convertible preferred stock, common stock and warrants, in both public and private offerings during the years ended December 31, 2020 and 2019, respectively.

We received approximately $13.9 million and $2.2 million cash proceeds from the exercise of warrants during the years ended December 31, 2020 and 2019, respectively.

We received approximately $13.7 million and $7.0 million in cash proceeds from the issuance of multiple notes payable during the years ended December 31, 2020 and 2019, respectively.

We received approximately $0.3 million in cash proceeds from issuances of debt with a related party during the year ended December 31, 2020.

We made aggregate debt payments of $2.0 million and $6.1 million during the years ended December 31, 2020 and 2019, respectively.

ITEM 7A. QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK.

Not Applicable.

ITEM 8. FINANCIAL STATEMENTS AND SUPPLEMENTARY DATA

The full text of our audited consolidated financial statements as of December 31, 2020 and 2019 and for the fiscal years ended December 31, 2020 and 2019, begins on page F-1 of this Annual Report on Form 10-K.

ITEM 9. CHANGES IN AND DISAGREEMENTS WITH ACCOUNTANTS ON ACCOUNTING AND FINANCIAL DISCLOSURE

None.

ITEM 9A. CONTROLS AND PROCEDURES

Evaluation of Disclosure Controls and Procedures

We, the management of Northwest Biotherapeutics, Inc. (the “Company”), are responsible for establishing and maintaining adequate internal control over financial reporting of the Company.

We maintain disclosure controls and procedures (as defined in Rules 13a-15(e) and 15d-15(e) under the Exchange Act) that are designed to ensure that information required to be disclosed in the reports that we file or submit under the Exchange Act is recorded, processed, summarized and reported within the time period specified in the SEC’s rules and forms, and that such information is accumulated and communicated to our management, including to our Chief Executive Officer and Principal Financial and Accounting Officer, as appropriate, to allow timely decisions regarding required disclosure.

29

As required by Rule 13a-15 under the Exchange Act, our management, including our Chief Executive Officer and Principal Financial and Accounting Officer, evaluated the effectiveness of the design and operation of our disclosure controls and procedures as of December 31, 2020. In making this assessment, the Company’s management used the criteria established in Internal Control — Integrated Framework (2013) issued by the Committee of Sponsoring Organizations of the Treadway Commission (“COSO”).

Our management concluded that as of December 31, 2020, our disclosure controls and procedures were effective, and previous noted deficiencies have been remediated, as described below.

Management’s Report on Internal Control Over Financial Reporting

The management of the Company is responsible for establishing and maintaining adequate internal control over financial reporting. The Company’s internal control over financial reporting is a process designed to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles. Because of its inherent limitations, internal control over financial reporting may not prevent or detect misstatements. In addition, projections of any evaluation of effectiveness to future periods are subject to the risk that controls may become inadequate because of changes in conditions, or that the degree of compliance with the policies or procedures may deteriorate.

A material weakness is a deficiency, or a combination of deficiencies, in internal control over financial reporting, such that there is a reasonable possibility that a material misstatement of the Company’s annual or interim financial statements will not be prevented or detected on a timely basis.

Management of the Company, including our CEO and Principal Financial and Accounting Officer, assessed the effectiveness of the Company’s internal control over financial reporting as of December 31, 2020. Based on this assessment, we determined that we have effectively designed and implemented, consistently performed, and tested the functioning of these controls.

Based on the efforts identified above, we have concluded that the previously identified material weaknesses in the Company’s internal control over financial reporting have been remediated through the following efforts:

The Company has added and implemented financial operational policies and related procedures which govern our system of internal controls over evaluating disclosures under ASC740. These policies were reviewed and tested to be effective as of December 31, 2020.

Because the material weakness was successfully remediated and additional material weaknesses were not identified, management, including our principal executive officer and principal financial officer, has concluded that our internal control over financial reporting was effective as of December 31, 2020.

Changes in Internal Control Over Financial Reporting

There were no changes, other than those described above, in our internal control over financial reporting during the fiscal quarter ended December 31, 2020 that have materially affected, or are reasonably likely to materially affect, our internal control over financial reporting.

ITEM 9B. OTHER INFORMATION

None.

PART III

ITEM 10. DIRECTORS, EXECUTIVE OFFICERS AND CORPORATE GOVERNANCE

The information required by Item 10 is hereby incorporated by reference from our 2021 Proxy Statement under the captions “Election of Directors” and “Code of Ethics.” To the extent that we do not file the 2021 Proxy Statement prior to the end of the 120-day period following December 31, 2020, we will amend this Annual Report on Form 10-K to provide the required information.

30

ITEM 11. EXECUTIVE COMPENSATION

Information required by this item will be contained in the Proxy Statement and is incorporated herein by reference.

ITEM 12. SECURITY OWNERSHIP OF CERTAIN BENEFICIAL OWNERS AND MANAGEMENT AND RELATED STOCKHOLDER MATTERS-EQUITY COMPENSATION PLAN INFORMATION

Information required by this item will be contained in the Proxy Statement and is incorporated herein by reference.

ITEM 13. CERTAIN RELATIONSHIPS, RELATED TRANSACTIONS AND DIRECTOR INDEPENDENCE

Information required by this item will be contained in the Proxy Statement and is incorporated herein by reference.

ITEM 14. PRINCIPAL ACCOUNTANT FEES AND SERVICES

Information required by this item will be contained in the Proxy Statement and is incorporated herein by reference.

ITEM 15. EXHIBITS AND FINANCIAL STATEMENT SCHEDULES

The Exhibits listed below are identified by numbers corresponding to the Exhibit Table of Item 601 of Regulation S-K. The Exhibits designated by an asterisk (*) are management contracts or compensatory plans or arrangements required to be filed pursuant to Item 15.

EXHIBIT INDEX

Exhibit

Number

    

Description

3.1

 

Seventh Amended and Restated Certificate of Incorporation (incorporated by reference to Exhibit 3.1 filed with the Registrant’s Amendment No. 1 to the Registration Statement on Form S-1(File No. 333-134320) on July 17, 2006).

3.2

 

Third Amended and Restated Bylaws of the Company (incorporated by reference to Exhibit 3.1 filed with the Registrant’s Current Report on Form 8-K on June 22, 2007).

3.3

 

Amendment to Seventh Amended and Restated Certificate of Incorporation (incorporated by reference to Exhibit 3.2 filed with the Registrant’s Current Report on Form 8-K on June 22, 2007).

3.5

 

Amendment to Seventh Amended and Restated Certificate of Incorporation (incorporated by reference to Exhibit 3.1 filed with the Registrant’s Quarterly Report on Form 10-Q on May 21, 2012).

3.6

 

Amendment to Seventh Amended and Restated Certificate of Incorporation (incorporated by reference to Exhibit 3.1 filed with the Registrant’s Current Report on Form 8-K on September 26, 2012).

3.7

 

Amendment to Third Amended and Restated Bylaws of the Company (incorporated by reference to Exhibit 3.1 filed with the Registrant’s Current Report on Form 8-K on December 11, 2012).

3.8

 

Amended and Restated Certificate of Designations of Series A Convertible Preferred Stock (incorporated by reference to Exhibit 3.1 filed with the Registrant’s Current Report on Form 8-K on December 21, 2017).

3.9

 

Amended and Restated Certificate of Designations of Series B Convertible Preferred Stock (incorporated by reference to Exhibit 3.1 filed with the Registrant’s Current Report on Form 8-K on January 4, 2018).

4.1

 

Description of Securities

4.2

 

Form of common stock certificate (incorporated by reference to Exhibit 4.1 filed with the Registrant’s Amendment No. 3 to the Registration Statement on Form S-1 (Registration No. 333-67350) on November 14, 2001).

31

4.3

 

Form of Warrant Agency Agreement by and between Northwest Biopharmaceuticals, Inc. and Computershare Trust Company, N.A. and Form of Warrant Certificate (incorporated by reference to Exhibit 4.2 filed with the Registrant’s Form S-1 on December 4, 2012).

10.49

 

Series E Common Stock Purchase Warrant (incorporated by reference as Exhibit 10.2 filed with the Company’s Current Report on Form 8-K/A on September 19, 2016).

10.50

 

Registration Rights Agreement dated August 22, 2016 (incorporated by reference as Exhibit 10.3 filed with the Company’s Current Report on Form 8-K/A on September 19, 2016).

10.64

 

Form of Warrant Repricing Letter Agreement dated August 7, 2017 by and between Northwest Biotherapeutics, Inc. and a certain institutional investor (incorporated by reference as Exhibit 10.1 filed with the Company’s Current Report on Form 8-K on August 7, 2017).

10.65

 

Form of Series A Common Stock Purchase Warrant (incorporated by reference as Exhibit 10.2 filed with the Company’s Current Report on Form 8-K on August 7, 2017).

10.66

 

Form of Securities Purchase Agreement, dated September 20, 2017, by and between Northwest Biotherapeutics, Inc. and certain institutional investors (incorporated by reference as Exhibit 10.1 filed with the Company’s Current Report on Form 8-K on September 22, 2017).

10.67

 

Form of Class A Common Stock Purchase Warrant (incorporated by reference as Exhibit 10.2 filed with the Company’s Current Report on Form 8-K on September 22, 2017).

10.70

 

Form of Class D-1 Common Stock Purchase Warrant (incorporated by reference as Exhibit 10.1 filed with the Company’s Current Report on Form 8-K on December 7, 2017).

10.72

 

Form of Subscription Agreement (incorporated by reference as Exhibit 10.3 filed with the Company’s Current Report on Form 8-K on December 7, 2017).

10.73

 

Settlement and Amendment Agreement (2016 Obligations Agreement), dated as of December 31, 2017, by and between Northwest Biotherapeutics, Inc. and Cognate BioServices, Inc.

10.74

 

Settlement and Amendment Agreement (2017 Obligations Agreement), dated as of December 31, 2017, by and between Northwest Biotherapeutics, Inc. and Cognate BioServices, Inc.

10.75

 

Note and Loan Agreement, dated as of March 14, 2018, by and between Northwest Biotherapeutics, Inc. and Linda F. Powers.

10.76

 

Note and Loan Agreement, dated as of March 19, 2018, by and between Northwest Biotherapeutics, Inc. and Linda F. Powers.

10.78

 

Form of Loan Agreement, dated as of November 7, 2018, by and between Northwest Biotherapeutics, Inc. and a Group of Private Lenders.

10.79

 

Contract Relating to Sale of Spicers, Sawston, Cambridge, dated as of December 5, 2018, by and between Aracaris Capital Limited and Huawei Technologies Research & Development (UK) Limited.

10.80

 

Lease Relating to Vision Centre, Sawston, Cambridge, by and between Aracaris Capital Limited and Aracaris Limited, dated as of December 14, 2018.

10.81

Equity Compensation Plan, dated May 29, 2020.

10.82

Note and Loan Agreement, dated August 14, 2021, by and between Northwest Biotherapeutics, Inc. and Iliad Research and Trading L.P.

10.83

Agreement to acquire Flaskworks, L.L.C, August 28, 2020.

32

10.84

Change in Registrant’s Accountants (incorporated by reference as Exhibit 16.1 filed with the Company’s Current Report on Form 8-K January 26, 2021).

10.85

Loan Agreement, dated March 1, 2021, by and between Northwest Biotherapeutics, Inc. and Streeterville Capital, L.L.C.

21.1

 

Subsidiaries of the Registrant.

23.1

 

Independent Registered Public Accounting Firm’s Consent.

31.1

 

Certification of the Principal Executive Officer pursuant to Section 302 of the Sarbanes Oxley Act of 2002.

32.1

 

Certification of the Principal Executive Officer pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.

101.INS

 

XBRL Instance Document.

101.SCH 

 

XBRL Schema Document.

101.CAL

 

XBRL Calculation Linkbase Document.

101.DEF

 

XBRL Definition Linkbase Document.

101.LAB 

 

XBRL Label Linkbase Document.

101.PRE

 

XBRL Presentation Linkbase Document.

*Confidential information in this exhibit has been omitted and filed separately with the SEC pursuant to a confidential treatment request.

33

ITEM 16.FORM 10–K SUMMARY

None.

SIGNATURES

Pursuant to the requirements of Section 13 or 15(d) of the Securities Exchange Act of 1934, the registrant has duly caused this Annual Report on Form 10-K to be signed on its behalf by the undersigned, thereunto duly authorized.

NORTHWEST BIOTHERAPEUTICS, INC.

(Registrant)

Date: March 31, 2021

By:

/s/ Linda F. Powers

Linda F. Powers,

President and Chief Executive Officer

Principal Executive Officer

Principal Financial and Accounting Officer

Pursuant to the requirements of the Securities Exchange Act of 1934, this Annual Report on Form 10-K has been signed below by the following persons on behalf of the Registrant and in the capacities and on the dates indicated.

Signature

    

Title

    

Date

/s/ Linda F. Powers

President and Chief Executive Officer

March 31, 2021

Linda F. Powers

Principal Executive Officer

Principal Financial and Accounting Officer

/s/ Alton L. Boynton

Director

March 31, 2021

Alton L. Boynton

/s/ Navid Malik

Director

March 31, 2021

Dr. Navid Malik

/s/ Jerry Jasinowski

Director

March 31, 2021

Jerry Jasinowski

/s/ J. Cofer Black

Director

March 31, 2021

J. Cofer Black

34

Report of Independent Registered Public Accounting Firm

To the Board of Directors and Stockholders

Northwest Biotherapeutics, Inc.

Bethesda, Maryland

Opinion on the Financial Statements

We have audited the accompanying balance sheets of Northwest Biotherapeutics, Inc. and Subsidiaries (the “Company”) as of December 31, 2020, and the related consolidated statements of operations and comprehensive loss, stockholders’ deficit, and cash flows for the year then ended, and the related notes (collectively referred to as the “financial statements”). In our opinion, the consolidated financial statements present fairly, in all material respects, the financial position of the Company as of December 31, 2020, and the results of its operations and its cash flows for the year then ended in conformity with accounting principles generally accepted in the United States of America.

Substantial Doubt about the Company's Ability to Continue as a Going Concern

The accompanying consolidated financial statements have been prepared assuming that the Company will continue as a going concern. As discussed in Note 2 to the consolidated financial statements, the Company has recurring losses and negative cash flows from operations that raise substantial doubt about its ability to continue as a going concern. Management’s evaluations of the events and conditions and management’s plans regarding those matters are also described in Note 2. The consolidated financial statements do not include any adjustments that might result from the outcome of this uncertainty.

Basis for Opinion

These consolidated financial statements are the responsibility of the Company’s management. Our responsibility is to express an opinion on the Company’s consolidated financial statements based on our audit. We are a public accounting firm registered with the Public Company Accounting Oversight Board of the United States of America (“PCAOB”) and are required to be independent with respect to the Company in accordance with the U.S. federal securities laws and the applicable rules and regulations of the Securities and Exchange Commission and the PCAOB.

We conducted our audit in accordance with the standards of the PCAOB. Those standards require that we plan and perform the audit to obtain reasonable assurance about whether the consolidated financial statements are free of material misstatement, whether due to error or fraud. The Company is not required to have, nor were we engaged to perform, an audit of its internal control over financial reporting. As part of our audits, we are required to obtain an understanding of internal control over financial reporting, but not for the purpose of expressing an opinion on the effectiveness of the Company’s internal control over financial reporting. Accordingly, we express no such opinion.

Our audits included performing procedures to assess the risks of material misstatement of the consolidated financial statements, whether due to error or fraud, and performing procedures that respond to those risks. Such procedures included examining, on a test basis, evidence regarding the amounts and disclosures in the consolidated financial statements. Our audits also included evaluating the accounting principles used and significant estimates made by management, as well as evaluating the overall presentation of the consolidated financial statements. We believe that our audits provide a reasonable basis for our opinion.

Critical Audit Matter – Debt and Equity Accounting Considerations

The critical audit matter communicated below is a matter arising from the current period audit of the financial statements that was communicated or required to be communicated to the Company’s Audit Committee and that: (i) relates to accounts or disclosures that are material to the financial statements and (ii) involved especially challenging, subjective, or complex judgements. The communication of critical audit matters does not alter in any way our opinion on the consolidated financial statements, taken as a whole, and we are not, by communicating the critical audit matter below, providing a separate opinion on the critical audit matter or on the accounts or disclosures to which it relates.

F-2

Critical Audit Matter Description

As disclosed in Notes 4, 8, and 11 to the consolidated financial statements, the Company had various debt, derivative, and equity transactions where management evaluated required accounting considerations, significant estimates, and judgements around certain features, the possibility of conversion or redemption, and the valuation of certain components of the financings, including the valuation around certain freestanding and embedded derivatives. Certain features were initially measured at fair value and subsequently have been remeasured to fair value at each reporting period.

There is no current observable market for these types of features and, as such, the Company determined the fair value of the freestanding instruments or embedded derivatives using the Black-Scholes-Merton or the Monte Carlo option pricing model to measure the fair value of the debt and/or equity instrument both with and without the derivative liability features. As a result, a high degree of auditor judgment and effort was required in performing audit procedures to evaluate the various components of these instruments.

How the Critical Audit Matter Was Addressed In the Audit

Our principal audit procedures performed to address this critical audit matter included the following:

We obtained an understanding of the internal controls and processes surrounding complex debt, derivative liabilities, and equity transactions.
We obtained a listing and of all debt, derivative liabilities, and equity transactions and management’s accounting analysis supporting these transactions. We evaluated the conclusions reached to ensure these were recorded in accordance with the relevant accounting guidance.
We identified and evaluated the accounting considerations in determining the nature of the various features and weighting of evidence, the potential bifurcation of these instruments, and considerations related to the determination of the fair value of the various debt and equity instruments and the conversion and redemption features that include complex valuation models and assumptions utilized by management. We reviewed the fair value models used, significant assumptions, and underlying data used in the models.
We evaluated the disclosures surrounding debt, derivative liabilities, and equity transactions to ensure these were disclosed in accordance with the relevant accounting guidance.

We have served as the Company’s auditors since 2021.

/s/ Cherry Bekaert LLP

Tampa, Florida

March 31, 2021

F-3

REPORT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM

To the Shareholders and Board of Directors of

Northwest Biotherapeutics, Inc.

Opinion on the Financial Statements

We have audited the accompanying consolidated balance sheet of Northwest Biotherapeutics, Inc. and Subsidiaries (the “Company”) as of December 31, 2019, the related statements of operations and comprehensive loss, changes in stockholders’ deficit and cash flows for the year ended December 31, 2019, and the related notes (collectively referred to as the “financial statements”).  In our opinion, the financial statements present fairly, in all material respects, the financial position of the Company as of December 31, 2019, and the results of its operations and its cash flows for the year ended December 31, 2019, in conformity with accounting principles generally accepted in the United States of America.

We also have audited, in accordance with the standards of the Public Company Accounting Oversight Board (United States) ("PCAOB"), the Company's internal control over financial reporting as of December 31, 2019, based on the criteria established in Internal Control - Integrated Framework issued by the Committee of Sponsoring Organizations of the Treadway Commission (COSO) in 2013 and our report dated March 16, 2020, expressed an unqualified opinion on the effectiveness of the Company’s internal control over financial reporting, except for the restatement as to the effectiveness of internal control over financial reporting for the material weakness related to ineffective designed controls over the evaluation and conclusion of contingencies under ASC 740, as to which the date is June 23, 2020.

Explanatory Paragraph – Going Concern

The accompanying consolidated financial statements have been prepared assuming that the Company will continue as a going concern. As more fully described in Note 2, the Company has incurred recurring operating losses and net operating cash flow deficits, and needs to raise additional funds to meet its obligations and sustain its operations. These conditions raise substantial doubt about the Company's ability to continue as a going concern. Management's plans in regard to these matters are also described in Note 2. The consolidated financial statements do not include any adjustments that might result from the outcome of this uncertainty.

Change in Accounting Principle

As discussed in Note 3 to the consolidated financial statements, the Company has changed its method of accounting for leases in 2019 due to the adoption of the guidance in ASC Topic 842, Leases (“Topic 842”).

Basis for Opinion

These financial statements are the responsibility of the Company's management. Our responsibility is to express an opinion on the Company's financial statements based on our audit. We are a public accounting firm registered with the Public Company Accounting Oversight Board (United States) ("PCAOB") and are required to be independent with respect to the Company in accordance with the U.S. federal securities laws and the applicable rules and regulations of the Securities and Exchange Commission and the PCAOB.

We conducted our audit in accordance with the standards of the PCAOB. Those standards require that we plan and perform the audit to obtain reasonable assurance about whether the financial statements are free of material misstatement, whether due to error or fraud. Our audit included performing procedures to assess the risks of material misstatement of the financial statements, whether due to error or fraud, and performing procedures that respond to those risks. Such procedures included examining, on a test basis, evidence regarding the amounts and disclosures in the financial statements. Our audit also included evaluating the accounting principles used and significant estimates made by management, as well as evaluating the overall presentation of the financial statements. We believe that our audit provides a reasonable basis for our opinion.

/s/ Marcum LLP

Marcum LLP

F-4

We served as the Company’s auditor from 2013 to 2021.

New York, NY

March 16, 2020, except for the restatement as to the effectiveness of internal control over financial reporting for the material weakness related to ineffective designed controls over the evaluation and conclusion of contingencies under ASC 740, as to which the date is June 23, 2020.

F-5

NORTHWEST BIOTHERAPEUTICS, INC.

CONSOLIDATED BALANCE SHEETS

(in thousands, except share and per share data)

    

December 31, 

    

December 31, 

2020

2019

(As revised) (Note 14)

ASSETS

 

  

 

Current assets:

 

  

 

  

Cash and cash equivalents

$

9,983

$

372

Prepaid expenses and other current assets

 

5,528

 

2,828

Total current assets

 

15,511

 

3,200

Non-current assets:

 

 

  

Property, plant and equipment, net

 

1,040

 

281

Construction in progress

9,074

1,685

Right-of-use asset, net

4,489

4,679

Indefinite-lived intangible asset

1,292

Goodwill

626

Other assets

 

867

 

798

Total non-current assets

 

17,388

 

7,443

TOTAL ASSETS

$

32,899

$

10,643

LIABILITIES AND STOCKHOLDERS’ DEFICIT

 

 

  

Current liabilities:

 

 

  

Accounts payable and accrued expenses

$

7,380

$

6,348

Accounts payable and accrued expenses to related parties and affiliates

 

5,363

 

3,844

Convertible notes, net

 

3,830

 

568

Notes payable, net

 

2,437

 

5,501

Notes payable to related party

 

 

66

Contingent payable derivative liability

8,275

7,261

Warrant liability

 

354,972

 

20,213

Lease liabilities

167

395

Total current liabilities

 

382,424

 

44,196

Non-current liabilities:

 

  

 

  

Note payable, net of current portion, net

 

8,507

 

6,588

Lease liabilities, net of current portion

4,916

4,914

Total non-current liabilities

 

13,423

 

11,502

Total liabilities

 

395,847

 

55,698

COMMITMENTS AND CONTINGENCIES (Note 12)

 

  

 

  

Stockholders’ deficit:

 

  

 

  

Preferred stock ($0.001 par value); 100,000,000 shares authorized as of December 31, 2020 and 2019, respectively

Common stock ($0.001 par value); 1,200,000,000 shares authorized; 829.6 million and 614.3 million shares issued and outstanding as of December 31, 2020 and 2019, respectively

 

830

 

614

Additional paid-in capital

 

1,008,665

 

794,900

Stock subscription receivable

 

(79)

 

(10)

Accumulated deficit

 

(1,371,216)

 

(841,395)

Accumulated other comprehensive income

 

(1,148)

 

836

Total stockholders’ deficit

 

(362,948)

 

(45,055)

TOTAL LIABILITIES AND STOCKHOLDERS’ DEFICIT

$

32,899

$

10,643

See accompanying notes to the consolidated financial statements

F-6

NORTHWEST BIOTHERAPEUTICS, INC.

CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS

(in thousands, except per share data)

For the Years ended

December 31, 

2020

    

2019

(As revised) (Note 14)

Revenues:

  

 

  

Research and other

$

1,291

$

2,410

Total revenues

 

1,291

 

2,410

Operating costs and expenses:

 

  

 

  

Research and development

 

33,637

 

14,106

General and administrative

 

50,992

 

12,541

Legal expenses

 

3,267

 

3,742

Total operating costs and expenses

 

87,896

 

30,389

Loss from operations

 

(86,605)

 

(27,979)

Other income (expense):

 

 

  

Change in fair value of derivative liabilities

 

(435,351)

 

11,828

Loss from extinguishment of debt

 

(1,582)

 

(1,941)

Interest expense

 

(8,544)

 

(2,975)

Foreign currency transaction gain

 

2,261

 

255

Total other income (expense)

 

(443,216)

 

7,167

Net loss

$

(529,821)

$

(20,812)

Other comprehensive loss

Foreign currency translation adjustment

(1,984)

(164)

Total comprehensive loss

$

(531,805)

$

(20,976)

Net loss per share applicable to common stockholders - basic and diluted

$

(0.73)

$

(0.04)

Weighted average shares used in computing basic and diluted loss per share

725,129

564,188

See accompanying notes to the consolidated financial statements

F-7

NORTHWEST BIOTHERAPEUTICS, INC.

CONSOLIDATED STATEMENTS OF CHANGES IN STOCKHOLDERS’ DEFICIT

(in thousands)

Accumulated

Additional

Other

Total

Common Stock

Paid-in

Subscription

Accumulated

Comprehensive

Stockholders’

    

Shares

    

Par value

    

Capital

    

Receivable

Deficit

    

Income (Loss)

    

Equity (Deficit)

Balance at January  1, 2019

 

523,232

 

$

523

 

$

775,741

 

$

(10)

 

$

(825,385)

 

$

1,000

 

$

(48,131)

Issuance of common stock and warrants for cash in a registered direct offering (net of $2.7 million warrant liability and $0.4 million cash offering cost)

 

32,708

 

33

 

4,040

 

 

 

 

4,073

Warrants exercised for cash

 

9,532

 

10

 

2,210

 

 

 

 

2,220

Reclassification of warrant liabilities related to warrants exercised for cash

 

 

 

1,759

 

 

 

 

1,759

Issuance of common stock and warrants for conversion of debt and accrued interest

 

35,480

 

35

 

9,138

 

 

 

 

9,173

Stock-based compensation

 

1,340

 

1

 

1,818

 

 

 

 

1,819

Cumulative effect of adopting new accounting standard

 

 

 

 

 

4,802

 

 

4,802

Issuance of common shares in connection with a settlement agreement

 

12,000

 

12

 

(12)

 

 

 

 

Beneficial conversion feature related to amended convertible note

 

 

 

68

 

 

 

 

68

Reclass between shares payable and additional paid-in capital

 

 

 

138

 

 

 

 

138

Net loss  (As revised) (Note 14)

 

 

 

 

 

(20,812)

 

 

(20,812)

Cumulative translation adjustment

 

 

 

 

 

 

(164)

 

(164)

Balance at December 31, 2019

 

614,292

614

794,900

(10)

(841,395)

836

(45,055)

Issuance of common stock and warrants for cash in a registered direct offering (net of $10.3 million warrant liability and $0.6 million cash offering cost)

97,981

98

16,462

(69)

16,491

Issuance of common stock and warrants for conversion of debt and accrued interest

58,368

58

19,591

19,649

Warrants exercised for cash

47,511

48

13,867

13,915

Reclassification of warrant liabilities related to warrants exercised for cash

22,701

22,701

Cashless warrants exercise

7,086

7

(7)

Cashless option exercise

71

-

Reclassification of warrant liabilities related to cashless warrants exercise

9,478

9,478

Beneficial conversion feature related to amended convertible note

44

44

Issuance of common stock in connection with Flaskworks acquisition

655

1

1,132

1,133

Stock-based compensation

3,667

4

52,205

52,209

Reclassification of warrant liabilities related to sequencing policy

78,292

78,292

Net loss

-

(529,821)

(529,821)

Cumulative translation adjustment

-

(1,984)

(1,984)

Balance at December 31, 2020

829,631

$

830

$

1,008,665

$

(79)

$

(1,371,216)

$

(1,148)

$

(362,948)

See accompanying notes to the consolidated financial statements

F-8

NORTHWEST BIOTHERAPEUTICS, INC.

CONSOLIDATED STATEMENTS OF CASH FLOWS

(in thousands)

For the Years ended

December 31, 

2020

    

2019

(As revised) (Note 14)

Cash Flows from Operating Activities:

  

 

  

Net loss

$

(529,821)

$

(20,812)

Reconciliation of net loss to net cash used in operating activities:

 

 

Depreciation and amortization

 

87

 

21

Amortization of debt discount

 

3,013

 

1,430

Change in fair value of derivatives

 

435,351

 

(11,828)

Change in fair value of contingent liability

913

Loss from extinguishment of debt

 

1,582

 

1,941

Amortization of operating lease right-of-use asset

338

(322)

Stock-based compensation related to warrants modification

 

 

3

Stock-based compensation for services

 

52,209

 

1,819

Non-cash interest expense

4,270

Subtotal of non-cash charges

 

497,763

 

(6,936)

Changes in operating assets and liabilities:

 

  

 

  

Prepaid expenses and other current assets

 

(2,350)

 

(1,226)

Other non-current assets

 

(31)

 

(11)

Accounts payable and accrued expenses

 

1,702

 

30

Related party accounts payable and accrued expenses

 

431

 

(3,230)

Lease liabilities

213

326

Net cash used in operating activities

 

(32,093)

 

(31,859)

Cash Flows from Investing Activities:

 

  

 

  

Purchase of equipment and construction in progress

 

(6,610)

 

(360)

Acquisition of Flaskworks, net of cash

(1,532)

Net cash used in investing activities

 

(8,142)

 

(360)

Cash Flows from Financing Activities:

 

  

 

  

Proceeds from issuance of common stock and warrants in a registered direct offering, net

 

26,814

 

6,874

Proceeds from exercise of warrants

 

13,915

 

2,220

Proceeds from warrants modification

 

4

 

7

Proceeds from issuance of notes payable, net

 

8,557

 

7,000

Proceeds from issuance of convertible notes payable, net

 

5,115

 

Proceeds from issuance of convertible notes payable to related party

 

315

 

Repayment of notes payable

 

(1,556)

 

(420)

Repayment of notes payable to related parties

 

(379)

 

(329)

Repayment of convertible notes payable

 

(89)

 

Repayment of convertible notes payable to related parties

(5,400)

Net cash provided by financing activities

 

52,696

 

9,952

Effect of exchange rate changes on cash and cash equivalents

 

(2,850)

 

415

Net increase (decrease) in cash and cash equivalents

 

9,611

 

(21,852)

Cash and cash equivalents, beginning of the year

 

372

 

22,224

Cash and cash equivalents, end of the year

$

9,983

$

372

Supplemental disclosure of cash flow information

 

  

 

  

Interest payments on notes payable  

$

$

(43)

Interest payments on notes payable to related party

$

(9)

$

(177)

Interest payments on convertible notes payable

$

(11)

$

Interest payments on convertible notes payable to related party

$

(19)

$

(795)

See accompanying notes to the consolidated financial statement

F-9

NORTHWEST BIOTHERAPEUTICS, INC.

CONSOLIDATED STATEMENTS OF CASH FLOWS

(in thousands)

For the Years ended

December 31, 

2020

    

2019

(As revised) (Note 14)

Supplemental schedule of non-cash investing and financing activities:

  

 

  

Issuance of common stock as consideration related to Flaskworks acquisition

$

220

$

Cashless warrants exercise

$

7

$

Reclassification of warrant liabilities related to warrants exercised for cash

$

22,701

$

1,759

Reclassification of warrant liabilities related to cashless warrants exercise

$

9,478

$

Reclassification of warrant liabilities related to sequencing policy

$

78,292

$

Issuance of common stock and warrants for conversion of debt and accrued interest

$

8,230

$

7,313

Offering cost related to warrant liability

$

4,876

$

2,693

Deferred offering cost

$

$

108

Issuance of warrants in conjunction with convertible note payable

$

153

$

Issuance of warrants in connection with debt modification

$

395

$

Warrant modification in connection with debt amendment

$

91

$

Beneficial conversion feature related to amended convertible note

$

44

$

68

Reclass between shares payable and additional paid-in capital

$

$

138

Capital expenditures included in accounts payable

$

1,088

$

947

Conversion of outstanding accounts payables to note payable and contingent payable

$

$

8,560

Issuance of common shares in connection with a settlement agreement

$

$

12

See accompanying notes to the consolidated financial statement

F-10

Table of Contents

NORTHWEST BIOTHERAPEUTICS, INC.

Notes to the Consolidated Financial Statements

1. Organization and Description of Business

Northwest Biotherapeutics, Inc. and its wholly owned subsidiaries NW Bio GmbH, Aracaris Ltd, Aracaris Capital, Ltd, and Northwest Biotherapeutics B.V. (collectively, the “Company”, “we”, “us” and “our”) were organized to discover and develop innovative immunotherapies for cancer. The Company has developed DCVax® platform technologies for both operable and inoperable solid tumor cancers. The Company has wholly owned subsidiaries in the U.K. and on April 25, 2019, the Company established a new wholly owned subsidiary Northwest Biotherapeutics B.V. in the Netherlands, where the European Medicines Agency is relocating.

The Company relies upon contract manufacturers for production of its DCVax products, research and development services, distribution and logistics, and related services, in compliance with the Company’s specifications and the applicable regulatory requirements.

On August 28, 2020, the Company acquired Flaskworks, LLC (“Flaskworks”), a company that has developed a system to close and automate the manufacturing of cell therapy products such as DCVax®.

2. Financial Condition, Going Concern and Management Plans

The Company has incurred annual net operating losses since its inception. The Company had a net loss of $529.8 million, which included a cash loss of $32 million and a non-cash loss of $497.8 million, for the year ended December 31, 2020. The increase in net loss for the year ended December 31, 2020 was primarily due to the increased stock price, which resulted in significant non-cash loss from the change on the derivative liability. The Company used approximately $32.1 million of cash in its operating activities for the year ended December 31, 2020. Management believes that the Company has access to capital resources through the sale of equity and debt financing arrangements. However, the Company has not secured any commitments for new financing for this specific purpose at this time.

The Company does not expect to generate material revenue in the near future from the sale of products and is subject to all of the risks and uncertainties that are typically faced by biotechnology companies that devote substantially all of their efforts to R&D and clinical trials and do not yet have commercial products. The Company expects to continue incurring annual losses for the foreseeable future. The Company’s existing liquidity is not sufficient to fund its operations, anticipated capital expenditures, working capital and other financing requirements until the Company reaches significant revenues. Until that time, the Company will need to obtain additional equity and/or debt financing, especially if the Company experiences downturns in its business that are more severe or longer than anticipated, or if the Company experiences significant increases in expense levels resulting from being a publicly-traded company or from expansion of operations. If the Company attempts to obtain additional equity or debt financing, the Company cannot assume that such financing will be available to the Company on favorable terms, or at all. Because of recurring operating losses and operating cash flow deficits, there is substantial doubt about the Company’s ability to continue as a going concern within one year from the date of this filing. The consolidated financial statements have been prepared assuming that the Company will continue as a going concern, and do not include any adjustments to reflect the possible future effects on the recoverability and classification of assets, or the amounts and classification of liabilities that may result from the outcome of this uncertainty.

As also previously reported, coronavirus-related difficulties have impacted most aspects of the process, especially with the successive waves of COVID cases in many areas. The independent service firms have had limited capacity, and restrictions on operations. Key experts at certain specialized service providers have been unavailable for periods of time due to illness in their family.  Other experts have gone on extended leave due to restrictions on operations. Clinical trial site personnel have been unavailable due to being reassigned for COVID, and the limited site personnel have had to work under restrictions. Committee processes and regulatory processes have been similarly focused on COVID matters and delayed on other matters. Firms such as the ones storing the Phase III trial tissue samples that are needed for certain analyses, and the firms conducting the analyses, continue to have only limited operations. Even logistical matters such as the shipping of materials have been, and continue to be, subjected to substantial restrictions and delays.

3. Summary of Significant Accounting Policies

Basis of Presentation

The accompanying consolidated financial statements of the Company were prepared in accordance with generally accepted accounting principles in the U.S. (“U.S. GAAP”) and include the assets, liabilities, revenues and expenses of the wholly owned subsidiaries in Germany, United Kingdom and Netherlands. All intercompany transactions and accounts have been eliminated in consolidation.

F-11

Table of Contents

NORTHWEST BIOTHERAPEUTICS, INC.

Notes to the Consolidated Financial Statements

Consolidation

The Company’s policy is to consolidate all entities in which it can vote a majority of the outstanding voting stock. In addition, the Company consolidates entities that meet the definition of a variable interest entity (VIE) for which the Company is the primary beneficiary, if any. The primary beneficiary is the party who has the power to direct the activities of a VIE that most significantly impact the entity’s economic performance and who has an obligation to absorb losses of the entity or a right to receive benefits from the entity that could potentially be significant to the VIE.

As of December 31, 2020, the Company did not consolidate any VIE's as the Company has concluded that it is not the primary beneficiary.

Use of Estimates

In preparing consolidated financial statements in conformity with U.S. GAAP, management is required to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements, as well as the reported amounts of expenses during the reporting period. Due to inherent uncertainty involved in making estimates, actual results reported in future periods may be affected by changes in these estimates.

On an ongoing basis, the Company evaluates its estimates and judgments, including valuing equity securities in share-based payment arrangements, estimating the fair value of financial instruments recorded as derivative liabilities, useful lives of depreciable assets and whether impairment charges may apply. The Company bases its estimates on historical experience and on various other assumptions that it believes to be reasonable under the circumstances, the results of which form the basis for making judgments about the carrying values of assets and liabilities and the reported amounts of revenues and expenses that are not readily apparent from other sources. Actual results could differ from those estimates, particularly given the significant social and economic disruptions and uncertainties associated with the ongoing coronavirus pandemic ("COVID-19") and the COVID-19 control responses.

Concentration of Credit Risk

Financial instruments that potentially subject the Company to concentration of credit risk consist of cash accounts in a financial institution, which at times may exceed the Federal depository insurance coverage (“FDIC”) of $250,000. As of December 31, 2020, of the total $10 million in cash and cash equivalents, $0.6 million was held by foreign subsidiaries. The Company had not experienced losses on these accounts and management believes the Company is not exposed to significant risks on such accounts.

Property, Plant and Equipment

Property and equipment are stated at cost. Depreciation and amortization are provided for using straight-line methods, in amounts sufficient to charge the cost of depreciable assets to operations over their estimated service lives. Repairs and maintenance costs are charged to operations as incurred.

Costs for capital assets not yet placed into service are capitalized as construction in progress on the consolidated balance sheets and will be depreciated once placed into service.

The Company assesses its long-lived assets for impairment whenever facts and circumstances indicate that the carrying amounts may not be fully recoverable. To analyze recoverability, the Company projects undiscounted net future cash flows over the remaining lives of such assets. If these projected undiscounted net future cash flows are less than the carrying amounts, an impairment loss would be recognized, resulting in a write-down of the assets with a corresponding charge to earnings. The impairment loss is measured based upon the difference between the carrying amounts and the fair values of the assets.

F-12

Table of Contents

NORTHWEST BIOTHERAPEUTICS, INC.

Notes to the Consolidated Financial Statements

Goodwill and Intangible Assets

Goodwill is the excess of purchase price over the fair value of identified net assets of businesses acquired. The Company's intangible asset with an indefinite life is related to in-process research and development ("IPR&D") programs acquired in the Flaskworks Acquisition, as the Company expects future research and development on these programs to provide the Company with substantial benefit for a period that extends beyond the foreseeable horizon. Intangible assets with indefinite useful lives are measured at their respective fair values as of the acquisition date. The Company does not amortize goodwill and intangible assets with indefinite useful lives. Intangible assets related to IPR&D projects are considered to be indefinite lived until the completion or abandonment of the associated R&D efforts. If and when development is complete, which generally occurs if and when regulatory approval to market a product is obtained, the associated assets would be deemed finite lived and would then be amortized based on their respective estimated useful lives at that point in time.

The Company has one operating segment and one reporting unit. The Company reviews goodwill and indefinite-lived intangible assets at least annually for possible impairment. Goodwill and indefinite-lived intangible assets are reviewed for possible impairment between annual tests if an event occurs or circumstances change that would more likely than not reduce the fair value of the reporting unit or the indefinite-lived intangible assets below their carrying values. No impairment charge was recognized for the year ended December 31, 2020.

Fair Value of Financial Instruments

ASC 820, Fair Value Measurements, provides guidance on the development and disclosure of fair value measurements. Under this accounting guidance, fair value is defined as an exit price, representing the amount that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date. As such, fair value is a market-based measurement that should be determined based on assumptions that market participants would use in pricing an asset or a liability.

The accounting guidance classifies fair value measurements in one of the following three categories for disclosure purposes:

Level 1:    Quoted prices in active markets for identical assets or liabilities.

Level 2:    Inputs other than Level 1 prices for similar assets or liabilities that are directly or indirectly observable in the marketplace.

Level 3:    Unobservable inputs which are supported by little or no market activity and values determined using pricing models, discounted cash flow methodologies, or similar techniques, as well as instruments for which the determination of fair value requires significant judgment or estimation.

The Company accounts for the issuance of common stock purchase warrants issued in connection with the equity offerings in accordance with the provisions of ASC 815, Derivatives and Hedging ("ASC 815"). The Company classifies as equity any contracts that (i) require physical settlement or net-share settlement or (ii) gives the Company a choice of net-cash settlement or settlement in its own shares (physical settlement or net-share settlement). The Company accounts for certain common stock warrants outstanding as a liability at fair value and adjusts the instruments to fair value at each reporting period. This liability is subject to re-measurement at each balance sheet date until exercised, and any change in fair value is recognized in its Consolidated Statements of Operations and Comprehensive Loss. The fair value of the warrants issued by the Company has been estimated using Monte Carlo simulation and or a Black Scholes model. The warrant liabilities are valued using Level 3 valuation inputs (see Note 4).

Embedded Conversion Features

The Company evaluates embedded conversion features within convertible debt instruments to determine whether the embedded conversion feature(s) should be bifurcated from the host instrument and accounted for as a derivative at fair value with changes in fair value recorded in the Statement of Operations. If the conversion feature does not require recognition of a bifurcated derivative, the convertible debt instrument is evaluated for consideration of any beneficial conversion feature (“BCF”) requiring separate recognition. When the Company record a BCF, the intrinsic value of the BCF is recorded as a debt discount against the face amount of the respective debt instrument (offset to additional paid-in capital) and amortized to interest expense over the life of the debt.

F-13

Table of Contents

NORTHWEST BIOTHERAPEUTICS, INC.

Notes to the Consolidated Financial Statements

Derivative Financial Instruments

The Company has derivative financial instruments that are not hedges and do not qualify for hedge accounting. Changes in the fair value of these instruments are recorded in other income (expense), on a net basis in the Consolidated Statements of Operations and Comprehensive Loss.

Contingent payable derivative liability

During the year ended December 31, 2019, the Company entered into a settlement agreement with Cognate BioServices, resolving past matters and providing for the restart of DCVax®-Direct Production.

As part of this overall settlement, the Company also provided a contingent note payable (the “Contingent Payable Derivative”) of $10 million, which is only payable upon the Company’s first financing after DCVax product approval in or outside the U.S. If such product approval has not been obtained by the seventh anniversary of the agreement, such Contingent Payable Derivative will expire without becoming payable.

On a quarterly basis, management makes estimates for key performance milestones and uses the expected dates as the inputs for valuation. The fair value of the Contingent Payable Derivative has been estimated using Monte Carlo simulation, which are valued using Level 3 valuation inputs.

Leases

Prior to January 1, 2019, the Company recognized rent expense on a straight-line basis over the lease period and accounts for the difference between straight-line rent and actual lease payments as deferred rent.

Subsequent to the adoption of the new leasing standard on January 1, 2019, the Company recognizes a lease asset for its right to use the underlying asset and a lease liability for the corresponding lease obligation. The Company determines whether an arrangement is or contains a lease at contract inception. Operating leases with a duration greater than one year are included in right-of-use assets, lease liabilities, and lease liabilities, net of current portion in the Company’s consolidated balance sheets. Right-of-use assets and liabilities are recognized at the lease commencement date based on the present value of lease payments over the lease term. In determining the net present value of lease payments, the Company uses its incremental borrowing rate based on the information available at the lease commencement date. The incremental borrowing rate represents the interest rate the Company would incur at lease commencement to borrow an amount equal to the lease payments on a collateralized basis over the term of a lease. The Company considers a lease term to be the non-cancelable period that it has the right to use the underlying asset.

The operating lease right-of-use assets also include any lease payments made and exclude lease incentives. Lease expense is recognized on a straight-line basis over the expected lease term. Variable lease expenses are recorded when incurred.

Foreign Currency Translation and Transactions

The Company has operations in Germany, the United Kingdom and Netherlands in addition to the U.S. The Company translated its assets and liabilities into U.S. dollars using end of period exchange rates and revenues and expenses are translated into U.S. dollars using weighted average rates. Foreign currency translation adjustments are reported as a separate component of accumulated other comprehensive income (loss) within stockholders’ equity deficit.

The Company converts receivables and payables denominated in other than the Company’s functional currency at the exchange rate as of the balance sheet date. The resulting transaction exchange gains or losses related to intercompany receivable and payables, are included in other income and expense.

F-14

Table of Contents

NORTHWEST BIOTHERAPEUTICS, INC.

Notes to the Consolidated Financial Statements

Comprehensive Loss

The Company reports comprehensive loss and its components in its consolidated financial statements. Comprehensive loss consists of net loss and foreign currency translation adjustments, affecting stockholders’ equity deficit that, under U.S, GAAP, is excluded from net loss.

Revenue Recognition

The Company recognizes revenue in accordance with the terms stipulated under the patient service contract. In various situations, the Company receives certain payments for DCVax®-L for patient treatment. These payments are assessed and recognized in accordance with ASC 606 in the period when the performance obligation has been met.

Accrued Outsourcing Costs

Substantial portions of our preclinical studies and clinical trials are performed by third-party laboratories, medical centers, contract research organizations and other vendors (collectively “CROs”). These CROs generally bill monthly or quarterly for services performed, or bill based upon milestones achieved. For clinical studies, expenses are accrued when services are performed. The Company monitors patient enrollment, the progress of clinical studies and related activities through internal reviews of data that is tracked by the CROs under contractual arrangements, correspondence with the CROs and visits to clinical sites.

Research and Development Costs

Research and development costs are charged to operations as incurred and consist primarily of clinical trial related costs (including costs for collection, validation and analysis of trial results), related party manufacturing costs, consulting costs, contract research and development costs, clinical site costs and compensation costs.

Income Taxes

The Company evaluates its tax positions and estimates its current tax exposure along with assessing temporary differences that result from different book to tax treatment of items not currently deductible for tax purposes. These differences result in deferred tax assets and liabilities on the Company’s Consolidated Balance Sheets, which are estimated based upon the difference between the financial statement and tax bases of assets and liabilities using the enacted tax rates that will be in effect when these differences reverse. In general, deferred tax assets represent future tax benefits to be received when certain expenses previously recognized in the Company’s Consolidated Statements of Comprehensive Loss become deductible expenses under applicable income tax laws or loss or credit carryforwards are utilized. Accordingly, realization of the Company’s deferred tax assets is dependent on future taxable income against which these deductions, losses and credits can be utilized.

The Company must assess the likelihood that the Company’s deferred tax assets will be recovered from future taxable income, and to the extent the Company believes that recovery is not more likely than not, the Company must establish a valuation allowance. Management judgment is required in determining the Company’s provision for income taxes, the Company’s deferred tax assets and liabilities and any valuation allowance recorded against the Company’s net deferred tax assets. Excluding foreign operations, the Company recorded a full valuation allowance at each balance sheet date presented because, based on the available evidence, the Company believes it is more likely than not that it will not be able to utilize all of its deferred tax assets in the future. The Company intends to maintain the full valuation allowance until sufficient evidence exists to support the reversal of the valuation allowance.

Stock Based Compensation

The Company measures stock-based compensation to employees, consultants, and Board members at fair value on the grant date of the award. Compensation cost is recognized as expense on a straight-line basis over the requisite service period of the award. For awards that have a performance condition, compensation cost is measured based on the fair value of the award on the grant date, the date performance targets are established, and is expensed over the requisite service period for each separately vesting tranche when achievement of the performance condition becomes probable. The Company assess the probability of the performance conditions being

F-15

Table of Contents

NORTHWEST BIOTHERAPEUTICS, INC.

Notes to the Consolidated Financial Statements

met on a continuous basis. Forfeitures are recognized when they occur. Prior to January 1, 2019, share-based compensation cost for non-employees was re-measured at every reporting period.

The Company estimates the fair value of stock option grants that do not contain market-based vesting conditions using the Black-Scholes option pricing model and the assumptions used in calculating the fair value of stock-based awards represent management’s best estimates and involve inherent uncertainties and the application of management’s judgment.

Expected Term - The expected term of options represents the period that the Company’s stock-based awards are expected to be outstanding based on the simplified method, which is the half-life from vesting to the end of its contractual term.

Expected Volatility - The Company computes stock price volatility over expected terms based on its historical common stock trading prices.

Risk-Free Interest Rate - The Company bases the risk-free interest rate on the implied yield available on U. S. Treasury zero-coupon issues with an equivalent remaining term.

Expected Dividend - The Company has never declared or paid any cash dividends on its common shares and does not plan to pay cash dividends in the foreseeable future, and, therefore, uses an expected dividend yield of zero in its valuation models.

The Company is also required to make estimates as to the probability of achieving the specific performance conditions. If actual results are not consistent with the Company’s assumptions and judgments used in making these estimates, the Company may be required to increase or decrease compensation expense, which could be material to the Company’s consolidated results of operations.

Debt Extinguishment

The Company accounts for the income or loss from extinguishment of debt by comparing the difference between the reacquisition price and the net carrying amount of the debt being extinguished and recognizes this as gain or loss when the debt is extinguished. The gain or loss from debt extinguishment is recorded in the consolidated statements of operations under “other income (expense)” as loss from extinguishment of convertible debt.

Sequencing

The Company adopted a sequencing policy under ASC 815-40-35 whereby in the event that reclassification of contracts from equity to liabilities is necessary pursuant to ASC 815 due to the Company’s inability to demonstrate it has sufficient authorized shares. This was previously the result of certain financial instruments with a potentially indeterminable number of shares and most recently due to the company committing more shares than authorized. While temporary suspensions are in place to keep the potential exercises beneath the number authorized, certain instruments are classified as liabilities, after allocating available authorized shares on the basis of the earliest grant date of potentially dilutive instruments. Pursuant to ASC 815, issuance of stock based awards to the Company’s employees, nonemployees or directors are not subject to the sequencing policy.

Loss per Share

Basic loss per share is computed on the basis of the weighted average number of shares outstanding for the reporting period. Diluted loss per share is computed on the basis of the weighted average number of common shares plus dilutive potential common shares outstanding using the treasury stock method. Any potentially dilutive securities are anti-dilutive due to the Company’s net losses. For the years presented, there is no difference between the basic and diluted net loss per share.

Recent Accounting Standards

Income Taxes

In December 2019, the FASB issued ASU No. 2019-12, “Income Taxes (Topic 740): Simplifying the Accounting for Income Taxes (“ASU 2019-12”), which is intended to simplify various aspects related to accounting for income taxes. ASU 2019-12 removes certain

F-16

Table of Contents

NORTHWEST BIOTHERAPEUTICS, INC.

Notes to the Consolidated Financial Statements

exceptions to the general principles in Topic 740 and also clarifies and amends existing guidance to improve consistent application. This guidance is effective for fiscal years, and interim periods within those fiscal years, beginning after December 15, 2020, with early adoption permitted. The Company is currently evaluating the impact of this standard on its consolidated financial statements and related disclosures.

Debt

In August 2020, the FASB issued ASU No. 2020-06, Debt—Debt with Conversion and Other Options (Subtopic 470-20) and Derivatives and Hedging—Contracts in Entity’s Own Equity (Subtopic 815-40): Accounting for Convertible Instruments and Contracts in an Entity’s Own Equity, which simplifies accounting for convertible instruments by removing major separation models required under current GAAP. The ASU removes certain settlement conditions that are required for equity contracts to qualify for the derivative scope exception and it also simplifies the diluted earnings per share calculation in certain areas. This ASU is effective for annual reporting periods beginning after December 15, 2021, including interim periods within those fiscal years. Early adoption is permitted, but no earlier than fiscal years beginning after December 15, 2020. This update permits the use of either the modified retrospective or fully retrospective method of transition. The Company is currently evaluating the impact this ASU will have on the its consolidated financial statements and related disclosures.

4. Fair Value Measurements

In accordance with ASC 820 (Fair Value Measurements and Disclosures), the Company uses various inputs to measure the outstanding warrants, certain embedded conversion feature associated with convertible debt and contingent payable to Cognate BioServices on a recurring basis to determine the fair value of the liability.

Fair value measured at December 31, 2020

    

    

Quoted prices in active

    

Significant other

    

Significant

Fair value at

markets

observable inputs

unobservable inputs

December 31, 2020

(Level 1)

(Level 2)

(Level 3)

Warrant liability

$

354,972

$

$

$

354,972

Embedded conversion option

2,507

2,507

Contingent payable derivative liability

 

8,275

 

 

 

8,275

Total fair value

$

365,754

$

$

$

365,754

Fair value measured at December 31, 2019

    

    

Quoted prices in active

    

Significant other

    

Significant

Fair value at

markets

observable inputs

unobservable inputs

December 31, 2019

(Level 1)

(Level 2)

(Level 3)

Warrant liability

$

20,213

$

$

$

20,213

Contingent payable derivative liability

 

7,261

 

 

 

7,261

Total fair value

$

27,474

$

$

$

27,474

There were no transfers between Level 1, 2 or 3 during the years ended December 31, 2020 and 2019.

F-17

Table of Contents

NORTHWEST BIOTHERAPEUTICS, INC.

Notes to the Consolidated Financial Statements

The following table presents changes in Level 3 liabilities measured at fair value for the years ended December 31, 2020 and 2019. Both observable and unobservable inputs were used to determine the fair value of positions that the Company has classified within the Level 3 category. Unrealized gains and losses associated with liabilities within the Level 3 category include changes in fair value that were attributable to both observable (e.g., changes in market interest rates) and unobservable (e.g., changes in unobservable long- dated volatilities) inputs (in thousands).

Contingent

Embedded

Payable

Warrant

Conversion

Derivative

    

Liability

    

Option

    

Liability

    

Total

Balance - January 1, 2019

$

29,995

$

357

$

$

30,352

Additional contingent liability in connection with a settlement agreement

6,602

6,602

Additional warrant liability

4,110

4,110

Extinguishment of derivative liabilities

(3)

(3)

Extinguishment of warrant liabilities related to warrants exercised for cash

(1,759)

(1,759)

Change in fair value

(12,133)

(354)

659

(11,828)

Balance - December 31, 2019

20,213

7,261

27,474

Additional warrant liability

18,864

18,864

Reclassification of warrant liabilities

(110,471)

(110,471)

Extinguishment of embedded conversion option due to debt conversion and debt repayment

(8,271)

(8,271)

Additional embedded conversion option

2,807

2,807

Change in fair value

426,366

7,971

1,014

435,351

Balance - December 31, 2020

$

354,972

$

2,507

$

8,275

$

365,754

A summary of the weighted average (in aggregate) significant unobservable inputs (Level 3 inputs) used in measuring the Company’s warrant liabilities and embedded conversion feature that are categorized within Level 3 of the fair value hierarchy as of December 31, 2020 and 2019 is as follows:

    

As of December 31, 2020

 

Warrant

Embedded

Contingent Payable

 

Liability

Conversion Option

Derivative Liability

 

Strike price

$

0.28

$

0.59

$

1.53

Contractual term (years)

 

1.6

 

0.9

 

1.4

Volatility (annual)

 

116

%  

 

106

%  

 

126

%

Risk-free rate

 

0.2

%  

 

0.1

%  

 

0.1

%

Dividend yield (per share)

 

0

%  

 

0

%  

 

0

%

As of December 31, 2019

 

    

Warrant

    

Contingent Payable

 

Liability

Derivative Liability

 

Strike price

$

0.21

$

0.21

Contractual term (years)

 

1.4

 

1.0

Volatility (annual)

 

74

%  

 

62

%  

Risk-free rate

 

2

%  

 

2

%  

Dividend yield (per share)

 

0

%  

 

0

%  

* contingent payable derivative liability based on stock price as of December 31, 2020 and December 31, 2019

5. Flaskworks Acquisition

On August 28, 2020, the Company completed the acquisition of Flaskworks (the “Acquisition”), whereby Flaskworks became a wholly-owned subsidiary of the Company.

F-18

Table of Contents

NORTHWEST BIOTHERAPEUTICS, INC.

Notes to the Consolidated Financial Statements

The Unit Purchase Agreement was executed and closed on August 28, 2020. The Company acquired 100% of the ownership units of Flaskworks. Flaskworks was previously owned by its technical founders and Corning Inc. The technical team from Flaskworks has joined the Company as part of the Acquisition. It is anticipated that the Flaskworks system will enable substantial scale-up of production volumes of DCVax products and substantial reduction of production costs. The Company’s buildout of the Sawston, UK facility has been designed to proceed in phases, as modules, both for efficiency in the timing of capital costs and to allow flexibility in operations and usage. The Company anticipates that implementation of the Flaskworks system will enable certain phases of the buildout to be simplified and streamlined.

The total purchase price was approximately $4.3 million, of which $1.7 million was paid in cash at closing, up to $2.01 million will be paid in stock subject to milestone-based vesting (see Note 6), and $0.7 million was paid in either cash or stock, or a combination thereof, within 120 days after the closing. Between October and December 2020, $0.5 million was paid in cash upon the seller’s election.

In addition to the $0.5 million cash payment, on December 25, 2020, upon the seller’s election, the Company issued 654,762 shares in equivalent of $0.2 million special consideration payment pursuant to the Unit Purchase Agreement. The $0.336 per share price was established by the Unit Purchase Agreement. The incremental change in fair value of the shares resulting from market price increase was approximately $0.9 million, which was recognized as a component of general and administrative expense in the consolidated statement of operations.

Based on the Company's preliminary valuation, the total estimated consideration of $2.1 million has been allocated to assets acquired and liabilities assumed as of the acquisition date as follows (amount in thousands):

Cash

    

$

146

Current assets

 

135

Fixed assets, net

 

188

Indefinite-lived intangible asset

 

1,292

Security deposits

 

8

Total assets acquired

 

1,769

Accounts payable

 

(12)

Accrued expenses

 

(240)

Total liabilities assumed

 

(252)

Net identifiable assets acquired

 

1,517

Goodwill

 

626

Total estimated consideration (1)

$

2,143

Less special consideration paid in cash and stock

$

(465)

Less cash acquired

 

(146)

Total consideration paid, net of cash acquired

$

1,532

(1)The purchase price allocation excludes $2.01 million stock consideration, which was recorded as stock-based compensation for accounting purposes, although the treatment for tax purposes is anticipated to be different (see Note 6), and $0.2 million payable for services not related to the Acquisition in either cash or stock within 120 days after the closing.

The Acquisition was accounted for under the acquisition method of accounting in accordance with US GAAP. As such, results of operations for Flaskworks are included in the accompanying consolidated statements of operations since the Acquisition date, and the assets acquired and liabilities assumed were recorded at their fair value as of the Acquisition date.

Accordingly, goodwill has been measured as the excess of the total consideration over the amounts assigned to the identifiable assets acquired and liabilities assumed. Based on the Company's preliminary valuation, the Company recorded goodwill of approximately $0.6 million, which was primarily related to the acquisition of the assembled workforce and other indefinite-lived intangible asset of approximate $1.3 million in connection with the Acquisition. The $0.6 million of goodwill is expected to be deductible for tax purposes.

F-19

Table of Contents

NORTHWEST BIOTHERAPEUTICS, INC.

Notes to the Consolidated Financial Statements

The acquired Licensed IP Agreement was identified as an intangible asset and valued separate and apart from goodwill. Specifically, the Company used the Relief-from-Royalty Method, a form of the Income Approach, to estimate the fair value of the Licensed IP Agreement based on projected sales and cash flow. In application of the Relief-from-Royalty Method, we estimate the value of the Licensed IP Agreement by capitalizing the royalties saved because the Company owns the specific technology and the owner of the technology realizes a benefit from owning the intangible asset rather than paying a rent or royalty for the use of the asset.

The royalty rate used for this Licensed IP Agreement was based on the rate and terms indicated in the license agreement that was corroborated with the Company’s external research of third-party royalty rates for technology and patents in the pharma, healthcare, and medical industries. The estimation of fair value was determined based on the projected sales assuming commercialization of Flaskworks’ products and the respective royalty rate, tax affected and discounted to the present using a discount rate based on Flaskworks’ weighted average cost of capital.

The preliminary purchase price allocation is adjusted, as necessary, up to one year after the acquisition closing date if management obtains more information regarding asset valuations and liabilities assumed.

6. Stock-based Compensation

The following table summarizes total stock-based compensation expense recognized for the years ended December 31, 2020 and 2019 (in thousands):

    

For the years ended

December 31,

 

2020

 

2019

Research and development

$

19,792

$

471

General and administrative (1)

 

32,163

 

1,350

Total stock-based compensation expense

$

51,955

$

1,821

(1)The general and administrative expense during the years ended December 31, 2020 and 2019 is related to the applicable vesting portion of stock options awards made in the past and new options granted during the year ended December 31, 2020 to directors, employees and external consultants.

The Black-Scholes option pricing model is used to estimate the fair value of stock options granted. The weighted average assumptions used in calculating the fair values of stock options that were granted during the years ended December 31, 2020 and 2019:

    

For the years ended

 

December 31,

 

Grant Date

2020

2019

 

Exercise price

$

0.26

$

0.20

Expected term (years)

 

5.2

 

5.6

Expected stock price volatility

 

98

%  

 

86

%

Risk-free rate of interest

 

0

%  

 

1

%

The total unrecognized compensation cost was approximately $17 million as of December 31, 2020, and will be recognized over the next 1.8 years.

Stock Options

Equity Compensation Plan

On May 29, 2020, the Board of Directors of the Company approved a new equity compensation plan (the “Plan”). The Company’s prior plan was adopted in 2007, was updated in amended and restated plans that were approved by shareholders in 2012 and 2013, and expired in 2017 (the “Prior Plan”).

F-20

Table of Contents

NORTHWEST BIOTHERAPEUTICS, INC.

Notes to the Consolidated Financial Statements

The Plan is substantially similar to the Prior Plan. The Plan has a 10-year life, and allows for awards to employees, directors and consultants of the Company, as did the Prior Plan. The Plan allows for any type of equity security to be awarded, as did the Prior Plan. The awards and their terms (including vesting) will be determined by the Board and applicable Committees, as was the case under the Prior Plan. The Plan establishes a pool of potential equity compensation equal to twenty percent of the outstanding securities of the Company, which is on an evergreen basis as under the Prior Plan.

The following table summarizes stock option activity for the Company’s option plans during the years ended December 31, 2020 and 2019 (amount in thousands, except per share number):

    

    

    

Weighted

    

Average

Weighted

Remaining

Number of

Average Exercise

Contractual Life

Total Intrinsic

Shares

Price

(in years)

Value

Outstanding as of January 1, 2019

 

100,159

0.24

 

9.3

Granted

4,500

0.22

10.4

Outstanding as of December 31, 2019

104,659

$

0.24

8.4

$

Granted (Approved 2018-2020) (1)

208,525

0.37

(3)

10.0

Cashless exercise

 

(94)

 

0.34

 

Forfeited/expired

 

(4,250)

 

0.22

 

 

Outstanding as of December 31, 2020

 

308,840

$

0.33

 

8.9

$

372,219

Options vested (2)

 

223,720

$

0.30

 

8.7

$

276,432

(1)The options granted during the year ended December 31, 2020 included options already approved at various times during the 3 years 2018 - 2020 but not issued until Q3 2020, and also included options that will vest for performance and milestones going forward over the next 2 years. The options included awards to key external consultants and vendors in addition to internal parties.
(2)Approximately 128 million vested options as of December 31, 2020 are not exercisable until January 15, 2021. See Note 15 below under Subsequent Events for more information about additional options suspensions for further periods.
(3)The weighted average exercise price of the Q3 2020 options was initially $0.25. However, subsequently, the exercise price was amended to a weighted average exercise price of $0.36.

Stock Options Modification

On April 30, 2020, the Company's CEO, Linda Powers agreed to not exercise approximately 39.2 million existing options held by her for 6 months, until November 1, 2020 and correspondingly extended the contractual term for 6 months. The Company recognized approximately $78,000 of incremental stock-based compensation for this modification during the year ended December 31, 2020, based on the following weighted average assumptions:

    

Post Modification

    

Pre Modification

 

Exercise price

$

0.23

$

0.23

Expected term (years)

 

4.3

 

4.0

Expected stock price volatility

 

97

%

 

97

%

Risk-free rate of interest

 

0

%  

 

0

%

F-21

Table of Contents

NORTHWEST BIOTHERAPEUTICS, INC.

Notes to the Consolidated Financial Statements

For another officer, on August 5, 2020, the Company cancelled 1.75 million options which were originally issued in December 2019 and issued 3 million options (the “Replacement Options”) with an exercise price of $0.22 and vesting of 1/3 immediately and the remaining 2/3 vesting ratably over the following 24 months from the grant date. The incremental stock-based compensation for this modification was approximately $0.3 million based on the following weighted average assumptions, which will be amortized over the new vesting terms.

    

Post Modification

    

Pre Modification

 

Exercise price

$

0.22

$

0.22

Expected term (years)

 

5.3

 

4.7

Expected stock price volatility

 

96

%  

 

97

%

Risk-free rate of interest

 

0

%  

 

0

%

Flaskworks Acquisition

On August 28, 2020, the Company entered into a Unit Purchase Agreement (the “Agreement”) to acquire Flaskworks. Included in the consideration pursuant to the Agreement was Stock Consideration in the amount of approximately $2 million. This Stock Consideration is issued in the form of Rights to receive such value in shares issued pursuant to and subject to the vesting criteria set forth in a Rights Issuance Agreement entered into in connection with the closing of Flaskworks Acquisition. Because the Rights were subject to future employment and performance conditions, the Stock Consideration was not included in consideration payable for the Flaskworks Acquisition but rather was recorded as contingent consideration payable to employees for accounting purposes. The Company anticipates that the treatment of this Stock Consideration for tax purposes may be different than for accounting purposes, and will reflect the fact that this Stock Consideration was payment for acquisition of the ownership interests of certain shareholders of Flaskworks.

On December 1, 2020, the Company issued 1.5 million shares of common stock based upon the Flaskworks team having completed a significant milestone, in accordance with the Rights Issuance Agreement entered on August 28, 2020. During the year ended December 31, 2020, the Company recognized approximately $1.0 million stock-based compensation related to the Flaskworks Acquisition. Approximate $0.5 million was recognized in general and administrative and $0.5 million was recognized in research and development.

7. Property, Plant and Equipment

Property, plant and equipment consist of the following at December 31, 2020 and 2019 (in thousands):

    

December 31, 

    

December 31, 

    

Estimated

2020

2019

Useful Life

Leasehold improvements

$

81

$

186

 

Lesser of lease term or estimated useful life

Office furniture and equipment

 

219

 

59

 

3-5 years

Computer equipment and software

 

1,403

 

611

 

3-5 years

Land in the United Kingdom

93

90

NA

 

1,796

 

946

Less: accumulated depreciation

 

(756)

 

(665)

 

  

Total property, plant and equipment, net

$

1,040

$

281

 

  

Construction in progress

$

9,074

$

1,685

 

  

Depreciation expense was approximately $87,000 and $21,000 for the years ended December 31, 2020 and 2019, respectively.

Construction in Progress

In connection with the Company’s manufacturing facility in U.K, the Company has incurred and is incurring costs with certain vendors to design and build out certain stages of the facility. Additionally, the Company purchased certain manufacturing equipment that has been or will be installed in connection with the buildout. These costs were all capitalized and recorded as part of construction in progress as of December 31, 2020 and 2019. Upon completion of the buildout, all costs associated with the buildout will be recorded as manufacturing equipment or leasehold improvement, and amortized over the estimated useful life of the facility.

F-22

Table of Contents

NORTHWEST BIOTHERAPEUTICS, INC.

Notes to the Consolidated Financial Statements

8. Notes Payable

The following two tables summarize outstanding debt as of December 31, 2020 and December 31, 2019, respectively (amount in thousands):

    

    

Stated

    

    

    

    

Embedded

    

Interest

Conversion

Remaining

Conversion

Carrying

Maturity Date

Rate

Price

Face Value

Debt Discount

Option

Value

Short term convertible notes payable

 

  

 

  

 

  

 

  

 

  

 

  

 

  

6% unsecured (1)

 

Due

 

6

%  

$

3.09

$

135

$

$

$

135

8% unsecured (3) (4)

 

4/30/2021

 

8

%  

$

0.85

 

2,125

 

(937)

 

2,507

 

3,695

2,260

(937)

2,507

3,830

Short term notes payable

 

  

 

  

 

  

 

  

 

  

 

  

 

  

8% unsecured (5)

 

Various

 

8

%  

 

N/A

 

1,785

 

(51)

 

 

1,734

10% unsecured (6)

 

Various

 

10

%  

 

N/A

 

263

 

 

 

263

12% unsecured (7)

 

On Demand

 

12

%  

 

N/A

 

440

 

 

 

440

 

2,488

 

(51)

 

 

2,437

Long term notes payable

 

  

 

  

 

  

 

  

 

  

 

  

 

  

8% unsecured (10)

 

Various

 

8

%  

 

N/A

 

7,160

 

(496)

 

 

6,664

6% secured (11)

 

3/25/2025

 

6

%  

 

N/A

 

1,843

 

 

 

1,843

 

9,003

 

(496)

 

 

8,507

Ending balance as of December 31, 2020

$

13,751

$

(1,484)

$

2,507

$

14,774

    

    

Stated

    

    

    

    

Interest

Conversion

Remaining

Carrying

Maturity Date

Rate

Price

Face Value

Debt Discount

Value

Short term convertible notes payable

 

  

 

  

 

  

 

  

 

  

 

  

6% unsecured (1)

 

Due

 

6

%  

$

3.09

$

135

$

$

135

10% unsecured (2)

 

4/18/2020

 

10

%  

$

0.22

 

500

 

(67)

 

433

 

635

(67)

 

568

Short term notes payable

 

  

 

  

 

  

 

  

 

  

 

  

8% unsecured (5)

 

Various

 

8

%  

 

N/A

 

555

 

(43)

 

512

10% unsecured (6)

 

Various

 

10

%  

 

N/A

 

3,551

 

(73)

 

3,478

12% unsecured (7)

 

On Demand

 

12

%  

 

N/A

 

440

 

 

440

0% unsecured (8)

 

8/1/2020

 

0

%  

 

N/A

 

1,156

 

(85)

 

1,071

 

5,702

 

(201)

 

 

5,501

Short term notes payable - related parties

 

  

 

  

 

  

 

  

 

  

 

  

10% unsecured - Related Parties (9)

 

On Demand

 

10

%  

 

N/A

 

66

 

 

66

 

66

 

 

 

66

Long term notes payable

 

  

 

  

 

  

 

  

 

  

 

  

8% unsecured (5)

 

Various

 

8

%  

 

N/A

 

7,008

 

(420)

 

6,588

 

7,008

 

(420)

 

 

6,588

Ending balance as of December 31, 2019

$

13,411

$

(688)

$

12,723

(1)This $135,000 note as of December 31, 2020 and 2019 consists of two separate 6% notes in the amounts of $110,000 and $25,000. In regard to the $110,000 note, the Company has made ongoing attempts to locate the creditor to repay or convert this note, but has been unable to locate the creditor to date. In regard to the $25,000 note, the holder has elected to convert these notes into equity, the Company has delivered the applicable conversion documents to the holder, and the Company is waiting for the holder to execute and return the documents.
(2)In February 2020, the Company entered into multiple one-year convertible notes (the “February Notes”) with multiple holders (the “Holders”) for an aggregate principal amount of $1.0 million. The Notes are convertible into common shares of the Company at $0.21 per share and bear interest at the rate of 10% per annum. Upon issuance of the February Notes, the Holders also received a 2-year warrant to purchase a total of 1.4 million common shares of the Company at an exercise price of $0.35 per share. The fair value of the warrants was approximately $79,000 on the grant date.

F-23

Table of Contents

NORTHWEST BIOTHERAPEUTICS, INC.

Notes to the Consolidated Financial Statements

During the year ended December 31, 2020, the Company converted the entire February Notes, including $68,000 accrued interest into approximate 5.1 million shares of the Company's common stock.

In April 2020, the Company entered into a six-month convertible note (the “April Note”) with an individual investor (the “Holder”) with an aggregate principal amount of $0.8 million for cash proceeds of $0.7 million. The Company also incurred approximately $69,000 placement agent costs, including both a cash fee and the fair value of common stock warrants issued to the placement agent, which was recognized as additional debt discount.

The April Note bears interest at the rate of 10% per annum and is convertible into common shares of the Company at $0.17 per share plus a warrant to purchase a number of exercise shares equal to 50% of the number of common shares issued upon conversion (the “Conversion Warrants”). The Conversion Warrants will be exercisable until April 9, 2022 beginning on November 1, 2020, with an exercise price of $0.20 per share. The conversion option within the April Note is required to be bifurcated at fair value, which was approximately $0.4 million on the issuance date, resulting in additional debt discount to the April Note.

As consideration for entering into the April Note, the Company also agreed to amend the Holder’s existing outstanding warrants to purchase 5.1 million common shares of the Company. The exercise price of the warrants was amended from $0.25 per share to $0.20 per share. The incremental change in fair value resulting from the amendment was approximately $51,000, which was recognized as additional debt discount to the April Note.

On August 3, 2020, the Company converted approximately $0.8 million of outstanding principal and $26,000 of accrued interest of the April Note into approximately 5.1 million shares of common stock and 2.5 million warrants with fair value of approximately $2.4 million. The Company also extinguished $1.5 million embedded derivative liability and $0.2 million unamortized debt discount upon the conversion. The Company recorded approximately $0.3 million debt extinguishment loss.

In April 2020, the Company entered into a Note Amendment Agreement (the “Amendment”) with an individual holder of a short-term convertible note, primarily to agree on the following changes:

-Reclassed $75,000 accrued interest as of amendment date to the outstanding principal amount;
-Extended the maturity date of a convertible note with approximately $0.6 million of principal outstanding, as of the amendment date, to October 18, 2020 (the “Amended Note”);
-Reduced the conversion price from $0.22 to $0.181
-Issued a new 2-year warrant for up to 2.3 million shares of the Company’s common stock at an exercise price of $0.25 per share valued at $115,000 on the amendment date;

The amendment was recognized as a debt extinguishment, resulting in a loss on debt extinguishment of approximately $70,000.

During the year ended December 31, 2020, the Company converted the entire Amended Note of approximately $0.6 million, including $28,000 accrued interest into approximately 3.3 million shares of common stock.

(3)In May 2020, the Company entered into a six-month convertible note (the “May Note”) with an individual investor (the “Holder”) with an aggregate principal amount of $0.6 million. The May Note contains an original issue discount (“OID”) in the amount of $50,000.

The May Note bears interest at the rate of 8% per annum and is convertible into common shares of the Company at $0.25 plus a warrant to purchase a number of exercise shares equal to 40% of the number of common shares issued upon conversion (the “Conversion Warrants”). The Conversion Warrants will be exercisable until November 28, 2022 beginning on November 1, 2020 with exercise price of $0.25 per share. The conversion option within the May Note required bifurcation at fair value, which was approximately $0.5 million on the issuance date, resulting in additional debt discount to the May Note.

F-24

Table of Contents

NORTHWEST BIOTHERAPEUTICS, INC.

Notes to the Consolidated Financial Statements

On October 1, 2020, the Company converted the entire $0.6 million of the May Note including $19,000 accrued interest, into approximately 2.3 million shares of the Company's common stock and 0.9 million warrants with fair value of approximate $3.4 million. The Company also extinguished $2.8 million embedded derivative liability upon the conversion.

In August 2020, the Company entered into another convertible note (the "August Note") with the same investor as the May Note (the "Holder") with an aggregate principal amount of $1.1 million. The August Note contains OID in the amount of $110,000.

The August Note bears interest at the rate of 8% per annum and is convertible into common shares of the Company at $0.345 plus a warrant to purchase a number of exercise shares equal to 35% of the number of common shares issued upon conversion (the "Conversion Warrants"). The Conversion Warrants will be exercisable until February 4, 2023 beginning on December 15, 2020 with exercise price of $0.34 per share. The conversion option within the August Note is required to be bifurcated at fair value, which was approximately $0.6 million on the issuance date, resulting in additional debt discount to the August Note.

On September 29, 2020, the Company converted entire $1.1 million of August Note into approximately 3.3 million shares of the Company's common stock and 1.1 million warrants with fair value of approximate $3.3 million. The Company also extinguished $2.3 million embedded derivative liability and $0.5 million unamortized debt discount upon the conversion. The company recorded approximately $0.4 million debt extinguishment loss.

(4)In October 2020, the Company entered into a convertible note (the "October Note") with the same investor as the August Note (the "Holder") with an aggregate principal amount of $2.1 million. The October Note contains OID in the amount of $200,000.

The October Note bears interest at the rate of 8% per annum and is convertible into common shares of the Company at $0.85 plus a warrant to purchase a number of exercise shares equal to 30% of the number of common shares issued upon conversion (the "Conversion Warrants"). The Conversion Warrants will be exercisable until January 12, 2022 beginning on January 15, 2021 with exercise price of $2.00 per share. The conversion option within the October Note is required to be bifurcated at fair value, which was approximately $1.4 million on the issuance date, resulting in additional debt discount of $1.4 million to the October Note.

(5)During the year ended December 31, 2020, the Company converted approximately $5.8 million of outstanding principal and $0.6 million of accrued interest into approximately 29.1 million shares of the Company’s common stock with a fair value of $7.6 million. The Company recognized approximately $1.2 million in debt extinguishment loss from this conversion.
(6)In May 2020, the Company converted approximately $0.3 million of outstanding principal and accrued interest into approximately 1.3 million shares of the Company’s common stock with a fair value of $0.5 million. The Company recognized approximately $0.2 million in debt extinguishment loss from this conversion.

In August 2020, the Company extinguished approximately $1.5 million of outstanding principal and accrued interest into approximately 4.8 million shares of the Company's common stock and 1.7 million warrants. The Company also modified certain existing warrants and issued additional 6.5 million warrants consideration for certain suspension. The Company also agreed to amend the remaining outstanding $1.5 million outstanding debt. The note became convertible at a conversion price of $0.34 (the “Amended August Note”). The amendment was accounted as debt extinguishment and the Company recognized approximately $1.6 million in debt extinguishment loss from this transaction.

During the year ended December 31, 2020, the Company made $0.1 million cash payment and converted approximate $1.4 million outstanding debt including $15,000 accrued interest into approximately 4.1 million shares of the Company’s common stock.

During the year ended December 31, 2020, the Company entered into multiple Note Extension Agreements with multiple holders, primarily resulting in the following changes:

-Extended the maturity dates of promissory notes with outstanding principal balances aggregating approximately $3.3 million for an additional 6 to 12 months from the original maturity date;
-Issued new 2-year warrants to purchase up to 10.3 million shares of the Company’s common stock at an exercise prices ranging from $0.20 and $0.23 per share valued at approximately $0.5 million on the amendment date;

F-25

Table of Contents

NORTHWEST BIOTHERAPEUTICS, INC.

Notes to the Consolidated Financial Statements

The Note Extension Agreements for approximately $2.3 million of outstanding principal of promissory notes was recognized as a debt modification, while the amendments for approximately $1.0 million of outstanding principal of promissory notes was recognized as a debt extinguishment, resulting in a loss on extinguishment of debt of approximately $0.1 million.

(7)The $440,000 balance of outstanding principal as of December 31, 2020 and 2019 consists of two separate 12% demand notes in the amounts of $300,000 and $140,000.
(8)On May 28, 2019, the Company issued a deferred note to a third-party vendor pursuant to a settlement agreement resolving past matters and providing for the restart of DCVax®-Direct Production. During the year ended December 31, 2020, the Company made full repayment of $1.2 million to the note holder.
(9)On September 26, 2018, Advent BioServices (“Advent”), a related party of the Company, provided a short-term loan in the amount of $65,000. The loan bore interest at 10% per annum, and is payable upon demand, with 7 days’ prior written notice to the Company. During the year ended December 31, 2020, the Company made full repayment to Advent, including all outstanding interest.

Between February and May 2020, the Company entered into multiple demand loan agreements with Leslie Goldman, the Company’s Senior Vice President, General Counsel, for an aggregate principal amount of $0.3 million (the “Goldman Notes”). The Goldman Notes bear interest rate at 10% per annum, and are repayable upon 15 days' notice from Mr. Goldman.

The Goldman Notes are convertible into common shares of the Company at conversion prices ranging from $0.23 to $0.25 per share. Additionally, the Company agreed to issue warrants to Mr. Goldman to purchase 0.6 million shares of the Company’s common stock (the “Initial Warrants”) in conjunction with the Goldman Notes. The Initial Warrants have a five - year term and are exercisable at prices ranging from $0.23 and $0.25 per share. The fair value of the Initial Warrants was approximately $66,000, which was recognized as debt discount to the Goldman Notes at the issuance date. The conversion option within the Goldman Notes were required to be bifurcated at fair value, which was approximately $36,000 on the issuance date, resulting in additional debt discount to the Goldman Notes.

Upon conversion, Mr. Goldman would also receive a five-year term warrant to purchase a number of the Company’s common shares equal to 50% of the number of common shares issued upon conversion of the Goldman Notes (the “Conversion Warrants”). The Conversion Warrants will be exercisable at $0.25 per share.

During the year ended December 31, 2020, the Company made full repayment of $0.3 million to Mr. Goldman, including all outstanding interest. Upon the repayment, the Company also extinguished $1.6 million embedded derivative liability, which was recorded as debt extinguishment gain.

(10)During the year ended December 31, 2020, the Company entered into two note purchase agreements (the “Notes”) with same investor for an aggregate principal amount of approximate $7.2 million. The Notes bear interest at 8% per annum with 21-month term. There are no repayments during the first 7 months of the term. The Notes are amortized in 14 installments starting in month 8. The Notes carry an original issue discount of $650,000 and $10,000 legal costs that were reimbursable to the investor.
(11)Cambridge Loan

On March 26, 2020, the Company entered into a Loan Agreement (the “Loan Agreement”) with Cambridge & Peterborough Combined Authority (the “Lender”) for a loan of £1.35 million (approximately $1.7 million) (the “Loan”) for the current phase of buildout of the Sawston facility. The Company received funds on April 6, 2020. The Lender provides funding for selected economic development projects in the Cambridge region through a competitive selection process.

Under the Loan Agreement, there will be no repayments during the first year of the Loan term, although interest will accrue. Following the first anniversary, repayment of the Loan principal and interest will take place over 4 years, for a total term of 5 years.  The interest rate on the Loan is 6.25% per annum.

F-26

Table of Contents

NORTHWEST BIOTHERAPEUTICS, INC.

Notes to the Consolidated Financial Statements

In conjunction with the Loan, the Company agreed to enter into a Security Agreement with the Lender under which the Company granted a security interest in the Company’s 17-acre property in Sawston, U.K. to secure the Loan.  No other tangible or intangible assets of the Company or its subsidiaries are subject to any security interest. Such security interest on the 17-acre property will be released upon completion of repayment

PPP Loan

The Company received a loan under the Coronavirus Aid, Relief and Economic Security (“CARES”) Act’s Paycheck Protection Program (“PPP”). The PPP loan was received on May 20, 2020 in the amount of $0.4 million. The current terms of the PPP loan is two years with a maturity date of May 20, 2022 and it contains a favorable fixed annual interest rate of 1.00%. Payments of principal and interest on the PPP Loan are deferred for the first six months of the term of the PPP Loan until November 20, 2020. The Company used the loan to make payments for payroll, health and disability insurance and rent.

The Company submitted a PPP loan forgiveness application to the Lender on October 26, 2020, with the amount which may be forgiven equal to the sum of qualifying expenses, including payroll costs, covered rent obligations, and covered utility payments incurred by the Company during the twenty-four week period beginning on May 20, 2020, calculated in accordance with the terms of the CARES Act. The forgiveness application was approved on December 7, 2020. The Company recorded approximate $0.4 million debt extinguishment gain from the forgiveness of PPP Loan.

The following table summarizes total interest expenses related to outstanding debt for the years ended December 31, 2020 and 2019, respectively (in thousands):

For the year ended

December 31, 

    

2020

    

2019

Interest expenses related to outstanding notes:

  

 

  

Contractual interest

$

1,231

$

1,168

Amortization of debt discount

 

2,891

 

1,430

Total interest expenses related to outstanding notes

 

4,122

 

2,598

Interest expenses related to outstanding notes to related parties:

 

 

Contractual interest

 

20

 

366

Amortization of debt discount

 

122

 

Total interest expenses related to outstanding notes to related parties

 

142

 

366

Interest expenses related to forbearance of debt to related parties

4,270

Other interest expenses

 

10

 

11

Total interest expense

$

8,544

$

2,975

The following table summarizes the principal amounts of the Company’s debt obligations as of December 31, 2020 (amount in thousands):

Payment Due by Period

Less than

1 to 2

3 to 5

    

Total

    

1 Year

    

Years

    

Years

Short term convertible notes payable

6% unsecured

$

135

$

135

$

$

8% unsecured

2,125

2,125

Short term notes payable

8% unsecured

1,785

1,785

10% unsecured

263

263

12% unsecured

440

440

Long term notes payable

8% unsecured

7,160

7,160

6% secured

1,843

1,843

Total

$

13,751

$

4,748

$

7,160

$

1,843

F-27

Table of Contents

NORTHWEST BIOTHERAPEUTICS, INC.

Notes to the Consolidated Financial Statements

9. Net Loss per Share Applicable to Common Stockholders

Basic loss per common share is computed by dividing net loss by the weighted average number of common shares outstanding during the reporting period. Diluted loss per common share is computed similar to basic loss per common share except that it reflects the potential dilution that could occur if dilutive securities or other obligations to issue common stock were exercised or converted into common stock.

The following securities were not included in the diluted net loss per share calculation because their effect was anti-dilutive as of the periods presented (in thousands):

For the year ended

December 31, 

    

2020

    

2019

Common stock options

 

308,840

 

104,659

Common stock warrants

 

328,979

 

347,734

Contingently issuable warrants

 

2,774

 

11,739

Convertible notes and accrued interest

 

2,617

 

2,617

Potentially dilutive securities

 

643,210

 

466,749

10. Related Party Transactions

Advent BioServices Agreement

The Company has a Manufacturing Services Agreement with Advent BioServices for manufacture of DCVax-L products at an existing facility in London, as previously reported. The Company also has an Ancillary Services Agreement with Advent, which establishes a structure under which Advent will submit Statements of Work (“SOWs”) for activities related to the development of the Sawston facility and the compassionate use activities in the UK, as previously reported. The Ancillary Services Agreement had an original term of 8 months, which ended in July 2020. The Company extended the term by 12 months, and did not make any other changes.

Related Party Expenses and Accounts Payable

The following table summarizes expenses incurred to related parties (i.e., amounts invoiced) during the year ended December 31, 2020 and 2019 (amount in thousands) (some of which were for previous periods’ services and remain unpaid as noted in the second table below):

For the year ended

December 31, 

2020

    

2019

(As revised) (Note 14)

Advent BioServices

$

7,543

 

$

5,735

During the years ended December 31, 2020 and 2019, the Company capitalized $3.6 million and $0.9 million costs related to Sawston buildout in addition to the costs disclosed in the above table.

The following table summarizes outstanding unpaid accounts payable and the accrued amount under the SOWs relating to the Sawston Facility and the compassionate use programs held by related parties as of December 31, 2020 and outstanding unpaid accounts payable

F-28

Table of Contents

NORTHWEST BIOTHERAPEUTICS, INC.

Notes to the Consolidated Financial Statements

as of December 31, 2019 (amount in thousands). These unpaid amounts include part of the expenses reported in the table above and also certain expenses incurred in prior periods.

    

December 31, 2020

    

December 31, 2019

(As revised) (Note 14)

Advent BioServices – amount invoiced

$

3,734

$

834

Advent BioServices – amount accrued

1,629

3,002

Accounts payable and accrued expenses to Advent BioServices

$

5,363

$

3,836

Related Parties Loans

Linda F. Powers - Demand Loans

Between February 2018 and April 2018, the Company’s Chief Executive Officer, Linda Powers, loaned the Company aggregate funding of $5.4 million pursuant to convertible Notes. The Notes were 15-day demand notes, for loans provided as short-term bridge loans. However, repayment was not completed for nearly 1-1/2 years.

During the year ended December 31, 2019, the Company repaid the $5.4 million principal and approximately $0.8 million interest.

Loan from Advent BioServices

Advent BioServices provided a short-term loan to the Company in the amount of $65,000 on September 26, 2018. The loan bore interest at 10% per annum, and is payable upon demand, with 7 days’ prior written notice to the Company.

During the year ended December 31, 2020, the Company made full repayment of $73,000 to Advent, including all outstanding interest.

Loan from Leslie Goldman

During the year ended December 31, 2020, the Company's Senior Vice President, General Counsel, Leslie Goldman, loaned the Company $315,000 pursuant to various convertible notes (the “Notes”). The Notes bore interest rate at 10% per annum and fifty percent warrant coverage, and are repayable upon 15 days' notice from the holder. The Notes were convertible, in whole or in part, into stock together with warrants.

During the year ended December 31, 2020, the Company made full repayment of $0.3 million to Mr. Goldman, including all outstanding interest.

Warrants issued to Linda Powers

On July 2, 2020, the Company issued approximately 15.2 million warrants (the "Forbearance Warrants") to Ms. Powers in consideration for Ms. Powers' previously reported forbearance and extension of loans of $5.4 million from Ms. Powers to the Company. These warrants were approved by the Board in November 2018 when the loans were long overdue, as previously reported, and the warrants were re-approved in January 2020, but were not issued until July 2, 2020.

The Forbearance Warrants have an exercise price of $0.21 per share with 5-year contractual term. The fair value of the Forbearance Warrants was approximately $4.3 million on the grant date, which was recognized as an additional interest expense.

F-29

Table of Contents

NORTHWEST BIOTHERAPEUTICS, INC.

Notes to the Consolidated Financial Statements

The following table summarizes total interest expenses related to outstanding notes to related parties for the three months and nine months ended December 31, 2020 and 2019, respectively (in thousands):

For the year ended

December 31, 2020

    

2020

    

2019

Interest expenses related to outstanding notes to related parties:

 

  

 

  

Contractual interest

$

20

$

366

Amortization of debt discount

 

122

 

Interest expenses related to forbearance of debt to related parties

4,270

Total interest expense

$

4,412

$

366

11. Stockholders’ Deficit

2020 Activities

Registered Direct Offering

Between January and February 2020, the Company issued an aggregate of 34.5 million shares of its common stock in a registered direct offering (the “Offering”). The net proceeds from the Offering were approximately $5.7 million, after deducting offering costs of $0.4 million paid by the Company.

In connection with the Offering, the Company also issued approximately 8.5 million 2-year term warrants with an exercise price of $0.25 per share to the investors and approximately 0.8 million 2-year term warrants with an exercise price between $0.17 and $0.21 per share to placement agent in this direct offering. The fair value of these new issued warrants was approximately $1.0 million. Additionally, the Company agreed to extend by twelve months the maturity date of certain existing warrants already held by some of those investors. The Company recorded an incremental change of approximately $2.5 million on the fair value of warrants due to the modifications, which was recorded as part of offering cost during the year ended December 31, 2020.

During April 2020, the Company issued an aggregate of 19.9 million shares of its common stock and 11.3 million new issued warrants in a registered direct offering (the "April Financing"). The common stock was offered at a price of $0.153 per share. The warrants are exercisable at $0.20 per share. The net proceeds from the April Financing were approximately $3.0 million, after deducting offering costs of $68,000 paid by the Company. An approximate $0.8 million of proceeds were allocated to warrant liabilities.

During May 2020, the Company issued an aggregate 14.2 million shares of its common stock and 5.6 million new issued warrants in a registered direct offering (the "May Financing"). The common stock was offered at a price between $0.17 and $0.225 per share. The warrants have an exercise price between $0.22 and $0.23 per share and an exercise period between 1.5-2.5 years. The Company received approximately $2.9 million from the May Financing. An approximate $0.9 million of proceeds were allocated to warrant liabilities.

All of the warrants issued in the May Financings were not exercisable until November 1, 2020. In addition, as part of these agreements, the investors who have existing outstanding warrants that had not already been suspended until November 1, suspended approximately 14.6 million existing warrants until November 1, 2020.

On August 5, 2020, the Company entered into financings totaling approximately $8 million (the "August Financing"). The financings were comprised of:

Approximately $7 million from an offering at $0.32 per share of newly registered common stock of approximately 21.8 million shares with 20-35% warrants coverage. The warrants are exercisable at $0.34 per share for approximately 5.3 million shares, with an exercise period of 18 to 30 months. The fair value of these 5.3 million warrants was approximately $1.5 million.
$1 million from a convertible note (the "August Note") which is convertible at $0.345 per share. The August Note carries no warrants unless it is converted. If, and only to the extent, the note is converted it will carry 35% warrants exercisable at $0.34 per share.
F-30
NORTHWEST BIOTHERAPEUTICS, INC.
Notes to the Consolidated Financial Statements
All of the new warrants issued in the August Financing were suspended until December 15, 2020.
In addition, as part of these agreements, the investors who have existing outstanding warrants that had not yet been suspended, suspended approximately 75.5 million additional existing warrant exercise shares until December 15, 2020. In consideration for the suspension of the 75.5 million existing warrant shares as part of the August Financing, the Company issued approximately 12.5 million warrants with an exercise price of $0.34 per share and an exercise period ranging from approximately 13.5 to 25.5 months following the termination of the suspensions. These suspension consideration warrants were also suspended until the same December date.
Only the common stock sold directly or underlying the warrants and convertible note were registered in this transaction.

On October 12, 2020, the Company entered into financings totaling approximately $11.9 million (the “Offering”). The financings were comprised of:

Approximately $10 million from an offering at $0.816 per share (based upon the average 10 day closing price ending on October 12, 2020) of newly registered common stock of approximately 12.2 million shares with 30% warrants coverage. The warrants are exercisable at an exercise price of $2.00 per share for approximately 3.6 million shares, with an exercise period of 12 months (following a 3-month suspension after issuance). The fair value of these 3.6 million warrants was approximately $1.2 million.
Approximately $1.9 million from a convertible note which is convertible at $0.85 per share (the “Note”). The Note carries no warrants unless it is converted. If, and only to the extent, the Note is converted it will carry 30% warrants with an exercise price of $2.00 per share and an exercise period of 12 months (following a 3-month suspension after issuance).
All of the new warrants issued in the Offering are suspended until January 15, 2021.

In addition, as part of these agreements, certain investors who have existing outstanding warrants that have not yet been suspended are now suspending approximately 3.5 million additional existing warrant exercise shares until January 15, 2021.

In consideration for the suspension of the 3.5 million existing warrant shares as part of the Offering, the Company issued approximately 261,000 warrants with an exercise price of $2.00 per share and an exercise period of 12 months (following a 3-month suspension after issuance). These suspension consideration warrants are also suspended until the same January date.

Warrants Exercised for Cash

During the year ended December 31, 2020, the Company issued 47.5 million shares of its common stock from warrants exercised for cash. The Company received $13.9 million in cash.

Cashless Warrants Exercise

During the year ended December 31, 2020, The Company issued approximately 7.1 million shares of common stock upon 8.6 million warrant cashless exercises with weighted average exercise price of $0.22.

Debt Conversion

During the year ended December 31, 2020, the Company converted approximately $13.9 million outstanding debt and interest into 58.4 million shares of common stock and 6.2 million warrants, see Note 8 for further details.

Flaskworks Shares Issuance

On December 1, 2020, the Company issued 1.5 million shares of common stock based upon the Flaskworks team having completed a significant milestone, in accordance with the Rights Issuance Agreement entered on August 28, 2020.

F-31

Table of Contents

NORTHWEST BIOTHERAPEUTICS, INC.

Notes to the Consolidated Financial Statements

On December 25, 2020, upon the seller’s election, the Company issued 0.7 million shares in equivalent of $0.2 million special consideration payment pursuant to the Unit Purchase Agreement. The $0.336 per share price was established by the Unit Purchase Agreement. The incremental change in fair value of the shares resulting from market price increase was approximately $0.9 million, which was recognized as additional general and administrative expense on the consolidated statement of operations.

2019 Activities

Registered Direct Offering

During the year ended December 31, 2019, the Company issued an aggregate of 32.7 million shares of its common stock at a purchase price between $0.19 and $0.23 per share to certain institutional investors in multiple registered direct offerings (the “Offering”). Included with the Offering were 1.3 million shares of common stock which were issued from the conversion of an existing loan and the related accrued interest totaling $306,000. The net proceeds from the Offering were approximately $6.9 million, after deducting offering costs of $0.3 million paid by the Company.

In connection with the Offering, the Company did not issue any additional warrants for the new investment by the investors, but the Company, in effect, agreed to modify certain existing warrants already held by some of those investors. The Company extended the expiration date for additional 12 to 18 months after the original expiration date and the weighted average exercise price of warrants was reduced by an amount ranging from 2 to 8 cents as well. The Company recorded an incremental change of $2.5 million on the fair value of warrants due to the modification and recorded it as part of offering cost during the year ended December 31, 2019.

Debt Conversion

During the year ended December 31, 2019, the Company converted debt of approximately $6.8 million of principal and $0.7 million of accrued interest into approximately 35.5 million shares of the Company’s common stock at a fair value of $9.2 million. The Company recorded approximately $1.7 million of debt extinguishment loss from the conversion.

Warrants Exercised for Cash

During the year ended December 31, 2019, the Company issued 9.5 million shares of its common stock from warrants exercised for cash. The Company received $2.2 million in cash.

Shares Settlement

On May 28, 2019, the Company entered into a settlement agreement with Cognate BioServices, resolving past matters and providing for the restart of DCVax®-Direct Production (see Note 8).

As part of the settlement agreement, the number of shares of the Company’s common stock which the Company was to issue to Cognate was substantially reduced: 52 million shares of the Company’s common stock which the Company had previously agreed to issue to Cognate were reduced to 12 million shares. The Company considers the reduction in shares owed to Cognate a modification. Because the 52 million shares were never issued and the modification, which resulted in a decrease in fair value, is not a forfeiture, previously recognized expense related to services performed by Cognate is not reversed in connection with this modification. During the year ended December 31, 2019, the Company recorded $12,000 in its common stock par and reduced same amount in additional paid-in capital.

F-32

Table of Contents

NORTHWEST BIOTHERAPEUTICS, INC.

Notes to the Consolidated Financial Statements

Stock Purchase Warrants

The following is a summary of warrant activity for the years ended December 31, 2020 and 2019 (dollars in thousands, except per share data):

    

Number of

    

Weighted Average

    

Remaining

Warrants

Exercise Price

Contractual Term

Outstanding as of January 1, 2019

 

372,153

$

0.29

 

1.97

Warrants granted

 

8,067

 

0.23

 

  

Warrants exercised for cash

 

(9,532)

 

0.23

 

  

Warrants expired and cancelled

 

(11,215)

 

0.62

 

  

Outstanding as of December 31, 2019

 

359,473

$

0.27

 

1.42

Warrants granted

88,658

0.22

Contingently issuable warrants (1)

 

2,774

 

1.48

 

  

Warrants exercised for cash

 

(47,511)

 

0.29

 

  

Cashless warrants exercise

(8,631)

0.22

Warrants expired and cancelled

 

(63,010)

 

0.32

 

  

Outstanding as of December 31, 2020 (2)

 

331,753

$

0.28

 

1.61

(1)The approximately 2.8 million warrants represent compensation warrants to be issued to the Company’s CEO, Linda Powers, in accordance with her warrants and options suspension agreement dated November 1, 2020.
(2)As of December 31, 2020, approximately 62.1 million warrants were not exercisable until January 15, 2021. Subsequent to January 15, 2021, the Company suspended 58.8 million warrants until February 28, 2021.

As of December 31, 2020, approximately 272.8 million warrants were treated as liability warrants due to the sequencing policy (see note 3).

Warrant Adjustments

Between April and August 2020, the Company undertook negotiations related to certain warrant adjustments, including suspending certain outstanding warrants, making them unexercisable for a defined period, and suspending extensions of the warrants during that period.

As previously reported, on May 10, 2020, for a number of unrelated warrant holders, the Company agreed to issue 17.5% new warrants and extend the investors' current warrant terms by six months, in consideration of the investor's suspension of the current and newly issued warrants until November 1, 2020. The unrelated investors suspended warrants for the purchase of approximately 81 million shares of the Company’s common stock. The Company agreed to issue new warrants to purchase 14.2 million shares of the Company’s common stock to these investors under the suspension agreements, and these additional warrants were also suspended until November 1, 2020.

On August 5, 2020, the investors who had existing outstanding warrants, that had not yet been suspended, suspended approximately 75.5 million additional existing warrant exercise shares until December 15, 2020. In consideration for the suspension of the 75.5 million existing warrant shares as part of the August Financing, the Company issued approximately 12.5 million warrants with an exercise price of $0.34 per share and an exercise period ranging from approximately 13.5 to 25.5 months following the termination of the suspensions. These suspension consideration warrants were also suspended until December 15, 2020.

On April 30, 2020, the Company entered into an agreement with its CEO, Linda Powers, in regard to approximately 90 million warrants and options held by Ms. Powers. She agreed to suspend approximately 60 million existing warrants and options held or due to her until November 1, 2020, making them unexercisable during this period. In consideration, the Company extended the exercise period of a separate 29 million existing warrants held by Ms. Powers (not part of the 60 million warrants and options), and Ms. Powers also agreed to suspend those 29 million warrants until November 1, 2020. The extension of the 29 million warrants provides an exercise period of 2-1/2 years after the suspension period.

F-33

Table of Contents

NORTHWEST BIOTHERAPEUTICS, INC.

Notes to the Consolidated Financial Statements

On October 31, 2020, the Company further extended the suspension of approximately 157 million of those 171 million warrants and options through December 15, 2020. Furthermore, other holders agreed to new suspensions of approximately 21 million additional warrants (in addition to the 157 million suspended) through December 15, 2020, making for a total of approximately 178 million suspensions through December 15, 2020.

Still another 96 million warrants (beyond the 178 million described above) were also suspended earlier in connection with other new share purchases. Consequently, a total of approximately 274 million warrants and options were suspended through December 15, 2020.

On December 15, 2020, the Company further extended the suspension of approximately 183 million warrants and options held by the Company’s certain officers and board of directors until January 15, 2021. Total warrants and options suspended until January 15, 2021 were approximately 190 million. See Note 15 below under Subsequent Events for more information about additional suspensions of warrants and options suspensions for further periods.

12. Commitments and Contingencies

Operating Lease

The Company adopted ASC Topic 842 - Leases as of January 1, 2019, using the transition method per ASU No. 2018-11 issued on July 2018 wherein entities were allowed to initially apply the new leases standard at adoption date and recognize a cumulative-effect adjustment to the opening balance of retained earnings in the period of adoption. Accordingly, all periods prior to January 1, 2019 were presented in accordance with the previous ASC Topic 840, Leases, and no retrospective adjustments were made to the comparative periods presented. Adoption of ASC 842 resulted in an increase to total assets and liabilities due to the recording of operating lease right-of-use assets ("ROU") and operating lease liabilities of approximately $4.3 million, as of January 1, 2019.  On March 4, 2019, the Company recognized additional $0.6 million ROU and lease liabilities to its amended office lease in the U.S. The adoption did not materially impact the Company’s consolidated statements of operations or cash flows.

The Company has operating leases for corporate offices in the U.S., U.K., Germany and the Netherlands, and for manufacturing facilities in the U.K. Leases with an initial term of 12 months or less are not recorded in the balance sheet. The Company has elected the practical expedient to account for each separate lease component of a contract and its associated non-lease components as a single lease component, thus causing all fixed payments to be capitalized. The Company also elected the package of practical expedients permitted within the new standard, which among other things, allows the Company to carry forward historical lease classification. The renewal options have not been included in the calculation of the lease liabilities and ROU as the Company is not reasonably certain to exercise the options. Variable lease payment amounts that cannot be determined at the commencement of the lease such as increases in lease payments based on changes in index rates or usage, are not included in the ROU assets or liabilities. These are expensed as incurred and recorded as variable lease expense.

At December 31, 2020, the Company had operating lease liabilities of approximately $5.1 million for both the 20-year lease of the building for the manufacturing facility in Sawston, U.K., and the current office lease in the U.S. and ROU of approximately $4.5 million for the Sawston lease and US office lease, which were included in the consolidated balance sheet.

F-34

Table of Contents

NORTHWEST BIOTHERAPEUTICS, INC.

Notes to the Consolidated Financial Statements

The following summarizes quantitative information about the Company’s operating leases (amount in thousands):

For the Year ended

December 31, 2020

    

U.K

    

U.S

    

Total

Lease cost

Operating lease cost

$

610

$

330

$

940

Short-term lease cost

44

44

Variable lease cost

45

20

65

Total

$

699

$

350

$

1,049

Other information

Operating cash flows from operating leases

$

(661)

$

(332)

$

(993)

Weighted-average remaining lease term - operating leases

9.1

0.2

Weighted-average discount rate - operating leases

12

%

12

%

For the Year ended

December 31, 2019

    

U.K

    

U.S

    

Total

Lease cost

 

  

 

  

 

  

Operating lease cost

$

607

$

247

$

854

Short-term lease cost

 

50

 

81

 

131

Variable lease cost

 

 

15

 

15

Total

$

657

$

343

$

1,000

Other information

 

 

 

Operating cash flows from operating leases

$

$

(244)

$

(244)

Weighted-average remaining lease term – operating leases

 

10.0

 

0.9

 

  

Weighted-average discount rate – operating leases

 

12

%  

 

12

%  

 

  

The Company recorded lease costs as a component of general and administrative expense during the years ended December 31, 2020 and 2019.

Maturities of our operating leases, excluding short-term leases, are as follows:

    

U.K

    

U.S

    

Total

Year ended December 31, 2021

$

644

$

84

$

728

Year ended December 31, 2022

644

644

Year ended December 31, 2023

644

644

Year ended December 31, 2024

644

644

Thereafter

8,990

8,990

Total

11,566

84

11,650

Less present value discount

(6,565)

(2)

(6,567)

Operating lease liabilities included in the Consolidated Balance Sheet at December 31, 2020

$

5,001

$

82

$

5,083

Manufacturing Services Agreements

The Company has a manufacturing services agreement with Advent BioServices in the U.K.

F-35

Table of Contents

NORTHWEST BIOTHERAPEUTICS, INC.

Notes to the Consolidated Financial Statements

Advent BioServices

On May 14, 2018, the Company entered into a DCVax®-L Manufacturing and Services Agreement (“MSA”) with Advent BioServices, a related party which was formerly part of Cognate BioServices and was spun off separately as part of an institutional financing of Cognate. The Advent Agreement provides for manufacturing of DCVax-L products at an existing facility in London. The Agreement is structured in the same manner as the Company’s prior agreements with Cognate BioServices. The Advent Agreement provides for a program initiation payment of approximately $1.0 million (which was fully paid in 2018), in connection with technology transfer and operations to the U.K. from Germany, development of new Standard Operating Procedures (SOPs) for the London facility, selection of new suppliers and auditing for GMP compliance, and other preparatory activities. The Advent Agreement provides for certain payments for achievement of milestones and, as was the case under the prior agreement with Cognate BioServices, the Company is required to pay certain fees for dedicated production capacity reserved exclusively for DCVax production, and pay for manufacturing of DCVax-L products for a certain minimum number of patients, whether or not the Company fully utilizes the dedicated capacity and number of patients. Either party may terminate the MSA on twelve months’ notice, to allow for transition arrangements by both parties.

On November 8, 2019, the Company and Advent entered into an Ancillary Services Agreement with an 8-month Term for U.K. Facility Development Activities and Compassionate Use Program Activities. The Ancillary Services Agreement establishes a structure under which Advent will develop Statements of Work (“SOWs”) for each portion of the U.K. Facility Development Activities and Compassionate Use Program Activities, and will deliver those SOWs to the Company for review and approval. After an SOW is approved by the Company, Advent will proceed with or continue the applicable services and will invoice the Company pursuant to the SOW. Since both the U.K. Facility Development and the Compassionate Use Program involve pioneering and uncertainties in most aspects, the invoicing under the Ancillary Services Agreement is on the basis of costs incurred plus fifteen percent. The Ancillary Services Agreement had an original term of 8 months, which ended in July 2020. The Company extended the term by 12 months, and did not make any other changes.

German Tax Matter

The German tax authorities have audited our wholly owned subsidiary, NW Bio GmbH, for 2013-2015. During those years, NWBio, Inc. sent funds to NWBio GmbH to pay for operating expenses and costs associated with the Phase III clinical trial. The German tax authorities have asserted that the subsidiary should have charged NWBio parent company a  profit margin on top of these costs, that they will deem that such a profit margin was charged by the subsidiary (even though it was not) and that they will tax this deemed profit margin, although neither NW Bio, Inc. nor NW Bio GmbH made any profit during the period in question (or at any other time), and even though the funds provided by NW Bio, Inc. were used by NW Bio GmbH entirely for operating expenses and clinical trial costs.   They have also made claims for other taxes including penalties and interest.

In July, NW Bio GmbH submitted substantial documentation to refute the assessments of the German tax authorities.  The authorities responded in December that they were open to settlement negotiations.

On February 12, 2021, the German tax authorities agreed in principle with the Company’s settlement offer. The Company has accrued for the Company approved tax settlement offer of 351,000 (approximately $421,000 as of December 31, 2020) for the years under audit, with an addition of 156,000 (approximately $187,000) for the more recent years to date.  Penalties and interest are still under negotiation. After considering further negotiations, under its evaluation under ASC 740, it is the view of the Company currently that it is not more likely than not that the resolution of these tax matters will ultimately result in a net material charge to the Company.

13. Income Taxes

No provision was made for U.S. taxes on undistributed foreign earning as such earnings are considered to be permanently reinvested. It is not practicable to determine the amount of additional tax, if any that might be payable on those earnings if repatriated.

F-36

Table of Contents

NORTHWEST BIOTHERAPEUTICS, INC.

Notes to the Consolidated Financial Statements

The tax effects of temporary differences and tax loss and credit carry forwards that give rise to significant portions of deferred tax assets and liabilities at December 31, 2020 and 2019 are comprised of the following (in thousands):

    

As of December 31, 2020

    

As of December 31, 2019

Deferred tax asset

 

  

 

  

Net operating loss carryforward

$

185,308

$

176,140

Research and development credit carry forwards

 

18,580

 

16,983

Stock based compensation and other

 

22,997

 

14,565

Total deferred tax assets

 

226,885

 

207,688

Valuation Allowance

 

(226,885)

 

(207,688)

Deferred tax asset, net of allowance

$

$

The Company has identified the United States, Maryland, Germany and United Kingdom as significant tax jurisdictions.

The Company’s U.S. net operating loss (“NOL”) carryforwards for tax purposes as of December 31, 2020, are approximately $654.5 million. Unused NOL carryforwards from years prior to 2018 of $547.0 million will begin to expire in 2020 through 2037. NOL incurred in 2018 and later amount to $107.5 million and shall carryforward indefinitely. NOL carryforwards are generally available to offset future taxable income; however, the utilization of NOL may be limited under the Internal Revenue Code Section 382 as a result of changes in ownership of the Company’s stock over the loss periods and prior to utilization of the carryforwards. The Company also has approximately $18.6 million in research and development tax credits available to offset federal income tax in future periods. If unused, these credits expire through 2037. The Company’s NOL carryforwards for foreign tax purposes as of December 31, 2020 are $30.0 million. NOL in the United Kingdom and Germany of $13.3 million and $16.5 million respectively do not expire over time. NOL in the Netherlands of $208,000 will begin to expire in 2025 through 2031. The Company’s tax years are still open under statute from 2016 to present, although NOL carryovers from prior tax years are subject to examination and adjustments to the extent utilized in future years.

In assessing the realization of deferred tax assets, management considers whether it is more likely than not that some portion or all of the deferred tax assets will be realized. The ultimate realization of deferred tax assets is dependent upon the generation of future taxable income during the period in which those temporary differences become deductible. Management considers the scheduled reversal of deferred tax liabilities, projected future taxable income and taxing strategies in making this assessment. In case the deferred tax assets will not be realized in future periods, the Company has provided a valuation allowance for the full amount of the deferred tax assets at December 31, 2020 and 2019.

F-37

Table of Contents

NORTHWEST BIOTHERAPEUTICS, INC.

Notes to the Consolidated Financial Statements

The expected tax expense (benefit) based on the U.S. federal statutory rate is reconciled with actual tax expense (benefit) as follows:

(dollars in thousands)

    

As of December 31, 2020

    

As of December 31, 2019

 

Statutory federal income tax rate

 

21.0

%  

21.0

%  

State taxes, net of federal tax benefit

 

1.1

%  

8.9

%  

Tax rate differential on foreign income

 

0.0

%  

(0.4)

%  

Derivative gain or loss

 

(17.3)

%  

12.2

%  

Expiration of net operating losses

 

(1.5)

%  

(7.9)

%  

Other permanent items and true ups

 

(0.1)

%  

(2.3)

%  

R&D Credit

 

0.3

%  

3.0

%  

Change in valuation allowance

 

(3.5)

%  

(34.5)

%  

Income tax provision (benefit)

 

0.0

%  

0.0

%  

    

As of December 31, 2020

    

As of December 31, 2019

Federal

 

  

 

  

Current

$

$

Deferred

 

(15,539)

 

(5,183)

State

 

 

  

Current

 

 

Deferred

 

(4,327)

 

(1,421)

Foreign

 

 

  

Current

 

 

  

Deferred

 

670

 

(404)

Change in valuation allowance

 

19,196

 

7,008

Income tax provision (benefit)

$

$

ASC 740 prescribes a recognition threshold and a measurement attribute for the financial statement recognition and measurement of tax positions taken or expected to be taken in a tax return. For those benefits to be recognized, a tax position must be more-likely-than-not to be sustained upon examination by taxing authorities. As of December 31, 2020, and 2019, there were no uncertain tax positions. The Company’s policy for recording interest and penalties associated with uncertain tax positions is to record such expense as a component of income tax expense. There were no amounts accrued for penalties or interest during the year ended December 31, 2020. Management is currently unaware of any issues under review that could result in significant payments, accruals or material deviations from its position.

14. Revision to Prior Period Financial Statements

During the course of preparing the quarterly report on Form 10-Q for the three and nine months ended September 30, 2020 and 2019, the Company identified an error in its accrual and capitalization related to the Sawston Facility and research and development costs under the Advent Ancillary Services Agreement. This resulted in an understatement of construction in progress of $1.5 million as of December 31, 2019, and an understatement of accounts payable and accrued expenses to related parties and affiliates of $3.0 million as of December 31, 2019.

The Company concluded that the error was not material to any prior annual period and the error had no material impact to any prior interim period. Nevertheless, the Company has revised its historical consolidated financial statements to properly reflect research and development expenses, capitalization of construction in progress and accrued liabilities in the prior periods.

The effect of the revisions to the consolidated financial statements is as follows (amount in thousands):

F-38

Table of Contents

NORTHWEST BIOTHERAPEUTICS, INC.

Notes to the Consolidated Financial Statements

Consolidated Balance Sheet

As of December 31, 2019

As Previously

 

    

  Reported 

    

Adjustments

    

As Revised

Construction in progress

$

171

$

1,514

$

1,685

Total non-current assets

 

5,929

 

1,514

 

7,443

TOTAL ASSETS

$

9,129

$

1,514

$

10,643

 

  

 

  

 

  

Accounts payable and accrued expenses to related parties and affiliates

$

842

$

3,002

$

3,844

Total current liabilities

 

41,194

 

3,002

 

44,196

Total liabilities

 

52,696

 

3,002

 

55,698

 

  

 

  

 

  

Accumulated deficit

 

(839,907)

 

(1,488)

 

(841,395)

Total stockholders' deficit

 

(43,567)

 

(1,488)

 

(45,055)

TOTAL LIABILITIES AND STOCKHOLDERS' DEFICIT

$

9,129

$

1,514

$

10,643

Consolidated Statement of Operations

For the year ended

December 31, 2019

As Previously

 

    

  Reported 

    

Adjustments

    

As Revised

Research and development expenses

$

13,590

$

516

$

14,106

Total operating costs and expenses

 

29,873

 

516

 

30,389

Loss from operations

 

(27,463)

 

(516)

 

(27,979)

Net loss

$

(20,296)

$

(516)

$

(20,812)

Total comprehensive loss

$

(20,460)

$

(516)

$

(20,976)

Consolidated Statement of Cash Flows

For the year ended

December 31, 2019

As Previously

 

    

  Reported 

    

Adjustments

    

As Revised

Cash Flows from Operating Activities:

  

  

  

Net loss

$

(20,296)

$

(516)

$

(20,812)

Related party accounts payable and accrued expenses

 

(3,746)

 

516

 

(3,230)

Net cash used in operating activities

$

(31,859)

$

$

(31,859)

Supplemental schedule of non-cash investing and financing activities:

 

  

 

  

 

  

Capital expenditures included in accounts payable and accrued expenses to related parties and affiliates

$

$

947

$

947

15. Subsequent Events

Debt Offering

On March 1, 2021, the Company entered into a Commercial Loan Agreement (the “Note”) with an individual investor for an aggregate principal amount of $10 million. The Note bears interest at 8% per annum with a 22-month term. There are no repayments during the first 8 months of the term. The note is amortized in 14 installments starting on November 1, 2021. The Note carries an original issue discount of $1 million and $5,000 legal costs that were reimbursable to the investor.

F-39

Table of Contents

NORTHWEST BIOTHERAPEUTICS, INC.

Notes to the Consolidated Financial Statements

Warrants and Options Suspension

On January 15, 2021, the Company further extended the suspension of approximately 256 million warrants and options held by certain officers and directors of the Company until February 28, 2021.

On February 28, 2021, the Company further extended the suspension of approximately 262 million warrants and options held by certain officers and directors of the Company until April 30, 2021.

A total 262 million warrants and options will be suspended until April 30, 2021.

Warrants Exercised for Cash and Cashless Warrants Exercise

Between January and March 2021, the Company received $0.7 million from the exercise of warrants with an exercise price between $0.175 and $0.34. The Company issued approximately 2.6 million shares of common stock upon these warrant exercises.

Between January and March 2021, certain warrants allowing for cashless exercise were exercised, with exercise prices between $0.22 and $0.52. The Company issued approximately 2.1 million shares of common stock upon 2.6 million warrant exercises.

Stock Options Exercised for Cash and Cashless Stock Options Exercise

Between January and March 2021, the Company received $46,000 from the exercise of stock options with an exercise price of $0.25. The Company issued approximately 0.2 million shares of common stock upon these options exercises.

Between January and March 2021, certain stock options holders elected to cashless exercise their options, with exercise prices between $0.25 and $0.34. The Company issued approximately 3.1 million shares of common stock upon 3.7 million options exercises.

Debt Conversion

Between January and March 2021, the Company converted approximately $4.6 million outstanding debt and interest into approximately 4.5 million shares of common stock.

F-40

EX-4.1 2 nwbo-20201231xex4d1.htm EXHIBIT 4.1

Exhibit 4.1

DESCRIPTION OF THE REGISTRANT’S SECURITIES REGISTERED PURSUANT TO

SECTION 12 OF THE SECURITIES EXCHANGE ACT OF 1934

The following description of the common stock of Northwest Biotherapeutics, Inc. (the “Corporation,” “us,” “our” or ”we”) does not purport to be complete and is subject to, and qualified in its entirety by, our certificate of incorporation, as amended (“certificate”), and our amended and restated bylaws (“bylaws”), each of which is incorporated by reference as an exhibit to the Annual Report on Form 10-K of which this exhibit is a part.

General

Our authorized capital stock consists of 1,200,000,000 shares of common stock, par value $0.001 per share, and 100,000,000 shares of preferred stock, par value $0.001 per share. We have one class of securities registered under Section 12 of the Securities Exchange Act of 1934, our common stock, which is listed on the OTCQB tier of the OTC Markets under the symbol “NWBO.” There are no shares of preferred stock outstanding.

Common Stock

Voting rights. The holders of our common stock are entitled to one vote per share on all matters submitted to a vote of stockholders. A plurality of the votes cast is required for stockholders to elect directors. All other matters put to a stockholder vote generally require the approval of a majority of the votes cast by the shares represented at a meeting of the stockholders, except as otherwise provided by our certificate or bylaws or required by law. Stockholders do not have cumulative voting rights.

Dividends. Subject to the prior rights of any series of preferred stock which may from time to time be outstanding, the holders of our common stock are entitled to receive such dividends, if any, as may be declared from time to time by our board of directors out of legally available funds. As of the date of this filing, we have not declared or paid any cash dividends on our shares of common stock.

Liquidation. In the event we are liquidated, dissolved or our affairs are wound up, after we pay or make adequate provision for all of our known debts and liabilities, each holder of common stock will receive distributions pro rata out of assets that we can legally use to pay distributions, subject to any rights that are granted to the holders of any class or series of preferred stock.

Preemptive, subscription and conversion rights. Our common stock is not redeemable and has no preemptive, subscription or conversion rights.

Transfer agent. The transfer agent and registrar for our common stock is Computershare Trust Company, N.A. Its address is P.O. Box 30170, College Station, Texas 77842 and its phone number is (866) 282-9695

Our common stock is subject and subordinate to any rights and preferences granted under our certificate and any rights and preferences which may be granted to any series of preferred stock by our board pursuant to the authority conferred upon our board under our certificate.

1


Anti-Takeover Provisions

Some provisions of our certificate, bylaws and Delaware law may have the effect of delaying, discouraging or preventing a change in control of us or changes in our management. Pursuant to our certificate and bylaws:

·

the board of directors is authorized to issue preferred stock without stockholder approval;

·

the board of directors is expressly authorized to make, alter or repeal any provision of our bylaws

·

stockholders may only alter, amend, rescind or adopt the bylaws with the affirmative vote of two-thirds of the voting power of all outstanding stock of the Corporation, voting together as a single class;

·

the board of directors is classified, with members serving staggered three-year terms

·

stockholders may not cumulate votes in the election of directors;

·

stockholders may take action only at a duly called meeting of the stockholders, and stockholders are not permitted to act by written consent or cause the Corporation to call a special meeting;

·

special meetings of the stockholders may only be called by the Chairman of the Board (if any) or the Chief Executive Officer and shall be called by the Secretary at the written request, or by resolution adopted by the affirmative vote of a majority of the Corporations directors;

·

a director may be removed from office only for cause at a special meeting of stockholders called for that purpose, by the affirmative vote of the holders of not less than two-thirds of the shares entitled to elect the Director or Directors whose removal is being sought;

·

stockholders must satisfy advance notice procedures to submit proposals or nominate directors for consideration at a stockholders meeting; and

·

we will indemnify officers and directors against losses that they may incur as a result of investigations and legal proceedings resulting from their services to us, which may include services in connection with takeover defense measures.

In addition, we are subject to the provisions of Section 203 of the Delaware General Corporation Law (“DGCL”). In general, the statute prohibits a publicly held Delaware corporation from engaging in a “business combination” with an “interested stockholder” for a period of three years after the date that the person became an interested stockholder unless, with some exceptions, the business combination or the transaction in which the person became an interested stockholder is approved in a prescribed manner. Generally, a “business combination” includes a merger, asset or stock sale or other transaction resulting in a financial benefit to the stockholder, and an “interested stockholder” is a person who, together with affiliates and associates, owns (or within three years prior, did own) 15% or more of the corporation’s outstanding voting stock. This provision may have the effect of delaying, deferring or preventing a change in control without further action by the stockholders.

2


EX-10.81 3 nwbo-20201231xex10d81.htm EXHIBIT 10.81

Exhibit 10.81

NORTHWEST BIOTHERAPEUTICS, INC.

2020 EQUITY COMPENSATION PLAN

1. GENERAL.

(a) Eligible Award Recipients. The persons eligible to receive Awards are Employees, Directors and Consultants inside and outside of the United States.

(b) Available Securites. The Plan provides for the grant of any type of equity security, equity-linked security or equity security equivalent, including without limitation, the following: (i) Incentive Stock Options, (ii) Nonstatutory Stock Options, (iii) Stock Awards (including restricted stock units), (iv) Purchase Rights, or (vi) other forms of derivative securities with underlying Common Stock (each an “Award”).

(c) General Purpose. The Company, by means of the Plan, seeks to secure and retain the services of the group of persons eligible to receive Awards as set forth in Section 1(a), to provide incentives for such persons to exert maximum efforts for the success of the Company and any Affiliate and to provide a means by which such eligible recipients may be given an opportunity to benefit from increases in value of the Common Stock through the granting of Awards.

2. ADMINISTRATION.

(a) Administration by Board. The Board shall administer the Plan except to the extent the Board delegates administration of the Plan to a Committee or Committees, as provided in Section 2(c).

(b) Powers of Board. The Board shall have the power, pursuant to the Plan and/or otherwise:

(i) To determine from time to time (A) which of the persons eligible under the Plan shall be granted Awards; (B) when and how each Award shall be granted, and whether and to what extent an award is deemed to be made under the Plan or outside of the Plan; (C) what type or combination of types of Award shall be granted; (D) the provisions of each Award granted (which need not be identical), including, without limitation, the vesting schedule and terms, the time or times when a person shall be permitted to receive cash or Common Stock pursuant to an Award, and any tax payment or make-whole arrangements; (E) the number of shares of Common Stock with respect to which an Award shall be granted to each such person and (F) other terms of an Award.

(ii) To construe and interpret the Plan and Awards, and to establish, amend and revoke rules and regulations for the Plan’s administration. The Board, in the exercise of this power, may correct any defect, omission or inconsistency in the Plan or in any Award in a manner and to the extent it shall deem necessary or expedient to make the Plan or Award fully effective.

(iii) To settle all controversies regarding the Plan and Awards.

(iv) To determine case by case whether to accelerate the time at which an Award may be exercised or the time during which and/or basis upon which an Award or any part thereof will vest in accordance with the Plan, notwithstanding the provisions in the Award stating the time at which it may be exercised or the time during which and/or basis upon which it will vest, or to make other case by case changes provided that such changes are not adverse to the Awardholder and/or the Awardholder consents in writing to the changes.

(v) To suspend or terminate the Plan at any time. Suspension or termination of the Plan shall not impair rights and obligations under any Award granted while the Plan was in effect except with the written consent of the affected Participant.

(vi) To amend the Plan in any respect the Board deems necessary or advisable, including, without limitation, relating to Incentive Stock Options and certain nonqualified deferred compensation under Section 409A of the Code and to bring the Plan and/or Awards into compliance therewith, subject to the limitations, if any, of applicable law.

1


(vii) To approve forms of Awards for use under the Plan and to amend the terms of any one or more Awards, including, but not limited to, amendments to provide terms more favorable to the Participant than previously provided in the Award, subject to any specified limits in the Plan that are not subject to Board discretion; provided however, that the Participant’s rights under any Award shall not be adversely affected by any such amendment unless (A) the Company requests the consent of the affected Participant, and (B) such Participant consents in writing.

(viii) Generally, to exercise such powers and to perform such acts as the Board deems necessary or expedient to promote the best interests of the Company, pursuant to the Plan or otherwise, and that are not in conflict with the provisions of existing Awards.

(ix) To adopt such procedures and/or sub- or separate plans as are necessary or appropriate to provide for Awards to Employees, Directors or Consultants who are foreign nationals or employed outside the United States.

(c) Delegation to Committee(s).

(i) General. The Board may delegate some or all of the administration of the Plan to a Committee or Committees. If administration of the Plan is delegated to a Committee, the Committee shall have, in connection with the administration of the Plan, the powers theretofore possessed by the Board to the extent that such powers have been delegated to the Committee, including the power to delegate to a subcommittee of the Committee any of the administrative powers the Committee is authorized to exercise (and references in this Plan to the Board shall thereafter be to the Committee or subcommittee), subject, however, to such resolutions, not inconsistent with the provisions of the Plan, as may be adopted from time to time by the Board. The Board may retain the authority to concurrently administer the Plan with the Committee(s) and may, at any time, revest in the Board some or all of the powers previously delegated to the Committee, Committees, subcommittee or subcommittees.

(ii) Rule 16b-3 Compliance. In the sole discretion of the Board, the Committee may consist solely of two (2) or more Non-Employee Directors, in accordance with Rule 16b-3. In addition, the Board or the Committee, in its sole discretion, may delegate to a Committee which need not consist of Non-Employee Directors the authority to grant Awards to eligible persons who are not then subject to Section 16 of the Exchange Act.

(d) Effect of Board’s Decision. All determinations, interpretations and constructions made by the Board in good faith shall not be subject to review by any person and shall be final, binding and conclusive on all persons.

3. SECURITIES SUBJECT TO THE PLAN.

(a) Notwithstanding any other provision of this Plan or other document, and subject only to adjustments for stock splits, reverse splits and similar transactions which apply to all issued and outstanding securities of the Company, the number of Securities that may be issued pursuant to Awards made under this Plan shall equal twenty percent (20%) of the total issued and outstanding Securities of the Company at the Calculation Date, provided that in no event shall the number of issuable Securities be decreased. “Calculation Date” means any date on which the outstanding capitalization of the Company is increased.

(b) If any Securities issued pursuant to an Award expire or are forfeited back to the Company, then the shares which expire or are forfeited shall revert to and again become available for issuance under the Plan. Notwithstanding the provisions of this subsection 3(b), if and to the extent that applicable law precludes the reissuance of any such shares pursuant to Incentive Stock Options, then, only to such extent, any such shares shall not be subsequently issued pursuant to the exercise of Incentive Stock Options but in such case may be subsequently issued as Non-Statutory Options or other Awards.

4. ELIGIBILITY.

(a) Eligibility for Specific Options. To the extent required by applicable law, Incentive Stock Options may be granted only to employees of the Company or a parent or subsidiary (as such terms are defined in Sections 424(e) and (f) of the Code). Awards other than Incentive Stock Options may be granted to Employees, Directors and Consultants of the Company or an Affiliate of the Company.

2


(b) Ten Percent Stockholders. To the extent required by applicable law, a Ten Percent Stockholder shall not be granted an Incentive Stock Option unless the exercise price of such Option is at least one hundred ten percent (110%) of the Fair Market Value on the date of grant, and the Option is not exercisable after the expiration of five (5) years from the date of grant, provided however, that Ten Percent Stockholders may be granted Non-qualified Stock Options at any exercise price and exercise terms agreed by the parties (subject to Section 5 hereof).

5. AWARD PROVISIONS.

Each Award shall be in such form and shall contain such terms and conditions as the Board shall deem appropriate. Options may be separately designated Incentive Stock Options or Nonstatutory Stock Options at the time of grant. If an Option is not specifically designated as an Incentive Stock Option, then the Option shall be deemed to be a Nonstatutory Stock Option. The provisions of separate Awards need not be identical and, notwithstanding anything to the contrary in this Plan, the nature, terms and conditions of all Awards shall be determined by the Board or Committee in good faith, in its sole discretion, to be in the best interests of the Company. Pursuant to such Board or Committee determinations, each Award shall include (through incorporation of provisions hereof by reference in the Award or otherwise) the following categories of provisions:

(a) Term. Subject to the provisions of Section 4(b) regarding Ten Percent Stockholders, the term (which need not be the same for different Award grants) shall be determined by the Board and set forth in the Award. No Award shall be exercisable after the expiration of ten (10) years from the date it becomes exercisable, or such shorter period specified in the Award, unless the term is extended.

(b) Price. For Incentive Stock Options, subject to the provisions of Section 4(b) hereof, the exercise price of each Incentive Stock Option shall, to the extent required by law, be not less than one hundred percent (100%) of the Fair Market Value of the Common Stock subject to the Option on the date the Option is granted. Notwithstanding the foregoing, an Option or other Securities may be granted to any party with an exercise price at any level below one hundred percent (100%) of the Fair Market Value of the Common Stock underlying such Option or other Securities (i) if such Option or other Security is not an Incentive Stock Option, (ii) if such Option or other Security is granted pursuant to an assumption of or substitution for another option in a manner consistent with the provisions of Section 424(a) of the Code (whether or not such options are Incentive Stock Options), or (iii) if the Board determines the grant of such Option or other Security to be in the best interests of the Company to attract, retain or incentivize an Employee, Director or Consultant. The price per share for each Award shall be established by the Board or Committee, taking into account considerations such as relevant market factors and any noncash consideration to be received by the Company from the recipient of the Award.

(c) Consideration. The purchase price of Common Stock acquired pursuant to the exercise of an Option shall be paid, to the extent permitted by applicable law and as determined by the Board in its sole discretion, by any combination of the methods of payment set forth below. The Board shall have the authority to grant Options that do not permit all of the following methods of payment (or otherwise restrict the ability to use certain methods) and/or to grant Options that require the consent of the Company to utilize a particular method of payment. AwardThe methods of payment permitted by this Section 5(c) are:

(i) by cash, check, bank draft or money order payable to the Company;

(ii) pursuant to a program developed under Regulation T as promulgated by the Federal Reserve Board that, prior to the issuance of the stock subject to the Option, results in either the receipt of cash (or check) by the Company or the receipt of irrevocable instructions to pay the aggregate exercise price to the Company from the sales proceeds;

(iii) cashless exercise pursuant to provisions therefor; or

(iv) by any other form of legal consideration that may be acceptable to the Board.

(d) Transferability and Exercise of Awards. The Board may, in an Award, impose such limitations on the transferability of Awards (or Securities issued pursuant to an exercise of an Award) as the Board shall determine, but may only do so by setting forth such restrictions explicitly in the Award. In the absence of such an explicit

3


restriction, an Award shall be freely transferable by the Awardholder to the maximum extent allowed by law.

(e) Beneficiary Designation. The Awardholder may, by written notice to the Company, by will or by other legally permitted methods designate a third party who, in the event of the death of the Awardholder, shall thereafter be the beneficiary of an Award with the right receive the Award and any consideration resulting from an Award exercise.

(f) Vesting Generally. The total number of Securities subject to an Award may vest and therefore become receivable, nonforfeitable or exercisable in periodic installments that may or may not be equal. The installments may be based upon time, upon trigger events and/or upon achievement of milestones, or any combination of such factors and/or other factors. The Award may be subject to such other terms and conditions on the time or times when it may or may not be exercised as the Board may deem appropriate. The vesting provisions of individual Awards may vary. The provisions of this Section 5(f) are subject to any terms and conditions of individual Awards.

(g) Disability of Awardholder. In the event that an Awardholder’s Continuous Service terminates as a result of the Awardholder’s Disability, the Awardholder may exercise or manage his or her Award according to its terms, or as otherwise determined by the Board (provided that such Board determination shall not modify the terms of an existing Award in a manner adverse to the Awardholder).

(h) Death of Awardholder. In the event that an Awardholder’s Continuous Service terminates as a result of the Awardholder’s death, then the Award may be exercised or managed according to its terms by the Awardholder’s estate or applicable heirs, or by persons designated by the Awardholder in written notice to the Company as the beneficiary of the Award upon the Awardholder’s death.

6. COVENANTS OF THE COMPANY.

(a) Availability of Shares. During the terms of the Awards, the Company shall keep available at all times the number of shares of Common Stock reasonably required to satisfy such Awards.

(b) Securities Law Compliance. The Company shall seek to obtain from each regulatory commission or agency having jurisdiction over the Plan such authority as may be required to grant Awards and to issue and sell Securities upon exercise of the Awards; provided, however , that this undertaking shall not require the Company to register under the Securities Act the Plan, any Award or any Securities issued or issuable pursuant to any such Award. If, after reasonable efforts, the Company is unable to obtain from any such regulatory commission or agency the authority that counsel for the Company deems necessary for the lawful issuance and sale of Securities under the Plan, the Company shall be relieved from any liability for a reasonable period of time for failure to issue and sell Securities upon exercise of such Awards unless and until such authority is obtained, provided that the Company continues to use best efforts to obtain such authority.

(c) Company Obligations. The Company shall have no duty or obligation to any Awardholder to advise such holder as to the time or manner of exercising such Award. Furthermore, the Company shall have no duty or obligation to warn or otherwise advise such holder of a pending termination or expiration of an Award or a possible period in which the Award may not be exercised. The Company may have a duty or obligation to minimize the tax consequences of an Award to the holder of such Award, as provided in an Award or pursuant to an agreement relating thereto.

7. ADJUSTMENTS UPON CHANGES IN COMMON STOCK; OTHER CORPORATE EVENTS.

(a) Capitalization Adjustments. In the event of a Capitalization Adjustment, the number of Securities subject to the Plan shall adjust automatically as provided in Section 3(a) above. In no event will fractional shares of Common Stock be issued under the Plan.

(b) Dissolution or Liquidation. In the event of a dissolution or liquidation of the Company, all outstanding Awards shall become fully vested, and/or exercisable (to the extent such Awards have not previously expired or terminated).

(c) Corporate Transaction. In the event of a Corporate Transaction, vesting of all Awards, and the time at which such Awards may be exercised, will be accelerated in full to a date at least one business day prior to the effective

4


time of such Corporate Transaction (contingent upon the effectiveness of the Corporate Transaction). If there is a Corporate Transaction and any Award is not exercised, such Award will continue to remain outstanding per its terms except that in lieu of being exercisable forSecurities of the Company, it will be exercisable for the consideration which would have been received in the Corporate Transaction had it been exercised for such Securities before the Corporate Transaction took place.

8. TERM AND TERMINATION OR SUSPENSION OF THE PLAN.

(a) Plan Effective Date. The Plan shall become effective on the Effective Date determined by the Board.

(b) Plan Term. Unless sooner terminated by the Board pursuant to Section 2, the Plan shall automatically terminate on the day before the tenth (10th) anniversary of the Effective Date. The Plan may be suspended temporarily by the Board in its sole discretion. No new Awards may be granted under the Plan while the Plan is suspended or after it is terminated, provided, however, that the issuance of Awards that were approved by the Board while the Plan was not suspended or terminated shall be completed.

(c) No Impairment of Rights. Termination of the Plan shall not impair rights and obligations under any Award approved or granted while the Plan was in effect except with the written consent of the affected Participant.

9. MISCELLANEOUS.

(a) Corporate Action for Awards. Corporate action (such as Board approval) relating to an Award to any Participant shall be deemed effective as of the date of such corporate action, unless otherwise determined by the Board, regardless of when the instrument, certificate, or letter evidencing the Award is communicated to, or actually received by or executed or accepted by, the Participant.

(b) No Employment or Other Service Rights. Nothing in the Plan, any Award or other instrument executed thereunder or in connection with any Award granted pursuant to the Plan shall confer upon any Participant any right to continue to serve the Company or an Affiliate in the capacity in effect at the time the Award was granted or shall affect the right of the Company or an Affiliate to terminate (i) the employment of an Employee with or without notice and with or without cause (except as otherwise provided in an employment agreement or other agreement), (ii) the service of a Consultant pursuant to the terms of such Consultant’s agreement with the Company or an Affiliate, or (iii) the service of a Director pursuant to the Bylaws of the Company or an Affiliate, and any applicable provisions of the corporate law of the state and/or country in which the Company or the Affiliate is incorporated, as the case may be.

(c) Incentive Stock Option $100,000 Limitation. To the extent required by applicable law, to the extent that the aggregate Fair Market Value (determined at the time of grant) of Common Stock with respect to which Incentive Stock Options are exercisable for the first time by any Optionholder during any calendar year (under all plans of the Company and any Affiliates) exceeds one hundred thousand dollars ($100,000), the Options or portions thereof that exceed such limit (according to the order in which they were granted) shall be treated as Nonstatutory Stock Options, notwithstanding any contrary provision of the applicable Option Agreement(s).

(d) Withholding Obligations. Unless prohibited by the terms of an Award, the Company may, in its sole discretion, satisfy any federal, state or local tax withholding obligation relating to an Award by any of the following means (in addition to the Company’s right to withhold from any compensation paid to the Participant by the Company) or by a combination of such means: (i) causing the Participant to tender a cash payment; (ii) with the approval of the Board to the extent required for compliance with Rule 16b-3, withholding shares of Common Stock from the shares of Common Stock issued or otherwise issuable to the Participant in connection with the Award; (iii) withholding cash from an Award settled in cash; or (iv) by such other method as may be set forth in the Award.

(e) Electronic Delivery. Any reference herein to a “written” agreement or document shall include any agreement or document delivered electronically.

(f) Deferrals. To the extent permitted by applicable law, the Board, with consent of the Awardholder in his or her discretion, may determine that the delivery of Securities or the payment of cash, upon the exercise, vesting or

5


settlement of all or a portion of any Award may be deferred and may establish programs and procedures for deferral elections to be made by Participants. Deferrals by Participants will be made in accordance with Section 409A of the Code. Consistent with Section 409A of the Code, the Board may provide for distributions while a Participant is still an employee. The Board is authorized to make deferrals of Awards, with consent of the Awardholder, and determine (also with the consent of the Awardholder, except in cases of termination for cause) when, and in what annual percentages, Participants may receive payments, including lump sum payments, following the Participant’s termination of employment or retirement, and implement such other terms and conditions consistent with the provisions of the Plan and in accordance with applicable law.

10. CHOICE OF LAW.

The law of the State of Delaware shall govern all questions concerning the construction, validity and interpretation of this Plan, without regard to such state’s conflict of laws rules.

11. DEFINITIONS. As used in the Plan, the definitions contained in this Section 13 shall apply to the capitalized terms indicated below:

(a) Affiliate” means, at the time of determination, any “parent” or “subsidiary” of the Company as such terms are defined in Rule 405 of the Securities Act, as well as any party under common majority ownership with the Company. The Board shall have the authority to determine “affiliate” status and the time or times at which “affiliate” status is determined.

(b) Award” means a written document signed by the Company evidencing the terms and conditions of an Award grant. Each Award shall be subject to the terms and conditions of the Plan.

(c) Awardholder” means a person to whom an Award is granted pursuant to the Plan or, if applicable, such other person who holds an outstanding Award (including, without limitation, an assignee or transferee).

(d) Board” means the Board of Directors of the Company.

(e) “Calculation Date” means any date on which the outstanding capitalization of the Company is increased (including, without limitation, by issuance of any Company Securities). As provided in Section 3(a), the aggregate number of Company Securities that may be issued pursuant to Awards under this Plan shall equal twenty percent (20%) of the total issued and outstanding Securities of the Company at the Calculation Date, provided that in no event shall the number of issuable shares be decreased.

(f) Capitalization Adjustment” means any change that is made in, or other events that occur with respect to, the Securities subject to the Plan or subject to any Award after the Effective Date (through merger, consolidation, reorganization, recapitalization, reincorporation, stock dividend, dividend in property other than cash, stock split, liquidating dividend, combination of shares, exchange of shares, change in corporate structure or other transaction not involving the receipt of consideration by the Company).

(f) Change in Control” means, unless otherwise determined by the Board, the occurrence, in a single transaction or in a series of transactions, of any one or more of the following events:

(i) any Exchange Act Person becomes the Owner, directly or indirectly, of securities of the Company representing more than fifty percent (50%) of the combined voting power of the Company’s then outstanding securities other than by virtue of a merger, consolidation or similar transaction. Notwithstanding the foregoing, a Change in Control shall not be deemed to occur (A) on account of the acquisition of securities of the Company by an investor or any other Exchange Act Person from the Company in a transaction or series of transactions which are initiated by the Company and/or expressly approved by the Company’s Board of Directors, the primary purpose of which is to obtain financing for the Company through the issuance by the Company of securities, or (B) solely because the level of Ownership held by any Exchange Act Person (the “Subject Person ”) exceeds the designated percentage threshold of the outstanding voting securities as a result of a repurchase or other acquisition of voting securities by the Company reducing the number of shares outstanding, provided that if a Change in Control would occur (but for the operation of this sentence) as a result of the acquisition of voting securities by the Company, and after such share

6


acquisition, the Subject Person becomes the Owner of any additional voting securities that, assuming the repurchase or other acquisition had not occurred, increases the percentage of the then outstanding voting securities Owned by the Subject Person over the designated percentage threshold. For the avoidance of doubt, in the event of acquisitions of securities and/or interests therein by one or more investors and/or other parties, directly or indirectly, representing more than fifty percent (50%) of the combined voting power of the Company’s then outstanding securities, in a single transaction or a series of transactions that in whole or in part have not been initiated by the Company or expressly approved by the Company’s Board of Directors, then a Change in Control shall be deemed to have occurred.

(ii) there is consummated a merger, consolidation or similar transaction involving (directly or indirectly) the Company and, immediately after the consummation of such merger, consolidation or similar transaction, the stockholders of the Company immediately prior thereto do not Own, directly or indirectly, either (A) outstanding voting securities representing more than fifty percent (50%) of the combined outstanding voting power of the surviving Entity in such merger, consolidation or similar transaction or (B) more than fifty percent (50%) of the combined outstanding voting power of the parent of the surviving Entity in such merger, consolidation or similar transaction, in each case in substantially the same proportions as their Ownership of the outstanding voting securities of the Company immediately prior to such transaction;

(iii) the stockholders of the Company approve or the Board approves a plan of dissolution or liquidation of all or substantially all of the Company, or a dissolution or liquidation of all or substantially all of the Company shall otherwise occur, except for a liquidation into a parent corporation; or

(iv) there is consummated a sale, lease, exclusive license or other disposition of all or substantially all of the consolidated assets of the Company and its Subsidiaries, other than a sale, lease, license or other disposition of all or substantially all of the consolidated assets of the Company and its Subsidiaries to an Entity, more than fifty percent (50%) of the combined voting power of the voting securities of which are Owned by stockholders of the Company in substantially the same proportions as their Ownership of the outstanding voting securities of the Company immediately prior to such sale, lease, license or other disposition.

For the avoidance of doubt, the term Change in Control shall not include a sale of assets, merger or other transaction effected exclusively for the purpose of changing the domicile of the Company.

Notwithstanding the foregoing or any other provision of this Plan, the definition of Change in Control (or any analogous term) in an Award shall supersede the foregoing definition with respect to such Awards; provided, however, that if no definition of Change in Control or any analogous term is set forth in such an individual Award, the Board shall determine whether the foregoing definition or an alternative definition shall apply.

(h) Code” means the Internal Revenue Code of 1986, as amended.

(i) Committee” means a committee of one (1) or more Directors to whom authority has been delegated by the Board in accordance with Section 2(c).

(j) Common Stock” means the common stock of the Company and any securities exercisable for or convertible into Common Stock.

(k) Company” means Northwest Biotherapeutics, Inc., a Delaware corporation.

(l) Consultant” means any person, including an advisor, who (i) renders consulting or advisory services or other services to or for the benefit of the Company or an Affiliate, whether or not such person is compensated for such services apart from Awards under the Plan, or (ii) is serving as a member of the board of directors or management of an Affiliate. However, service solely as a Director of the Company, or payment of a fee solely for such service as a Director and not for any other services, shall not cause such Director to be considered a “Consultant” for purposes of the Plan.

(m) Continuous Service” means that the Participant’s service with the Company or an Affiliate, whether as an Employee, Director or Consultant, is not interrupted or terminated. A change in the capacity in which the Participant

7


renders service to the Company or an Affiliate as an Employee, Consultant or Director or a change in the entity for which the Participant renders such service, provided that there is no interruption or termination of the Participant’s service with the Company or an Affiliate, shall not terminate a Participant’s Continuous Service. For example, a change in status from an employee of the Company to a consultant to an Affiliate or to a Director shall not constitute an interruption of Continuous Service. To the extent permitted by law, the Board or the chief executive officer of the Company, in that party’s sole discretion, may determine whether Continuous Service shall be considered interrupted in the case of any leave of absence approved by that party, including sick leave, military leave or any other personal leave, or in the case of a gap in service in connection with a change in capacity or change of entity.

(n) Corporate Transaction” means the occurrence, in a single transaction or in a series of transactions, of any one or more of the following events:

(i) a sale or other disposition of all or substantially all, as determined by the Board in its sole discretion, of the consolidated assets of the Company and its Subsidiaries;

(ii) a Change of Control;

(iii) the consummation of a merger, consolidation or similar transaction following which the Company is not the surviving corporation; or

(iv) the consummation of a merger, consolidation or similar transaction following which the Company is the surviving corporation but the shares of Common Stock outstanding immediately preceding the merger, consolidation or similar transaction are converted or exchanged by virtue of the merger, consolidation or similar transaction into other property, whether in the form of securities, cash or otherwise.

(o) Director” means a member of the Board of the Company.

(p) Disability” means the permanent or temporary (i) inability of a person to perform or fulfill all employment services in the usual manner or (ii) disability within the meaning of Section 22(e)(3) of the Code.

(q) Effective Date” means the date of approval of this Plan by the Board.

(r) Employee” means any person employed by the Company or an Affiliate.

(s) Entity” means a corporation, partnership, limited liability company or other entity.

(t) Exchange Act” means the Securities Exchange Act of 1934, as amended.

(u) Exchange Act Person” means any natural person, Entity or “group” (within the meaning of Section 13(d) or 14(d) of the Exchange Act), except that “Exchange Act Person” shall not include (i) the Company or any Subsidiary of the Company, (ii) any employee benefit plan of the Company or any Subsidiary of the Company or any trustee or other fiduciary holding securities under an employee benefit plan of the Company or any Subsidiary of the Company, (iii) an underwriter temporarily holding securities pursuant to an offering of such securities, (iv) an Entity Owned, directly or indirectly, by the stockholders of the Company in substantially the same proportions as their Ownership of stock of the Company; or (v) any natural person, Entity or “group” (within the meaning of Section 13(d) or 14(d) of the Exchange Act) that, as of the Effective Date of the Plan as set forth in Section 11, is the Owner, directly or indirectly, of securities of the Company representing more than twenty five percent (25%) of the combined voting power of the Company’s then outstanding securities.

(v) Fair Market Value” means, as of any date, the value of the Common Stock determined as follows:

(i) If the Common Stock is listed on any established stock exchange or traded on any established market, the Fair Market Value of a share of Common Stock shall be the closing sales price for such stock (or the closing bid, if no sales were reported) as quoted on such exchange or market (or the exchange or market with the greatest volume of trading in the Common Stock) for the last market trading day prior to the date of determination, as reported in The Wall Street Journal or such other source as the Board deems reliable.

8


(ii) In the absence of such markets for the Common Stock, the Fair Market Value shall be determined by the Board in good faith.

(w) Incentive Stock Option” means an option granted pursuant to Section 5 of the Plan that is intended to be, and qualifies as, an “incentive stock option” within the meaning of Section 422 of the Code and the regulations promulgated thereunder.

(x) Non-Employee Director” means a Director who either (i) is not a current employee or officer of the Company or an Affiliate, or (ii) is otherwise considered a “non-employee director” for purposes of Rule 16b-3.

(y) Nonstatutory Stock Option” means any option granted pursuant to the Plan that does not qualify as an Incentive Stock Option.

(z) Officer” means a person who is an officer of the Company within the meaning of Section 16 of the Exchange Act and the rules and regulations promulgated thereunder.

(aa) Option” means an Incentive Stock Option or a Nonstatutory Stock Option to purchase shares of Common Stock granted pursuant to the Plan.

(bb) Own ,” “Owned ,” “Owner ,” “Ownership” A person or Entity shall be deemed to “Own,” to have “Owned,” to be the “Owner” of, or to have acquired “Ownership” of securities if such person or Entity, directly or indirectly, through any contract, arrangement, understanding, relationship or otherwise, has or shares voting power, which includes the power to vote or to direct the voting, with respect to such securities.

(cc) Participant” means a person to whom an Award is granted pursuant to the Plan or, if applicable, such other person who holds an outstanding Award (including, without limitation, an assignee or transferee).

(dd) Plan” means this Northwest Biotherapeutics, Inc. 2020 Equity Compensation Plan.

(ee)Purchase Rights” means the grant to Employees, Directors and Consultants of the Company or an Affiliate of opportunities to make purchases of Common Stock.

(ff) Rule 16b-3” means Rule 16b-3 promulgated under the Exchange Act or any successor to Rule 16b-3, as in effect from time to time.

(gg) “Securities” means any type of equity security, equity-linked security or equity security equivalent, direct or contingent, including without limitation, Common Stock, preferred stock, restricted stock units, warrants, options and other securities of any kind directly or indirectly exercisable for or convertible into Common Stock.

(hh) Securities Act” means the Securities Act of 1933, as amended.

(ii) Stock Awards” means awards of any Securities.

(jj) Subsidiary” means, with respect to the Company, (i) any corporation of which more than fifty percent (50%) of the voting power of the outstanding capital stock is directly or indirectly Owned by the Company, and (ii) any partnership, limited liability company or other entity in which the Company has a direct or indirect interest (whether in the form of voting or participation in profits or capital) of more than fifty percent (50%).

(kk) Ten Percent Stockholder” means a person who Owns (or is deemed to Own pursuant to Section 424(d) of the Code) stock possessing more than ten percent (10%) of the total combined voting power of all classes of stock of the Company or an Affiliate.

9


EX-10.82 4 nwbo-20201231xex10d82.htm EXHIBIT 10.82

Exhibit 10.82

NOTE PURCHASE AGREEMENT

THIS NOTE PURCHASE AGREEMENT (this "Agreement"), dated as of August 14, 2020, is entered into by and between NORTHWEST BIOTHERAPEUTICS, INC., a Delaware corporation ("Company"), and ILIAD RESEARCH AND TRADING, L.P., a Utah limited partnership, its successors and/or assigns ("Investor").

A.           Investor desires to purchase and Company desires to issue and sell, upon the terms and conditions set forth in this Agreement, a Promissory Note, in the form attached hereto as Exhibit A, in the original principal amount of $5,505,000.00 (the "Note").

B.            This Agreement, the Note, and all other certificates, documents, agreements, resolutions and instruments delivered to any party under or in connection with this Agreement, as the same may be amended from time to time, are collectively referred to herein as the "Transaction Documents".

NOW, THEREFORE, in consideration of the above recitals and other good and valuable consideration, the receipt and adequacy of which are hereby acknowledged, Company  and  Investor hereby agree as follows:

1.            Purchase and Sale of Note.

1.1.         Purchase of Note. Company shall issue and sell to Investor and Investor agrees to purchase from Company the Note. In consideration for the issuance of the Note, Investor shall pay the Purchase Price (as defined below) to Company.

1.2.         Form of Payment. On the Closing Date, Investor shall pay the Purchase Price to Company via wire transfer of immediately available funds against delivery of the Note.

1.3.         Closing Date. Subject to the satisfaction (or written waiver) of the conditions set forth in Section 5 and Section 6 below, the date and time of the issuance and sale of the Note pursuant to this Agreement (the "Closing Date") shall be 5:00 p.m., Eastern Time on or about August 14, 2020, or such other mutually agreed upon time. The closing of the transactions contemplated by this Agreement (the "Closing") shall occur on the Closing Date by means of the exchange by express courier and email of .pdf documents, but shall be deemed to have occurred at the offices of Hansen Black Anderson Ashcraft PLLC in Lehi, Utah.

1.4.         Collateral for the Note. The Note shall not be secured.

1.5.         Original Issue Discount; Transaction Expenses. The  Note carries  an original issue discount of $500,000.00 (the "OID"). In addition, Company agrees to pay $5,000.00 to Investor to cover Investor's legal fees, accounting costs, due diligence, monitoring and other  transaction  costs incurred in connection  with the  purchase and sale of the Note (the "Transaction  Expense Amount"),  all of which amount is included in the initial principal balance of the Note. The "Purchase Price", therefore, shall be $5,000,000.00, computed as follows: $5,505,000.00  original principal balance, less the OID, less the Transaction Expense Amount.

2.            Investor's Representations and Warranties. Investor represents and warrants to Company that: (i) this Agreement has been duly and validly authorized; (ii) this Agreement constitutes a valid and binding agreement of Investor enforceable in accordance with its terms; and (iii) Investor 1s  an "accredited investor" as that term is defined in Rule 501(a) of Regulation D of the 1933 Act.

3.            Representations and Warranties of Company. Company represents and warrants to Investor that: (i) Company is a corporation duly organized, validly existing and in good standing under

1


the laws of its state of incorporation and has the requisite corporate power to own its properties and to carry on its business as now being conducted; (ii) Company is duly qualified as a foreign corporation to do business and is in good standing in each jurisdiction where the nature of the business conducted or property owned by it makes such qualification necessary; (iii) Company has registered its shares of common stock, $0.001 par value per share (the "Common Stock"), under Section 12(g) of the Securities Exchange Act of 1934, as amended (the "1934 Act"), and is obligated to file reports pursuant to Section 13 or Section 15(d) of the 1934 Act; (iv) each of the Transaction Documents and the transactions contemplated hereby and thereby, have been duly and validly authorized by Company; (v) this Agreement, the Note, and the other Transaction Documents have been duly executed and delivered by Company and constitute the valid and binding obligations of Company enforceable in accordance with their terms, subject as to enforceability only to general principles of equity and to bankruptcy, insolvency, moratorium, and other similar laws affecting the enforcement of creditors' rights generally; (vi) the execution and delivery of the Transaction Documents by Company and the consummation by Company of the other transactions contemplated by the Transaction Documents do not and will not conflict with or result in a breach by Company of any of the terms or provisions of, or constitute a default under (a) Company's formation documents or bylaws, each as currently in effect, (b) any indenture, mortgage, deed of trust, or other material agreement or instrument to which Company is a party or by which it or any of its properties or assets are bound, including any listing agreement for the Common Stock, or (c) any existing applicable law, rule, or regulation or any applicable decree, judgment, or order of any court, United States federal or state regulatory body, administrative agency, or other governmental body having jurisdiction over Company or any of Company's properties or assets; (vii) no further authorization, approval or consent of any court, governmental body, regulatory agency, self-regulatory organization, or stock exchange or market or the stockholders or any lender of Company is required to be obtained by Company for the issuance of the Note to Investor; (viii) none of Company's filings with the SEC contained, at the time they were filed, any untrue statement of a material fact or omitted to state any material fact required to be stated therein or necessary to make the statements made therein, in light of the circumstances under which they were made, not misleading; (ix) Company has filed all reports, schedules, forms, statements and other documents required to be filed by Company with the SEC under the 1934 Act on a timely basis or has received a valid extension of such time of filing and has filed any such report, schedule, form, statement or other document prior to the expiration of any such extension; (x) Company has not consummated any financing transaction that has not been disclosed in a periodic or other filing with the SEC under the 1934 Act; (xi) Company is not, nor has it ever been, a "Shell Company," as such type of"issuer" is described in Rule 144(i)(l) under the 1933 Act or is in compliance with Rule 144(i)(2) under the 1933 Act; (xii) with respect to any commissions, placement agent or finder's fees or similar payments that will or would become due and owing by Company to any person or entity as a result of this Agreement or the transactions contemplated hereby ("Broker Fees"), any such Broker Fees will be made in full compliance with all applicable laws and regulations and only to a person or entity that is a registered investment adviser or registered broker-dealer; (xiii) Investor shall have no obligation with respect to any Broker Fees or with respect to any claims made by or on behalf of other persons for fees of a type contemplated in this subsection that may be due in connection with the transactions contemplated hereby and Company shall indemnify and hold harmless each of Investor, Investor's employees, officers, directors, stockholders, managers, agents, and partners, and their respective affiliates, from and against all claims, losses, damages, costs (including the costs of preparation and attorneys' fees) and expenses suffered in respect of any such claimed or existing Broker Fees; and (xiv) neither Investor nor any of  its officers, directors, members, managers, employees, agents or representatives has made any representations or warranties to Company or any of its officers, directors, employees, agents or representatives except as expressly set forth in the Transaction Documents and, in making its decision to enter into the transactions contemplated by the Transaction Documents, Company is not relying on any representation, warranty, covenant or promise of Investor or its officers, directors, members, managers, employees, agents or representatives other than as set forth in the Transaction Documents.

2


4.            Company Covenants. Until all of Company's obligations under the Note are paid and performed in full, or within the timeframes otherwise specifically set forth below, Company will at all times comply with the following covenants: (i) Company will timely file on the applicable deadline all reports required to be filed with the SEC pursuant to Sections 13 or lS(d) of the 1934 Act, and will take all reasonable action under its control to ensure that adequate current public information with respect to Company, as required in accordance with Rule 144 of the 1933 Act, is publicly available, and will not terminate its status as an issuer required to file reports under the 1934 Act even if the 1934 Act or the rules and regulations thereunder would permit such termination; (ii) the Common Stock shall be listed or quoted for trading on any of(a) NYSE, (b) NASDAQ, (c) OTCQX, (d) OTCQB, or (e) OTC Pink Current Information; and (iii) trading in Company's Common Stock will not be suspended, halted, chilled, frozen, reach zero bid or otherwise cease on Company's principal trading market.

5.            Conditions to Company's Obligation to Sell. The obligation of Company hereunder to issue and sell the Note to Investor at the Closing is subject to the satisfaction, at or before the Closing Date, of each of the following conditions:

5.1.         Investor shall have executed this Agreement and delivered the same to Company.

5.2.         Investor shall have delivered the Purchase Price to Company in accordance with Section 1.2 above.

6.            Conditions to Investor's Obligation to Purchase. The obligation of Investor hereunder to purchase the Note at the Closing is subject to the satisfaction, at or before the Closing Date, of each of the following conditions, provided that these conditions are for Investor's sole benefit and may be waived by Investor at any time in its sole discretion:

6.1.         Company shall have executed this Agreement and the Note and delivered the same to Investor.

6.2.         Company shall have delivered to Investor a fully executed Secretary' s Certificate substantially in the form attached hereto as Exhibit B evidencing Company's approval of the Transaction Documents.

6.3.         Company shall have delivered to Investor fully executed copies of all other Transaction Documents required to be executed by Company herein or therein.

7.            Miscellaneous. The provisions set forth in this Section 7 shall apply to this Agreement, as well as all other Transaction Documents as if these terms were fully set forth therein; provided, however, that in the event there is a conflict between any provision set forth in this Section 7 and any provision in any other Transaction Document, the provision in such other Transaction Document shall govern.

7.1.         Certain Capitalized Terms. To the extent any capitalized term used in any Transaction Document is defined in any other Transaction Document (as noted therein), such capitalized term shall remain applicable in the Transaction Document in which it is so used even if the other Transaction Document (wherein such term is defined) has been released, satisfied, or is otherwise cancelled or terminated.

7.2.         Arbitration of Claims. The parties shall submit all Claims (as defined in Exhibit .C.) arising under this Agreement or any other Transaction Document or other agreement between the parties and their affiliates to binding arbitration pursuant to the arbitration provisions set forth in Exhibit.C. attached hereto (the "Arbitration Provisions") . The parties hereby acknowledge and agree that the Arbitration Provisions are unconditionally binding on the parties hereto and are severable from all other provisions of this Agreement. By executing this Agreement, Company represents, warrants and covenants

3


that Company has reviewed the Arbitration Provisions carefully, consulted with legal counsel about such provisions (or waived its right to do so), understands that the Arbitration Provisions are intended to allow for the expeditious and efficient resolution of any dispute hereunder, agrees to the terms and limitations set forth in the Arbitration Provisions, and that Company will not take a position contrary to the foregoing representations. Company acknowledges and agrees that Investor may rely upon the foregoing representations and covenants of Company regarding the Arbitration Provisions.

7.3.        Governing Law; Venue. This Agreement shall be governed by and interpreted in accordance with the laws of the State of Utah for contracts to be wholly performed in such state and without giving effect to the principles thereof regarding the conflict of laws. Each party consents to and expressly agrees that exclusive venue for arbitration of any dispute arising out of or relating to any Transaction Document or the relationship of the parties or their affiliates shall be in Salt Lake County, Utah. Without modifying the parties' obligations to resolve disputes hereunder pursuant to the Arbitration Provisions, for any litigation arising in connection with any of the Transaction Documents, each party hereto hereby (i) consents to and expressly submits to the exclusive personal jurisdiction of any state or federal court sitting in Salt Lake County, Utah, (ii) expressly submits to the exclusive venue of any such court for the purposes hereof, and (iii) waives any claim of improper venue and any claim or objection that such courts are an inconvenient forum or any other claim or objection to the bringing of any such proceeding in such jurisdictions or to any claim that such venue of the suit, action or proceeding is improper.

7.4.        Specific Perfonnance. Company acknowledges and agrees that irreparable damage may occur to Investor in the event that Company fails to perform any material provision of this Agreement or any of the other Transaction Documents in accordance with its specific terms. It is accordingly agreed that Investor shall be entitled to an injunction or injunctions to cure breaches of the provisions of this Agreement or such other Transaction Document and to enforce specifically the terms and provisions hereof or thereof, this being in addition to any other remedy to which any Investor may be entitled under the Transaction Documents, at law or in equity. For the avoidance of doubt, in the event Investor seeks to obtain an injunction against Company or specific performance of any provision of any Transaction Document, such action shall not be a waiver of any right of Investor under any Transaction Document, at law, or in equity, including without limitation its rights to arbitrate any Claim pursuant to the terms of the Transaction Documents.

7.5.         Counterparts. Each Transaction Document may be executed in any number of counterparts, each of which shall be deemed an original, but all of which together shall constitute one instrument. The parties hereto confirm that any electronic copy of another party's executed counterpart of a Transaction Document (or such party's signature page thereof) will be deemed to be an executed original thereof.

7.6.         Document Imaging. Investor shall be entitled, in its sole discretion, to image or make copies of all or any selection of the agreements, instruments, documents, and items and records governing, arising from or relating to this loan, including, without limitation, this Agreement and the other Transaction Documents, and Investor may destroy or archive the paper originals. The parties hereto (i) waive any right to insist or require that Investor produce paper originals, (ii) agree that such images shall be accorded the same force and effect as the paper originals, (iii) agree that Investor is entitled to use such images in lieu of destroyed or archived originals for any purpose, including as admissible evidence in any demand, presentment or other proceedings, and (iv) further agree that any executed facsimile (faxed), scanned, emailed, or other imaged copy of this Agreement or any other Transaction Document shall be deemed to be of the same force and effect as the original manually executed document.

7.7.         Headings. The headings of this Agreement are for convenience of reference only and shall not form part of, or affect the interpretation of, this Agreement.

4


7.8.         Severability. In the event that any provision of this Agreement is invalid or unenforceable under any applicable statute or rule of law, then such provision shall be deemed inoperative to the extent that it may conflict therewith and shall be deemed modified to conform to such statute or rule of law. Any provision hereof which may prove invalid or unenforceable under any law shall not affect the validity or enforceability of any other provision hereof.

7.9.         Entire Agreement. This Agreement, together with the other Transaction Documents, contains the entire understanding of the parties with respect to the matters covered herein and therein and, except as specifically set forth herein or therein, neither Company nor Investor makes any representation, warranty, covenant or undertaking with respect to such matters.

7.10.       No Reliance. Company acknowledges and agrees that neither Investor nor any of its officers, directors, members, managers, representatives or agents has made any representations or warranties to Company or any of its officers, directors, representatives, agents or employees except as expressly set forth in the Transaction Documents and, in making its decision to enter into the transactions contemplated by the Transaction Documents, Company is not relying on any representation, warranty, covenant or promise of Investor or its officers, directors, members, managers, agents or representatives other than as set forth in the Transaction Documents.

7.11.       Amendments. No provision of this Agreement may be waived or amended other than by an instrument in writing signed by the parties hereto.

7.12.       Notices. Any notice required or permitted hereunder shall be given in writing and via email to lgoldman@nwbio.com and lpowers@nwbio.com (unless otherwise specified herein) and shall be deemed effectively given on the earliest of: (i) the date delivered, if delivered by personal delivery as against written receipt therefor or by email to an executive officer, or by facsimile (with successful transmission confirmation), (ii) the earlier of the date delivered or the fifth business day after deposit, postage prepaid, in the United States Postal Service by certified mail, or (iii) the earlier of the date delivered or the fifth business day after mailing by express courier, with delivery costs and fees prepaid, in each case, addressed to each of the other parties thereunto entitled at the following addresses (or at such other addresses as such party may designate by five (5) calendar days' advance written notice similarly given to each of the other parties hereto):

If to Company:

Northwest Biotherapeutics, Inc.

Attn: Linda Powers and Les Goldman

4800 Montgomery Lane, Suite 800

Bethesda, Maryland 20814

If to Investor:

Iliad Research and Trading, L.P.

Attn: John Fife

303 East Wacker Drive, Suite 1040

Chicago, Illinois 60601

5


With a copy to (which copy shall not constitute notice):

Hansen Black Anderson Ashcraft PLLC

Attn: Jonathan Hansen

3051 West Maple Loop Drive,

Suite 325 Lehi, Utah 84043

7.13.      Successors and Assigns. This Agreement or any of the severable rights and obligations inuring to the benefit of or to be performed by Investor hereunder  may be assigned  by Investor to a third party, including its financing sources, in whole or in part, without the need to obtain Company's consent thereto. Company may not assign its rights or obligations under this Agreement or delegate its duties hereunder without the prior written consent of Investor.

7.14.      Survival. The representations and warranties  of Company  and the agreements and covenants set forth in this Agreement shall survive the Closing hereunder notwithstanding any due diligence investigation conducted by or on behalf of Investor. Company agrees to indemnify and hold harmless Investor and all its officers, directors, employees, attorneys, and agents for loss or damage arising as a result of or related to any breach by Company of any of its representations, warranties and covenants set forth in this Agreement or any of its covenants and obligations under this Agreement, including advancement of expenses as they are incurred.

7.15.      Further Assurances. Each party shall do and perform, or cause to be done and performed, all such further acts and things, and shall execute and deliver all such other agreements, certificates,  instruments and documents, as the other party may reasonably request in order to carry out the intent and accomplish the purposes of this Agreement and the consummation of the transactions contemplated hereby.

7.16.      Investor's Rights and Remedies Cumulative; Liquidated Damages. All rights, remedies, and powers conferred in this Agreement and the Transaction Documents are cumulative and not exclusive of any other rights or remedies, and shall be in addition to every other right, power, and remedy that Investor may have, whether specifically granted in this Agreement or any other Transaction Document, or existing at law, in equity, or by statute, and any and all such rights and remedies may be exercised from time to time and as often and in such order as Investor may deem expedient. The parties acknowledge and agree that upon Company's failure to comply with the provisions of the Transaction Documents, Investor's damages would be uncertain and difficult (if not impossible) to accurately estimate because of the parties' inability to predict future interest rates, Investor's increased risk, and  the uncertainty of the availability of a suitable substitute investment opportunity for Investor, among other reasons. Accordingly, any fees, charges, and default interest due under the Note and the other Transaction Documents are intended by the parties to be, and shall be deemed, liquidated damages. The parties agree that such liquidated damages are a reasonable estimate of Investor's actual damages  and  not a penalty, and shall not be deemed in any way to limit any other right or remedy Investor may have hereunder,  at law or in equity. The parties acknowledge and agree that under the circumstances existing at the time this Agreement is entered into, such liquidated damages are fair and reasonable and are not penalties. All fees, charges, and default interest provided for in the Transaction Documents are agreed to by the parties to be based upon the obligations and the risks assumed by the parties as of the Closing Date and are consistent with investments of this type. The liquidated damages provisions of the Transaction Documents shall not limit or preclude a party from pursuing any other remedy available at law or in equity; provided, however, that the liquidated damages provided for in the Transaction Documents are intended to be in lieu of actual damages.

7.17.       Attorneys'  Fees and Cost of Collection. In the event of any arbitration  or action at law or in equity to enforce or interpret the terms of this Agreement or any of the other Transaction

6


Documents, the parties agree that the party who is awarded the most money shall be deemed  the prevailing party for all purposes and shall therefore  be entitled to an additional award of the full amount of the reasonable attorneys' fees, deposition costs, and expenses paid by such prevailing party in connection with arbitration or litigation without reduction or apportionment based upon the individual claims or defenses giving rise to the fees and expenses. Nothing herein shall restrict or impair an arbitrator's or a court's power to award fees and expenses for frivolous or bad faith pleading. If (i) the Note is placed in the hands of an attorney for collection or enforcement  prior to commencing arbitration or legal proceedings, or is collected or enforced through any arbitration or legal proceeding, or Investor otherwise takes action to collect amounts due under the Note or to enforce the provisions of the Note; or (ii) there occurs any bankruptcy, reorganization, receivership of Company or other proceedings affecting Company's creditors' rights and involving a claim under the Note; then Company shall pay the costs incurred by Investor for such collection, enforcement or action or in connection with such bankruptcy, reorganization, receivership or other proceeding, including, without limitation, reasonable attorneys' fees, expenses, deposition costs, and disbursements.

7.18.        Waiver. No waiver of any provision of this Agreement shall be effective unless it is in the form of a writing signed by the party granting the waiver. No waiver of any provision or consent to any prohibited action shall constitute a waiver of any other provision or consent to any other prohibited action, whether or not similar. No waiver or consent shall constitute a continuing waiver or consent or commit a party to provide a waiver or consent in the future except to the extent specifically set forth in writing.

7.19.        Waiver of Jury Trial. EACH PARTY TO THIS AGREEMENT IRREVOCABLY WAIVES ANY AND ALL RIGHTS SUCH PARTY MAY HAVE TO DEMAND THAT ANY ACTION, PROCEEDING OR COUNTERCLAIM ARISING OUT OF OR IN ANY WAY RELATED TO THIS AGREEMENT, ANY OTHER TRANSACTION DOCUMENT, OR THE RELATIONSHIPS OF THE PARTIES HERETO BE TRIED BY JURY. THIS WAIVER EXTENDS TO ANY AND ALL RIGHTS TO DEMAND A TRIAL BY JURY ARISING UNDER COMMON LAW OR ANY APPLICABLE STATUTE, LAW, RULE OR REGULATION. FURTHER, EACH PARTY HERETO ACKNOWLEDGES THAT SUCH PARTY IS KNOWINGLY AND VOLUNTARILY WAIVING SUCH PARTY'S RIGHT TO DEMAND TRIAL BY JURY.

7.20.        Time is of the Essence. Time is expressly made of the essence with respect to each and every provision of this Agreement and the other Transaction Documents.

7.21.        Voluntary Agreement. Company has carefully read this Agreement and each of the other Transaction Documents and has asked any questions needed for Company to understand the terms, consequences and binding effect of this Agreement and each of the other Transaction Documents and fully understand them. Company has had the opportunity to seek the advice of an attorney of Company's choosing, or has waived the right to do so, and is executing this Agreement and each of the other Transaction Documents voluntarily and without  any duress or undue influence by Investor or anyone else.

[Remainder of page intentionally left blank; signature page follows]

7


IN WITNESS WHEREOF, the undersigned Investor and Company have caused this Agreement to be duly executed as of the date first above written.

SUBSCRIPTION AMOUNT:

Principal Amount of Note:

$5,505,000.00

Purchase Price:

$5,000,000.00

INVESTOR:

ILIAD RESEARCH AND TRADJNG, L.P.

By: Iliad Management, LLC, its General Partner

By: Fife Trading, Inc., its Manager

By: /s/ John M. Fife

President

COMPANY:

By:|/s/ Leslie J. Goldman

Senior VP General Counsel

ATTACHED EXHIBITS:

Exhibit A

Note

ExhibitB

Secretary's Certificate

Exhibit C

Arbitration Provisions

[Signature Page to Note Purchase Agreement]


PROMISSORY NOTE

U.S. $5,505,000.00

August 14, 2020

FOR VALUE RECEIVED, Northwest Biotherapeutics, Inc., a Delaware corporation ("Borrower"), promises to pay in lawful money of the United States of America to the order of Iliad Research and Trading, L.P., a Utah limited partnership, or its successors or assigns ("Lender"), the principal sum of $5,505,000.00, together with all other amounts due under this Promissory Note (this "Note"). This Note is issued pursuant to that certain Note Purchase Agreement of even date herewith between Borrower and Lender (the "Purchase Agreement").

1.            PAYMENT. Borrower shall pay to Lender the entire outstanding balance of this Note on or before the date that is twenty-one (21) months from the date hereof (the "Maturity Date"). Borrower will make all payments of sums due hereunder to Lender at Lender's address set forth in the Purchase Agreement, or at such other place as Lender may designate in writing. Unless otherwise agreed or required by applicable law, payments will be applied first to any unpaid collection costs and late charges, then to accrued interest and finally to principal.

2.            INTEREST. Interest shall accrue on the outstanding balance of this Note at the rate of eight percent (8%) per annum from the date hereof until this Note is paid in full. Upon the occurrence of an Event of Default (as defined below), interest shall accrue on the outstanding balance of this Note at the lesser of the rate of fifteen percent (15%) per annum or the maximum rate permitted by applicable law. All interest calculations hereunder shall be computed on the basis of a 360-day year comprised of twelve (12) thirty (30) day months, shall compound daily and shall be payable in accordance with the terms of this Note.

3.            ORIGINAL ISSUE DISCOUNT; TRANSACTION EXPENSES. This Note carries an original issue discount of $500,000.00. In addition, Borrower agrees to pay $5,000.00 to Lender to cover Lender's legal fees, accounting costs, due diligence, monitoring and other transaction costs incurred in connection with the purchase and sale of this Note, all of which amounts are included in the initial principal balance of this Note and are fully earned and payable as of the date hereof.

4.            PREPAYMENT. Borrower may pay all or any portion of the amount owed earlier than it is due; provided that in the event Borrower elects to prepay all or any portion of the outstanding balance, it shall pay to Lender 115% of the portion of the outstanding balance Borrower elects to prepay. Early payments of less than all principal, fees and interest outstanding will not, unless agreed to by Lender in writing, relieve Borrower of Borrower's remaining obligations hereunder.

5.            REDEMPTIONS. Beginning on the date that is seven (7) months from the date hereof and at the intervals indicated below until this Note is paid in full, Lender shall have the right to redeem up to one fourteenth (1/14) of the principal and accrued interest then outstanding for each month remaining on the term of the Note (each monthly exercise, a "Monthly Redemption Amount") by providing written notice (each, a "Monthly Redemption Notice") delivered to Borrower by facsimile, email, mail, overnight courier, or personal delivery; provided, however, that if Lender does not exercise any Monthly Redemption Amount in its corresponding month then such Monthly Redemption Amount shall be available for Lender to exercise in any future month in addition to such future month's Monthly Redemption Amount.


Upon receipt of any Monthly Redemption Notice, Borrower shall pay the applicable Monthly Redemption Amount multiplied by 110% in cash to Lender within five (5) business days of Borrower's receipt of such Monthly Redemption Notice.

6.            EVENT OF DEFAULT. The occurrence of any of the following shall constitute an "Event of Default" under this Note:

(a)          Failure to Pay. Borrower shall fail to pay when due, whether at stated maturity, upon acceleration or otherwise, any principal or interest payment, or any other payment required under the terms ofthis Note on the date due.

(b)          Breaches of Covenants. Borrower or any other person or entity defaults or otherwise fails to observe or perform any covenant, obligation, condition or agreement of Borrower contained herein or in any other Transaction Document (as defined in the Purchase Agreement).

(c)          Representations and Warranties. Any representation or warranty made by Borrower to Lender in this Note, the Purchase Agreement, any other Transaction Document, or any related agreement shall be false, incorrect, incomplete or misleading in any material respect when made or furnished.

(d)          Voluntary Bankruptcy or Insolvency Proceedings. Borrower shall (i) apply for or consent to the appointment of a receiver, trustee, liquidator or custodian of itself or of all or a substantial part of its property, (ii) make a general assignment for the benefit of its or any of its creditors, (iii) be dissolved or liquidated, or (iv) commence a voluntary case or other proceeding seeking liquidation, reorganization or other relief with respect to itself or its debts under any bankruptcy, insolvency or other similar law now or hereafter in effect or consent to any such relief or to the appointment of or taking possession of its property by any official in an involuntary case or other proceeding commenced against it.

(e)          Involuntary Bankruptcy or Insolvency Proceedings. Proceedings for the appointment of a receiver, trustee, liquidator, or custodian of Borrower or of all or a substantial part of its property, or an involuntary case or other proceedings seeking liquidation, reorganization, or other relief with respect to Borrower or its debts under any bankruptcy, insolvency or other similar law now or hereafter in effect shall be commenced and an order for relief entered or such proceeding shall not be dismissed or discharged within sixty (60) days of commencement.

(f)           Judgment. A judgment or judgments for the payment of money in excess of the sum of $500,000.00 in the aggregate shall be rendered against Borrower and either (i) the judgment creditor executes on such judgment or (ii) such judgment remains unpaid   or undischarged for more than sixty (60) days from the date of entry thereof or such longer period during which execution of such judgment shall be stayed during an appeal from such judgment.

(g)          Attachment. Any execution or attachment shall be issued whereby any substantial part of the property of Borrower shall be taken and the same shall not have been vacated or stayed within thirty (30) days after the issuance thereof.

2


(h)           Cross Default. Borrower breaches or any event of default occurs under any term or provision of any Other Agreement (as defined hereafter). For purposes hereof, "Other Agreement" means collectively, all existing and future agreements and instruments between, among or by Borrower, on the one hand, and Lender, on the other hand.

7.            ACCELERATION; REMEDIES.

(a)           At any time following the occurrence of an Event of Default (other than an Event of Default referred to in Sections 6(d) and 6(e)), Lender may, by written notice to Borrower, declare all unpaid principal, plus all accrued interest and other amounts due hereunder to be immediately due and payable at the Mandatory Default Amount (as defined below) without presentment, demand, protest or any other notice of any kind, all of which are hereby expressly waived, anything contained herein to the contrary notwithstanding. Upon the occurrence or existence of any Event of Default described in Sections 6(d) and 6(e). immediately and without notice, all outstanding unpaid principal, plus all accrued interest and other amounts due hereunder shall automatically become immediately due and payable at the Mandatory Default Amount, without presentment, demand, protest or any other notice of any kind, all of which are hereby expressly waived, anything contained herein to the contrary notwithstanding. In addition to the foregoing remedies, upon the occurrence or existence of any Event of Default, Lender may exercise any other right, power or remedy permitted to it by law, either by suit in equity or by action at law, or both. For purposes hereof, the term "Mandatory Default Amount" means an amount equal to 115% of the outstanding balance of this Note (which outstanding balance, for avoidance of doubt, shall include principal, interest, fees and any previously incurred prepayment penalty or redemption premium) as of the date the applicable Event of Default occurred, plus all interest, fees, and charges that may accrue on such outstanding balance thereafter.

(b)          Upon the occurrence of a Change in Control (as defined below), and without further notice to Borrower, all unpaid principal, plus all accrued interest, original issue discount, and other amounts due hereunder, shall become immediately due and payable. For purposes hereof, a "Change in Control" means a sale of all or substantially all of Borrower's assets, or a merger, consolidation, or other capital reorganization of Borrower with or into another company, and does not include a significant equity financing; provided however that a merger, consolidation, or other capital reorganization in which the holders of the equity of Borrower outstanding immediately prior to such transaction continue to hold (either by the voting securities remaining outstanding or by being converted into voting securities of the surviving entity) more than fifty percent (50%) of the total voting power represented by the voting securities of Borrower, or such surviving entity, outstanding immediately after such transaction shall not constitute a Change in Control.

8.            UNCONDITIONAL OBLIGATION; NO OFFSET. Borrower acknowledges that this Note is an unconditional, valid, binding and enforceable obligation of Borrower not subject to offset, deduction or counterclaim of any kind. Borrower hereby waives any rights of offset it now has or may have hereafter against Lender, its successors and assigns, and agrees to make all payments due hereunder in accordance with the terms ofthis Note.

9.            NO USURY. Notwithstanding any other provision contained in this Note or in any instrument given to evidence the obligations evidenced hereby: (a) the rates of interest and charges provided for herein and therein shall in no event exceed the rates and charges which

3


result in interest being charged at a rate equaling the maximum allowed by law; and (b) if, for any reason whatsoever, Lender ever receives as interest in connection with the transaction of which this Note is a part an amount which would result in interest being charged at a rate exceeding the maximum allowed by law, such amount or portion thereof as would otherwise be excessive interest shall automatically be applied toward reduction of the unpaid principal balance then outstanding hereunder and not toward payment of interest.

10.          ATTORNEYS' FEES. If this Note is placed in the hands of an attorney for collection or enforcement prior to commencing arbitration or legal proceedings, or is collected or enforced through any arbitration or legal proceeding, or Lender otherwise takes action to collect overdue amounts due under this Note or to enforce the provisions of this Note, then Borrower shall pay the reasonable costs incurred by Lender for such collection, enforcement or action including, without limitation, reasonable attorneys' fees and disbursements.

11.          GOVERNING LAW; VENUE. This Note shall be construed and enforced in accordance with, and all questions concerning the construction, validity, interpretation and performance of this Note shall be governed by, the internal laws of the State of Utah, without giving effect to any choice of law or conflict of law provision or rule (whether of the State of Utah or any other jurisdictions) that would cause the application of the laws of any jurisdictions other than the State of Utah. The provisions set forth in the Purchase Agreement to determine the proper venue for any disputes are incorporated herein by this reference.

12.          ARBITRATION OF DISPUTES. Borrower agrees that any dispute arising under this Note shall be subject to the Arbitration Provisions (as defined in the Purchase Agreement) set forth as an exhibit to the Purchase Agreement.

13.          WAIVERS. Borrower hereby waives presentment, notice of nonpayment, notice of dishonor, protest, demand and diligence.

14.          LOSS OR MUTILATION. On receipt by Borrower of evidence reasonably satisfactory to Borrower of the loss, theft, destruction or mutilation of this Note and, in the case of any such loss, theft or destruction of this Note, on delivery of an indemnity agreement reasonably satisfactory in form and amount to Borrower or, in the case of any such mutilation, on surrender and cancellation of such Note, Borrower at its expense will execute and deliver, in lieu thereof, a new Note oflike amount and tenor.

15.          NOTICES. Any notice required or permitted hereunder shall be given in the manner provided in the subsection titled "Notices" in the Purchase Agreement, the terms of which are incorporated herein by this reference.

16.          AMENDMENT AND WAIVER. This Note and its terms and conditions may be

amended, waived or modified only in writing by Borrower and Lender.

17.          SEVERABILITY. If any part of this Note is construed to be in violation of any law, such part shall be modified to achieve the objective of the parties to the fullest extent permitted and the balance of this Note shall remain in full force and effect.

4


18.          ASSIGNMENTS. Borrower may not assign this Note without the prior written consent of Lender. This Note may be offered, sold, assigned or transferred by Lender without the consent of Borrower.

19.          FINAL NOTE. This Note, together with the other Transaction Documents, contains the complete understanding and agreement of Borrower and Lender and supersedes all prior representations, warranties, agreements, arrangements, understandings, and negotiations. THIS NOTE, TOGETHER WITH THE OTHER TRANSACTION DOCUMENTS, REPRESENTS THE FINAL AGREEMENT BETWEEN THE PARTIES AND MAY NOT BE CONTRADICTED BY EVIDENCE OF ANY ALLEGED PRIOR, CONTEMPORANEOUS, OR SUBSEQUENT ORAL AGREEMENTS OF THE PARTIES. THERE ARE NO UNWRITTEN ORAL AGREEMENTS BETWEEN THE PARTIES.

20.          WAIVER OF JURY TRIAL. BORROWER IRREVOCABLY WAIVES ANY AND ALL RIGHTS IT MAY HAVE TO DEMAND THAT ANY ACTION, PROCEEDING OR COUNTERCLAIM ARISING OUT OF OR IN ANY WAY RELATED TO THIS NOTE OR THE RELATIONSHIPS OF THE PARTIES HERETO BE TRIED BY JURY. THIS WAIVER EXTENDS TO ANY AND ALL RIGHTS TO DEMAND A TRIAL BY JURY ARISING UNDER COMMON LAW OR ANY APPLICABLE STATUTE, LAW, RULE OR REGULATION. FURTHER, BORROWER ACKNOWLEDGES THAT IT KNOWINGLY AND VOLUNTARILY IS WAIVING SUCH PARTY'S RIGHT TO DEMAND TRIAL BY JURY.

21.          TIME IS OF THE ESSENCE. Time is of the essence of this Note and each and every provision hereof in which time is an element.

22.          LIQUIDATED DAMAGES. Lender and Borrower agree that in the event Borrower fails to comply with any of the tenns or provisions of this Note, Lender's damages would be uncertain and difficult (if not impossible) to accurately estimate because of the parties' inability to predict future interest rates and other relevant factors. Accordingly, Lender and Borrower agree that any fees, balance adjustments, default interest or other charges assessed under this Note are not penalties but instead are intended by the parties to be, and shall be deemed, liquidated damages.

[Remainder of page intentionally left blank]

5


IN WI1NESS WHEREOF, Borrower has caused this Note to be issued as of the date first set forth above.

BORROWER:

NORTHWEST BIOTHERAPEUTICS, INC.

/s/ Leslie J. Goldman

Title: Senior Vic President, General Counsel

[Signature Page to Promissory Note]


EXHIBITC

ARBITRATION PROVISIONS

1.     Dispute Resolution. For purposes of this Exhibit C. the term "Claims" means any disputes, claims, demands, causes of action, requests for injunctive relief, requests for specific  performance,  liabilities, damages, losses, or controversies whatsoever arising from, related to, or connected with the transactions contemplated in the Transaction Documents and any communications between the parties related thereto, including without limitation any claims of mutual mistake, mistake, fraud, misrepresentation, failure of formation, failure of consideration, promissory estoppel, unconscionability, failure of condition precedent, rescission, and any statutory claims, tort claims, contract claims, or claims to void, invalidate or terminate the Agreement (or these Arbitration Provisions (defined below)) or any of the other Transaction Documents. The term "Claims" specifically excludes a dispute over Calculations. The parties to the Agreement (the "parties") hereby agree that the arbitration provisions set forth in this Exhibit C ("Arbitration Provisions")  are binding on each of them. As a result, any attempt to rescind  the Agreement  (or these Arbitration  Provisions)  or declare the Agreement (or these Arbitration Provisions) or any other Transaction Document invalid or unenforceable for any reason is subject to these Arbitration  Provisions. These Arbitration  Provisions  shall also survive any termination or expiration of the Agreement. Any capitalized term not defined in these Arbitration Provisions shall have the meaning set forth in the Agreement.

2.    Arbitration. Except as otherwise provided herein, all Claims must be submitted to arbitration ("Arbitration") to be conducted exclusively in Salt Lake County or Utah County, Utah and pursuant to the terms set forth in these Arbitration Provisions. Subject to the arbitration appeal right  provided  for  in Paragraph 5 below (the "Appeal  Right"), the  parties agree that the award of the  arbitrator rendered pursuant to Paragraph 4 below (the "Arbitration Award") shall be (a) final and binding upon the  parties, (b) the sole and exclusive remedy between them regarding any Claims, counterclaims, issues, or accountings presented or pleaded to the arbitrator, and (c) promptly payable in United States dollars free of any tax, deduction or offset (with respect to monetary awards). Subject to the Appeal Right, any costs or fees, including without limitation attorneys' fees, incurred in connection with or incident to enforcing the Arbitration Award shall, to the maximum extent permitted by law, be charged against the party resisting such enforcement. The Arbitration Award shall include default interest (as defined or otherwise provided for in the  Note, "Default Interest") (with respect to monetary awards) at the rate specified in the Note for Default Interest both before and after the Arbitration Award. Judgment upon the Arbitration Award will be entered and enforced by any state or federal court sitting in Salt Lake County, Utah.

3.    The Arbitration Act. The parties hereby incorporate herein the provisions and procedures set forth in the Utah Uniform Arbitration Act, U.C.A. § 788-11-101 et seq. (as amended or superseded from time to time, the "Arbitration Act"). Notwithstanding the foregoing, pursuant to, and to the maximum extent permitted by, Section 105 of the Arbitration Act, in the event of conflict or variation between the terms of these Arbitration Provisions and the provisions of the  Arbitration Act, the  terms of these Arbitration  Provisions shall control and the parties hereby waive or otherwise agree to vary the effect of all requirements of the  Arbitration  Act that may conflict with or vary from these Arbitration Provisions.

4.     Arbitration Proceedings. Arbitration between the parties will be subject to the following:

4.1       Initiation of Arbitration. Pursuant to Section 110 of the  Arbitration Act, the  parties agree that a party may initiate Arbitration by giving written notice to the other party ("Arbitration Notice") in the same manner that notice is permitted under Section 7.12 of the Agreement; provided, however, that the Arbitration Notice may not be given by email or fax. Arbitration will be deemed initiated as of  the  date that the Arbitration Notice is deemed delivered to such other party under Section 7.12 of the Agreement (the "Service Date"). After the Service Date, information may be delivered, and notices may be given, by email or fax pursuant to Section 7.12 of the Agreement or any other method permitted thereunder. The Arbitration Notice must describe the nature of the controversy, the remedies sought, and the election to commence Arbitration proceedings. All Claims in the Arbitration Notice must be pleaded consistent with the Utah Rules of Civil Procedure.

Arbitration Provisions, Page 1


4.2          Selection and Payment of Arbitrator.

(a)   Within ten (10) calendar days after the Service Date, Investor shall select and submit to Company the names of three (3) arbitrators that are designated as "neutrals" or qualified arbitrators by Utah ADR Services (http :// www.utahadrse rvices.com)  (such three (3) designated  persons hereunder are referred to herein as the "Proposed Arbitrators"). For the avoidance of doubt, each Proposed Arbitrator must be qualified as a "neutral" with Utah ADR Services. Within five (5) calendar days after Investor has submitted to Company the names of the Proposed Arbitrators, Company must select, by written notice to Investor, one (1) of the Proposed Arbitrators to act as the arbitrator for the parties under these Arbitration Provisions. If Company fails to select one of the Proposed  Arbitrators in writing within such 5-day period, then  Investor may select the arbitrator from the Proposed Arbitrators by providing written notice of such selection to Company.

(b)  If Investor fails to submit to Company the Proposed Arbitrators within ten (10) calendar days after the Service Date pursuant to subparagraph  (a) above, then  Company  may at  any time prior to Investor so designating the Proposed Arbitrators, identify the names of three (3) arbitrators that are designated as "neutrals" or qualified arbitrators by Utah ADR Service by written notice to Investor. Investor may then, within five (5) calendar days after Company has submitted notice of its Proposed Arbitrators to Investor, select, by written notice to Company, one (1) of the Proposed Arbitrators to act as the arbitrator for the parties under these Arbitration Provisions. If Investor fails to select in writing and within such 5-day period one (1) of the three (3) Proposed Arbitrators selected by Company, then Company may select the arbitrator from its three (3) previously selected Proposed Arbitrators by providing written notice of such selection to Investor.

(c)  If a Proposed Arbitrator chosen to serve as arbitrator declines or is otherwise unable to serve as arbitrator, then the party that selected such Proposed Arbitrator may select one (1) of the other three (3) Proposed Arbitrators within three (3) calendar days of the date the chosen Proposed Arbitrator declines or notifies the parties he or she is unable to serve as arbitrator. If all three (3) Proposed Arbitrators decline or are otherwise unable to serve as arbitrator, then the arbitrator selection process shall begin again in accordance with this Paragraph 4.2.

(d)  The date that the Proposed Arbitrator selected pursuant to this Paragraph 4.2 agrees in writing (including via email) delivered to both parties to serve as the arbitrator hereunder is referred to herein as the "Arbitration Commencement Date". If an arbitrator resigns or is unable to act during the Arbitration, a replacement arbitrator shall be chosen in accordance with this Paragraph 4.2 to continue the Arbitration.  If Utah ADR Services ceases to exist or to provide a list of neutrals and there is no successor thereto, then the arbitrator shall be selected under the then prevailing rules of the American Arbitration Association.

(e)  Subject to Paragraph 4.10 below, the cost of the arbitrator must be paid equally by both parties. Subject to Paragraph 4.10 below, if one party refuses or fails to pay its portion of the arbitrator fee, then the other party can advance such unpaid amount (subject to the accrual of Default Interest thereupon), with such amount being added to or subtracted from, as applicable, the Arbitration Award.

4.3      Applicability of Certain Utah Rules. The parties agree that the Arbitration shall be conducted generally in accordance with the Utah Rules of Civil Procedure and the Utah Rules of Evidence. More specifically, the Utah Rules of Civil Procedure shall apply, without limitation, to the filing of any pleadings, motions or memoranda, the conducting of discovery, and the taking of any depositions. The Utah Rules of Evidence shall apply to any hearings, whether telephonic or in person, held by the arbitrator. Notwithstanding the foregoing, it is the parties' intent that the incorporation of such rules will in no event supersede these Arbitration Provisions. In the event of any conflict between the Utah Rules of Civil Procedure ortheUtah Rules of Evidence and these Arbitration Provisions, these Arbitration Provisions shall control.

4.4      Answer and Default. An answer and any counterclaims to the Arbitration Notice shall be required to be delivered to the party initiating the Arbitration within twenty (20) calendar days after the Arbitration Commencement Date. If an answer is not delivered by the required deadline, the  arbitrator must provide written  notice to  the defaulting  party stating that the arbitrator  will enter a default award  against such  party if such party does not file an answer within five (5) calendar days of receipt of such notice. If an answer is not filed within the five (5) day extension period, the arbitrator must render a default award, consistent with the relief requested in the  Arbitration  Notice, against a party that fails to submit an answer within such time period.

Arbitration Provisions, Page 2


4.5      Related Litigation. The party that delivers the Arbitration Notice to the other party shall have the option to also commence concurrent legal proceedings with any state or federal court sitting in Salt Lake County, Utah ("Litigation Proceedings"), subject to the following: (a) the complaint in the Litigation Proceedings is to be substantially similar to the claims set forth in the Arbitration Notice, provided that an additional cause of action to compel arbitration  will also be included therein, (b) so long as the  other party files an answer to the complaint in the Litigation Proceedings and an answer to the Arbitration Notice, the Litigation Proceedings will be stayed pending an Arbitration Award (or Appeal Panel Award (defined below), as applicable)  hereunder, (c) if the  other party fails to file an answer in the Litigation  Proceedings or an answer in the Arbitration proceedings, then the party initiating Arbitration shall be entitled to a default judgment consistent with the relief requested, to be entered in the Litigation Proceedings, and (d) any legal or procedural issue arising under the Arbitration Act that requires a decision of a court of competent jurisdiction may be determined in the Litigation Proceedings. Any award of the arbitrator (or of the Appeal Panel (defined below)) may be entered in such Litigation Proceedings pursuant to the Arbitration Act.

4.6      Discovery. Pursuant to Section 118(8) of the Arbitration  Act, the  parties agree that discovery shall be conducted as follows:

(a)  Written discovery will only be allowed if the likely benefits of the proposed written discovery outweigh the burden or expense thereof, and the written discovery sought is likely to reveal information that will satisfy a specific element of a claim or defense already pleaded in the Arbitration. The party seeking written  discovery shall always have the  burden of showing that all of the  standards and limitations  set  forth in these Arbitration Provisions are  satisfied. The scope of discovery in the Arbitration  proceedings shall also be limited as follows:

(i)       To facts directly connected with the transactions contemplated by the Agreement.

(ii)      To facts and information that cannot be obtained from another source or in another manner that is more convenient, less burdensome or less expensive than in the manner requested.

(b)   No party shall be allowed (i) more than fifteen (15) interrogatories (including discrete subparts), (ii) more than fifteen (15) requests for admission (including discrete subparts), (iii) more than ten

(10) document requests (including discrete subparts),  or  (iv)  more than three (3) depositions  (excluding expert depositions)  for a maximum of seven (7) hours per deposition. The costs associated with depositions will be borne by the party taking the  deposition. The party defending  the  deposition  will submit a notice to the party taking the deposition of the estimated attorneys' fees that such party expects to incur in connection with defending the deposition. If the  party defending the deposition fails to submit an estimate of attorneys' fees within five (5) calendar days of its receipt of a deposition notice, then such party shall be deemed to have waived its right to the estimated attorneys' fees. The party taking the  deposition  must  pay  the  party defending the deposition the estimated attorneys' fees prior to taking the deposition, unless such obligation is deemed to be waived as set forth in the immediately preceding sentence. If the party taking the deposition believes that the estimated attorneys' fees are unreasonable, such  party  may  submit  the  issue  to  the arbitrator for a decision. All depositions will be taken in Utah.

(c)  All discovery requests (including document production requests included in deposition notices) must be submitted in writing to the arbitrator and the  other  party.  The  party  submitting  the  written discovery requests must include with such discovery requests a detailed explanation of how the proposed discovery requests satisfy the requirements of these Arbitration Provisions and the Utah Rules of Civil Procedure. The receiving party will then be allowed, within five (5) calendar days of receiving the proposed

discovery requests, to submit to the arbitrator an estimate of the attorneys' fees and costs associated with responctlng to such written discovery requests and a written challenge to each applicable discovery request. After  receipt  of an  estimate  of attorneys'  fees and  costs and/or  challenge(s)  to  one or  more discovery requests, consistent with subparagraph (c) above, the arbitrator will within three (3) calendar days make a finding as to the likely attorneys' fees and costs associated with responding to the discovery requests and issue an order that (i) requires the requesting party to prepay the attorneys' fees and costs associated with responding to the discovery requests, and (ii) requires the responding party to respond to the discovery requests as limited by the arbitrator within twenty-five (25) calendar days of the arbitrator's finding with respect to such discovery requests. If a party entitled to submit an estimate of attorneys' fees and costs and/or a challenge to discovery requests fails to do so within such 5-day period, the arbitrator will make a finding that (A) there are no attorneys' fees or costs associated with responding to such discovery requests,

Arbitration Provisions, Page 3


and (B) the responding party must respond to such discovery requests (as may be limited by the arbitrator) within twenty-five (25) calendar days of the arbitrator's finding with respect to such discovery requests. Any party submitting any written discovery requests, including without limitation interrogatories, requests for production subpoenas to a party or a third party, or requests for admissions, must prepay the estimated attorneys' fees and costs, before the responding party has any obligation to produce or respond to the same, unless such obligation is deemed waived as set forth above.

(d)   In order to allow a written discovery request, the  arbitrator  must find  that  the discovery request satisfies the standards set forth in these Arbitration Provisions and the Utah Rules of Civil Procedure. The arbitrator must strictly enforce these standards. If a discovery request does  not satisfy  any of  the standards set forth in these Arbitration Provisions or the Utah Rules of Civil Procedure, the arbitrator may modify such discovery request to satisfy the applicable  standards, or strike such  discovery  request  in whole or in part.

(e)  Each party may submit expert reports  (and  rebuttals thereto), provided  that such reports  must be submitted within sixty (60) days of the Arbitration Commencement Date. Each party will be allowed a maximum of two (2) experts. Expert reports must contain the following:  (i) a complete statement of all opinions the expert will offer at trial and the basis and reasons for them; (ii) the expert's name and qualifications, including a list of all the expert's publications within the preceding ten (10) years, and a list of any other cases in which the expert has testified at trial or in a deposition or prepared a report within the preceding ten  (10) years; and (iii) the compensation  to be paid for the expert's report and testimony. The parties are entitled  to depose any other  party's expert witness  one (1)  time for no more than  four (4) hours. An expert may not testify in a party's case-in-chief concerning any matter not fairly disclosed in the expert report.

4.6      Dispositive Motions.  Each party shall have the right to submit dispositive motions pursuant Rule 12 or Rule 56 of the Utah Rules of Civil Procedure (a "Dispositive Mot ion"). The party submitting the Dispositive Motion may, but  is not required  to, deliver to the arbitrator and to the other party a memorandum in support (the "Memorandum in Support") of the Dispositive Motion. Within seven (7) calendar days of delivery of the  Memorandum in Support, the other party shall deliver to the arbitrator and to the other party a memorandum in opposition to the Memorandum in Support (the "Memorandum in Opposition"). Within seven (7) calendar days of delivery of the Memorandum in Opposition, as applicable, the party that submitted the Memorandum in Support shall deliver to the arbitrator and to the other party a reply memorandum to the Memorandum in Opposition ("Reply Me morandum"). If the applicable party shall fail to deliver the Memorandum in Opposition as required above, or if the other party fails to deliver the Reply Memorandum as required above, then the applicable party shall lose its right to so deliver the same, and the Dispositive Motion shall proceed regardless.

4.7       Confidentiality. All information disclosed by either party (or such party's agents) during the Arbitration process (including without limitation information disclosed during the discovery process or any Appeal (defined below)) shall be considered confidential in nature. Each party agrees not to disclose any confidential information received from the other party (or its agents) during the Arbitration process (including without limitation during the discovery  process or any Appeal)  unless (a) prior to or after the time of disclosure such information becomes public knowledge or part of the public domain, not as a result of any inaction or action of the receiving party or its agents, (b) such information is required by a court order, subpoena or similar legal duress to be disclosed if such receiving party has notified the other party thereof in writing and given it a reasonable opportunity to obtain a protective order from a court of competent jurisdiction prior to disclosure, or (c) such information is disclosed to the receiving party's agents, representatives and legal counsel on a need to know basis who each agree in writing not to disclose such information to any third party. Pursuant to Section 118(5) of the Arbitration Act, the arbitrator is hereby authorized and directed to issue a protective order to prevent the disclosure of privileged information and confidential information upon the written request of either party.

4.8      Authorization; Timing; Scheduling Order. Subject to all other portions of  these  Arbitration Provisions, the parties hereby authorize and  direct the arbitrator  to take such actions and  make such  rulings as may be necessary to carry out the parties' intent for the Arbitration proceedings to be efficient and expeditious. Pursuant to Section 120  of the  Arbitration Act, the  parties hereby agree that an Arbitration Award must be made within one hundred twenty (120) calendar days after the Arbitration Commencement Date. The arbitrator is hereby authorized and  directed to  hold a scheduling conference within ten (10)

Arbitration Provisions, Page 4


calendar days after the Arbitration Commencement Date in order to establish a scheduling order with various binding deadlines for discovery, expert testimony, and the submission of documents by the  parties to enable the arbitrator to render a decision prior to the end of such 120-day period.

4.9       Relief The arbitrator shall have the right to award or include in the Arbitration Award (or in a preliminary ruling) any relief which the arbitrator deems proper under the circumstances, including, without limitation, specific performance and injunctive relief, provided that the arbitrator may not award exemplary or punitive damages.

4.10     Fees and Costs. As part of the Arbitration Award, the arbitrator is hereby directed to require the losing party (the party being awarded the least amount of money by the arbitrator, which, for the avoidance of doubt, shall be determined without regard to any statutory fines, penalties, fees, or other charges awarded to any party) to (a) pay the full amount of any unpaid costs and fees of the Arbitration, and (b) reimburse the prevailing party for all reasonable attorneys' fees, arbitrator costs and fees, deposition costs, other discovery costs, and other expenses, costs or fees paid or otherwise incurred by the prevailing party in connection with the Arbitration.

5.    Arbitration Appeal.

5.1       Initiation of Appeal. Following the entry of the Arbitration Award, either party (the "Appellant") shall have a period of thirty (30) calendar days in which to notify the other party (the "Appellee"), in writing, that the Appellant elects to appeal (the "Appeal")  the  Arbitration Award (such notice, an "Appeal Notice") to a panel of arbitrators as provided in Paragraph  5.2  below.  The date the Appellant delivers an Appeal  Notice to the Appellee is referred to herein as the "Appeal  Date". The Appeal Notice must be delivered to the Appellee in accordance with the provisions of Paragraph 4.1 above with respect to delivery of an Arbitration Notice.  In addition, together with delivery of the Appeal Notice to the Appellee, the Appellant must also pay for (and provide proof of such payment to the Appellee together with delivery of the Appeal Notice) a bond in the amount of 110% of the sum the Appellant owes to the Appellee as a result of the Arbitration Award the Appellant is appealing.  In the event an Appellant delivers an Appeal Notice to the Appellee (together with proof of payment of the applicable bond) in compliance with the provisions of this Paragraph 5.1, the Appeal will occur as a matter of right and, except as specifically set  forth herein, will not be further conditioned.   In the  event a party does not deliver an Appeal Notice (along with proof of payment of the  applicable bond) to the other party within the  deadline prescribed  in this Paragraph  5.1, such  party shall lose its right to appeal the Arbitration Award. If no party delivers an Appeal Notice (along with proof of payment of the applicable bond) to the other party within the deadline described in this Paragraph 5.1, the Arbitration Award shall be final. The parties acknowledge and agree that any Appeal shall be deemed part of the parties' agreement to arbitrate for purposes of these Arbitration Provisions and the Arbitration Act.

5.2      Selection and Payment of Appeal Panel. In the event an Appellant delivers an Appeal Notice to the Appellee (together with proof of payment of the applicable bond) in compliance with the provisions of Paragraph 5.1 above, the Appeal will be heard by a three (3) person arbitration panel (the "Appeal Panel").

(a)       Within ten (10) calendar days after the Appeal Date, the Appellee shall select and submit to the Appellant the  names of five (5) arbitrators  that are designated  as "neutrals" or qualified arbitrators  by Utah ADR Services (http: // www.utahadrse rvices.com) (such five (5) designated persons hereunder are referred to herein as the "Proposed Appeal Arbitrators"). For the avoidance of doubt, each Proposed Appeal Arbitrator must be qualified as a "neutral" with Utah ADR Services, and shall not be the arbitrator who rendered the Arbitration Award being appealed (the "Original Arbitrator"). Within five (5) calendar days after the Appellee has submitted to the Appellant the names of the Proposed Appeal Arbitrators, the Appellant must select by v.n-itt<>n notice to the Appellee, three (3) of the Propo:sed Appeal Arbitrator:, to act a:, themembers of the Appeal Panel. If the Appellant fails to select three (3) of the  Proposed  Appeal Arbitrators in writing within such 5-day period, then the Appellee may select such three (3) arbitrators from the Proposed Appeal Arbitrators by providing written notice of such selection to the Appellant.

(b)       If the Appellee fails to submit to the Appellant the names of the Proposed Appeal Arbitrators within ten (10) calendar days after the Appeal Date pursuant to subparagraph (a) above, then the Appellant may at any time prior to the Appellee so designating the Proposed Appeal Arbitrators, identify the names of five (5) arbitrators that are designated as "neutralsl) or qualified arbitrators by Utah ADR Service (none of whom may be the Original Arbitrator) by written notice to the Appellee. The Appellee may then, within five

(5) calendar days after the Appellant has submitted notice of its selected arbitrators to the Appellee, select, by

Arbitration Provisions, Page 5


written notice to the Appellant, three (3) of such selected arbitrators to serve on the Appeal Panel. If the Appellee fails to select in writing within such 5-day period three (3) of the arbitrators selected by the Appellant to serve as the members of the Appeal Panel, then the Appellant may select the three (3) members of the Appeal Panel from the Appellant's list of five (5) arbitrators by providing written notice of such selection to the Appellee.

(c)      If a selected Proposed Appeal Arbitrator declines or is otherwise unable to serve, then the party that selected such Proposed Appeal Arbitrator may select one (1) of the other five (5) designated Proposed Appeal Arbitrators within three (3) calendar days of the date a chosen Proposed Appeal Arbitrator declines or notifies the parties he or she is unable to serve as an arbitrator. If at least three (3) of the five (5) designated Proposed Appeal Arbitrators decline or are otherwise unable to serve, then the Proposed Appeal Arbitrator selection process shall begin again in accordance  with this Paragraph 5.2;  provided, however, that any Proposed Appeal Arbitrators who have already agreed to serve shall remain on the Appeal Panel.

(d)      The date that all three (3) Proposed Appeal Arbitrators selected pursuant to this Paragraph 5.2 agree in writing (including via email) delivered to both the Appellant and the Appellee to  serve as members of the Appeal Panel hereunder is referred to herein as the "Appeal Commencement Date".  No later than five (5) calendar days after the Appeal Commencement Date, the Appellee shall designate in writing (including via email) to the Appellant and the Appeal Panel the  name of one (1) of the  three (3) members of the Appeal Panel to serve as the lead arbitrator in the Appeal proceedings. Each member of the Appeal Panel shall be deemed an arbitrator for purposes of these Arbitration Provisions and the Arbitration Act, provided that, in conducting the Appeal, the Appeal Panel may only act or make determinations upon the approval or vote of no less than the majority vote of its members,  as announced  or communicated  by the  lead arbitrator on the Appeal Panel. If an arbitrator on the Appeal Panel ceases or is unable to act during the Appeal proceedings, a replacement arbitrator shall be chosen in accordance with Paragraph 5.2 above to continue the Appeal as a member of the Appeal Panel. If Utah ADR Services ceases to exist or to provide a list of neutrals, then the arbitrators for the Appeal Panel shall be selected under the then prevailing rules of the American Arbitration Association.

(d) Subject to Paragraph 5.7 below, the cost of the Appeal Panel must be paid entirely by the

Appellant.

5.3      Appeal Procedure. The Appeal will be deemed an appeal of the entire Arbitration Award. In conducting the Appeal, the Appeal Panel shall conduct a de novo review of all Claims described or otherwise set forth in the Arbitration Notice. Subject to the foregoing and all other provisions of this Paragraph 5, the Appeal Panel shall conduct the Appeal in a manner the Appeal Panel considers appropriate for a fair and expeditious disposition of the Appeal, may hold one or more hearings and permit oral argument, and may review all previous evidence and discovery, together with all briefs, pleadings and other documents filed with the Original Arbitrator (as well as any documents filed with the Appeal Panel pursuant to Paragraph 5.4(a) below). Notwithstanding the foregoing, in connection with the Appeal, the Appeal Panel shall not permit the parties to conduct any additional discovery or raise any new Claims to be arbitrated, shall not permit new witnesses or affidavits, and shall not base any of its findings or determinations on the Original Arbitrator's findings or the Arbitration Award.

5.4      Timing.

(a)      Within seven (7) calendar days of the Appeal Commencement Date, the Appellant (i) shall deliver or cause to be delivered to the Appeal Panel copies of the Appeal Notice, all discovery conducted in connection with the Arbitration, and all briefs, pleadings and other documents filed with  the  Original Arbitrator (which material Appellee shall have the right to review and supplement if necessary), and (ii) may, but is not required to, deliver to the Appeal Panel and to the Appellee a Memorandum in Support of the Appellant's arguments concerning or position with respect to all Claims, counterclaims, issues, or accountings presented or pleaded in the Arbitration. Within seven (7) calendar days of the Appellant's delivery of the Memorandum in Support, as applicable, the Appellee shall deliver to the Appeal Panel and to the Appellant a Memorandum in Opposition to the Memorandum in Support. Within seven (7) calendar days of the Appellee's delivery of the Memorandum in Opposition, as applicable, the Appellant shall deliver to the Appeal Panel and to the Appellee a Reply Memorandum to the Memorandum in Opposition. If the Appellant shall fail to substantially comply with the requirements of clause (i) of this subparagraph (a), the Appellant shall lose its right to appeal the Arbitration Award, and the Arbitration Award shall be final. If the Appellee shall fail to deliver the Memorandum in Opposition as required above, or if the Appellant shall fail to deliver the Reply

Arbitration Provisions, Page 6


Memorandum as required above, then the Appellee or the Appellant, as the case may be, shall lose its right to so deliver the same, and the Appeal shall proceed regardless.

(b)       Subject to subparagraph  (a) above, the  parties  hereby agree that the Appeal  must be heard by the Appeal Panel within thirty (30) calendar days of the Appeal Commencement Date, and that the Appeal Panel must render its decision within thirty (30) calendar days after  the Appeal  is heard  (and  in  no event later than sixty (60) calendar days after the Appeal Commencement Date).

5.5      Appeal Panel Award. The Appeal Panel shall issue its decision (the "Appeal Panel Award") through the lead arbitrator on the Appeal Panel. Notwithstanding any other provision contained herein, the Appeal Panel Award shall (a) supersede in its entirety and make of no further force or effect the Arbitration Award (provided that any protective orders issued by the Original Arbitrator shall remain in full force and effect), (b) be final and binding upon the parties, with no further rights of appeal, (c) be the sole and exclusive remedy between the parties regarding any Claims, counterclaims, issues, or accountings  presented or pleaded in the Arbitration, and (d) be promptly payable in United States dollars free of any tax, deduction  or offset (with respect to monetary awards). Any costs or fees, including without limitation attorneys' fees, incurred in connection with or incident to enforcing the Appeal Panel Award shall, to the maximum extent permitted by law, be charged against the party resisting such enforcement. The Appeal Panel Award shall include Default Interest (with  respect to monetary awards)  at the rate specified  in the  Note for Default Interest both before and after the Arbitration Award. Judgment upon the Appeal Panel Award will be entered and enforced by a state or federal court sitting in Salt Lake County, Utah.

5.6       Relief The Appeal Panel shall have the right to award or include in the Appeal Panel Award any relief which the Appeal Panel deems proper under the circumstances, including, without limitation, specific performance and injunctive relief, provided that the Appeal Panel may not award exemplary or punitive damages.

5.7       Fees and Costs. As part of the Appeal Panel Award, the Appeal Panel is hereby directed to require the losing party (the party being awarded the least amount of money by the  arbitrator,  which, for  the avoidance of doubt, shall be determined without regard to any statutory  fines,  penalties,  fees,  or  other charges awarded to any party) to (a) pay the full amount of any unpaid costs and fees of the  Arbitration  and the Appeal Panel, and (b) reimburse the prevailing party (the party being awarded the most amount of money by the Appeal Panel, which, for the avoidance of doubt, shall be determined without regard to any statutory fines, penalties, fees, or  other charges awarded  to any part) the reasonable attorneys' fees, arbitrator and Appeal Panel costs and fees, deposition costs, other discovery costs, and other expenses, costs or fees paid or otherwise incurred by the prevailing party in connection with the Arbitration (including without limitation in connection with the Appeal).

6.     Miscellaneous.

6.1      Severability. If any part of these Arbitration Provisions is found to violate or be illegal under applicable law, then such provision shall be modified to the minimum  extent  necessary to  make such provision enforceable under applicable law, and the remainder of the Arbitration Provisions shall remain unaffected and in full force and effect.

6.2      Governing Law. These Arbitration Provisions shall be governed by the laws of the State of Utah without regard to the conflict of laws principles therein.

6.3       Interpretation. The headings of these Arbitration Provisions are for convenience of reference only and shall not form part of, or affect the interpretation of, these Arbitration Provisions.

6.4      Waiver. No waiver of any provision of these Arbitration Provisions shall be effective unless it is in the form of a writing signed by the party granting the waiver.

6.5   Time is of the Essence. Time is expressly made of the essence with respect to each and every provision of these Arbitration Provisions.

[Remainder of page intentionally left blank}

Arbitration Provisions, Page 7


EX-10.83 5 nwbo-20201231xex10d83.htm EXHIBIT 10.83

Exhibit 10.83

Execution Version

UNIT PURCHASE AGREEMENT

UNIT PURCHASE AGREEMENT, dated as of August 28, 2020 (this “Agreement”), among Northwest Biotherapeutics, Inc., a Delaware corporation (the “Buyer”), Flaskworks, LLC, a Massachusetts limited liability company (“Flaskworks”), and each of the other Persons (as hereinafter defined) set forth on the signature pages hereto (each, a “Seller” and collectively, the “Sellers”).

RECITALS

A.The Sellers own 100% of the issued and outstanding Units (the “Units”), of Flaskworks.

B.The Sellers wish to sell to the Buyer, and the Buyer wishes to purchase from the Sellers, the Units, upon the terms and subject to the conditions of this Agreement.

AGREEMENT

In consideration of the foregoing and the mutual covenants and agreements herein contained, and intending to be legally bound hereby, the parties agree as follows:

ARTICLE I

PURCHASE AND SALE

Section 1.1Purchase and Sale of the Units. Upon the terms and subject to the conditions of this Agreement, at the Closing, the Sellers shall sell, convey, assign, transfer and deliver the Units to the Buyer for an aggregate purchase price equal to the sum of each Seller’s Cash Closing Consideration, Stock Closing Consideration and Special Consideration, plus the Buyer-Paid Expenses, in each case, as set forth on the Closing Payment Schedule (the “Purchase Price”), to be paid as set forth in this Article.

Section 1.2Closing. The sale and purchase of the Units shall take place at a closing to be held in Boston, Massachusetts via the remote exchange of documents, effective as of 12:01 a.m., Eastern time on the date hereof, or at such other place or at such other time or on such other date as the Sellers and the Buyer mutually may agree in writing (the “Closing” and such date, the “Closing Date”).

Section 1.3Closing Actions; Closing Payments; Other Payments.

(a)

At the Closing, the Buyer shall:

(i)deliver or cause to be delivered to each applicable Seller payment in an amount equal to the Cash Closing Consideration amount(s) set forth next to such Seller’s name on the Closing Payment Schedule (or, to the extent set forth on the Closing Payment schedule, deliver or cause to be delivered to Flaskworks for distribution to the applicable Sellers through Flaskworks’ payroll system, less applicable employee income tax withholdings);


(ii)deliver or cause to be delivered to each applicable Seller rights to receive Shares with an aggregate value equal to the Stock Closing Consideration amount set forth next to such Seller’s name on the Closing Payment Schedule (such rights and the underlying Shares to be issued pursuant to, and subject to the applicable vesting and other terms set forth in, the applicable Rights Issuance Agreement);

(iii)deliver or cause to be delivered to the Sellers a counterpart to each Special Consideration Agreement, Rights Issuance Agreement, Special Expense Agreement and Installment Expense Agreement required by the Closing Payment Schedule, duly executed by the Buyer; and

(iv)on behalf of Flaskworks, deliver or cause to be delivered to each applicable recipient of Buyer-Paid Expenses payment in an amount equal to the Cash Closing Expenses amount set forth next to such Person’s name on the Closing Payment Schedule.

(b)

At the Closing, the Sellers shall deliver or cause to be delivered to Buyer:

(i)a duly executed counterpart to each Special Consideration Agreement, Rights Issuance Agreement, Special Expense Agreement, and/or Installment Expense Agreement from each of the Sellers and each recipient of Buyer-Paid Expenses, as required by the Closing Payment Schedule;

(ii)an executed certificate from each of the Sellers duly completed pursuant to Section 1446(f) of the Internal Revenue Code of 1986, as amended (the “Code”) and the Treasury Regulations promulgated thereunder certifying that each such Seller is not a “foreign person” within the meaning of Section 1446(f) of the Code;

(iii)duly executed copies of the consents, waivers, approvals and authorizations of Governmental Authorities and third parties set forth on Schedule 1.3(b)(iii);

(iv)a duly executed termination agreement between Flaskworks and Corning Incorporated (“Corning”) with respect to that certain Supply Agreement between Corning and Flaskworks, as amended and supplemented to date, in form and substance reasonably satisfactory to the Buyer;

(v)duly executed letters of resignation, effective on the Closing Date, of all officers and managers/directors of Flaskworks, provided that Mr. Shashi Murthy shall resign in all capacities other than his capacity as an employee of Flaskworks;

(vi)duly executed invention assignment agreements in form and substance reasonably satisfactory to the Buyer from each of Mr. Shashi Murthy and Mr. Andrew Kozbial;

(vii)a duly executed License Agreement Amendment;

(viii)duly executed Payoff Letters with respect to each of the Employee Loans;

2


(ix)instruments of transfer executed by each Seller for the Units held by such Seller, duly endorsed in blank in proper from for transfer with appropriate transfer stamps, if any, affixed; and

(x)duly executed copies of such other documents relating to Flaskworks and the transactions contemplated hereby as the Buyer may reasonably request.

(c)Other Payments. Following the Closing, the Buyer shall pay any Special Consideration, Special Expenses and Installment Expenses to the Persons, in the amounts, and in accordance with the procedures, set forth in the Closing Payment Schedule.

(d)The Buyer’s obligation to pay the Purchase Price shall be deemed satisfied upon the Buyer’s payment of the amounts specified in Section 1.3, in each case, to the Persons, in the amounts, and in accordance with the procedures, set forth on the Closing Payment Schedule, and the Buyer shall not be responsible or liable to any Person with respect to the division of such amounts among the Sellers or the recipients of payments made on account of Buyer-Paid Expenses.

(e)All payments hereunder (including with respect to payments, if any, made pursuant to Article VI hereof) shall be made by wire transfer of immediately available funds in United States dollars to such account(s) as may be designated to the payor by the payee(s) at least five business days prior to the applicable payment date. The Buyer shall be entitled to rely in all respects on the Closing Payment Schedule in making all payments due under this Agreement (including with respect to payments, if any, made pursuant to Article VI hereof), and the Buyer shall not be responsible or have any liability to any Person for any inaccuracy thereof or omission therein. Each Seller hereby acknowledges that such Seller does not have any right or claim to any consideration with respect to its Units or in connection with the transactions contemplated hereby other than that set forth beside such Seller’s name in the Closing Payment Schedule (except to the extent that Seller ultimately is owed any amounts pursuant to Article VI).

Section 1.4Waiver; Termination of Agreements; New Operating Agreement. Except as contemplated by Section 5.5, each Seller, by his, her or its execution of this Agreement or acceptance of the portion of the Purchase Price allocated to such Seller on the Closing Payment Schedule, hereby waives (i) any required notice, if any, to which such Person is entitled (including under Flaskworks’ governing documents, the Equity Documents, the Delaware General Corporation Law, as amended, the Massachusetts Limited Liability Company Act, as amended (collectively, “State Law”) and any agreement, arrangement or understanding or other Law pursuant to which such Person may have rights or be bound) in connection with this Agreement and the Ancillary Agreements and the consummation of the transactions contemplated hereby and thereby; (ii) any period of time that is required to elapse (including under Flaskworks’ governing documents, the Equity Documents, State Law and any agreement, arrangement or understanding or other Law pursuant to which such Person may have rights or be bound) before the execution and delivery of this Agreement and the Ancillary Agreements or the consummation of the transactions contemplated hereby and thereby, if any; and (iii) any and all pre-emptive rights, rights of first refusal, co-sale or other rights of any kind it may have under the Equity Documents as a result of, or in connection with this Agreement and the Ancillary Agreements and the consummation of the transactions contemplated hereby and thereby (for the

3


avoidance of doubt, including any rights pursuant to Section 2.11(c) of the Flaskworks LLC Agreement). Effective as of immediately prior to the Closing, without any further action by any party hereto, each Equity Document is hereby terminated in its entirety and no party thereto shall have any further rights or obligations thereunder. Upon the Closing, without any further action on the part of any party, the Flaskworks LLC Agreement shall be replaced in its entirety with the form of limited liability company agreement attached hereto as Exhibit F, with Buyer as the sole member of Flaskworks (the “New Flaskworks LLC Agreement”).

ARTICLE II

REPRESENTATIONS AND WARRANTIES OF THE SELLERS

Each of the Sellers, severally and not jointly, hereby represents and warrants to the Buyer as follows:

Section 2.1Organization and Qualification. If such Seller is a legal entity, such Seller is duly organized, validly existing and in good standing under the laws of its jurisdiction of organization and has all necessary corporate power and authority to own the Units owned by it.

Section 2.2Authority. If such Seller is a legal entity, such Seller has full corporate, power and authority to execute and deliver this Agreement and each Ancillary Agreement to which it is a party, to perform its obligations hereunder and thereunder and to consummate the transactions contemplated hereby and thereby. If such Seller is a natural person, such Seller has legal capacity to execute and deliver this Agreement and each Ancillary Agreement to which it is a party, to perform its obligations hereunder and thereunder and to consummate the transactions contemplated hereby and thereby. If such Seller is a legal entity, the execution, delivery and performance by the Seller of this Agreement and each Ancillary Agreement to which it is a party, and the consummation of the transactions contemplated hereby and thereby, have been duly and validly authorized by all necessary corporate action on the part of such Seller, and this Agreement and each Ancillary Agreement to which it is a party have been duly executed and delivered by such Seller and, assuming due authorization, execution and delivery by the Buyer, are legal, valid, binding and enforceable upon and against such Seller (except as enforcement may be limited by applicable bankruptcy, insolvency, reorganization, moratorium or similar laws affecting creditors’ rights generally and by general principles of equity). If such Seller is a natural person, this Agreement and each Ancillary Agreement to which it is a party have been duly executed and delivered by such Seller and, assuming due authorization, execution and delivery by the Buyer, are legal, valid, binding and enforceable upon and against such Sellers (except as enforcement may be limited by applicable bankruptcy, insolvency, reorganization, moratorium or similar laws affecting creditors’ rights generally and by general principles of equity). If such Seller is married, and any of the Units of such Seller constitute community property or otherwise need spousal or other approval for this Agreement to be legal, valid and binding, this Agreement and each Ancillary Agreement to which it is a party has been duly and validly executed and delivered by such Seller’s spouse and, assuming due authorization, execution and delivery by the Buyer, constitute legal, valid and binding obligations of such Seller’s spouse, enforceable upon and against such Seller’s spouse, (except as enforcement may be limited by applicable bankruptcy, insolvency, reorganization, moratorium or similar laws affecting creditors’ rights generally and by general principles of equity).

4


Section 2.3No Conflict; Required Filings and Consents. The execution, delivery and performance by such Seller of this Agreement and each of the Ancillary Agreements and the consummation by such Seller of the transactions contemplated hereby and thereby do not and will not (a) violate any provision of the organizational documents of such Seller; (b) violate in any material respect any federal, state or local statute, law, regulation, order, injunction or decree (“Law”) applicable to such Seller; (c) conflict with, create a breach or default under, require any consent of or notice to or give to any third party any right of modification, acceleration or cancellation, or result in the creation of any lien, security interest, charge or encumbrance upon any property or right of such Seller or upon any Units, pursuant to, any Contract, agreement, license, permit or other instrument to which such Seller is a party or by which such Seller’s properties, assets (including the Units) or rights may be bound, affected or benefited, except for any such breaches, defaults or other occurrences that, individually or in the aggregate, are not and would not reasonably be expected to have a Material Adverse Effect; (d) allow the imposition of any material fees or penalties or require the offering or making of any payment to a third party on the part of such Seller; or (e) assuming the accuracy of the representations and warranties made by the Buyer in Article IV hereof, require any consent or approval of, registration or filing with, or notice to any federal, state or local governmental authority or any agency or instrumentality thereof (a “Governmental Authority”), except in the case of clause (e) for such consents, approvals, registrations, filings or notices the failure of which to be obtained or made, individually or in the aggregate, would not reasonably be expected to materially impair, or prevent or materially delay, the ability of such Seller to consummate transactions contemplated by this Agreement and the Ancillary Agreements.

Section 2.4Units. Such Seller is the record and beneficial owner of its respective Units, free and clear of any charge, limitation, condition, mortgage, lien, security interest, adverse claim, encumbrance or restriction of any kind (collectively, “Encumbrances”). Such Seller has the right, authority and power to sell, convey, assign, transfer and deliver the Units owned by such Seller to the Buyer. Upon delivery to the Buyer of executed instruments of transfer for the Units at the Closing and the Buyer’s payment of the Purchase Price, the Buyer shall acquire good, valid and marketable title to the Units, free and clear of any Encumbrance.

Section 2.5Litigation. There is no claim, action, suit, proceeding, inquiry, investigation or arbitration by or before any governmental, regulatory, administrative, judicial or arbitral body (an “Action”) pending or to the best knowledge of such Seller threatened (a) to restrain or prevent the consummation of the transactions contemplated hereby; or (b) that might affect the right of the Buyer to own and vote such Seller’s Units, nor is there any basis for any of the foregoing. There is no outstanding or to the best knowledge of such Seller threatened order, writ, judgment, injunction, decree, determination or award of, or investigation by, any Governmental Authority relating to such Seller with respect to Flaskworks, or any of Flaskworks’ properties or assets, any of its officers or managers or members or the transactions contemplated by this Agreement or the Ancillary Agreements.

Section 2.6Brokers. No broker, finder or agent will have any claim against the Buyer (or after the Closing, Flaskworks) for any fees or commissions in connection with the transactions contemplated by this Agreement and each of the Ancillary Agreements based on arrangements made by or on behalf of such Seller.

5


ARTICLE III

REPRESENTATIONS AND WARRANTIES OF FLASKWORKS

Flaskworks hereby represents and warrants to the Buyer as follows:

Section 3.1Organization and Qualification. Flaskworks is a limited liability company duly organized, validly existing and in good standing under the laws of Massachusetts, and has full limited liability company power and authority to own, lease and operate its properties and to carry on its business. Flaskworks is duly qualified or licensed as a foreign limited liability company to do business, and is in good standing, in each jurisdiction where the character of its properties or the nature of its business makes such qualification or licensing necessary, except as has not, or would not reasonably be expected to materially impair the ability of Flaskworks or the Sellers to timely consummate, or prevent, any of the transactions contemplated by this Agreement or the Ancillary Agreements or to have, individually or in the aggregate, a material adverse effect on the business, properties, financial condition or results of operations of Flaskworks (a “Material Adverse Effect”).

Section 3.2Authority. Flaskworks has full limited liability company power and authority to execute and deliver this Agreement and each Ancillary Agreement to which it is a party, to perform its obligations hereunder and thereunder and to consummate the transactions contemplated hereby and thereby. The execution, delivery and performance by Flaskworks of this Agreement and each Ancillary Agreement to which it is a party, and the consummation of the transactions contemplated hereby and thereby, have been duly and validly authorized by all necessary limited liability company action on the part of Flaskworks, and this Agreement and each Ancillary Agreement to which it is a party have been duly executed and delivered by Flaskworks and, assuming due authorization, execution and delivery by the Buyer, are legal, valid, binding and enforceable upon and against Flaskworks (except as enforcement may be limited by applicable bankruptcy, insolvency, reorganization, moratorium or similar laws affecting creditors’ rights generally and by general principles of equity).

Section 3.3No Conflict; Required Filings and Consents. The execution, delivery and performance by Flaskworks of this Agreement and each of the Ancillary Agreements and the consummation by Flaskworks of the transactions contemplated hereby and thereby do not and will not (a) violate any provision of the certificate of formation (as amended to date, the “Certificate”) or the amended and restated limited liability company agreement of Flaskworks (as amended to date, the “Flaskworks LLC Agreement”); (b) violate in any material respect any Law applicable to Flaskworks; (c) conflict with, create a breach or default under, require any consent of or notice to or give to any third party any right of modification, acceleration or cancellation, or result in the creation of any lien, security interest, charge or encumbrance upon any property or right of the Sellers or Flaskworks pursuant to, any Contract, agreement, license, permit or other instrument to which the Sellers or Flaskworks is a party or by which the Sellers, Flaskworks or any of Flaskworks’ properties, assets or rights may be bound, affected or benefited, except for any such breaches, defaults or other occurrences that, individually or in the aggregate, are not and would not reasonably be expected to have a Material Adverse Effect; (d) allow the imposition of any material fees or penalties or require the offering or making of any payment to a third party on the part of Flaskworks; or (e) assuming the accuracy of the representations and warranties made by the Buyer in Article IV hereof, require any consent or

6


approval of, registration or filing with, or notice to any Governmental Authority, except in the case of clause (e) for such consents, approvals, registrations, filings or notices the failure of which to be obtained or made, individually or in the aggregate, would not reasonably be expected to materially impair the ability of Flaskworks or the Sellers to timely consummate, or prevent, any of the transactions contemplated by this Agreement or the Ancillary Agreements.

Section 3.4Capitalization. Schedule 3.4 sets forth a complete and accurate list, as of the date hereof, of all record owners of the issued and outstanding Units (of any and all classes), indicating the respective number and class of Units held by each. Except for the Units, Flaskworks has not issued or agreed to issue any (a) Units or other equity, ownership or voting interests; (b) securities or instruments convertible into or exchangeable for Units or other equity, ownership or voting interests; or (c) equity-equivalents, earnings, profits or revenue-based or equity-based rights. All Units have been duly authorized and validly issued, are fully paid and nonassessable and were issued in compliance with all applicable federal and state securities laws. Other than the rights under to the Equity Documents that are waived pursuant to Section 1.4 hereof, there are no outstanding obligations of Flaskworks to issue, sell, transfer, repurchase or redeem any Units or other equity interests of Flaskworks, or any securities or instruments convertible into or exchangeable for or that otherwise give rights with respect to Units or other equity interests of Flaskworks, or that relate to the holding, voting or disposition thereof. No Units have been issued in violation of any rights, agreements, commitments or arrangements under applicable Law, the Certificate, the Flaskworks LLC Agreement or any Contract or agreement to which Flaskworks is a party or by which it is bound. There are no voting trusts, stockholder agreements, proxies or other agreements or understandings in effect with respect to the voting or transfer of any of the Units. Flaskworks has obtained valid waivers with respect to any rights by other parties to purchase any of the Units covered by this Agreement.

Section 3.5Subsidiaries. Flaskworks does not presently own or control, directly or indirectly, any interest in any other entity of any type. Flaskworks is not a participant in any joint venture, partnership or similar arrangement.

Section 3.6Financial Statements.

(a)True and complete copies of the unaudited balance sheet of Flaskworks as at December 31, 2018, December 31, 2019, and the related unaudited statements of income, retained earnings, unitholders’ equity and changes in financial position of Flaskworks, together with all related notes and schedules thereto (collectively referred to as the “Financial Statements”) and the unaudited balance sheet of Flaskworks as at April 30, 2020, and the related statements of income, retained earnings, unitholders’ equity and changes in financial position of Flaskworks, together with all related notes and schedules thereto (collectively referred to as the “Interim Financial Statements”) are attached hereto as Schedule 3.6(a). Each of the Financial Statements and the Interim Financial Statements (i) accurately reflect and have been prepared in accordance with the books and records of Flaskworks, (ii) have been prepared in accordance with United States GAAP applied on a consistent basis throughout the periods indicated (except as may be indicated in the notes thereto) and (iii) fairly present, in all material respects, the financial position, results of operations and cash flows of Flaskworks as at the respective dates thereof and for the respective periods indicated therein, except as otherwise noted therein and

7


subject, in the case of the Interim Financial Statements, to normal and recurring year-end adjustments that will not, individually or in the aggregate, be material.

(b)The books of account and financial records of Flaskworks are true and correct and have been prepared and are maintained in accordance with sound accounting practice. Flaskworks has not made any changes in its accounting practice since December 31, 2019.

Section 3.7Absence of Undisclosed Liabilities. Except as and to the extent adequately accrued or reserved against in the audited balance sheet of Flaskworks as at December 31, 2019 (such balance sheet, together with all related notes and schedules thereto, the “Balance Sheet”), Flaskworks has no liability or obligation of any nature, whether accrued, absolute, contingent or otherwise, known or unknown and whether or not required by United States GAAP to be reflected on a balance sheet of Flaskworks, except for liabilities and obligations incurred in the ordinary course of business consistent with past practice since the date of the Balance Sheet that are not, individually or in the aggregate in excess of $20,000.

Section 3.8Absence of Certain Changes or Events. Since the date of the Balance Sheet: (a) Flaskworks has conducted its business only in the ordinary course consistent with past practice; (b) no event or development has had, or would reasonably be expected to have, individually or in the aggregate a Material Adverse Effect; (c) Flaskworks has not suffered any loss, damage, destruction or other casualty affecting any of its material properties or assets, whether or not covered by insurance; and (d) Flaskworks has preserved substantially intact its business organization and assets, has kept available the services of its current officers, employees and consultants and has preserved the goodwill of its customers, suppliers and employees. Since the date of the Balance Sheet, the Sellers have not caused Flaskworks to, and Flaskworks did not, (i) declare, set aside, make or pay any dividend or other distribution on or with respect to any of Flaskworks’ units or other equity or ownership interest, (ii) accelerate the collection of or discount any accounts receivable, delay the payment of accounts payable or defer expenses or capital expenditures, reduce inventories, or otherwise increase cash on hand, (iii) make any payments to Related Parties pursuant to Contract or otherwise or (iv) or make any other changes in the management of working capital, or modify practices with respect thereto.

Section 3.9Compliance with Law; Permits. Flaskworks is and has been since January 28, 2016 in compliance in all material respects with all Laws applicable to it and there is no investigation pending, or to the best knowledge of the Sellers, threatened by any Governmental Authority regarding a material violation of any such Law. Flaskworks is in possession of all permits, licenses and other authorizations of any Governmental Authority (“Permits”) necessary for it to own, lease and operate its properties and to carry on its business as currently conducted, and is and has been in compliance in all material respects with all such Permits. To the best knowledge of the Sellers, there is no basis for the revocation or withdrawal of any Permit. Flaskworks will continue to have the use and benefit of all Permits following the consummation of the transactions contemplated hereby.

Section 3.10Litigation. There is no Action pending or to the best knowledge of the Sellers threatened (a) affecting Flaskworks, its officers or directors in regards to their actions as such, its assets or its business; (b) to restrain or prevent the consummation of the transactions

8


contemplated hereby; or (c) that might affect the right of the Buyer to own and vote the Units, nor is there any basis for any of the foregoing. There is no outstanding or to the best knowledge of the Sellers threatened order, writ, judgment, injunction, decree, determination or award of, or investigation by, any Governmental Authority relating to Flaskworks, any of its properties or assets, any of its officers or managers or members or the transactions contemplated by this Agreement or the Ancillary Agreements. There is no Action initiated by Flaskworks pending, or which Flaskworks or any of its subsidiaries has commenced preparations to initiate, against any other Person. The foregoing includes, without limitation, actions, suits, proceedings or investigations pending or threatened in writing (or any basis therefor known to Flaskworks) involving the prior employment of any of Flaskworks’ employees, their services provided in connection with Flaskworks’ business, any information or techniques allegedly proprietary to any of their former employers or their obligations under any agreements with prior employers.

Section 3.11Employee Benefit Plans. Except as set forth on Schedule 3.11, there are no current employment Contracts or consulting agreements by which Flaskworks is bound, and no deferred compensation, bonus, incentive compensation, option, severance or termination pay agreement or plan or any other employee benefit plan, agreement, arrangement or commitment, whether formal or informal, maintained, entered into or contributed to, or which is required to be maintained, entered into or contributed to, by Flaskworks for the benefit of any current or former employee, officer or director of Flaskworks, or with respect to which Flaskworks has any liability, contingent or otherwise (collectively, “Benefit Plans”). None of the Benefit Plans is a multiemployer plan (as defined in Section 3(37) of the Employee Retirement Income Security Act of 1974, as amended (“ERISA”)), is subject to Title IV of ERISA or Section 412 of the Code, or provides post-employment welfare benefits (except to the extent required by Section 4980B of the Code). All of the Benefit Plans currently comply, and have complied in the past, both as to form and operation, with the terms of such Benefit Plans and with the applicable provisions of ERISA, the Code and other applicable Law.

Section 3.12Labor and Employment Matters. Flaskworks is not a party to any Contract or collective bargaining agreement with any labor organization. No organization or representation question, labor dispute or unfair labor practice or complaint is pending or has been threatened in the past five years.

Section 3.13Real and Personal Property.

(a)Flaskworks does not own any Real Property. Schedule 3.13 sets forth a true and complete list of all real property and interests in real property leased or subleased by Flaskworks or which Flaskworks otherwise has a right to use or occupy (the “Real Property”). Flaskworks has good and marketable leasehold title to all Real Property, in each case together with all plants, buildings, improvements and fixtures thereon, free and clear of all Encumbrances, other than Encumbrances for current taxes not yet past due and Encumbrances that do not, individually or in the aggregate, materially impair the ownership, use and operation of the related assets (collectively, “Permitted Encumbrances”). No parcel of Real Property is or is to the best knowledge of the Sellers threatened to (i) become subject to any governmental decree or order to be sold or is or (ii) be condemned, expropriated or otherwise taken by any public authority. True and complete copies of all leases (including all amendments) in respect of

9


or affecting any Real Property have been delivered to the Buyer. Flaskworks has valid licenses and/or permits to operate on the Real Property listed in Schedule 3.13(a).

(b)Flaskworks has good and valid title to or a valid leasehold interest in all of its personal property, including all personal property reflected on the Balance Sheet or acquired in the ordinary course of business since the date of the Balance Sheet, except for any personal property sold or otherwise disposed of for fair value since the date of the Balance Sheet in the ordinary course of business consistent with past practice. None of the personal property owned or leased by Flaskworks is subject to any Encumbrance other than Permitted Encumbrances. Each item of tangible personal property of Flaskworks is in all material respects in good operating condition and repair, ordinary wear and tear excepted, and is adequate for the uses to which it is being put.

(c)The assets owned or leased by Flaskworks constitute all of the assets necessary for Flaskworks to carry on its business as currently conducted.

Section 3.14Taxes. Flaskworks has filed all income and other material tax returns and other reports required of it under all federal, state, local and foreign tax laws and there are in effect no waivers of applicable statutes of limitations with respect to taxes for any year. All such returns and reports are correct and complete in all material respects. Flaskworks has paid in full all taxes and other material amounts due thereunder, including without limitation all taxes that Flaskworks is obligated to withhold from amounts paid or payable to or benefits conferred upon employees, creditors and third parties. There are no accrued and unpaid federal, state, country, local or foreign taxes of Flaskworks that exceed the reserve for tax liability set forth on the face of the Interim Financial Statements. There have been no tax examinations or audits of Flaskworks, nor are any in progress. Flaskworks has not agreed, nor is it required, to make any adjustments pursuant to Section 481(a) of the Code or any similar provision of state or local law by reason of a change of accounting method initiated by it or any other relevant party. Flaskworks is not and has not been a party to any “listed transaction” as defined in Treasury Regulation Section 1.6011-4(b)(2) or to any other transaction that is a “reportable transaction” pursuant to Treasury Regulation Section 1.6011-4(b). Flaskworks has not applied for or received a loan pursuant to the Paycheck Protection Program as established under Title I of the Coronavirus Aid, Relief, and Economic Security Act, Pub.L. 116–136 (116th Cong.) (Mar. 27, 2020), requested or received any tax credits under any Stimulus Legislation, or deferred any payment of taxes under any Stimulus Legislation, Internal Revenue Service Notice 2020-18, Internal Revenue Service Notice 2020-20, or Internal Revenue Service Notice 2020-23.

Section 3.15Environmental Matters.

(a)(i) Neither Flaskworks, the Sellers nor to the best knowledge of the Sellers any previous owner, occupant or user of any Real Property or any other Person has engaged in or permitted any operation or activity at or upon, or any use or occupancy of, any Real Property that has resulted in a Release of any Hazardous Materials on, under, in or about any Real Property, or involved the generation, manufacture, storage, treatment or disposal of any Hazardous Materials at or on any Real Property, nor to the best knowledge of the Sellers, have any Hazardous Materials migrated from any Real Property to any adjacent properties; (ii) Flaskworks has received no notices, requests for information, claims, subpoenas or summons from any person

10


that allege any violation by Flaskworks of Environmental Law or Environmental Permits, whether or not corrected, or any Environmental Liabilities of Flaskworks; (iii) there are no pending or threatened Actions against Flaskworks or any of its respective predecessors in interest alleging any material violation of Environmental Law or Environmental Permits or any material Environmental Liability and, to the Sellers’ knowledge, there exists no basis for any Action, citation, or directive against Flaskworks or the Sellers involving claims for Environmental Liabilities; (iv) Flaskworks is and has been in compliance in all material respects with all Environmental Law and Environmental Permits; (v) Flaskworks has obtained all Permits, licenses, registrations and other authorizations required pursuant to Environmental Laws (“Environmental Permits”); all such Environmental Permits are in full force and effect; and Flaskworks has not received any notice regarding the revocation, suspension or amendment of any Environmental Permit; and (vi) the Sellers have supplied the Buyer with true and complete copies of all notices, reports (including Phase I and Phase II environmental site assessments, as applicable) and other documents received by the Sellers or in the Sellers’ possession relating to (A) any environmental conditions at any facility or real property ever owned, operated or leased by Flaskworks or any of its respective predecessors in interest, (B) Flaskworks’ compliance with Environmental Law or Environmental Permits or (C) any Environmental Liability of Flaskworks or any of its respective predecessors-in-interest.

Section 3.16Material Contracts. Schedule 3.16 lists all agreements, arrangements or understandings, whether written or oral (“Contracts”), that are material to Flaskworks or its business, for the avoidance of doubt, including, but not limited to, all Contracts (a) with respect to Real Property, (b) with respect to Intellectual Property, (c) that involves aggregate receivables or liabilities of Flaskworks in excess of $20,000 on an annual basis, (d) with any Governmental Authority or (e) that limits, or purports to limit, the ability of Flaskworks to compete in any line of business or with any Person or in any geographic area or during any period of time, or that restricts the right of Flaskworks to sell to or purchase from any Person or to hire any person,(each, a “Material Contract”). Each Material Contract is legal, valid, binding and enforceable, and is in full force and effect (except as enforcement may be limited by applicable bankruptcy, insolvency, reorganization, moratorium or similar laws affecting creditors’ rights generally and by general principles of equity). Flaskworks is not, and to the best knowledge of the Sellers, no other party is in breach or violation of, or (with or without notice or lapse of time or both) default under any Material Contract, nor has Flaskworks or any Seller received any written claim of any such breach, violation or default. The Sellers have delivered to the Buyer true and complete copies of all Material Contracts, including any amendments thereto.

Section 3.17Related Party Interests and Transactions. There is no agreement, arrangement or understanding between any Seller, any of the Sellers’ Affiliates, or any of their respective officers, directors or employees or any family member (each of the foregoing, including the Sellers, a “Related Party”), on the one hand, and Flaskworks or any Affiliate of Flaskworks, on the other hand, nor any advances or other amounts owing to or from Flaskworks by or to any Related Party, except for any such arrangements, understandings, advances or amounts set forth on Schedule 3.17 and with respect to which the underlying documentation has been provided to the Buyer prior to the date hereof. No Related Party (a) owns or has owned, directly or indirectly any interest in any property, assets or rights used in the business of Flaskworks or has or has had any material commercial, industrial, banking, consulting, legal, accounting, charitable or other business relationship with or interest in any of Flaskworks’

11


customers, suppliers, service providers, joint venture partners, licensees or competitors, (b) is or has been involved in any business dealings or transactions with Flaskworks other than in the ordinary course of business at prevailing market terms or (c) except for the Sellers themselves (excluding any Seller that is not a natural person) is or has been employed by Flaskworks.

Section 3.18Intellectual Property.

(a)Schedule 3.18(a) sets forth a true and complete list of all issued, registered and applied-for Intellectual Property owned or purported to be owned by Flaskworks. Flaskworks is the sole and exclusive beneficial and record owner of all of such Intellectual Property, and all such Intellectual Property is valid, subsisting and, to Flaskworks’ knowledge, enforceable. Flaskworks owns or otherwise holds valid rights to use all Intellectual Property used or contemplated to be used in the operation of its business as currently conducted, and all such rights are free of all Encumbrances (except Permitted Encumbrances). The consummation of the transactions contemplated by this Agreement and each of the Ancillary Agreements will not alter or impair the ownership or right of Flaskworks to use any Intellectual Property used or contemplated to be used in the operation of its business as currently conducted. The development, manufacture, sale, distribution or other commercial exploitation of products, and the provision of any services, by or on behalf of Flaskworks, and the operation of the businesses of Flaskworks, in each case, as conducted on the date hereof and as conducted since January 28, 2016, does not infringe upon or, misappropriate, in each case, in any material respect, and has not infringed upon or misappropriated any Intellectual Property of any third party in any material respect. To the best knowledge of the Sellers, no valid basis for any such infringement or misappropriation claim exists. Flaskworks has taken reasonable measures to protect the secrecy, confidentiality and value of all trade secrets used in the business of Flaskworks, including entering into appropriate confidentiality agreements with all officers, directors, employees, and other Persons with access to such trade secrets. None of such trade secrets has been disclosed or authorized to be disclosed to any Person other than to employees or agents of Flaskworks for use in connection with the business of Flaskworks or pursuant to a confidentiality or non-disclosure agreement that reasonably protects the interest of Flaskworks in and to such matters. To the best knowledge of the Sellers, no unauthorized disclosure of any such trade secrets has occurred. All Intellectual Property developed by or for Flaskworks was conceived, invented, reduced to practice, authored or otherwise created solely by either employees of Flaskworks acting within the scope of their employment, or independent contractors of Flaskworks pursuant to agreements containing an assignment of Intellectual Property to Flaskworks. No Person who was involved in, or who contributed to, the creation or development of any Intellectual Property, has performed services for the United States or a foreign government, university, college, or other educational or medical institution or research center in a manner that would affect Flaskworks’ rights in the Intellectual Property.

(b)Flaskworks (i) takes reasonable measures, directly or indirectly, to ensure the confidentiality, privacy and security of customer, employee and other confidential information and (ii) complies and has complied with applicable data protection, privacy and similar Laws, directives and codes of practice in any jurisdiction relating to any data processed by Flaskworks.

12


Section 3.19Certain Contractual Arrangements. None of Mr. Shashi Murthy, Ms. Lekhana Bhandary and Mr. Andrew Kozbial is party to any Contract that would or would reasonably be expected to prevent or materially impair such Person’s ability to work in the Business, as conducted by Flaskworks or otherwise, in each case, on Buyer’s behalf, following the Closing.

Section 3.20Brokers. No broker, finder or agent will have any claim against the Buyer (or after the Closing, Flaskworks) for any fees or commissions in connection with the transactions contemplated by this Agreement and each of the Ancillary Agreements based on arrangements made by or on behalf of the Sellers or Flaskworks.

ARTICLE IV

REPRESENTATIONS AND WARRANTIES OF THE BUYER

The Buyer hereby represents and warrants to the Sellers as follows:

Section 4.1Organization. The Buyer is a corporation duly organized, validly existing and in good standing under the laws of Delaware.

Section 4.2Authority. The Buyer has full corporate power and authority to execute, deliver and perform its obligations under this Agreement and the Ancillary Agreements to which it is a party and to consummate the transactions contemplated hereby. This Agreement and the Ancillary Agreements to which it is a party have been duly executed and delivered by the Buyer and, assuming due authorization, execution and delivery by each of the Sellers, are legal, valid, binding and enforceable upon and against the Buyer (except as enforcement may be limited by applicable bankruptcy, insolvency, reorganization, moratorium or similar laws affecting creditors’ rights generally and by general principles of equity).

Section 4.3Required Filings and Consents. Assuming the accuracy of the representations and warranties made by the Sellers in Article II hereof, the execution, delivery and performance by the Buyer of this Agreement and the Ancillary Agreements and the consummation by the Buyer of the transactions contemplated hereby and thereby do not and will not require any consent or approval of, registration or filing with, or notice to any Governmental Authority, except for any filings with the U.S. securities and exchange commission and such other consents, approvals, registrations, filings or notices the failure of which to be obtained or made, individually or in the aggregate, would not reasonably be expected to materially impair the ability of Buyer to timely consummate, or prevent, any of the transactions contemplated by this Agreement or the Ancillary Agreements.

Section 4.4Brokers. No broker, finder or agent will have any claim against the Sellers for any fees or commissions in connection with the transactions contemplated by this Agreement or any Ancillary Agreement based on arrangements made by or on behalf of the Buyer.

13


ARTICLE V

COVENANTS

Section 5.1Transfer of Permits. Effective as of the Closing, the Sellers duly and validly transferred or caused to be transferred to Flaskworks without any additional consideration all Permits that are held in the name of any Seller or any of its Affiliates (other than Flaskworks) on behalf of Flaskworks and used in connection with the business of Flaskworks, and the representations, covenants and agreements contained herein shall apply to such Permits as if held by Flaskworks on the date hereof.

Section 5.2Confidentiality.

(a)From and after the Closing, until the third anniversary of the Closing Date, each Seller shall not, and each Seller shall cause its Affiliates (other than Flaskworks) and its and their respective Representatives not to, use for any purpose other than to benefit the Buyer or disclose to any third Person, any Confidential Information; provided, however, that any such Person may disclose Confidential Information to the extent (i) such disclosure is required by Law or legal process, (ii) unless impossible or otherwise prohibited by Law or legal process, such Person notifies the Buyer of the existence, terms and circumstances surrounding such disclosure obligation and consults with the Buyer on the advisability of taking steps available under applicable Law to resist or narrow such disclosure obligation, (iii) such Person cooperates reasonably with any efforts of the Buyer, if any, to obtain an order or other reliable assurance that confidential treatment will be accorded to the disclosed Confidential Information, and (iv) such Person discloses only that portion of the Confidential Information that it is so required to disclose. Effective as of the Closing, the Sellers hereby assign to the Buyer all of the Sellers’ right, title and interest in and to any confidentiality agreements entered into by the Sellers (or their Affiliates or Representatives) in connection with any transaction involving the acquisition or purchase of all or any portion of Flaskworks. From and after the Closing, the Sellers shall take all actions reasonably requested by the Buyer, at Buyer’s sole cost, in order to assist in enforcing the rights so assigned. For the avoidance of doubt, Sellers who are employed by Flaskworks or Buyer following the Closing shall be permitted to use Confidential Information in the course of performing their respective responsibilities pursuant to such employment (during the course of such employment).

(b)Corning has used, and if such process has not been completed as of the date hereof, will use as rapidly as practicable, its commercially reasonable efforts to destroy or to return to Flaskworks any Confidential Information of Flaskworks, including any drawings, specifications or other information and materials, in any embodiment, relating to the design, development and/or operation of any equipment and/or systems (including any software) related to the Flaskworks Business, in each case, its possession or under its control (including any copies, excerpts and/or summaries thereof), including by expunging all such information from any storage media or device containing such information, provided that (i) it is not required to expunge any system back-up media such as copies of any computer records or files containing Confidential Information created solely pursuant to automatic archiving or back-up procedures on secured central storage servers and that cannot reasonably be expunged and (ii) it is permitted to retain one copy of the Confidential Information solely for the purpose of monitoring compliance with its obligations under Section 5.2 (Confidentiality) and agrees that it shall not

14


knowingly access, review or distribute any of such materials other than to the extent it determines in good faith that doing so is necessary to monitor compliance with its obligations under Section 5.2 (Confidentiality). Notwithstanding any of the foregoing, Corning and its Affiliates will continue to be bound by their obligations under Section 5.2 (Confidentiality), including for the avoidance of doubt with respect to the information retained pursuant to the foregoing clause (ii).

Section 5.3Non-Competition; Non-Solicitation.

(a)For a period of six (6) months following the Closing with respect to Andrew Kozbial, and for a period of eighteen (18) months following the Closing for each of Jennifer Rossi and Shashi Murthy, each such Person shall not, and shall cause its respective Affiliates not to, directly or indirectly through any Person or contractual arrangement:

(i)engage or assist in the design, development, optimization, evaluation, testing, production, sale, licensing, usage (whether for proprietary operations, contract services or otherwise) or commercialization of any bioreactor or other equipment or system for the culture, maturation, activation, transformation or other production or manipulation of any type of living cell (the “Business”), or perform management, executive or supervisory functions with respect to, own, operate, join, control, render financial assistance to, receive any economic benefit from, exert any influence upon, participate in, render services or advice to, or allow any of its officers or employees to be connected as an officer, employee, partner, member, stockholder, consultant or otherwise with, any business or Person that competes in whole or in part with the Business; provided, however, that for purposes of Section 5.3, ownership of securities having no more than two percent of the outstanding voting power of any competitor which are listed on any national securities exchange shall not be deemed to be a violation of Section 5.3 so long as the Person owning such securities has no other association or relationship with such competitor. For the avoidance of doubt, Sellers who are employed by Flaskworks or Buyer following the Closing shall not be restricted by this Section 5.3(a)(i) with respect to the performance of their respective responsibilities pursuant to such employment (during the course of such employment) and the applicable period for each such Person set forth in Section 5.3(a) shall continue to run during the course of such employment;

(ii)solicit, recruit or hire any person who at any time on or after the date of this Agreement is a Covered Employee (as hereinafter defined); provided, that the foregoing shall not prohibit (A) a general solicitation to the public of general advertising or similar methods of solicitation by search firms not specifically directed at Covered Employees or (B) such Seller or any of its respective Affiliates from soliciting, recruiting or hiring any Covered Employee who has ceased to be employed or retained by Flaskworks, the Buyer or any of their respective Affiliates for at least 12 months. For purposes of Section 5.3, “Covered Employees” means, collectively, officers, managers and employees of Flaskworks, the Buyer and their respective Affiliates. For the avoidance of doubt, Sellers who are employed by Flaskworks or Buyer following the Closing shall not be restricted by this Section 5.3(a)(ii) with respect to the performance of their respective responsibilities pursuant to such employment (during the course of such employment) and the applicable period for each such Person set forth in Section 5.3(a) shall continue to run during the course of such employment;

15


(iii)solicit Business from any Customer (as hereinafter defined), refer Business from any Customer to any Person or be paid commissions based on Business sales received from any Customer by any Person. For purposes of Section 5.3, the term “Customer” means any Person to which any Seller, Flaskworks, the Buyer or any of their respective Affiliates provided products or services of the Business during the 12-month period prior to the time at which a determination must be made as to whether such Person is a Customer; provided, that the foregoing shall not prohibit any referral of Business by any Seller or Flaskworks to the Buyer; or

(iv)disparage the Buyer or any of its Affiliates in any way that would reasonably be expected to adversely affect the goodwill, reputation or business relationships of the Buyer or any of its Affiliates with the public generally, or with any of their customers, suppliers or employees.

(b)Each Seller acknowledges that the covenants of the Sellers set forth in Section 5.3 are an essential element of this Agreement and that any breach by such Persons of any provision of Section 5.3 will result in irreparable injury to the Buyer. Each Seller acknowledges that in the event of such a breach, in addition to all other remedies available at law, the Buyer shall be entitled to equitable relief, including injunctive relief, and an equitable accounting of all earnings, profits or other benefits arising therefrom, as well as such other damages as may be appropriate. Each Seller has independently consulted with its counsel and after such consultation agrees that the covenants set forth in Section 5.3 are reasonable and proper to protect the legitimate interest of the Buyer.

(c)If a court of competent jurisdiction determines that the character, duration or geographical scope of the provisions of Section 5.3 are unreasonable, it is the intention and the agreement of the parties that these provisions shall be construed by the court in such a manner as to impose only those restrictions on the Sellers’ conduct that are reasonable in light of the circumstances and as are necessary to assure to the Buyer the benefits of this Agreement. If, in any judicial proceeding, a court shall refuse to enforce all of the separate covenants of Section 5.3 because taken together they are more extensive than necessary to assure to the Buyer the intended benefits of this Agreement, it is expressly understood and agreed by the parties that the provisions hereof that, if eliminated, would permit the remaining separate provisions to be enforced in such proceeding, shall be deemed eliminated, for the purposes of such proceeding, from this Agreement.

(d)Notwithstanding the foregoing, the Buyer hereby acknowledges that Jennifer Rossi is employed by Kerafast, Inc. and its affiliate Absolute Antibody Limited and such employment, as it involves or relates to antibodies or reagents (but not including any work with respect to the manufacture of systems or processes), shall not to be deemed to be in violation of Section 5.3(a)(i) or Section 5.3(a)(ii).

Section 5.4Affiliate Arrangements; Release of Obligations.

(a)Except as set forth on Schedule 5.4, all Contracts between Flaskworks, on the one hand, and the Sellers and their respective Affiliates (other than Flaskworks), on the other

16


hand, were cancelled without any consideration or further liability to any party and without the need for any further documentation, effective as of immediately prior to the Closing.

(b)Effective as of the Closing, each Seller does hereby, for itself and each of its Affiliates (excluding Flaskworks) and each of its and their Related Parties (each, a “Seller Releasing Party”), irrevocably release, waive and absolutely forever discharge Flaskworks and all its respective, past, present and future directors, officers, managers, agents, consultants, representatives, successors and assigns (collectively, the “Released Persons”), from any and all actions, causes of action, suits, debts, dues, sums of money, accounts, bonds, bills, covenants, Contracts, controversies, agreements, promises, variances, trespasses, damages, judgments, executions, claims and demands of every type and nature whatsoever, known or unknown, at law or in equity (each a “Claim” and collectively, the “Claims”), that any Seller Releasing Party has had, may now have or may hereinafter have against any Released Person relating to, arising out of or resulting from any matter, act or omission whatsoever during all periods through the Closing and whether or not first asserted before or after the Closing (together, the “Released Matters”). The Released Matters shall not include (i) any agreement listed on Schedule 5.4, (ii) this Agreement or any Ancillary Agreement, (iii) the rights expressly contemplated to survive the Closing pursuant to Section 5.5, and (iv) any right of any Seller Releasing Party that is a natural person to salary, bonus, expense reimbursement or other ordinary compensation earned in the capacity as a manager, officer or employee of Flaskworks and that is set forth on Schedule 5.4(b)(iv). It is the intention of such Seller in providing this release to the Released Persons, and in giving and receiving the consideration called for in this Agreement, that this release shall be effective as a full and final accord and satisfaction and general release of and from all Released Matters and the final resolution by the applicable Seller Releasing Party, Flaskworks and its subsidiaries of all Released Matters.

Section 5.5Manager and Officer Indemnification. Prior to Closing, Flaskworks purchased a D&O tail policy to be in effect for, and with a claims period of, six years following the Closing (the “Tail Policy”). Buyer shall take no steps to terminate the D&O tail policy during such six year period and shall not be required to pay any premium, fee, deductible or other amount with respect to the Tail Policy. Any indemnification payable by Flaskworks or Buyer (such paying party, the “Payor”) with respect to the managers and officers of Flaskworks (including for the avoidance of doubt with respect to any Person represented by such a manager and their respective affiliates) will be limited to proceeds paid to the Payor on account of valid insurance claims made under the Tail Policy. In the event that the Buyer or Flaskworks or any of their respective successors or assigns (a) consolidates with or merges into any other Person or (b) transfers all or substantially all of its properties or assets to any Person, then, and in each case, the successors and assigns of Buyer or Flaskworks, as the case may be, shall assume the obligations set forth in this Section 5.5. The obligations of Buyer under this Section 5.5 shall not be terminated or modified in such a manner as to adversely any Indemnified Person without the consent of such affected Person.

Section 5.6Public Announcements. No party to this Agreement shall, and each shall cause its Affiliates and its and their Representatives not to, issue any press release or make any other public statement with respect to this Agreement, the Ancillary Agreements and the other transactions contemplated hereby and thereby, except for any such disclosure, release or public

17


statement that is necessary under applicable Law or stock exchange (including for this purpose, the OTC Markets) rule, reporting obligation or similar requirement.

Section 5.7Further Assurances. Following the Closing, each party hereto shall from time to time do such further acts and execute and deliver such further documents regarding its obligations hereunder as may be reasonably required for the purpose of (a) accomplishing the purposes of this Agreement or (b) assuring and confirming the validity of any documents of conveyance to be delivered at Closing.

ARTICLE VI

INDEMNIFICATION

Section 6.1Survival of Representations and Warranties. The representations and warranties of Flaskworks, the Sellers and the Buyer contained in this Agreement, the Ancillary Agreements and any schedule, certificate or other document delivered pursuant hereto or in connection with the transactions contemplated hereby shall be continuing and survive the Closing for a period of twelve (12) months, and shall in no way be affected by any investigation or knowledge of the subject matter thereof made by or on behalf of the Sellers or the Buyer; provided, however that (a) the representations and warranties set forth in Section 3.14 (Taxes) shall survive until the close of business on the 90th day following the expiration of the applicable statute of limitations (giving effect to any waiver, mitigation or extension thereof) and (b) any representation in the case of fraud shall survive the Closing for a period of 20 years. The covenants and agreements of the parties contained in this Agreement and in any Ancillary Agreement shall survive the Closing until the expiration of the statute of limitations following the date all performance thereunder was due to be performed; provided, however, that the obligation to provide indemnification pursuant to and in accordance with the other provisions of this Article VI shall survive for a period of 20 years.

Section 6.2Indemnification by the Sellers. Each Seller, severally and not jointly, shall save, defend, indemnify and hold harmless the Buyer and its Affiliates (including Flaskworks) and the respective Representatives, successors and assigns of each of the foregoing, from and against any and all losses, damages, liabilities, deficiencies, claims, interest, awards, judgments, penalties, costs and expenses (including reasonable attorneys’ fees, costs and other out-of-pocket expenses incurred in investigating, preparing or defending the foregoing) (hereinafter collectively, “Losses”), asserted against, incurred, sustained or suffered by any of the foregoing as a result of, arising out of or relating to:

(a)any breach of any representation or warranty made by such Seller in Article II of this Agreement, or any Ancillary Agreement, schedule, certificate or other document delivered pursuant hereto or in connection with the transactions contemplated hereby;

(b)any breach of any representation or warranty made by Flaskworks contained in this Agreement, or any Ancillary Agreement, schedule, certificate or other document delivered pursuant hereto or in connection with the transactions contemplated hereby;

(c)any breach of any covenant or agreement by such Seller or Flaskworks contained in this Agreement or in any Ancillary Agreement;

18


(d)(i) any and all taxes (including any interest, additions and penalties with respect thereto, but excluding the portion of any Transfer Taxes payable by Buyer pursuant to Section 8.4) imposed on Flaskworks, or for which Flaskworks is liable, with respect to all periods ending on or before the Closing Date, or a pro rata portion (based on the proration under Section 8.2) of any such taxes for any period that ends after but includes the Closing Date or (ii) any and all income taxes (including any interest, additions and penalties with respect thereto) incurred or otherwise payable by the Sellers as a result of the consummation of the transactions contemplated hereby;

(e)any inaccuracy of or omission in the Closing Payment Schedule (including with respect to Buyer-Paid Expenses);

(f)any claims by direct or indirect equity holders or employees, or former equity holders or employees, or any Persons claiming to be an equity holder, in each case of Flaskworks or any of its Affiliates, relating to any claims against any of the foregoing entities arising prior to the Closing, including any claims with respect to the sale, purchase, termination, cancellation, expiration, redemption, forfeiture or conversion of the equity securities of Flaskworks in connection with this Agreement, any Ancillary Agreement or otherwise;

(g)any claims by any member, officer, manager, employee or other agent of Flaskworks for indemnification required under Flaskworks’ organizational documents (including under the New Flaskworks LLC Agreement) or otherwise by reason of the fact that such Person was a member, officer, manager, employee or other agent of Flaskworks for acts or omissions occurring prior to the Closing, in each case, to the extent not reimbursed by applicable insurance; and

(h)

any and all (i) Transaction Expenses and (ii) Indebtedness.

Section 6.3Indemnification by the Buyer. The Buyer shall save, defend, indemnify and hold harmless the Sellers and their respective Representatives, successors and assigns of each of the foregoing from and against any and all Losses asserted against, incurred, sustained or suffered by any of the foregoing as a result of, arising out of or relating to:

(a)any breach of any representation or warranty made by the Buyer contained in this Agreement, Ancillary Agreement or any schedule, certificate or other document delivered pursuant hereto or in connection with the transactions contemplated hereby; and

(b)any breach of any covenant or agreement by the Buyer contained in this Agreement or any Ancillary Agreement.

Section 6.4Procedures. Whenever any claim shall arise for indemnification hereunder, the party entitled to indemnification (the “Indemnified Party”) shall promptly provide written notice of such claim to the party obligated to provide such indemnification (the “Indemnifying Party”) describing such claim in reasonable detail (such notice, a “Claim Notice”). The failure to promptly deliver a Claim Notice, however, shall not release the Indemnifying Party from any of its obligations under this Article VI except to the extent that the Indemnifying Party is materially prejudiced by such failure. In connection with any claim giving rise to indemnity hereunder resulting from or arising out of any claim, action or demand by a

19


Person who is not a party to this Agreement, the Indemnifying Party, if it acknowledges in writing its obligation to indemnify the Indemnified Party with respect to such claim, shall have the right, at its sole cost and expense and upon written notice to the Indemnified Party within 15 days of receipt of a Claim Notice in respect of such claim, to assume the defense thereof with counsel reasonably satisfactory to the Indemnified Party. Notwithstanding the foregoing, the Indemnifying Party may not assume the defense of any claim for equitable or injunctive relief or any claim that would impose criminal liability on the Indemnified Party (or its Affiliates), and the Indemnified Party shall have the right to defend, at the expense of the Indemnifying Party, any such claim. If the Indemnifying Party assumes the defense of such a claim, the Indemnified Party may participate in the defense of any such claim, action or demand with its counsel and at its own cost and expense. If the Indemnifying Party does not assume the defense of any such claim, the Indemnified Party may, but shall not be obligated to, defend against such claim in such manner as it may deem appropriate (and the Indemnifying Party shall cooperate with the Indemnified Party with respect to such defense), including, but not limited to, settling such claim, after giving notice to the Indemnifying Party, on such terms as the Indemnified Party may deem appropriate. No action taken by the Indemnified Party in accordance with such defense and settlement shall relieve the Indemnifying Party of its indemnification obligations with respect to any damages resulting therefrom. In no event may the Indemnifying Party settle any such claim without the Indemnified Party’s prior written consent (which consent shall not be unreasonably withheld, conditioned or delayed).

Section 6.5Limitations on Indemnification.

(a)Notwithstanding anything to the contrary herein the total aggregate amount in respect of which the Sellers shall be liable for indemnification under any provision of Section 6.2 shall not exceed (i) fifteen percent (15%) of the Purchase Price received by the Sellers hereunder and, (ii) with respect to each Seller, shall not exceed the proportionate amount of the Purchase Price received by the Sellers hereunder, provided, however, that the foregoing clause (i) shall not apply to Losses claimed pursuant to Sections 6.2(c) (but only with respect to a breach of Section 5.2 or 5.3), 6.2(d), 6.2(e), 6.2(f), 6.2(g) and 6.2(h) or arising out of or relating to the representations and warranties set forth in Section 3.14 (Taxes) (the maximum aggregate amount in respect of which the Sellers shall be liable for indemnification shall not exceed the Purchase Price received by the Sellers hereunder); and the foregoing clauses (i) and (ii) shall not apply in cases involving fraud. For the avoidance of doubt, no Seller shall be liable for the fraud or intentional misrepresentation of any other Seller.

(b)For purposes of calculating the amount of any Loss arising from a breach of any representation or warranty subject to indemnification under Section 6.2(a), as well as for purposes of determining whether there has been a breach of any such representation or warranty, all “material”, “materially”, “in all material respects”, “Material Adverse Effect”, and other like qualifications shall be disregarded.

(c)For the avoidance of doubt and notwithstanding anything herein to the contrary, nothing herein shall be deemed to limit Buyer’s remedies against Sellers or any other Person with respect to infringement or similar impermissible uses by such Persons of the intellectual property of or licensed by Flaskworks and/or the Buyer and its Affiliates.

20


Section 6.6Tax Treatment. The parties agree to treat any amounts payable pursuant to this Article VI as an adjustment to the purchase price for all tax-related purposes to the extent permitted by Law.

ARTICLE VII

GENERAL PROVISIONS

Section 7.1Fees and Expenses. Except as otherwise provided herein, all fees and expenses incurred in connection with or related to this Agreement, the Ancillary Agreements and the transactions contemplated hereby and thereby shall be paid by the party incurring such fees or expenses, provided that all Transaction Expenses shall be paid by the Sellers and not by Flaskworks. If Flaskworks shall pay or be liable for any fee, expense, or liability described in this Section, the sum of all such payments or liabilities shall be paid by the Sellers to the Buyer upon demand.

Section 7.2Amendment and Modification. This Agreement may not be amended, modified or supplemented in any manner, whether by course of conduct or otherwise, except by an instrument in writing specifically designated as an amendment hereto, signed on behalf of each party.

Section 7.3Waiver. No failure or delay of either party in exercising any right or remedy hereunder shall operate as a waiver thereof. Any such waiver by a party shall be valid only if set forth in writing by such party.

Section 7.4Notices. All notices and other communications hereunder shall be in writing and shall be deemed duly given if delivered personally or sent by e-mail, overnight courier or registered or certified mail, postage prepaid, to the address set forth on the signature pages hereto opposite the party to receive such notice, or to such other address as may be designated in writing by such party.

Section 7.5Entire Agreement. This Agreement and the Ancillary Agreements constitute the entire agreement, and supersedes all prior written agreements, arrangements and understandings and all prior and contemporaneous oral agreements, arrangements and understandings between the parties with respect to the subject matter of this Agreement. No party to this Agreement shall have any legal obligation to enter into the transactions contemplated hereby unless and until this Agreement shall have been executed and delivered by each of the parties.

Section 7.6Third-Party Beneficiaries. Except as provided in Article VI and in Section 5.5 (for the limited purpose set forth therein), nothing in this Agreement shall confer upon any person other than the parties and their respective successors and permitted assigns any right of any nature.

Section 7.7Governing Law. This Agreement and all disputes or controversies arising out of or relating to this Agreement, the Ancillary Agreements or the transactions contemplated hereby shall be governed by, and construed in accordance with, the internal laws of the State of Delaware, without regard to the laws of any other jurisdiction that might be applied because of the conflicts of laws principles of the State of Delaware.

21


Section 7.8Submission to Jurisdiction. Each of the parties irrevocably agrees that any legal action or proceeding arising out of or relating to this Agreement or the Ancillary Agreements brought by any party or its successors or assigns against the other party shall be brought and determined in the Court of Chancery of the State of Delaware, provided, that if jurisdiction is not then available in the Court of Chancery of the State of Delaware, then any such legal action or proceeding may be brought in any federal court located in the State of Delaware or any other Delaware state court, and each of the parties hereby irrevocably submits to the exclusive jurisdiction of the aforesaid courts for itself and with respect to its property, generally and unconditionally, with regard to any such action or proceeding arising out of or relating to this Agreement, the Ancillary Agreements and the transactions contemplated hereby and thereby. Each of the parties agrees not to commence any action, suit or proceeding relating thereto except in the courts described above in Delaware, other than actions in any court of competent jurisdiction to enforce any judgment, decree or award rendered by any such court in Delaware as described herein.

Section 7.9Waiver of Jury Trial. EACH OF THE PARTIES TO THIS AGREEMENT HEREBY IRREVOCABLY WAIVES ALL RIGHT TO A TRIAL BY JURY IN ANY ACTION, PROCEEDING OR COUNTERCLAIM ARISING OUT OF OR RELATING TO THIS AGREEMENT, THE ANCILLARY AGREEMENTS OR THE TRANSACTIONS CONTEMPLATED HEREBY OR THEREBY.

Section 7.10Assignment; Successors. Neither this Agreement nor any of the rights, interests or obligations under this Agreement may be assigned or delegated, in whole or in part, by operation of law or otherwise, by either party without the prior written consent of the other party, and any such assignment without such prior written consent shall be null and void; provided, however, that the Buyer may assign this Agreement to any Affiliate of the Buyer without the prior consent of the Seller; provided further, that no assignment shall limit the assignor’s obligations hereunder. Subject to the preceding sentence, this Agreement will be binding upon the parties and their respective successors and assigns, heirs and executors.

Section 7.11Enforcement. The parties agree that irreparable damage would occur in the event that any of the provisions of this Agreement were not performed in accordance with their specific terms or were otherwise breached. Accordingly, each of the parties shall be entitled to specific performance of the terms hereof, including an injunction or injunctions to prevent breaches of this Agreement and to enforce specifically the terms and provisions of this Agreement, this being in addition to any other remedy to which such party is entitled at law or in equity. Each of the parties hereby further waives (a) any defense in any action for specific performance that a remedy at law would be adequate and (b) any requirement under any Law to post security as a prerequisite to obtaining equitable relief.

Section 7.12Severability. Whenever possible, each provision or portion of any provision of this Agreement shall be interpreted in such manner as to be effective and valid under applicable Law, but if any provision or portion of any provision of this Agreement is held by any court of competent jurisdiction to be invalid, illegal or unenforceable in any respect under any applicable Law or rule in any jurisdiction, so long as the economic and legal substance of the transactions contemplated hereby are not affected in any manner materially adverse to any party, such holding or action shall be strictly construed and shall not affect the validity or effect of any

22


other provision hereof, as long as the remaining provisions, taken together, are sufficient to carry out the overall intentions of the parties as evidenced hereby.

Section 7.13Counterparts. This Agreement may be executed in counterparts (including facsimile, .pdf and electronic transmission counterparts), all of which shall be considered one and the same instrument and shall become effective when one or more counterparts have been signed by each of the parties and delivered to the other party.

Section 7.14Interpretation. When a reference is made in this Agreement to a Section, Article, Exhibit or Schedule such reference shall be to a Section, Article, Exhibit or Schedule of this Agreement unless otherwise indicated. The headings contained in this Agreement or in any Exhibit or Schedule are for convenience of reference purposes only and shall not affect in any way the meaning or interpretation of this Agreement. All words used in this Agreement will be construed to be of such gender or number as the circumstances require. All Exhibits and Schedules annexed hereto or referred to herein are hereby incorporated in and made a part of this Agreement as if set forth herein. The word “including” and words of similar import when used in this Agreement will mean “including, without limitation,” unless otherwise specified. The words “hereof,” “herein” and “hereunder” and words of similar import when used in this Agreement shall refer to the Agreement as a whole and not to any particular provision in this Agreement. The term “or” is not exclusive. The word “will” shall be construed to have the same meaning and effect as the word “shall.” References to days mean calendar days unless otherwise specified.

Section 7.15Certain Defined Terms. For purposes of this Agreement, certain terms used herein shall have the meanings set forth in Annex A.

ARTICLE VIII

TAXES

Section 8.1Tax Treatment. For U.S. federal income tax purposes, the parties hereto agree to treat the purchase of Units pursuant to this Agreement in the manner required by Situation 2 of Revenue Ruling 99-6, such that Flaskworks terminates as a partnership under Section 708(b)(1)(A) of the Code, Flaskworks is deemed to make a liquidating distribution of the assets held by Flaskworks to the Sellers and the Buyer is deemed to acquire, by purchase from the Sellers, all of the assets held by Flaskworks immediately following the deemed distribution.

Section 8.2Proration. For all purposes under this Agreement involving the determination of taxes (including the determination of taxes that imposed on, or for which Flaskworks is liable, for purposes of Section 6.2(c)), in the case of taxes that are payable with respect to any period that includes but does not end on the Closing Date, the portion of any such tax that is allocable to the portion of the period ending on the close of the Closing Date shall be (i) in the case of taxes that are (x) based upon or related to income or receipts, (y) imposed in connection with the sale or other transfer or assignment of property (real or personal, tangible or intangible) or other transaction-based taxes or (z) employment, social security or other similar taxes, deemed equal to the amount which would be payable if the taxable year ended at the close of business on the Closing Date; and (ii) in the case of taxes imposed on a periodic basis with respect to any assets, deemed to be the amount of such taxes for the entire period (or, in the case

23


of such taxes determined on an arrears basis, the amount of such taxes for the immediately preceding period) multiplied by a fraction the numerator of which is the number of calendar days in the period ending at the close of business on the Closing Date and the denominator of which is the number of calendar days in the entire period.

Section 8.3Cooperation on Tax Matters. Buyer and Seller shall cooperate, as and to the extent reasonably requested by the other party and at the requesting party’s expense, in connection with the filing of tax returns pursuant to this Agreement and any action, suit, demand or other proceeding with respect to taxes relating to the transaction pursuant to this Agreement.

Section 8.4Transfer Taxes. All Transfer Taxes payable on or in connection with the transfer of the Units to Buyer and the transactions contemplated by this Agreement shall be borne and paid fifty percent (50%) by Buyer and fifty percent (50%) by Seller when due in compliance with applicable Laws. The Party responsible under applicable Law for filing the applicable tax return with respect to such Transfer Tax shall prepare and file all necessary tax returns and other documentation required to be filed by it with respect to all Transfer Taxes, and, if required by applicable Law, the Parties will, and will cause their applicable Affiliates to, join in the execution of any such tax returns and other documentation. Seller and Buyer agree to cooperate with each other in the filing of any tax returns with respect to Transfer Taxes, including by promptly supplying any information in its possession that is reasonably necessary to complete such tax returns and other documentation.

[The remainder of this page is intentionally left blank.]

24


IN WITNESS WHEREOF, the Buyer, Flaskworks and the Sellers have caused this Agreement to be executed as of the date first written above (and with respect to the Buyer and Flaskworks, by their respective officers thereunto duly authorized).

BUYER

    

Address for Notices:

NORTHWEST BIOTHERAPEUTICS, INC.

Linda Powers, Leslie J. Goldman

4800 Montgomery Lane

Suite 800

/s/ Leslie J Goldman

Bethesda, MD 20814

Name: Leslie J Goldman

E-mail: lpow ers@nwbio.com;

Title: Senior Counsel

lgoldman@nwbio.com

With a copy to:

Brian Lane

Gibson, Dunn & Crutcher LLP

1050 Connecticut Avenue NW

Washington, DC 20036

E-mail: BLane@gibsondunn.com

FLASKWORKS

FLASKWORKS, LLC.

Address for Notices:

By:

/s/ Jennifer M Rossi

165 Waltham Street

Name:

Jennifer M Rossi, PHD

Newton, MA 02465

President & CEO

SELLER

By:

/s/ Shashi Murthy

Address for Notices:

Name: Shashi Murthy

165 Waltham Street

Newton, MA 02465

By:

/s/ Andrew Kozbial

Address for Notices:

Name: Andrew Kozbial

165 Waltham Street

Newton, MA 02465

By:

/s/ Keith L Olson

Coming Incorporated

Name: Vice President, CLS

One Riverfront Plaza Coming, NY 14831

Corning Incorporated

Attention: Corporate Secretary


ANNEX A

Certain Defined Terms

For purposes of this Agreement:

Affiliate” means, with respect to any Person, any person that, directly or indirectly, through one or more intermediaries, controls, is controlled by, or is under common control with such person.

Ancillary Agreements” means each Special Consideration Agreement, Rights Issuance Agreement, Special Expense Agreement and Installment Expense Agreement, and all other agreements, documents and instruments required to be delivered by any party pursuant to this Agreement, and any other agreements, documents or instruments entered into at or prior to Closing in connection with this Agreement or the transactions contemplated hereby.

Cash Closing Consideration” means with respect to a Person, the amount and type of consideration designated as “Cash Closing Consideration” set forth next to such Person’s name on the Closing Payment Schedule.

Cash Closing Expenses” means with respect to a Person, the amount and type of expenses designated as “Cash Closing Expenses” set forth next to such Person’s name on the Closing Payment Schedule.

Closing Payment Schedule” means the schedule attached hereto as Exhibit A (which shall form a part of this Agreement) setting forth, as of the Closing Date: (a) the name of each Seller and each recipient of Buyer-Paid Expenses; (b) for each Seller, (i) the number and class of Units held by such Person and (ii) the amount and form (i.e., cash and/or Shares) of consideration payable to such Seller, broken down into each individual component thereof and noting the manner in which each such item will be paid; and (c) for each recipient of Cash Closing Expenses, Special Expenses or Installment Expenses, the amount and form (i.e., cash and/or Shares) of consideration payable to such Person at the Closing as a component of the Purchase Price (“Buyer-Paid Expenses”), broken down into each individual component thereof and noting the manner in which each such item will be paid. The Closing Payment Schedule shall also set forth applicable procedures for payment of consideration and expenses set forth thereon, including any agreements required to be entered into in connection therewith.

Confidential Information” means all material information and data relating to Flaskworks, except for data or information that is or becomes available to the public other than as a result of a breach by any Seller of this Section, that was in the Sellers’ possession or available to the Sellers prior to receipt from Flaskworks, that is or becomes available to the Sellers on a nonconfidential basis from a source other than Flaskworks, or that is independently developed by the Sellers or others on its behalf without reference to or reliance on any Confidential Information.


control,” as used in the definition of Affiliate, means, with respect to a corporation, the right to exercise directly or indirectly, 50% or more of the voting rights attributable to the controlled corporation, and, with respect to any partnership, trust, other entity or association, the possession, directly or indirectly, of the power to direct or cause the direction of the management or policies of the controlled entity.

Employee Loans” means each of the outstanding loans made to Flaskworks by each of Shashi Murthy and Jennifer Rossi.

Environmental Law” means all Laws (including common law), statutes, regulations, rules, policy, guidance, ordinances, codes, orders, approvals and similar items, of all Governmental Authorities and all judicial and administrative and regulatory writs, injunctions, decrees, judgments and orders relating to (A) occupational health or safety; (B) the protection of public health, natural resources or the environment; (C) the treatment, storage, disposal, handling or release of Hazardous Materials or Remediation of Releases; or (D) exposure of persons to Hazardous Materials.

Environmental Liabilities” means all fees (including, but not limited to, attorneys’ and consultants’ fees), costs and expenses (including, but not limited to, costs of investigation, monitoring and cleanup), fines, penalties, judgments, settlements and liabilities, whether accrued, fixed or contingent, known or unknown, and whether or not included in a schedule to this Agreement, any of which are incurred at any time arising out of, based on or resulting from (A) the presence or Release of Hazardous Materials into the environment, on or prior to the Closing Date, upon, beneath, or from any Real Property or other location (whether or not owned or operated by the Sellers or Flaskworks at the time such Hazardous Materials were present or released) where the Sellers or Flaskworks conducted operations or generated, stored, released, sent, transported, disposed or arranged for the disposal of Hazardous Materials, (B) human exposure to Hazardous Materials or (C) any violation of Environmental Law by the Sellers on or prior to the Closing.

Equity Documents” means all agreements, arrangements and understandings governing or otherwise defining the terms of the Units as of immediately prior to the Closing, including any awards thereof, including the Flaskworks LLC Agreement.

Hazardous Materials” means any substance, material, chemical or waste that is defined, classified or regulated as a “hazardous waste,” “hazardous substance,” “toxic substance,” “pollutant” or “contaminant” under any Environmental Law, including but not limited to gasoline, diesel fuel or other petroleum hydrocarbons, polychlorinated biphenyls, asbestos, lead or urea formaldehyde foam insulation, the presence of which requires reporting, investigation, monitoring, maintenance, removal, abatement, mitigation or Remediation under any Environmental Law or which causes or threatens to cause a nuisance, trespass or other tortious condition or poses a hazard to human health and safety or the environment.

Indebtedness” means, without duplication, (i) the unpaid principal amount, accrued interest, premiums, penalties and other fees, expenses (if any), and other payment obligations and amounts due (including such amounts that would become due as a result of the

2


consummation of the transactions contemplated by this Agreement) in respect of any indebtedness for borrowed money or evidenced by notes, bonds, debentures or other similar instruments, obligations with respect to interest-rate hedging, swaps or similar financial arrangements; (ii) all obligations under capitalized leases with respect to which Flaskworks is liable; (iii) any amounts for the deferred purchase price of goods and services, including any earn out liabilities associated with past acquisitions; (iv) all deposits and monies received in advance; (v) all indebtedness created or arising under any conditional sale or other title retention agreement with respect to property acquired by any company; and (vi) all obligations of the type referred to in clauses (i) through (v) of other Persons for the payment of which Flaskworks is responsible or liable, as obligor, guarantor, surety or otherwise, including any guarantee of such obligations; provided, that Indebtedness shall not include the Specified Short-Term Debt, any Buyer-Paid Expenses or any other component of the Purchase Price.

Installment Expense Agreement” means an agreement substantially in the form attached hereto as Exhibit B, between Flaskworks and the Installment Payee with respect to the payment to the Installment Payee of expenses due as of the Closing Date.

Installment Expenses” means the amount designated as “Installment Expenses” set forth next to the Installment Payee’s name on the Closing Payment Schedule.

Installment Payee” means the Person denoted as such on the Closing Payment Schedule.

Intellectual Property” means all intellectual property rights of every kind and description throughout the world, including all U.S and non-U.S. (i) trademarks, service marks, brand names, corporate names, certification marks, collective marks, Internet domain names, trade dress, and other indicia of origin, including all registrations and applications for all of the foregoing, and all goodwill associated with all of the foregoing; (ii) patents, patent applications and invention disclosures; (iii) trade secrets, including know-how, proprietary information, inventions, discoveries and ideas, whether tangible or intangible and whether stored, compiled or memorialized physically, electronically, graphically, photographically or in writing; (iv) published and unpublished works of authorship (including software), copyrights therein and thereto, moral rights and rights of attribution, including all registrations and applications for all of the foregoing; and (v) all other intellectual property or proprietary rights, remedies and claims or causes of action arising out of or related to any infringement, misappropriation or other violation of any of the foregoing, including rights to recover for past, present and future violations thereof.

License Agreement Amendment” means an amended and restated version of that certain license agreement between Northeastern University and Flaskworks (as amended and restated prior to such time), in form and substance reasonably satisfactory to the Buyer.

Payoff Letter” means a duly executed letter in form and substance reasonably satisfactory to the Buyer, in which the payee agrees that, upon payment of the amount specified in such payoff letter, all obligations of Flaskworks arising under or related to the applicable indebtedness is repaid, discharged and extinguished in full and all Encumbrances in connection therewith shall be released.

3


Person” means any individual, corporation, partnership, trust, limited liability company, association, governmental body or agency, or other entity.

Release” means any spilling, leaking, pumping, emitting, emptying, pouring, discharging, depositing, injecting, escaping, leaching, migrating, dumping, or disposing (including the abandonment or discarding of barrels, containers or other receptacles containing Hazardous Materials) into the environment.

Remediation” means (A) any remedial action, remedy, response or removal action as those terms are defined in 42 U.S.C. § 9601, (B) any corrective action as that term has been construed pursuant to 42 U.S.C. § 6924, and (C) any measures or actions required or undertaken to investigate, assess, evaluate, monitor, or otherwise delineate the presence or Release of any Hazardous Material in or into the environment or to prevent, clean up or minimize a Release or threatened release of Hazardous Materials.

Rights Issuance Agreement” means an agreement substantially in the form attached hereto as Exhibit C, between a recipient of Stock Closing Consideration (as dictated by the Closing Payment Schedule) and the Buyer, with respect to the issuance of Stock Closing Consideration to such recipient.

Shares” means shares of common stock of the Buyer issued based upon a value equal to the trailing five-trading day volume-weighted average closing price of the Buyer’s stock on the OTCQB Venture Market on the Closing Date. Such Shares shall be unregistered securities when issued and will bear restrictive legends to that effect.

Special Consideration” means with respect to a Person, the amount and type of consideration designated as “Special Consideration” set forth next to such Person’s name on the Closing Payment Schedule.

Special Consideration Agreement” means an agreement substantially in the form attached hereto as Exhibit D, between a recipient of Special Consideration (as dictated by the Closing Payment Schedule) and the Buyer, with respect to the issuance of Special Consideration to such recipient.

Special Expense Agreement” means an agreement substantially in the form attached hereto as Exhibit E, between a recipient of Special Expenses (as dictated by the Closing Payment Schedule) and the Buyer, with respect to the issuance of Special Expenses to such recipient.

Special Expenses” means with respect to a Person, the amount and type of expenses designated as “Special Expenses” set forth next to such Person’s name on the Closing Payment Schedule.

Specified Short-Term Debt” means the Indebtedness of Flaskworks set forth on Schedule A. (For the purposes of this definition only, the proviso at the end of the definition of “Indebtedness” shall not be deemed to apply.)

4


Stimulus Legislation” means, collectively, the Families First Coronavirus Response Act, Pub. L. No. 116-127 (116th Cong.) (Mar. 18, 2020), the Coronavirus Aid, Relief, and Economic Security Act, Pub.L. 116–136 (116th Cong.) (Mar. 27, 2020), and any similar legislation enacted between March 18, 2020 (inclusive) and the Closing Date.

Stock Closing Consideration” means with respect to a Person, the amount and type of consideration designated as “Stock Closing Consideration” set forth next to such Person’s name on the Closing Payment Schedule.

Transaction Expenses” means any fees and expenses payable by Flaskworks or the Sellers in connection with the transactions contemplated by this Agreement or the Ancillary Agreements, including, without limitation, fees and expenses payable to all attorneys, accountants, financial advisors and other professionals and bankers’, brokers’ or finders’ fees for persons not engaged by the Buyer, but excluding any Buyer-Paid Expenses or any other component of the Purchase Price.

Transfer Taxes” means any U.S., state, county, local, non-U.S. and other sales, use, transfer, goods and services, value added, conveyance, documentary transfer, stamp duty, recording or other similar tax, fee or charge imposed on or in connection with the transactions contemplated by or the instruments executed under or in connection with this Agreement or the recording of any sale, transfer, or assignment or property (or any interest therein) effected pursuant to this Agreement.

5


EXHIBIT A

Closing Payment Schedule


Execution Version

Exhibit A

Closing Payment Schedule

Person

Consideration

Sellers

Shashi Murthy

Units Owned: 2,636,147 Class A-1 Units

Cash Closing Consideration:

·

$100,000 loan repayment, payable in cash at Closing

·

$50,000 loan repayment, payable in cash at Closing

$82,894.32 in deferred salary, to be paid off by Buyer (to Flaskworks for further distribution to Mr. Murthy through the Flaskworks payroll system, less applicable employee income tax withholdings)

Stock Closing Consideration: Rights issued at Closing to receive $1,945,056 in Shares issued pursuant to, and subject to the vesting criteria set forth in, a Rights Issuance Agreement entered into with effect as of the Closing

Jennifer Rossi

Units Owned: 465,203 Class B Units

Cash Closing Consideration: $15,000 loan repayment, payable in cash at Closing

$47,983.24 in deferred salary, to be paid off by Buyer (to Flaskworks for further distribution to Ms. Rossi through the Flaskworks payroll system, less applicable employee income tax withholdings)

Special Consideration: $465,203 change-of-control payment, payable in accordance with the procedures set forth below

Andrew Kozbial

Units Owned: 63,292 Class B Units

Stock Closing Consideration: Rights issued at Closing to receive $63,292 in Shares issued pursuant to, and subject to the vesting criteria set forth in, a Rights Issuance Agreement entered into with effect as of the Closing

Corning Incorporated

Units Owned: 750,000 Class A-2 Units

Cash Closing Consideration: $900,000, payable in cash at Closing

Cash Closing Expenses: $98,928, payable in cash at Closing


Person

Consideration

Non-Seller Recipients of Buyer-Paid Expenses

Northeastern University

Cash Closing Expenses: $51,895.16 patent cost reimbursement and licensing fees, payable in cash at Closing

Special Expenses: $116,652, payable in accordance with the procedures set forth below and pursuant to a Special Expense Agreement entered into with effect as of the Closing

Fikst Product Development

Cash Closing Expenses: $32,194.29, payable in cash at Closing

Brown Rudnick LLP

(“Installment Payee”)

Cash Closing Expenses: $271,220.32, payable in cash at Closing [Note: represents 75% of $361,627.10]

Installment Expenses: $90,406.78, payable in two equal cash installments of $45,203.39 on each of the 30th and 60th day following the Closing (or, if any such date is not a business day, on the business day immediately preceding such date) [Note: each installment represents 12.5% of $361,627.10]

All payments to such payee shall be made pursuant to an Installment Expense Agreement entered into with effect as of the Closing.

Procedures for Payment of Special Consideration / Special Expenses: No earlier than the 90th day, and no later than the 120th day after the Closing Date, each Person entitled to Special Consideration and/or Special Expenses as set forth above shall deliver to the Buyer a written notice executed by an authorized representative of such Person electing to receive the Special Consideration and/or Special Expenses due to it hereunder, in the form of cash, Shares or a combination thereof. Within five business days after receipt of such notice from such a Person and upon execution by such Person of (a) a Special Consideration Agreement (if and only if such Person elected to receive any Special Consideration in the form of Shares) or (b) the appropriate exhibits(s) to a Special Expense Agreement, as applicable, Buyer shall deliver or cause to be delivered to such Person the form and amount of Special Consideration and/or Special Expenses elected by such Party. Any Shares issued pursuant to such arrangement shall be unregistered securities when issued and will bear restrictive legends to that effect.

2


EXHIBIT B

Installment Expense Agreement


Graphic

MICHAEL J. COHEN

direct dial: 617.856.8296

fax: 617.289.0553

mcohen@brownrudnick.com

August 28, 2020

Flaskworks, LLC; Northwest Biotherapeutics, Inc.

RE:Acknowledgement of Obligations and Amendment to Engagement Letter

Dear Dr. Murthy and Ms. Powers:

This letter confirms your agreements regarding the obligations of (i) Flaskworks, LLC (the “Client”), and, (ii) following the closing of the transactions contemplated by that certain unit purchase agreement among Client, the current members of Client, and NWBio (as defined below) (the “Purchase Agreement”), Northwest Biotherapeutics, Inc. as the sole member of Client (“NWBio”, and together with Client, the “Payor”), jointly and severally, to pay Brown Rudnick LLP ("Firm") for legal services rendered by the Firm to the Client.

The Client acknowledges that, in accordance with the engagement letter dated as of May 13, 2016 (the "Engagement Letter"), the Firm has provided, and may continue to provide, legal and other professional services to the Client for which the Client is liable to the Firm for fees, costs, and expenses (“Legal Fees”). This letter modifies the payment obligations under the Engagement Letter.

Client agrees that as of August 28, 2020, the unpaid balance of the Legal Fees is $361,627.10 (the “Existing Balance”), which is now fully and unconditionally due and payable in cash by the Client to the Firm, without offset, defense, discount, or counterclaim of any kind, nature, or description whatsoever. The Existing Balance reflects all amounts reflected through our invoice dated August 25, 2020, does not include any time that we have worked but not yet billed or any expenses which we have incurred but not yet invoiced for reimbursement.

Concurrently with the closing of the transactions contemplated by the Purchase Agreement (the “Closing”), the Payor agrees to pay to the Firm in immediately available funds $271,220.32 towards satisfaction of the Existing Balance. Payor agrees to pay the balance of the Existing Balance in two (2) equal installments of $45,203.39, the first thereof no later than the thirtieth (30th) day following the Closing, an amount equal to , and the second thereof no later than the sixtieth (60th) day following the Closing, in each case in immediately available funds. Payor further agrees to pay any Legal Fees in excess of the Existing Balance (whether incurred prior to August 28, 2020 or thereafter) within thirty (30) days of the rendering of an invoice therefor.

Graphic


Graphic

Dr. Murthy and Ms. Powers

August 28, 2020

Page 2

In the event that the Payor shall fail to timely satisfy any of its obligations hereunder or under the Engagement Letter (as modified hereby), then, without limitation of any other rights of the Firm: (a) the Firm shall have the right in its sole and absolute discretion to terminate its engagement as legal counsel to the Client (and NWBio, to the extent applicable), and (b) the entire unpaid amount of the Legal Fees (including without limitation the Existing Balance) shall thereupon and without further notice be accelerated and become automatically due and payable in full and in immediately available funds. Interest shall accrue thereafter on any and all amounts owed to the Firm at the rate of twelve percent (12.0%) per annum, which shall be due and payable upon demand. Nothing in this letter shall impair any lien or other rights the Firm may have with respect to the assets or properties of the Client, all of which are expressly preserved.

This letter represents the entire agreement and understanding concerning the subject matter hereof between the parties hereto, and supersedes all other prior agreements, understandings, negotiations and discussions regarding such subject matter.

Each of Client and NWBio agree that, notwithstanding that the Firm provides legal representation to the Client in other matters, the Firm has not provided legal representation to Client or NWBio in connection with the preparation of this letter. Each of the Client and NWBio acknowledges that the Firm as advised the Client and NWBio to, and the Client and NWBio has had a reasonable opportunity to, seek the advice of independent legal counsel in connection with this letter.

[Remainder of page intentionally left blank.]


Graphic

Dr. Murthy and Ms. Powers

August 28, 2020

Page 3

To confirm your agreement to the terms of this letter and the agreements contained herein, please return a countersigned copy of this letter to me.

   

BROWN RUDNICK LLP

By:

Michael J. Cohen, Partner

CLIENT:

FLASKWORKS, LLC

By:

Name:

Title:

NWBIO:

NORTHWEST BIOTHERAPEUTICS, INC.

By:

Name:

Title:


EXHIBIT C

Rights Issuance Agreement


THE SHARES OF COMMON STOCK AWARDED PURSUANT TO THIS AGREEMENT WILL NOT BE REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED, OR ANY STATE SECURITIES LAWS AND MAY NOT BE OFFERED OR SOLD UNLESS REGISTERED THEREUNDER OR UNLESS AN EXEMPTION FROM SUCH REGISTRATION IS AVAILABLE. TRANSFER OF SUCH SHARES IS ALSO RESTRICTED BY THE TERMS OF THIS AGREEMENT.

NORTHWEST BIOTHERAPEUTICS, INC.

RIGHTS ISSUANCE AGREEMENT

THIS AGREEMENT (this “Agreement”) is entered into as of August 28, 2020 (the “Closing Date”), between Northwest Biotherapeutics, Inc., a Delaware corporation (the “Company”), and the undersigned recipient (“Recipient”).

WHEREAS, pursuant to that certain Unit Purchase Agreement, dated as of August 28, 2020 (the “Purchase Agreement”), among the Company and each of the other Persons set forth on the signature pages thereto, Recipient will receive the right to receive, subject to the vesting conditions set forth herein, the number of shares of the Company’s Common Stock, par value $0.001 per share (“Common Stock”), set forth across from such party’s name on Exhibit A hereto (such shares, the “Shares”). Capitalized terms used but not otherwise defined herein will have the meanings set forth in the Purchase Agreement

NOW, THEREFORE, it is agreed as follows:

1.Grant of Rights. The Company hereby grants to Recipient as of the Closing Date the right to receive [•] shares of Common Stock, which shall vest and be issued in accordance with the terms and conditions of this Agreement (such rights, the “Rights”). Recipient irrevocably agrees on behalf of Recipient and Recipient’s successors and permitted assigns to all of the terms and conditions of the award as set forth in or pursuant to this Agreement.

2.

Vesting; Settlement; Termination.

(a)Subject to the other conditions set forth in this Agreement, the Rights shall become vested as follows:

(i)Twenty-five percent (25%) of the Rights shall vest upon completion of all of the following:

(A)delivery to the Company by Recipient of a document listing all technical and regulatory requirements for the deployment of the EDEN system to manufacture DCVax-L, together with a detailed timeline;

(B)the initiation of EDEN system consumable sourcing from Saint Gobain or an equivalent supplier, via issued purchase order;


(C)the technology transfer of all relevant Company manufacturing protocols for DCVax-L to Flaskworks’ Boston site;

(D)

readiness of the EDEN prototype for testing at Advent

Bioservices; and

(E)

a period of ninety (90) days after the Closing.

(ii)Twenty-five percent (25%) of the Rights shall vest upon the demonstration to the Company’s reasonable satisfaction that the EDEN system can replicate the Company’s current DCVax-L manufacturing process as verified by yield, phenotype and functional assay data.

(iii)Twenty-five percent (25%) of the Rights shall vest upon the completion to the Company’s reasonable satisfaction of comparability studies that demonstrate equivalence between EDEN and the Company’s current process for DCVax-L, and equivalence of the DCVax-L products manufactured through EDEN and those manufactured through the Company’s current process. For purposes of this Agreement, “Completion” shall mean that all applicable data is available and prepared in a consolidated format sufficient for submission to regulatory agencies in the UK, US, Canada and EU.

(iv)Twenty-five percent (25%) of the Rights shall vest upon approval by the regulator in the US or EU of the comparability of the EDEN process and the Company’s current processes, and the comparability of DCVax-L products manufactured through EDEN and those manufactured through the Company’s current processes, for commercial use.

(b)Notwithstanding anything herein to the contrary, all Rights, whether or not vested in accordance with the vesting schedule set forth in Section 2(a) above shall vest, in each case, provided that the Recipient remains employed by the Company or its affiliate and the Recipient (in Recipient’s capacity as an employee of the Company or its affiliate) have not abandoned work on the EDEN system prior to such time:

(i)as of immediately prior to the consummation of a Change in Control of the Company (as defined in the Company’s Second Amended and Restated 2007 Stock Plan);

(ii)upon Recipient’s termination without Cause from employment (“Employment”) by the Company or its applicable affiliate; and/or

(iii)

in the event of Recipient’s death.

(c)The Rights that have vested are referred to herein as “Vested Rights.” The Rights that have not vested are referred to herein as “Unvested Rights.”

(d)Vested Rights shall be settled by the delivery to Recipient or a designated brokerage firm of one share of Common Stock (subject to equitable adjustment for any stock splits or similar transaction as of such date) per Vested Right within 30 days following the vesting of such Rights; provided that Recipient has satisfied all of the tax withholding

2


obligations described in Section 7 below, and that Recipient has completed, signed and returned any documents and taken any additional action that the Company deems appropriate to enable it to accomplish the delivery of the shares of Common Stock. For the avoidance of doubt, each payment hereunder shall be treated as a separate payment for purposes of Section 409A of the Internal Revenue Code of 1986, as amended.

(e)Notwithstanding anything contained in this Agreement to the contrary, upon Recipient’s termination of Employment for any reason (excluding Recipient’s death or termination without Cause by the Company or its applicable affiliate), any then Unvested Rights held by Recipient shall be forfeited and canceled as of the date of such termination (the “Termination Date”). Further, upon Recipient’s termination of Employment for Cause, any then Vested Rights not yet settled and any shares of Common Stock previously issued in respect of Vested Rights held by Recipient shall be forfeited and canceled as of the Termination Date.

(f)

For purposes of this agreement, “Cause” shall mean any of the following:

(i)Recipient has been convicted of (or has entered a plea of nolo contendere to) any felony or a misdemeanor involving moral turpitude;

(ii)Recipient failed to substantially perform Recipient’s material duties, which failure lasted for a period of at least fifteen (15) days after delivery to Recipient of a written notice of such failure;

(iii)Recipient’s fraud, embezzlement or other act of material dishonesty with respect to the Company or any of its affiliates; or

(iv)Recipient’s material breach of this Agreement or any other agreement between Recipient and the Company or any affiliate; provided that Recipient has been given written notice of any such alleged breach and an opportunity to cure such breach within fifteen (15) days after Recipient’s receipt of such notice.

3.

Representations. Recipient represents to the Company the following:

(a)Recipient is familiar with the Company’s business affairs and financial condition and has acquired sufficient information about the Company to reach an informed and knowledgeable decision to acquire the Common Stock underlying the Rights. Recipient is acquiring the Common Stock issuable hereunder for investment for his or her own account only and not with a view to, or for resale in connection with, any “distribution” thereof within the meaning of the Securities Act.

(b)Recipient understands that the shares of Common Stock issuable hereunder have not been registered under the Securities Act by reason of a specific exemption therefrom, which exemption depends upon, among other things, the bona fide nature of Recipient’s investment intent as expressed herein.

(c)Recipient understands that, in addition to the restrictions set forth in this Agreement, the shares of Common Stock issuable hereunder are “restricted securities” under applicable U.S. federal and state securities laws and that, pursuant to these laws, Recipient must

3


hold such shares indefinitely unless they are registered with the Securities and Exchange Commission and qualified by state authorities, or an exemption from such registration and qualification requirements is available. Recipient acknowledges that the Company has no obligation to register or qualify the shares of Common Stock issuable hereunder for resale. Recipient further acknowledges that if an exemption from registration or qualification is available, it may be conditioned on various requirements including, but not limited to, the time and manner of sale, the holding period for the shares of Common Stock issuable hereunder, and requirements relating to the Company which are outside of Recipient’s control, and which the Company is under no obligation and may not be able to satisfy.

(d)Recipient understands that Recipient may suffer adverse tax consequences as a result of Recipient’s acquisition, holding or disposition of the Rights and/or the shares of Common Stock issuable hereunder. Recipient represents that Recipient has consulted any tax consultants Recipient deems advisable in connection with the acquisition, holding and disposition of the Rights and the shares of Common Stock issuable hereunder (or has knowingly chosen not to consult a tax advisor) and that Recipient is not relying on the Company or its employees, officers, directors, attorneys or accountants for any tax advice.

(e)

[Accredited Investor Version: Financial Status.

(i)Recipient is an Accredited Investor (as defined in Rule 501(a)(3), (4), (5), (6), (7) or (8) of Regulation D promulgated under the Securities Act) because, (A) Recipient’s individual net worth or joint net worth with Recipient’s spouse at the time of the execution of this Agreement is in excess of $1,000,000, (B) Recipient had an individual income in excess of $200,000 in each of the two (2) most recent years or joint income with Recipient’s spouse in excess of $300,000 in each of those years and has a reasonable expectation of reaching the same income level in the current year or (C) Recipient is an executive officer or director of the Company or its subsidiaries.

(ii)Recipient is able to bear the economic risk of an investment in the Common Stock for an indefinite period of time, has adequate means of providing for his or her current financial needs and personal contingencies, has no need for liquidity in the investment in the Common Stock, understands that Recipient may not be able to liquidate his or her investment in the Company in an emergency, if at all, and can afford a complete loss of the investment.

(iii)Recipient has delivered to the Company an executed Confidential Investment Qualification Questionnaire in the form(s) attached hereto as Exhibit B. The information contained therein is complete and accurate in all material respects.]

(f)

[Alternative Version: Purchaser Representative; Sophistication; Financial

Status.

(i)Representative. Recipient hereby acknowledges and consents to the appointment of Shashi Murthy to act as Recipient’s “purchaser representative” in connection with evaluating the merits and risks of the issuance of Rights (and underlying Shares) hereunder (the “Representative”). Recipient has received from Shashi Murthy a letter describing any

4


material relationship between he and the Company and its affiliates, which has existed during the last two years or is contemplated to exist in the future.

(ii)Representative is an Accredited Investor (as defined in Rule 501(a)(3), (4), (5), (6), (7) or (8) of Regulation D promulgated under the Securities Act) because, (A) Representative’s individual net worth or joint net worth with Representative’s spouse at the time of the execution of this Agreement is in excess of $1,000,000, (B) Representative had an individual income in excess of $200,000 in each of the two (2) most recent years or joint income with Representative’s spouse in excess of $300,000 in each of those years and has a reasonable expectation of reaching the same income level in the current year or (C) Representative is an executive officer or director of the Company or its subsidiaries.

(iii)Representative has delivered to the Company an executed Confidential Investment Qualification Questionnaire in the form(s) attached hereto as Exhibit B. The information contained therein is complete and accurate in all material respects.

(iv)Recipient is able to bear the economic risk of an investment in the Common Stock for an indefinite period of time, has adequate means of providing for his or her current financial needs and personal contingencies, has no need for liquidity in the investment in the Common Stock, understands that Recipient may not be able to liquidate his or her investment in the Company in an emergency, if at all, and can afford a complete loss of the investment.

(v)Recipient has such knowledge and experience in financial and business matters that Recipient: (i) is capable of evaluating the merits and risks of the transactions contemplated by the issuance of the Rights (and underlying Shares) hereunder; or (ii)if Recipient does not have the knowledge and experience described in the preceding clause (i), Recipient has relied upon and believes that Representative has such knowledge and experience.]

4.Rights as a Stockholder. Subject to the provisions of this Agreement, Recipient shall not have voting rights or dividend rights with respect to shares of Common Stock underlying the Rights unless and until such shares of Common Stock are reflected as issued and outstanding shares on the Company’s stock ledger.

5.Certification. To the extent the Company determines to certificate the shares of Common Stock issued hereunder, such shares, to the extent applicable, shall be subject to the following provisions, and Recipient covenants and agrees to Recipient’s obligations set forth in this Section 5.

(a)In addition to other legends that may be required by applicable law or as deemed appropriate by the Company, all certificates issued hereunder shall be endorsed the following legends:

THE SECURITIES REPRESENTED BY THIS CERTIFICATE HAVE NOT BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE “ACT”), OR THE SECURITIES LAWS OF ANY JURISDICTION. SUCH SECURITIES MAY NOT BE OFFERED, SOLD, TRANSFERRED, PLEDGED, ASSIGNED, ENCUMBERED,

5


HYPOTHECATED OR OTHERWISE DISPOSED OF EXCEPT (I) PURSUANT TO A REGISTRATION STATEMENT WITH RESPECT TO SUCH SECURITIES THAT IS EFFECTIVE UNDER THE ACT OR APPLICABLE STATE SECURITIES LAW OR (II) IN A TRANSACTION THAT DOES NOT REQUIRE REGISTRATION UNDER THE ACT OR APPLICABLE STATE SECURITIES LAW, INCLUDING PURSUANT TO RULE 144 OR RULE 144A, PROVIDED THAT, EXCEPT IN THE CASE OF ANY TRANSACTION EXEMPT FROM REGISTRATION REQUIREMENT OF THE ACT PURSUANT TO RULE 144 OR RULE 144A, AN OPINION OF COUNSEL SHALL BE FURNISHED TO THE ISSUER (IF REQUESTED BY THE ISSUER) IN FORM AND SUBSTANCE REASONABLY SATISFACTORY TO THE ISSUER, TO THE EFFECT THAT SUCH TRANSACTION DOES NOT REQUIRE REGISTRATION UNDER THE ACT AND/OR APPLICABLE STATE SECURITIES LAW.

6.No Guarantee of Continued Employment or other Service Rights. Nothing in this Agreement shall confer upon or grant any greater right to Recipient to continue to serve the Company or any of its affiliates in the capacity in effect at the time of this Agreement, nor shall this Agreement affect the rights of the Company or any of its affiliates to terminate, where applicable (i) the employment of Recipient for any reason, or no reason, with or without cause and with or without notice, (ii) the employment of Recipient pursuant to the terms of such Recipient’s employment or other service agreement(s) with the Company or any of its affiliates, (iii) the service as a consultant of Recipient pursuant to the terms of such Recipient’s consulting agreement with the Company or any of its affiliates, or (iv) the service of Recipient as a director or manager of the Company or any of its affiliates, as the case may be, and any provisions of applicable law.

7.

Withholding Obligations.

(a)At any time requested by the Company, Recipient hereby authorizes withholding from payroll and any other amounts payable to Recipient, and otherwise agrees to pay to the Company any sums required to satisfy the federal, state, local and foreign tax withholding obligations of the Company or any of its subsidiaries, if any, which arise in connection with the Rights and/or the issuance of any shares of Common Stock hereunder. Promptly upon request from the Company, Recipient shall demonstrate to the reasonable satisfaction of the Company that Recipient has paid all taxes incurred in connection with the award, vesting or settlement of the Rights.

(b)Unless the tax withholding obligations of the Company and/or any subsidiary are satisfied, the Company shall have no obligation to issue any shares of Common Stock in respect of the Rights or release such shares from any escrow provided for herein.

(c)Notwithstanding anything to the contrary in this Agreement, Recipient may be permitted, in the sole discretion of the Company, to pay the statutory minimum withholding tax obligation incurred by reason of the vesting, settlement or transfer of any Rights by delivery of a

6


properly executed notice instructing the Company to withhold shares of Common Stock otherwise deliverable to Recipient hereunder having an aggregate fair market value (as determined by the Company in its sole discretion) on the date the obligation arises equal to the amount required to be withheld. ALTHOUGH IT IS CONTEMPLATED THAT RECIPIENT MAY BE PERMITTED TO USE THE WITHHOLDING OF SHARES TO SATISFY RECIPIENT’S TAX OBLIGATIONS, THERE IS NO ASSURANCE THAT THE COMPANY WILL BE IN A POSITION TO ALLOW RECIPIENT TO USE THIS OPTION AT THE TIME A TAX OBLIGATION ARISES.

8.

Miscellaneous.

(a)The Company may impose such restrictions, conditions or limitations as it determines appropriate as to the timing and manner of any resales by Recipient or other subsequent transfers by Recipient of any shares issued as a result of or under this Agreement, including without limitation (i) restrictions under an insider trading policy, (ii) restrictions that may be necessary in the absence of an effective registration statement under the Securities Act, covering the shares of Common Stock issued hereunder and (iii) restrictions as to the use of a specified brokerage firm or other agent for such resales or other transfers. Any sale of the shares of Common Stock issued hereunder must also comply with other applicable laws and regulations governing the sale of such shares.

(b)From time to time, the parties will execute and deliver, or cause to be executed and delivered, such documents and instruments as may be reasonably necessary to consummate the transactions contemplated by this Agreement.

(c)This Agreement and the Purchase Agreement constitute the entire agreement, and supersede all prior written agreements, arrangements and understandings and all prior and contemporaneous oral agreements, arrangements and understandings between the parties with respect to the subject matter of this Agreement.

(d)This Agreement and all disputes or controversies arising out of or relating to this Agreement shall be governed by, and construed in accordance with, the internal laws of the State of Delaware, without regard to the laws of any other jurisdiction that might be applied because of the conflicts of laws principles of the State of Delaware.

(e)This Agreement may be executed in counterparts (including facsimile, .pdf and electronic transmission counterparts), all of which shall be considered one and the same instrument and shall become effective when one or more counterparts have been signed by each of the parties and delivered to the other party.

(f)This Agreement may not be amended, modified or supplemented in any manner, whether by course of conduct or otherwise, except by an instrument in writing specifically designated as an amendment hereto, signed on behalf of each party.

(g)All notices and other communications hereunder shall be in writing and shall be deemed duly given if delivered personally or sent by e mail, overnight courier or registered or certified mail, postage prepaid, to the address set forth on the signature pages hereto opposite the

7


party to receive such notice, or to such other address as may be designated in writing by such party.

[Signature page follows]

8


IN WITNESS WHEREOF, each of the parties hereto has executed this Agreement, in the case of the Company by its duly authorized officer, as of the date first above written.

COMPANY

Address for Notices:

NORTHWEST BIOTHERAPEUTICS, INC.

4800 Montgomery Lane

Suite 800

Bethesda, MD 20814

E-mail: []

By:

Name:

Title:

RECIPIENT

Address for Notices:

By:

[]

Name:

[]

Title:

E-mail: []


[Signature Page to Rights Issuance Agreement]


EXHIBIT A

Name:

Number of Shares underlying the Rights

[Shashi Murthy][Andrew Kozbial]

[]


EXHIBIT B

CERTIFICATION OF STATUS AS AN ACCREDITED INVESTOR

(Print or Type Recipient’s Name)


Reference is made to the Rights Issuance Agreement (the “Agreement”), dated as of even date herewith, by and between Northwest Biotherapeutics, Inc. (the “Company”) and the undersigned (“Undersigned”). Capitalized terms not otherwise defined herein shall have the same meanings specified in the Agreement. The Undersigned hereby certifies, pursuant to the Agreement, that:

1.Regulation D Matters

Undersigned is an “Accredited Investor” as that such term is defined in Rule 501(a) of Regulation D promulgated under the Securities Act, unless Item VII below is marked with an “X” or similar check mark. Undersigned meets each of the following “Accredited Investor” categories marked with an “X” or similar check mark:

i.

an organization described in Section 501(c)(3) of the Internal Revenue Code of 1986, as amended (the “Code”), corporation, Massachusetts or similar business trust, or partnership not formed for the specific purpose of acquiring the Common Stock offered, with total assets in excess of $5,000,000;

ii.

a director, executive officer, or general partner of the issuer of the securities being offered or sold;

iii.

a natural person whose individual net worth, or joint net worth with his or her spouse, at the time of his or her purchase exceeds $1,000,000;1


1    In calculating “individual net worth” or “joint net worth” for purposes of this item, the Recipient must exclude the value of his, her or its primary residence. The related amount of indebtedness secured by the primary residence up to its fair market value may also be excluded from the calculation, but any indebtedness secured by the residence in excess of such fair market value must be treated as a liability and deducted from the Recipient’s net worth. Even if such fair market value exceeds the aggregate amount of indebtedness secured by the Recipient’s primary residence, any increase in the amount of such indebtedness incurred within 60 days before the Recipient enters into this Subscription Agreement must be treated as a liability and deducted from the Recipient’s net worth.


iv.

a natural person who had an individual income in excess of $200,000 in each of the two most recent years or joint income2 with that person’s spouse in excess of $300,000 in each of those years and has a reasonable expectation of reaching the same income level in the current year;

v.

a trust, with total assets in excess of $5,000,000, not formed for the specific purpose of acquiring the Common Stock offered, whose purchase is directed by a sophisticated person as described in Rule 506(b)(2)(ii) of Regulation D;

vi.

an entity in which all of the equity owners are Accredited Investors; or

vii.

none of the above (Undersigned is not an Accredited Investor).

IN WITNESS WHEREOF, the Undersigned has executed this Certificate on the date set forth below.

Dated:

, 2020

Name:


2    For purposes of this item, “joint income” means adjusted gross income as reported for U.S. Federal income tax purposes, including any income attributable to a spouse or to property owned by a spouse, increased by the following amounts (including any amounts attributable to a spouse or to property owned by a spouse): (i) the amount of any interest income received which is tax-exempt under Section 103 of the Code, (ii) the amount of losses claimed as a limited partner in a limited partnership (as reported on Schedule E of Form 1040), (iii) any deduction claimed for depletion under Section 611 et seq. of the Code, and (iv) any amount by which income from long-term capital gains has been reduced in arriving at adjusted gross income pursuant to the provisions of Section 1202 of the Code prior to its repeal by the Tax Reform Act of 1986.


EXHIBIT D

Special Consideration Agreement


SPECIAL CONSIDERATION AGREEMENT

THIS SPECIAL CONSIDERATION AGREEMENT (this “Agreement”), dated as of [•], 2020, is entered into between Northwest Biotherapeutics, Inc., a Delaware corporation (the “Company”), and the undersigned recipient (“Recipient”).

WHEREAS, pursuant to that certain Unit Purchase Agreement, dated as of August 28, 2020 (the “Purchase Agreement”), among the Company and each of the other Persons set forth on the signature pages thereto, the Recipient has elected to receive the number of shares of the Company’s Common Stock, par value $0.001 per share (“Common Stock”), set forth in Section 1.1 below (such shares, the “Shares”). Capitalized terms used but not otherwise defined herein will have the meanings set forth in the Purchase Agreement.

NOW, THEREFORE, it is agreed as follows:

ARTICLE I

DELIVERY OF SECURITIES

1.1 Issuance of Shares. Subject to the terms and conditions set forth herein and in reliance on the representations and warranties of the parties contained herein, the Company hereby agrees to deliver to Recipient [•] shares of Common Stock. The Company shall deliver to Recipient the shares and appropriate evidence of issuance of the Shares. Each Share so delivered shall be registered on the books and records of the Company in the name of Recipient.

ARTICLE II

REPRESENTATIONS AND WARRANTIES OF THE COMPANY

The Company hereby represents and warrants to Recipient as follows:

2.1Organization and Authority. The Company is a corporation duly organized, validly existing and in good standing under the laws of Delaware.

2.2Authorization. The Company has full corporate power and authority to execute, deliver and perform its obligations under this Agreement and to deliver the Shares to the Recipient. This Agreement has been duly executed and delivered by the Company and, assuming due authorization, execution and delivery by the Recipient, is legal, valid, binding and enforceable upon and against the Company (except as enforcement may be limited by applicable bankruptcy, insolvency, reorganization, moratorium or similar laws affecting creditors’ rights generally and by general principles of equity).

2.3Validity of Securities. The Shares to be issued pursuant to this Agreement have been duly and validly issued.


ARTICLE III

REPRESENTATIONS AND WARRANTIES OF RECIPIENT

Recipient hereby represents and warrants to the Company as follows:

3.1

Investment Intent and Eligibility.

(a)Recipient is an “accredited investor” within the meaning of Rule 501(a) under Regulation D promulgated under the Securities Act of 1933, as amended (the “Securities Act”), and the certifications made by Recipient in Appendix I in connection with this subscription are true and complete.

(b)Recipient has such knowledge and experience in financial and business matters as to be capable of evaluating the merits and risks of his, her or its prospective investment and is able, without materially impairing his financial condition, to hold the Shares for an indefinite period of time and to suffer a complete loss on such investment.

(c)Recipient has prior investment experience, or will rely upon his, her, or its financial advisor in connection with evaluating his, her or its decision to invest in the Shares.

(d)Recipient is acquiring the Shares for its own account, for investment and not with a view towards resale or distribution.

(e)Recipient has not been convicted, within the last ten years, of any felony or misdemeanor, and is not subject to any order, judgment or decree of any court, or subject to any order of any of the US Securities and Exchange Commission (the “SEC”), the Financial Industry Regulatory Authority, the U.S. Postal Service, a stock exchange or a state regulator, in each case entered within the last five years, that restrains or enjoins Recipient from engaging or continuing to engage in any conduct or practice: (i) in connection with the purchase or sale of any security; (ii) involving the making of any false filing with the SEC; or (iii) arising out of the conduct of the business of an underwriter, broker, dealer, municipal securities dealer, investment adviser or paid solicitor of purchasers of securities or from engaging in the business of securities, insurance or banking.

3.2Delivery of Information; Material Changes. Any information which Recipient has furnished to the Company with respect to Recipient’s financial position and business experience is correct and complete as of the date hereof. Recipient promptly notified the Company of any material changes in any of the representations or warranties set forth in this Agreement (including in Appendix 1) prior to the date hereof.

3.3

Receipt of Information; No Representations or Warranties.

(a)Recipient has carefully evaluated the risks involved in investing in the Shares. Recipient has been afforded the opportunity to ask such questions as he, she or it has deemed necessary of, and to receive answers from, representatives of the Company concerning the terms and conditions of the offering of the Shares and the merits and risks of acquiring the Shares. Recipient has received information about the Company and the Shares requested by or on behalf


of Recipient and has reviewed such information to the satisfaction of Recipient as Recipient has deemed appropriate in making an investment decision with respect to the Shares.

(b)Recipient acknowledges that, except as expressly provided herein, it is acquiring the Shares without any representation or warranty, express or implied, at law or in equity, by the Company, any of the other direct or indirect owners of the Company, or any of their respective officers, directors, employees, affiliates or advisors.

3.4Reliance. Recipient understands that the Company is relying upon its representations and warranties herein in determining whether Recipient is suitable as a recipient of the Shares, whether the Shares may be issued to Recipient without first registering the Shares under the Securities Act and all applicable state securities laws.

3.5Acknowledgement of Risk. Recipient acknowledges that an investment in the Company includes a high degree of risk and that Recipient could lose his, her or its entire investment. Recipient acknowledges that the Company has no current plans to file a registration statement to register the Shares with the SEC and that the Company has no obligation to Recipient to register such Shares in the future.

ARTICLE IV

MISCELLANEOUS

4.1

Transfer Restrictions. Recipient acknowledges and agrees that:

(a)the offering and sale of the Shares is intended to be exempt from registration under the Securities Act, by virtue of the provisions of either Section 4(2) of the Securities Act or Rule 506 of Regulation D promulgated under the Securities Act by the SEC;

(b)none of the Shares have been registered under the Securities Act or any securities or “Blue Sky” laws of any state;

(c)none of the Shares may be offered, sold, transferred, pledged, hypothecated or otherwise assigned unless such Shares are registered under the Securities Act or any securities or “Blue Sky” laws of any state or an exemption from such registration is available; and

(d)certificate(s), if any, representing the Shares and each such certificate issued to any subsequent transferee of the Shares shall bear a conspicuous legend in substantially the following form (unless transferred in the manner described in the following legend):

THE SECURITIES REPRESENTED BY THIS CERTIFICATE HAVE NOT BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE “ACT”), OR THE SECURITIES LAWS OF ANY JURISDICTION. SUCH SECURITIES MAY NOT BE OFFERED, SOLD, TRANSFERRED, PLEDGED, ASSIGNED,ENCUMBERED, HYPOTHECATED OR OTHERWISE DISPOSED OF EXCEPT (I) PURSUANT TO A REGISTRATION STATEMENT WITH RESPECT TO SUCH SECURITIES THAT IS EFFECTIVE UNDER THE ACT OR APPLICABLE


STATE SECURITIES LAW OR (II) IN A TRANSACTION THAT DOES NOT REQUIRE REGISTRATION UNDER THE ACT OR APPLICABLE STATE SECURITIES LAW, INCLUDING PURSUANT TO RULE 144 OR RULE 144A, PROVIDED THAT, EXCEPT IN THE CASE OF ANY TRANSACTION EXEMPT FROM REGISTRATION REQUIREMENT OF THE ACT PURSUANT TO RULE 144 OR RULE 144A, AN OPINION OF COUNSEL SHALL BE FURNISHED TO THE ISSUER (IF REQUESTED BY THE ISSUER) IN FORM AND SUBSTANCE REASONABLY SATISFACTORY TO THE ISSUER, TO THE EFFECT THAT SUCH TRANSACTION DOES NOT REQUIRE REGISTRATION UNDER THE ACT AND/OR APPLICABLE STATE SECURITIES LAW.

4.2Further Assurances. From time to time, the parties will execute and deliver, or cause to be executed and delivered, such documents and instruments as may be reasonably necessary to consummate the transactions contemplated by this Agreement.

4.3Entire Agreement. This Agreement and the Purchase Agreement constitute the entire agreement, and supersedes all prior written agreements, arrangements and understandings and all prior and contemporaneous oral agreements, arrangements and understandings between the parties with respect to the subject matter of this Agreement.

4.4Amendment and Modification. This Agreement may not be amended, modified or supplemented in any manner, whether by course of conduct or otherwise, except by an instrument in writing specifically designated as an amendment hereto, signed on behalf of each party.

4.5Governing Law. This Agreement and all disputes or controversies arising out of or relating to this Agreement shall be governed by, and construed in accordance with, the internal laws of the State of Delaware, without regard to the laws of any other jurisdiction that might be applied because of the conflicts of laws principles of the State of Delaware.

4.6Notices. All notices and other communications hereunder shall be in writing and shall be deemed duly given if delivered personally or sent by e mail, overnight courier or registered or certified mail, postage prepaid, to the address set forth on the signature pages hereto opposite the party to receive such notice, or to such other address as may be designated in writing by such party.

4.7Counterparts. This Agreement may be executed in counterparts (including facsimile, .pdf and electronic transmission counterparts), all of which shall be considered one and the same instrument and shall become effective when one or more counterparts have been signed by each of the parties and delivered to the other party.

[Signature Page Follows]


IN WITNESS WHEREOF, the parties hereto have executed this Agreement as of the date first written above.

COMPANY

   

Address for Notices:

NORTHWEST BIOTHERAPEUTICS, INC.

4800 Montgomery Lane

Suite 800

Bethesda, MD 20814

By:

E-mail: []

Name:

Title:

RECIPIENT

Address for Notices:

By:

[]

Name:

[]

Title:

E-mail: []


[Signature Page to Special Consideration Agreement]


APPENDIX I

CERTIFICATION OF STATUS AS AN ACCREDITED INVESTOR

(Print or Type Recipient’s Name)


Reference is made to the Special Consideration Agreement (the “Agreement”), dated as of even date herewith, by and between Northwest Biotherapeutics, Inc. (the “Company”) and the undersigned (“Undersigned”). Capitalized terms not otherwise defined herein shall have the same meanings specified in the Agreement. The Undersigned hereby certifies, pursuant to the Agreement, that:

1.Regulation D Matters

Undersigned is an “Accredited Investor” as that such term is defined in Rule 501(a) of Regulation D promulgated under the Securities Act, unless Item VII below is marked with an “X” or similar check mark. Undersigned meets each of the following “Accredited Investor” categories marked with an “X” or similar check mark:

i.

an organization described in Section 501(c)(3) of the Internal Revenue Code of 1986, as amended (the “Code”), corporation, Massachusetts or similar business trust, or partnership not formed for the specific purpose of acquiring the Common Stock offered, with total assets in excess of $5,000,000;

ii.

a director, executive officer, or general partner of the issuer of the securities being offered or sold;

iii.

a natural person whose individual net worth, or joint net worth with his or her spouse, at the time of his or her purchase exceeds $1,000,000;1


1     In calculating “individual net worth” or “joint net worth” for purposes of this item, the Recipient must exclude the value of his, her or its primary residence. The related amount of indebtedness secured by the primary residence up to its fair market value may also be excluded from the calculation, but any indebtedness secured by the residence in excess of such fair market value must be treated as a liability and deducted from the Recipient’s net worth. Even if such fair market value exceeds the aggregate amount of indebtedness secured by the Recipient’s primary residence, any increase in the amount of such indebtedness incurred within 60 days before the Recipient enters into this Subscription Agreement must be treated as a liability and deducted from the Recipient’s net worth.


iv.

a natural person who had an individual income in excess of $200,000 in each of the two most recent years or joint income2 with that person’s spouse in excess of $300,000 in each of those years and has a reasonable expectation of reaching the same income level in the current year;

v.

a trust, with total assets in excess of $5,000,000, not formed for the specific purpose of acquiring the Common Stock offered, whose purchase is directed by a sophisticated person as described in Rule 506(b)(2)(ii) of Regulation D;

vi.

an entity in which all of the equity owners are Accredited Investors; or

vii.

none of the above (Undersigned is not an Accredited Investor).

IN WITNESS WHEREOF, the Undersigned has executed this Certificate on the date set forth below.

Dated:

, 2020

Name:


2     For purposes of this item, “joint income” means adjusted gross income as reported for U.S. Federal income tax purposes, including any income attributable to a spouse or to property owned by a spouse, increased by the following amounts (including any amounts attributable to a spouse or to property owned by a spouse): (i) the amount of any interest income received which is tax-exempt under Section 103 of the Code, (ii) the amount of losses claimed as a limited partner in a limited partnership (as reported on Schedule E of Form 1040), (iii) any deduction claimed for depletion under Section 611 et seq. of the Code, and (iv) any amount by which income from long-term capital gains has been reduced in arriving at adjusted gross income pursuant to the provisions of Section 1202 of the Code prior to its repeal by the Tax Reform Act of 1986.


EXHIBIT E

Special Expense Agreement

2


SPECIAL EXPENSE AGREEMENT

This Special Expense Agreement (this “Agreement”) is made and entered into as of August 28, 2020, by and among Corning Incorporated, a New York corporation (“Payee”), Flaskworks, LLC, a Massachusetts limited liability company (the “Company”), and Northwest Biotherapeutics, Inc., a Delaware corporation (“Buyer”).

WHEREAS, Buyer, the Company and Payee are parties to that certain Unit Purchase Agreement dated as of the date hereof by and among Buyer, the Company and each of the other persons and entities set forth on the signature pages thereto (the “Purchase Agreement”); and

WHEREAS, the Purchase Agreement requires the payoff of the $98,928.00 in expenses (the “Expenses”) owed to Payee by the Company and contemplates that such payoff will be evidenced by the delivery of this Agreement at the Closing (as defined in the Purchase Agreement) and the payment to Payee at such time of the Expenses by Buyer in cash.

AGREEMENT

NOW, THEREFORE, in consideration of their mutual covenants contained herein, the receipt and efficiency of which are hereby acknowledged, the Parties hereto (the “Parties” and each individually, a “Party”) agree as follows:

1.Payoff Acknowledgment. Payee hereby acknowledges that (a) as of the date hereof, the Expenses set forth herein are the sole remaining expenses owed to Payee by the Company excluding, for the avoidance of doubt, any amounts payable as consideration to Payee as a seller under the Purchase Agreement and (b) upon the payment of the Expenses in accordance with Section 2 hereof, (i) all obligations of the Company to the Payee as of the date hereof shall be repaid, discharged and extinguished in full and (ii) the Company, the Buyer and their respective affiliates are released and discharged from any liability with respect to the Expenses and shall have no further obligations with respect thereto.

2.Mechanics for Payment. The Expenses shall be paid in accordance with the Purchase Agreement and the Closing Payment Schedule (as defined therein) attached thereto.

3.Miscellaneous. This Agreement may not be amended, modified or supplemented in any manner, whether by course of conduct or otherwise, except by an instrument in writing specifically designated as an amendment hereto, signed on behalf of each Party. This letter may be executed in multiple counterparts and by facsimile signature, each of which shall be deemed an original and all of which together shall constitute one instrument. Neither this Agreement nor any of the rights, interests or obligations under this Agreement may be assigned or delegated, in whole or in part, by operation of law or otherwise, by any Party without the prior written consent of the other Parties, and any such assignment without such prior written consent shall be null and void. This Agreement and all disputes or controversies arising out of or relating to this Agreement shall be governed by, and construed in accordance with, the internal laws of the State of Delaware, without regard to the laws of any other jurisdiction that might be applied because of


the conflicts of laws principles of the State of Delaware. All notices and other communications hereunder shall be in writing and shall be deemed duly given if delivered personally or sent by e- mail, overnight courier or registered or certified mail, postage prepaid, to the address set forth on the signature pages hereto opposite the Party to receive such notice, or to such other address as may be designated in writing by such Party.

[Signature Page Follows]


IN WITNESS WHEREOF, the Parties hereto have executed this Agreement as of the date first written above.

BUYER

    

Address for Notices:

NORTHWEST BIOTHERAPEUTICS, INC.

4800 Montgomery Lane

Suite 800

Bethesda, MD 20814

E-mail: lpowers@nwbio.com;

By:

lgoldman@nwbio.com

Name:

Title:

PAYEE

Address for Notices:

[]

[]

By:

Name:

Title:

COMPANY

Address for Notices:

FLASKWORKS, LLC

38 Wareham Street, 3rd Floor

Boston, MA 02118

E-mail:

shashi.k.murthy@flaskworks.com

By:

Name:

Title:


SPECIAL EXPENSE AGREEMENT

This Special Expense Agreement (this "Agreement") is made and entered into as of August 28, 2020, by and among Northeastern University ("Payee"), Flaskworks, LLC, a Massachusetts limited liability company (the "Company"), and Northwest Biotherapeutics, Inc., a Delaware corporation ("Buyer").

WHEREAS, Buyer and the Company are parties to that certain Unit Purchase Agreement dated as of the date hereof by and among Buyer, the Company and each of the other persons and entities set forth on the signature pages thereto (the "Purchase Agreement"); and

WHEREAS, the Purchase Agreement requires the payoff of the $168,547.16 in expenses (the "Expenses") owed to Payee by the Company and contemplates that such payoff will be evidenced by (a) the payment by Buyer to Payee at the Closing (as defined in the Purchase Agreement) of $51,895.16 the ("Cash Payment") out of the total amount of Expenses and (b) the delivery of this Agreement at the Closing and the subsequent payment to Payee ofan amount equal to the Expenses, less the Cash Payment (such $116,652 difference, the "Remaining Expenses") by Buyer in cash, shares of Buyer's common stock ("Shares"), or some combination thereof, at the election of Payee, which election is to be made between the 901h and 1201h day following the date hereof.

AGREEMENT

NOW, THEREFORE, in consideration of their mutual covenants contained herein, the receipt and efficiency of which are hereby acknowledged, the Parties hereto (the "Parties" and each individually, a "Party") agree as follows:

1.Payoff Acknowledgment. Payee hereby acknowledges that (a) as of the date hereof, the Expenses set forth herein are the sole remaining expenses owed to Payee by the Company excluding, for the avoidance of doubt, any amounts due following the date hereof under that certain License Agreement by and between Payee and the Company, as amended and restated as of the date hereof (the "License Agreement") and (b) upon the payment of the Remaining Expenses in accordance with Section 2 hereof and of the Cash Payment, (i) all obligations of the Company to the Payee as of the date hereof shall be repaid, discharged and extinguished in full and (ii) the Company, the Buyer and their respective affiliates are released and discharged from any liability with respect to the Expenses and shall have no further obligations with respect thereto.

2.Mechanics for Payment. The Remaining Expenses shall be paid in accordance Section 10 of the License Agreement. In the event that Payee elects to receive any Shares, it shall execute and deliver in to Buyer in connection with such election the form of agreement attached hereto as Exhibit A.

3.Miscellaneous. This Agreement may not be amended, modified or supplemented in any manner, whether by course of conduct or otherwise, except by an instrument in writing

Page 1 of 11


specifically designated as an amendment hereto, signed on behalf of each Party. This letter may be executed in multiple counterparts and by facsimile sig nat w-e, each of which shall be deemed an original and all of which together shall constitute one instrument. Neither this Agreement nor any of the rights , interests or obligations under this Agreement may be assigned or deleg ated, in whole or in part, by operation of law or otherwise, by any Party without the prior written consent of the other Parties, and any such assignment without such prior written consent shall be null and void. This Agreement and all disputes or controversies arising out of or relating to this Agreement shall be governed by, and constrned in accordance with, the internal laws of the State of Delaware, without regard to the laws of any other jurisdiction that might be applied because of the conflicts oflaws principles of the State of Delaware . All notices and other communications hereunder shall be in writing and shall be deemed duly given if delivered personally or sent by e­ mail, overnight courier or registered or certified mail, postage prepaid, to the address set forth on the signature pages hereto opposite the Pa1ty to receive such notice, or to such other address as may be designated in writing by such Party.

[Signature page follows]

Page 2 of 11


IN WITNESS WHEREOF, the Parties hereto have executed this Agreement as of the date first written above.

BUYER

   

Address for Notices:

NORTHWEST BIOTHERAPEUTICS, INC.

4800 Montgomery Lane

Suite 800

Bethesda, MD 20814

E-mail: lpowers@nwbio.com;

By:

lgoldman@nwbio.com

Name:

Title:

PAYEE

Address for Notices:

[]

[]

By:

Name:

Title:

COMPANY

Address for Notices:

FLASKWORKS, LLC

38 Wareham Street, 3rd Floor

Boston, MA 02118

E-mail:

By:

shashi.k.murthy@flaskworks.com

Name:

Title:


EXHIBIT A

AGREEMENT FOR PAYMENT OF EXPENSES IN SHARES

Page 4 of 11


AGREEMENT FOR PAYMENT OF EXPENSES IN SHARES

TIDS AGREEMENT FOR PAYMENT OF EXPENSES IN SHARES (this "Agreement"), dated as of [· ], 2020 , is entered into between Northwest Biotherapeut ics , Inc., a Delaware corporation (the "Company"), and the undersigned recipient ("Recipient").

WHE REAS, pursuant to that certain Special Expense Agreement dated as of the date hereof by and among Recipient , Flaskworks , LLC, a Massachusetts limited liability company , and the Company, and in connection with the transactions contemplated by that certain Unit Purchase Agreement, dated as of [· ], 2020 (the "Purchase Agreement") , among the Company and each of the other Persons set forth on the signature pages thereto, the Recipient has elected to receive the number of shares of the Company's Common Stock, par value $0.001 per share ("Common Stock"), set forth in Section 1.1 below (such shares , the "Shares"). Capitalized tenns used but not otherwise defined herein will have the meanings set forth in the Purchase Agreement.

NOW, THEREFORE, it is agreed as follows:

ARTICLE I

DELIVERY OF SECURITIES

1.I Issuance of Shares.  Subject to the terms and conditions set forth herein and in reliance on the representations and warranties of the parties contained herein, the Company hereby agrees to deliver to Recipient [· ] shares of Common Stock. The Company shall deliver to Recipient the shares and appropriate evidence of issuance of the Shares. Each Share so delivered shall be registered on the books and records of the Company in the name of Recipient.

ARTICLE II

REPRESENTATIONS AND WARRANTIES OF THE COMPANY

The Company hereby represents and warrants to Recipient as follows:

2.1Organization and Authority. he Company is a corporation duly organized, validly existing and in good standjng under the laws of Delaware .

2.2Authorization. The Company has full corporate power and authority to execute, deliver and perform its obligations under this Agreement and to deliver the Shares to the Recipient. This Agreement has been duly executed and delivered by the Company and, assuming due authori zation, execution and delivery by the Recipie nt, is legal, valid, binding and enforceable upon and against the Company (except as enforcement may be limited by applicable bankm ptcy, insolvency , reorganization, moratorium or similar laws affecting creditors' rights generally and by general principles of equity).

2.3Validity of Securities. The Shares to be issued pursuant to this Agreement have been duly and validly iss ued.

Page 5 of 11


ARTICLE III

REPRESENTATIONS AND \VARRANTIES OF RECIPIENT

Recipient hereby represents  and  warrants to the Company  as follows:

3.1 Investment Intent and Eligibi lit y.

(a)Recipient is an "accredited investor" within the meaning of Rule 501(a) under Regulation D promulgated under the Securities Act of 193 3, as amended (the "Securities Act"), and  the certifications made by Recipient in Appendix I in connection with this subscription are true and complete.

(b)Recipient has such knowledge and experience in financial and business matters as to be capable of evaluating the merits and risks of his, her or its prospective investment and is able, without materially impairing his financial condition, to hold the Shares for an indefinite period of time and to suffer a complete loss on such investment.

(c)Recipient has prior investment experience, or will rely upon his, her, or its financial advisor in connection with evaluating his , her or its decision to invest in the Shares.

(d)Recipient is acquiring the Shares for its own account, for investment and not with a view towards resale or distribution.

(e)Recipient has not been convicted, within the last ten years, of any felony or misdemeanor , and is not subject to any order, judgment or decree of any comt, or subject to any order of any of the US Securities and Exchange Commission (the "SEC''), the Financial Industry Regulatory Authori ty, the U.S. Postal Service, a stock exchange or a state regula tor, in each case entered within the last five years, that restrains or enjoins Recipient from engaging or continuing to engage in any conduct or practice: (i) in connection with the purchase or sale of any securi ty; (ii) involving the making of any false filing with the SEC; or (iii) arising out of the conduct of the business of an unde rwriter , broker, dealer, municipal securities dealer, investment adviser or paid solicitor of purchasers of securities or from engaging in the business of securiti es, insurance or banking .

3.2Delive ry ofl nfonnation; Material Changes . Any info1m at ion which Recipient has furnished to the Company with respect to Recipient's financial position and business experience is correct and complete as of the date hereof. Recipient promptly notified the Company of any material changes in any of the representations or warranties set forth  in  this Agreement  (including in Appendix 1) prior to the date hereof.

3.3

Receipt of Information; No Representations or Wan-anties.

(a)Recipient has carefully evaluated the risks involved in investing in the Shares. Recipient has been afforded the opportunity to ask such questions as he, she or it has deemed necessary of, and to receive answers from, representatives of the Company concerning the terms and conditions of the offering of the Shares and the merits and risks of acquiring the Shares. Recipient has received information about the Company and the Shares requested by or on behalf

Page 6 of 11


of Recipient and has reviewed such information to the satisfaction of Recipient as Recipient has deemed appropriate in making an investment decision with respect to the Shares.

(b)Recipient acknowledges that, except as expressly provided herein , it is acquiring the Shares without any representation or warranty, express or implied, at law or in equity, by the Company, any of the other direct or indirect owners of the Company, or any of their respective officers, directors, employees, affiliates or advisors.

3.4Reliance. Recipient understands that the Company is relying upon its representations and warranties herein in determining whether Recipient is suitable as a recipient of the Shares, whether the Shares may be issued to Recipient without first registering the Shares under the Securities Act and all applicable state securities laws.

3.5Acknowledgement of Risk. Recipient acknowledges that an investment in the Company includes a high degree of risk and that Recipient could lose his, her or its entire investment. Recipient acknowledges that the Company has no current plans to file a registration statement to register the Shares with tbe SEC and that the Company has no obligation to Recipient to register such Shares in the future.

ARTICLE IV

MISCELLANEOUS

4.1

Transfer Restrictions. Recipient acknowledges and agrees that:

(a)the offering and sale of the Shares is intended to be exempt from registration under the Securities Act, by virtue of the provisions of either Section 4(2) of the Securities Act or Rule 506 of Regulation D promulgated under the Securities Act by the SEC;

(b)none of the Shares have been registered under the Securities Act or any securities or "Blue Sky" laws of any state;

(c)none of the Shares may be offered, sold, transferred, pledged, hypothecated or otherwise assigned unless such Shares are registered under the Securities Act or any securities or "Blue Sky" laws of any state or an exemption from such registration is availab le; and

(d)certificate(s), if any, representing the Shares and each such certificate issued to any subsequent transferee of the Shares shall bear a conspicuous legend in substantially the following form (unless transferred in the manner described in the following legend):

THE SECURITIES REPRESENTED BY THIS CERTIFICATE HAVE NOT BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE "ACT") , OR THE SECURITIES LAWS OF ANY JURJSDIC TION. SUCH S CURITIES MAY NOT BE OFFERED, SOLD, RANSF RRED, P EDGED, ASSIGNED, CUMBERED, HYPOTHECA TED OR OTHER WISE DISPOSED OF EXCEPT (I) PURSUANT TO A REGISTRATION STATEMENTWITH RESPECT TO SUCH SECURITIES THAT IS EFFECTIVE UND R THE ACT OR APPLICABLE

Page 7 of 11


STATE SECURITIES LAW OR (II) IN A TRANSACTION THAT DOES NOT REQUIRE REGISTRATION UNDER THE ACT OR APPLICABLE STATE SECURITIES LAW, INCLUDING PURSUANT TO RULE 144 OR RULE 144A, PROVIDED  THAT,   EXCEPT   IN  THE  CAS   OF   ANY  TRANSACTION EXEM PT FROM REGISTRATION REQUIREM NT OF THE ACT PURSUANT TO RULE 144 OR RULE 144A, AN OPINION OF  COUNSEL SHALL BE FURNISHED TO THE ISSUER (IF REQUESTED BY THE ISSUER) 1N FORM AND SUBSTANCE REASONABLY SATISFACTORY TO THE ISSUER, TO THE EFFECT THAT SUCH TRANSACTION  DOES  NOT REQUIRE REGISTRATION UNDER  THE  ACT  AND/OR  APPLICABLE STATE SECURITIES LAW.

4.2Further Assurances. From time to time, the parties will execute and deliver, or cause to be executed and delivered, such documents and instruments as may be reasonably necessary to con ummate the transactions contemplated by this Agreement.

4.3Entire Agreement.  This Agreement and the Special Expense Agreement constitute the entire agreement, and supersedes all prior written agreements, arrangements and understandings and all prior and contemporaneous oral agreements, arrangements and understandings between the parties with respect to the subject matter of this Agreement.

4.4Amendment and Modification. This Agreement may not be amended, modified or supplemented in any manner, whether  by course of conduct or otherwise,  except  by an instrument in writing specifically designated as an amendment hereto, signed on behalf of each party.

4.5Governing Law. This Agreement and all disputes or controversies arising out of or relating to this Agreement shall be governed by, and construed in accordance with, the internal laws of the State of Delaware, without regard to the laws of any other jurisdiction that might be applied because of the conflicts of laws principles of the State of Delaware.

4.6Notices. All notices and other communications hereunder shall be in writing and shall be deemed duly given if delivered personally or sent bye  mail, overnight courier or registered or certified mail, postage prepaid, to the address set forth on the signature pages hereto opposite the party to receive such notice, or to such other address as may be designated in writing by such party.

4.7Counterparts. This Agreement may be executed in counterparts (including facsimile, .pdf and electronic transmission  counterparts), all of which shall be considered  one and the same instrument and shall become effective when one or more counterparts bave been signed by each of the parties and delivered to the other patty.

[Signature Page Follows]

Page 8 of 11


IN WITNESS WHEREOF, the parties hereto have executed this Agreement as of the date first written above.

COMPANY

   

Address for Notices :

NORTHW ST BIOTH RAP UTICS, INC.

4800 Montgomery Lane

Suite 800

By:

Bethesda, MD 20814

Name:

E-mail: []

Title:

RECIPIENT

Address for Notices :

By:

[]

Name:

[]

Title:

E-mail: []

Page 9 of 11


[Signature Page to

Agreement for

Payment of Expenses

in Shares]

Page 10 of 11


APPENDI X I

CERTIFICATION OF STATUS AS AN ACCREDITED INVESTOR

(Print or Type Recipient's Name)


Reference is made to the Agreement for Payment of Expenses in Shares (the "Agreement"), dated as of even date herewith, by and between Northwest Biotherapeutics, Inc. (the "Company") and the undersigned ("Undersigned"). Capitalized terms not otherwise defined herein sha ll have the same meanings specified in the Agreement. The Undersigned hereby certifies, pursuant to the Agreement, that:

1.

Regulation D Matters

Undersigned is an " Accredi ted Investor" as that such term is defined in Rule 50 l (a) of Regulation D promulgated under the Securities Act, unless Item VII below is marked with an "X" or similar check mark. Undersigned meets each of the following "Accredited Investor" categories marked with an "X" or similar check mark:

i. an organization described in Section 501(c)(3) of the Internal Revenue Code of 1986, as amended (the "Code"), corporation, Massachusetts or similar business trust, or partnership not formed for the specific purpose of acquiring the Common Stock offered, with total assets in excess of 5,000,000;

ii. adirec tor, executive officer, or general partner of the issuer of the securities being offered or sold;

iii. a natural person whose individual net worth, or joint net worth with his or her spouse at the time of his or her purchase exceeds $1 000,000;

iv. a natural person who had an individual income in excess of $200,000 in each of the two most recent years or joint income with that person's spouse in excess of $300,000 in each of those years and has a reasonable expectation ofreaching the same income level in the current year;

v. a trust, with total assets in excess of $5,000,000, not formed for the specific purpose of acquiring the Common Stock offered, whose purchase is directed by a sophisticated person as described in Rule 506(b)(2)(ii) of Regulation D;

vi .an entity in which all of the equity owners are Accredited Investors; or

vii. none of the above (Undersigned is not an Accredited Investor).

Page 11 of 11


IN WITNESS WHEREOF, the Undersigned bas executed thjs Certificate on tbe date set forth below.

Dated:

, 2020

Name:

Page 12 of 11


EXHIBIT F

New Flaskworks LLC Agreement

3


Execution Version

SECOND AMENDED AND RESTATED OPERATING AGREEMENT

OF

FLASKWORKS, LLC

This Second Amended and Restated Operating Agreement (this “Agreement”) of Flaskworks, LLC (the “Company”) is entered into and shall be effective as of August 28, 2020, by Northwest Biotherapeutics, Inc., as the sole member (the “Member”).

The Member, by execution of this Agreement, hereby forms a limited liability company pursuant to and in accordance with the Massachusetts Limited Liability Company Act, as amended from time to time (the “Act”), and hereby agrees as follows:

1.Name. The name of the limited liability company is Flaskworks, LLC. The business of the Company may be conducted under that name or, upon compliance with applicable laws, any other name that the Member deems appropriate or advisable.

2.Filing of Certificates. The Member is authorized to execute, deliver and file any other certificates, notices or documents (and any amendments and/or restatements thereof) necessary for the Company to qualify to do business in any jurisdiction in which the Company may wish to conduct business.

3.Purposes. The purposes of the Company are to engage in any lawful act, business or activity for which limited liability companies may be organized under the Act and that the Member shall approve.

4.Powers. In furtherance of its purposes, but subject to all of the provisions of this Agreement, the Company shall have and may exercise all the powers now or hereafter conferred by the Commonwealth of Massachusetts law on limited liability companies formed under the Act and all powers necessary, convenient or incidental to accomplish its purposes as set forth in Section 3.

5.Office and Agent. The Company will continuously maintain a registered office and registered agent in the Commonwealth of Massachusetts as required by the Act. The principal office will be as the Member from time to time may determine. The Company also may have such offices, anywhere within and without the Commonwealth of Massachusetts, as the Member from time to time may determine, or the business of the Company may require.

6.Member. The name and the mailing address of the Member are as follows:

Name

Address

Northwest Biotherapeutics, Inc.

4800 Montgomery Lane, Suite 800

Bethesda, MD 20814


7.Limited Liability. Except as otherwise provided by the Act, the debts, obligations and liabilities of the Company, whether arising in contract, tort or otherwise, shall be solely the debts, obligations and liabilities of the Company, and the Member shall not be obligated personally for any such debt, obligation or liability of the Company solely by reason of being a member of the Company.

8.Capital Contributions. The Member is deemed admitted as a member of the Company upon its execution and delivery of this Agreement.

9.Additional Contributions. The Member is not required to make any capital contribution to the Company. However, the Member may voluntarily make capital contributions to the Company at any time.

10.Allocation of Profits and Losses. For so long as the Member is the sole member of the Company, the Company’s profits and losses shall be allocated solely to the Member.

11.Distributions. Distributions shall be made to the Member at the times and in the aggregate amounts determined by the Member. Notwithstanding any provision to the contrary contained in this Agreement, the Company shall not make a distribution to the Member on account of its interest in the Company if such distribution would violate the Act or other applicable law.

12.Management. In accordance with the Act, management of the Company shall be vested in the Member. The Member shall have the power to do any and all acts necessary, convenient or incidental to or for the furtherance of the purposes of the Company described herein, including all powers, statutory or otherwise, possessed by members of a limited liability company under the laws of the Commonwealth of Massachusetts. Notwithstanding any other provision of this Agreement (other than the last sentence of this Section), the Member is authorized to execute and deliver any document on behalf of the Company without any vote or consent of any other person. The Member has the authority to bind the Company. Notwithstanding any other provision herein, the Member shall not take any action that would cause the Company to fail to be treated as an entity disregarded for US federal (and applicable state) income tax purposes.

13.Officers. The Member may, from time to time as it deems advisable, select natural persons who are employees or agents of the Company and designate them as officers of the Company (the “Officers”) and assign titles (including, without limitation, President, Vice President, Secretary, and Treasurer) to any such person. Unless the Member decides otherwise, if the title is one commonly used for officers of a business entity formed under the Act or other corporate law of the Commonwealth of Massachusetts, the assignment of such title shall constitute the delegation to such person of the authorities and duties that are normally associated with that office. Any delegation pursuant to this Section may be revoked at any time by the Member. An Officer may be removed with or without cause by the Member.

2


14.Other Business Opportunities. The Member and any person or entity affiliated with the Member may engage in or possess an interest in other business opportunities or ventures (unconnected with the Company) of every kind and description, independently or with others, including, without limitation, businesses that may compete with the Company. Neither the Member nor any person or entity affiliated with the Member shall be required to present any such business opportunity or venture to the Company, even if the opportunity is of the character that, if presented to the Company, could be taken by it. Neither the Company nor any person or entity affiliated with the Company shall have any rights in or to such business opportunities or ventures or the income or profits derived therefrom by virtue of this Agreement, notwithstanding any duty otherwise existing at law or in equity. The provisions of this Section shall apply to the Member solely in its capacity as member of the Company and shall not be deemed to modify any contract or arrangement otherwise agreed to by the Company and the Member.

15.

Exculpation and Indemnification.

(a)None of the Member or any of its current or former affiliates, stockholders, equityholders, officers, directors, employees or agents, any manager or officer of the Company prior to the adoption of this Agreement, or any affiliate, stockholder, equityholder, manager, officer, director, employee or agent of the Company after the adoption of this Agreement (including in each case the executors, heirs, assigns, successors or other legal representatives of any such persons) (collectively, the “Covered Persons”) shall be liable to the Company, the Member or any other person or entity who is a party to or is otherwise bound by this Agreement for any loss, damage or claim incurred by reason of any act or omission performed or omitted by such Covered Person in good faith on behalf of the Company and in a manner reasonably believed to be within the scope of the authority conferred on such Covered Person by this Agreement, unless such Covered Person engaged in fraud, gross negligence, intentional misconduct or a knowing violation of applicable law.

(b)To the fullest extent permitted by applicable law, a Covered Person shall be entitled to indemnification from the Company for any loss, damage or claim incurred by such Covered Person by reason of any act or omission performed or omitted by such Covered Person in good faith on behalf of the Company and in a manner reasonably believed to be within the scope of the authority conferred on such Covered Person by this Agreement, unless such Covered Person engaged in fraud, gross negligence, intentional misconduct or a knowing violation of applicable law; provided, however, that any indemnity under this Section shall be provided out of and to the extent of Company assets only, and the Member shall not have any personal liability on account thereof.

(c)To the fullest extent permitted by applicable law, expenses (including reasonable and documented legal fees) incurred by a Covered Person in defending any claim, demand, action, suit or proceeding shall, from time to time, be advanced by the Company prior to the final disposition of such claim, demand, action, suit or proceeding upon receipt by the Company of an undertaking by or on behalf of the Covered Person to repay such amount if it shall be determined that the Covered Person is not entitled to be indemnified as authorized in this Section.

3


(d)A Covered Person shall be fully protected in relying in good faith upon the records of the Company and upon such information, opinions, reports or statements presented to the Company by the person or entity as to matters the Covered Person reasonably believes are within such other person or entity’s professional or expert competence and who has been selected with reasonable care by or on behalf of the Company, including information, opinions, reports or statements as to the value and amount of the assets, liabilities, or any other facts pertinent to the existence and amount of assets from which distributions to the Member might properly be paid.

(e)Notwithstanding the foregoing provisions of this Section, the Company shall indemnify a Covered Person in connection with a proceeding (or part thereof) initiated by such Covered Person only if such proceeding (or part thereof) was authorized by the Member; provided, however, that a Covered Person shall be entitled to reimbursement of his or her reasonable and documented counsel fees with respect to a proceeding (or part thereof) initiated by such Covered Person to enforce his or her right to indemnity or advancement of expenses under the provisions of this Section to the extent the Covered Person is successful on the merits in such proceeding (or part thereof)

(f)The foregoing provisions of this Section shall survive any termination of this Agreement. Notwithstanding anything herein to the contrary, (i) the Company shall not exculpate, indemnify, or otherwise protect any Covered Person resulting from a breach by such person of this Agreement or any other agreement between such Covered Person and the Company, any affiliates of the Company, or any other Covered Person (including, for the avoidance of doubt, that certain Unit Purchase Agreement, dated as of August 28, 2020, by and among the Member and each of the parties set forth on the signature pages thereto (the “Purchase Agreement”)) and (ii) any indemnification or other payments pursuant to this Section 15 owed to any person that was a manager or officer of the Company prior to the adoption of this Agreement (with respect to claims relating to conduct during the period prior to the adoption of this Agreement) shall be limited and paid out of proceeds paid on account of valid insurance claims made under the applicable “Tail Policy” (as defined in the Purchase Agreement).

16.

Dissolution.

(a)The Company shall dissolve and its affairs shall be wound up upon the first to occur of: (i) the written consent of the Member, (ii) the entry of a decree of judicial dissolution of the Company as provided in the Act, or (iii) the occurrence of any other event which, pursuant to any non-waivable provision of the Act, causes dissolution of the Company.

(b)In the event of dissolution, the Company shall conduct only such activities as are necessary to wind up its affairs (including the sale of the assets of the Company in an orderly manner), and the assets or proceeds from the sale of the assets of the Company shall be applied in the manner, and in the order of priority, set forth in the Act.

4


17.Benefits of Agreement; No Third-Party Rights. The provisions of this Agreement are intended solely to benefit the Member (unless express provision is made herein to the contrary) and, to the fullest extent permitted by applicable law, shall not be construed as conferring any benefit upon any other person or entity, or upon any creditor of the Company (and no such person, entity or creditor shall be a third-party beneficiary of this Agreement), and the Member shall have no duty or obligation to any such person, entity or creditor of the Company to make any contributions or payments to the Company.

18.Severability of Provisions. Each provision of this Agreement shall be considered severable and if for any reason any provision or provisions herein are determined to be invalid, unenforceable or illegal under any existing or future law, such invalidity, unenforceability or illegality shall not impair the operation of or affect those portions of this Agreement which are valid, enforceable and legal.

19.Entire Agreement. This Agreement constitutes the entire agreement of the Member with respect to the subject matter hereof.

20.Governing Law. This Agreement shall be governed by, and construed under, the laws of the Commonwealth of Massachusetts (without regard to conflict of laws principles), all rights and remedies being governed by said laws.

21.Amendments. This Agreement may not be modified, altered, supplemented or amended except pursuant to a written agreement executed and delivered by the Member.

[The remainder of this page is intentionally left blank.]

5


IN WITNESS WHEREOF, the undersigned, intending to be legally bound hereby, has duly executed this Agreement as of the date first written above.

NORTHWEST BIOTHERAPEUTICS, INC.

By:

Name:

Title:

Second Amended and Restated Operating Agreement – Flaskworks, LLC


Schedule A

1.

Unsecured Promissory Note Agreement, dated June 30, 2020, between Buyer, as holder, and Flaskworks, as maker, with aggregate principal face amount of $30,000.

2.

Unsecured Promissory Note Agreement, dated August 6, 2020, between Buyer, as holder, and Flaskworks, as maker, with aggregate principal face amount of $25,000.


Execution Version

DISCLOSURE SCHEDULE

This Disclosure Schedule is made and given pursuant to Articles II and III of the Unit Purchase Agreement, dated as of August 28, 2020 (the “Agreement”), between Northwest Biotherapeutics, Inc., a Delaware corporation (the “Buyer”), and each of the other Persons set forth on the signature pages to the Agreement (each, a “Seller” and collectively, the “Sellers”). All capitalized terms used but not defined herein shall have the meanings as defined in the Agreement. The section or subsection numbers below correspond to the section or subsection numbers of the representations and warranties in the Agreement and this Disclosure Schedule is qualified in its entirety by reference to the Agreement. Inclusion of any item in this Disclosure Schedule (1) does not represent a determination that such item is material or establish a standard of materiality, (2) does not represent a determination that such item did not arise in the ordinary course of business, (3) does not represent a determination that the transactions contemplated by the Agreement require the consent of third parties, and (4) shall not constitute, or be deemed to be, an admission to any third Person concerning such item. Headings have been inserted in this Disclosure Schedule for convenience of reference only and shall not have the effect of amending or changing the express description of the sections or subsections as set forth in the Agreement.


Section 3.4 of Disclosure Schedule

Equity Capitalization of the Company

No. of Units

% Ownership

Class A-l Unitholders

Shashi Murthy

2,636,147

65.02%

Class A-2 Unitholders

Corning Incorporated

750,000

18.50%

Class B Unitholders (Profits Interests)

Jennifer Rossi

465,203

11.48%

Andrew Kozbial

63,292

1.56%

Unallocated Pool

139,410

3.44%

Total

4,054,052

100.00%


Schedule 3.6(a) of Disclosure Schedule

Financial Statements Attached.


Schedule 3.7 of Disclosure Schedule

See Schedule A.


Section 3.11 of Disclosure Schedule

1.

Under the Offer Letter, dated September 21, 2016, by and between Flaskworks, LLC and Jennifer Rossi, as amended on May 12, 2017 and the date hereof, Jennifer Rossi is entitled to a cash bonus in connection with a change of control of the Company.

2.

Supply Agreement, dated September 13, 2018, made by and between Corning Incorporated and Flaskworks, LLC.

3.

Admission Letter, dated October 22, 2018, made by and between Flaskworks, LLC and Jennifer Rossi.

4.

Admission Letter, dated October 22, 2018, made by and between Flaskworks, LLC and Andrew Kozbial.


Section 3.13 of Disclosure Schedule

1.

License Agreement with Triple Ring Technologies for the lease of office and laboratory space at 38 Wareham Street, 3rd Floor, Boston, MA 02118.


Section 3.16 of Disclosure Schedule

1.

Supply Agreement, dated September 13, 2018, made by and between Corning Incorporated and Flaskworks, LLC (to be terminated in connection with closing).

2.

License Agreement with Triple Ring Technologies for the lease of office and laboratory space at 38 Wareham Street, 3rd Floor, Boston, MA 02118.

3.

Exclusive Patent License Agreement, dated November 30, 2016, made by and between Northeastern University and Flaskworks, LLC.

4.

Notice of Award to Shashi Murthy of a National Science Foundation SBIR Phase II grant dated August 28, 2019.

7


Section 3.17 of Disclosure Schedule

·

Jennifer Rossi is entitled to a cash bonus in connection with a change of control of the Company.

·

Shashi Murthy has loaned the company an aggregate principal amount of $150,000 and Jennifer Rossi has loaned the Company an aggregate principal amount of $15,000.

8


Section 3.18 of Disclosure Schedule

(a)

Patents and Patent Applications

BR Ref. No.

Application/Publ.

No.

Patent No.

Country

Status

Owner

1

FLAS- 001/00US

62/185,906

US

Converted

Licensed from Northeastern University

Record unavailable

2

FLAS- 001/00WO

PCT/US2016/040042 WO/2017/004169

WO

National Stage

Licensed from Northeastern University

Owner: Northeastern University Inventors: Shashi K.

Murthy/Bradley B. Collier Priority 62/185906

3

FLAS- 001/01EP

16818659.1

EP3313434

EP

Pending

Licensed from Northeastern University

Owner: Northeastern University Inventors: Shashi K. Murthy/Bradley B. Collier

Nat. PCT/US2016/040042

Priority 62/185906

4

FLAS- 001/01US

15/736257

20180171296

US

Allowed

Licensed from Northeastern University

Owner: Northeastern University Inventors: Shashi K. Murthy/Bradley B. Collier

Nat. PCT/US2016/040042

Priority 62/185906

5

FLAS- 002/00US_0

62/250,630

US

Converted

Licensed from Northeastern University

Record unavailable

6

FLAS- 002/00US_01

62/250,618

US

Converted

Licensed from Northeastern University

Record unavailable

7

FLAS- 002/01WO

PCT/US2016/060701 WO/2017/079674

WO

National Stage

Licensed from Northeastern University

Owner: Northeastern University Inventor: Shashi K. Murthy Priority 62/250618 and 62/250630

8

FLAS- 002/01EP

16819715.0

EP3371295

EP

Pending

Licensed from Northeastern University

Owner: Northeastern University Inventor: Shashi K. Murthy Nat. PCT/US2016/060701

Priority 62/250618 and 62/250630

9

FLAS- 002/01US

15/970664

20180251723

US

Pending

Licensed from Northeastern University

Owner: Northeastern University Inventor: Shashi K. Murthy

Response to office action due 5/6/2020

9


BR Ref. No.

Application/Publ.

No.

Patent No.

Country

Status

Owner

Cont. PCT/US2016/060701

Priority claim: 62/250618 and 62/250630

10

FLAS- 003/00US_0

62/356,504

US

Converted

Licensed from Northeastern University

Record unavailable

11

FLAS- 003/00US_1

62/357,937

US

Converted

Licensed from Northeastern University

Record unavailable

12

FLAS- 003/00WO

PCT/US2017/039538 WO/2018/005521

WO

National Stage

Licensed from Northeastern University

Owner: Northeastern University Inventor: Shashi K. Murthy

Priority 62/356504 and 62/357937

13

FLAS- 003/01CN

201780038219.2

CN109312282

CN

Pending

Licensed from Northeastern University

Owner: Northeastern University Inventor: Shashi K. Murthy Nat. PCT/US2017/039538

Priority 62/356504 and 62/357937

14

FLAS- 003/01EP

17771906.9

EP3478818

EP

Pending

Licensed from Northeastern University

Owner: Northeastern University Inventor: Shashi K. Murthy Nat. PCT/US2017/039538

Priority 62/356504 and 62/357937

15

FLAS-003/01JP

2018567803

JP

Pending

Licensed from Northeastern University

Owner: Northeastern University Inventor: Shashi K. Murthy Nat. PCT/US2017/039538

Priority 62/356504 and 62/357937

16

FLAS- 003/01US

16/310680

US

Pending

Licensed from Northeastern University

Record unavailable

17

FLAS- 004/00US

16/192062

US

Allowed

Assigned to Flaskworks, LLC Record unavailable

18

FLAS- 004/01WO

PCT/US2019/060695

WO

Pending

Assigned to Flaskworks, LLC Record unavailable

FLAS- 004/01US

16/841,197 (filed on 04-06-2020)

US

Pending

Assigned to Flaskworks, LLC Continuation of 16/192062

19

FLAS- 005/00US

62/828696

US

Pending

Assigned to Flaskworks, LLC Record unavailable

20

FLAS- 006/00US

16/539916

US

Pending

Assigned to Flaskworks, LLC Record unavailable

10


BR Ref. No.

Application/Publ.

No.

Patent No.

Country

Status

Owner

21

FLAS- 007/00US

62/923963

US

Pending

Assigned to Flaskworks, LLC Record unavailable

22

FLAS- 008/00US

62/923967

US

Pending

Assigned to Flaskworks, LLC Record unavailable

23

FLAS- 009/00US

62/923973

US

Pending

Assigned to Flaskworks, LLC Record unavailable

24

FLAS- 010/00US

62/923975

US

Pending

Assigned to Flaskworks, LLC Record unavailable

25

FLAS- 011/00US

62/923978

US

Pending

Assigned to Flaskworks, LLC Record unavailable

26

FLAS- 012/00US

62/923982

US

Pending

Assigned to Flaskworks, LLC Record unavailable

Trademarks and Trademark Applications

BR Ref. No.

Mark

Drawing Code

Application Serial No.

Registratio n No.

Countr y

Status

Owner/ Next Action

33365/18

STANDAR D CHARACT ER MARK

88/182010

US

Allowed

Flaskworks, LLC

Statement of Use or Extension due

7/30/2020

33365/23

STANDAR D CHARACT ER MARK

88/553706

US

Allowed

Flaskworks, LLC

Statement of Use or Extension

due 7/28/2020

33365/17

STANDAR D CHARACT ER MARK

88/182005

US

Allowed

Flaskworks, LLC

Statement of Use or Extension

due 7/30/2020

11


BR Ref. No.

Mark

Drawing Code

Application Serial No.

Registratio n No.

Countr y

Status

Owner/ Next Action

33365/19

DESIGN PLUS WORDS, LETTERS, AND/OR NUMBERS

88/195551

5945774

US

Registered

Flaskworks, LLC

Decl. of Use due 12/24/2025

33365/15

STANDAR D CHARACT ER MARK

88/181978

5945727

US

Registered

Flaskworks, LLC

Decl. of Use due 12/24/2025

33365/22

STANDAR D CHARACT ER MARK

88/553686

5990620

US

Registered

Flaskworks, LLC

Decl. of

Use due 2/18/2026

33365/16

STANDAR D CHARACT ER MARK

88/181996

6019871

US

Registered

Flaskworks, LLC

Decl. of Use due 3/24/2026

U.S. Registered Copyrights: None.

Domain Name

Domain Name

Creation Date

Expiration Date

Registrant Name/Organization

Registrar

Flaskworks.com

1/25/2016

1/25/2021

Private registration

GoDaddy.com

12


Section 5.4

(b)(iv)1

Shashi Murths’s deferred salary amount: $82,894.32

Jennifer Rossi’s deferred salary amount that will not be covered by company funds at closing: $47,983.24

Andrew Kozbial was paid his salary earned to date on August 11, 2020. He will be owed salary from August 12, 2020 to the Closing Date at a daily rate of approximately $246.58 based on his annual salary of $90,000.00


1 These figures do not include the extra 8% required to be paid for payroll tax purposes.


EX-10.85 6 nwbo-20201231xex10d85.htm EXHIBIT 10.85

Exhibit 10.85

COMMERCIAL LOAN AGREEMENT

THIS COMMERCIAL LOAN AGREEMENT (this “Loan Agreement”), dated as of March 1, 2021, is entered into by and between NORTHWEST BIOTHERAPEUTICS, INC., a Delaware corporation (“Borrower”), and STREETERVILLE CAPITAL, LLC, a Utah limited liability company, its successors and/or assigns (“Lender”).

A.           Lender desires to loan and Borrower desires to borrow, upon the terms and conditions set forth in this Loan Agreement, a Promissory Note in the form attached hereto as Exhibit A, in the original principal amount of $11,005,000.00 (the Loan).

B.           This Loan Agreement, the Note, and all other certificates, documents, agreements, resolutions and instruments delivered to any party under or in connection with this Loan Agreement, as the same may be amended from time to time, are collectively referred to herein as the Loan Documents.

NOW, THEREFORE, in consideration of the above recitals and other good and valuable consideration, the receipt and adequacy of which are hereby acknowledged, Borrower and Lender hereby agree as follows:

1.  Promissory Note.

1.1.  Promissory Note. On the Closing Date Borrower shall execute and deliver the Promissory Note to Lender, and in consideration for delivery of the Note, Lender shall pay the Loan Amount (as defined below) to Borrower.

1.2.  Form of Payment. On the Closing Date, Lender shall pay the Loan Amount to Borrower via wire transfer of immediately available funds against delivery of the Note.

1.3.  Closing Date. Subject to the satisfaction (or written waiver) of the conditions set forth in Section 5 and Section 6 below, the date and time of the execution of the Loan Documents pursuant to this Loan Agreement (the Closing Date) shall be 5:00 p.m., Eastern Time on or about March 1, 2021, or such other mutually agreed upon time. The closing of the transactions contemplated by this Loan Agreement (the Closing) shall occur on the Closing Date by means of the exchange by express courier and email of .pdf documents, but shall be deemed to have occurred at the offices of Hansen Black Anderson Ashcraft PLLC in Lehi, Utah.

1.4.  Collateral for the Note. The Note shall not be secured.

1.5.  Original Issue Discount; Transaction Expenses. The Note carries an original issue discount of $1,000,000.00 (the OID). In addition, Borrower agrees to pay $5,000.00 to Lender to cover Lenders legal fees, accounting costs, due diligence, monitoring and other transaction costs incurred in connection with the execution of the Note (the Transaction Expense Amount), all of which amount is included in the initial principal balance of the Note. The Loan Amount, therefore, shall be $10,000,000.00, computed as follows: $11,005,000.00 original principal balance, less the OID, less the Transaction Expense Amount.

2.  Lenders Representations and Warranties. Lender represents and warrants to Borrower that: (i) this Loan Agreement has been duly and validly authorized; and (ii) this Loan Agreement constitutes a valid and binding agreement of Lender enforceable in accordance with its terms.

1


3.  Representations and Warranties of Borrower. Borrower represents and warrants to Lender that: (i) Borrower is a corporation duly organized, validly existing and in good standing under the laws of its state of incorporation and has the requisite corporate power to own its properties and to carry on its business as now being conducted; (ii) Borrower is duly qualified as a foreign corporation to do business and is in good standing in each jurisdiction where the nature of the business conducted or property owned by it makes such qualification necessary; (iii) Borrower has registered its shares of common stock, $0.001 par value per share (the “Common Stock”), under Section 12(g) of the Securities Exchange Act of 1934, as amended (the “1934 Act”), and is obligated to file reports pursuant to Section 13 or Section 15(d) of the 1934 Act; (iv) each of the Transaction Documents and the transactions contemplated hereby and thereby, have been duly and validly authorized by Borrower; (v) this Loan Agreement, the Note, and the other Transaction Documents have been duly executed and delivered by Borrower and constitute the valid and binding obligations of Borrower enforceable in accordance with their terms, subject as to enforceability only to general principles of equity and to bankruptcy, insolvency, moratorium, and other similar laws affecting the enforcement of creditors’ rights generally; (vi) the execution and delivery of the Transaction Documents by Borrower and the consummation by Borrower of the other transactions contemplated by the Transaction Documents do not and will not conflict with or result in a breach by Borrower of any of the terms or provisions of, or constitute a default under (a) Borrower’s formation documents or bylaws, each as currently in effect, (b) any indenture, mortgage, deed of trust, or other material agreement or instrument to which Borrower is a party or by which it or any of its properties or assets are bound, including any listing agreement for the Common Stock, or (c) any existing applicable law, rule, or regulation or any applicable decree, judgment, or order of any court, United States federal or state regulatory body, administrative agency, or other governmental body having jurisdiction over Borrower or any of Borrower’s properties or assets; (vii) no further authorization, approval or consent of any court, governmental body, regulatory agency, self-regulatory organization, or stock exchange or market or the stockholders or any lender of Borrower is required to be obtained by Borrower for the issuance of the Note to Lender; (viii) none of Borrower’s filings with the SEC contained, at the time they were filed, any untrue statement of a material fact or omitted to state any material fact required to be stated therein or necessary to make the statements made therein, in light of the circumstances under which they were made, not misleading; (ix) Borrower has filed all reports, schedules, forms, statements and other documents required to be filed by Borrower with the SEC under the 1934 Act on a timely basis or has received a valid extension of such time of filing ; (x) Borrower has not consummated any financing transaction that has not been disclosed in a periodic or other filing with the SEC under the 1934 Act; (xi) Borrower is not, nor has it ever been, a “Shell Company,” as such type of “issuer” is described in Rule 144(i)(1) under the 1933 Act or is in compliance with Rule 144(i)(2) under the 1933 Act; (xii) with respect to any commissions, placement agent or finder’s fees or similar payments that will or would become due and owing by Borrower to any person or entity as a result of this Loan Agreement or the transactions contemplated hereby (“Broker Fees”), any such Broker Fees will be made in full compliance with all applicable laws and regulations and only to a person or entity that is a registered investment adviser or registered broker-dealer; (xiii) Lender shall have no obligation with respect to any Broker Fees or with respect to any claims made by or on behalf of other persons for fees of a type contemplated in this subsection that may be due in connection with the transactions contemplated hereby and Borrower shall indemnify and hold harmless each of Lender, Lender’s employees, officers, directors, stockholders, managers, agents, and partners, and their respective affiliates, from and against all claims, losses, damages, costs (including the costs of preparation and attorneys’ fees) and expenses suffered in respect of any such claimed or existing Broker Fees; and (xiv) neither Lender nor any of its officers, directors, members, managers, employees, agents or representatives has made any representations or warranties to Borrower or any of its officers, directors, employees, agents or representatives except as expressly set forth in the Transaction Documents Borrower, and in making its decision to enter into the transactions contemplated by the Transaction Documents, Borrower is not relying on any representation, warranty, covenant or promise of Lender or its officers, directors, members, managers, employees, agents or representatives other than as set forth in the Transaction Documents.

2


4.  Borrowers Covenants. Until all of Borrower obligations under the Note are paid and performed in full, or within the timeframes otherwise specifically set forth below, Borrower will at all times comply with the following covenants: (i) Borrower will timely file on the applicable deadline all reports required to be filed with the SEC pursuant to Sections 13 or 15(d) of the 1934 Act, and will take all reasonable action under its control to ensure that adequate current public information with respect to Borrower, as required in accordance with Rule 144 of the 1933 Act, is publicly available, and will not terminate its status as an issuer required to file reports under the 1934 Act even if the 1934 Act or the rules and regulations thereunder would permit such termination; (ii) the Common Stock shall be listed or quoted for trading on any of (a) NYSE, (b) NASDAQ, (c) OTCQX, (d) OTCQB, or (e) OTC Pink Current Information; and (iii) trading in Borrowers Common Stock will not be suspended, halted, chilled, frozen, reach zero bid or otherwise cease on Borrowers principal trading market.

5.  Conditions to Borrowers Obligation to deliver the Note. The obligation of Borrower hereunder to issue and deliver the Note to Lender at the Closing is subject to the satisfaction, at or before the Closing Date, of each of the following conditions:

5.1.  Lender shall have executed this Loan Agreement and delivered the same to Borrower.

5.2.  Lender shall have delivered the Loan Amount to Borrower in accordance with Section 1.2 above.

6.  Conditions to Lenders Obligation to Pay Borrower the Loan Amount. The obligation of Lender to pay Borrower the Loan Amount at the Closing is subject to the satisfaction, at or before the Closing Date, of each of the following conditions, provided that these conditions are for Lenders sole benefit and may be waived by Lender at any time in its sole discretion:

6.1.  Borrower shall have executed this Loan Agreement and the Note and delivered the same to Lender.

6.2.  Borrower shall have delivered to Lender a fully executed Secretary’s Certificate substantially in the form attached hereto as Exhibit B evidencing Borrowers approval of the Transaction Documents.

6.3.  Borrower shall have delivered to Lender fully executed copies of all other Transaction Documents required to be executed by Borrower herein or therein.

7.  Miscellaneous. The provisions set forth in this Section 7 shall apply to this Loan Agreement, as well as all other Transaction Documents as if these terms were fully set forth therein; provided, however, that in the event there is a conflict between any provision set forth in this Section 7 and any provision in any other Transaction Document, the provision in such other Transaction Document shall govern.

7.1.  Certain Capitalized Terms. To the extent any capitalized term used in any Transaction Document is defined in any other Transaction Document (as noted therein), such capitalized term shall remain applicable in the Transaction Document in which it is so used even if the other Transaction Document (wherein such term is defined) has been released, satisfied, or is otherwise cancelled or terminated.

7.2.  Arbitration of Claims. The parties shall submit all Claims (as defined in Exhibit C) arising under this Loan Agreement or any other Transaction Document or other agreement between the

3


parties and their affiliates to binding arbitration pursuant to the arbitration provisions set forth in Exhibit C attached hereto (the “Arbitration Provisions”). The parties hereby acknowledge and agree that the Arbitration Provisions are unconditionally binding on the parties hereto and are severable from all other provisions of this Loan Agreement. By executing this Loan Agreement, Borrower represents, warrants and covenants that Borrower has reviewed the Arbitration Provisions carefully, consulted with legal counsel about such provisions (or waived its right to do so), understands that the Arbitration Provisions are intended to allow for the expeditious and efficient resolution of any dispute hereunder, agrees to the terms and limitations set forth in the Arbitration Provisions, and that Borrower will not take a position contrary to the foregoing representations. Borrower acknowledges and agrees that Lender may rely upon the foregoing representations and covenants of Borrower regarding the Arbitration Provisions.

7.3.  Governing Law; Venue. This Loan Agreement shall be governed by and interpreted in accordance with the laws of the State of Utah for contracts to be wholly performed in such state and without giving effect to the principles thereof regarding the conflict of laws. Each party consents to and expressly agrees that exclusive venue for arbitration of any dispute arising out of or relating to any Transaction Document or the relationship of the parties or their affiliates shall be in Salt Lake County, Utah. Without modifying the parties’ obligations to resolve disputes hereunder pursuant to the Arbitration Provisions, for any litigation arising in connection with any of the Transaction Documents, each party hereto hereby (i) consents to and expressly submits to the exclusive personal jurisdiction of any state or federal court sitting in Salt Lake County, Utah, (ii) expressly submits to the exclusive venue of any such court for the purposes hereof, and (iii) waives any claim of improper venue and any claim or objection that such courts are an inconvenient forum or any other claim or objection to the bringing of any such proceeding in such jurisdictions or to any claim that such venue of the suit, action or proceeding is improper.

7.4.  Specific Performance. Borrower acknowledges and agrees that irreparable damage may occur to Lender in the event that Borrower fails to perform any material provision of this Loan Agreement or any of the other Transaction Documents in accordance with its specific terms. It is accordingly agreed that Lender shall be entitled to an injunction or injunctions to cure breaches of the provisions of this Loan Agreement or such other Transaction Document and to enforce specifically the terms and provisions hereof or thereof, this being in addition to any other remedy to which any Lender may be entitled under the Transaction Documents, at law or in equity. For the avoidance of doubt, in the event Lender seeks to obtain an injunction against Borrower or specific performance of any provision of any Transaction Document, such action shall not be a waiver of any right of Lender under any Transaction Document, at law, or in equity, including without limitation its rights to arbitrate any Claim pursuant to the terms of the Transaction Documents.

7.5.  Counterparts. Each Transaction Document may be executed in any number of counterparts, each of which shall be deemed an original, but all of which together shall constitute one instrument. The parties hereto confirm that any electronic copy of another partys executed counterpart of a Transaction Document (or such partys signature page thereof) will be deemed to be an executed original thereof.

7.6.  Document Imaging. Lender shall be entitled, in its sole discretion, to image or make copies of all or any selection of the agreements, instruments, documents, and items and records governing, arising from or relating to this Loan, including, without limitation, this Loan Agreement and the other Transaction Documents, and Lender may destroy or archive the paper originals. The parties hereto (i) waive any right to insist or require that Lender produce paper originals, (ii) agree that such images shall be accorded the same force and effect as the paper originals, (iii) agree that Lender is entitled to use such images in lieu of destroyed or archived originals for any purpose, including as admissible evidence in any demand, presentment or other proceedings, and (iv) further agree that any executed facsimile (faxed),

4


scanned, emailed, or other imaged copy of this Loan Agreement or any other Transaction Document shall be deemed to be of the same force and effect as the original manually executed document.

7.7.  Headings. The headings of this Loan Agreement are for convenience of reference only and shall not form part of, or affect the interpretation of, this Loan Agreement.

7.8.  Severability. In the event that any provision of this Loan Agreement is invalid or unenforceable under any applicable statute or rule of law, then such provision shall be deemed inoperative to the extent that it may conflict therewith and shall be deemed modified to conform to such statute or rule of law. Any provision hereof which may prove invalid or unenforceable under any law shall not affect the validity or enforceability of any other provision hereof.

7.9.  Entire Agreement. This Loan Agreement, together with the other Transaction Documents, contains the entire understanding of the parties with respect to the matters covered herein and therein and, except as specifically set forth herein or therein, neither Borrower nor

7.10.   Lender makes any representation, warranty, covenant or undertaking with respect to such matters.

7.11.   No Reliance. Borrower acknowledges and agrees that neither Lender nor any of its officers, directors, members, managers, representatives or agents has made any representations or warranties to Borrower or any of its officers, directors, representatives, agents or employees except as expressly set forth in the Transaction Documents and, in making its decision to enter into the transactions contemplated by the Transaction Documents, Borrower is not relying on any representation, warranty, covenant or promise of Lender or its officers, directors, members, managers, agents or representatives other than as set forth in the Transaction Documents.

7.12.   Amendments. No provision of this Loan Agreement may be waived or amended other than by an instrument in writing signed by the parties hereto.

7.13.   Notices. Any notice required or permitted hereunder shall be given in writing and via email to lgoldman@nwbio.com and lpowers@nwbio.com (unless otherwise specified herein) and shall be deemed effectively given on the earliest of: (i) the date delivered, if delivered by personal delivery as against written receipt therefor or by email to an executive officer, or by facsimile (with successful transmission confirmation), (ii) the earlier of the date delivered or the fifth business day after deposit, postage prepaid, in the United States Postal Service by certified mail, or (iii) the earlier of the date delivered or the fifth business day after mailing by express courier, with delivery costs and fees prepaid, in each case, addressed to each of the other parties thereunto entitled at the following addresses (or at such other addresses as such party may designate by five (5) calendar days advance written notice similarly given to each of the other parties hereto):

If to Borrower:

    

Northwest Biotherapeutics, Inc.

Attn:

Linda Powers and Les Goldman

4800 Montgomery Lane, Suite 800

Bethesda, Maryland 20814

5


If to Lender:

    

Streeterville Capital, LLC

Attn:

John Fife

303 East Wacker Drive, Suite 1040

Chicago, Illinois 60601

With a copy to (which copy shall not constitute notice):

    

Hansen Black Anderson Ashcraft PLLC

Attn:

Jonathan Hansen

3051 West Maple Loop Drive, Suite 325

Lehi, Utah 84043

7.14.   Successors and Assigns. This Loan Agreement or any of the severable rights and obligations inuring to the benefit of or to be performed by

7.15.   Lender hereunder may be assigned by Lender to a third party, including its financing sources, in whole or in part, without the need to obtain Borrower’s consent thereto. Borrower may not assign its rights or obligations under this Loan Agreement or delegate its duties hereunder without the prior written consent of Lender.

7.16.   Survival. The representations and warranties of Borrower and the agreements and covenants set forth in this Loan Agreement shall survive the Closing hereunder notwithstanding any due diligence investigation conducted by or on behalf of Lender. Borrower agrees to indemnify and hold harmless Lender and all its officers, directors, employees, attorneys, and agents for loss or damage arising as a result of or related to any breach by Borrower of any of its representations, warranties and covenants set forth in this Loan Agreement or any of its covenants and obligations under this Loan Agreement, including advancement of expenses as they are incurred.

7.17.   Further Assurances. Each party shall do and perform, or cause to be done and performed, all such further acts and things, and shall execute and deliver all such other agreements, certificates, instruments and documents, as the other party may reasonably request in order to carry out the intent and accomplish the purposes of this Loan Agreement and the consummation of the transactions contemplated hereby.

7.18.   Lenders Rights and Remedies Cumulative; Liquidated Damages. All rights, remedies, and powers conferred in this Loan Agreement and the Transaction Documents are cumulative and not exclusive of any other rights or remedies, and shall be in addition to every other right, power, and remedy that Lender may have, whether specifically granted in this Loan Agreement or any other Transaction Document, or existing at law, in equity, or by statute, and any and all such rights and remedies may be exercised from time to time and as often and in such order as Lender may deem expedient. The parties acknowledge and agree that upon Borrowers failure to comply with the provisions of the Transaction Documents, Lenders damages would be uncertain and difficult (if not impossible) to accurately estimate because of the parties inability to predict future interest rates, Lenders increased risk, and the uncertainty of the availability of a suitable substitute lending opportunity for Lender, among other reasons. Accordingly, any fees, charges, and default interest due under the Note and the other Transaction Documents are intended by the parties to be, and shall be deemed, liquidated damages. The parties agree that such liquidated damages are a reasonable estimate of Lenders actual damages and not a penalty, and shall not be deemed in any way to limit any other right or remedy Lender may have hereunder, at law or in equity. The parties acknowledge and agree that under the circumstances existing at the time this Loan Agreement is entered into, such liquidated damages are fair and reasonable and are not penalties. All fees,

6


charges, and default interest provided for in the Transaction Documents are agreed to by the parties to be based upon the obligations and the risks assumed by the parties as of the Closing Date and are consistent with investments of this type. The liquidated damages provisions of the Transaction Documents shall not limit or preclude a party from pursuing any other remedy available at law or in equity; provided, however, that the liquidated damages provided for in the Transaction Documents are intended to be in lieu of actual damages.

7.19.   Attorneys Fees and Cost of Collection. In the event of any arbitration or action at law or in equity to enforce or interpret the terms of this Loan Agreement or any of the other Transaction Documents, the parties agree that the party who is awarded the most money shall be deemed the prevailing party for all purposes and shall therefore be entitled to an additional award of the full amount of the reasonable attorneys fees, deposition costs, and expenses paid by such prevailing party in connection with arbitration or litigation without reduction or apportionment based upon the individual claims or defenses giving rise to the fees and expenses. Nothing herein shall restrict or impair an arbitrators or a courts power to award fees and expenses for frivolous or bad faith pleading. If (i) the Note is placed in the hands of an attorney for collection or enforcement prior to commencing arbitration or legal proceedings, or is collected or enforced through any arbitration or legal proceeding, or Lender otherwise takes action to collect amounts due under the Note or to enforce the provisions of the Note; or (ii) there occurs any bankruptcy, reorganization, receivership of Borrower or other proceedings affecting Borrowers creditors rights and involving a claim under the Note; then Borrower shall pay the costs incurred by Lender for such collection, enforcement or action or in connection with such bankruptcy, reorganization, receivership or other proceeding, including, without limitation, reasonable attorneys fees, expenses, deposition costs, and disbursements.

7.20.   Waiver. No waiver of any provision of this Loan Agreement shall be effective unless it is in the form of a writing signed by the party granting the waiver. No waiver of any provision or consent to any prohibited action shall constitute a waiver of any other provision or consent to any other prohibited action, whether or not similar. No waiver or consent shall constitute a continuing waiver or consent or commit a party to provide a waiver or consent in the future except to the extent specifically set forth in writing.

7.21.       Waiver of Jury Trial. EACH PARTY TO THIS LOAN AGREEMENT IRREVOCABLY WAIVES ANY AND ALL RIGHTS SUCH PARTY MAY HAVE TO DEMAND THAT ANY ACTION, PROCEEDING OR COUNTERCLAIM ARISING OUT OF OR IN ANY WAY RELATED TO THIS LOAN AGREEMENT, ANY OTHER TRANSACTION DOCUMENT, OR THE RELATIONSHIPS OF THE PARTIES HERETO BE TRIED BY JURY. THIS WAIVER EXTENDS TO ANY AND ALL RIGHTS TO DEMAND A TRIAL BY JURY ARISING UNDER COMMON LAW OR ANY APPLICABLE STATUTE, LAW, RULE OR REGULATION. FURTHER, EACH PARTY HERETO ACKNOWLEDGES THAT SUCH PARTY IS KNOWINGLY AND VOLUNTARILY WAIVING SUCH PARTYS RIGHT TO DEMAND TRIAL BY JURY.

7.22.   Time is of the Essence. Time is expressly made of the essence with respect to each and every provision of this Loan Agreement and the other Transaction Documents.

7.23.   Voluntary Agreement. Borrower has carefully read this Loan Agreement and each of the other Transaction Documents and has asked any questions needed for Borrower to understand the terms, consequences and binding effect of this Loan Agreement and each of the other Transaction Documents and fully understand them. Borrower has had the opportunity to seek the advice of an attorney of Borrowers choosing, or has waived the right to do so, and is executing this Loan Agreement and each

7


of the other Transaction Documents voluntarily and without any duress or undue influence by Lender or anyone else.

[Remainder of page intentionally left blank; signature page follows]

8


IN WITNESS WHEREOF, the undersigned Lender and Borrower have caused this Loan Agreement to be duly executed as of the date first above written.

LOAN AMOUNTS:

Principal Amount of Note to be Paid to Lender:

    

$

11,005,000.00 

 

Loai Amount to be Paid to Borrower :

$

10,000,000.00

LENDER :

STREETERVILLE CAPITAL , LLC

By:

_/s/ John M. Fife

John M. Fife, President

BORROWER:

NORTHWEST BIOTHERAP EUTICS, INC.

By:

/s/ Leslie J. Goldman

Leslie J. Goldman

Senior Vice President, General Counsel

ATTACHED EXHIBITS:

Exhibit A

Note

Exhibit B

Secretary's Certificate

Exhibit C

Arbitration Provisions

[Signature Page to Loan Agreement}


EXHIBIT C

ARBITRATION PROVISIONS

1.  Dispute Resolution. For purposes of this Exhibit C, the term Claims means any disputes, claims, demands, causes of action, requests for injunctive relief, requests for specific performance, liabilities, damages, losses, or controversies whatsoever arising from, related to, or connected with the transactions contemplated in the Transaction Documents and any communications between the parties related thereto, including without limitation any claims of mutual mistake, mistake, fraud, misrepresentation, failure of formation, failure of consideration, promissory estoppel, unconscionability, failure of condition precedent, rescission, and any statutory claims, tort claims, contract claims, or claims to void, invalidate or terminate the Agreement (or these Arbitration Provisions (defined below)) or any of the other Transaction Documents. The term Claims specifically excludes a dispute over Calculations. The parties to the Agreement (the parties) hereby agree that the arbitration provisions set forth in this Exhibit C (Arbitration Provisions) are binding on each of them. As a result, any attempt to rescind the Agreement (or these Arbitration Provisions) or declare the Agreement (or these Arbitration Provisions) or any other Transaction Document invalid or unenforceable for any reason is subject to these Arbitration Provisions. These Arbitration Provisions shall also survive any termination or expiration of the Agreement. Any capitalized term not defined in these Arbitration Provisions shall have the meaning set forth in the Agreement.

2.      Arbitration. Except as otherwise provided herein, all Claims must be submitted to arbitration (Arbitration) to be conducted exclusively in Salt Lake County or Utah County, Utah and pursuant to the terms set forth in these Arbitration Provisions. Subject to the arbitration appeal right provided for in Paragraph 5 below (the Appeal Right), the parties agree that the award of the arbitrator rendered pursuant to Paragraph 4 below (the Arbitration Award) shall be (a) final and binding upon the parties, (b) the sole and exclusive remedy between them regarding any Claims, counterclaims, issues, or accountings presented or pleaded to the arbitrator, and (c) promptly payable in United States dollars free of any tax, deduction or offset (with respect to monetary awards). Subject to the Appeal Right, any costs or fees, including without limitation attorneys fees, incurred in connection with or incident to enforcing the Arbitration Award shall, to the maximum extent permitted by law, be charged against the party resisting such enforcement. The Arbitration Award shall include default interest (as defined or otherwise provided for in the Note, Default Interest) (with respect to monetary awards) at the rate specified in the Note for Default Interest both before and after the Arbitration Award. Judgment upon the Arbitration Award will be entered and enforced by any state or federal court sitting in Salt Lake County, Utah.

3.  The Arbitration Act. The parties hereby incorporate herein the provisions and procedures set forth in the Utah Uniform Arbitration Act, U.C.A. § 78B11101 et seq. (as amended or superseded from time to time, the Arbitration Act). Notwithstanding the foregoing, pursuant to, and to the maximum extent permitted by, Section 105 of the Arbitration Act, in the event of conflict or variation between the terms of these Arbitration Provisions and the provisions of the Arbitration Act, the terms of these Arbitration Provisions shall control and the parties hereby waive or otherwise agree to vary the effect of all requirements of the Arbitration Act that may conflict with or vary from these Arbitration Provisions.

4.  Arbitration Proceedings. Arbitration between the parties will be subject to the following:

4.1 Initiation of Arbitration. Pursuant to Section 110 of the Arbitration Act, the parties agree that a party may initiate Arbitration by giving written notice to the other party (Arbitration Notice) in the same manner that notice is permitted under Section 7.12 of the Agreement; provided, however, that the Arbitration Notice may not be given by email or fax. Arbitration will be deemed initiated as of the date that the Arbitration Notice is deemed delivered to such other party under Section 7.12 of the Agreement (the Service Date). After the Service Date, information may be delivered, and notices may be given, by email or fax pursuant to Section 7.12 of the Agreement or any other method permitted thereunder. The Arbitration Notice must describe the nature of the controversy, the remedies sought, and the election to commence Arbitration proceedings. All Claims in the Arbitration Notice must be pleaded consistent with the Utah Rules of Civil Procedure.

4.2 Selection and Payment of Arbitrator.

(a)  Within ten (10) calendar days after the Service Date, Lender shall select and submit to Borrower the names of three (3) arbitrators that are designated as neutrals or qualified arbitrators by Utah ADR

Arbitration Provisions, Page 1


Services ( http://www.utahadrservices.com) (such three (3) designated persons hereunder are referred to herein as the Proposed Arbitrators). For the avoidance of doubt, each Proposed Arbitrator must be qualified as a neutral with Utah ADR Services. Within five (5) calendar days after Lender has submitted to Borrower the names of the Proposed Arbitrators, Borrower must select, by written notice to Lender, one (1) of the Proposed Arbitrators to act as the arbitrator for the parties under these Arbitration Provisions. If Borrower fails to select one of the Proposed Arbitrators in writing within such 5day period, then Lender may select the arbitrator from the Proposed Arbitrators by providing written notice of such selection to Borrower.

(b)  If Lender fails to submit to Borrower the Proposed Arbitrators within ten (10) calendar daysafter the Service Date pursuant to subparagraph (a) above, then Borrower may at any time prior to Lender so designating the Proposed Arbitrators, identify the names of three (3) arbitrators that are designated as neutrals or qualified arbitrators by Utah ADR Service by written notice to Lender. Lender may then, within five (5) calendar days after Borrower has submitted notice of its Proposed Arbitrators to Lender, select, by written notice to Borrower, one (1) of the Proposed Arbitrators to act as the arbitrator for the parties under these Arbitration Provisions. If Lender fails to select in writing and within such 5day period one (1) of the three (3) Proposed Arbitrators selected by Borrower, then Borrower may select the arbitrator from its three (3) previously selected Proposed Arbitrators by providing written notice of such selection to Lender.

(c)  If a Proposed Arbitrator chosen to serve as arbitrator declines or is otherwise unable to serve as arbitrator, then the party that selected such Proposed Arbitrator may select one (1) of the other three (3) Proposed Arbitrators within three (3) calendar days of the date the chosen Proposed Arbitrator declines or notifies the parties he or she is unable to serve as arbitrator. If all three (3) Proposed Arbitrators decline or are otherwise unable to serve as arbitrator, then the arbitrator selection process shall begin again in accordance with this Paragraph 4.2.

(d)              The date that the Proposed Arbitrator selected pursuant to this Paragraph 4.2 agrees in writing (including via email) delivered to both parties to serve as the arbitrator hereunder is referred to herein as the Arbitration Commencement Date. If an arbitrator resigns or is unable to act during the Arbitration, a replacement arbitrator shall be chosen in accordance with this Paragraph 4.2 to continue the Arbitration. If Utah ADR Services ceases to exist or to provide a list of neutrals and there is no successor thereto, then the arbitrator shall be selected under the then prevailing rules of the American Arbitration Association.

(e)  Subject to Paragraph 4.10 below, the cost of the arbitrator must be paid equally by both parties. Subject to Paragraph 4.10 below, if one party refuses or fails to pay its portion of the arbitrator fee, then the other party can advance such unpaid amount (subject to the accrual of Default Interest thereupon), with such amount being added to or subtracted from, as applicable, the Arbitration Award.

4.3 Applicability of Certain Utah Rules. The parties agree that the Arbitration shall be conducted generally in accordance with the Utah Rules of Civil Procedure and the Utah Rules of Evidence. More specifically, the Utah Rules of Civil Procedure shall apply, without limitation, to the filing of any pleadings, motions or memoranda, the conducting of discovery, and the taking of any depositions. The Utah Rules of Evidence shall apply to any hearings, whether telephonic or in person, held by the arbitrator. Notwithstanding the foregoing, it is the parties intent that the incorporation of such rules will in no event supersede these Arbitration Provisions. In the event of any conflict between the Utah Rules of Civil Procedure or the Utah Rules of Evidence and these Arbitration Provisions, these Arbitration Provisions shall control.

4.4 Answer and Default. An answer and any counterclaims to the Arbitration Notice shall be required to be delivered to the party initiating the Arbitration within twenty (20) calendar days after the Arbitration Commencement Date. If an answer is not delivered by the required deadline, the arbitrator must provide written notice to the defaulting party stating that the arbitrator will enter a default award against such party if such party does not file an answer within five (5) calendar days of receipt of such notice. If an answer is not filed within the five (5) day extension period, the arbitrator must render a default award, consistent with the relief requested in the Arbitration Notice, against a party that fails to submit an answer within such time period.

4.5 Related Litigation. The party that delivers the Arbitration Notice to the other party shall have the option to also commence concurrent legal proceedings with any state or federal court sitting in Salt Lake County, Utah (Litigation Proceedings), subject to the following: (a) the complaint in the Litigation Proceedings is to be substantially similar to the claims set forth in the Arbitration Notice, provided that an additional cause of action to compel arbitration will also be included therein, (b) so long as the other party files an answer to the complaint in the Litigation Proceedings and an answer to the Arbitration Notice, the Litigation

Arbitration Provisions, Page 2


Proceedings will be stayed pending an Arbitration Award (or Appeal Panel Award (defined below), as applicable) hereunder, (c) if the other party fails to file an answer in the Litigation Proceedings or an answer in the Arbitration proceedings, then the party initiating Arbitration shall be entitled to a default judgment consistent with the relief requested, to be entered in the Litigation Proceedings, and (d) any legal or procedural issue arising under the Arbitration Act that requires a decision of a court of competent jurisdiction may be determined in the Litigation Proceedings. Any award of the arbitrator (or of the Appeal Panel (defined below)) may be entered in such Litigation Proceedings pursuant to the Arbitration Act.

4.6 Discovery. Pursuant to Section 118(8) of the Arbitration Act, the parties agree that discovery shall be conducted as follows:

(a)             Written discovery will only be allowed if the likely benefits of the proposed written discovery outweigh the burden or expense thereof, and the written discovery sought is likely to reveal information that will satisfy a specific element of a claim or defense already pleaded in the Arbitration. The party seeking written discovery shall always have the burden of showing that all of the standards and limitations set forth in these Arbitration Provisions are satisfied. The scope of discovery in the Arbitration proceedings shall also be limited as follows:

(i)To facts directly connected with the transactions contemplated by the Agreement.

(ii)To facts and information that cannot be obtained from another source or in another manner that is more convenient, less burdensome or less expensive than in the manner requested.

(b)  No party shall be allowed (i) more than fifteen (15) interrogatories (including discrete subparts), (ii) more than fifteen (15) requests for admission (including discrete subparts), (iii) more than ten (10) document requests (including discrete subparts), or (iv) more than three (3) depositions (excluding expert depositions) for a maximum of seven (7) hours per deposition. The costs associated with depositions will be borne by the party taking the deposition. The party defending the deposition will submit a notice to the party taking the deposition of the estimated attorneys fees that such party expects to incur in connection with defending the deposition. If the party defending the deposition fails to submit an estimate of attorneys fees within five (5) calendar days of its receipt of a deposition notice, then such party shall be deemed to have waived its right to the estimated attorneys fees. The party taking the deposition must pay the party defending the deposition the estimated attorneys fees prior to taking the deposition, unless such obligation is deemed to be waived as set forth in the immediately preceding sentence. If the party taking the deposition believes that the estimated attorneys fees are unreasonable, such party may submit the issue to the arbitrator for a decision. All depositions will be taken in Utah.

(c)  All discovery requests (including document production requests included in deposition notices) must be submitted in writing to the arbitrator and the other party. The party submitting the written discovery requests must include with such discovery requests a detailed explanation of how the proposed discovery requests satisfy the requirements of these Arbitration Provisions and the Utah Rules of Civil Procedure. The receiving party will then be allowed, within five (5) calendar days of receiving the proposed discovery requests, to submit to the arbitrator an estimate of the attorneys fees and costs associated with responding to such written discovery requests and a written challenge to each applicable discovery request. After receipt of an estimate of attorneys fees and costs and/or challenge(s) to one or more discovery requests, consistent with subparagraph (c) above, the arbitrator will within three (3) calendar days make a finding as to the likely attorneys fees and costs associated with responding to the discovery requests and issue an order that (i) requires the requesting party to prepay the attorneys fees and costs associated with responding to the discovery requests, and (ii) requires the responding party to respond to the discovery requests as limited by the arbitrator within twentyfive (25) calendar days of the arbitrators finding with respect to such discovery requests. If a party entitled to submit an estimate of attorneys fees and costs and/or a challenge to discovery requests fails to do so within such 5day period, the arbitrator will make a finding that (A) there are no attorneys fees or costs associated with responding to such discovery requests, and (B) the responding party must respond to such discovery requests (as may be limited by the arbitrator) within twentyfive (25) calendar days of the arbitrators finding with respect to such discovery requests. Any party submitting any written discovery requests, including without limitation interrogatories, requests for production subpoenas to a party or a third party, or requests for admissions, must prepay the estimated attorneys fees and costs, before the responding party has any obligation to produce or respond to the same, unless such obligation is deemed waived as set forth above.

Arbitration Provisions, Page 3


(d)   In order to allow a written discovery request, the arbitrator must find that the discovery request satisfies the standards set forth in these Arbitration Provisions and the Utah Rules of Civil Procedure. The arbitrator must strictly enforce these standards. If a discovery request does not satisfy any of the standards set forth in these Arbitration Provisions or the Utah Rules of Civil Procedure, the arbitrator may modify such discovery request to satisfy the applicable standards, or strike such discovery request in whole or in part.

(e)  Each party may submit expert reports (and rebuttals thereto), provided that such reports must be submitted within sixty (60) days of the Arbitration Commencement Date. Each party will be allowed a maximum of two (2) experts. Expert reports must contain the following: (i) a complete statement of all opinions the expert will offer at trial and the basis and reasons for them; (ii) the experts name and qualifications, including a list of all the experts publications within the preceding ten (10) years, and a list of any other cases in which the expert has testified at trial or in a deposition or prepared a report within the preceding ten (10) years; and (iii) the compensation to be paid for the experts report and testimony. The parties are entitled to depose any other partys expert witness one (1) time for no more than four (4) hours. An expert may not testify in a partys caseinchief concerning any matter not fairly disclosed in the expert report.

4.6 Dispositive Motions. Each party shall have the right to submit dispositive motions pursuant Rule 12 or Rule 56 of the Utah Rules of Civil Procedure (a Dispositive Motion). The party submitting the Dispositive Motion may, but is not required to, deliver to the arbitrator and to the other party a memorandum in support (the Memorandum in Support) of the Dispositive Motion. Within seven (7) calendar days of delivery of the Memorandum in Support, the other party shall deliver to the arbitrator and to the other party a memorandum in opposition to the Memorandum in Support (the Memorandum in Opposition). Within seven (7) calendar days of delivery of the Memorandum in Opposition, as applicable, the party that submitted the Memorandum in Support shall deliver to the arbitrator and to the other party a reply memorandum to the Memorandum in Opposition (Reply Memorandum). If the applicable party shall fail to deliver the Memorandum in Opposition as required above, or if the other party fails to deliver the Reply Memorandum as required above, then the applicable party shall lose its right to so deliver the same, and the Dispositive Motion shall proceed regardless.

4.7 Confidentiality. All information disclosed by either party (or such partys agents) during the Arbitration process (including without limitation information disclosed during the discovery process or any Appeal (defined below)) shall be considered confidential in nature. Each party agrees not to disclose any confidential information received from the other party (or its agents) during the Arbitration process (including without limitation during the discovery process or any Appeal) unless (a) prior to or after the time of disclosure such information becomes public knowledge or part of the public domain, not as a result of any inaction or action of the receiving party or its agents, (b) such information is required by a court order, subpoena or similar legal duress to be disclosed if such receiving party has notified the other party thereof in writing and given it a reasonable opportunity to obtain a protective order from a court of competent jurisdiction prior to disclosure, or (c) such information is disclosed to the receiving partys agents, representatives and legal counsel on a need to know basis who each agree in writing not to disclose such information to any third party. Pursuant to Section 118(5) of the Arbitration Act, the arbitrator is hereby authorized and directed to issue a protective order to prevent the disclosure of privileged information and confidential information upon the written request of either party.

4.8 Authorization; Timing; Scheduling Order. Subject to all other portions of these Arbitration Provisions, the parties hereby authorize and direct the arbitrator to take such actions and make such rulings as may be necessary to carry out the parties intent for the Arbitration proceedings to be efficient and expeditious. Pursuant to Section 120 of the Arbitration Act, the parties hereby agree that an Arbitration Award must be made within one hundred twenty (120) calendar days after the Arbitration Commencement Date. The arbitrator is hereby authorized and directed to hold a scheduling conference within ten (10) calendar days after the Arbitration Commencement Date in order to establish a scheduling order with various binding deadlines for discovery, expert testimony, and the submission of documents by the parties to enable the arbitrator to render a decision prior to the end of such 120day period.

4.9 Relief. The arbitrator shall have the right to award or include in the Arbitration Award (or in a preliminary ruling) any relief which the arbitrator deems proper under the circumstances, including, without limitation, specific performance and injunctive relief, provided that the arbitrator may not award exemplary or punitive damages.

4.10  Fees and Costs. As part of the Arbitration Award, the arbitrator is hereby directed to require the losing party (the party being awarded the least amount of money by the arbitrator, which, for the avoidance of

Arbitration Provisions, Page 4


doubt, shall be determined without regard to any statutory fines, penalties, fees, or other charges awarded to any party) to (a) pay the full amount of any unpaid costs and fees of the Arbitration, and (b) reimburse the prevailing party for all reasonable attorneys fees, arbitrator costs and fees, deposition costs, other discovery costs, and other expenses, costs or fees paid or otherwise incurred by the prevailing party in connection with the Arbitration.

5.  Arbitration Appeal.

5.1 Initiation of Appeal. Following the entry of the Arbitration Award, either party (the Appellant) shall have a period of thirty (30) calendar days in which to notify the other party (the Appellee), in writing, that the Appellant elects to appeal (the Appeal) the Arbitration Award (such notice, an Appeal Notice) to a panel of arbitrators as provided in Paragraph 5.2 below. The date the Appellant delivers an Appeal Notice to the Appellee is referred to herein as the Appeal Date. The Appeal Notice must be delivered to the Appellee in accordance with the provisions of Paragraph 4.1 above with respect to delivery of an Arbitration Notice. In addition, together with delivery of the Appeal Notice to the Appellee, the Appellant must also pay for (and provide proof of such payment to the Appellee together with delivery of the Appeal Notice) a bond in the amount of 110% of the sum the Appellant owes to the Appellee as a result of the Arbitration Award the Appellant is appealing. In the event an Appellant delivers an Appeal Notice to the Appellee (together with proof of payment of the applicable bond) in compliance with the provisions of this Paragraph 5.1, the Appeal will occur as a matter of right and, except as specifically set forth herein, will not be further conditioned. In the event a party does not deliver an Appeal Notice (along with proof of payment of the applicable bond) to the other party within the deadline prescribed in this Paragraph 5.1, such party shall lose its right to appeal the Arbitration Award. If no party delivers an Appeal Notice (along with proof of payment of the applicable bond) to the other party within the deadline described in this Paragraph 5.1, the Arbitration Award shall be final. The parties acknowledge and agree that any Appeal shall be deemed part of the parties agreement to arbitrate for purposes of these Arbitration Provisions and the Arbitration Act.

5.2 Selection and Payment of Appeal Panel. In the event an Appellant delivers an Appeal Notice to the Appellee (together with proof of payment of the applicable bond) in compliance with the provisions of Paragraph 5.1 above, the Appeal will be heard by a three (3) person arbitration panel (the Appeal Panel).

(a)Within ten (10) calendar days after the Appeal Date, the Appellee shall select and submit to the Appellant the names of five (5) arbitrators that are designated as neutrals or qualified arbitrators by Utah ADR Services (http://www.utahadrservices.com) (such five (5) designated persons hereunder are referred to herein as the Proposed Appeal Arbitrators). For the avoidance of doubt, each Proposed Appeal Arbitrator must be qualified as a neutral with Utah ADR Services, and shall not be the arbitrator who rendered the Arbitration Award being appealed (the Original Arbitrator). Within five (5) calendar days after the Appellee has submitted to the Appellant the names of the Proposed Appeal Arbitrators, the Appellant must select, by written notice to the Appellee, three (3) of the Proposed Appeal Arbitrators to act as the members of the Appeal Panel. If the Appellant fails to select three (3) of the Proposed Appeal Arbitrators in writing within such 5day period, then the Appellee may select such three (3) arbitrators from the Proposed Appeal Arbitrators by providing written notice of such selection to the Appellant.

(b)If the Appellee fails to submit to the Appellant the names of the Proposed Appeal Arbitrators within ten (10) calendar days after the Appeal Date pursuant to subparagraph (a) above, then the Appellant may at any time prior to the Appellee so designating the Proposed Appeal Arbitrators, identify the names of five (5) arbitrators that are designated as neutrals or qualified arbitrators by Utah ADR Service (none of whom may be the Original Arbitrator) by written notice to the Appellee. The Appellee may then, within five (5) calendar days after the Appellant has submitted notice of its selected arbitrators to the Appellee, select, by written notice to the Appellant, three (3) of such selected arbitrators to serve on the Appeal Panel. If the Appellee fails to select in writing within such 5day period three (3) of the arbitrators selected by the Appellant to serve as the members of the Appeal Panel, then the Appellant may select the three (3) members of the Appeal Panel from the Appellants list of five (5) arbitrators by providing written notice of such selection to the Appellee.

(c)   If a selected Proposed Appeal Arbitrator declines or is otherwise unable to serve, then the party that selected such Proposed Appeal Arbitrator may select one (1) of the other five (5) designated Proposed Appeal Arbitrators within three (3) calendar days of the date a chosen Proposed Appeal Arbitrator declines or notifies the parties he or she is unable to serve as an arbitrator. If at least three (3) of the five (5) designated Proposed Appeal Arbitrators decline or are otherwise unable to serve, then the Proposed Appeal

Arbitration Provisions, Page 5


Arbitrator selection process shall begin again in accordance with this Paragraph 5.2; provided, however, that any Proposed Appeal Arbitrators who have already agreed to serve shall remain on the Appeal Panel.

(d)  The date that all three (3) Proposed Appeal Arbitrators selected pursuant to this Paragraph

5.2 agree in writing (including via email) delivered to both the Appellant and the Appellee to serve as members of the Appeal Panel hereunder is referred to herein as the Appeal Commencement Date. No later than five (5) calendar days after the Appeal Commencement Date, the Appellee shall designate in writing (including via email) to the Appellant and the Appeal Panel the name of one (1) of the three (3) members of the Appeal Panel to serve as the lead arbitrator in the Appeal proceedings. Each member of the Appeal Panel shall be deemed an arbitrator for purposes of these Arbitration Provisions and the Arbitration Act, provided that, in conducting the Appeal, the Appeal Panel may only act or make determinations upon the approval or vote of no less than the majority vote of its members, as announced or communicated by the lead arbitrator on the Appeal Panel.

If an arbitrator on the Appeal Panel ceases or is unable to act during the Appeal proceedings, a replacement arbitrator shall be chosen in accordance with Paragraph 5.2 above to continue the Appeal as a member of the Appeal Panel. If Utah ADR Services ceases to exist or to provide a list of neutrals, then the arbitrators for the Appeal Panel shall be selected under the then prevailing rules of the American Arbitration Association.

(d) Subject to Paragraph 5.7 below, the cost of the Appeal Panel must be paid entirely by the Appellant.

5.3  Appeal Procedure. The Appeal will be deemed an appeal of the entire Arbitration Award. In conducting the Appeal, the Appeal Panel shall conduct a de novo review of all Claims described or otherwise set forth in the Arbitration Notice. Subject to the foregoing and all other provisions of this Paragraph 5, the Appeal Panel shall conduct the Appeal in a manner the Appeal Panel considers appropriate for a fair and expeditious disposition of the Appeal, may hold one or more hearings and permit oral argument, and may review all previous evidence and discovery, together with all briefs, pleadings and other documents filed with the Original Arbitrator (as well as any documents filed with the Appeal Panel pursuant to Paragraph 5.4(a) below). Notwithstanding the foregoing, in connection with the Appeal, the Appeal Panel shall not permit the parties to conduct any additional discovery or raise any new Claims to be arbitrated, shall not permit new witnesses or affidavits, and shall not base any of its findings or determinations on the Original Arbitrators findings or the Arbitration Award.

5.4 Timing.

(a)  Within seven (7) calendar days of the Appeal Commencement Date, the Appellant (i) shall deliver or cause to be delivered to the Appeal Panel copies of the Appeal Notice, all discovery conducted in connection with the Arbitration, and all briefs, pleadings and other documents filed with the Original Arbitrator (which material Appellee shall have the right to review and supplement if necessary), and (ii) may, but is not required to, deliver to the Appeal Panel and to the Appellee a Memorandum in Support of the Appellants arguments concerning or position with respect to all Claims, counterclaims, issues, or accountings presented or pleaded in the Arbitration. Within seven (7) calendar days of the Appellants delivery of the Memorandum in Support, as applicable, the Appellee shall deliver to the Appeal Panel and to the Appellant a Memorandum in Opposition to the Memorandum in Support. Within seven (7) calendar days of the Appellees delivery of the Memorandum in Opposition, as applicable, the Appellant shall deliver to the Appeal Panel and to the Appellee a Reply Memorandum to the Memorandum in Opposition. If the Appellant shall fail to substantially comply with the requirements of clause (i) of this subparagraph (a), the Appellant shall lose its right to appeal the Arbitration Award, and the Arbitration Award shall be final. If the Appellee shall fail to deliver the Memorandum in Opposition as required above, or if the Appellant shall fail to deliver the Reply Memorandum as required above, then the Appellee or the Appellant, as the case may be, shall lose its right to so deliver the same, and the Appeal shall proceed regardless.

(b)   Subject to subparagraph (a) above, the parties hereby agree that the Appeal must be heard by the Appeal Panel within thirty (30) calendar days of the Appeal Commencement Date, and that the Appeal Panel must render its decision within thirty (30) calendar days after the Appeal is heard (and in no event later than sixty (60) calendar days after the Appeal Commencement Date).

5.5 Appeal Panel Award. The Appeal Panel shall issue its decision (the Appeal Panel Award) through the lead arbitrator on the Appeal Panel. Notwithstanding any other provision contained herein, the Appeal Panel Award shall (a) supersede in its entirety and make of no further force or effect the Arbitration Award (provided that any protective orders issued by the Original Arbitrator shall remain in full force and effect), (b)

Arbitration Provisions, Page 6


be final and binding upon the parties, with no further rights of appeal, (c) be the sole and exclusive remedy between the parties regarding any Claims, counterclaims, issues, or accountings presented or pleaded in the Arbitration, and (d) be promptly payable in United States dollars free of any tax, deduction or offset (with respect to monetary awards). Any costs or fees, including without limitation attorneys fees, incurred in connection with or incident to enforcing the Appeal Panel Award shall, to the maximum extent permitted by law, be charged against the party resisting such enforcement. The Appeal Panel Award shall include Default Interest (with respect to monetary awards) at the rate specified in the Note for Default Interest both before and after the Arbitration Award. Judgment upon the Appeal Panel Award will be entered and enforced by a state or federal court sitting in Salt Lake County, Utah.

5.6 Relief. The Appeal Panel shall have the right to award or include in the Appeal Panel Award any relief which the Appeal Panel deems proper under the circumstances, including, without limitation, specific performance and injunctive relief, provided that the Appeal Panel may not award exemplary or punitive damages.

5.7 Fees and Costs. As part of the Appeal Panel Award, the Appeal Panel is hereby directed to require the losing party (the party being awarded the least amount of money by the arbitrator, which, for the avoidance of doubt, shall be determined without regard to any statutory fines, penalties, fees, or other charges awarded to any party) to (a) pay the full amount of any unpaid costs and fees of the Arbitration and the Appeal Panel, and (b) reimburse the prevailing party (the party being awarded the most amount of money by the Appeal Panel, which, for the avoidance of doubt, shall be determined without regard to any statutory fines, penalties, fees, or other charges awarded to any part) the reasonable attorneys fees, arbitrator and Appeal Panel costs and fees, deposition costs, other discovery costs, and other expenses, costs or fees paid or otherwise incurred by the prevailing party in connection with the Arbitration (including without limitation in connection with the Appeal).

6.  Miscellaneous.

6.1 Severability. If any part of these Arbitration Provisions is found to violate or be illegal under applicable law, then such provision shall be modified to the minimum extent necessary to make such provision enforceable under applicable law, and the remainder of the Arbitration Provisions shall remain unaffected and in full force and effect.

6.2 Governing Law. These Arbitration Provisions shall be governed by the laws of the State of Utah without regard to the conflict of laws principles therein.

6.3 Interpretation. The headings of these Arbitration Provisions are for convenience of reference only and shall not form part of, or affect the interpretation of, these Arbitration Provisions.

6.4 Waiver. No waiver of any provision of these Arbitration Provisions shall be effective unless it is in the form of a writing signed by the party granting the waiver.

6.5 Time is of the Essence. Time is expressly made of the essence with respect to each and every provision of these Arbitration Provisions.

[Remainder of page intentionally left blank]

Arbitration Provisions, Page 7


EX-21.1 7 nwbo-20201231xex21d1.htm EXHIBIT 21.1

EXHIBIT 21.1

Subsidiaries of the Registrant

Name:

    

Jurisdiction

Aracaris, Ltd.

 

United Kingdom

 

 

 

Aracaris Capital, Ltd.

 

United Kingdom

 

 

 

NW Bio Gmbh

 

Germany

 

 

 

Northwest Biotherapeutics B.V.

 

Netherlands

Flaskworks LLC

 

United States


EX-23.1 8 nwbo-20201231xex23d1.htm EXHIBIT 23.1

Exhibit 23.1

INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM’S CONSENT

We consent to the incorporation by reference in the Registration Statement of Northwest Biotherapeutics, Inc. on Form S-3 [File No. 333-213777 and 333-234248] of our report dated March 16, 2020, except for the restatement as to the effectiveness of internal control over financial reporting for the material weakness related to ineffective designed controls over the evaluation and conclusion of contingencies under ASC 740, as to which the date is June 23, 2020, which includes an explanatory paragraph as to the Company’s ability to continue as a going concern, with respect to our audit of the consolidated financial statements of Northwest Biotherapeutics, Inc. as of December 31, 2019 and for the year ended December 31, 2019, which report is included in this Annual Report on Form 10-K of Northwest Biotherapeutics, Inc. for the year ended December 31, 2020.

Our report on the consolidated financial statements refers to a change in the method of accounting for leases due to the adoption of the guidance in ASC Topic 842 effective January 1, 2019.

/s/ Marcum LLP

Marcum LLP

New York, NY

March 31, 2021


EX-31.1 9 nwbo-20201231xex31d1.htm EXHIBIT 31.1

EXHIBIT 31.1

SECTION 302 CERTIFICATION

I, Linda F. Powers, certify that:

(1)I have reviewed this annual report on Form 10-K of Northwest Biotherapeutics, Inc.;

(2)Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;

(3)Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;

(4)I am responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)), and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15 (f)), for the registrant and have:

(a)

Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;

(b)

Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;

(c)

Evaluated the effectiveness of the registrant’s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and

(d)

Disclosed in this report any change in the registrant’s internal control over financial reporting that occurred during the registrant’s most recent fiscal quarter (the registrant’s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant’s internal control over financial reporting; and

(5)I have disclosed, based on my most recent evaluation of internal control over financial reporting, to the registrant’s auditors and the audit committee of the registrant’s Board of Directors (or persons performing the equivalent functions):

(a)

All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant’s ability to record, process, summarize and report financial information; and

(b)

Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant’s internal control over financial reporting.

Date: March 31, 2021

By:

/s/ Linda F. Powers

Name:

Linda F. Powers

Title:

President and Chief Executive Officer

Principal Executive Officer

Principal Financial and Accounting Officer


EX-32.1 10 nwbo-20201231xex32d1.htm EXHIBIT 32.1

EXHIBIT 32.1

CERTIFICATION PURSUANT TO

18 U.S.C. SECTION 1350,

AS ADOPTED PURSUANT TO

SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002

In connection with the annual report of Northwest Biotherapeutics, Inc. (the “Company”) on Form 10-K for the year ended December 31, 2020, as filed with the Securities and Exchange Commission (the “Report”), I, Linda F. Powers, certify, pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that:

(1)The Report fully complies with the requirements of section 13(a) or 15(d) of the Securities Exchange Act of 1934; and
(2)The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.

Date: March 31, 2021

By:

/s/ Linda F. Powers

Name:

Linda F. Powers

Title:

President and Chief Executive Officer

Principal Executive Officer

Principal Financial and Accounting Officer


EX-101.SCH 11 nwbo-20201231.xsd XBRL TAXONOMY EXTENSION SCHEMA 00100 - Statement - CONSOLIDATED BALANCE SHEETS link:presentationLink link:calculationLink link:definitionLink 00200 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS - Calc 2 link:presentationLink link:calculationLink link:definitionLink 00200 - Statement - CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS link:presentationLink link:calculationLink link:definitionLink 00400 - Statement - CONSOLIDATED STATEMENTS OF CASH FLOWS link:presentationLink link:calculationLink link:definitionLink 40401 - Disclosure - Fair Value Measurements (Details) link:presentationLink link:calculationLink link:definitionLink 40501 - Disclosure - Flaskworks Acquisition (Details) link:presentationLink link:calculationLink link:definitionLink 41002 - Disclosure - Related Party Transactions - Total interest expenses (Details) link:presentationLink link:calculationLink link:definitionLink 41201 - Disclosure - Commitments and Contingencies (Details) link:presentationLink link:calculationLink link:definitionLink 41202 - Disclosure - Commitments and Contingencies - maturities of our operating leases (Details) link:presentationLink link:calculationLink link:definitionLink 41202 - Disclosure - Commitments and Contingencies - maturities of our operating leases (Details) - Calc 2 link:presentationLink link:calculationLink link:definitionLink 41301 - Disclosure - Income Taxes - Summary of Deferred Tax Assets and Liabilities (Details) link:presentationLink link:calculationLink link:definitionLink 41303 - Disclosure - Income Taxes - Summary of Tax Provision Benefit (Details) link:presentationLink link:calculationLink link:definitionLink 00105 - Statement - CONSOLIDATED BALANCE SHEETS (Parenthetical) link:presentationLink link:calculationLink link:definitionLink 00300 - Statement - CONSOLIDATED STATEMENTS OF CHANGES IN STOCKHOLDERS' DEFICIT link:presentationLink link:calculationLink link:definitionLink 00305 - Statement - CONSOLIDATED STATEMENTS OF CHANGES IN STOCKHOLDERS' DEFICIT (Parenthetical) link:presentationLink link:calculationLink link:definitionLink 30603 - Disclosure - Stock-based Compensation (Tables) link:presentationLink link:calculationLink link:definitionLink 40201 - Disclosure - Financial Condition, Going Concern and Management Plans (Details Textual) link:presentationLink link:calculationLink link:definitionLink 40301 - Disclosure - Summary of Significant Accounting Policies (Details) link:presentationLink link:calculationLink link:definitionLink 40402 - Disclosure - Fair Value Measurements - Changes in Level 3 liabilities (Details) link:presentationLink link:calculationLink link:definitionLink 40403 - Disclosure - Fair Value Measurements - Weighted average (in aggregate) significant unobservable inputs (Details) link:presentationLink link:calculationLink link:definitionLink 40601 - Disclosure - Stock-based Compensation - Stock option activity (Details) link:presentationLink link:calculationLink link:definitionLink 40602 - Disclosure - Stock-based Compensation - Assumptions (Details) link:presentationLink link:calculationLink link:definitionLink 40603 - Disclosure - Stock-based Compensation - Summary of stock-based compensation expense (Details) link:presentationLink link:calculationLink link:definitionLink 40604 - Disclosure - Stock-based Compensation - Additional Information (Details) link:presentationLink link:calculationLink link:definitionLink 40701 - Disclosure - Property, Plant and Equipment (Details) link:presentationLink link:calculationLink link:definitionLink 40702 - Disclosure - Property, Plant and Equipment - Additional Information (Details) link:presentationLink link:calculationLink link:definitionLink 40801 - Disclosure - Notes Payable (Details) link:presentationLink link:calculationLink link:definitionLink 40803 - Disclosure - Notes Payable - Mortgage Loan (Details) link:presentationLink link:calculationLink link:definitionLink 40804 - Disclosure - Notes Payable - summary of the company's contractual obligations on debt principal (Details) link:presentationLink link:calculationLink link:definitionLink 40805 - Disclosure - Notes Payable - Additional Information (Details) link:presentationLink link:calculationLink link:definitionLink 40901 - Disclosure - Net Earnings (Loss) per Share Applicable to Common Stockholders (Details) link:presentationLink link:calculationLink link:definitionLink 41001 - Disclosure - Related Party Transactions - Summary of outstanding unpaid accounts payable held by related parties (Details) link:presentationLink link:calculationLink link:definitionLink 41003 - Disclosure - Related Party Transactions - Additional Information (Details) link:presentationLink link:calculationLink link:definitionLink 41101 - Disclosure - Stockholders' Deficit (Details) link:presentationLink link:calculationLink link:definitionLink 41102 - Disclosure - Stockholders' Deficit - Additional Information (Details link:presentationLink link:calculationLink link:definitionLink 41203 - Disclosure - Commitments and Contingencies - Additional Information (Details) link:presentationLink link:calculationLink link:definitionLink 41302 - Disclosure - Income Taxes - Reconcilation of U.S. Federal Statutory Tax Expense (Benefit) (Details) link:presentationLink link:calculationLink link:definitionLink 41304 - Disclosure - Income Taxes - Additional information (Details) link:presentationLink link:calculationLink link:definitionLink 41401 - Disclosure - Revision to Prior Period Financial Statements -Consolidated Balance Sheet (Details) link:presentationLink link:calculationLink link:definitionLink 41402 - Disclosure - Revision to Prior Period Financial Statements - Consolidated Statement of Operations (Detaills) link:presentationLink link:calculationLink link:definitionLink 41403 - Disclosure - Revision to Prior Period Financial Statements - Consolidated Statement of Cash Flows (Detaills) link:presentationLink link:calculationLink link:definitionLink 41501 - Disclosure - Subsequent Events (Details) link:presentationLink link:calculationLink link:definitionLink 00090 - Document - Document and Entity Information link:presentationLink link:calculationLink link:definitionLink 10101 - Disclosure - Organization and Description of Business link:presentationLink link:calculationLink link:definitionLink 10201 - Disclosure - Financial Condition, Going Concern and Management Plans link:presentationLink link:calculationLink link:definitionLink 10301 - Disclosure - Summary of Significant Accounting Policies link:presentationLink link:calculationLink link:definitionLink 10401 - Disclosure - Fair Value Measurements link:presentationLink link:calculationLink link:definitionLink 10501 - Disclosure - Flaskworks Acquisition link:presentationLink link:calculationLink link:definitionLink 10601 - Disclosure - Stock-based Compensation link:presentationLink link:calculationLink link:definitionLink 10701 - Disclosure - Property, Plant and Equipment link:presentationLink link:calculationLink link:definitionLink 10801 - Disclosure - Notes Payable link:presentationLink link:calculationLink link:definitionLink 10901 - Disclosure - Net Loss per Share Applicable to Common Stockholders link:presentationLink link:calculationLink link:definitionLink 11001 - Disclosure - Related Party Transactions link:presentationLink link:calculationLink link:definitionLink 11101 - Disclosure - Stockholders' Deficit link:presentationLink link:calculationLink link:definitionLink 11201 - Disclosure - Commitments and Contingencies link:presentationLink link:calculationLink link:definitionLink 11301 - Disclosure - Income Taxes link:presentationLink link:calculationLink link:definitionLink 11401 - Disclosure - Revision to Prior Period Financial Statements link:presentationLink link:calculationLink link:definitionLink 11501 - Disclosure - Subsequent Events link:presentationLink link:calculationLink link:definitionLink 20302 - Disclosure - Summary of Significant Accounting Policies (Policies) link:presentationLink link:calculationLink link:definitionLink 30403 - Disclosure - Fair Value Measurements (Tables) link:presentationLink link:calculationLink link:definitionLink 30503 - Disclosure - Flaskworks Acquisition (Tables) link:presentationLink link:calculationLink link:definitionLink 30703 - Disclosure - Property, Plant and Equipment (Tables) link:presentationLink link:calculationLink link:definitionLink 30803 - Disclosure - Notes Payable (Tables) link:presentationLink link:calculationLink link:definitionLink 30903 - Disclosure - Net Loss per Share Applicable to Common Stockholders (Tables) link:presentationLink link:calculationLink link:definitionLink 31003 - Disclosure - Related Party Transactions (Tables) link:presentationLink link:calculationLink link:definitionLink 31103 - Disclosure - Stockholders' Deficit (Tables) link:presentationLink link:calculationLink link:definitionLink 31203 - Disclosure - Commitments and Contingencies (Tables) link:presentationLink link:calculationLink link:definitionLink 31303 - Disclosure - Income Taxes (Tables) link:presentationLink link:calculationLink link:definitionLink EX-101.CAL 12 nwbo-20201231_cal.xml XBRL TAXONOMY EXTENSION CALCULATION LINKBASE EX-101.DEF 13 nwbo-20201231_def.xml XBRL TAXONOMY EXTENSION DEFINITION LINKBASE EX-101.LAB 14 nwbo-20201231_lab.xml XBRL TAXONOMY EXTENSION LABEL LINKBASE EX-101.PRE 15 nwbo-20201231_pre.xml XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE GRAPHIC 16 nwbo-20201231xex10d83001.jpg GRAPHIC begin 644 nwbo-20201231xex10d83001.jpg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nwbo-20201231xex10d83002.jpg GRAPHIC begin 644 nwbo-20201231xex10d83002.jpg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nwbo-20201231xex10d83003.jpg GRAPHIC begin 644 nwbo-20201231xex10d83003.jpg M_]C_X 02D9)1@ ! @ 0 ! #_VP!# @&!@<&!0@'!P<)"0@*#!0-# L+ M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#7J#A(6&AXB)BI*3E)66EYB9FJ*CI*6FIZBIJK*SM+6VM[BYNL+#Q,7& MQ\C)RM+3U-76U]C9VN'BX^3EYN?HZ>KQ\O/T]?;W^/GZ_\0 'P$ P$! 0$! M 0$! 0 $" P0%!@<("0H+_\0 M1$ @$"! 0#! <%! 0 0)W $" M Q$$!2$Q!A)!40=A<1,B,H$(%$*1H;'!"2,S4O 58G+1"A8D-.$E\1<8&1HF M)R@I*C4V-S@Y.D-$149'2$E*4U155E=865IC9&5F9VAI:G-T=79W>'EZ@H.$ MA8:'B(F*DI.4E9:7F)F:HJ.DI::GJ*FJLK.TM;:WN+FZPL/$Q<;'R,G*TM/4 MU=;7V-G:XN/DY>;GZ.GJ\O/T]?;W^/GZ_]H # ,! (1 Q$ /P#Q&BBBI ** M** "BBB@ HHHH .U?3?P%_Y$!O\ KX;^0KYD[5]-_ 7_ )$!O^OAOY"F@/F2 MBBBD 4444 %%%% !1110 =J^F_@+_P B W_7PW\A7S)VKZ;^ O\ R(#?]?#? MR%- ?,E%%%( HHH/ H **])T3X,:WKNC6^IP7=ND4ZAE#-R,T:K\$?%.G6C7 M$'D7849*QM\WX#%,#S:BGF*1+G[.ZE)-X0JPY!SBO3[7X%Z[U?3?P%_Y$!O^OAOY"O&O$_PJ\2^&+1KN:%+BU49:2$[MH]^*]E^ M O\ R(!_Z^#_ "%- ?,E%%%( I#T-+2'H: />?$ES<6OP#TR2WFDB?\ =#6(F-L%NXC"FP,,[>!2NDKLN$)5)"[FU\#-:VTSKC8!@_SZ MU!\&-/O=+\(3VE_"T5RETV]6'L*:L]A2C*#Y9*S/E?S$_O"D\U/[PKZ-.F6& M/^/&V_[]+_A2?V98?\^-M_WZ7_"F2?.?FI_>%!D3:?F%?1G]F6'_ #XVW_?I M?\*7^S+#'_'C;?\ ?I?\* "?PW?^*_@EI>GZ8$:1 MG4I;>WM5(+N) 3BOH;042/1[9(U5%"#"J, <4SQ"2-(EP2.*3 \*^,GB'3)Y M-%T#3YTG:RE4R.IR!VQFNN\?$#PEH)[^4O\ (5!'8VM=U MKD$+Z79*\2,H48!4''2HJ*\&CLR^I[/$PG:]CQ+3-6NM(NUN;.8QNIR1G@_6 MO;_"?BNU\0Z?Y@*QW2?ZU/?UKGA9VW_/M#_WP*T=&ABBN)?+C1,J,[5 [UA2 2O#2Y[&;3IXB'/R6:ZW_X!__9 end XML 19 nwbo-20201231x10k_htm.xml IDEA: XBRL DOCUMENT 0001072379 us-gaap:SubsequentEventMember 2021-02-28 0001072379 nwbo:SubscriptionReceivableMember 2020-01-01 2020-12-31 0001072379 nwbo:AprilFinancingMember 2020-04-01 2020-04-30 0001072379 nwbo:FlaskworksMember 2020-12-01 2020-12-01 0001072379 us-gaap:RetainedEarningsMember 2020-12-31 0001072379 us-gaap:AdditionalPaidInCapitalMember 2020-12-31 0001072379 us-gaap:AccumulatedTranslationAdjustmentMember 2020-12-31 0001072379 nwbo:SubscriptionReceivableMember 2020-12-31 0001072379 us-gaap:RetainedEarningsMember 2019-12-31 0001072379 us-gaap:AdditionalPaidInCapitalMember 2019-12-31 0001072379 us-gaap:AccumulatedTranslationAdjustmentMember 2019-12-31 0001072379 nwbo:SubscriptionReceivableMember 2019-12-31 0001072379 us-gaap:RetainedEarningsMember 2018-12-31 0001072379 us-gaap:AdditionalPaidInCapitalMember 2018-12-31 0001072379 us-gaap:AccumulatedTranslationAdjustmentMember 2018-12-31 0001072379 nwbo:SubscriptionReceivableMember 2018-12-31 0001072379 2018-09-26 0001072379 us-gaap:CommonStockMember 2020-12-31 0001072379 us-gaap:CommonStockMember 2019-12-31 0001072379 us-gaap:CommonStockMember 2018-12-31 0001072379 us-gaap:EmbeddedDerivativeFinancialInstrumentsMember us-gaap:FairValueInputsLevel3Member 2019-12-31 0001072379 nwbo:WarrantLiabilityMember us-gaap:FairValueInputsLevel3Member 2019-12-31 0001072379 srt:MinimumMember nwbo:CashlessOptionsExerciseMember us-gaap:SubsequentEventMember 2021-01-01 2021-03-31 0001072379 srt:MaximumMember nwbo:CashlessOptionsExerciseMember us-gaap:SubsequentEventMember 2021-01-01 2021-03-31 0001072379 us-gaap:EmployeeStockOptionMember 2020-01-01 2020-12-31 0001072379 2020-08-05 0001072379 2020-08-05 2020-08-05 0001072379 nwbo:PreModificationMember 2020-08-05 2020-08-05 0001072379 nwbo:PostModificationMember 2020-08-05 2020-08-05 0001072379 nwbo:PreModificationMember 2020-01-01 2020-12-31 0001072379 nwbo:PostModificationMember 2020-01-01 2020-12-31 0001072379 nwbo:PreModificationMember 2020-12-31 0001072379 nwbo:PostModificationMember 2020-12-31 0001072379 nwbo:PreModificationMember 2020-08-05 0001072379 nwbo:PostModificationMember 2020-08-05 0001072379 srt:MinimumMember 2019-12-31 0001072379 srt:MaximumMember 2019-12-31 0001072379 srt:CumulativeEffectPeriodOfAdoptionAdjustmentMember us-gaap:RetainedEarningsMember 2019-12-31 0001072379 srt:CumulativeEffectPeriodOfAdoptionAdjustmentMember 2019-12-31 0001072379 nwbo:Mr.GoldmanMember 2020-01-01 2020-12-31 0001072379 nwbo:AdventBioServicesNotesMember 2020-01-01 2020-12-31 0001072379 us-gaap:ConvertibleDebtMember us-gaap:SubsequentEventMember 2021-03-01 2021-03-01 0001072379 nwbo:GoldmanNoteMember 2020-01-01 2020-12-31 0001072379 2019-05-28 2019-05-28 0001072379 nwbo:SawstonBuildoutMember 2020-01-01 2020-12-31 0001072379 nwbo:AdventBioservicesMember 2020-01-01 2020-12-31 0001072379 nwbo:SawstonBuildoutMember 2019-01-01 2019-12-31 0001072379 nwbo:AdventBioservicesMember 2019-01-01 2019-12-31 0001072379 srt:MinimumMember us-gaap:PropertyPlantAndEquipmentOtherTypesMember 2020-01-01 2020-12-31 0001072379 srt:MinimumMember us-gaap:FurnitureAndFixturesMember 2020-01-01 2020-12-31 0001072379 srt:MaximumMember us-gaap:PropertyPlantAndEquipmentOtherTypesMember 2020-01-01 2020-12-31 0001072379 srt:MaximumMember us-gaap:FurnitureAndFixturesMember 2020-01-01 2020-12-31 0001072379 us-gaap:GeographicDistributionDomesticMember us-gaap:PropertyPlantAndEquipmentOtherTypesMember 2020-12-31 0001072379 us-gaap:GeographicDistributionDomesticMember us-gaap:LeaseholdImprovementsMember 2020-12-31 0001072379 us-gaap:GeographicDistributionDomesticMember us-gaap:FurnitureAndFixturesMember 2020-12-31 0001072379 country:GB us-gaap:LandMember 2020-12-31 0001072379 us-gaap:GeographicDistributionDomesticMember us-gaap:PropertyPlantAndEquipmentOtherTypesMember 2019-12-31 0001072379 us-gaap:GeographicDistributionDomesticMember us-gaap:LeaseholdImprovementsMember 2019-12-31 0001072379 us-gaap:GeographicDistributionDomesticMember us-gaap:FurnitureAndFixturesMember 2019-12-31 0001072379 country:GB us-gaap:LandMember 2019-12-31 0001072379 nwbo:AprilNotesMember us-gaap:ShortTermDebtMember nwbo:TenPercentUnsecuredMember 2020-04-01 2020-04-30 0001072379 2020-08-28 2020-08-28 0001072379 nwbo:RegisteredDirectOfferingMember 2020-01-01 2020-12-31 0001072379 us-gaap:AccumulatedTranslationAdjustmentMember 2020-01-01 2020-12-31 0001072379 us-gaap:AccumulatedTranslationAdjustmentMember 2019-01-01 2019-12-31 0001072379 country:DE us-gaap:ForeignCountryMember 2020-12-31 0001072379 country:US 2019-12-31 0001072379 country:GB 2019-12-31 0001072379 country:US 2019-03-04 0001072379 2019-01-01 0001072379 nwbo:SixPercentageNotePayableOneMember 2020-12-31 0001072379 nwbo:NoteDueIn2011Member 2020-12-31 0001072379 nwbo:SixPercentageNotePayableOneMember 2019-12-31 0001072379 nwbo:NoteDueIn2011Member 2019-12-31 0001072379 us-gaap:RetainedEarningsMember 2020-01-01 2020-12-31 0001072379 us-gaap:RetainedEarningsMember 2019-01-01 2019-12-31 0001072379 country:US 2020-01-01 2020-12-31 0001072379 country:GB 2020-01-01 2020-12-31 0001072379 country:US 2019-01-01 2019-12-31 0001072379 country:GB 2019-01-01 2019-12-31 0001072379 nwbo:RelatedPartyMember us-gaap:NotesPayableOtherPayablesMember 2020-01-01 2020-12-31 0001072379 nwbo:RelatedPartyMember us-gaap:ConvertibleNotesPayableMember 2020-01-01 2020-12-31 0001072379 us-gaap:ConvertibleNotesPayableMember 2020-01-01 2020-12-31 0001072379 nwbo:RelatedPartyMember us-gaap:NotesPayableOtherPayablesMember 2019-01-01 2019-12-31 0001072379 nwbo:RelatedPartyMember us-gaap:ConvertibleNotesPayableMember 2019-01-01 2019-12-31 0001072379 nwbo:ForbearanceOfDebtToRelatedPartiesMember 2020-01-01 2020-12-31 0001072379 us-gaap:EmbeddedDerivativeFinancialInstrumentsMember 2020-12-31 0001072379 nwbo:WarrantLiabilityMember 2020-12-31 0001072379 nwbo:ContingentPayableDerivativeLiabilityMember 2020-12-31 0001072379 nwbo:WarrantLiabilityMember 2019-12-31 0001072379 nwbo:ContingentPayableDerivativeLiabilityMember 2019-12-31 0001072379 us-gaap:EmbeddedDerivativeFinancialInstrumentsMember 2018-12-31 0001072379 nwbo:WarrantLiabilityMember 2018-12-31 0001072379 nwbo:WarrantLiabilityMember 2019-01-01 2019-12-31 0001072379 nwbo:ContingentPayableDerivativeLiabilityMember 2019-01-01 2019-12-31 0001072379 us-gaap:WarrantMember nwbo:RegisteredDirectOfferingMember 2020-01-01 2020-12-31 0001072379 nwbo:PlacementAgentMember us-gaap:WarrantMember 2020-01-01 2020-12-31 0001072379 nwbo:DirectOfferingMember 2020-01-01 2020-12-31 0001072379 nwbo:DirectOfferingMember 2019-01-01 2019-12-31 0001072379 nwbo:PromissoryNoteMember nwbo:TenPercentUnsecuredMember 2020-01-01 2020-12-31 0001072379 nwbo:GoldmanNoteMember 2020-12-31 0001072379 country:NL 2020-12-31 0001072379 country:DE 2020-12-31 0001072379 nwbo:PaycheckProtectionProgramLoanCaresActMember 2020-05-20 2020-05-20 0001072379 srt:MinimumMember nwbo:TenPercentUnsecuredMember 2020-01-01 2020-12-31 0001072379 srt:MaximumMember nwbo:TenPercentUnsecuredMember 2020-01-01 2020-12-31 0001072379 nwbo:ForbearanceWarrantsMember 2020-01-01 2020-12-31 0001072379 nwbo:AdventBioServicesNotesMember 2018-09-26 2018-09-26 0001072379 us-gaap:ShortTermDebtMember nwbo:SixPercentUnsecurbleMember 2020-01-01 2020-12-31 0001072379 us-gaap:ShortTermDebtMember nwbo:EightPercentUnsecuredMember 2020-01-01 2020-12-31 0001072379 nwbo:ShortTermNotesPayableMember nwbo:TwelvePercentUnsecuredMember 2020-01-01 2020-12-31 0001072379 nwbo:ShortTermNotesPayableMember nwbo:TenPercentUnsecuredMember 2020-01-01 2020-12-31 0001072379 nwbo:ShortTermNotesPayableMember nwbo:EightPercentUnsecuredMember 2020-01-01 2020-12-31 0001072379 nwbo:LongTermNotesPayableMember nwbo:SixPercentSecuredMember 2020-01-01 2020-12-31 0001072379 nwbo:LongTermNotesPayableMember nwbo:EightPercentUnsecuredMember 2020-01-01 2020-12-31 0001072379 us-gaap:ShortTermDebtMember nwbo:TenPercentUnsecuredMember 2019-01-01 2019-12-31 0001072379 us-gaap:ShortTermDebtMember nwbo:SixPercentUnsecurbleMember 2019-01-01 2019-12-31 0001072379 nwbo:ShortTermNotesPayableRelatedPartiesMember nwbo:TenPercentUnsecuredMember 2019-01-01 2019-12-31 0001072379 nwbo:ShortTermNotesPayableMember nwbo:ZeroPercentUnsecuredMember 2019-01-01 2019-12-31 0001072379 nwbo:ShortTermNotesPayableMember nwbo:TwelvePercentUnsecuredMember 2019-01-01 2019-12-31 0001072379 nwbo:ShortTermNotesPayableMember nwbo:TenPercentUnsecuredMember 2019-01-01 2019-12-31 0001072379 nwbo:ShortTermNotesPayableMember nwbo:EightPercentUnsecuredMember 2019-01-01 2019-12-31 0001072379 nwbo:LongTermNotesPayableMember nwbo:EightPercentUnsecuredMember 2019-01-01 2019-12-31 0001072379 srt:ExecutiveOfficerMember nwbo:AdventBioServicesNotesMember 2020-12-31 0001072379 nwbo:SixPercentUnsecurbleMember 2020-12-31 0001072379 nwbo:PaycheckProtectionProgramLoanCaresActMember 2020-05-20 0001072379 nwbo:AdventBioServicesNotesMember 2018-09-26 0001072379 us-gaap:ConvertiblePreferredStockMember 2019-12-31 0001072379 us-gaap:ConvertibleDebtMember us-gaap:SubsequentEventMember 2021-03-01 0001072379 nwbo:DebtInstrumentRedemptionMoreThanThreeAndLessThanFiveYearMember nwbo:LongTermNotesPayableMember nwbo:SixPercentSecuredMember 2020-12-31 0001072379 nwbo:DebtInstrumentRedemptionMoreThanOneAndLessThanTwoYearMember nwbo:LongTermNotesPayableMember nwbo:EightPercentUnsecuredMember 2020-12-31 0001072379 nwbo:DebtInstrumentRedemptionLessThanOneYearMember nwbo:ShortTermNotesPayableMember nwbo:TwelvePercentUnsecuredMember 2020-12-31 0001072379 nwbo:DebtInstrumentRedemptionLessThanOneYearMember nwbo:ShortTermNotesPayableMember nwbo:TenPercentUnsecuredMember 2020-12-31 0001072379 nwbo:DebtInstrumentRedemptionLessThanOneYearMember nwbo:ShortTermNotesPayableMember nwbo:EightPercentUnsecuredMember 2020-12-31 0001072379 nwbo:DebtInstrumentRedemptionLessThanOneYearMember nwbo:ShortTermConvertibleNoteMember nwbo:SixPercentUnsecuredMember 2020-12-31 0001072379 nwbo:DebtInstrumentRedemptionLessThanOneYearMember nwbo:ShortTermConvertibleNoteMember nwbo:EightPercentUnsecuredMember 2020-12-31 0001072379 nwbo:ShortTermNotesPayableMember nwbo:TwelvePercentUnsecuredMember 2020-12-31 0001072379 nwbo:ShortTermNotesPayableMember nwbo:TenPercentUnsecuredMember 2020-12-31 0001072379 nwbo:ShortTermNotesPayableMember nwbo:EightPercentUnsecuredMember 2020-12-31 0001072379 nwbo:ShortTermConvertibleNoteMember nwbo:SixPercentUnsecuredMember 2020-12-31 0001072379 nwbo:ShortTermConvertibleNoteMember nwbo:EightPercentUnsecuredMember 2020-12-31 0001072379 nwbo:PromissoryNoteMember nwbo:TenPercentUnsecuredMember 2020-12-31 0001072379 nwbo:LongTermNotesPayableMember nwbo:SixPercentSecuredMember 2020-12-31 0001072379 nwbo:LongTermNotesPayableMember nwbo:EightPercentUnsecuredMember 2020-12-31 0001072379 nwbo:TwelvePercentUnsecuredMember 2020-12-31 0001072379 nwbo:TenPercentUnsecuredMember 2020-12-31 0001072379 nwbo:ShortTermNotesPayableMember 2020-12-31 0001072379 nwbo:NotesMember 2020-12-31 0001072379 nwbo:LongTermNotesPayableMember 2020-12-31 0001072379 nwbo:DebtInstrumentRedemptionMoreThanThreeAndLessThanFiveYearMember 2020-12-31 0001072379 nwbo:DebtInstrumentRedemptionMoreThanOneAndLessThanTwoYearMember 2020-12-31 0001072379 nwbo:DebtInstrumentRedemptionLessThanOneYearMember 2020-12-31 0001072379 nwbo:AprilNotesMember us-gaap:ShortTermDebtMember nwbo:TenPercentUnsecuredMember 2020-04-30 0001072379 nwbo:CambridgePeterboroughCombinedAuthorityMember 2020-03-26 0001072379 nwbo:ShortTermNotesPayableRelatedPartiesMember nwbo:TenPercentUnsecuredMember 2019-12-31 0001072379 nwbo:ShortTermNotesPayableMember nwbo:ZeroPercentUnsecuredMember 2019-12-31 0001072379 nwbo:ShortTermNotesPayableMember nwbo:TwelvePercentUnsecuredMember 2019-12-31 0001072379 nwbo:ShortTermNotesPayableMember nwbo:TenPercentUnsecuredMember 2019-12-31 0001072379 nwbo:ShortTermNotesPayableMember nwbo:EightPercentUnsecuredMember 2019-12-31 0001072379 nwbo:LongTermNotesPayableMember nwbo:EightPercentUnsecuredMember 2019-12-31 0001072379 us-gaap:ShortTermDebtMember 2019-12-31 0001072379 nwbo:TwelvePercentUnsecuredMember 2019-12-31 0001072379 nwbo:ShortTermNotesPayableRelatedPartiesMember 2019-12-31 0001072379 nwbo:ShortTermNotesPayableMember 2019-12-31 0001072379 nwbo:LongTermNotesPayableMember 2019-12-31 0001072379 us-gaap:ShortTermDebtMember nwbo:SixPercentUnsecurbleMember 2020-12-31 0001072379 nwbo:TenPercentUnsecuredMember 2020-08-31 0001072379 srt:MinimumMember nwbo:GoldmanNoteMember 2020-05-31 0001072379 srt:MaximumMember nwbo:GoldmanNoteMember 2020-05-31 0001072379 srt:MinimumMember us-gaap:ShortTermDebtMember nwbo:TenPercentUnsecuredMember 2020-04-30 0001072379 srt:MaximumMember us-gaap:ShortTermDebtMember nwbo:TenPercentUnsecuredMember 2020-04-30 0001072379 us-gaap:ShortTermDebtMember nwbo:TenPercentUnsecuredMember 2019-12-31 0001072379 us-gaap:ShortTermDebtMember nwbo:SixPercentUnsecurbleMember 2019-12-31 0001072379 nwbo:AugustFinancingMember 2020-08-05 2020-08-05 0001072379 nwbo:AfterAmendmentMember nwbo:TenPercentUnsecuredMember 2020-01-01 2020-12-31 0001072379 us-gaap:ConvertibleDebtSecuritiesMember 2020-01-01 2020-12-31 0001072379 us-gaap:ConvertiblePreferredStockMember 2019-01-01 2019-12-31 0001072379 us-gaap:ShortTermDebtMember nwbo:TenPercentUnsecuredMember 2020-10-18 2020-10-18 0001072379 nwbo:AugustNoteMember 2020-09-29 2020-09-29 0001072379 nwbo:TwelvePercentUnsecuredMember 2020-01-01 2020-12-31 0001072379 nwbo:TwelvePercentUnsecuredMember 2019-01-01 2019-12-31 0001072379 srt:ExecutiveOfficerMember 2020-12-31 0001072379 srt:ExecutiveOfficerMember 2018-04-30 0001072379 nwbo:AfterAmendmentMember nwbo:TenPercentUnsecuredMember 2020-12-31 0001072379 nwbo:EightPercentUnsecuredMember 2020-12-31 0001072379 nwbo:MayNoteMember 2020-10-01 0001072379 nwbo:AugustNoteMember 2020-09-29 0001072379 nwbo:AprilNotesMember nwbo:TenPercentUnsecuredMember 2020-08-03 0001072379 nwbo:TenPercentUnsecuredMember 2020-05-31 0001072379 nwbo:ShortTermNotesPayableRelatedPartiesMember 2019-01-01 2019-12-31 0001072379 srt:ScenarioPreviouslyReportedMember 2019-01-01 2019-12-31 0001072379 nwbo:RegisteredDirectOfferingMember 2019-12-31 0001072379 nwbo:MayFinancingMember 2020-05-31 0001072379 srt:MinimumMember nwbo:CashlessWarrantsExerciseMember us-gaap:SubsequentEventMember 2021-03-31 0001072379 srt:MaximumMember nwbo:CashlessWarrantsExerciseMember us-gaap:SubsequentEventMember 2021-03-31 0001072379 srt:MinimumMember us-gaap:SubsequentEventMember 2021-03-31 0001072379 srt:MaximumMember us-gaap:SubsequentEventMember 2021-03-31 0001072379 srt:MinimumMember nwbo:AfterAmendmentMember nwbo:TenPercentUnsecuredMember 2020-12-31 0001072379 srt:MaximumMember nwbo:AfterAmendmentMember nwbo:TenPercentUnsecuredMember 2020-12-31 0001072379 srt:MinimumMember nwbo:PlacementAgentMember 2020-12-31 0001072379 nwbo:RegisteredDirectOfferingMember 2020-12-31 0001072379 nwbo:PlacementAgentMember 2020-12-31 0001072379 nwbo:ForbearanceWarrantsMember 2020-12-31 0001072379 us-gaap:ConvertibleNotesPayableMember nwbo:OctoberFinancingMember 2020-10-12 0001072379 us-gaap:CommonStockMember nwbo:OctoberFinancingMember 2020-10-12 0001072379 us-gaap:ConvertibleNotesPayableMember nwbo:AugustFinancingMember 2020-08-05 0001072379 us-gaap:CommonStockMember nwbo:AugustFinancingMember 2020-08-05 0001072379 nwbo:WarrantsIssuedAsConsiderationForWarrantsSuspensionMember nwbo:AugustFinancingMember 2020-08-05 0001072379 srt:MinimumMember nwbo:MayFinancingMember 2020-05-31 0001072379 srt:MaximumMember nwbo:MayFinancingMember 2020-05-31 0001072379 nwbo:MayNoteMember 2020-05-31 0001072379 nwbo:GoldmanNoteMember 2020-05-31 0001072379 srt:MinimumMember nwbo:AprilNotesMember nwbo:TenPercentUnsecuredMember 2020-04-30 0001072379 srt:MaximumMember nwbo:AprilNotesMember nwbo:TenPercentUnsecuredMember 2020-04-30 0001072379 us-gaap:ShortTermDebtMember nwbo:TenPercentUnsecuredMember 2020-04-30 0001072379 nwbo:AprilNotesMember nwbo:TenPercentUnsecuredMember 2020-04-30 0001072379 nwbo:AprilFinancingMember 2020-04-30 0001072379 nwbo:FebruaryNotesMember us-gaap:ShortTermDebtMember nwbo:TenPercentUnsecuredMember 2020-02-29 0001072379 nwbo:FlaskworksMember 2020-10-01 2020-12-31 0001072379 nwbo:FlaskworksMember 2020-12-25 0001072379 us-gaap:WarrantMember 2020-01-01 2020-12-31 0001072379 nwbo:ConvertibleNotesMember 2020-01-01 2020-12-31 0001072379 nwbo:CommonStockWarrantsLiabilityTreatmentMember 2020-01-01 2020-12-31 0001072379 nwbo:CommonStockOptionsMember 2020-01-01 2020-12-31 0001072379 us-gaap:WarrantMember 2019-01-01 2019-12-31 0001072379 nwbo:ConvertibleNotesMember 2019-01-01 2019-12-31 0001072379 nwbo:CommonStockWarrantsLiabilityTreatmentMember 2019-01-01 2019-12-31 0001072379 nwbo:CommonStockOptionsMember 2019-01-01 2019-12-31 0001072379 us-gaap:NotesPayableOtherPayablesMember 2020-01-01 2020-12-31 0001072379 us-gaap:NotesPayableOtherPayablesMember 2019-01-01 2019-12-31 0001072379 nwbo:ShortTermNotesPayableRelatedPartiesMember 2020-01-01 2020-12-31 0001072379 us-gaap:ResearchAndDevelopmentExpenseMember 2020-12-01 2020-12-01 0001072379 us-gaap:GeneralAndAdministrativeExpenseMember 2020-12-01 2020-12-01 0001072379 us-gaap:ResearchAndDevelopmentExpenseMember 2020-01-01 2020-12-31 0001072379 us-gaap:GeneralAndAdministrativeExpenseMember 2020-01-01 2020-12-31 0001072379 nwbo:FlaskworksMember 2020-01-01 2020-12-31 0001072379 us-gaap:ResearchAndDevelopmentExpenseMember 2019-01-01 2019-12-31 0001072379 us-gaap:GeneralAndAdministrativeExpenseMember 2019-01-01 2019-12-31 0001072379 nwbo:AncillaryServicesAgreementMember 2020-12-31 0001072379 nwbo:AdventBioServicesNotesMember 2020-12-31 0001072379 nwbo:AdventBioServicesAgreementMember 2020-12-31 0001072379 nwbo:AncillaryServicesAgreementMember 2019-12-31 0001072379 nwbo:AdventBioServicesNotesMember 2019-12-31 0001072379 nwbo:AdventBioServicesAgreementMember 2019-12-31 0001072379 nwbo:OctoberNoteMember 2020-10-01 2020-10-31 0001072379 nwbo:AugustNoteMember 2020-08-01 2020-08-31 0001072379 nwbo:MayNoteMember 2020-05-01 2020-05-31 0001072379 nwbo:GoldmanNoteMember 2020-02-01 2020-05-31 0001072379 nwbo:FebruaryNotesMember us-gaap:ShortTermDebtMember nwbo:TenPercentUnsecuredMember 2020-02-01 2020-02-29 0001072379 us-gaap:ForeignCountryMember 2021-02-12 2021-02-12 0001072379 us-gaap:SubsequentEventMember 2021-01-01 2021-03-31 0001072379 nwbo:FlaskworksMember 2020-08-05 0001072379 2020-04-01 2020-04-30 0001072379 nwbo:AdventBioserivicesMember 2018-05-14 2018-05-14 0001072379 nwbo:MayFinancingMember 2020-05-01 2020-05-31 0001072379 nwbo:AprilFinancingMember 2020-01-01 2020-12-31 0001072379 us-gaap:CommonStockMember 2020-10-12 2020-10-12 0001072379 srt:ExecutiveOfficerMember 2020-01-01 2020-12-31 0001072379 nwbo:CashlessWarrantsExerciseMember us-gaap:SubsequentEventMember 2021-01-01 2021-03-31 0001072379 us-gaap:CommonStockMember 2020-01-01 2020-12-31 0001072379 nwbo:CashlessOptionsExerciseMember us-gaap:SubsequentEventMember 2021-01-01 2021-03-31 0001072379 nwbo:AprilNotesMember nwbo:TenPercentUnsecuredMember 2020-04-01 2020-04-30 0001072379 us-gaap:ConvertibleDebtMember us-gaap:SubsequentEventMember 2021-11-01 2021-11-01 0001072379 country:US 2020-12-31 0001072379 country:GB 2020-12-31 0001072379 us-gaap:LeaseholdImprovementsMember 2020-01-01 2020-12-31 0001072379 nwbo:ShareSettlementAgreementMember 2019-01-01 2019-12-31 0001072379 nwbo:FlaskworksMember 2020-12-25 2020-12-25 0001072379 us-gaap:ShortTermDebtMember nwbo:EightPercentUnsecuredMember 2020-12-31 0001072379 us-gaap:ShortTermDebtMember 2020-12-31 0001072379 us-gaap:EmbeddedDerivativeFinancialInstrumentsMember 2019-01-01 2019-12-31 0001072379 us-gaap:ShortTermDebtMember nwbo:TenPercentUnsecuredMember 2020-04-01 2020-04-30 0001072379 nwbo:WarrantLiabilityMember 2020-01-01 2020-12-31 0001072379 nwbo:ContingentPayableDerivativeLiabilityMember 2020-01-01 2020-12-31 0001072379 us-gaap:EmbeddedDerivativeFinancialInstrumentsMember us-gaap:FairValueInputsLevel3Member 2019-01-01 2019-12-31 0001072379 nwbo:WarrantLiabilityMember us-gaap:FairValueInputsLevel3Member 2019-01-01 2019-12-31 0001072379 nwbo:TenPercentUnsecuredMember 2020-08-01 2020-08-31 0001072379 nwbo:AncillaryServicesAgreementMember 2020-01-01 2020-12-31 0001072379 nwbo:AugustFinancingMember 2020-08-01 2020-08-31 0001072379 nwbo:CognateBioServicesNotesMember nwbo:ContingentNotePayableMember 2020-12-31 0001072379 nwbo:CambridgePeterboroughCombinedAuthorityMember 2020-03-26 2020-03-26 0001072379 nwbo:AprilNotesMember us-gaap:ShortTermDebtMember 2020-04-01 2020-04-30 0001072379 us-gaap:InvestorMember us-gaap:ConvertibleDebtMember us-gaap:SubsequentEventMember 2021-03-01 0001072379 nwbo:OctoberNoteMember 2020-10-31 0001072379 nwbo:AugustNoteMember 2020-08-31 0001072379 us-gaap:InvestorMember us-gaap:ConvertibleDebtMember us-gaap:SubsequentEventMember 2021-03-01 2021-03-01 0001072379 nwbo:NotesMember 2020-01-01 2020-12-31 0001072379 nwbo:MayNoteMember 2020-10-01 2020-10-01 0001072379 nwbo:AprilNotesMember nwbo:TenPercentUnsecuredMember 2020-08-03 2020-08-03 0001072379 nwbo:TenPercentUnsecuredMember 2020-05-01 2020-05-31 0001072379 nwbo:FebruaryNotesMember nwbo:TenPercentUnsecuredMember 2020-01-01 2020-12-31 0001072379 nwbo:AprilNotesMember nwbo:TenPercentUnsecuredMember 2020-01-01 2020-12-31 0001072379 nwbo:TenPercentUnsecuredMember 2020-01-01 2020-12-31 0001072379 nwbo:EightPercentUnsecuredMember 2020-01-01 2020-12-31 0001072379 us-gaap:FairValueInputsLevel3Member 2020-12-31 0001072379 us-gaap:FairValueInputsLevel2Member 2020-12-31 0001072379 us-gaap:FairValueInputsLevel1Member 2020-12-31 0001072379 us-gaap:FairValueInputsLevel3Member 2019-12-31 0001072379 us-gaap:FairValueInputsLevel2Member 2019-12-31 0001072379 us-gaap:FairValueInputsLevel1Member 2019-12-31 0001072379 us-gaap:GeographicDistributionDomesticMember 2020-12-31 0001072379 us-gaap:GeographicDistributionDomesticMember 2019-12-31 0001072379 srt:MinimumMember nwbo:MayFinancingMember 2020-05-01 2020-05-31 0001072379 srt:MaximumMember nwbo:MayFinancingMember 2020-05-01 2020-05-31 0001072379 nwbo:PlacementAgentMember 2020-01-01 2020-12-31 0001072379 nwbo:ForbearanceWarrantsMember 2020-07-02 2020-07-02 0001072379 nwbo:WarrantsThroughDecemberFifteenTwoThousandAndTwentyMember 2020-10-12 2020-10-12 0001072379 nwbo:WarrantsOherNewSharePurchasesMember 2020-10-12 2020-10-12 0001072379 us-gaap:SubsequentEventMember 2021-04-30 0001072379 2020-12-15 0001072379 2020-10-12 0001072379 nwbo:AugustFinancingMember 2020-08-05 0001072379 us-gaap:ConvertibleNotesPayableMember nwbo:AugustFinancingMember 2020-08-05 2020-08-05 0001072379 2020-05-10 2020-05-10 0001072379 2018-12-31 0001072379 2018-01-01 2018-12-31 0001072379 us-gaap:CommonStockMember nwbo:AugustFinancingMember 2020-08-05 2020-08-05 0001072379 us-gaap:SubsequentEventMember 2021-02-28 2021-02-28 0001072379 2020-10-31 2020-10-31 0001072379 us-gaap:SubsequentEventMember 2021-01-15 2021-01-15 0001072379 us-gaap:ConvertibleNotesPayableMember nwbo:OctoberFinancingMember 2020-10-12 2020-10-12 0001072379 us-gaap:CommonStockMember nwbo:OctoberFinancingMember 2020-10-12 2020-10-12 0001072379 nwbo:OctoberFinancingMember 2020-10-12 2020-10-12 0001072379 srt:MinimumMember us-gaap:CommonStockMember nwbo:AugustFinancingMember 2020-08-05 2020-08-05 0001072379 srt:MinimumMember nwbo:WarrantsIssuedAsConsiderationForWarrantsSuspensionMember nwbo:AugustFinancingMember 2020-08-05 2020-08-05 0001072379 srt:MaximumMember us-gaap:CommonStockMember nwbo:AugustFinancingMember 2020-08-05 2020-08-05 0001072379 srt:MaximumMember nwbo:WarrantsIssuedAsConsiderationForWarrantsSuspensionMember nwbo:AugustFinancingMember 2020-08-05 2020-08-05 0001072379 2020-11-01 0001072379 nwbo:WarrantsIssuedAsConsiderationForWarrantsSuspensionMember 2020-10-31 0001072379 2020-04-30 0001072379 us-gaap:SubsequentEventMember 2021-01-15 0001072379 nwbo:OctoberFinancingMember 2020-10-12 0001072379 2020-05-10 0001072379 srt:RevisionOfPriorPeriodErrorCorrectionAdjustmentMember nwbo:ErrorCorrectionAccrualAndCapitalizationErrorsMember 2019-01-01 2019-12-31 0001072379 nwbo:FlaskworksMember 2020-08-28 2020-08-28 0001072379 nwbo:FlaskworksMember 2020-08-28 0001072379 us-gaap:EmbeddedDerivativeFinancialInstrumentsMember 2020-01-01 2020-12-31 0001072379 nwbo:AncillaryServicesAgreementMember 2019-11-08 2019-11-08 0001072379 us-gaap:CommonStockMember 2019-01-01 2019-12-31 0001072379 us-gaap:AdditionalPaidInCapitalMember 2020-01-01 2020-12-31 0001072379 us-gaap:AdditionalPaidInCapitalMember 2019-01-01 2019-12-31 0001072379 2019-01-01 2019-12-31 0001072379 2020-12-31 0001072379 srt:RevisionOfPriorPeriodErrorCorrectionAdjustmentMember nwbo:ErrorCorrectionAccrualAndCapitalizationErrorsMember 2019-12-31 0001072379 srt:ScenarioPreviouslyReportedMember 2019-12-31 0001072379 srt:RevisionOfPriorPeriodErrorCorrectionAdjustmentMember 2019-12-31 0001072379 2019-12-31 0001072379 2020-06-30 0001072379 2021-03-26 0001072379 2020-01-01 2020-12-31 shares iso4217:USD pure iso4217:USD shares nwbo:installment iso4217:EUR iso4217:GBP nwbo:segment 0001072379 --12-31 2020 FY false NORTHWEST BIOTHERAPEUTICS INC true 829600000 614300000 0 0.37 P2Y P5Y P8M P12M 0.5 P5Y P2Y P2Y P30M P12M P3M P12M P12M P2Y6M 4300000 600000 10-K true 2020-12-31 false 001-35737 DE 94-3306718 4800 Montgomery Lane Suite 800 Bethesda MD 20814 240 497-9024 Common Stock, par value $0.001 per share NWBO No No Yes Yes Non-accelerated Filer false false 234821000 842137013 9983000 372000 5528000 2828000 15511000 3200000 1040000 281000 9074000 1685000 4489000 4679000 1292000 0 626000 0 867000 798000 17388000 7443000 32899000 10643000 7380000 6348000 5363000 3844000 3830000 568000 2437000 5501000 66000 8275000 7261000 354972000 20213000 167000 395000 382424000 44196000 8507000 6588000 4916000 4914000 13423000 11502000 395847000 55698000 0.001 0.001 100000000 100000000 0.001 0.001 1200000000 1200000000 829600000 614300000 830000 614000 1008665000 794900000 79000 10000 -1371216000 -841395000 -1148000 836000 -362948000 -45055000 32899000 10643000 1291000 2410000 1291000 2410000 33637000 14106000 50992000 12541000 3267000 3742000 87896000 30389000 -86605000 -27979000 -435351000 11828000 -1582000 -1941000 8544000 2975000 2261000 255000 -443216000 7167000 -529821000 -20812000 1984000 164000 -531805000 -20976000 -0.73 -0.04 725129 564188 523232000 523000 775741000 -10000 -825385000 1000000 -48131000 2700000 400000 32708 33000 4040000 4073000 9532 10000 2210000 2220000 1759000 1759000 35480 35000 9138000 9173000 1340 1000 1818000 1819000 4802000 4802000 12000 12000 -12000 68000 68000 138000 138000 -20812000 -20812000 -164000 -164000 614292 614000 794900000 -10000 -841395000 836000 -45055000 10300000 600000 97981 98000 16462000 -69000 16491000 58368 58000 19591000 19649000 47511 48000 13867000 13915000 22701000 22701000 7086 7000 -7000 71 9478000 9478000 44000 44000 655 1000 1132000 1133000 3667 4000 52205000 0 0 0 52209000 78292000 78292000 -529821000 -529821000 -1984000 -1984000 829631 830000 1008665000 -79000 -1371216000 -1148000 -362948000 -529821000 -20812000 87000 21000 3013000 1430000 -435351000 11828000 -913000 -1582000 -1941000 338000 -322000 3000 52209000 1819000 4270000 497763000 -6936000 2350000 1226000 31000 11000 1702000 30000 431000 -3230000 213000 326000 -32093000 -31859000 6610000 360000 1532000 -8142000 -360000 26814000 6874000 13915000 2220000 4000 7000 8557000 7000000 5115000 315000 1556000 420000 379000 329000 89000 5400000 52696000 9952000 -2850000 415000 9611000 -21852000 372000 22224000 9983000 372000 43000 9000 177000 11000 19000 795000 220000 7000 22701000 1759000 9478000 78292000 8230000 7313000 4876000 2693000 108000 153000 395000 91000 44000 68000 138000 1088000 947000 8560000 12000 <p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;text-align:justify;margin:0pt 0pt 12pt 0pt;">1. Organization and Description of Business</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">Northwest Biotherapeutics, Inc. and its wholly owned subsidiaries NW Bio GmbH, Aracaris Ltd, Aracaris Capital, Ltd, and Northwest Biotherapeutics B.V. (collectively, the “Company”, “we”, “us” and “our”) were organized to discover and develop innovative immunotherapies for cancer. The Company has developed DCVax® platform technologies for both operable and inoperable solid tumor cancers. The Company has wholly owned subsidiaries in the U.K. and on April 25, 2019, the Company established a new wholly owned subsidiary Northwest Biotherapeutics B.V. in the Netherlands, where the European Medicines Agency is relocating.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 10pt 0pt;">The Company relies upon contract manufacturers for production of its DCVax products, research and development services, distribution and logistics, and related services, in compliance with the Company’s specifications and the applicable regulatory requirements. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">On August 28, 2020, the Company acquired Flaskworks, LLC (“Flaskworks”), a company that has developed a system to close and automate the manufacturing of cell therapy products such as DCVax®.</p> <p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;text-align:justify;margin:0pt 0pt 12pt 0pt;">2. Financial Condition, Going Concern and Management Plans</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">The Company has incurred annual net operating losses since its inception. The Company had a net loss of $529.8 million, which included a cash loss of $32 million and a non-cash loss of $497.8 million, for the year ended December 31, 2020. The increase in net loss for the year ended December 31, 2020 was primarily due to the increased stock price, which resulted in significant non-cash loss from the change on the derivative liability. The Company used approximately $32.1 million of cash in its operating activities for the year ended December 31, 2020. Management believes that the Company has access to capital resources through the sale of equity and debt financing arrangements. However, the Company has not secured any commitments for new financing for this specific purpose at this time.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">The Company does not expect to generate material revenue in the near future from the sale of products and is subject to all of the risks and uncertainties that are typically faced by biotechnology companies that devote substantially all of their efforts to R&amp;D and clinical trials and do not yet have commercial products. The Company expects to continue incurring annual losses for the foreseeable future. The Company’s existing liquidity is not sufficient to fund its operations, anticipated capital expenditures, working capital and other financing requirements until the Company reaches significant revenues. Until that time, the Company will need to obtain additional equity and/or debt financing, especially if the Company experiences downturns in its business that are more severe or longer than anticipated, or if the Company experiences significant increases in expense levels resulting from being a publicly-traded company or from expansion of operations. If the Company attempts to obtain additional equity or debt financing, the Company cannot assume that such financing will be available to the Company on favorable terms, or at all. Because of recurring operating losses and operating cash flow deficits, there is substantial doubt about the Company’s ability to continue as a going concern within one year from the date of this filing. The consolidated financial statements have been prepared assuming that the Company will continue as a going concern, and do not include any adjustments to reflect the possible future effects on the recoverability and classification of assets, or the amounts and classification of liabilities that may result from the outcome of this uncertainty.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">As also previously reported, coronavirus-related difficulties have impacted most aspects of the process, especially with the successive waves of COVID cases in many areas. The independent service firms have had limited capacity, and restrictions on operations. Key experts at certain specialized service providers have been unavailable for periods of time due to illness in their family.  Other experts have gone on extended leave due to restrictions on operations. Clinical trial site personnel have been unavailable due to being reassigned for COVID, and the limited site personnel have had to work under restrictions. Committee processes and regulatory processes have been similarly focused on COVID matters and delayed on other matters. Firms such as the ones storing the Phase III trial tissue samples that are needed for certain analyses, and the firms conducting the analyses, continue to have only limited operations. Even logistical matters such as the shipping of materials have been, and continue to be, subjected to substantial restrictions and delays.</p> -529800000 32000000 497800000 -32100000 <p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;text-align:justify;margin:0pt 0pt 12pt 0pt;">3. Summary of Significant Accounting Policies</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;text-align:justify;margin:0pt 0pt 12pt 0pt;">Basis of Presentation</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">The accompanying consolidated financial statements of the Company were prepared in accordance with generally accepted accounting principles in the U.S. (“U.S. GAAP”) and include the assets, liabilities, revenues and expenses of the wholly owned subsidiaries in Germany, United Kingdom and Netherlands. All intercompany transactions and accounts have been eliminated in consolidation.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;text-align:justify;margin:0pt 0pt 12pt 0pt;">Consolidation</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">The Company’s policy is to consolidate all entities in which it can vote a majority of the outstanding voting stock. In addition, the Company consolidates entities that meet the definition of a variable interest entity (VIE) for which the Company is the primary beneficiary, if any. The primary beneficiary is the party who has the power to direct the activities of a VIE that most significantly impact the entity’s economic performance and who has an obligation to absorb losses of the entity or a right to receive benefits from the entity that could potentially be significant to the VIE.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">As of December 31, 2020, the Company did not consolidate any VIE's as the Company has concluded that it is not the primary beneficiary.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;text-align:justify;margin:0pt 0pt 12pt 0pt;">Use of Estimates</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">In preparing consolidated financial statements in conformity with U.S. GAAP, management is required to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements, as well as the reported amounts of expenses during the reporting period. Due to inherent uncertainty involved in making estimates, actual results reported in future periods may be affected by changes in these estimates.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">On an ongoing basis, the Company evaluates its estimates and judgments, including valuing equity securities in share-based payment arrangements, estimating the fair value of financial instruments recorded as derivative liabilities, useful lives of depreciable assets and whether impairment charges may apply. The Company bases its estimates on historical experience and on various other assumptions that it believes to be reasonable under the circumstances, the results of which form the basis for making judgments about the carrying values of assets and liabilities and the reported amounts of revenues and expenses that are not readily apparent from other sources. Actual results could differ from those estimates, particularly given the significant social and economic disruptions and uncertainties associated with the ongoing coronavirus pandemic ("COVID-19") and the COVID-19 control responses.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Concentration of Credit Risk</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">Financial instruments that potentially subject the Company to concentration of credit risk consist of cash accounts in a financial institution, which at times may exceed the Federal depository insurance coverage (“FDIC”) of $250,000. As of December 31, 2020, of the total $10 million in cash and cash equivalents, $0.6 million was held by foreign subsidiaries. The Company had not experienced losses on these accounts and management believes the Company is not exposed to significant risks on such accounts.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;text-align:justify;margin:0pt 0pt 12pt 0pt;">Property, Plant and Equipment</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">Property and equipment are stated at cost. Depreciation and amortization are provided for using straight-line methods, in amounts sufficient to charge the cost of depreciable assets to operations over their estimated service lives. Repairs and maintenance costs are charged to operations as incurred.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">Costs for capital assets not yet placed into service are capitalized as construction in progress on the consolidated balance sheets and will be depreciated once placed into service.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">The Company assesses its long-lived assets for impairment whenever facts and circumstances indicate that the carrying amounts may not be fully recoverable. To analyze recoverability, the Company projects undiscounted net future cash flows over the remaining lives of such assets. If these projected undiscounted net future cash flows are less than the carrying amounts, an impairment loss would be recognized, resulting in a write-down of the assets with a corresponding charge to earnings. The impairment loss is measured based upon the difference between the carrying amounts and the fair values of the assets.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;text-align:justify;margin:0pt 0pt 12pt 0pt;">Goodwill and Intangible Assets</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">Goodwill is the excess of purchase price over the fair value of identified net assets of businesses acquired. The Company's intangible asset with an indefinite life is related to in-process research and development ("IPR&amp;D") programs acquired in the Flaskworks Acquisition, as the Company expects future research and development on these programs to provide the Company with substantial benefit for a period that extends beyond the foreseeable horizon. Intangible assets with indefinite useful lives are measured at their respective fair values as of the acquisition date. The Company does not amortize goodwill and intangible assets with indefinite useful lives. Intangible assets related to IPR&amp;D projects are considered to be indefinite lived until the completion or abandonment of the associated R&amp;D efforts. If and when development is complete, which generally occurs if and when regulatory approval to market a product is obtained, the associated assets would be deemed finite lived and would then be amortized based on their respective estimated useful lives at that point in time.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">The Company has one operating segment and one reporting unit. The Company reviews goodwill and indefinite-lived intangible assets at least annually for possible impairment. Goodwill and indefinite-lived intangible assets are reviewed for possible impairment between annual tests if an event occurs or circumstances change that would more likely than not reduce the fair value of the reporting unit or the indefinite-lived intangible assets below their carrying values. <span style="-sec-ix-hidden:Hidden_oUSWpFQ08kK4q5HI-uY4-A;"><span style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:justify;">No</span></span> impairment charge was recognized for the year ended December 31, 2020.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;text-align:justify;margin:0pt 0pt 12pt 0pt;">Fair Value of Financial Instruments</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">ASC 820, Fair Value Measurements, provides guidance on the development and disclosure of fair value measurements. Under this accounting guidance, fair value is defined as an exit price, representing the amount that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date. As such, fair value is a market-based measurement that should be determined based on assumptions that market participants would use in pricing an asset or a liability.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">The accounting guidance classifies fair value measurements in one of the following three categories for disclosure purposes:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:41.25pt;text-align:justify;text-indent:-41.25pt;margin:0pt 0pt 12pt 18pt;">Level 1:    Quoted prices in active markets for identical assets or liabilities.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:44.65pt;text-align:justify;text-indent:-44.65pt;margin:0pt 0pt 12pt 18pt;">Level 2:    Inputs other than Level 1 prices for similar assets or liabilities that are directly or indirectly observable in the marketplace.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:44.65pt;text-align:justify;text-indent:-44.65pt;margin:0pt 0pt 12pt 18pt;">Level 3:    Unobservable inputs which are supported by little or no market activity and values determined using pricing models, discounted cash flow methodologies, or similar techniques, as well as instruments for which the determination of fair value requires significant judgment or estimation.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">The Company accounts for the issuance of common stock purchase warrants issued in connection with the equity offerings in accordance with the provisions of ASC 815, Derivatives and Hedging ("ASC 815"). The Company classifies as equity any contracts that (i) require physical settlement or net-share settlement or (ii) gives the Company a choice of net-cash settlement or settlement in its own shares (physical settlement or net-share settlement). The Company accounts for certain common stock warrants outstanding as a liability at fair value and adjusts the instruments to fair value at each reporting period. This liability is subject to re-measurement at each balance sheet date until exercised, and any change in fair value is recognized in its Consolidated Statements of Operations and Comprehensive Loss. The fair value of the warrants issued by the Company has been estimated using Monte Carlo simulation and or a Black Scholes model. The warrant liabilities are valued using Level 3 valuation inputs (see Note 4).</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;text-align:justify;margin:0pt 0pt 12pt 0pt;">Embedded Conversion Features</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">The Company evaluates embedded conversion features within convertible debt instruments to determine whether the embedded conversion feature(s) should be bifurcated from the host instrument and accounted for as a derivative at fair value with changes in fair value recorded in the Statement of Operations. If the conversion feature does not require recognition of a bifurcated derivative, the convertible debt instrument is evaluated for consideration of any beneficial conversion feature (“BCF”) requiring separate recognition. When the Company record a BCF, the intrinsic value of the BCF is recorded as a debt discount against the face amount of the respective debt instrument (offset to additional paid-in capital) and amortized to interest expense over the life of the debt.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Derivative Financial Instruments</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">The Company has derivative financial instruments that are not hedges and do not qualify for hedge accounting. Changes in the fair value of these instruments are recorded in other income (expense), on a net basis in the Consolidated Statements of Operations and Comprehensive Loss.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Contingent payable derivative liability</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">During the year ended December 31, 2019, the Company entered into a settlement agreement with Cognate BioServices, resolving past matters and providing for the restart of DCVax®-Direct Production.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">As part of this overall settlement, the Company also provided a contingent note payable (the “Contingent Payable Derivative”) of $10 million, which is only payable upon the Company’s first financing after DCVax product approval in or outside the U.S. If such product approval has not been obtained by the seventh anniversary of the agreement, such Contingent Payable Derivative will expire without becoming payable.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">On a quarterly basis, management makes estimates for key performance milestones and uses the expected dates as the inputs for valuation. The fair value of the Contingent Payable Derivative has been estimated using Monte Carlo simulation, which are valued using Level 3 valuation inputs.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;text-align:justify;margin:0pt 0pt 12pt 0pt;">Leases</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">Prior to January 1, 2019, the Company recognized rent expense on a straight-line basis over the lease period and accounts for the difference between straight-line rent and actual lease payments as deferred rent.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">Subsequent to the adoption of the new leasing standard on January 1, 2019, the Company recognizes a lease asset for its right to use the underlying asset and a lease liability for the corresponding lease obligation. The Company determines whether an arrangement is or contains a lease at contract inception. Operating leases with a duration greater than one year are included in right-of-use assets, lease liabilities, and lease liabilities, net of current portion in the Company’s consolidated balance sheets. Right-of-use assets and liabilities are recognized at the lease commencement date based on the present value of lease payments over the lease term. In determining the net present value of lease payments, the Company uses its incremental borrowing rate based on the information available at the lease commencement date. The incremental borrowing rate represents the interest rate the Company would incur at lease commencement to borrow an amount equal to the lease payments on a collateralized basis over the term of a lease. The Company considers a lease term to be the non-cancelable period that it has the right to use the underlying asset.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">The operating lease right-of-use assets also include any lease payments made and exclude lease incentives. Lease expense is recognized on a straight-line basis over the expected lease term. Variable lease expenses are recorded when incurred.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;text-align:justify;margin:0pt 0pt 12pt 0pt;">Foreign Currency Translation and Transactions</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">The Company has operations in Germany, the United Kingdom and Netherlands in addition to the U.S. The Company translated its assets and liabilities into U.S. dollars using end of period exchange rates and revenues and expenses are translated into U.S. dollars using weighted average rates. Foreign currency translation adjustments are reported as a separate component of accumulated other comprehensive income (loss) within stockholders’ equity deficit.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">The Company converts receivables and payables denominated in other than the Company’s functional currency at the exchange rate as of the balance sheet date. The resulting transaction exchange gains or losses related to intercompany receivable and payables, are included in other income and expense.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;text-align:justify;margin:0pt 0pt 12pt 0pt;">Comprehensive Loss</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">The Company reports comprehensive loss and its components in its consolidated financial statements. Comprehensive loss consists of net loss and foreign currency translation adjustments, affecting stockholders’ equity deficit that, under U.S, GAAP, is excluded from net loss.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;text-align:justify;margin:0pt 0pt 12pt 0pt;">Revenue Recognition</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">The Company recognizes revenue in accordance with the terms stipulated under the patient service contract. In various situations, the Company receives certain payments for DCVax®-L for patient treatment. These payments are assessed and recognized in accordance with ASC 606 in the period when the performance obligation has been met.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;text-align:justify;margin:0pt 0pt 12pt 0pt;">Accrued Outsourcing Costs</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">Substantial portions of our preclinical studies and clinical trials are performed by third-party laboratories, medical centers, contract research organizations and other vendors (collectively “CROs”). These CROs generally bill monthly or quarterly for services performed, or bill based upon milestones achieved. For clinical studies, expenses are accrued when services are performed. The Company monitors patient enrollment, the progress of clinical studies and related activities through internal reviews of data that is tracked by the CROs under contractual arrangements, correspondence with the CROs and visits to clinical sites.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;text-align:justify;margin:0pt 0pt 12pt 0pt;">Research and Development Costs</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">Research and development costs are charged to operations as incurred and consist primarily of clinical trial related costs (including costs for collection, validation and analysis of trial results), related party manufacturing costs, consulting costs, contract research and development costs, clinical site costs and compensation costs.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;text-align:justify;margin:0pt 0pt 12pt 0pt;">Income Taxes</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">The Company evaluates its tax positions and estimates its current tax exposure along with assessing temporary differences that result from different book to tax treatment of items not currently deductible for tax purposes. These differences result in deferred tax assets and liabilities on the Company’s Consolidated Balance Sheets, which are estimated based upon the difference between the financial statement and tax bases of assets and liabilities using the enacted tax rates that will be in effect when these differences reverse. In general, deferred tax assets represent future tax benefits to be received when certain expenses previously recognized in the Company’s Consolidated Statements of Comprehensive Loss become deductible expenses under applicable income tax laws or loss or credit carryforwards are utilized. Accordingly, realization of the Company’s deferred tax assets is dependent on future taxable income against which these deductions, losses and credits can be utilized.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">The Company must assess the likelihood that the Company’s deferred tax assets will be recovered from future taxable income, and to the extent the Company believes that recovery is not more likely than not, the Company must establish a valuation allowance. Management judgment is required in determining the Company’s provision for income taxes, the Company’s deferred tax assets and liabilities and any valuation allowance recorded against the Company’s net deferred tax assets. Excluding foreign operations, the Company recorded a full valuation allowance at each balance sheet date presented because, based on the available evidence, the Company believes it is more likely than not that it will not be able to utilize all of its deferred tax assets in the future. The Company intends to maintain the full valuation allowance until sufficient evidence exists to support the reversal of the valuation allowance.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;text-align:justify;margin:0pt 0pt 12pt 0pt;">Stock Based Compensation</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">The Company measures stock-based compensation to employees, consultants, and Board members at fair value on the grant date of the award. Compensation cost is recognized as expense on a straight-line basis over the requisite service period of the award. For awards that have a performance condition, compensation cost is measured based on the fair value of the award on the grant date, the date performance targets are established, and is expensed over the requisite service period for each separately vesting tranche when achievement of the performance condition becomes probable. The Company assess the probability of the performance conditions being </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">met on a continuous basis. Forfeitures are recognized when they occur. Prior to January 1, 2019, share-based compensation cost for non-employees was re-measured at every reporting period.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">The Company estimates the fair value of stock option grants that do not contain market-based vesting conditions using the Black-Scholes option pricing model and the assumptions used in calculating the fair value of stock-based awards represent management’s best estimates and involve inherent uncertainties and the application of management’s judgment.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 36pt;"><i style="font-style:italic;">Expected Term </i>- The expected term of options represents the period that the Company’s stock-based awards are expected to be outstanding based on the simplified method, which is the half-life from vesting to the end of its contractual term.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 36pt;"><i style="font-style:italic;">Expected Volatility</i> - The Company computes stock price volatility over expected terms based on its historical common stock trading prices.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 36pt;"><i style="font-style:italic;">Risk-Free Interest Rate</i> - The Company bases the risk-free interest rate on the implied yield available on U. S. Treasury zero-coupon issues with an equivalent remaining term.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 36pt;"><i style="font-style:italic;">Expected Dividend</i> - The Company has never declared or paid any cash dividends on its common shares and does not plan to pay cash dividends in the foreseeable future, and, therefore, uses an expected dividend yield of zero in its valuation models.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">The Company is also required to make estimates as to the probability of achieving the specific performance conditions. If actual results are not consistent with the Company’s assumptions and judgments used in making these estimates, the Company may be required to increase or decrease compensation expense, which could be material to the Company’s consolidated results of operations.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;text-align:justify;margin:0pt 0pt 12pt 0pt;">Debt Extinguishment</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">The Company accounts for the income or loss from extinguishment of debt by comparing the difference between the reacquisition price and the net carrying amount of the debt being extinguished and recognizes this as gain or loss when the debt is extinguished. The gain or loss from debt extinguishment is recorded in the consolidated statements of operations under “other income (expense)” as loss from extinguishment of convertible debt.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;text-align:justify;margin:0pt 0pt 12pt 0pt;">Sequencing</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">The Company adopted a sequencing policy under ASC 815-40-35 whereby in the event that reclassification of contracts from equity to liabilities is necessary pursuant to ASC 815 due to the Company’s inability to demonstrate it has sufficient authorized shares. This was previously the result of certain financial instruments with a potentially indeterminable number of shares and most recently due to the company committing more shares than authorized. While temporary suspensions are in place to keep the potential exercises beneath the number authorized, certain instruments are classified as liabilities, after allocating available authorized shares on the basis of the earliest grant date of potentially dilutive instruments. Pursuant to ASC 815, issuance of stock based awards to the Company’s employees, nonemployees or directors are not subject to the sequencing policy.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;text-align:justify;margin:0pt 0pt 12pt 0pt;">Loss per Share</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">Basic loss per share is computed on the basis of the weighted average number of shares outstanding for the reporting period. Diluted loss per share is computed on the basis of the weighted average number of common shares plus dilutive potential common shares outstanding using the treasury stock method. Any potentially dilutive securities are anti-dilutive due to the Company’s net losses. For the years presented, there is no difference between the basic and diluted net loss per share.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;text-align:justify;margin:0pt 0pt 12pt 0pt;">Recent Accounting Standards</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><i style="font-style:italic;text-decoration:underline;text-decoration-color:#000000;">Income Taxes</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">In December 2019, the FASB issued ASU No. 2019-12, “Income Taxes (Topic 740): Simplifying the Accounting for Income Taxes (“ASU 2019-12”), which is intended to simplify various aspects related to accounting for income taxes. ASU 2019-12 removes certain </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">exceptions to the general principles in Topic 740 and also clarifies and amends existing guidance to improve consistent application. This guidance is effective for fiscal years, and interim periods within those fiscal years, beginning after December 15, 2020, with early adoption permitted. The Company is currently evaluating the impact of this standard on its consolidated financial statements and related disclosures.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;text-align:justify;margin:0pt 0pt 12pt 0pt;"><i style="text-decoration:underline;">Debt</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">In August 2020, the FASB issued ASU No. 2020-06, Debt—Debt with Conversion and Other Options (Subtopic 470-20) and Derivatives and Hedging—Contracts in Entity’s Own Equity (Subtopic 815-40): Accounting for Convertible Instruments and Contracts in an Entity’s Own Equity, which simplifies accounting for convertible instruments by removing major separation models required under current GAAP. The ASU removes certain settlement conditions that are required for equity contracts to qualify for the derivative scope exception and it also simplifies the diluted earnings per share calculation in certain areas. This ASU is effective for annual reporting periods beginning after December 15, 2021, including interim periods within those fiscal years. Early adoption is permitted, but no earlier than fiscal years beginning after December 15, 2020. This update permits the use of either the modified retrospective or fully retrospective method of transition. The Company is currently evaluating the impact this ASU will have on the its consolidated financial statements and related disclosures.</p> <p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;text-align:justify;margin:0pt 0pt 12pt 0pt;">Basis of Presentation</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">The accompanying consolidated financial statements of the Company were prepared in accordance with generally accepted accounting principles in the U.S. (“U.S. GAAP”) and include the assets, liabilities, revenues and expenses of the wholly owned subsidiaries in Germany, United Kingdom and Netherlands. All intercompany transactions and accounts have been eliminated in consolidation.</p> <p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;text-align:justify;margin:0pt 0pt 12pt 0pt;">Consolidation</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">The Company’s policy is to consolidate all entities in which it can vote a majority of the outstanding voting stock. In addition, the Company consolidates entities that meet the definition of a variable interest entity (VIE) for which the Company is the primary beneficiary, if any. The primary beneficiary is the party who has the power to direct the activities of a VIE that most significantly impact the entity’s economic performance and who has an obligation to absorb losses of the entity or a right to receive benefits from the entity that could potentially be significant to the VIE.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">As of December 31, 2020, the Company did not consolidate any VIE's as the Company has concluded that it is not the primary beneficiary.</p> <p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;text-align:justify;margin:0pt 0pt 12pt 0pt;">Use of Estimates</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">In preparing consolidated financial statements in conformity with U.S. GAAP, management is required to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements, as well as the reported amounts of expenses during the reporting period. Due to inherent uncertainty involved in making estimates, actual results reported in future periods may be affected by changes in these estimates.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">On an ongoing basis, the Company evaluates its estimates and judgments, including valuing equity securities in share-based payment arrangements, estimating the fair value of financial instruments recorded as derivative liabilities, useful lives of depreciable assets and whether impairment charges may apply. The Company bases its estimates on historical experience and on various other assumptions that it believes to be reasonable under the circumstances, the results of which form the basis for making judgments about the carrying values of assets and liabilities and the reported amounts of revenues and expenses that are not readily apparent from other sources. Actual results could differ from those estimates, particularly given the significant social and economic disruptions and uncertainties associated with the ongoing coronavirus pandemic ("COVID-19") and the COVID-19 control responses.</p> <p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Concentration of Credit Risk</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">Financial instruments that potentially subject the Company to concentration of credit risk consist of cash accounts in a financial institution, which at times may exceed the Federal depository insurance coverage (“FDIC”) of $250,000. As of December 31, 2020, of the total $10 million in cash and cash equivalents, $0.6 million was held by foreign subsidiaries. The Company had not experienced losses on these accounts and management believes the Company is not exposed to significant risks on such accounts.</p> 250000 10000000 600000 <p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;text-align:justify;margin:0pt 0pt 12pt 0pt;">Property, Plant and Equipment</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">Property and equipment are stated at cost. Depreciation and amortization are provided for using straight-line methods, in amounts sufficient to charge the cost of depreciable assets to operations over their estimated service lives. Repairs and maintenance costs are charged to operations as incurred.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">Costs for capital assets not yet placed into service are capitalized as construction in progress on the consolidated balance sheets and will be depreciated once placed into service.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">The Company assesses its long-lived assets for impairment whenever facts and circumstances indicate that the carrying amounts may not be fully recoverable. To analyze recoverability, the Company projects undiscounted net future cash flows over the remaining lives of such assets. If these projected undiscounted net future cash flows are less than the carrying amounts, an impairment loss would be recognized, resulting in a write-down of the assets with a corresponding charge to earnings. The impairment loss is measured based upon the difference between the carrying amounts and the fair values of the assets.</p> <p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;text-align:justify;margin:0pt 0pt 12pt 0pt;">Goodwill and Intangible Assets</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">Goodwill is the excess of purchase price over the fair value of identified net assets of businesses acquired. The Company's intangible asset with an indefinite life is related to in-process research and development ("IPR&amp;D") programs acquired in the Flaskworks Acquisition, as the Company expects future research and development on these programs to provide the Company with substantial benefit for a period that extends beyond the foreseeable horizon. Intangible assets with indefinite useful lives are measured at their respective fair values as of the acquisition date. The Company does not amortize goodwill and intangible assets with indefinite useful lives. Intangible assets related to IPR&amp;D projects are considered to be indefinite lived until the completion or abandonment of the associated R&amp;D efforts. If and when development is complete, which generally occurs if and when regulatory approval to market a product is obtained, the associated assets would be deemed finite lived and would then be amortized based on their respective estimated useful lives at that point in time.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">The Company has one operating segment and one reporting unit. The Company reviews goodwill and indefinite-lived intangible assets at least annually for possible impairment. Goodwill and indefinite-lived intangible assets are reviewed for possible impairment between annual tests if an event occurs or circumstances change that would more likely than not reduce the fair value of the reporting unit or the indefinite-lived intangible assets below their carrying values. <span style="-sec-ix-hidden:Hidden_oUSWpFQ08kK4q5HI-uY4-A;"><span style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:justify;">No</span></span> impairment charge was recognized for the year ended December 31, 2020.</p> 1 1 <p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;text-align:justify;margin:0pt 0pt 12pt 0pt;">Fair Value of Financial Instruments</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">ASC 820, Fair Value Measurements, provides guidance on the development and disclosure of fair value measurements. Under this accounting guidance, fair value is defined as an exit price, representing the amount that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date. As such, fair value is a market-based measurement that should be determined based on assumptions that market participants would use in pricing an asset or a liability.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">The accounting guidance classifies fair value measurements in one of the following three categories for disclosure purposes:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:41.25pt;text-align:justify;text-indent:-41.25pt;margin:0pt 0pt 12pt 18pt;">Level 1:    Quoted prices in active markets for identical assets or liabilities.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:44.65pt;text-align:justify;text-indent:-44.65pt;margin:0pt 0pt 12pt 18pt;">Level 2:    Inputs other than Level 1 prices for similar assets or liabilities that are directly or indirectly observable in the marketplace.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:44.65pt;text-align:justify;text-indent:-44.65pt;margin:0pt 0pt 12pt 18pt;">Level 3:    Unobservable inputs which are supported by little or no market activity and values determined using pricing models, discounted cash flow methodologies, or similar techniques, as well as instruments for which the determination of fair value requires significant judgment or estimation.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">The Company accounts for the issuance of common stock purchase warrants issued in connection with the equity offerings in accordance with the provisions of ASC 815, Derivatives and Hedging ("ASC 815"). The Company classifies as equity any contracts that (i) require physical settlement or net-share settlement or (ii) gives the Company a choice of net-cash settlement or settlement in its own shares (physical settlement or net-share settlement). The Company accounts for certain common stock warrants outstanding as a liability at fair value and adjusts the instruments to fair value at each reporting period. This liability is subject to re-measurement at each balance sheet date until exercised, and any change in fair value is recognized in its Consolidated Statements of Operations and Comprehensive Loss. The fair value of the warrants issued by the Company has been estimated using Monte Carlo simulation and or a Black Scholes model. The warrant liabilities are valued using Level 3 valuation inputs (see Note 4).</p> <p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;text-align:justify;margin:0pt 0pt 12pt 0pt;">Embedded Conversion Features</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">The Company evaluates embedded conversion features within convertible debt instruments to determine whether the embedded conversion feature(s) should be bifurcated from the host instrument and accounted for as a derivative at fair value with changes in fair value recorded in the Statement of Operations. If the conversion feature does not require recognition of a bifurcated derivative, the convertible debt instrument is evaluated for consideration of any beneficial conversion feature (“BCF”) requiring separate recognition. When the Company record a BCF, the intrinsic value of the BCF is recorded as a debt discount against the face amount of the respective debt instrument (offset to additional paid-in capital) and amortized to interest expense over the life of the debt.</p> <p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Derivative Financial Instruments</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">The Company has derivative financial instruments that are not hedges and do not qualify for hedge accounting. Changes in the fair value of these instruments are recorded in other income (expense), on a net basis in the Consolidated Statements of Operations and Comprehensive Loss.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Contingent payable derivative liability</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">During the year ended December 31, 2019, the Company entered into a settlement agreement with Cognate BioServices, resolving past matters and providing for the restart of DCVax®-Direct Production.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">As part of this overall settlement, the Company also provided a contingent note payable (the “Contingent Payable Derivative”) of $10 million, which is only payable upon the Company’s first financing after DCVax product approval in or outside the U.S. If such product approval has not been obtained by the seventh anniversary of the agreement, such Contingent Payable Derivative will expire without becoming payable.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">On a quarterly basis, management makes estimates for key performance milestones and uses the expected dates as the inputs for valuation. The fair value of the Contingent Payable Derivative has been estimated using Monte Carlo simulation, which are valued using Level 3 valuation inputs.</p> 10000000 <p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;text-align:justify;margin:0pt 0pt 12pt 0pt;">Leases</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">Prior to January 1, 2019, the Company recognized rent expense on a straight-line basis over the lease period and accounts for the difference between straight-line rent and actual lease payments as deferred rent.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">Subsequent to the adoption of the new leasing standard on January 1, 2019, the Company recognizes a lease asset for its right to use the underlying asset and a lease liability for the corresponding lease obligation. The Company determines whether an arrangement is or contains a lease at contract inception. Operating leases with a duration greater than one year are included in right-of-use assets, lease liabilities, and lease liabilities, net of current portion in the Company’s consolidated balance sheets. Right-of-use assets and liabilities are recognized at the lease commencement date based on the present value of lease payments over the lease term. In determining the net present value of lease payments, the Company uses its incremental borrowing rate based on the information available at the lease commencement date. The incremental borrowing rate represents the interest rate the Company would incur at lease commencement to borrow an amount equal to the lease payments on a collateralized basis over the term of a lease. The Company considers a lease term to be the non-cancelable period that it has the right to use the underlying asset.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">The operating lease right-of-use assets also include any lease payments made and exclude lease incentives. Lease expense is recognized on a straight-line basis over the expected lease term. Variable lease expenses are recorded when incurred.</p> <p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;text-align:justify;margin:0pt 0pt 12pt 0pt;">Foreign Currency Translation and Transactions</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">The Company has operations in Germany, the United Kingdom and Netherlands in addition to the U.S. The Company translated its assets and liabilities into U.S. dollars using end of period exchange rates and revenues and expenses are translated into U.S. dollars using weighted average rates. Foreign currency translation adjustments are reported as a separate component of accumulated other comprehensive income (loss) within stockholders’ equity deficit.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">The Company converts receivables and payables denominated in other than the Company’s functional currency at the exchange rate as of the balance sheet date. The resulting transaction exchange gains or losses related to intercompany receivable and payables, are included in other income and expense.</p> <p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;text-align:justify;margin:0pt 0pt 12pt 0pt;">Comprehensive Loss</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">The Company reports comprehensive loss and its components in its consolidated financial statements. Comprehensive loss consists of net loss and foreign currency translation adjustments, affecting stockholders’ equity deficit that, under U.S, GAAP, is excluded from net loss.</p> <p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;text-align:justify;margin:0pt 0pt 12pt 0pt;">Revenue Recognition</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">The Company recognizes revenue in accordance with the terms stipulated under the patient service contract. In various situations, the Company receives certain payments for DCVax®-L for patient treatment. These payments are assessed and recognized in accordance with ASC 606 in the period when the performance obligation has been met.</p> <p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;text-align:justify;margin:0pt 0pt 12pt 0pt;">Accrued Outsourcing Costs</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">Substantial portions of our preclinical studies and clinical trials are performed by third-party laboratories, medical centers, contract research organizations and other vendors (collectively “CROs”). These CROs generally bill monthly or quarterly for services performed, or bill based upon milestones achieved. For clinical studies, expenses are accrued when services are performed. The Company monitors patient enrollment, the progress of clinical studies and related activities through internal reviews of data that is tracked by the CROs under contractual arrangements, correspondence with the CROs and visits to clinical sites.</p> <p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;text-align:justify;margin:0pt 0pt 12pt 0pt;">Research and Development Costs</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">Research and development costs are charged to operations as incurred and consist primarily of clinical trial related costs (including costs for collection, validation and analysis of trial results), related party manufacturing costs, consulting costs, contract research and development costs, clinical site costs and compensation costs.</p> <p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;text-align:justify;margin:0pt 0pt 12pt 0pt;">Income Taxes</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">The Company evaluates its tax positions and estimates its current tax exposure along with assessing temporary differences that result from different book to tax treatment of items not currently deductible for tax purposes. These differences result in deferred tax assets and liabilities on the Company’s Consolidated Balance Sheets, which are estimated based upon the difference between the financial statement and tax bases of assets and liabilities using the enacted tax rates that will be in effect when these differences reverse. In general, deferred tax assets represent future tax benefits to be received when certain expenses previously recognized in the Company’s Consolidated Statements of Comprehensive Loss become deductible expenses under applicable income tax laws or loss or credit carryforwards are utilized. Accordingly, realization of the Company’s deferred tax assets is dependent on future taxable income against which these deductions, losses and credits can be utilized.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">The Company must assess the likelihood that the Company’s deferred tax assets will be recovered from future taxable income, and to the extent the Company believes that recovery is not more likely than not, the Company must establish a valuation allowance. Management judgment is required in determining the Company’s provision for income taxes, the Company’s deferred tax assets and liabilities and any valuation allowance recorded against the Company’s net deferred tax assets. Excluding foreign operations, the Company recorded a full valuation allowance at each balance sheet date presented because, based on the available evidence, the Company believes it is more likely than not that it will not be able to utilize all of its deferred tax assets in the future. The Company intends to maintain the full valuation allowance until sufficient evidence exists to support the reversal of the valuation allowance.</p> <p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;text-align:justify;margin:0pt 0pt 12pt 0pt;">Stock Based Compensation</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">The Company measures stock-based compensation to employees, consultants, and Board members at fair value on the grant date of the award. Compensation cost is recognized as expense on a straight-line basis over the requisite service period of the award. For awards that have a performance condition, compensation cost is measured based on the fair value of the award on the grant date, the date performance targets are established, and is expensed over the requisite service period for each separately vesting tranche when achievement of the performance condition becomes probable. The Company assess the probability of the performance conditions being </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">met on a continuous basis. Forfeitures are recognized when they occur. Prior to January 1, 2019, share-based compensation cost for non-employees was re-measured at every reporting period.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">The Company estimates the fair value of stock option grants that do not contain market-based vesting conditions using the Black-Scholes option pricing model and the assumptions used in calculating the fair value of stock-based awards represent management’s best estimates and involve inherent uncertainties and the application of management’s judgment.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 36pt;"><i style="font-style:italic;">Expected Term </i>- The expected term of options represents the period that the Company’s stock-based awards are expected to be outstanding based on the simplified method, which is the half-life from vesting to the end of its contractual term.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 36pt;"><i style="font-style:italic;">Expected Volatility</i> - The Company computes stock price volatility over expected terms based on its historical common stock trading prices.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 36pt;"><i style="font-style:italic;">Risk-Free Interest Rate</i> - The Company bases the risk-free interest rate on the implied yield available on U. S. Treasury zero-coupon issues with an equivalent remaining term.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 36pt;"><i style="font-style:italic;">Expected Dividend</i> - The Company has never declared or paid any cash dividends on its common shares and does not plan to pay cash dividends in the foreseeable future, and, therefore, uses an expected dividend yield of zero in its valuation models.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">The Company is also required to make estimates as to the probability of achieving the specific performance conditions. If actual results are not consistent with the Company’s assumptions and judgments used in making these estimates, the Company may be required to increase or decrease compensation expense, which could be material to the Company’s consolidated results of operations.</p> <p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;text-align:justify;margin:0pt 0pt 12pt 0pt;">Debt Extinguishment</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">The Company accounts for the income or loss from extinguishment of debt by comparing the difference between the reacquisition price and the net carrying amount of the debt being extinguished and recognizes this as gain or loss when the debt is extinguished. The gain or loss from debt extinguishment is recorded in the consolidated statements of operations under “other income (expense)” as loss from extinguishment of convertible debt.</p> <p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;text-align:justify;margin:0pt 0pt 12pt 0pt;">Sequencing</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">The Company adopted a sequencing policy under ASC 815-40-35 whereby in the event that reclassification of contracts from equity to liabilities is necessary pursuant to ASC 815 due to the Company’s inability to demonstrate it has sufficient authorized shares. This was previously the result of certain financial instruments with a potentially indeterminable number of shares and most recently due to the company committing more shares than authorized. While temporary suspensions are in place to keep the potential exercises beneath the number authorized, certain instruments are classified as liabilities, after allocating available authorized shares on the basis of the earliest grant date of potentially dilutive instruments. Pursuant to ASC 815, issuance of stock based awards to the Company’s employees, nonemployees or directors are not subject to the sequencing policy.</p> <p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;text-align:justify;margin:0pt 0pt 12pt 0pt;">Loss per Share</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">Basic loss per share is computed on the basis of the weighted average number of shares outstanding for the reporting period. Diluted loss per share is computed on the basis of the weighted average number of common shares plus dilutive potential common shares outstanding using the treasury stock method. Any potentially dilutive securities are anti-dilutive due to the Company’s net losses. For the years presented, there is no difference between the basic and diluted net loss per share.</p> <p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;text-align:justify;margin:0pt 0pt 12pt 0pt;">Recent Accounting Standards</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><i style="font-style:italic;text-decoration:underline;text-decoration-color:#000000;">Income Taxes</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">In December 2019, the FASB issued ASU No. 2019-12, “Income Taxes (Topic 740): Simplifying the Accounting for Income Taxes (“ASU 2019-12”), which is intended to simplify various aspects related to accounting for income taxes. ASU 2019-12 removes certain </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">exceptions to the general principles in Topic 740 and also clarifies and amends existing guidance to improve consistent application. This guidance is effective for fiscal years, and interim periods within those fiscal years, beginning after December 15, 2020, with early adoption permitted. The Company is currently evaluating the impact of this standard on its consolidated financial statements and related disclosures.</p> <p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;text-align:justify;margin:0pt 0pt 12pt 0pt;"><i style="text-decoration:underline;">Debt</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">In August 2020, the FASB issued ASU No. 2020-06, Debt—Debt with Conversion and Other Options (Subtopic 470-20) and Derivatives and Hedging—Contracts in Entity’s Own Equity (Subtopic 815-40): Accounting for Convertible Instruments and Contracts in an Entity’s Own Equity, which simplifies accounting for convertible instruments by removing major separation models required under current GAAP. The ASU removes certain settlement conditions that are required for equity contracts to qualify for the derivative scope exception and it also simplifies the diluted earnings per share calculation in certain areas. This ASU is effective for annual reporting periods beginning after December 15, 2021, including interim periods within those fiscal years. Early adoption is permitted, but no earlier than fiscal years beginning after December 15, 2020. This update permits the use of either the modified retrospective or fully retrospective method of transition. The Company is currently evaluating the impact this ASU will have on the its consolidated financial statements and related disclosures.</p> <p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;text-align:justify;margin:0pt 0pt 12pt 0pt;">4. Fair Value Measurements</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">In accordance with ASC 820 (Fair Value Measurements and Disclosures), the Company uses various inputs to measure the outstanding warrants, certain embedded conversion feature associated with convertible debt and contingent payable to Cognate BioServices on a recurring basis to determine the fair value of the liability. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">​</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:43.61%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.54%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.38%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:13.13%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.34%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.81%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.32%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:11.48%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:43.61%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;visibility:hidden;">​</span></p></td><td colspan="11" style="vertical-align:bottom;white-space:nowrap;width:54.9%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Fair value measured at December 31, 2020</b></p></td></tr><tr><td style="vertical-align:bottom;width:43.61%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">    </b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">    </b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:14.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Quoted prices in active</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">    </b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Significant other</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">    </b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Significant</b></p></td></tr><tr><td style="vertical-align:bottom;width:43.61%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Fair value at</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:14.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">markets</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">observable inputs</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">unobservable inputs</b></p></td></tr><tr><td style="vertical-align:bottom;width:43.61%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.97%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">December 31, 2020</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:14.52%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">(Level 1)</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.15%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">(Level 2)</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.8%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">(Level 3)</b></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:43.61%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;">Warrant liability</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 354,972</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:13.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> —</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.81%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> —</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:11.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 354,972</p></td></tr><tr><td style="vertical-align:bottom;width:43.61%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;">Embedded conversion option</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 2,507</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> —</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.81%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> —</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 2,507</p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:43.61%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;">Contingent payable derivative liability </p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.42%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.54%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 8,275</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.38%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:13.13%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> —</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.34%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.81%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> —</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.32%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:11.48%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 8,275</p></td></tr><tr><td style="vertical-align:bottom;width:43.61%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;">Total fair value</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.54%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 365,754</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.38%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.13%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> —</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.34%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.81%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> —</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.32%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.48%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 365,754</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">​</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:43.59%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.54%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.49%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.38%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:13.13%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.49%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.34%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.81%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.32%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:11.48%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:43.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;visibility:hidden;">​</span></p></td><td colspan="11" style="vertical-align:bottom;white-space:nowrap;width:54.92%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Fair value measured at December 31, 2019</b></p></td></tr><tr><td style="vertical-align:bottom;width:43.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">    </b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">    </b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:14.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Quoted prices in active</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">    </b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Significant other</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">    </b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Significant</b></p></td></tr><tr><td style="vertical-align:bottom;width:43.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Fair value at</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:14.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">markets</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">observable inputs</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">unobservable inputs</b></p></td></tr><tr><td style="vertical-align:bottom;width:43.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.97%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">December 31, 2019</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:14.52%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">(Level 1)</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.15%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">(Level 2)</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.8%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">(Level 3)</b></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:43.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">Warrant liability</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 20,213</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:13.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> —</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.81%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> —</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:11.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 20,213</p></td></tr><tr><td style="vertical-align:bottom;width:43.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">Contingent payable derivative liability</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.54%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 7,261</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.38%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.13%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> —</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.34%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.81%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> —</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.32%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.48%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 7,261</p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:43.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">Total fair value</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.42%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.54%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 27,474</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.38%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:13.13%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> —</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.34%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.81%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> —</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.32%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:11.48%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 27,474</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">​</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">There were no transfers between Level 1, 2 or 3 during the years ended December 31, 2020 and 2019.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">The following table presents changes in Level 3 liabilities measured at fair value for the years ended December 31, 2020 and 2019. Both observable and unobservable inputs were used to determine the fair value of positions that the Company has classified within the Level 3 category. Unrealized gains and losses associated with liabilities within the Level 3 category include changes in fair value that were attributable to both observable (e.g., changes in market interest rates) and unobservable (e.g., changes in unobservable long- dated volatilities) inputs (in thousands).</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">​</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;white-space:nowrap;width:58.51%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.77%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.1%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:7.72%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.77%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.1%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:7.25%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.77%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.1%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:7.25%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.77%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.1%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:7.72%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:58.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Contingent</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:58.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Embedded</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Payable</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:58.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Warrant</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Conversion</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Derivative</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:58.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">    </b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.82%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Liability</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">    </b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.36%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Option</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">    </b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.36%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Liability</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">    </b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.82%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Total</b></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:58.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><b style="font-weight:bold;">Balance - January 1, 2019</b></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><b style="font-weight:bold;">$</b></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:7.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><b style="font-weight:bold;"> 29,995</b></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><b style="font-weight:bold;">$</b></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:7.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><b style="font-weight:bold;"> 357</b></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><b style="font-weight:bold;">$</b></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:7.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><b style="font-weight:bold;"> —</b></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><b style="font-weight:bold;">$</b></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:7.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><b style="font-weight:bold;"> 30,352</b></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:58.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0pt 6pt;">Additional contingent liability in connection with a settlement agreement</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> —</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> —</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 6,602</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 6,602</p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:58.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0pt 6pt;">Additional warrant liability</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:7.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 4,110</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:7.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> —</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:7.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> —</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:7.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 4,110</p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:58.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0pt 6pt;">Extinguishment of derivative liabilities </p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> —</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (3)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> —</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (3)</p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:58.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0pt 6pt;">Extinguishment of warrant liabilities related to warrants exercised for cash</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:7.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (1,759)</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:7.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> —</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:7.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> —</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:7.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (1,759)</p></td></tr><tr><td style="vertical-align:bottom;width:58.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0pt 6pt;">Change in fair value</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.1%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.72%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (12,133)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.1%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.25%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (354)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.1%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.25%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 659</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.1%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.72%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (11,828)</p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:58.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><b style="font-weight:bold;">Balance - December 31, 2019</b></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:7.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 20,213</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:7.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> —</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:7.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 7,261</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:7.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 27,474</p></td></tr><tr><td style="vertical-align:bottom;width:58.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0pt 6pt;">Additional warrant liability</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 18,864</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> —</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> —</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 18,864</p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:58.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0pt 6pt;">Reclassification of warrant liabilities </p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:7.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (110,471)</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:7.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> —</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:7.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> —</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:7.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (110,471)</p></td></tr><tr><td style="vertical-align:bottom;width:58.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0pt 6pt;">Extinguishment of embedded conversion option due to debt conversion and debt repayment</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> —</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (8,271)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> —</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (8,271)</p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:58.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0pt 6pt;">Additional embedded conversion option</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:7.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> —</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:7.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 2,807</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:7.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> —</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:7.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 2,807</p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:58.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0pt 6pt;">Change in fair value</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.1%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.72%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 426,366</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.1%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.25%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 7,971</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.1%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.25%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 1,014</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.1%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.72%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 435,351</p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:58.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><b style="font-weight:bold;">Balance - December 31, 2020</b></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0pt 6pt;"><span style="margin-left:0pt;visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.1%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><b style="font-weight:bold;">$</b></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:7.72%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><b style="font-weight:bold;"> 354,972</b></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.1%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><b style="font-weight:bold;">$</b></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:7.25%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><b style="font-weight:bold;"> 2,507</b></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.1%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><b style="font-weight:bold;">$</b></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:7.25%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><b style="font-weight:bold;"> 8,275</b></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.1%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><b style="font-weight:bold;">$</b></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:7.72%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><b style="font-weight:bold;"> 365,754</b></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">​</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">A summary of the weighted average (in aggregate) significant unobservable inputs (Level 3 inputs) used in measuring the Company’s warrant liabilities and embedded conversion feature that are categorized within Level 3 of the fair value hierarchy as of December 31, 2020 and 2019 is as follows:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">​</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:61.83%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:0.93%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:4.71%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.47%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.62%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.47%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.3%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:11.17%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.54%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:61.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:justify;margin:0pt;">    </p></td><td colspan="8" style="vertical-align:bottom;white-space:nowrap;width:35.13%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">As of December 31, 2020</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:justify;margin:0pt;"> </p></td></tr><tr><td style="vertical-align:bottom;width:61.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:5.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Warrant</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Embedded</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Contingent Payable</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:justify;margin:0pt;"> </p></td></tr><tr><td style="vertical-align:bottom;width:61.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:5.64%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Liability</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.06%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Conversion Option</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.48%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Derivative Liability</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:justify;margin:0pt;"> </p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:61.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">Strike price</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:0.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:4.71%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 0.28</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 0.59</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:11.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 1.53</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">​</span></p></td></tr><tr><td style="vertical-align:bottom;width:61.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">Contractual term (years)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.71%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 1.6</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 0.9</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 1.4</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">​</span></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:61.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">Volatility (annual)</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:0.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"> </p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:4.71%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 116</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">%  </p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"> </p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 106</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">%  </p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"> </p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:11.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 126</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">%</p></td></tr><tr><td style="vertical-align:bottom;width:61.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">Risk-free rate</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.71%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 0.2</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">%  </p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 0.1</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">%  </p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 0.1</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">%</p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:61.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">Dividend yield (per share)</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:0.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"> </p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:4.71%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 0</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">%  </p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"> </p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 0</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">%  </p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"> </p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:11.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 0</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">%</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">​</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:71.15%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.17%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.34%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:7.53%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.48%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:11.44%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.48%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:71.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;visibility:hidden;">​</span></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:24.18%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">As of December 31, 2019</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:justify;margin:0pt;"> </p></td></tr><tr><td style="vertical-align:bottom;width:71.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">    </b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Warrant</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:justify;margin:0pt;"><b style="font-weight:bold;">    </b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Contingent Payable</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:justify;margin:0pt;"><b style="font-weight:bold;"> </b></p></td></tr><tr><td style="vertical-align:bottom;width:71.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.87%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Liability</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.82%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Derivative Liability</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:justify;margin:0pt;"><b style="font-weight:bold;"> </b></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:71.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">Strike price</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:7.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 0.21</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:11.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 0.21</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">​</span></p></td></tr><tr><td style="vertical-align:bottom;width:71.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">Contractual term (years)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 1.4</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 1.0</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">​</span></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:71.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">Volatility (annual)</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"> </p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:7.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 74</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">%  </p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"> </p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:11.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 62</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">%  </p></td></tr><tr><td style="vertical-align:bottom;width:71.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">Risk-free rate</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 2</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">%  </p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 2</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">%  </p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:71.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">Dividend yield (per share)</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"> </p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:7.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 0</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">%  </p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"> </p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:11.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 0</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">%  </p></td></tr></table><div style="font-family:'Times New Roman','Times','serif';font-size:10.0pt;margin-bottom:0pt;margin-top:0pt;min-height:1.19em;position:relative;width:100%;"><div style="background-color:#000000;height:1pt;position:relative;top:0.6em;width:25.0%;border:none;margin:0 auto 0 0;"/></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">* contingent payable derivative liability based on stock price as of December 31, 2020 and December 31, 2019</p> <p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">​</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:43.61%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.54%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.38%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:13.13%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.34%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.81%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.32%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:11.48%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:43.61%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;visibility:hidden;">​</span></p></td><td colspan="11" style="vertical-align:bottom;white-space:nowrap;width:54.9%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Fair value measured at December 31, 2020</b></p></td></tr><tr><td style="vertical-align:bottom;width:43.61%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">    </b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">    </b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:14.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Quoted prices in active</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">    </b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Significant other</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">    </b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Significant</b></p></td></tr><tr><td style="vertical-align:bottom;width:43.61%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Fair value at</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:14.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">markets</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">observable inputs</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">unobservable inputs</b></p></td></tr><tr><td style="vertical-align:bottom;width:43.61%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.97%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">December 31, 2020</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:14.52%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">(Level 1)</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.15%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">(Level 2)</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.8%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">(Level 3)</b></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:43.61%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;">Warrant liability</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 354,972</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:13.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> —</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.81%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> —</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:11.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 354,972</p></td></tr><tr><td style="vertical-align:bottom;width:43.61%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;">Embedded conversion option</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 2,507</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> —</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.81%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> —</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 2,507</p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:43.61%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;">Contingent payable derivative liability </p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.42%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.54%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 8,275</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.38%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:13.13%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> —</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.34%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.81%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> —</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.32%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:11.48%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 8,275</p></td></tr><tr><td style="vertical-align:bottom;width:43.61%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;">Total fair value</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.54%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 365,754</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.38%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.13%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> —</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.34%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.81%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> —</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.32%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.48%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 365,754</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">​</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:43.59%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.54%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.49%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.38%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:13.13%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.49%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.34%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.81%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.32%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:11.48%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:43.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;visibility:hidden;">​</span></p></td><td colspan="11" style="vertical-align:bottom;white-space:nowrap;width:54.92%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Fair value measured at December 31, 2019</b></p></td></tr><tr><td style="vertical-align:bottom;width:43.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">    </b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">    </b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:14.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Quoted prices in active</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">    </b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Significant other</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">    </b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Significant</b></p></td></tr><tr><td style="vertical-align:bottom;width:43.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Fair value at</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:14.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">markets</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">observable inputs</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">unobservable inputs</b></p></td></tr><tr><td style="vertical-align:bottom;width:43.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.97%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">December 31, 2019</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:14.52%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">(Level 1)</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.15%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">(Level 2)</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.8%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">(Level 3)</b></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:43.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">Warrant liability</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 20,213</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:13.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> —</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.81%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> —</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:11.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 20,213</p></td></tr><tr><td style="vertical-align:bottom;width:43.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">Contingent payable derivative liability</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.54%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 7,261</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.38%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.13%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> —</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.34%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.81%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> —</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.32%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.48%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 7,261</p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:43.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">Total fair value</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.42%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.54%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 27,474</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.38%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:13.13%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> —</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.34%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.81%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> —</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.32%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:11.48%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 27,474</p></td></tr></table> 354972000 0 0 354972000 2507000 0 0 2507000 8275000 0 0 8275000 365754000 0 0 365754000 20213000 0 0 20213000 7261000 0 0 7261000 27474000 0 0 27474000 <p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">The following table presents changes in Level 3 liabilities measured at fair value for the years ended December 31, 2020 and 2019. Both observable and unobservable inputs were used to determine the fair value of positions that the Company has classified within the Level 3 category. Unrealized gains and losses associated with liabilities within the Level 3 category include changes in fair value that were attributable to both observable (e.g., changes in market interest rates) and unobservable (e.g., changes in unobservable long- dated volatilities) inputs (in thousands).</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">​</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;white-space:nowrap;width:58.51%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.77%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.1%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:7.72%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.77%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.1%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:7.25%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.77%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.1%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:7.25%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.77%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.1%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:7.72%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:58.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Contingent</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:58.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Embedded</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Payable</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:58.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Warrant</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Conversion</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Derivative</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:58.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">    </b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.82%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Liability</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">    </b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.36%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Option</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">    </b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.36%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Liability</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">    </b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.82%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Total</b></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:58.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><b style="font-weight:bold;">Balance - January 1, 2019</b></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><b style="font-weight:bold;">$</b></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:7.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><b style="font-weight:bold;"> 29,995</b></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><b style="font-weight:bold;">$</b></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:7.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><b style="font-weight:bold;"> 357</b></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><b style="font-weight:bold;">$</b></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:7.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><b style="font-weight:bold;"> —</b></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><b style="font-weight:bold;">$</b></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:7.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><b style="font-weight:bold;"> 30,352</b></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:58.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0pt 6pt;">Additional contingent liability in connection with a settlement agreement</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> —</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> —</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 6,602</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 6,602</p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:58.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0pt 6pt;">Additional warrant liability</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:7.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 4,110</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:7.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> —</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:7.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> —</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:7.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 4,110</p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:58.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0pt 6pt;">Extinguishment of derivative liabilities </p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> —</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (3)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> —</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (3)</p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:58.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0pt 6pt;">Extinguishment of warrant liabilities related to warrants exercised for cash</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:7.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (1,759)</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:7.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> —</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:7.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> —</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:7.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (1,759)</p></td></tr><tr><td style="vertical-align:bottom;width:58.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0pt 6pt;">Change in fair value</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.1%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.72%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (12,133)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.1%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.25%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (354)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.1%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.25%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 659</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.1%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.72%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (11,828)</p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:58.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><b style="font-weight:bold;">Balance - December 31, 2019</b></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:7.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 20,213</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:7.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> —</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:7.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 7,261</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:7.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 27,474</p></td></tr><tr><td style="vertical-align:bottom;width:58.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0pt 6pt;">Additional warrant liability</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 18,864</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> —</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> —</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 18,864</p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:58.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0pt 6pt;">Reclassification of warrant liabilities </p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:7.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (110,471)</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:7.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> —</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:7.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> —</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:7.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (110,471)</p></td></tr><tr><td style="vertical-align:bottom;width:58.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0pt 6pt;">Extinguishment of embedded conversion option due to debt conversion and debt repayment</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> —</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (8,271)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> —</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (8,271)</p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:58.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0pt 6pt;">Additional embedded conversion option</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:7.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> —</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:7.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 2,807</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:7.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> —</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:7.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 2,807</p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:58.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0pt 6pt;">Change in fair value</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.1%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.72%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 426,366</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.1%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.25%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 7,971</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.1%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.25%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 1,014</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.1%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.72%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 435,351</p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:58.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><b style="font-weight:bold;">Balance - December 31, 2020</b></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0pt 6pt;"><span style="margin-left:0pt;visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.1%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><b style="font-weight:bold;">$</b></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:7.72%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><b style="font-weight:bold;"> 354,972</b></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.1%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><b style="font-weight:bold;">$</b></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:7.25%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><b style="font-weight:bold;"> 2,507</b></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.1%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><b style="font-weight:bold;">$</b></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:7.25%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><b style="font-weight:bold;"> 8,275</b></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.1%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><b style="font-weight:bold;">$</b></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:7.72%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><b style="font-weight:bold;"> 365,754</b></p></td></tr></table> 29995000 357000 30352000 6602000 6602000 4110000 4110000 -3000 -3000 1759000 1759000 -12133000 -354000 659000 -11828000 20213000 7261000 27474000 18864000 18864000 110471000 110471000 -8271000 -8271000 2807000 2807000 426366000 7971000 1014000 435351000 354972000 2507000 8275000 365754000 <p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">A summary of the weighted average (in aggregate) significant unobservable inputs (Level 3 inputs) used in measuring the Company’s warrant liabilities and embedded conversion feature that are categorized within Level 3 of the fair value hierarchy as of December 31, 2020 and 2019 is as follows:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">​</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:61.83%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:0.93%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:4.71%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.47%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.62%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.47%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.3%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:11.17%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.54%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:61.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:justify;margin:0pt;">    </p></td><td colspan="8" style="vertical-align:bottom;white-space:nowrap;width:35.13%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">As of December 31, 2020</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:justify;margin:0pt;"> </p></td></tr><tr><td style="vertical-align:bottom;width:61.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:5.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Warrant</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Embedded</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Contingent Payable</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:justify;margin:0pt;"> </p></td></tr><tr><td style="vertical-align:bottom;width:61.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:5.64%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Liability</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.06%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Conversion Option</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.48%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Derivative Liability</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:justify;margin:0pt;"> </p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:61.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">Strike price</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:0.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:4.71%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 0.28</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 0.59</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:11.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 1.53</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">​</span></p></td></tr><tr><td style="vertical-align:bottom;width:61.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">Contractual term (years)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.71%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 1.6</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 0.9</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 1.4</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">​</span></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:61.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">Volatility (annual)</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:0.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"> </p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:4.71%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 116</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">%  </p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"> </p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 106</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">%  </p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"> </p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:11.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 126</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">%</p></td></tr><tr><td style="vertical-align:bottom;width:61.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">Risk-free rate</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.71%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 0.2</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">%  </p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 0.1</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">%  </p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 0.1</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">%</p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:61.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">Dividend yield (per share)</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:0.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"> </p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:4.71%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 0</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">%  </p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"> </p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 0</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">%  </p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"> </p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:11.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 0</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">%</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">​</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:71.15%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.17%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.34%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:7.53%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.48%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:11.44%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.48%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:71.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;visibility:hidden;">​</span></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:24.18%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">As of December 31, 2019</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:justify;margin:0pt;"> </p></td></tr><tr><td style="vertical-align:bottom;width:71.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">    </b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Warrant</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:justify;margin:0pt;"><b style="font-weight:bold;">    </b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Contingent Payable</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:justify;margin:0pt;"><b style="font-weight:bold;"> </b></p></td></tr><tr><td style="vertical-align:bottom;width:71.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.87%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Liability</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.82%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Derivative Liability</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:justify;margin:0pt;"><b style="font-weight:bold;"> </b></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:71.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">Strike price</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:7.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 0.21</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:11.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 0.21</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">​</span></p></td></tr><tr><td style="vertical-align:bottom;width:71.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">Contractual term (years)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 1.4</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 1.0</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">​</span></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:71.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">Volatility (annual)</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"> </p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:7.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 74</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">%  </p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"> </p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:11.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 62</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">%  </p></td></tr><tr><td style="vertical-align:bottom;width:71.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">Risk-free rate</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 2</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">%  </p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 2</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">%  </p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:71.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">Dividend yield (per share)</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"> </p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:7.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 0</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">%  </p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"> </p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:11.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 0</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">%  </p></td></tr></table><div style="font-family:'Times New Roman','Times','serif';font-size:10.0pt;margin-bottom:0pt;margin-top:0pt;min-height:1.19em;position:relative;width:100%;"><div style="background-color:#000000;height:1pt;position:relative;top:0.6em;width:25.0%;border:none;margin:0 auto 0 0;"/></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">* contingent payable derivative liability based on stock price as of December 31, 2020 and December 31, 2019</p> 0.28 0.59 1.53 P1Y7M6D P0Y10M24D P1Y4M24D 1.16 1.06 1.26 0.002 0.001 0.001 0 0 0 0.21 0.21 P1Y4M24D P1Y 0.74 0.62 0.02 0.02 0 0 <p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">5. Flaskworks Acquisition</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">On August 28, 2020, the Company completed the acquisition of Flaskworks (the “Acquisition”), whereby Flaskworks became a wholly-owned subsidiary of the Company. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">The Unit Purchase Agreement was executed and closed on August 28, 2020. The Company acquired 100% of the ownership units of Flaskworks. Flaskworks was previously owned by its technical founders and Corning Inc. The technical team from Flaskworks has joined the Company as part of the Acquisition. It is anticipated that the Flaskworks system will enable substantial scale-up of production volumes of DCVax products and substantial reduction of production costs. The Company’s buildout of the Sawston, UK facility has been designed to proceed in phases, as modules, both for efficiency in the timing of capital costs and to allow flexibility in operations and usage. The Company anticipates that implementation of the Flaskworks system will enable certain phases of the buildout to be simplified and streamlined.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">The total purchase price was approximately $4.3 million, of which $1.7 million was paid in cash at closing, up to $2.01 million will be paid in stock subject to milestone-based vesting (see Note 6), and $0.7 million was paid in either cash or stock, or a combination thereof, within 120 days after the closing. Between October and December 2020, $0.5 million was paid in cash upon the seller’s election. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">In addition to the $0.5 million cash payment, on December 25, 2020, upon the seller’s election, the Company issued 654,762 shares in equivalent of $0.2 million special consideration payment pursuant to the Unit Purchase Agreement. The $0.336 per share price was established by the Unit Purchase Agreement. The incremental change in fair value of the shares resulting from market price increase was approximately $0.9 million, which was recognized as a component of general and administrative expense in the consolidated statement of operations.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">Based on the Company's preliminary valuation, the total estimated consideration of $2.1 million has been allocated to assets acquired and liabilities assumed as of the acquisition date as follows (amount in thousands):</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">​</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:84.97%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.7%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.62%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:84.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">Cash</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">    </p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 146</p></td></tr><tr><td style="vertical-align:bottom;width:84.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">Current assets</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 135</p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:84.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">Fixed assets, net</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"> </p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 188</p></td></tr><tr><td style="vertical-align:bottom;width:84.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">Indefinite-lived intangible asset</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 1,292</p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:84.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">Security deposits</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.7%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"> </p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.62%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 8</p></td></tr><tr><td style="vertical-align:bottom;width:84.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0pt 6pt;"><b style="font-weight:bold;">Total assets acquired</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.62%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 1,769</p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:84.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">Accounts payable</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"> </p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (12)</p></td></tr><tr><td style="vertical-align:bottom;width:84.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">Accrued expenses</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.62%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (240)</p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:84.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0pt 6pt;"><b style="font-weight:bold;">Total liabilities assumed</b></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.7%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"> </p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.62%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (252)</p></td></tr><tr><td style="vertical-align:bottom;width:84.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><b style="font-weight:bold;">Net identifiable assets acquired</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><b style="font-weight:bold;"> </b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><b style="font-weight:bold;"> 1,517</b></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:84.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">Goodwill</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.7%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"> </p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.62%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 626</p></td></tr><tr><td style="vertical-align:bottom;width:84.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><b style="font-weight:bold;">Total estimated consideration </b><sup style="font-size:7.5pt;font-weight:bold;line-height:100%;top:0pt;vertical-align:top;">(1)</sup></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><b style="font-weight:bold;">$</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.62%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><b style="font-weight:bold;"> 2,143</b></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:84.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">​</span></p></td></tr><tr><td style="vertical-align:bottom;width:84.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">Less special consideration paid in cash and stock</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (465)</p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:84.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">Less cash acquired</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.7%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"> </p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.62%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (146)</p></td></tr><tr><td style="vertical-align:bottom;width:84.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">Total consideration paid, net of cash acquired</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.62%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 1,532</p></td></tr></table><div style="font-family:'Times New Roman','Times','serif';font-size:10.0pt;margin-bottom:0pt;margin-top:0pt;min-height:1.19em;position:relative;width:100%;"><div style="background-color:#000000;height:1pt;position:relative;top:0.6em;width:25.0%;border:none;margin:0 auto 0 0;"/></div><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;">(1)</td><td style="padding:0pt;"><span style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:justify;">The purchase price allocation excludes $2.01 </span><span style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:justify;">million stock consideration, which was recorded as stock-based compensation for accounting purposes, although the treatment for tax purposes is anticipated to be different (see Note 6), and $0.2 million payable for services not related to the Acquisition in either cash or stock within 120 days after the closing.</span></td></tr></table><div style="margin-top:12pt;"/><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">The Acquisition was accounted for under the acquisition method of accounting in accordance with US GAAP. As such, results of operations for Flaskworks are included in the accompanying consolidated statements of operations since the Acquisition date, and the assets acquired and liabilities assumed were recorded at their fair value as of the Acquisition date. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">Accordingly, goodwill has been measured as the excess of the total consideration over the amounts assigned to the identifiable assets acquired and liabilities assumed. Based on the Company's preliminary valuation, the Company recorded goodwill of approximately $0.6 million, which was primarily related to the acquisition of the assembled workforce and other indefinite-lived intangible asset of approximate $1.3 million in connection with the Acquisition. The $0.6 million of goodwill is expected to be deductible for tax purposes. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">The acquired Licensed IP Agreement was identified as an intangible asset and valued separate and apart from goodwill. Specifically, the Company used the Relief-from-Royalty Method, a form of the Income Approach, to estimate the fair value of the Licensed IP Agreement based on projected sales and cash flow. In application of the Relief-from-Royalty Method, we estimate the value of the Licensed IP Agreement by capitalizing the royalties saved because the Company owns the specific technology and the owner of the technology realizes a benefit from owning the intangible asset rather than paying a rent or royalty for the use of the asset.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">The royalty rate used for this Licensed IP Agreement was based on the rate and terms indicated in the license agreement that was corroborated with the Company’s external research of third-party royalty rates for technology and patents in the pharma, healthcare, and medical industries. The estimation of fair value was determined based on the projected sales assuming commercialization of Flaskworks’ products and the respective royalty rate, tax affected and discounted to the present using a discount rate based on Flaskworks’ weighted average cost of capital.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">The preliminary purchase price allocation is adjusted, as necessary, up to one year after the acquisition closing date if management obtains more information regarding asset valuations and liabilities assumed.</p> 1 4300000 1700000 2010000.00 700000 500000 500000 654762 200000 0.336 900000 <p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">Based on the Company's preliminary valuation, the total estimated consideration of $2.1 million has been allocated to assets acquired and liabilities assumed as of the acquisition date as follows (amount in thousands):</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">​</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:84.97%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.7%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.62%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:84.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">Cash</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">    </p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 146</p></td></tr><tr><td style="vertical-align:bottom;width:84.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">Current assets</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 135</p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:84.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">Fixed assets, net</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"> </p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 188</p></td></tr><tr><td style="vertical-align:bottom;width:84.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">Indefinite-lived intangible asset</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 1,292</p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:84.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">Security deposits</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.7%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"> </p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.62%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 8</p></td></tr><tr><td style="vertical-align:bottom;width:84.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0pt 6pt;"><b style="font-weight:bold;">Total assets acquired</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.62%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 1,769</p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:84.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">Accounts payable</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"> </p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (12)</p></td></tr><tr><td style="vertical-align:bottom;width:84.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">Accrued expenses</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.62%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (240)</p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:84.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0pt 6pt;"><b style="font-weight:bold;">Total liabilities assumed</b></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.7%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"> </p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.62%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (252)</p></td></tr><tr><td style="vertical-align:bottom;width:84.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><b style="font-weight:bold;">Net identifiable assets acquired</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><b style="font-weight:bold;"> </b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><b style="font-weight:bold;"> 1,517</b></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:84.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">Goodwill</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.7%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"> </p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.62%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 626</p></td></tr><tr><td style="vertical-align:bottom;width:84.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><b style="font-weight:bold;">Total estimated consideration </b><sup style="font-size:7.5pt;font-weight:bold;line-height:100%;top:0pt;vertical-align:top;">(1)</sup></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><b style="font-weight:bold;">$</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.62%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><b style="font-weight:bold;"> 2,143</b></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:84.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">​</span></p></td></tr><tr><td style="vertical-align:bottom;width:84.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">Less special consideration paid in cash and stock</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (465)</p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:84.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">Less cash acquired</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.7%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"> </p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.62%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (146)</p></td></tr><tr><td style="vertical-align:bottom;width:84.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">Total consideration paid, net of cash acquired</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.62%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 1,532</p></td></tr></table> 2100000 146000 135000 188000 1292000 8000 1769000 12000 240000 252000 1517000 626000 2143000 465000 146000 1532000 2010000.00 200000 600000 1300000 600000 <p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;text-align:justify;margin:0pt 0pt 12pt 0pt;">6. Stock-based Compensation</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">The following table summarizes total stock-based compensation expense recognized for the years ended December 31, 2020 and 2019 (in thousands):</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">​</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:75.96%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.39%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.51%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.1%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.39%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.51%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.1%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:75.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:justify;margin:0pt;">    </p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:21.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">For the years ended</b></p></td></tr><tr><td style="vertical-align:bottom;width:75.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:21.63%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">December 31,</b></p></td></tr><tr><td style="vertical-align:bottom;width:75.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:justify;margin:0pt;"> </p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.62%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2020</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:justify;margin:0pt;"> </p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.62%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2019</b></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:75.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">Research and development</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 19,792</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 471</p></td></tr><tr><td style="vertical-align:bottom;width:75.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">General and administrative<sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;"> (1)</sup></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.51%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.1%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 32,163</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.51%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.1%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 1,350</p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:75.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">Total stock-based compensation expense</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.51%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.1%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 51,955</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.51%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.1%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 1,821</p></td></tr></table><div style="font-family:'Times New Roman','Times','serif';font-size:10.0pt;margin-bottom:0pt;margin-top:0pt;min-height:1.19em;position:relative;width:100%;"><div style="background-color:#000000;height:1pt;position:relative;top:0.6em;width:25.0%;border:none;margin:0 auto 0 0;"/></div><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;">(1)</td><td style="padding:0pt;"><span style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:justify;">The general and administrative expense during the years ended December 31, 2020 and 2019 is related to the applicable vesting portion of stock options awards made in the past and new options granted during the year ended December 31, 2020 to directors, employees and external consultants.</span></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">​</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">The Black-Scholes option pricing model is used to estimate the fair value of stock options granted. The weighted average assumptions used in calculating the fair values of stock options that were granted during the years ended December 31, 2020 and 2019: </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">​</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:75.31%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.21%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.34%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:7.87%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.48%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.34%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:7.87%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.54%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:75.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;">    </p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:20.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">For the years ended</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:justify;margin:0pt;"> </p></td></tr><tr><td style="vertical-align:bottom;width:75.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:20.92%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">December 31,</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:justify;margin:0pt;"> </p></td></tr><tr><td style="vertical-align:bottom;width:75.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:justify;margin:0pt;"><b style="font-weight:bold;">Grant Date</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.22%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2020</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.22%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2019</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:justify;margin:0pt;"> </p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:75.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">Exercise price</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:7.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 0.26</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:7.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 0.20</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">​</span></p></td></tr><tr><td style="vertical-align:bottom;width:75.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">Expected term (years)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 5.2</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 5.6</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">​</span></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:75.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">Expected stock price volatility</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"> </p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:7.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 98</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">%  </p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"> </p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:7.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 86</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">%</p></td></tr><tr><td style="vertical-align:bottom;width:75.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">Risk-free rate of interest</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 0</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">%  </p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 1</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">%</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">​</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">The total unrecognized compensation cost was approximately $17 million as of December 31, 2020, and will be recognized over the next 1.8 years.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;text-align:justify;margin:0pt 0pt 12pt 0pt;">Stock Options</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><span style="text-decoration:underline;text-decoration-color:#000000;">Equity Compensation Plan</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">On May 29, 2020, the Board of Directors of the Company approved a new equity compensation plan (the “Plan”). The Company’s prior plan was adopted in 2007, was updated in amended and restated plans that were approved by shareholders in 2012 and 2013, and expired in 2017 (the “Prior Plan”).</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">The Plan is substantially similar to the Prior Plan. The Plan has a 10-year life, and allows for awards to employees, directors and consultants of the Company, as did the Prior Plan. The Plan allows for any type of equity security to be awarded, as did the Prior Plan. The awards and their terms (including vesting) will be determined by the Board and applicable Committees, as was the case under the Prior Plan. The Plan establishes a pool of potential equity compensation equal to twenty percent of the outstanding securities of the Company, which is on an evergreen basis as under the Prior Plan.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">The following table summarizes stock option activity for the Company’s option plans during the years ended December 31, 2020 and 2019 (amount in thousands, except per share number):</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">​</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:47.26%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.94%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.58%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.94%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.22%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.58%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.16%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.58%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.94%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.22%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.53%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:47.26%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">    </b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">    </b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">    </b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Weighted</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">    </b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td></tr><tr><td style="vertical-align:bottom;width:47.26%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Average</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td></tr><tr><td style="vertical-align:bottom;width:47.26%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Weighted</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Remaining</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td></tr><tr><td style="vertical-align:bottom;width:47.26%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Number of</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Average Exercise</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Contractual Life</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Total Intrinsic</b></p></td></tr><tr><td style="vertical-align:bottom;width:47.26%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.58%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Shares</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.8%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Price</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.58%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">(in years)</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.75%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Value</b></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:47.26%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">Outstanding as of January 1, 2019</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"> </p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 100,159</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 0.24</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"> </p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 9.3</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> —</p></td></tr><tr><td style="vertical-align:bottom;width:47.26%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0pt 6pt;">Granted</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.58%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 4,500</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.22%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.58%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 0.22</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.58%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 10.4</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.22%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.53%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> —</p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:47.26%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">Outstanding as of December 31, 2019</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 104,659</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 0.24</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 8.4</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> —</p></td></tr><tr><td style="vertical-align:bottom;width:47.26%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0pt 6pt;">Granted (Approved 2018-2020) (1)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 208,525</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 0.37</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">(3)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 10.0</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> —</p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:47.26%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0pt 6pt;">Cashless exercise</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"> </p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (94)</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"> </p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 0.34</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> —</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"> </p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> —</p></td></tr><tr><td style="vertical-align:bottom;width:47.26%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0pt 6pt;">Forfeited/expired</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.58%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (4,250)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.22%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.58%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 0.22</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.58%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> —</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.22%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.53%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> —</p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:47.26%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">Outstanding as of December 31, 2020</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"> </p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.58%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 308,840</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.22%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.58%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 0.33</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"> </p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.58%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 8.9</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.22%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.53%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 372,219</p></td></tr><tr><td style="vertical-align:bottom;width:47.26%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">Options vested (2)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 223,720</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 0.30</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 8.7</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 276,432</p></td></tr></table><div style="font-family:'Times New Roman','Times','serif';font-size:10.0pt;margin-bottom:0pt;margin-top:0pt;min-height:1.19em;position:relative;width:100%;"><div style="background-color:#000000;height:1pt;position:relative;top:0.6em;width:25.0%;border:none;margin:0 auto 0 0;"/></div><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;">(1)</td><td style="padding:0pt;"><span style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:justify;">The options granted during the year ended December 31, 2020 included options already approved at various times during the 3 years 2018 - 2020 but not issued until Q3 2020, and also included options that will vest for performance and milestones going forward over the next 2 years. The options included awards to key external consultants and vendors in addition to internal parties.</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;">(2)</td><td style="padding:0pt;"><span style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:justify;">Approximately 128 </span><span style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:justify;">million vested options as of December 31, 2020 are not exercisable until January 15, 2021. See Note 15 below under Subsequent Events for more information about additional options suspensions for further periods.</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;">(3)</td><td style="padding:0pt;"><span style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:justify;">The weighted average exercise price of the Q3 2020 options was initially </span><span style="-sec-ix-hidden:Hidden_EsoAtG4ld0qmE1IBieM8Gw;"><span style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:justify;">$0.25</span></span><span style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:justify;">. However, subsequently, the exercise price was amended to a weighted average exercise price of $0.36.</span></td></tr></table><div style="margin-top:12pt;"/><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><span style="text-decoration:underline;">Stock Options Modification</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">On April 30, 2020, the Company's CEO, Linda Powers agreed to not exercise approximately 39.2 million existing options held by her for 6 months, until November 1, 2020 and correspondingly extended the contractual term for 6 months. The Company recognized approximately $78,000 of incremental stock-based compensation for this modification during the year ended December 31, 2020, based on the following weighted average assumptions:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">​</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:67.77%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.39%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.51%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:11.37%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.48%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.51%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:11.37%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.54%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:67.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">    </b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.89%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Post Modification</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">    </b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.89%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Pre Modification</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;"> </b></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:67.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;">Exercise price</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:11.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 0.23</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:11.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 0.23</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td></tr><tr><td style="vertical-align:bottom;width:67.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;">Expected term (years)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 4.3</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 4.0</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:67.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;">Expected stock price volatility</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:11.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 97</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;">%</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:11.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 97</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;">%</p></td></tr><tr><td style="vertical-align:bottom;width:67.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;">Risk-free rate of interest</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 0</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;">%  </p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 0</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;">%</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">​</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">For another officer, on August 5, 2020, the Company cancelled 1.75 million options which were originally issued in December 2019 and issued 3 million options (the “Replacement Options”) with an exercise price of $0.22 and vesting of 1/3 immediately and the remaining 2/3 vesting ratably over the following 24 months from the grant date. The incremental stock-based compensation for this modification was approximately $0.3 million based on the following weighted average assumptions, which will be amortized over the new vesting terms.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">​</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:67.77%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.39%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.51%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:11.37%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.48%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.51%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:11.37%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.54%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:67.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:justify;margin:0pt;"><b style="font-weight:bold;">    </b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.89%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Post Modification</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:justify;margin:0pt;"><b style="font-weight:bold;">    </b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.89%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Pre Modification</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;"> </b></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:67.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">Exercise price</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:11.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 0.22</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:11.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 0.22</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">​</span></p></td></tr><tr><td style="vertical-align:bottom;width:67.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">Expected term (years)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 5.3</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 4.7</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">​</span></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:67.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">Expected stock price volatility</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"> </p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:11.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 96</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">%  </p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"> </p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:11.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 97</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">%</p></td></tr><tr><td style="vertical-align:bottom;width:67.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">Risk-free rate of interest</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 0</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">%  </p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 0</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">%</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">​</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><i style="font-style:italic;">Flaskworks Acquisition</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">On August 28, 2020, the Company entered into a Unit Purchase Agreement (the “Agreement”) to acquire Flaskworks. Included in the consideration pursuant to the Agreement was Stock Consideration in the amount of approximately $2 million. This Stock Consideration is issued in the form of Rights to receive such value in shares issued pursuant to and subject to the vesting criteria set forth in a Rights Issuance Agreement entered into in connection with the closing of Flaskworks Acquisition. Because the Rights were subject to future employment and performance conditions, the Stock Consideration was not included in consideration payable for the Flaskworks Acquisition but rather was recorded as contingent consideration payable to employees for accounting purposes. The Company anticipates that the treatment of this Stock Consideration for tax purposes may be different than for accounting purposes, and will reflect the fact that this Stock Consideration was payment for acquisition of the ownership interests of certain shareholders of Flaskworks.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">On December 1, 2020, the Company issued 1.5 million shares of common stock based upon the Flaskworks team having completed a significant milestone, in accordance with the Rights Issuance Agreement entered on August 28, 2020. During the year ended December 31, 2020, the Company recognized approximately $1.0 million stock-based compensation related to the Flaskworks Acquisition. Approximate $0.5 million was recognized in general and administrative and $0.5 million was recognized in research and development.</p> <p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">The following table summarizes total stock-based compensation expense recognized for the years ended December 31, 2020 and 2019 (in thousands):</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">​</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:75.96%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.39%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.51%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.1%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.39%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.51%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.1%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:75.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:justify;margin:0pt;">    </p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:21.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">For the years ended</b></p></td></tr><tr><td style="vertical-align:bottom;width:75.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:21.63%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">December 31,</b></p></td></tr><tr><td style="vertical-align:bottom;width:75.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:justify;margin:0pt;"> </p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.62%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2020</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:justify;margin:0pt;"> </p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.62%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2019</b></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:75.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">Research and development</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 19,792</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 471</p></td></tr><tr><td style="vertical-align:bottom;width:75.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">General and administrative<sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;"> (1)</sup></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.51%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.1%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 32,163</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.51%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.1%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 1,350</p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:75.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">Total stock-based compensation expense</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.51%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.1%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 51,955</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.51%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.1%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 1,821</p></td></tr></table><div style="font-family:'Times New Roman','Times','serif';font-size:10.0pt;margin-bottom:0pt;margin-top:0pt;min-height:1.19em;position:relative;width:100%;"><div style="background-color:#000000;height:1pt;position:relative;top:0.6em;width:25.0%;border:none;margin:0 auto 0 0;"/></div><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;">(1)</td><td style="padding:0pt;"><span style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:justify;">The general and administrative expense during the years ended December 31, 2020 and 2019 is related to the applicable vesting portion of stock options awards made in the past and new options granted during the year ended December 31, 2020 to directors, employees and external consultants.</span></td></tr></table> 19792000 471000 32163000 1350000 51955000 1821000 <p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">​</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:75.31%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.21%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.34%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:7.87%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.48%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.34%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:7.87%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.54%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:75.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;">    </p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:20.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">For the years ended</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:justify;margin:0pt;"> </p></td></tr><tr><td style="vertical-align:bottom;width:75.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:20.92%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">December 31,</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:justify;margin:0pt;"> </p></td></tr><tr><td style="vertical-align:bottom;width:75.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:justify;margin:0pt;"><b style="font-weight:bold;">Grant Date</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.22%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2020</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.22%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2019</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:justify;margin:0pt;"> </p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:75.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">Exercise price</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:7.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 0.26</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:7.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 0.20</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">​</span></p></td></tr><tr><td style="vertical-align:bottom;width:75.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">Expected term (years)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 5.2</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 5.6</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">​</span></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:75.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">Expected stock price volatility</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"> </p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:7.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 98</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">%  </p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"> </p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:7.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 86</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">%</p></td></tr><tr><td style="vertical-align:bottom;width:75.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">Risk-free rate of interest</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 0</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">%  </p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 1</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">%</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">​</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:67.77%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.39%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.51%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:11.37%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.48%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.51%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:11.37%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.54%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:67.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">    </b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.89%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Post Modification</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">    </b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.89%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Pre Modification</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;"> </b></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:67.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;">Exercise price</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:11.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 0.23</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:11.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 0.23</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td></tr><tr><td style="vertical-align:bottom;width:67.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;">Expected term (years)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 4.3</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 4.0</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:67.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;">Expected stock price volatility</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:11.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 97</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;">%</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:11.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 97</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;">%</p></td></tr><tr><td style="vertical-align:bottom;width:67.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;">Risk-free rate of interest</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 0</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;">%  </p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 0</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;">%</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">​</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:67.77%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.39%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.51%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:11.37%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.48%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.51%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:11.37%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.54%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:67.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:justify;margin:0pt;"><b style="font-weight:bold;">    </b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.89%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Post Modification</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:justify;margin:0pt;"><b style="font-weight:bold;">    </b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.89%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Pre Modification</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;"> </b></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:67.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">Exercise price</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:11.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 0.22</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:11.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 0.22</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">​</span></p></td></tr><tr><td style="vertical-align:bottom;width:67.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">Expected term (years)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 5.3</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 4.7</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">​</span></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:67.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">Expected stock price volatility</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"> </p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:11.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 96</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">%  </p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"> </p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:11.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 97</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">%</p></td></tr><tr><td style="vertical-align:bottom;width:67.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">Risk-free rate of interest</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 0</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">%  </p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 0</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">%</p></td></tr></table> 0.26 0.20 P5Y2M12D P5Y7M6D 0.98 0.86 0 0.01 17000000 P1Y9M18D <p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">The following table summarizes stock option activity for the Company’s option plans during the years ended December 31, 2020 and 2019 (amount in thousands, except per share number):</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">​</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:47.26%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.94%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.58%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.94%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.22%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.58%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.16%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.58%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.94%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.22%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.53%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:47.26%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">    </b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">    </b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">    </b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Weighted</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">    </b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td></tr><tr><td style="vertical-align:bottom;width:47.26%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Average</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td></tr><tr><td style="vertical-align:bottom;width:47.26%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Weighted</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Remaining</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td></tr><tr><td style="vertical-align:bottom;width:47.26%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Number of</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Average Exercise</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Contractual Life</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Total Intrinsic</b></p></td></tr><tr><td style="vertical-align:bottom;width:47.26%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.58%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Shares</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.8%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Price</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.58%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">(in years)</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.75%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Value</b></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:47.26%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">Outstanding as of January 1, 2019</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"> </p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 100,159</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 0.24</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"> </p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 9.3</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> —</p></td></tr><tr><td style="vertical-align:bottom;width:47.26%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0pt 6pt;">Granted</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.58%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 4,500</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.22%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.58%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 0.22</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.58%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 10.4</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.22%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.53%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> —</p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:47.26%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">Outstanding as of December 31, 2019</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 104,659</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 0.24</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 8.4</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> —</p></td></tr><tr><td style="vertical-align:bottom;width:47.26%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0pt 6pt;">Granted (Approved 2018-2020) (1)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 208,525</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 0.37</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">(3)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 10.0</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> —</p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:47.26%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0pt 6pt;">Cashless exercise</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"> </p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (94)</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"> </p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 0.34</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> —</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"> </p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> —</p></td></tr><tr><td style="vertical-align:bottom;width:47.26%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0pt 6pt;">Forfeited/expired</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.58%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (4,250)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.22%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.58%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 0.22</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.58%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> —</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.22%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.53%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> —</p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:47.26%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">Outstanding as of December 31, 2020</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"> </p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.58%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 308,840</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.22%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.58%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 0.33</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"> </p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.58%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 8.9</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.22%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.53%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 372,219</p></td></tr><tr><td style="vertical-align:bottom;width:47.26%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">Options vested (2)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 223,720</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 0.30</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 8.7</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 276,432</p></td></tr></table><div style="font-family:'Times New Roman','Times','serif';font-size:10.0pt;margin-bottom:0pt;margin-top:0pt;min-height:1.19em;position:relative;width:100%;"><div style="background-color:#000000;height:1pt;position:relative;top:0.6em;width:25.0%;border:none;margin:0 auto 0 0;"/></div><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;">(1)</td><td style="padding:0pt;"><span style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:justify;">The options granted during the year ended December 31, 2020 included options already approved at various times during the 3 years 2018 - 2020 but not issued until Q3 2020, and also included options that will vest for performance and milestones going forward over the next 2 years. The options included awards to key external consultants and vendors in addition to internal parties.</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;">(2)</td><td style="padding:0pt;"><span style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:justify;">Approximately 128 </span><span style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:justify;">million vested options as of December 31, 2020 are not exercisable until January 15, 2021. See Note 15 below under Subsequent Events for more information about additional options suspensions for further periods.</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;">(3)</td><td style="padding:0pt;"><span style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:justify;">The weighted average exercise price of the Q3 2020 options was initially </span><span style="-sec-ix-hidden:Hidden_EsoAtG4ld0qmE1IBieM8Gw;"><span style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:justify;">$0.25</span></span><span style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:justify;">. However, subsequently, the exercise price was amended to a weighted average exercise price of $0.36.</span></td></tr></table><div style="margin-top:12pt;"/> 100159 0.24 P9Y3M18D 4500 0.22 P10Y4M24D 104659 0.24 P8Y4M24D 208525 0.37 P10Y 94 0.34 4250 0.22 308840 0.33 P8Y10M24D 372219000 223720 0.30 P8Y8M12D 276432000 128000000 0.36 39200000 P6M P6M 78000000 0.23 0.23 P4Y3M18D P4Y 0.97 0.97 0 0 1750000 3000000 0.22 300000 0.22 0.22 P5Y3M18D P4Y8M12D 0.96 0.97 0 0 2000000 1000000.0 500000 500000 <p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;text-align:justify;margin:0pt 0pt 12pt 0pt;">7. Property, Plant and Equipment</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">Property, plant and equipment consist of the following at December 31, 2020 and 2019 (in thousands):</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">​</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:top;width:44.51%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.32%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:7.68%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:0.94%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.15%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;width:32.9%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:44.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">    </b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">December 31, </b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">    </b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.09%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">December 31, </b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">    </b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:32.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Estimated</b></p></td></tr><tr><td style="vertical-align:bottom;width:44.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2020</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.09%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2019</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:32.9%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Useful Life</b></p></td></tr><tr style="height:14.35pt;"><td style="background-color:#cceeff;vertical-align:top;width:44.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">Leasehold improvements</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:7.68%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 81</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:0.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 186</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"> </p></td><td style="background-color:#cceeff;vertical-align:bottom;width:32.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">Lesser of lease term or estimated useful life</p></td></tr><tr><td style="vertical-align:top;width:44.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">Office furniture and equipment</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.68%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 219</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 59</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:32.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">3-5 years</p></td></tr><tr><td style="background-color:#cceeff;vertical-align:top;width:44.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">Computer equipment and software</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"> </p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:7.68%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 1,403</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:0.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"> </p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 611</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"> </p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:32.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">3-5 years</p></td></tr><tr><td style="vertical-align:top;width:44.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">Land in the United Kingdom</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.32%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.68%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 93</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.94%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.15%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 90</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:32.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">NA</p></td></tr><tr><td style="background-color:#cceeff;vertical-align:top;width:44.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"> </p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:7.68%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 1,796</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:0.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"> </p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 946</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:32.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">​</span></p></td></tr><tr><td style="vertical-align:top;width:44.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">Less: accumulated depreciation</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.32%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.68%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (756)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.94%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.15%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (665)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:32.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">  </p></td></tr><tr><td style="background-color:#cceeff;vertical-align:top;width:44.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">Total property, plant and equipment, net</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.32%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:7.68%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 1,040</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:0.94%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.15%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 281</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"> </p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:32.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">  </p></td></tr><tr><td style="vertical-align:top;width:44.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.32%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.68%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.94%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.15%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:32.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">​</span></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:top;width:44.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">Construction in progress</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.32%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:7.68%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 9,074</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:0.94%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.15%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 1,685</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"> </p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:32.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">  </p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">​</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">Depreciation expense was approximately $87,000 and $21,000 for the years ended December 31, 2020 and 2019, respectively.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><span style="text-decoration:underline;text-decoration-color:#000000;">Construction in Progress</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">In connection with the Company’s manufacturing facility in U.K, the Company has incurred and is incurring costs with certain vendors to design and build out certain stages of the facility. Additionally, the Company purchased certain manufacturing equipment that has been or will be installed in connection with the buildout. These costs were all capitalized and recorded as part of construction in progress as of December 31, 2020 and 2019. Upon completion of the buildout, all costs associated with the buildout will be recorded as manufacturing equipment or leasehold improvement, and amortized over the estimated useful life of the facility.</p> <p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">Property, plant and equipment consist of the following at December 31, 2020 and 2019 (in thousands):</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">​</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:top;width:44.51%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.32%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:7.68%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:0.94%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.15%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;width:32.9%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:44.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">    </b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">December 31, </b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">    </b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.09%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">December 31, </b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">    </b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:32.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Estimated</b></p></td></tr><tr><td style="vertical-align:bottom;width:44.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2020</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.09%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2019</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:32.9%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Useful Life</b></p></td></tr><tr style="height:14.35pt;"><td style="background-color:#cceeff;vertical-align:top;width:44.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">Leasehold improvements</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:7.68%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 81</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:0.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 186</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"> </p></td><td style="background-color:#cceeff;vertical-align:bottom;width:32.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">Lesser of lease term or estimated useful life</p></td></tr><tr><td style="vertical-align:top;width:44.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">Office furniture and equipment</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.68%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 219</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 59</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:32.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">3-5 years</p></td></tr><tr><td style="background-color:#cceeff;vertical-align:top;width:44.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">Computer equipment and software</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"> </p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:7.68%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 1,403</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:0.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"> </p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 611</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"> </p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:32.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">3-5 years</p></td></tr><tr><td style="vertical-align:top;width:44.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">Land in the United Kingdom</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.32%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.68%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 93</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.94%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.15%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 90</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:32.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">NA</p></td></tr><tr><td style="background-color:#cceeff;vertical-align:top;width:44.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"> </p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:7.68%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 1,796</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:0.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"> </p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 946</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:32.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">​</span></p></td></tr><tr><td style="vertical-align:top;width:44.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">Less: accumulated depreciation</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.32%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.68%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (756)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.94%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.15%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (665)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:32.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">  </p></td></tr><tr><td style="background-color:#cceeff;vertical-align:top;width:44.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">Total property, plant and equipment, net</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.32%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:7.68%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 1,040</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:0.94%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.15%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 281</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"> </p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:32.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">  </p></td></tr><tr><td style="vertical-align:top;width:44.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.32%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.68%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.94%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.15%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:32.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">​</span></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:top;width:44.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">Construction in progress</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.32%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:7.68%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 9,074</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:0.94%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.15%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 1,685</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"> </p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:32.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">  </p></td></tr></table> 81000 186000 Lesser of lease term or estimated useful life 219000 59000 P3Y P5Y 1403000 611000 P3Y P5Y 93000 90000 1796000 946000 756000 665000 1040000 281000 9074000 1685000 87000 21000 <p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;text-align:justify;margin:0pt 0pt 12pt 0pt;">8. Notes Payable</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">The following two tables summarize outstanding debt as of December 31, 2020 and December 31, 2019, respectively (amount in thousands):</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">​</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:38.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></td></tr><tr><td style="vertical-align:bottom;width:38.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">    </b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">    </b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:5.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Stated</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:justify;margin:0pt;">    </p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;">    </p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;">    </p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;">    </p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:7.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Embedded</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">    </b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:5.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td></tr><tr style="height:5.4pt;"><td style="vertical-align:bottom;width:38.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:5.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Interest</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:7.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Conversion</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Remaining</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:7.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Conversion</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:5.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Carrying</b></p></td></tr><tr><td style="vertical-align:bottom;width:38.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.09%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Maturity Date</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:5.34%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Rate</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:7.25%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Price</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:7.03%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Face Value</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.02%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Debt Discount</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:7.25%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Option</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:5.91%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Value</b></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:38.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:justify;margin:0pt;"><b style="font-weight:bold;">Short term convertible notes payable</b></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:justify;margin:0pt;"> </p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:7.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt;">  </p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:justify;margin:0pt;"> </p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:0.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:4.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt;">  </p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:justify;margin:0pt;"> </p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:6.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt;">  </p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:justify;margin:0pt;"> </p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:5.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt;">  </p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:justify;margin:0pt;"> </p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:7.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt;">  </p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:justify;margin:0pt;"> </p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:6.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt;">  </p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:justify;margin:0pt;"> </p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:0.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt;">  </p></td></tr><tr><td style="vertical-align:bottom;width:38.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:justify;margin:0pt;">6% unsecured (1)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:justify;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;">Due</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:justify;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 6</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:justify;margin:0pt;">%  </p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:justify;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 3.09</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:justify;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 135</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:justify;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> —</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:justify;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> —</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:justify;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 135</p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:38.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:justify;margin:0pt;">8% unsecured (3) (4)</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:justify;margin:0pt;"> </p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:7.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;">4/30/2021</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:justify;margin:0pt;"> </p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:0.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:4.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 8</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:justify;margin:0pt;">%  </p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:justify;margin:0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:6.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 0.85</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.12%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:justify;margin:0pt;"> </p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:5.91%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 2,125</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.42%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:justify;margin:0pt;"> </p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:7.6%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt;"> (937)</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.13%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:justify;margin:0pt;"> </p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:6.12%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 2,507</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:0.91%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:justify;margin:0pt;"> </p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:5%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 3,695</p></td></tr><tr><td style="vertical-align:bottom;width:38.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><b style="font-weight:bold;"> 2,260</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt;"><b style="font-weight:bold;"> (937)</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><b style="font-weight:bold;"> 2,507</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><b style="font-weight:bold;"> 3,830</b></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:38.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:justify;margin:0pt;"><b style="font-weight:bold;">Short term notes payable</b></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:justify;margin:0pt;"> </p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:7.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;">  </p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:justify;margin:0pt;"> </p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:0.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:4.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt;">  </p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:justify;margin:0pt;"> </p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:6.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt;">  </p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:justify;margin:0pt;"> </p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:5.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt;">  </p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:justify;margin:0pt;"> </p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:7.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt;">  </p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:justify;margin:0pt;"> </p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:6.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt;">  </p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:0.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:justify;margin:0pt;"> </p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt;">  </p></td></tr><tr><td style="vertical-align:bottom;width:38.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:justify;margin:0pt;">8% unsecured (5)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:justify;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;">Various</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:justify;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 8</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:justify;margin:0pt;">%  </p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:justify;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;">N/A</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:justify;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 1,785</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:justify;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt;"> (51)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:justify;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> —</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:justify;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 1,734</p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:38.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:justify;margin:0pt;">10% unsecured (6)</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:justify;margin:0pt;"> </p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:7.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;">Various</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:justify;margin:0pt;"> </p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:0.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:4.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 10</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:justify;margin:0pt;">%  </p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:justify;margin:0pt;"> </p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:6.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;">N/A</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:justify;margin:0pt;"> </p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:5.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 263</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:justify;margin:0pt;"> </p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:7.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> —</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:justify;margin:0pt;"> </p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:6.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> —</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:0.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:justify;margin:0pt;"> </p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 263</p></td></tr><tr><td style="vertical-align:bottom;width:38.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:justify;margin:0pt;">12% unsecured (7)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:justify;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;">On Demand</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:justify;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 12</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:justify;margin:0pt;">%  </p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:justify;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;">N/A</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:justify;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 440</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:justify;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> —</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:justify;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> —</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:justify;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 440</p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:38.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:justify;margin:0pt;"><b style="font-weight:bold;"> </b></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:7.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:0.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:4.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:6.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:5.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><b style="font-weight:bold;"> 2,488</b></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:justify;margin:0pt;"><b style="font-weight:bold;"> </b></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:7.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt;"><b style="font-weight:bold;"> (51)</b></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:justify;margin:0pt;"><b style="font-weight:bold;"> </b></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:6.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><b style="font-weight:bold;"> —</b></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:0.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:justify;margin:0pt;"><b style="font-weight:bold;"> </b></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><b style="font-weight:bold;"> 2,437</b></p></td></tr><tr><td style="vertical-align:bottom;width:38.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:justify;margin:0pt;"><b style="font-weight:bold;">Long term notes payable</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:justify;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;">  </p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:justify;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt;">  </p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:justify;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt;">  </p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:justify;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt;">  </p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:justify;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt;">  </p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:justify;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt;">  </p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:justify;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt;">  </p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:38.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:justify;margin:0pt;">8% unsecured (10)</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:justify;margin:0pt;"> </p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:7.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;">Various</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:justify;margin:0pt;"> </p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:0.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:4.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 8</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:justify;margin:0pt;">%  </p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:justify;margin:0pt;"> </p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:6.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;">N/A</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:justify;margin:0pt;"> </p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:5.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 7,160</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:justify;margin:0pt;"> </p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:7.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt;"> (496)</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:justify;margin:0pt;"> </p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:6.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> —</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:0.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:justify;margin:0pt;"> </p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 6,664</p></td></tr><tr><td style="vertical-align:bottom;width:38.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:justify;margin:0pt;">6% secured (11)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:justify;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;">3/25/2025</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:justify;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 6</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:justify;margin:0pt;">%  </p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:justify;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;">N/A</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.12%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:justify;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.91%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 1,843</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:justify;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.6%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> —</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.13%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:justify;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.12%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> —</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.91%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:justify;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:5%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 1,843</p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:38.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:justify;margin:0pt;"><b style="font-weight:bold;"> </b></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:7.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:0.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:4.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:6.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.12%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:5.91%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><b style="font-weight:bold;"> 9,003</b></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:justify;margin:0pt;"><b style="font-weight:bold;"> </b></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.42%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:7.6%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt;"><b style="font-weight:bold;"> (496)</b></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:justify;margin:0pt;"><b style="font-weight:bold;"> </b></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.13%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:6.12%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><b style="font-weight:bold;"> —</b></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:0.91%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:justify;margin:0pt;"><b style="font-weight:bold;"> </b></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:5%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><b style="font-weight:bold;"> 8,507</b></p></td></tr><tr><td style="vertical-align:bottom;width:38.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt;"><b style="font-weight:bold;"> </b><span style="font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt;"><b style="font-weight:bold;"> </b><span style="font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt;"><b style="font-weight:bold;"> </b><span style="font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt;"><b style="font-weight:bold;"> </b><span style="font-weight:bold;visibility:hidden;">​</span></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:38.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:justify;margin:0pt;"><b style="font-weight:bold;">Ending balance as of December 31, 2020</b></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:7.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:0.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:4.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:6.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.12%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:justify;margin:0pt;"><b style="font-weight:bold;">$</b></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:5.91%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><b style="font-weight:bold;"> 13,751</b></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.42%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:justify;margin:0pt;"><b style="font-weight:bold;">$</b></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:7.6%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt;"><b style="font-weight:bold;"> (1,484)</b></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.13%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:justify;margin:0pt;"><b style="font-weight:bold;">$</b></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:6.12%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><b style="font-weight:bold;"> 2,507</b></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:0.91%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:justify;margin:0pt;"><b style="font-weight:bold;">$</b></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:5%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><b style="font-weight:bold;"> 14,774</b></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">​</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:42.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></td></tr><tr><td style="vertical-align:bottom;width:42.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">    </b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">    </b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:7.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Stated</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">    </b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">    </p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">    </b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">    </b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;visibility:hidden;">​</span></p></td></tr><tr><td style="vertical-align:bottom;width:42.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:7.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Interest</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:7.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Conversion</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Remaining</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:7.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Carrying</b></p></td></tr><tr><td style="vertical-align:bottom;width:42.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.09%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Maturity Date</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:7.24%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Rate</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:7.25%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Price</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:7.24%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Face Value</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.02%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Debt Discount</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:7.22%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Value</b></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:42.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Short term convertible notes payable</b></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:7.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">  </p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:6.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">  </p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:6.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">  </p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:6.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">  </p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:7.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">  </p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:6.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">  </p></td></tr><tr><td style="vertical-align:bottom;width:42.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;">6% unsecured (1)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;">Due</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 6</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;">%  </p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 3.09</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 135</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> —</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 135</p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:42.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;">10% unsecured (2)</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:7.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;">4/18/2020</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:6.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 10</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;">%  </p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:6.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 0.22</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.12%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:6.12%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 500</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.42%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:7.6%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (67)</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:6.22%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 433</p></td></tr><tr><td style="vertical-align:bottom;width:42.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;"> </b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><b style="font-weight:bold;">635</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;"> (67)</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;"> </b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><b style="font-weight:bold;">568</b></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:42.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Short term notes payable</b></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:7.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">  </p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:6.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">  </p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:6.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">  </p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:6.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">  </p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:7.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">  </p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:6.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">  </p></td></tr><tr><td style="vertical-align:bottom;width:42.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;">8% unsecured (5)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;">Various</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 8</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;">%  </p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;">N/A</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 555</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (43)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 512</p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:42.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;">10% unsecured (6)</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:7.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;">Various</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:6.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 10</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;">%  </p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:6.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;">N/A</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:6.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 3,551</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:7.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (73)</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:6.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 3,478</p></td></tr><tr><td style="vertical-align:bottom;width:42.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;">12% unsecured (7)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;">On Demand</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 12</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;">%  </p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;">N/A</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.12%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.12%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 440</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.6%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> —</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.22%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 440</p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:42.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;">0% unsecured (8)</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:7.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;">8/1/2020</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:6.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 0</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;">%  </p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:6.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;">N/A</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.12%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:6.12%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 1,156</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.42%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:7.6%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (85)</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:6.22%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 1,071</p></td></tr><tr><td style="vertical-align:bottom;width:42.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;"> </b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><b style="font-weight:bold;"> 5,702</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;"> </b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;"> (201)</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;"> </b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;"> </b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><b style="font-weight:bold;"> 5,501</b></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:42.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Short term notes payable - related parties</b></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:7.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">  </p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:6.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">  </p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:6.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">  </p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:6.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">  </p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:7.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">  </p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:6.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">  </p></td></tr><tr><td style="vertical-align:bottom;width:42.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;">10% unsecured - Related Parties (9)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;">On Demand</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 10</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;">%  </p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;">N/A</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.12%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 66</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.6%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> —</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.22%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 66</p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:42.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;"> </b></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:7.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:6.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:6.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:6.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><b style="font-weight:bold;"> 66</b></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;"> </b></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:7.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><b style="font-weight:bold;"> —</b></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;"> </b></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;"> </b></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:6.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><b style="font-weight:bold;"> 66</b></p></td></tr><tr><td style="vertical-align:bottom;width:42.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Long term notes payable</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">  </p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">  </p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">  </p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">  </p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">  </p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">  </p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:42.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;">8% unsecured (5)</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:7.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;">Various</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:6.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 8</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;">%  </p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:6.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;">N/A</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.12%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:6.12%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 7,008</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.42%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:7.6%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (420)</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:6.22%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 6,588</p></td></tr><tr><td style="vertical-align:bottom;width:42.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;"> </b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.12%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.12%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><b style="font-weight:bold;"> 7,008</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;"> </b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.6%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;"> (420)</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;"> </b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;"> </b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.22%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><b style="font-weight:bold;"> 6,588</b></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:42.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:7.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:6.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:6.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:6.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:7.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:6.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td></tr><tr><td style="vertical-align:bottom;width:42.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Ending balance as of December 31, 2019</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.12%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">$</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.12%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><b style="font-weight:bold;"> 13,411</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">$</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.6%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;"> (688)</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">$</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.22%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><b style="font-weight:bold;"> 12,723</b></p></td></tr></table><div style="font-family:'Times New Roman','Times','serif';font-size:10.0pt;margin-bottom:0pt;min-height:1.19em;position:relative;width:100%;"><div style="background-color:#000000;height:1pt;position:relative;top:0.6em;width:25.0%;border:none;margin:0 auto 0 0;"/></div><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">(1)</td><td style="padding:0pt;"><span style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:justify;">This </span><span style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:justify;">$135,000</span><span style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:justify;"> note as of December 31, 2020 and 2019 consists of two separate </span><span style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:justify;">6%</span><span style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:justify;"> notes in the amounts of </span><span style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:justify;">$110,000</span><span style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:justify;"> and </span><span style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:justify;">$25,000</span><span style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:justify;">. In regard to the </span><span style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:justify;">$110,000</span><span style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:justify;"> note, the Company has made ongoing attempts to locate the creditor to repay or convert this note, but has been unable to locate the creditor to date. In regard to the </span><span style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:justify;">$25,000</span><span style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:justify;"> note, the holder has elected to convert these notes into equity, the Company has delivered the applicable conversion documents to the holder, and the Company is waiting for the holder to execute and return the documents.</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">(2)</td><td style="padding:0pt;"><span style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:justify;">In February 2020, the Company entered into multiple one-year convertible notes (the “February Notes”) with multiple holders (the “Holders”) for an aggregate principal amount of </span><span style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:justify;">$1.0</span><span style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:justify;"> million. The Notes are convertible into common shares of the Company at </span><span style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:justify;">$0.21</span><span style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:justify;"> per share and bear interest at the rate of </span><span style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:justify;">10%</span><span style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:justify;"> per annum. Upon issuance of the February Notes, the Holders also received a </span><span style="-sec-ix-hidden:Hidden_2JbScKrEkkO6cpKz3RpIbg;"><span style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:justify;">2-year</span></span><span style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:justify;"> warrant to purchase a total of </span><span style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:justify;">1.4</span><span style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:justify;"> million common shares of the Company at an exercise price of </span><span style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:justify;">$0.35</span><span style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:justify;"> per share. The fair value of the warrants was approximately </span><span style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:justify;">$79,000</span><span style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:justify;"> on the grant date.</span></td></tr></table><div style="margin-top:12pt;"/><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 18pt;">During the year ended December 31, 2020, the Company converted the entire February Notes, including $68,000 accrued interest into approximate 5.1 million shares of the Company's common stock.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 18pt;">In April 2020, the Company entered into a six-month convertible note (the “April Note”) with an individual investor (the “Holder”) with an aggregate principal amount of $0.8 million for cash proceeds of $0.7 million. The Company also incurred approximately $69,000 placement agent costs, including both a cash fee and the fair value of common stock warrants issued to the placement agent, which was recognized as additional debt discount.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 18pt;">The April Note bears interest at the rate of 10% per annum and is convertible into common shares of the Company at $0.17 per share plus a warrant to purchase a number of exercise shares equal to 50% of the number of common shares issued upon conversion (the “Conversion Warrants”). The Conversion Warrants will be exercisable until April 9, 2022 beginning on November 1, 2020, with an exercise price of $0.20 per share. The conversion option within the April Note is required to be bifurcated at fair value, which was approximately $0.4 million on the issuance date, resulting in additional debt discount to the April Note. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 18pt;">As consideration for entering into the April Note, the Company also agreed to amend the Holder’s existing outstanding warrants to purchase 5.1 million common shares of the Company. The exercise price of the warrants was amended from $0.25 per share to $0.20 per share. The incremental change in fair value resulting from the amendment was approximately $51,000, which was recognized as additional debt discount to the April Note.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 18pt;">On August 3, 2020, the Company converted approximately $0.8 million of outstanding principal and $26,000 of accrued interest of the April Note into approximately 5.1 million shares of common stock and 2.5 million warrants with fair value of approximately $2.4 million. The Company also extinguished $1.5 million embedded derivative liability and $0.2 million unamortized debt discount upon the conversion. The Company recorded approximately $0.3 million debt extinguishment loss.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 18pt;">In April 2020, the Company entered into a Note Amendment Agreement (the “Amendment”) with an individual holder of a short-term convertible note, primarily to agree on the following changes:</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Calibri';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">-</td><td style="padding:0pt;"><span style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:justify;">Reclassed </span><span style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:justify;">$75,000</span><span style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:justify;"> accrued interest as of amendment date to the outstanding principal amount;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Calibri';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">-</td><td style="padding:0pt;"><span style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:justify;">Extended the maturity date of a convertible note with approximately </span><span style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:justify;">$0.6</span><span style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:justify;"> million of principal outstanding, as of the amendment date, to October 18, 2020 (the “Amended Note”);</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Calibri';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">-</td><td style="padding:0pt;"><span style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:justify;">Reduced the conversion price from </span><span style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:justify;">$0.22</span><span style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:justify;"> to </span><span style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:justify;">$0.181</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Calibri';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">-</td><td style="padding:0pt;"><span style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:justify;">Issued a new </span><span style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:justify;">2</span><span style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:justify;">-year warrant for up to </span><span style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:justify;">2.3</span><span style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:justify;"> million shares of the Company’s common stock at an exercise price of </span><span style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:justify;">$0.25</span><span style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:justify;"> per share valued at </span><span style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:justify;">$115,000</span><span style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:justify;"> on the amendment date;</span></td></tr></table><div style="margin-top:12pt;"/><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 18pt;">The amendment was recognized as a debt extinguishment, resulting in a loss on debt extinguishment of approximately $70,000.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 18pt;">During the year ended December 31, 2020, the Company converted the entire Amended Note of approximately $0.6 million, including $28,000 accrued interest into approximately 3.3 million shares of common stock.</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">(3)</td><td style="padding:0pt;"><span style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:justify;">In May 2020, the Company entered into a six-month convertible note (the “May Note”) with an individual investor (the “Holder”) with an aggregate principal amount of </span><span style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:justify;">$0.6</span><span style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:justify;"> million. The May Note contains an original issue discount (“OID”) in the amount of </span><span style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:justify;">$50,000</span><span style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:justify;">.</span></td></tr></table><div style="margin-top:12pt;"/><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 18pt;">The May Note bears interest at the rate of 8% per annum and is convertible into common shares of the Company at $0.25 plus a warrant to purchase a number of exercise shares equal to 40% of the number of common shares issued upon conversion (the “Conversion Warrants”). The Conversion Warrants will be exercisable until November 28, 2022 beginning on November 1, 2020 with exercise price of $0.25 per share. The conversion option within the May Note required bifurcation at fair value, which was approximately $0.5 million on the issuance date, resulting in additional debt discount to the May Note.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 18pt;">On October 1, 2020, the Company converted the entire $0.6 million of the May Note including $19,000 accrued interest, into approximately 2.3 million shares of the Company's common stock and 0.9 million warrants with fair value of approximate $3.4 million. The Company also extinguished $2.8 million embedded derivative liability upon the conversion. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 18pt;">In August 2020, the Company entered into another convertible note (the "August Note") with the same investor as the May Note (the "Holder") with an aggregate principal amount of $1.1 million. The August Note contains OID in the amount of $110,000.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 18pt;">The August Note bears interest at the rate of 8% per annum and is convertible into common shares of the Company at $0.345 plus a warrant to purchase a number of exercise shares equal to 35% of the number of common shares issued upon conversion (the "Conversion Warrants"). The Conversion Warrants will be exercisable until February 4, 2023 beginning on December 15, 2020 with exercise price of $0.34 per share. The conversion option within the August Note is required to be bifurcated at fair value, which was approximately $0.6 million on the issuance date, resulting in additional debt discount to the August Note.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 18pt;">On September 29, 2020, the Company converted entire $1.1 million of August Note into approximately 3.3 million shares of the Company's common stock and 1.1 million warrants with fair value of approximate $3.3 million. The Company also extinguished $2.3 million embedded derivative liability and $0.5 million unamortized debt discount upon the conversion. The company recorded approximately $0.4 million debt extinguishment loss.</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">(4)</td><td style="padding:0pt;"><span style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:justify;">In October 2020, the Company entered into a convertible note (the "October Note") with the same investor as the August Note (the "Holder") with an aggregate principal amount of </span><span style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:justify;">$2.1</span><span style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:justify;"> million. The October Note contains OID in the amount of </span><span style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:justify;">$200,000</span><span style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:justify;">.</span></td></tr></table><div style="margin-top:12pt;"/><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 18pt;">The October Note bears interest at the rate of 8% per annum and is convertible into common shares of the Company at $0.85 plus a warrant to purchase a number of exercise shares equal to 30% of the number of common shares issued upon conversion (the "Conversion Warrants"). The Conversion Warrants will be exercisable until January 12, 2022 beginning on January 15, 2021 with exercise price of $2.00 per share. The conversion option within the October Note is required to be bifurcated at fair value, which was approximately $1.4 million on the issuance date, resulting in additional debt discount of $1.4 million to the October Note.</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:20.15pt;padding:0pt;">(5)</td><td style="padding:0pt;"><span style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:justify;">During the year ended December 31, 2020, the Company converted approximately </span><span style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:justify;">$5.8</span><span style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:justify;"> million of outstanding principal and </span><span style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:justify;">$0.6</span><span style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:justify;"> million of accrued interest into approximately </span><span style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:justify;">29.1</span><span style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:justify;"> million shares of the Company’s common stock with a fair value of </span><span style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:justify;">$7.6</span><span style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:justify;"> million. The Company recognized approximately </span><span style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:justify;">$1.2</span><span style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:justify;"> million in debt extinguishment loss from this conversion.</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">(6)</td><td style="padding:0pt;"><span style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:justify;">In May 2020, the Company converted approximately </span><span style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:justify;">$0.3</span><span style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:justify;"> million of outstanding principal and accrued interest into approximately </span><span style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:justify;">1.3</span><span style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:justify;"> million shares of the Company’s common stock with a fair value of </span><span style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:justify;">$0.5</span><span style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:justify;"> million. The Company recognized approximately </span><span style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:justify;">$0.2</span><span style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:justify;"> million in debt extinguishment loss from this conversion.</span></td></tr></table><div style="margin-top:12pt;"/><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 18pt;">In August 2020, the Company extinguished approximately $1.5 million of outstanding principal and accrued interest into approximately 4.8 million shares of the Company's common stock and 1.7 million warrants. The Company also modified certain existing warrants and issued additional 6.5 million warrants consideration for certain suspension. The Company also agreed to amend the remaining outstanding $1.5 million outstanding debt. The note became convertible at a conversion price of $0.34 (the “Amended August Note”). The amendment was accounted as debt extinguishment and the Company recognized approximately $1.6 million in debt extinguishment loss from this transaction.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 18pt;">During the year ended December 31, 2020, the Company made $0.1 million cash payment and converted approximate $1.4 million outstanding debt including $15,000 accrued interest into approximately 4.1 million shares of the Company’s common stock. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 18pt;">During the year ended December 31, 2020, the Company entered into multiple Note Extension Agreements with multiple holders, primarily resulting in the following changes:</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Calibri';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">-</td><td style="padding:0pt;"><span style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:justify;">Extended the maturity dates of promissory notes with outstanding principal balances aggregating approximately </span><span style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:justify;">$3.3</span><span style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:justify;"> million for an additional </span><span style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:justify;">6</span><span style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:justify;"> to </span><span style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:justify;">12 months</span><span style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:justify;"> from the original maturity date;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Calibri';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">-</td><td style="padding:0pt;"><span style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:justify;">Issued new </span><span style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:justify;">2</span><span style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:justify;">-year warrants to purchase up to </span><span style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:justify;">10.3</span><span style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:justify;"> million shares of the Company’s common stock at an exercise prices ranging from </span><span style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:justify;">$0.20</span><span style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:justify;"> and </span><span style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:justify;">$0.23</span><span style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:justify;"> per share valued at approximately </span><span style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:justify;">$0.5</span><span style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:justify;"> million on the amendment date;</span></td></tr></table><div style="margin-top:12pt;"/><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 18pt;">The Note Extension Agreements for approximately $2.3 million of outstanding principal of promissory notes was recognized as a debt modification, while the amendments for approximately $1.0 million of outstanding principal of promissory notes was recognized as a debt extinguishment, resulting in a loss on extinguishment of debt of approximately $0.1 million.</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">(7)</td><td style="padding:0pt;"><span style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:justify;">The </span><span style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:justify;">$440,000</span><span style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:justify;"> balance of outstanding principal as of December 31, 2020 and 2019 consists of two separate </span><span style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:justify;">12%</span><span style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:justify;"> demand notes in the amounts of </span><span style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:justify;">$300,000</span><span style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:justify;"> and </span><span style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:justify;">$140,000</span><span style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:justify;">.</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">(8)</td><td style="padding:0pt;"><span style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:justify;">On May 28, 2019, the Company issued a deferred note to a third-party vendor pursuant to a settlement agreement resolving past matters and providing for the restart of DCVax®-Direct Production. During the year ended December 31, 2020, the Company made full repayment of </span><span style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:justify;">$1.2</span><span style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:justify;"> million to the note holder.</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:20.15pt;padding:0pt;">(9)</td><td style="padding:0pt;"><span style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:justify;">On September 26, 2018, Advent BioServices (“Advent”), a related party of the Company, provided a short-term loan in the amount of </span><span style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:justify;">$65,000</span><span style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:justify;">. The loan bore interest at </span><span style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:justify;">10%</span><span style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:justify;"> per annum, and is payable upon demand, with </span><span style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:justify;">7 days</span><span style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:justify;">’ prior written notice to the Company. During the year ended December 31, 2020, the Company made full repayment to Advent, including all outstanding interest.</span></td></tr></table><div style="margin-top:12pt;"/><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 20.15pt;">Between February and May 2020, the Company entered into multiple demand loan agreements with Leslie Goldman, the Company’s Senior Vice President, General Counsel, for an aggregate principal amount of $0.3 million (the “Goldman Notes”). The Goldman Notes bear interest rate at 10% per annum, and are repayable upon 15 days' notice from Mr. Goldman.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 20.15pt;">The Goldman Notes are convertible into common shares of the Company at conversion prices ranging from $0.23 to $0.25 per share. Additionally, the Company agreed to issue warrants to Mr. Goldman to purchase 0.6 million shares of the Company’s common stock (the “Initial Warrants”) in conjunction with the Goldman Notes. The Initial Warrants have a <span style="-sec-ix-hidden:Hidden_vyli9FUruEKTsUlBoJJ2QQ;"><span style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:justify;">five</span></span> - year term and are exercisable at prices ranging from $0.23 and $0.25 per share. The fair value of the Initial Warrants was approximately $66,000, which was recognized as debt discount to the Goldman Notes at the issuance date. The conversion option within the Goldman Notes were required to be bifurcated at fair value, which was approximately $36,000 on the issuance date, resulting in additional debt discount to the Goldman Notes.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 20.15pt;">Upon conversion, Mr. Goldman would also receive a five-year term warrant to purchase a number of the Company’s common shares equal to 50% of the number of common shares issued upon conversion of the Goldman Notes (the “Conversion Warrants”). The Conversion Warrants will be exercisable at $0.25 per share.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 20.15pt;">During the year ended December 31, 2020, the Company made full repayment of $0.3 million to Mr. Goldman, including all outstanding interest. Upon the repayment, the Company also extinguished $1.6 million embedded derivative liability, which was recorded as debt extinguishment gain. </p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:20.15pt;padding:0pt;">(10)</td><td style="padding:0pt;"><span style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:justify;">During the year ended December 31, 2020, the Company entered into two note purchase agreements (the “Notes”) with same investor for an aggregate principal amount of approximate </span><span style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:justify;">$7.2</span><span style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:justify;"> million. The Notes bear interest at </span><span style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:justify;">8%</span><span style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:justify;"> per annum with </span><span style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:justify;">21-month</span><span style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:justify;"> term. There are no repayments during the first 7 months of the term. The Notes are amortized in </span><span style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:justify;">14</span><span style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:justify;"> installments starting in month 8. The Notes carry an original issue discount of </span><span style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:justify;">$650,000</span><span style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:justify;"> and </span><span style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:justify;">$10,000</span><span style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:justify;"> legal costs that were reimbursable to the investor.</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:20.15pt;padding:0pt;">(11)</td><td style="padding:0pt;"><span style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:justify;text-decoration:underline;text-decoration-color:#000000;">Cambridge Loan</span></td></tr></table><div style="margin-top:12pt;"/><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 20.15pt;">On March 26, 2020, the Company entered into a Loan Agreement (the “Loan Agreement”) with Cambridge &amp; Peterborough Combined Authority (the “Lender”) for a loan of £1.35 million (approximately $1.7 million) (the “Loan”) for the current phase of buildout of the Sawston facility. The Company received funds on April 6, 2020. The Lender provides funding for selected economic development projects in the Cambridge region through a competitive selection process.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 20.15pt;">Under the Loan Agreement, there will be no repayments during the first year of the Loan term, although interest will accrue. Following the first anniversary, repayment of the Loan principal and interest will take place over 4 years, for a total term of 5 years.  The interest rate on the Loan is 6.25% per annum.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 38.15pt;">In conjunction with the Loan, the Company agreed to enter into a Security Agreement with the Lender under which the Company granted a security interest in the Company’s 17-acre property in Sawston, U.K. to secure the Loan.  No other tangible or intangible assets of the Company or its subsidiaries are subject to any security interest. Such security interest on the 17-acre property will be released upon completion of repayment</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><span style="text-decoration:underline;text-decoration-color:#000000;">PPP Loan</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">The Company received a loan under the Coronavirus Aid, Relief and Economic Security (“CARES”) Act’s Paycheck Protection Program (“PPP”). The PPP loan was received on May 20, 2020 in the amount of $0.4 million. The current terms of the PPP loan is two years with a maturity date of May 20, 2022 and it contains a favorable fixed annual interest rate of 1.00%. Payments of principal and interest on the PPP Loan are deferred for the first six months of the term of the PPP Loan until November 20, 2020. The Company used the loan to make payments for payroll, health and disability insurance and rent.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">The Company submitted a PPP loan forgiveness application to the Lender on October 26, 2020, with the amount which may be forgiven equal to the sum of qualifying expenses, including payroll costs, covered rent obligations, and covered utility payments incurred by the Company during the twenty-four week period beginning on May 20, 2020, calculated in accordance with the terms of the CARES Act. The forgiveness application was approved on December 7, 2020. The Company recorded approximate $0.4 million debt extinguishment gain from the forgiveness of PPP Loan. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">The following table summarizes total interest expenses related to outstanding debt for the years ended December 31, 2020 and 2019, respectively (in thousands):</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">​</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:74.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></td></tr><tr><td style="vertical-align:bottom;width:74.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;visibility:hidden;">​</span></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:21.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">For the year ended </b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td></tr><tr><td style="vertical-align:bottom;width:74.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:21.13%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">December 31, </b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td></tr><tr><td style="vertical-align:bottom;width:74.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">    </b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.39%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2020</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">    </b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.39%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2019</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:74.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">Interest expenses related to outstanding notes:</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:7.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">  </p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"> </p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:7.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">  </p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">​</span></p></td></tr><tr><td style="vertical-align:bottom;width:74.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0pt 6pt;">Contractual interest</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 1,231</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 1,168</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">​</span></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:74.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0pt 6pt;">Amortization of debt discount</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.48%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"> </p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:7.91%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 2,891</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.48%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"> </p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:7.91%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 1,430</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">​</span></p></td></tr><tr><td style="vertical-align:bottom;width:74.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0pt 12pt;"><b style="font-weight:bold;">Total interest expenses related to outstanding notes</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><b style="font-weight:bold;"> </b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><b style="font-weight:bold;"> 4,122</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><b style="font-weight:bold;"> </b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><b style="font-weight:bold;"> 2,598</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">​</span></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:74.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">Interest expenses related to outstanding notes to related parties:</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"> </p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:7.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"> </p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:7.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">​</span></p></td></tr><tr><td style="vertical-align:bottom;width:74.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0pt 6pt;">Contractual interest</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 20</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 366</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">​</span></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:74.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0pt 6pt;">Amortization of debt discount</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.48%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"> </p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:7.91%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 122</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.48%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"> </p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:7.91%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> —</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">​</span></p></td></tr><tr><td style="vertical-align:bottom;width:74.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0pt 12pt;"><b style="font-weight:bold;">Total interest expenses related to outstanding notes to related parties</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><b style="font-weight:bold;"> </b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><b style="font-weight:bold;"> 142</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><b style="font-weight:bold;"> </b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><b style="font-weight:bold;"> 366</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">​</span></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:74.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">Interest expenses related to forbearance of debt to related parties</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:7.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 4,270</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:7.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> —</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">​</span></p></td></tr><tr><td style="vertical-align:bottom;width:74.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">Other interest expenses</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.91%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 10</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.91%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 11</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">​</span></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:74.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><b style="font-weight:bold;">Total interest expense</b></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.48%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><b style="font-weight:bold;">$</b></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:7.91%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><b style="font-weight:bold;"> 8,544</b></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.48%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><b style="font-weight:bold;">$</b></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:7.91%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><b style="font-weight:bold;"> 2,975</b></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">​</span></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">​</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">The following table summarizes the principal amounts of the Company’s debt obligations as of December 31, 2020 (amount in thousands):</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">​</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;white-space:nowrap;width:58.6%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.17%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:7.32%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.17%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:7.32%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.17%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:7.32%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.17%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:7.27%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:58.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td colspan="11" style="vertical-align:bottom;white-space:nowrap;width:39.53%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Payment Due by Period</b></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:58.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Less than</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">1 to 2</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.45%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">3 to 5</b></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:58.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">    </b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.49%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Total</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">    </b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.49%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">1 Year</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">    </b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.49%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Years</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">    </b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.45%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Years</b></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:58.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">Short term convertible notes payable</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:7.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:7.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:7.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:7.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">​</span></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:58.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0pt 6pt;">6% unsecured</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 135</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 135</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> —</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> —</p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:58.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0pt 6pt;">8% unsecured</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:7.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 2,125</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:7.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 2,125</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:7.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> —</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:7.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> —</p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:58.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">Short term notes payable</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> <span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> <span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">​</span></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:58.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0pt 6pt;">8% unsecured</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:7.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 1,785</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:7.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 1,785</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:7.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> —</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:7.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> —</p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:58.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0pt 6pt;">10% unsecured</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 263</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 263</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">​</span></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:58.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0pt 6pt;">12% unsecured</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:7.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 440</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:7.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 440</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:7.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> —</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:7.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> —</p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:58.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">Long term notes payable</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">​</span></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:58.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0pt 6pt;">8% unsecured </p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:7.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 7,160</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:7.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> —</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:7.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 7,160</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:7.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> —</p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:58.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0pt 6pt;">6% secured </p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.17%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.32%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 1,843</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.17%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.32%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> —</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.17%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.32%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> —</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.17%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.27%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 1,843</p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:58.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><b style="font-weight:bold;">Total</b></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.17%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><b style="font-weight:bold;">$</b></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:7.32%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><b style="font-weight:bold;"> 13,751</b></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.17%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><b style="font-weight:bold;">$</b></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:7.32%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><b style="font-weight:bold;"> 4,748</b></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.17%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><b style="font-weight:bold;">$</b></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:7.32%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><b style="font-weight:bold;"> 7,160</b></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.17%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><b style="font-weight:bold;">$</b></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:7.27%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><b style="font-weight:bold;"> 1,843</b></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p> <p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">​</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:38.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></td></tr><tr><td style="vertical-align:bottom;width:38.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">    </b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">    </b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:5.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Stated</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:justify;margin:0pt;">    </p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;">    </p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;">    </p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;">    </p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:7.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Embedded</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">    </b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:5.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td></tr><tr style="height:5.4pt;"><td style="vertical-align:bottom;width:38.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:5.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Interest</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:7.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Conversion</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Remaining</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:7.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Conversion</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:5.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Carrying</b></p></td></tr><tr><td style="vertical-align:bottom;width:38.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.09%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Maturity Date</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:5.34%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Rate</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:7.25%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Price</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:7.03%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Face Value</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.02%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Debt Discount</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:7.25%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Option</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:5.91%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Value</b></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:38.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:justify;margin:0pt;"><b style="font-weight:bold;">Short term convertible notes payable</b></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:justify;margin:0pt;"> </p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:7.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt;">  </p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:justify;margin:0pt;"> </p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:0.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:4.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt;">  </p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:justify;margin:0pt;"> </p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:6.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt;">  </p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:justify;margin:0pt;"> </p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:5.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt;">  </p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:justify;margin:0pt;"> </p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:7.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt;">  </p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:justify;margin:0pt;"> </p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:6.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt;">  </p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:justify;margin:0pt;"> </p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:0.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt;">  </p></td></tr><tr><td style="vertical-align:bottom;width:38.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:justify;margin:0pt;">6% unsecured (1)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:justify;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;">Due</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:justify;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 6</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:justify;margin:0pt;">%  </p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:justify;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 3.09</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:justify;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 135</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:justify;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> —</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:justify;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> —</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:justify;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 135</p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:38.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:justify;margin:0pt;">8% unsecured (3) (4)</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:justify;margin:0pt;"> </p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:7.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;">4/30/2021</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:justify;margin:0pt;"> </p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:0.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:4.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 8</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:justify;margin:0pt;">%  </p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:justify;margin:0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:6.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 0.85</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.12%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:justify;margin:0pt;"> </p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:5.91%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 2,125</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.42%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:justify;margin:0pt;"> </p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:7.6%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt;"> (937)</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.13%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:justify;margin:0pt;"> </p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:6.12%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 2,507</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:0.91%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:justify;margin:0pt;"> </p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:5%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 3,695</p></td></tr><tr><td style="vertical-align:bottom;width:38.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><b style="font-weight:bold;"> 2,260</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt;"><b style="font-weight:bold;"> (937)</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><b style="font-weight:bold;"> 2,507</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><b style="font-weight:bold;"> 3,830</b></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:38.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:justify;margin:0pt;"><b style="font-weight:bold;">Short term notes payable</b></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:justify;margin:0pt;"> </p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:7.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;">  </p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:justify;margin:0pt;"> </p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:0.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:4.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt;">  </p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:justify;margin:0pt;"> </p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:6.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt;">  </p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:justify;margin:0pt;"> </p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:5.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt;">  </p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:justify;margin:0pt;"> </p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:7.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt;">  </p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:justify;margin:0pt;"> </p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:6.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt;">  </p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:0.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:justify;margin:0pt;"> </p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt;">  </p></td></tr><tr><td style="vertical-align:bottom;width:38.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:justify;margin:0pt;">8% unsecured (5)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:justify;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;">Various</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:justify;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 8</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:justify;margin:0pt;">%  </p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:justify;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;">N/A</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:justify;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 1,785</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:justify;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt;"> (51)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:justify;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> —</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:justify;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 1,734</p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:38.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:justify;margin:0pt;">10% unsecured (6)</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:justify;margin:0pt;"> </p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:7.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;">Various</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:justify;margin:0pt;"> </p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:0.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:4.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 10</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:justify;margin:0pt;">%  </p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:justify;margin:0pt;"> </p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:6.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;">N/A</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:justify;margin:0pt;"> </p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:5.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 263</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:justify;margin:0pt;"> </p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:7.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> —</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:justify;margin:0pt;"> </p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:6.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> —</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:0.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:justify;margin:0pt;"> </p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 263</p></td></tr><tr><td style="vertical-align:bottom;width:38.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:justify;margin:0pt;">12% unsecured (7)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:justify;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;">On Demand</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:justify;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 12</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:justify;margin:0pt;">%  </p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:justify;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;">N/A</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:justify;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 440</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:justify;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> —</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:justify;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> —</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:justify;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 440</p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:38.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:justify;margin:0pt;"><b style="font-weight:bold;"> </b></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:7.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:0.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:4.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:6.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:5.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><b style="font-weight:bold;"> 2,488</b></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:justify;margin:0pt;"><b style="font-weight:bold;"> </b></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:7.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt;"><b style="font-weight:bold;"> (51)</b></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:justify;margin:0pt;"><b style="font-weight:bold;"> </b></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:6.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><b style="font-weight:bold;"> —</b></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:0.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:justify;margin:0pt;"><b style="font-weight:bold;"> </b></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><b style="font-weight:bold;"> 2,437</b></p></td></tr><tr><td style="vertical-align:bottom;width:38.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:justify;margin:0pt;"><b style="font-weight:bold;">Long term notes payable</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:justify;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;">  </p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:justify;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt;">  </p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:justify;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt;">  </p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:justify;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt;">  </p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:justify;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt;">  </p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:justify;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt;">  </p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:justify;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt;">  </p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:38.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:justify;margin:0pt;">8% unsecured (10)</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:justify;margin:0pt;"> </p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:7.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;">Various</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:justify;margin:0pt;"> </p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:0.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:4.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 8</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:justify;margin:0pt;">%  </p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:justify;margin:0pt;"> </p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:6.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;">N/A</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:justify;margin:0pt;"> </p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:5.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 7,160</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:justify;margin:0pt;"> </p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:7.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt;"> (496)</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:justify;margin:0pt;"> </p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:6.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> —</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:0.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:justify;margin:0pt;"> </p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 6,664</p></td></tr><tr><td style="vertical-align:bottom;width:38.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:justify;margin:0pt;">6% secured (11)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:justify;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;">3/25/2025</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:justify;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 6</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:justify;margin:0pt;">%  </p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:justify;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;">N/A</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.12%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:justify;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.91%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 1,843</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:justify;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.6%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> —</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.13%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:justify;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.12%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> —</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.91%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:justify;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:5%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 1,843</p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:38.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:justify;margin:0pt;"><b style="font-weight:bold;"> </b></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:7.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:0.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:4.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:6.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.12%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:5.91%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><b style="font-weight:bold;"> 9,003</b></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:justify;margin:0pt;"><b style="font-weight:bold;"> </b></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.42%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:7.6%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt;"><b style="font-weight:bold;"> (496)</b></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:justify;margin:0pt;"><b style="font-weight:bold;"> </b></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.13%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:6.12%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><b style="font-weight:bold;"> —</b></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:0.91%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:justify;margin:0pt;"><b style="font-weight:bold;"> </b></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:5%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><b style="font-weight:bold;"> 8,507</b></p></td></tr><tr><td style="vertical-align:bottom;width:38.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt;"><b style="font-weight:bold;"> </b><span style="font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt;"><b style="font-weight:bold;"> </b><span style="font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt;"><b style="font-weight:bold;"> </b><span style="font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt;"><b style="font-weight:bold;"> </b><span style="font-weight:bold;visibility:hidden;">​</span></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:38.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:justify;margin:0pt;"><b style="font-weight:bold;">Ending balance as of December 31, 2020</b></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:7.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:0.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:4.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:6.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.12%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:justify;margin:0pt;"><b style="font-weight:bold;">$</b></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:5.91%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><b style="font-weight:bold;"> 13,751</b></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.42%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:justify;margin:0pt;"><b style="font-weight:bold;">$</b></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:7.6%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt;"><b style="font-weight:bold;"> (1,484)</b></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.13%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:justify;margin:0pt;"><b style="font-weight:bold;">$</b></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:6.12%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><b style="font-weight:bold;"> 2,507</b></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:0.91%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:justify;margin:0pt;"><b style="font-weight:bold;">$</b></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:5%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><b style="font-weight:bold;"> 14,774</b></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">​</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:42.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></td></tr><tr><td style="vertical-align:bottom;width:42.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">    </b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">    </b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:7.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Stated</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">    </b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">    </p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">    </b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">    </b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;visibility:hidden;">​</span></p></td></tr><tr><td style="vertical-align:bottom;width:42.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:7.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Interest</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:7.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Conversion</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Remaining</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:7.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Carrying</b></p></td></tr><tr><td style="vertical-align:bottom;width:42.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.09%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Maturity Date</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:7.24%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Rate</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:7.25%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Price</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:7.24%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Face Value</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.02%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Debt Discount</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:7.22%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Value</b></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:42.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Short term convertible notes payable</b></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:7.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">  </p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:6.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">  </p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:6.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">  </p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:6.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">  </p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:7.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">  </p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:6.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">  </p></td></tr><tr><td style="vertical-align:bottom;width:42.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;">6% unsecured (1)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;">Due</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 6</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;">%  </p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 3.09</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 135</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> —</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 135</p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:42.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;">10% unsecured (2)</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:7.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;">4/18/2020</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:6.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 10</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;">%  </p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:6.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 0.22</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.12%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:6.12%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 500</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.42%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:7.6%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (67)</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:6.22%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 433</p></td></tr><tr><td style="vertical-align:bottom;width:42.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;"> </b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><b style="font-weight:bold;">635</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;"> (67)</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;"> </b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><b style="font-weight:bold;">568</b></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:42.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Short term notes payable</b></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:7.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">  </p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:6.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">  </p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:6.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">  </p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:6.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">  </p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:7.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">  </p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:6.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">  </p></td></tr><tr><td style="vertical-align:bottom;width:42.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;">8% unsecured (5)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;">Various</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 8</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;">%  </p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;">N/A</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 555</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (43)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 512</p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:42.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;">10% unsecured (6)</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:7.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;">Various</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:6.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 10</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;">%  </p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:6.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;">N/A</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:6.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 3,551</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:7.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (73)</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:6.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 3,478</p></td></tr><tr><td style="vertical-align:bottom;width:42.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;">12% unsecured (7)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;">On Demand</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 12</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;">%  </p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;">N/A</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.12%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.12%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 440</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.6%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> —</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.22%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 440</p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:42.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;">0% unsecured (8)</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:7.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;">8/1/2020</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:6.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 0</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;">%  </p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:6.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;">N/A</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.12%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:6.12%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 1,156</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.42%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:7.6%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (85)</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:6.22%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 1,071</p></td></tr><tr><td style="vertical-align:bottom;width:42.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;"> </b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><b style="font-weight:bold;"> 5,702</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;"> </b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;"> (201)</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;"> </b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;"> </b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><b style="font-weight:bold;"> 5,501</b></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:42.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Short term notes payable - related parties</b></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:7.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">  </p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:6.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">  </p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:6.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">  </p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:6.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">  </p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:7.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">  </p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:6.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">  </p></td></tr><tr><td style="vertical-align:bottom;width:42.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;">10% unsecured - Related Parties (9)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;">On Demand</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 10</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;">%  </p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;">N/A</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.12%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 66</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.6%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> —</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.22%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 66</p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:42.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;"> </b></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:7.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:6.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:6.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:6.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><b style="font-weight:bold;"> 66</b></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;"> </b></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:7.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><b style="font-weight:bold;"> —</b></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;"> </b></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;"> </b></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:6.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><b style="font-weight:bold;"> 66</b></p></td></tr><tr><td style="vertical-align:bottom;width:42.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Long term notes payable</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">  </p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">  </p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">  </p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">  </p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">  </p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">  </p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:42.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;">8% unsecured (5)</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:7.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;">Various</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:6.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 8</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;">%  </p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:6.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;">N/A</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.12%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:6.12%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 7,008</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.42%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:7.6%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (420)</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:6.22%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 6,588</p></td></tr><tr><td style="vertical-align:bottom;width:42.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;"> </b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.12%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.12%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><b style="font-weight:bold;"> 7,008</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;"> </b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.6%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;"> (420)</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;"> </b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;"> </b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.22%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><b style="font-weight:bold;"> 6,588</b></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:42.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:7.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:6.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:6.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:6.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:7.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:6.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td></tr><tr><td style="vertical-align:bottom;width:42.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Ending balance as of December 31, 2019</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.12%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">$</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.12%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><b style="font-weight:bold;"> 13,411</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">$</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.6%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;"> (688)</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">$</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.22%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><b style="font-weight:bold;"> 12,723</b></p></td></tr></table><div style="font-family:'Times New Roman','Times','serif';font-size:10.0pt;margin-bottom:0pt;min-height:1.19em;position:relative;width:100%;"><div style="background-color:#000000;height:1pt;position:relative;top:0.6em;width:25.0%;border:none;margin:0 auto 0 0;"/></div><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">(1)</td><td style="padding:0pt;"><span style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:justify;">This </span><span style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:justify;">$135,000</span><span style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:justify;"> note as of December 31, 2020 and 2019 consists of two separate </span><span style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:justify;">6%</span><span style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:justify;"> notes in the amounts of </span><span style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:justify;">$110,000</span><span style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:justify;"> and </span><span style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:justify;">$25,000</span><span style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:justify;">. In regard to the </span><span style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:justify;">$110,000</span><span style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:justify;"> note, the Company has made ongoing attempts to locate the creditor to repay or convert this note, but has been unable to locate the creditor to date. In regard to the </span><span style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:justify;">$25,000</span><span style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:justify;"> note, the holder has elected to convert these notes into equity, the Company has delivered the applicable conversion documents to the holder, and the Company is waiting for the holder to execute and return the documents.</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">(2)</td><td style="padding:0pt;"><span style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:justify;">In February 2020, the Company entered into multiple one-year convertible notes (the “February Notes”) with multiple holders (the “Holders”) for an aggregate principal amount of </span><span style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:justify;">$1.0</span><span style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:justify;"> million. The Notes are convertible into common shares of the Company at </span><span style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:justify;">$0.21</span><span style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:justify;"> per share and bear interest at the rate of </span><span style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:justify;">10%</span><span style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:justify;"> per annum. Upon issuance of the February Notes, the Holders also received a </span><span style="-sec-ix-hidden:Hidden_2JbScKrEkkO6cpKz3RpIbg;"><span style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:justify;">2-year</span></span><span style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:justify;"> warrant to purchase a total of </span><span style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:justify;">1.4</span><span style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:justify;"> million common shares of the Company at an exercise price of </span><span style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:justify;">$0.35</span><span style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:justify;"> per share. The fair value of the warrants was approximately </span><span style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:justify;">$79,000</span><span style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:justify;"> on the grant date.</span></td></tr></table><div style="margin-top:12pt;"/><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 18pt;">During the year ended December 31, 2020, the Company converted the entire February Notes, including $68,000 accrued interest into approximate 5.1 million shares of the Company's common stock.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 18pt;">In April 2020, the Company entered into a six-month convertible note (the “April Note”) with an individual investor (the “Holder”) with an aggregate principal amount of $0.8 million for cash proceeds of $0.7 million. The Company also incurred approximately $69,000 placement agent costs, including both a cash fee and the fair value of common stock warrants issued to the placement agent, which was recognized as additional debt discount.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 18pt;">The April Note bears interest at the rate of 10% per annum and is convertible into common shares of the Company at $0.17 per share plus a warrant to purchase a number of exercise shares equal to 50% of the number of common shares issued upon conversion (the “Conversion Warrants”). The Conversion Warrants will be exercisable until April 9, 2022 beginning on November 1, 2020, with an exercise price of $0.20 per share. The conversion option within the April Note is required to be bifurcated at fair value, which was approximately $0.4 million on the issuance date, resulting in additional debt discount to the April Note. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 18pt;">As consideration for entering into the April Note, the Company also agreed to amend the Holder’s existing outstanding warrants to purchase 5.1 million common shares of the Company. The exercise price of the warrants was amended from $0.25 per share to $0.20 per share. The incremental change in fair value resulting from the amendment was approximately $51,000, which was recognized as additional debt discount to the April Note.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 18pt;">On August 3, 2020, the Company converted approximately $0.8 million of outstanding principal and $26,000 of accrued interest of the April Note into approximately 5.1 million shares of common stock and 2.5 million warrants with fair value of approximately $2.4 million. The Company also extinguished $1.5 million embedded derivative liability and $0.2 million unamortized debt discount upon the conversion. The Company recorded approximately $0.3 million debt extinguishment loss.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 18pt;">In April 2020, the Company entered into a Note Amendment Agreement (the “Amendment”) with an individual holder of a short-term convertible note, primarily to agree on the following changes:</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Calibri';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">-</td><td style="padding:0pt;"><span style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:justify;">Reclassed </span><span style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:justify;">$75,000</span><span style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:justify;"> accrued interest as of amendment date to the outstanding principal amount;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Calibri';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">-</td><td style="padding:0pt;"><span style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:justify;">Extended the maturity date of a convertible note with approximately </span><span style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:justify;">$0.6</span><span style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:justify;"> million of principal outstanding, as of the amendment date, to October 18, 2020 (the “Amended Note”);</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Calibri';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">-</td><td style="padding:0pt;"><span style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:justify;">Reduced the conversion price from </span><span style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:justify;">$0.22</span><span style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:justify;"> to </span><span style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:justify;">$0.181</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Calibri';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">-</td><td style="padding:0pt;"><span style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:justify;">Issued a new </span><span style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:justify;">2</span><span style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:justify;">-year warrant for up to </span><span style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:justify;">2.3</span><span style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:justify;"> million shares of the Company’s common stock at an exercise price of </span><span style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:justify;">$0.25</span><span style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:justify;"> per share valued at </span><span style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:justify;">$115,000</span><span style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:justify;"> on the amendment date;</span></td></tr></table><div style="margin-top:12pt;"/><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 18pt;">The amendment was recognized as a debt extinguishment, resulting in a loss on debt extinguishment of approximately $70,000.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 18pt;">During the year ended December 31, 2020, the Company converted the entire Amended Note of approximately $0.6 million, including $28,000 accrued interest into approximately 3.3 million shares of common stock.</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">(3)</td><td style="padding:0pt;"><span style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:justify;">In May 2020, the Company entered into a six-month convertible note (the “May Note”) with an individual investor (the “Holder”) with an aggregate principal amount of </span><span style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:justify;">$0.6</span><span style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:justify;"> million. The May Note contains an original issue discount (“OID”) in the amount of </span><span style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:justify;">$50,000</span><span style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:justify;">.</span></td></tr></table><div style="margin-top:12pt;"/><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 18pt;">The May Note bears interest at the rate of 8% per annum and is convertible into common shares of the Company at $0.25 plus a warrant to purchase a number of exercise shares equal to 40% of the number of common shares issued upon conversion (the “Conversion Warrants”). The Conversion Warrants will be exercisable until November 28, 2022 beginning on November 1, 2020 with exercise price of $0.25 per share. The conversion option within the May Note required bifurcation at fair value, which was approximately $0.5 million on the issuance date, resulting in additional debt discount to the May Note.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 18pt;">On October 1, 2020, the Company converted the entire $0.6 million of the May Note including $19,000 accrued interest, into approximately 2.3 million shares of the Company's common stock and 0.9 million warrants with fair value of approximate $3.4 million. The Company also extinguished $2.8 million embedded derivative liability upon the conversion. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 18pt;">In August 2020, the Company entered into another convertible note (the "August Note") with the same investor as the May Note (the "Holder") with an aggregate principal amount of $1.1 million. The August Note contains OID in the amount of $110,000.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 18pt;">The August Note bears interest at the rate of 8% per annum and is convertible into common shares of the Company at $0.345 plus a warrant to purchase a number of exercise shares equal to 35% of the number of common shares issued upon conversion (the "Conversion Warrants"). The Conversion Warrants will be exercisable until February 4, 2023 beginning on December 15, 2020 with exercise price of $0.34 per share. The conversion option within the August Note is required to be bifurcated at fair value, which was approximately $0.6 million on the issuance date, resulting in additional debt discount to the August Note.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 18pt;">On September 29, 2020, the Company converted entire $1.1 million of August Note into approximately 3.3 million shares of the Company's common stock and 1.1 million warrants with fair value of approximate $3.3 million. The Company also extinguished $2.3 million embedded derivative liability and $0.5 million unamortized debt discount upon the conversion. The company recorded approximately $0.4 million debt extinguishment loss.</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">(4)</td><td style="padding:0pt;"><span style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:justify;">In October 2020, the Company entered into a convertible note (the "October Note") with the same investor as the August Note (the "Holder") with an aggregate principal amount of </span><span style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:justify;">$2.1</span><span style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:justify;"> million. The October Note contains OID in the amount of </span><span style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:justify;">$200,000</span><span style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:justify;">.</span></td></tr></table><div style="margin-top:12pt;"/><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 18pt;">The October Note bears interest at the rate of 8% per annum and is convertible into common shares of the Company at $0.85 plus a warrant to purchase a number of exercise shares equal to 30% of the number of common shares issued upon conversion (the "Conversion Warrants"). The Conversion Warrants will be exercisable until January 12, 2022 beginning on January 15, 2021 with exercise price of $2.00 per share. The conversion option within the October Note is required to be bifurcated at fair value, which was approximately $1.4 million on the issuance date, resulting in additional debt discount of $1.4 million to the October Note.</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:20.15pt;padding:0pt;">(5)</td><td style="padding:0pt;"><span style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:justify;">During the year ended December 31, 2020, the Company converted approximately </span><span style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:justify;">$5.8</span><span style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:justify;"> million of outstanding principal and </span><span style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:justify;">$0.6</span><span style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:justify;"> million of accrued interest into approximately </span><span style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:justify;">29.1</span><span style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:justify;"> million shares of the Company’s common stock with a fair value of </span><span style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:justify;">$7.6</span><span style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:justify;"> million. The Company recognized approximately </span><span style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:justify;">$1.2</span><span style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:justify;"> million in debt extinguishment loss from this conversion.</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">(6)</td><td style="padding:0pt;"><span style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:justify;">In May 2020, the Company converted approximately </span><span style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:justify;">$0.3</span><span style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:justify;"> million of outstanding principal and accrued interest into approximately </span><span style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:justify;">1.3</span><span style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:justify;"> million shares of the Company’s common stock with a fair value of </span><span style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:justify;">$0.5</span><span style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:justify;"> million. The Company recognized approximately </span><span style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:justify;">$0.2</span><span style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:justify;"> million in debt extinguishment loss from this conversion.</span></td></tr></table><div style="margin-top:12pt;"/><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 18pt;">In August 2020, the Company extinguished approximately $1.5 million of outstanding principal and accrued interest into approximately 4.8 million shares of the Company's common stock and 1.7 million warrants. The Company also modified certain existing warrants and issued additional 6.5 million warrants consideration for certain suspension. The Company also agreed to amend the remaining outstanding $1.5 million outstanding debt. The note became convertible at a conversion price of $0.34 (the “Amended August Note”). The amendment was accounted as debt extinguishment and the Company recognized approximately $1.6 million in debt extinguishment loss from this transaction.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 18pt;">During the year ended December 31, 2020, the Company made $0.1 million cash payment and converted approximate $1.4 million outstanding debt including $15,000 accrued interest into approximately 4.1 million shares of the Company’s common stock. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 18pt;">During the year ended December 31, 2020, the Company entered into multiple Note Extension Agreements with multiple holders, primarily resulting in the following changes:</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Calibri';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">-</td><td style="padding:0pt;"><span style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:justify;">Extended the maturity dates of promissory notes with outstanding principal balances aggregating approximately </span><span style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:justify;">$3.3</span><span style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:justify;"> million for an additional </span><span style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:justify;">6</span><span style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:justify;"> to </span><span style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:justify;">12 months</span><span style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:justify;"> from the original maturity date;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Calibri';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">-</td><td style="padding:0pt;"><span style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:justify;">Issued new </span><span style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:justify;">2</span><span style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:justify;">-year warrants to purchase up to </span><span style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:justify;">10.3</span><span style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:justify;"> million shares of the Company’s common stock at an exercise prices ranging from </span><span style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:justify;">$0.20</span><span style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:justify;"> and </span><span style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:justify;">$0.23</span><span style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:justify;"> per share valued at approximately </span><span style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:justify;">$0.5</span><span style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:justify;"> million on the amendment date;</span></td></tr></table><div style="margin-top:12pt;"/><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 18pt;">The Note Extension Agreements for approximately $2.3 million of outstanding principal of promissory notes was recognized as a debt modification, while the amendments for approximately $1.0 million of outstanding principal of promissory notes was recognized as a debt extinguishment, resulting in a loss on extinguishment of debt of approximately $0.1 million.</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">(7)</td><td style="padding:0pt;"><span style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:justify;">The </span><span style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:justify;">$440,000</span><span style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:justify;"> balance of outstanding principal as of December 31, 2020 and 2019 consists of two separate </span><span style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:justify;">12%</span><span style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:justify;"> demand notes in the amounts of </span><span style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:justify;">$300,000</span><span style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:justify;"> and </span><span style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:justify;">$140,000</span><span style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:justify;">.</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">(8)</td><td style="padding:0pt;"><span style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:justify;">On May 28, 2019, the Company issued a deferred note to a third-party vendor pursuant to a settlement agreement resolving past matters and providing for the restart of DCVax®-Direct Production. During the year ended December 31, 2020, the Company made full repayment of </span><span style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:justify;">$1.2</span><span style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:justify;"> million to the note holder.</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:20.15pt;padding:0pt;">(9)</td><td style="padding:0pt;"><span style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:justify;">On September 26, 2018, Advent BioServices (“Advent”), a related party of the Company, provided a short-term loan in the amount of </span><span style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:justify;">$65,000</span><span style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:justify;">. The loan bore interest at </span><span style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:justify;">10%</span><span style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:justify;"> per annum, and is payable upon demand, with </span><span style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:justify;">7 days</span><span style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:justify;">’ prior written notice to the Company. During the year ended December 31, 2020, the Company made full repayment to Advent, including all outstanding interest.</span></td></tr></table><div style="margin-top:12pt;"/><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 20.15pt;">Between February and May 2020, the Company entered into multiple demand loan agreements with Leslie Goldman, the Company’s Senior Vice President, General Counsel, for an aggregate principal amount of $0.3 million (the “Goldman Notes”). The Goldman Notes bear interest rate at 10% per annum, and are repayable upon 15 days' notice from Mr. Goldman.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 20.15pt;">The Goldman Notes are convertible into common shares of the Company at conversion prices ranging from $0.23 to $0.25 per share. Additionally, the Company agreed to issue warrants to Mr. Goldman to purchase 0.6 million shares of the Company’s common stock (the “Initial Warrants”) in conjunction with the Goldman Notes. The Initial Warrants have a <span style="-sec-ix-hidden:Hidden_vyli9FUruEKTsUlBoJJ2QQ;"><span style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:justify;">five</span></span> - year term and are exercisable at prices ranging from $0.23 and $0.25 per share. The fair value of the Initial Warrants was approximately $66,000, which was recognized as debt discount to the Goldman Notes at the issuance date. The conversion option within the Goldman Notes were required to be bifurcated at fair value, which was approximately $36,000 on the issuance date, resulting in additional debt discount to the Goldman Notes.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 20.15pt;">Upon conversion, Mr. Goldman would also receive a five-year term warrant to purchase a number of the Company’s common shares equal to 50% of the number of common shares issued upon conversion of the Goldman Notes (the “Conversion Warrants”). The Conversion Warrants will be exercisable at $0.25 per share.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 20.15pt;">During the year ended December 31, 2020, the Company made full repayment of $0.3 million to Mr. Goldman, including all outstanding interest. Upon the repayment, the Company also extinguished $1.6 million embedded derivative liability, which was recorded as debt extinguishment gain. </p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:20.15pt;padding:0pt;">(10)</td><td style="padding:0pt;"><span style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:justify;">During the year ended December 31, 2020, the Company entered into two note purchase agreements (the “Notes”) with same investor for an aggregate principal amount of approximate </span><span style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:justify;">$7.2</span><span style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:justify;"> million. The Notes bear interest at </span><span style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:justify;">8%</span><span style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:justify;"> per annum with </span><span style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:justify;">21-month</span><span style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:justify;"> term. There are no repayments during the first 7 months of the term. The Notes are amortized in </span><span style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:justify;">14</span><span style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:justify;"> installments starting in month 8. The Notes carry an original issue discount of </span><span style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:justify;">$650,000</span><span style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:justify;"> and </span><span style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:justify;">$10,000</span><span style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:justify;"> legal costs that were reimbursable to the investor.</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:20.15pt;padding:0pt;">(11)</td><td style="padding:0pt;"><span style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:justify;text-decoration:underline;text-decoration-color:#000000;">Cambridge Loan</span></td></tr></table><div style="margin-top:12pt;"/><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 20.15pt;">On March 26, 2020, the Company entered into a Loan Agreement (the “Loan Agreement”) with Cambridge &amp; Peterborough Combined Authority (the “Lender”) for a loan of £1.35 million (approximately $1.7 million) (the “Loan”) for the current phase of buildout of the Sawston facility. The Company received funds on April 6, 2020. The Lender provides funding for selected economic development projects in the Cambridge region through a competitive selection process.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 20.15pt;">Under the Loan Agreement, there will be no repayments during the first year of the Loan term, although interest will accrue. Following the first anniversary, repayment of the Loan principal and interest will take place over 4 years, for a total term of 5 years.  The interest rate on the Loan is 6.25% per annum.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 38.15pt;">In conjunction with the Loan, the Company agreed to enter into a Security Agreement with the Lender under which the Company granted a security interest in the Company’s 17-acre property in Sawston, U.K. to secure the Loan.  No other tangible or intangible assets of the Company or its subsidiaries are subject to any security interest. Such security interest on the 17-acre property will be released upon completion of repayment</p> Due 0.06 3.09 135000 135000 4/30/2021 0.08 0.85 2125000 937000 -2507000 3695000 2260000 937000 -2507000 3830000 Various 0.08 1785000 51000 1734000 Various 0.10 263000 263000 On Demand 0.12 440000 440000 2488000 51000 2437000 Various 0.08 7160000 496000 6664000 3/25/2025 0.06 1843000 1843000 9003000 496000 8507000 13751000 1484000 -2507000 14774000 Due 0.06 3.09 135000 135000 4/18/2020 0.10 0.22 500000 67000 433000 635000 67000 568000 Various 0.08 555000 43000 512000 Various 0.10 3551000 73000 3478000 On Demand 0.12 440000 440000 8/1/2020 0 1156000 85000 1071000 5702000 201000 5501000 On Demand 0.10 66000 66000 66000 66000 Various 0.08 7008000 420000 6588000 7008000 420000 6588000 13411000 688000 12723000 135000 135000 0.06 110000 25000 110000 25000 1000000.0 0.21 0.10 1400000 0.35 79000 68000 5100000 800000 700000 69000 0.10 0.17 0.50 0.20 400000 5100000 0.25 0.20 51000 800000 26000 5100000 2500000 2400000 1500000 200000 -300000 75000 600000 0.22 0.181 P2Y 2300000 0.25 115000 -70000 600000 28000 3300000 600000 50000 0.08 0.25 0.40 0.25 500000 600000 19000 2300000 900000 3400000 2800000 1100000 110000 0.08 0.345 0.35 0.34 600000 1100000 3300000 1100000 3300000 2300000 500000 -400000 2100000 200000 0.08 0.85 0.30 2.00 1400000 1400000 5800000 600000 29100000 7600000 -1200000 300000 1300000 500000 -200000 1500000 4800000 1700000 6500000 1500000 0.34 -1600000 100000 1400000 15000 4100000 3300000 P6M P12M P2Y 10300000 0.20 0.23 500000 2300000 1000000.0 -100000 440000 440000 0.12 0.12 300000 140000 1200000 65000 0.10 P7D 300000 0.10 P15D 0.23 0.25 600000 66000 36000 0.50 0.25 300000 1600000 7200000 0.08 P21M 14 650000 10000 1350000 1700000 P4Y P5Y 0.0625 400000 P2Y 0.0100 -400000 <p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">The following table summarizes total interest expenses related to outstanding debt for the years ended December 31, 2020 and 2019, respectively (in thousands):</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">​</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:74.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></td></tr><tr><td style="vertical-align:bottom;width:74.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;visibility:hidden;">​</span></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:21.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">For the year ended </b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td></tr><tr><td style="vertical-align:bottom;width:74.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:21.13%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">December 31, </b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td></tr><tr><td style="vertical-align:bottom;width:74.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">    </b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.39%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2020</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">    </b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.39%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2019</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:74.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">Interest expenses related to outstanding notes:</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:7.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">  </p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"> </p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:7.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">  </p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">​</span></p></td></tr><tr><td style="vertical-align:bottom;width:74.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0pt 6pt;">Contractual interest</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 1,231</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 1,168</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">​</span></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:74.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0pt 6pt;">Amortization of debt discount</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.48%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"> </p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:7.91%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 2,891</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.48%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"> </p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:7.91%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 1,430</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">​</span></p></td></tr><tr><td style="vertical-align:bottom;width:74.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0pt 12pt;"><b style="font-weight:bold;">Total interest expenses related to outstanding notes</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><b style="font-weight:bold;"> </b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><b style="font-weight:bold;"> 4,122</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><b style="font-weight:bold;"> </b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><b style="font-weight:bold;"> 2,598</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">​</span></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:74.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">Interest expenses related to outstanding notes to related parties:</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"> </p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:7.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"> </p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:7.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">​</span></p></td></tr><tr><td style="vertical-align:bottom;width:74.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0pt 6pt;">Contractual interest</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 20</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 366</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">​</span></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:74.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0pt 6pt;">Amortization of debt discount</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.48%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"> </p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:7.91%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 122</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.48%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"> </p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:7.91%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> —</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">​</span></p></td></tr><tr><td style="vertical-align:bottom;width:74.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0pt 12pt;"><b style="font-weight:bold;">Total interest expenses related to outstanding notes to related parties</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><b style="font-weight:bold;"> </b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><b style="font-weight:bold;"> 142</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><b style="font-weight:bold;"> </b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><b style="font-weight:bold;"> 366</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">​</span></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:74.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">Interest expenses related to forbearance of debt to related parties</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:7.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 4,270</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:7.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> —</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">​</span></p></td></tr><tr><td style="vertical-align:bottom;width:74.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">Other interest expenses</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.91%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 10</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.91%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 11</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">​</span></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:74.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><b style="font-weight:bold;">Total interest expense</b></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.48%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><b style="font-weight:bold;">$</b></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:7.91%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><b style="font-weight:bold;"> 8,544</b></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.48%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><b style="font-weight:bold;">$</b></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:7.91%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><b style="font-weight:bold;"> 2,975</b></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">​</span></p></td></tr></table> 1231000 1168000 2891000 1430000 4122000 2598000 20000 366000 122000 142000 366000 4270000 10000 11000 8544000 2975000 <p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">The following table summarizes the principal amounts of the Company’s debt obligations as of December 31, 2020 (amount in thousands):</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">​</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;white-space:nowrap;width:58.6%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.17%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:7.32%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.17%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:7.32%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.17%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:7.32%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.17%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:7.27%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:58.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td colspan="11" style="vertical-align:bottom;white-space:nowrap;width:39.53%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Payment Due by Period</b></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:58.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Less than</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">1 to 2</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.45%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">3 to 5</b></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:58.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">    </b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.49%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Total</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">    </b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.49%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">1 Year</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">    </b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.49%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Years</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">    </b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.45%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Years</b></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:58.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">Short term convertible notes payable</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:7.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:7.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:7.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:7.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">​</span></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:58.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0pt 6pt;">6% unsecured</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 135</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 135</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> —</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> —</p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:58.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0pt 6pt;">8% unsecured</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:7.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 2,125</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:7.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 2,125</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:7.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> —</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:7.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> —</p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:58.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">Short term notes payable</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> <span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> <span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">​</span></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:58.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0pt 6pt;">8% unsecured</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:7.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 1,785</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:7.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 1,785</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:7.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> —</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:7.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> —</p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:58.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0pt 6pt;">10% unsecured</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 263</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 263</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">​</span></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:58.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0pt 6pt;">12% unsecured</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:7.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 440</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:7.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 440</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:7.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> —</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:7.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> —</p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:58.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">Long term notes payable</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">​</span></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:58.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0pt 6pt;">8% unsecured </p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:7.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 7,160</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:7.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> —</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:7.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 7,160</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:7.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> —</p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:58.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0pt 6pt;">6% secured </p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.17%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.32%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 1,843</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.17%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.32%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> —</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.17%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.32%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> —</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.17%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.27%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 1,843</p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:58.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><b style="font-weight:bold;">Total</b></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.17%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><b style="font-weight:bold;">$</b></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:7.32%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><b style="font-weight:bold;"> 13,751</b></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.17%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><b style="font-weight:bold;">$</b></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:7.32%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><b style="font-weight:bold;"> 4,748</b></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.17%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><b style="font-weight:bold;">$</b></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:7.32%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><b style="font-weight:bold;"> 7,160</b></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.17%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><b style="font-weight:bold;">$</b></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:7.27%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><b style="font-weight:bold;"> 1,843</b></p></td></tr></table> 135000 135000 2125000 2125000 1785000 1785000 263000 263000 440000 440000 7160000 7160000 1843000 1843000 13751000 4748000 7160000 1843000 <p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;text-align:justify;margin:0pt 0pt 12pt 0pt;">9. Net Loss per Share Applicable to Common Stockholders</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">Basic loss per common share is computed by dividing net loss by the weighted average number of common shares outstanding during the reporting period. Diluted loss per common share is computed similar to basic loss per common share except that it reflects the potential dilution that could occur if dilutive securities or other obligations to issue common stock were exercised or converted into common stock.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">The following securities were not included in the diluted net loss per share calculation because their effect was anti-dilutive as of the periods presented (in thousands):</p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:78.05%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.17%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.79%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.17%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.79%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:78.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;visibility:hidden;">​</span></p></td><td colspan="3" style="vertical-align:bottom;white-space:nowrap;width:19.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">For the year ended </b></p></td></tr><tr><td style="vertical-align:bottom;width:78.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;visibility:hidden;">​</span></p></td><td colspan="3" style="vertical-align:bottom;white-space:nowrap;width:19.76%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">December 31, </b></p></td></tr><tr><td style="vertical-align:bottom;width:78.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">    </b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.79%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2020</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">    </b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.79%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2019</b></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:78.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">Common stock options</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"> </p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 308,840</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"> </p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 104,659</p></td></tr><tr><td style="vertical-align:bottom;width:78.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">Common stock warrants </p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 328,979</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 347,734</p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:78.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">Contingently issuable warrants</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"> </p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 2,774</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"> </p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 11,739</p></td></tr><tr><td style="vertical-align:bottom;width:78.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">Convertible notes and accrued interest</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.79%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 2,617</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.79%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 2,617</p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:78.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><b style="font-weight:bold;">Potentially dilutive securities</b></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><b style="font-weight:bold;"> </b></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.79%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><b style="font-weight:bold;"> 643,210</b></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><b style="font-weight:bold;"> </b></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.79%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><b style="font-weight:bold;"> 466,749</b></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p> <p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">The following securities were not included in the diluted net loss per share calculation because their effect was anti-dilutive as of the periods presented (in thousands):</p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:78.05%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.17%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.79%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.17%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.79%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:78.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;visibility:hidden;">​</span></p></td><td colspan="3" style="vertical-align:bottom;white-space:nowrap;width:19.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">For the year ended </b></p></td></tr><tr><td style="vertical-align:bottom;width:78.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;visibility:hidden;">​</span></p></td><td colspan="3" style="vertical-align:bottom;white-space:nowrap;width:19.76%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">December 31, </b></p></td></tr><tr><td style="vertical-align:bottom;width:78.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">    </b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.79%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2020</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">    </b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.79%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2019</b></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:78.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">Common stock options</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"> </p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 308,840</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"> </p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 104,659</p></td></tr><tr><td style="vertical-align:bottom;width:78.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">Common stock warrants </p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 328,979</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 347,734</p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:78.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">Contingently issuable warrants</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"> </p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 2,774</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"> </p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 11,739</p></td></tr><tr><td style="vertical-align:bottom;width:78.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">Convertible notes and accrued interest</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.79%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 2,617</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.79%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 2,617</p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:78.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><b style="font-weight:bold;">Potentially dilutive securities</b></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><b style="font-weight:bold;"> </b></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.79%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><b style="font-weight:bold;"> 643,210</b></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><b style="font-weight:bold;"> </b></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.79%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><b style="font-weight:bold;"> 466,749</b></p></td></tr></table> 308840000 104659000 328979000 347734000 2774000 11739000 2617000 2617000 643210000 466749000 <p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;text-align:justify;margin:0pt 0pt 12pt 0pt;">10. Related Party Transactions</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;text-align:justify;margin:0pt 0pt 12pt 0pt;">Advent BioServices Agreement</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">The Company has a Manufacturing Services Agreement with Advent BioServices for manufacture of DCVax-L products at an existing facility in London, as previously reported. The Company also has an Ancillary Services Agreement with Advent, which establishes a structure under which Advent will submit Statements of Work (“SOWs”) for activities related to the development of the Sawston facility and the compassionate use activities in the UK, as previously reported. The Ancillary Services Agreement had an original term of <span style="-sec-ix-hidden:Hidden_LYTW3e0ozkyIV3xbKRQFrA;"><span style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:justify;">8 months</span></span>, which ended in July 2020. The Company extended the term by <span style="-sec-ix-hidden:Hidden_LBTQ-4lc1Ue7er2694h5xQ;"><span style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:justify;">12 months</span></span>, and did not make any other changes.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;text-align:justify;margin:0pt 0pt 12pt 0pt;">Related Party Expenses and Accounts Payable</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">The following table summarizes expenses incurred to related parties (i.e., amounts invoiced) during the year ended December 31, 2020 and 2019 (amount in thousands) (some of which were for previous periods’ services and remain unpaid as noted in the second table below):</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">​</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80.51%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:67.76%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.11%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.26%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:7.63%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.11%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.58%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:15.45%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:67.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:28.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">For the year ended </b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td></tr><tr><td style="vertical-align:bottom;width:67.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:28.05%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">December 31, </b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td></tr><tr><td style="vertical-align:bottom;width:67.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.9%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2020</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">    </b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:17.04%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2019</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td></tr><tr><td style="vertical-align:bottom;width:67.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.26%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:17.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">(As revised) (Note 14)</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:67.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">Advent BioServices</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.26%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:7.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 7,543</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"> </p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:15.45%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 5,735</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">​</span></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">​</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 10pt 0pt;">During the years ended December 31, 2020 and 2019, the Company capitalized $3.6 million and $0.9 million costs related to Sawston buildout in addition to the costs disclosed in the above table.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">The following table summarizes outstanding <i style="font-style:italic;">unpaid</i> accounts payable and the accrued amount under the SOWs relating to the Sawston Facility and the compassionate use programs held by related parties as of December 31, 2020 and outstanding unpaid accounts payable </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">as of December 31, 2019 (amount in thousands). <i style="font-style:italic;">These unpaid amounts include part of the expenses reported in the table above and also certain expenses incurred in prior periods.</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="font-weight:bold;margin-bottom:12pt;visibility:hidden;">​</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:64.18%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.56%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:13.4%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.6%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:15.52%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:64.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">    </b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:14.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">December 31, 2020</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">    </b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:17.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">December 31, 2019</b></p></td></tr><tr><td style="vertical-align:bottom;width:64.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.56%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.4%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:17.12%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">(As revised) (Note 14)</b></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:64.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;">Advent BioServices – amount invoiced </p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:13.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 3,734</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:15.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 834</p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:64.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;">Advent BioServices – amount accrued</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.56%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.4%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 1,629</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.6%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.52%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 3,002</p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:64.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;">Accounts payable and accrued expenses to Advent BioServices</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.56%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">$</b></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:13.4%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><b style="font-weight:bold;"> 5,363</b></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.6%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">$</b></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:15.52%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><b style="font-weight:bold;"> 3,836</b></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:18pt;text-indent:-18pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">​</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;text-align:justify;margin:0pt 0pt 12pt 0pt;">Related Parties Loans</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;text-align:justify;margin:0pt 0pt 12pt 0pt;">Linda F. Powers - Demand Loans</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">Between February 2018 and April 2018, the Company’s Chief Executive Officer, Linda Powers, loaned the Company aggregate funding of $5.4 million pursuant to convertible Notes. The Notes were 15-day demand notes, for loans provided as short-term bridge loans. However, repayment was not completed for nearly 1-1/2 years.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">During the year ended December 31, 2019, the Company repaid the $5.4 million principal and approximately $0.8 million interest.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;text-align:justify;margin:0pt 0pt 12pt 0pt;">Loan from Advent BioServices </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">Advent BioServices provided a short-term loan to the Company in the amount of $65,000 on September 26, 2018. The loan bore interest at 10% per annum, and is payable upon demand, with 7 days’ prior written notice to the Company.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">During the year ended December 31, 2020, the Company made full repayment of $73,000 to Advent, including all outstanding interest.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><i style="font-style:italic;">Loan from Leslie Goldman</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">During the year ended December 31, 2020, the Company's Senior Vice President, General Counsel, Leslie Goldman, loaned the Company $315,000 pursuant to various convertible notes (the “Notes”). The Notes bore interest rate at 10% per annum and <span style="-sec-ix-hidden:Hidden_l5jnQwogLUSFPrFCR3LilA;"><span style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:justify;">fifty</span></span> percent warrant coverage, and are repayable upon 15 days' notice from the holder. The Notes were convertible, in whole or in part, into stock together with warrants.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">During the year ended December 31, 2020, the Company made full repayment of $0.3 million to Mr. Goldman, including all outstanding interest.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><i style="font-style:italic;">Warrants issued to Linda Powers</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">On July 2, 2020, the Company issued approximately 15.2 million warrants (the "Forbearance Warrants") to Ms. Powers in consideration for Ms. Powers' previously reported forbearance and extension of loans of $5.4 million from Ms. Powers to the Company. These warrants were approved by the Board in November 2018 when the loans were long overdue, as previously reported, and the warrants were re-approved in January 2020, but were not issued until July 2, 2020.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">The Forbearance Warrants have an exercise price of $0.21 per share with <span style="-sec-ix-hidden:Hidden_HlmfCc_WhkKzJ3Obndeh9Q;"><span style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:justify;">5-year</span></span> contractual term. The fair value of the Forbearance Warrants was approximately $4.3 million on the grant date, which was recognized as an additional interest expense.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">The following table summarizes total interest expenses related to outstanding notes to related parties for the three months and nine months ended December 31, 2020 and 2019, respectively (in thousands):</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">​</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:74.03%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.5%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.58%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.91%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.5%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.58%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.87%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:74.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:23.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">For the year ended </b></p></td></tr><tr><td style="vertical-align:bottom;width:74.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:23.46%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">December 31, 2020</b></p></td></tr><tr><td style="vertical-align:bottom;width:74.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">    </b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.5%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2020</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">    </b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.46%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2019</b></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:74.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;">Interest expenses related to outstanding notes to related parties:</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">  </p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">  </p></td></tr><tr><td style="vertical-align:bottom;width:74.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 6pt;">Contractual interest</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 20</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 366</p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:74.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 6pt;">Amortization of debt discount</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 122</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> —</p></td></tr><tr><td style="vertical-align:bottom;width:74.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;">Interest expenses related to forbearance of debt to related parties</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.58%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.91%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 4,270</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.58%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.87%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> —</p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:74.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Total interest expense</b></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.58%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">$</b></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.91%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><b style="font-weight:bold;"> 4,412</b></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.58%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">$</b></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.87%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><b style="font-weight:bold;"> 366</b></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="font-size:1pt;margin-bottom:12pt;visibility:hidden;">​</span></p> <p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">The following table summarizes expenses incurred to related parties (i.e., amounts invoiced) during the year ended December 31, 2020 and 2019 (amount in thousands) (some of which were for previous periods’ services and remain unpaid as noted in the second table below):</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">​</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80.51%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:67.76%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.11%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.26%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:7.63%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.11%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.58%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:15.45%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:67.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:28.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">For the year ended </b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td></tr><tr><td style="vertical-align:bottom;width:67.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:28.05%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">December 31, </b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td></tr><tr><td style="vertical-align:bottom;width:67.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.9%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2020</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">    </b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:17.04%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2019</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td></tr><tr><td style="vertical-align:bottom;width:67.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.26%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:17.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">(As revised) (Note 14)</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:67.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">Advent BioServices</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.26%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:7.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 7,543</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"> </p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:15.45%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 5,735</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">​</span></p></td></tr></table> 7543000 5735000 3600000 900000 <p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">The following table summarizes outstanding <i style="font-style:italic;">unpaid</i> accounts payable and the accrued amount under the SOWs relating to the Sawston Facility and the compassionate use programs held by related parties as of December 31, 2020 and outstanding unpaid accounts payable </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">as of December 31, 2019 (amount in thousands). <i style="font-style:italic;">These unpaid amounts include part of the expenses reported in the table above and also certain expenses incurred in prior periods.</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="font-weight:bold;margin-bottom:12pt;visibility:hidden;">​</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:64.18%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.56%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:13.4%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.6%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:15.52%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:64.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">    </b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:14.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">December 31, 2020</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">    </b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:17.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">December 31, 2019</b></p></td></tr><tr><td style="vertical-align:bottom;width:64.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.56%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.4%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:17.12%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">(As revised) (Note 14)</b></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:64.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;">Advent BioServices – amount invoiced </p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:13.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 3,734</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:15.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 834</p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:64.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;">Advent BioServices – amount accrued</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.56%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.4%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 1,629</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.6%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.52%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 3,002</p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:64.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;">Accounts payable and accrued expenses to Advent BioServices</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.56%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">$</b></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:13.4%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><b style="font-weight:bold;"> 5,363</b></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.6%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">$</b></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:15.52%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><b style="font-weight:bold;"> 3,836</b></p></td></tr></table> 3734000 834000 1629000 3002000 5363000 3836000 5400000 5400000 800000 65000 0.10 73000 315000 0.10 300000 15200000 5400000 0.21 4300000 20000 366000 122000 0 4270000 0 4412000 366000 <p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;text-align:justify;margin:0pt 0pt 12pt 0pt;">11. Stockholders’ Deficit</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;text-align:justify;margin:0pt 0pt 12pt 0pt;"><i style="text-decoration:underline;">2020 Activities</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><span style="text-decoration:underline;">Registered Direct Offering</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">Between January and February 2020, the Company issued an aggregate of 34.5 million shares of its common stock in a registered direct offering (the “Offering”). The net proceeds from the Offering were approximately $5.7 million, after deducting offering costs of $0.4 million paid by the Company.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">In connection with the Offering, the Company also issued approximately 8.5 million <span style="-sec-ix-hidden:Hidden_zix8vOrtckmRL1hSf2iLbQ;"><span style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:justify;">2-year</span></span> term warrants with an exercise price of $0.25 per share to the investors and approximately 0.8 million <span style="-sec-ix-hidden:Hidden_E9Ua_yiYQkyXMU_UkwySIA;"><span style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:justify;">2-year</span></span> term warrants with an exercise price between $0.17 and $0.21 per share to placement agent in this direct offering. The fair value of these new issued warrants was approximately $1.0 million. Additionally, the Company agreed to extend by twelve months the maturity date of certain existing warrants already held by some of those investors. The Company recorded an incremental change of approximately $2.5 million on the fair value of warrants due to the modifications, which was recorded as part of offering cost during the year ended December 31, 2020.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">During April 2020, the Company issued an aggregate of 19.9 million shares of its common stock and 11.3 million new issued warrants in a registered direct offering (the "April Financing"). The common stock was offered at a price of $0.153 per share. The warrants are exercisable at $0.20 per share. The net proceeds from the April Financing were approximately $3.0 million, after deducting offering costs of $68,000 paid by the Company. An approximate $0.8 million of proceeds were allocated to warrant liabilities.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">During May 2020, the Company issued an aggregate 14.2 million shares of its common stock and 5.6 million new issued warrants in a registered direct offering (the "May Financing"). The common stock was offered at a price between $0.17 and $0.225 per share. The warrants have an exercise price between $0.22 and $0.23 per share and an exercise period between 1.5-2.5 years. The Company received approximately $2.9 million from the May Financing. An approximate $0.9 million of proceeds were allocated to warrant liabilities.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;text-align:justify;margin:0pt 0pt 12pt 0pt;"><span style="font-weight:normal;">All of the warrants issued in the May Financings were not exercisable until November 1, 2020. In addition, as part of these agreements, the investors who have existing outstanding warrants that had not already been suspended until November 1, suspended approximately </span><span style="font-weight:normal;">14.6</span><span style="font-weight:normal;"> million existing warrants until November 1, 2020.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">On August 5, 2020, the Company entered into financings totaling approximately $8 million (the "August Financing"). The financings were comprised of:</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">●</td><td style="padding:0pt;"><span style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:justify;">Approximately </span><span style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:justify;">$7</span><span style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:justify;"> million from an offering at </span><span style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:justify;">$0.32</span><span style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:justify;"> per share of newly registered common stock of approximately </span><span style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:justify;">21.8</span><span style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:justify;"> million shares with </span><span style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:justify;">20</span><span style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:justify;">-</span><span style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:justify;">35%</span><span style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:justify;"> warrants coverage. The warrants are exercisable at </span><span style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:justify;">$0.34</span><span style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:justify;"> per share for approximately </span><span style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:justify;">5.3</span><span style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:justify;"> million shares, with an exercise period of </span><span style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:justify;">18</span><span style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:justify;"> to </span><span style="-sec-ix-hidden:Hidden_80iprjQY00inlcOh4uaxjQ;"><span style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:justify;">30 months</span></span><span style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:justify;">. The fair value of these </span><span style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:justify;">5.3</span><span style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:justify;"> million warrants was approximately </span><span style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:justify;">$1.5</span><span style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:justify;"> million.</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">●</td><td style="padding:0pt;"><span style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:justify;">$1 million from a convertible note (the "August Note") which is convertible at $0.345 per share. The August Note carries no warrants unless it is converted. If, and only to the extent, the note is converted it will carry 35% warrants exercisable at $0.34 per share.</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">●</td><td style="padding:0pt;"><span style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:justify;">All of the new warrants issued in the August Financing were suspended until December 15, 2020.</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">●</td><td style="padding:0pt;"><span style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:justify;">In addition, as part of these agreements, the investors who have existing outstanding warrants that had not yet been suspended, suspended approximately 75.5 </span><span style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:justify;">million additional existing warrant exercise shares until December 15, 2020. In consideration for the suspension of the 75.5 million existing warrant shares as part of the August Financing, the Company issued approximately 12.5 million warrants with an exercise price of $0.34 per share and an exercise period ranging from approximately </span><span style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:justify;">13.5</span><span style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:justify;"> to </span><span style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:justify;">25.5</span><span style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:justify;"> months following the termination of the suspensions. These suspension consideration warrants were also suspended until the same December date.</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">●</td><td style="padding:0pt;"><span style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:justify;">Only the common stock sold directly or underlying the warrants and convertible note were registered in this transaction.</span></td></tr></table><div style="margin-top:12pt;"/><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;text-align:justify;margin:0pt 0pt 12pt 0pt;"><span style="font-weight:normal;">On October 12, 2020, the Company entered into financings totaling approximately </span><span style="font-weight:normal;">$11.9</span><span style="font-weight:normal;"> million (the “Offering”). The financings were comprised of:</span></p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">●</td><td style="padding:0pt;"><span style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:justify;">Approximately $10 </span><span style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:justify;">million from an offering at $0.816 per share (based upon the average 10 day closing price ending on October 12, 2020) of newly registered common stock of approximately 12.2 million shares with 30% warrants coverage. The warrants are exercisable at an exercise price of $2.00 per share for approximately 3.6 million shares, with an exercise period of </span><span style="-sec-ix-hidden:Hidden_kp5lXyal50mI2dLnoxMFbQ;"><span style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:justify;">12 months</span></span><span style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:justify;"> (following a </span><span style="-sec-ix-hidden:Hidden_FKnpLUAnaUmzCrbfZjHOQg;"><span style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:justify;">3-month</span></span><span style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:justify;"> suspension after issuance). The fair value of these 3.6 million warrants was approximately $1.2 million.</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">●</td><td style="padding:0pt;"><span style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:justify;">Approximately $1.9 </span><span style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:justify;">million from a convertible note which is convertible at $0.85 per share (the “Note”). The Note carries no warrants unless it is converted. If, and only to the extent, the Note is converted it will carry 30% warrants with an exercise price of $2.00 per share and an exercise period of </span><span style="-sec-ix-hidden:Hidden_yxH2iNvT00q1N-eHPix5UQ;"><span style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:justify;">12 months</span></span><span style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:justify;"> (following a 3-month suspension after issuance).</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">●</td><td style="padding:0pt;"><span style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:justify;">All of the new warrants issued in the Offering are suspended until January 15, 2021.</span></td></tr></table><div style="margin-top:12pt;"/><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;text-align:justify;margin:0pt 0pt 12pt 0pt;"><span style="font-weight:normal;">In addition, as part of these agreements, certain investors who have existing outstanding warrants that have not yet been suspended are now suspending approximately </span><span style="font-weight:normal;">3.5</span><span style="font-weight:normal;"> million additional existing warrant exercise shares until January 15, 2021. </span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">In consideration for the suspension of the 3.5 million existing warrant shares as part of the Offering, the Company issued approximately 261,000 warrants with an exercise price of $2.00 per share and an exercise period of <span style="-sec-ix-hidden:Hidden_hD8G2ndfdUGDTwJDmsCSMA;"><span style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:justify;">12 months</span></span> (following a 3-month suspension after issuance). These suspension consideration warrants are also suspended until the same January date.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><span style="text-decoration:underline;text-decoration-color:#000000;">Warrants Exercised for Cash</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">During the year ended December 31, 2020, the Company issued 47.5 million shares of its common stock from warrants exercised for cash. The Company received $13.9 million in cash.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><span style="text-decoration:underline;text-decoration-color:#000000;">Cashless Warrants Exercise</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">During the year ended December 31, 2020, The Company issued approximately 7.1 million shares of common stock upon 8.6 million warrant cashless exercises with weighted average exercise price of $0.22.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><span style="text-decoration:underline;text-decoration-color:#000000;">Debt Conversion</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">During the year ended December 31, 2020, the Company converted approximately $13.9 million outstanding debt and interest into 58.4 million shares of common stock and 6.2 million warrants, see Note 8 for further details. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><span style="text-decoration:underline;text-decoration-color:#000000;">Flaskworks Shares Issuance</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">On December 1, 2020, the Company issued 1.5 million shares of common stock based upon the Flaskworks team having completed a significant milestone, in accordance with the Rights Issuance Agreement entered on August 28, 2020.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">On December 25, 2020, upon the seller’s election, the Company issued 0.7 million shares in equivalent of $0.2 million special consideration payment pursuant to the Unit Purchase Agreement. The $0.336 per share price was established by the Unit Purchase Agreement. The incremental change in fair value of the shares resulting from market price increase was approximately $0.9 million, which was recognized as additional general and administrative expense on the consolidated statement of operations. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><i style="font-style:italic;text-decoration:underline;text-decoration-color:#000000;">2019 Activities</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><span style="text-decoration:underline;text-decoration-color:#000000;">Registered Direct Offering</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">During the year ended December 31, 2019, the Company issued an aggregate of 32.7 million shares of its common stock at a purchase price between $0.19 and $0.23 per share to certain institutional investors in multiple registered direct offerings (the “Offering”). Included with the Offering were 1.3 million shares of common stock which were issued from the conversion of an existing loan and the related accrued interest totaling $306,000. The net proceeds from the Offering were approximately $6.9 million, after deducting offering costs of $0.3 million paid by the Company.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">In connection with the Offering, the Company did not issue any additional warrants for the new investment by the investors, but the Company, in effect, agreed to modify certain existing warrants already held by some of those investors. The Company extended the expiration date for additional 12 to 18 months after the original expiration date and the weighted average exercise price of warrants was reduced by an amount ranging from 2 to 8 cents as well. The Company recorded an incremental change of $2.5 million on the fair value of warrants due to the modification and recorded it as part of offering cost during the year ended December 31, 2019.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><span style="text-decoration:underline;text-decoration-color:#000000;">Debt Conversion</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">During the year ended December 31, 2019, the Company converted debt of approximately $6.8 million of principal and $0.7 million of accrued interest into approximately 35.5 million shares of the Company’s common stock at a fair value of $9.2 million. The Company recorded approximately $1.7 million of debt extinguishment loss from the conversion.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><span style="text-decoration:underline;text-decoration-color:#000000;">Warrants Exercised for Cash</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">During the year ended December 31, 2019, the Company issued 9.5 million shares of its common stock from warrants exercised for cash. The Company received $2.2 million in cash.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><span style="text-decoration:underline;text-decoration-color:#000000;">Shares Settlement</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">On May 28, 2019, the Company entered into a settlement agreement with Cognate BioServices, resolving past matters and providing for the restart of DCVax®-Direct Production (see Note 8).</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">As part of the settlement agreement, the number of shares of the Company’s common stock which the Company was to issue to Cognate was substantially reduced: 52 million shares of the Company’s common stock which the Company had previously agreed to issue to Cognate were reduced to 12 million shares. The Company considers the reduction in shares owed to Cognate a modification. Because the 52 million shares were never issued and the modification, which resulted in a decrease in fair value, is not a forfeiture, previously recognized expense related to services performed by Cognate is not reversed in connection with this modification. During the year ended December 31, 2019, the Company recorded $12,000 in its common stock par and reduced same amount in additional paid-in capital.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;text-align:justify;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;">Stock Purchase Warrants</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">The following is a summary of warrant activity for the years ended December 31, 2020 and 2019 (dollars in thousands, except per share data):</p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:65.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></td></tr><tr><td style="vertical-align:bottom;width:65.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">    </b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Number of</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">    </b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Weighted Average</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">    </b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Remaining</b></p></td></tr><tr><td style="vertical-align:bottom;width:65.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.03%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Warrants</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.74%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Exercise Price</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.56%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Contractual Term</b></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:65.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><b style="font-weight:bold;">Outstanding as of January 1, 2019</b></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><b style="font-weight:bold;"> </b></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:7.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><b style="font-weight:bold;"> 372,153</b></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><b style="font-weight:bold;">$</b></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><b style="font-weight:bold;"> 0.29</b></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><b style="font-weight:bold;"> </b></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:11.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><b style="font-weight:bold;"> 1.97</b></p></td></tr><tr><td style="vertical-align:bottom;width:65.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">Warrants granted</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 8,067</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 0.23</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">  </p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:65.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">Warrants exercised for cash</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"> </p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:7.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (9,532)</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"> </p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 0.23</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"> </p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:11.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">  </p></td></tr><tr><td style="vertical-align:bottom;width:65.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">Warrants expired and cancelled</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.03%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (11,215)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.62%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.12%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 0.62</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.56%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">  </p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:65.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><b style="font-weight:bold;">Outstanding as of December 31, 2019</b></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><b style="font-weight:bold;"> </b></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:7.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><b style="font-weight:bold;"> 359,473</b></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><b style="font-weight:bold;">$</b></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><b style="font-weight:bold;"> 0.27</b></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><b style="font-weight:bold;"> </b></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:11.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><b style="font-weight:bold;"> 1.42</b></p></td></tr><tr><td style="vertical-align:bottom;width:65.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">Warrants granted</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 88,658</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 0.22</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">​</span></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:65.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">Contingently issuable warrants (1)</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"> </p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:7.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 2,774</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"> </p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 1.48</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"> </p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:11.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">  </p></td></tr><tr><td style="vertical-align:bottom;width:65.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">Warrants exercised for cash</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (47,511)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 0.29</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">  </p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:65.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">Cashless warrants exercise</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:7.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (8,631)</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 0.22</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:11.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">​</span></p></td></tr><tr><td style="vertical-align:bottom;width:65.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">Warrants expired and cancelled</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.03%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (63,010)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.62%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.12%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 0.32</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.56%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">  </p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:65.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><b style="font-weight:bold;">Outstanding as of December 31, 2020 (2)</b></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><b style="font-weight:bold;"> </b></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:7.03%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><b style="font-weight:bold;"> 331,753</b></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.62%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><b style="font-weight:bold;">$</b></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.12%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><b style="font-weight:bold;"> 0.28</b></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><b style="font-weight:bold;"> </b></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:11.56%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><b style="font-weight:bold;">1.61</b></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">​</span></p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">(1)</td><td style="padding:0pt;"><span style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:justify;">The approximately 2.8 million warrants represent compensation warrants to be issued to the Company’s CEO, Linda Powers, in accordance with her warrants and options suspension agreement dated November 1, 2020. </span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">(2)</td><td style="padding:0pt;"><span style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:justify;">As of December 31, 2020, approximately 62.1 million warrants were not exercisable until January 15, 2021. Subsequent to January 15, 2021, the Company suspended 58.8 million warrants until February 28, 2021. </span></td></tr></table><div style="margin-top:12pt;"/><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">As of December 31, 2020, approximately 272.8 million warrants were treated as liability warrants due to the sequencing policy (see note 3).</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><span style="text-decoration:underline;text-decoration-color:#000000;">Warrant Adjustments</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">Between April and August 2020, the Company undertook negotiations related to certain warrant adjustments, including suspending certain outstanding warrants, making them unexercisable for a defined period, and suspending extensions of the warrants during that period.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">As previously reported, on May 10, 2020, for a number of unrelated warrant holders, the Company agreed to issue 17.5% new warrants and extend the investors' current warrant terms by six months, in consideration of the investor's suspension of the current and newly issued warrants until November 1, 2020. The unrelated investors suspended warrants for the purchase of approximately 81 million shares of the Company’s common stock. The Company agreed to issue new warrants to purchase 14.2 million shares of the Company’s common stock to these investors under the suspension agreements, and these additional warrants were also suspended until November 1, 2020.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">On August 5, 2020, the investors who had existing outstanding warrants, that had not yet been suspended, suspended approximately 75.5 million additional existing warrant exercise shares until December 15, 2020. In consideration for the suspension of the 75.5 million existing warrant shares as part of the August Financing, the Company issued approximately 12.5 million warrants with an exercise price of $0.34 per share and an exercise period ranging from approximately 13.5 to 25.5 months following the termination of the suspensions. These suspension consideration warrants were also suspended until December 15, 2020.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">On April 30, 2020, the Company entered into an agreement with its CEO, Linda Powers, in regard to approximately 90 million warrants and options held by Ms. Powers. She agreed to suspend approximately 60 million existing warrants and options held or due to her until November 1, 2020, making them unexercisable during this period. In consideration, the Company extended the exercise period of a separate 29 million existing warrants held by Ms. Powers (not part of the 60 million warrants and options), and Ms. Powers also agreed to suspend those 29 million warrants until November 1, 2020. The extension of the 29 million warrants provides an exercise period of <span style="-sec-ix-hidden:Hidden_eSI66MHJ1E-m97S0mml93g;"><span style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:justify;">2</span></span>-1/2 years after the suspension period.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">On October 31, 2020, the Company further extended the suspension of approximately 157 million of those 171 million warrants and options through December 15, 2020. Furthermore, other holders agreed to new suspensions of approximately 21 million additional warrants (in addition to the 157 million suspended) through December 15, 2020, making for a total of approximately 178 million suspensions through December 15, 2020.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">Still another 96 million warrants (beyond the 178 million described above) were also suspended earlier in connection with other new share purchases. Consequently, a total of approximately 274 million warrants and options were suspended through December 15, 2020.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">On December 15, 2020, the Company further extended the suspension of approximately 183 million warrants and options held by the Company’s certain officers and board of directors until January 15, 2021. Total warrants and options suspended until January 15, 2021 were approximately 190 million. See Note 15 below under Subsequent Events for more information about additional suspensions of warrants and options suspensions for further periods.</p> 34500000 5700000 400000 8500000 0.25 800000 0.17 0.21 1000000.0 2500000 19900000 11300000 0.153 0.20 3000000.0 68000 800000 14200000 5600000 0.17 0.225 0.22 0.23 P1Y6M P2Y6M 2900000 900000 14600000 8000000 7000000 0.32 21800000 0.20 0.35 0.34 5300000 P18Y 5300000 1500000 1000000 0.345 0.35 0.34 75500000 75500000 12500000 0.34 P13M15D P25M15D 11900000 10000000 0.816 12200000 0.30 2.00 3600000 3600000 1200000 1900000 0.85 0.30 2.00 3500000 3500000 261000 2.00 47500000 13900000 7100000 8600000 0.22 13900000 58400000 6200000 1500000 700000 200000 0.336 900000 32700000 0.19 0.23 1300000 306000000 6900000 300000 2500000 6800000 700000 35500000 9200000 1700000 9500000 2200000 52000000 12000000 52000000 12000 <p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">The following is a summary of warrant activity for the years ended December 31, 2020 and 2019 (dollars in thousands, except per share data):</p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:65.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></td></tr><tr><td style="vertical-align:bottom;width:65.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">    </b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Number of</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">    </b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Weighted Average</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">    </b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Remaining</b></p></td></tr><tr><td style="vertical-align:bottom;width:65.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.03%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Warrants</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.74%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Exercise Price</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.56%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Contractual Term</b></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:65.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><b style="font-weight:bold;">Outstanding as of January 1, 2019</b></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><b style="font-weight:bold;"> </b></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:7.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><b style="font-weight:bold;"> 372,153</b></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><b style="font-weight:bold;">$</b></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><b style="font-weight:bold;"> 0.29</b></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><b style="font-weight:bold;"> </b></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:11.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><b style="font-weight:bold;"> 1.97</b></p></td></tr><tr><td style="vertical-align:bottom;width:65.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">Warrants granted</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 8,067</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 0.23</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">  </p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:65.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">Warrants exercised for cash</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"> </p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:7.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (9,532)</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"> </p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 0.23</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"> </p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:11.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">  </p></td></tr><tr><td style="vertical-align:bottom;width:65.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">Warrants expired and cancelled</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.03%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (11,215)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.62%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.12%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 0.62</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.56%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">  </p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:65.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><b style="font-weight:bold;">Outstanding as of December 31, 2019</b></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><b style="font-weight:bold;"> </b></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:7.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><b style="font-weight:bold;"> 359,473</b></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><b style="font-weight:bold;">$</b></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><b style="font-weight:bold;"> 0.27</b></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><b style="font-weight:bold;"> </b></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:11.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><b style="font-weight:bold;"> 1.42</b></p></td></tr><tr><td style="vertical-align:bottom;width:65.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">Warrants granted</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 88,658</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 0.22</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">​</span></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:65.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">Contingently issuable warrants (1)</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"> </p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:7.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 2,774</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"> </p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 1.48</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"> </p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:11.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">  </p></td></tr><tr><td style="vertical-align:bottom;width:65.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">Warrants exercised for cash</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (47,511)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 0.29</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">  </p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:65.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">Cashless warrants exercise</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:7.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (8,631)</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 0.22</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:11.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">​</span></p></td></tr><tr><td style="vertical-align:bottom;width:65.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">Warrants expired and cancelled</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.03%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (63,010)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.62%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.12%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 0.32</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.56%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">  </p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:65.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><b style="font-weight:bold;">Outstanding as of December 31, 2020 (2)</b></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><b style="font-weight:bold;"> </b></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:7.03%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><b style="font-weight:bold;"> 331,753</b></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.62%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><b style="font-weight:bold;">$</b></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.12%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><b style="font-weight:bold;"> 0.28</b></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><b style="font-weight:bold;"> </b></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:11.56%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><b style="font-weight:bold;">1.61</b></p></td></tr></table> 372153 0.29 P1Y11M19D 8067 0.23 9532 0.23 11215 0.0062 359473 0.27 P1Y5M1D 88658 0.22 2774 1.48 47511 0.29 8631 0.22 63010 0.0032 331753 0.28 P1Y7M9D 2800000 62100000 58800000 272800000 0.175 81000000 14200000 75500000 12500000 0.34 P13M15D P25M15D 90000000 60000000 29000000 60000000 29000000 29000000 157000000 171000000 21000000 157000000 178000000 96000000 178000000 274000000 183000000 190000000 <p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;text-align:justify;margin:0pt 0pt 12pt 0pt;">12. Commitments and Contingencies</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;text-align:justify;margin:0pt 0pt 12pt 0pt;">Operating Lease</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">The Company adopted ASC Topic 842 - Leases as of January 1, 2019, using the transition method per ASU No. 2018-11 issued on July 2018 wherein entities were allowed to initially apply the new leases standard at adoption date and recognize a cumulative-effect adjustment to the opening balance of retained earnings in the period of adoption. Accordingly, all periods prior to January 1, 2019 were presented in accordance with the previous ASC Topic 840, Leases, and no retrospective adjustments were made to the comparative periods presented. Adoption of ASC 842 resulted in an increase to total assets and liabilities due to the recording of operating lease right-of-use assets ("ROU") and operating lease <span style="-sec-ix-hidden:Hidden_iZQjxf7UC0WK-s4iQ4ZHSQ;"><span style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:justify;">liabilities</span></span> of approximately $4.3 million, as of January 1, 2019.  On March 4, 2019, the Company recognized additional $0.6 million ROU and lease <span style="-sec-ix-hidden:Hidden_6_PkBLtvOka7v1rKeb8Duw;"><span style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:justify;">liabilities</span></span> to its amended office lease in the U.S. The adoption did not materially impact the Company’s consolidated statements of operations or cash flows.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">The Company has operating leases for corporate offices in the U.S., U.K., Germany and the Netherlands, and for manufacturing facilities in the U.K. Leases with an initial term of 12 months or less are not recorded in the balance sheet. The Company has elected the practical expedient to account for each separate lease component of a contract and its associated non-lease components as a single lease component, thus causing all fixed payments to be capitalized. The Company also elected the package of practical expedients permitted within the new standard, which among other things, allows the Company to carry forward historical lease classification. The renewal options have not been included in the calculation of the lease liabilities and ROU as the Company is not reasonably certain to exercise the options. Variable lease payment amounts that cannot be determined at the commencement of the lease such as increases in lease payments based on changes in index rates or usage, are not included in the ROU assets or liabilities. These are expensed as incurred and recorded as variable lease expense. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">At December 31, 2020, the Company had operating lease liabilities of approximately $5.1 million for both the 20-year lease of the building for the manufacturing facility in Sawston, U.K., and the current office lease in the U.S. and ROU of approximately $4.5 million for the Sawston lease and US office lease, which were included in the consolidated balance sheet.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">The following summarizes quantitative information about the Company’s operating leases (amount in thousands):</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">​</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;white-space:nowrap;width:65.38%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.3%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.2%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.17%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.15%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:65.38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td colspan="8" style="vertical-align:bottom;white-space:nowrap;width:32.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">For the Year ended</b></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:65.38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td colspan="8" style="vertical-align:bottom;white-space:nowrap;width:32.54%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">December 31, 2020</b></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:65.38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">    </b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.5%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">U.K</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">    </b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.47%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">U.S</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">    </b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.45%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Total</b></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:65.38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;">Lease cost</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:65.38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;">Operating lease cost</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 610</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 330</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 940</p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:65.38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;">Short-term lease cost</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 44</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> —</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 44</p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:65.38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;">Variable lease cost</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.3%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.2%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 45</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.17%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 20</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.15%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 65</p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:65.38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;">Total</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.3%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.2%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 699</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.29%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.17%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 350</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.29%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.15%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 1,049</p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:65.38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> <span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> <span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> <span style="visibility:hidden;">​</span></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:65.38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;">Other information</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> <span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> <span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> <span style="visibility:hidden;">​</span></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:65.38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;">Operating cash flows from operating leases</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (661)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (332)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (993)</p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:65.38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;">Weighted-average remaining lease term - operating leases</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;">9.1</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;">0.2</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:65.38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;">Weighted-average discount rate - operating leases</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 12</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;">%</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 12</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;">%</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">​</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:65.25%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.95%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.19%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.07%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.47%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.19%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.07%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.47%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.19%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.11%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:65.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td colspan="8" style="vertical-align:bottom;white-space:nowrap;width:32.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">For the Year ended</b></p></td></tr><tr><td style="vertical-align:bottom;width:65.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td colspan="8" style="vertical-align:bottom;white-space:nowrap;width:32.78%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">December 31, 2019</b></p></td></tr><tr><td style="vertical-align:bottom;width:65.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">    </b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.26%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">U.K</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">    </b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.26%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">U.S</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">    </b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.3%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Total</b></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:65.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;">Lease cost</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">  </p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">  </p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">  </p></td></tr><tr><td style="vertical-align:bottom;width:65.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;">Operating lease cost</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 607</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 247</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 854</p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:65.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;">Short-term lease cost</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 50</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 81</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 131</p></td></tr><tr><td style="vertical-align:bottom;width:65.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;">Variable lease cost</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.19%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.07%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> —</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.19%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.07%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 15</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.19%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.11%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 15</p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:65.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;">Total</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.19%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.07%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 657</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.19%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.07%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 343</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.19%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.11%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 1,000</p></td></tr><tr><td style="vertical-align:bottom;width:65.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;">Other information</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> <span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> <span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> <span style="visibility:hidden;">​</span></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:65.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;">Operating cash flows from operating leases</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> —</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (244)</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (244)</p></td></tr><tr><td style="vertical-align:bottom;width:65.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;">Weighted-average remaining lease term – operating leases</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;">10.0</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;">0.9</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">  </p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:65.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;">Weighted-average discount rate – operating leases</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 12</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;">%  </p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 12</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;">%  </p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">  </p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">​</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">The Company recorded lease costs as a component of general and administrative expense during the years ended December 31, 2020 and 2019.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">​</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">Maturities of our operating leases, excluding short-term leases, are as follows:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">​</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;white-space:nowrap;width:61.46%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.46%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.1%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.46%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.1%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.46%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.05%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:61.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">    </b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.56%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">U.K</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">    </b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.56%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">U.S</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">    </b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.51%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Total</b></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:61.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;">Year ended December 31, 2021</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 644</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 84</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 728</p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:61.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;">Year ended December 31, 2022</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 644</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> —</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 644</p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:61.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;">Year ended December 31, 2023</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 644</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> —</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 644</p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:61.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;">Year ended December 31, 2024</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 644</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> —</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 644</p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:61.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;">Thereafter</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.46%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.1%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 8,990</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.46%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.1%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> —</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.46%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.05%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 8,990</p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:61.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;">Total</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 11,566</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 84</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 11,650</p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:61.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;">Less present value discount</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.46%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.1%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (6,565)</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.46%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.1%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (2)</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.46%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.05%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (6,567)</p></td></tr><tr><td style="vertical-align:bottom;width:61.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;">Operating lease liabilities included in the Consolidated Balance Sheet at December 31, 2020</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.46%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.1%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 5,001</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.46%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.1%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 82</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.46%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.05%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 5,083</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">​</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;text-align:justify;margin:0pt 0pt 12pt 0pt;">Manufacturing Services Agreements</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">The Company has a manufacturing services agreement with Advent BioServices in the U.K.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;text-align:justify;margin:0pt 0pt 12pt 0pt;">Advent BioServices</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">On May 14, 2018, the Company entered into a DCVax®-L Manufacturing and Services Agreement (“MSA”) with Advent BioServices, a related party which was formerly part of Cognate BioServices and was spun off separately as part of an institutional financing of Cognate. The Advent Agreement provides for manufacturing of DCVax-L products at an existing facility in London. The Agreement is structured in the same manner as the Company’s prior agreements with Cognate BioServices. The Advent Agreement provides for a program initiation payment of approximately $1.0 million (which was fully paid in 2018), in connection with technology transfer and operations to the U.K. from Germany, development of new Standard Operating Procedures (SOPs) for the London facility, selection of new suppliers and auditing for GMP compliance, and other preparatory activities. The Advent Agreement provides for certain payments for achievement of milestones and, as was the case under the prior agreement with Cognate BioServices, the Company is required to pay certain fees for dedicated production capacity reserved exclusively for DCVax production, and pay for manufacturing of DCVax-L products for a certain minimum number of patients, whether or not the Company fully utilizes the dedicated capacity and number of patients. Either party may terminate the MSA on twelve months’ notice, to allow for transition arrangements by both parties.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">On November 8, 2019, the Company and Advent entered into an Ancillary Services Agreement with an 8-month Term for U.K. Facility Development Activities and Compassionate Use Program Activities. The Ancillary Services Agreement establishes a structure under which Advent will develop Statements of Work (“SOWs”) for each portion of the U.K. Facility Development Activities and Compassionate Use Program Activities, and will deliver those SOWs to the Company for review and approval. After an SOW is approved by the Company, Advent will proceed with or continue the applicable services and will invoice the Company pursuant to the SOW. Since both the U.K. Facility Development and the Compassionate Use Program involve pioneering and uncertainties in most aspects, the invoicing under the Ancillary Services Agreement is on the basis of costs incurred plus fifteen percent. The Ancillary Services Agreement had an original term of 8 months, which ended in July 2020. The Company extended the term by 12 months, and did not make any other changes.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><i style="font-style:italic;">German Tax Matter </i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">The German tax authorities have audited our wholly owned subsidiary, NW Bio GmbH, for 2013-2015. During those years, NWBio, Inc. sent funds to NWBio GmbH to pay for operating expenses and costs associated with the Phase III clinical trial. The German tax authorities have asserted that the subsidiary should have charged NWBio parent company a  profit margin on top of these costs, that they will deem that such a profit margin was charged by the subsidiary (even though it was not) and that they will tax this deemed profit margin, although neither NW Bio, Inc. nor NW Bio GmbH made any profit during the period in question (or at any other time), and even though the funds provided by NW Bio, Inc. were used by NW Bio GmbH entirely for operating expenses and clinical trial costs.   They have also made claims for other taxes including penalties and interest.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">In July, NW Bio GmbH submitted substantial documentation to refute the assessments of the German tax authorities.  The authorities responded in December that they were open to settlement negotiations.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;text-align:justify;margin:0pt 0pt 12pt 0pt;"><span style="font-weight:normal;">On February 12, 2021, the German tax authorities agreed in principle with the Company’s settlement offer. The Company has accrued for the Company approved tax settlement offer of </span><span style="font-weight:normal;">€351,000</span><span style="font-weight:normal;"> (approximately </span><span style="font-weight:normal;">$421,000</span><span style="font-weight:normal;"> as of December 31, 2020) for the years under audit, with an addition of </span><span style="font-weight:normal;">€156,000</span><span style="font-weight:normal;"> (approximately </span><span style="font-weight:normal;">$187,000</span><span style="font-weight:normal;">) for the more recent years to date.  Penalties and interest are still under negotiation. After considering further negotiations, under its evaluation under ASC 740, it is the view of the Company currently that it is not more likely than not that the resolution of these tax matters will ultimately result in a net material charge to the Company.</span></p> 4300000 600000 true 5100000 P20Y 4500000 <p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">The following summarizes quantitative information about the Company’s operating leases (amount in thousands):</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">​</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;white-space:nowrap;width:65.38%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.3%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.2%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.17%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.15%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:65.38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td colspan="8" style="vertical-align:bottom;white-space:nowrap;width:32.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">For the Year ended</b></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:65.38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td colspan="8" style="vertical-align:bottom;white-space:nowrap;width:32.54%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">December 31, 2020</b></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:65.38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">    </b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.5%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">U.K</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">    </b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.47%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">U.S</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">    </b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.45%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Total</b></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:65.38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;">Lease cost</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:65.38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;">Operating lease cost</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 610</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 330</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 940</p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:65.38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;">Short-term lease cost</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 44</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> —</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 44</p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:65.38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;">Variable lease cost</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.3%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.2%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 45</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.17%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 20</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.15%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 65</p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:65.38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;">Total</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.3%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.2%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 699</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.29%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.17%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 350</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.29%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.15%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 1,049</p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:65.38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> <span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> <span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> <span style="visibility:hidden;">​</span></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:65.38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;">Other information</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> <span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> <span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> <span style="visibility:hidden;">​</span></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:65.38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;">Operating cash flows from operating leases</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (661)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (332)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (993)</p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:65.38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;">Weighted-average remaining lease term - operating leases</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;">9.1</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;">0.2</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:65.38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;">Weighted-average discount rate - operating leases</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 12</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;">%</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 12</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;">%</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td></tr></table> 610000 330000 940000 44000 0 44000 45000 20000 65000 699000 350000 1049000 661000 332000 993000 P9Y1M6D P0Y2M12D 0.12 0.12 607000 247000 854000 50000 81000 131000 15000 15000 657000 343000 1000000 244000 244000 P10Y P0Y10M24D 0.12 0.12 <p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">Maturities of our operating leases, excluding short-term leases, are as follows:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">​</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;white-space:nowrap;width:61.46%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.46%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.1%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.46%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.1%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.46%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.05%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:61.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">    </b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.56%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">U.K</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">    </b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.56%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">U.S</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">    </b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.51%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Total</b></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:61.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;">Year ended December 31, 2021</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 644</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 84</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 728</p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:61.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;">Year ended December 31, 2022</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 644</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> —</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 644</p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:61.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;">Year ended December 31, 2023</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 644</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> —</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 644</p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:61.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;">Year ended December 31, 2024</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 644</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> —</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 644</p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:61.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;">Thereafter</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.46%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.1%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 8,990</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.46%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.1%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> —</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.46%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.05%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 8,990</p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:61.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;">Total</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 11,566</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 84</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 11,650</p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:61.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;">Less present value discount</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.46%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.1%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (6,565)</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.46%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.1%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (2)</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.46%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.05%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (6,567)</p></td></tr><tr><td style="vertical-align:bottom;width:61.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;">Operating lease liabilities included in the Consolidated Balance Sheet at December 31, 2020</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.46%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.1%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 5,001</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.46%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.1%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 82</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.46%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.05%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 5,083</p></td></tr></table> 644000 84000 728000 644000 0 644000 644000 0 644000 644000 0 644000 8990000 0 8990000 11566000 84000 11650000 6565000 2000 6567000 5001000 82000 5083000 1000000.0 P8M P12M 351000 421000 156000 187000 <p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;text-align:justify;margin:0pt 0pt 12pt 0pt;">13. Income Taxes</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">No provision was made for U.S. taxes on undistributed foreign earning as such earnings are considered to be permanently reinvested. It is not practicable to determine the amount of additional tax, if any that might be payable on those earnings if repatriated.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">The tax effects of temporary differences and tax loss and credit carry forwards that give rise to significant portions of deferred tax assets and liabilities at December 31, 2020 and 2019 are comprised of the following (in thousands):</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">​</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:57.29%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.38%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:18.11%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.46%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:18.02%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:57.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:justify;margin:0pt;"><b style="font-weight:bold;">    </b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:19.5%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">As of December 31, 2020</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:justify;margin:0pt;"><b style="font-weight:bold;">    </b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:19.49%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">As of December 31, 2019</b></p></td></tr><tr><td style="vertical-align:bottom;width:57.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:18.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:18.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">​</span></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:57.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">Deferred tax asset</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"> </p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:18.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">  </p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"> </p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:18.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">  </p></td></tr><tr><td style="vertical-align:bottom;width:57.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0pt 6pt;">Net operating loss carryforward</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:18.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 185,308</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:18.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 176,140</p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:57.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0pt 6pt;">Research and development credit carry forwards</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"> </p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:18.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 18,580</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"> </p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:18.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 16,983</p></td></tr><tr><td style="vertical-align:bottom;width:57.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0pt 6pt;">Stock based compensation and other</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.38%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:18.11%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 22,997</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.46%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:18.02%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 14,565</p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:57.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">Total deferred tax assets</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"> </p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:18.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 226,885</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"> </p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:18.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 207,688</p></td></tr><tr><td style="vertical-align:bottom;width:57.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">Valuation Allowance</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.38%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:18.11%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (226,885)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.46%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:18.02%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (207,688)</p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:57.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">Deferred tax asset, net of allowance</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.38%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:18.11%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> —</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.46%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:18.02%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> —</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">​</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><i style="font-style:italic;">The Company has identified the United States, Maryland, Germany and United Kingdom as significant tax jurisdictions.</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">The Company’s U.S. net operating loss (“NOL”) carryforwards for tax purposes as of December 31, 2020, are approximately $654.5 million. Unused NOL carryforwards from years prior to 2018 of $547.0 million will begin to expire in 2020 through 2037. NOL incurred in 2018 and later amount to $107.5 million and shall carryforward indefinitely. NOL carryforwards are generally available to offset future taxable income; however, the utilization of NOL may be limited under the Internal Revenue Code Section 382 as a result of changes in ownership of the Company’s stock over the loss periods and prior to utilization of the carryforwards. The Company also has approximately $18.6 million in research and development tax credits available to offset federal income tax in future periods. If unused, these credits expire through 2037. The Company’s NOL carryforwards for foreign tax purposes as of December 31, 2020 are $30.0 million. NOL in the United Kingdom and Germany of $13.3 million and $16.5 million respectively do not expire over time. NOL in the Netherlands of $208,000 will begin to expire in 2025 through 2031. The Company’s tax years are still open under statute from 2016 to present, although NOL carryovers from prior tax years are subject to examination and adjustments to the extent utilized in future years.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">In assessing the realization of deferred tax assets, management considers whether it is more likely than not that some portion or all of the deferred tax assets will be realized. The ultimate realization of deferred tax assets is dependent upon the generation of future taxable income during the period in which those temporary differences become deductible. Management considers the scheduled reversal of deferred tax liabilities, projected future taxable income and taxing strategies in making this assessment. In case the deferred tax assets will not be realized in future periods, the Company has provided a valuation allowance for the full amount of the deferred tax assets at December 31, 2020 and 2019.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">The expected tax expense (benefit) based on the U.S. federal statutory rate is reconciled with actual tax expense (benefit) as follows:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;text-align:justify;margin:0pt;">(dollars in thousands)</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">​</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:52.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:19.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:19.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.09%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></td></tr><tr><td style="vertical-align:bottom;width:52.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">    </b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:19.5%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">As of December 31, 2020</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:justify;margin:0pt;"><b style="font-weight:bold;">    </b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:19.5%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">As of December 31, 2019</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.09%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:justify;margin:0pt;"><b style="font-weight:bold;"> </b></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:52.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">Statutory federal income tax rate</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"> </p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:19.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 21.0</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:3.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">%  </p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:19.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 21.0</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:3.09%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">%  </p></td></tr><tr><td style="vertical-align:bottom;width:52.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">State taxes, net of federal tax benefit</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:19.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 1.1</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">%  </p></td><td style="vertical-align:bottom;white-space:nowrap;width:19.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 8.9</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.09%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">%  </p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:52.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">Tax rate differential on foreign income</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"> </p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:19.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 0.0</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:3.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">%  </p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:19.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (0.4)</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:3.09%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">%  </p></td></tr><tr><td style="vertical-align:bottom;width:52.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">Derivative gain or loss</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:19.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (17.3)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">%  </p></td><td style="vertical-align:bottom;white-space:nowrap;width:19.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 12.2</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.09%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">%  </p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:52.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">Expiration of net operating losses</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"> </p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:19.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (1.5)</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:3.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">%  </p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:19.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (7.9)</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:3.09%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">%  </p></td></tr><tr><td style="vertical-align:bottom;width:52.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">Other permanent items and true ups</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:19.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (0.1)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">%  </p></td><td style="vertical-align:bottom;white-space:nowrap;width:19.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (2.3)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.09%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">%  </p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:52.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">R&amp;D Credit</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"> </p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:19.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 0.3</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:3.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">%  </p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:19.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 3.0</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:3.09%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">%  </p></td></tr><tr><td style="vertical-align:bottom;width:52.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">Change in valuation allowance</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:19.5%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (3.5)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">%  </p></td><td style="vertical-align:bottom;white-space:nowrap;width:19.5%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (34.5)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.09%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">%  </p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:52.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">Income tax provision (benefit)</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"> </p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:19.5%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 0.0</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:3.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">%  </p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:19.5%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 0.0</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:3.09%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">%  </p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">​</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:57.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:17.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:17.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></td></tr><tr><td style="vertical-align:bottom;width:57.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">    </b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:19.5%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">As of December 31, 2020</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">    </b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:19.49%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">As of December 31, 2019</b></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:57.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">Federal</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"> </p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:17.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">  </p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"> </p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:17.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">  </p></td></tr><tr><td style="vertical-align:bottom;width:57.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0pt 6pt;">Current</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:17.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> —</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:17.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> —</p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:57.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0pt 6pt;">Deferred</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"> </p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:17.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (15,539)</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"> </p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:17.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (5,183)</p></td></tr><tr><td style="vertical-align:bottom;width:57.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">State</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:17.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:17.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">  </p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:57.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0pt 6pt;">Current</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"> </p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:17.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> —</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"> </p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:17.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> —</p></td></tr><tr><td style="vertical-align:bottom;width:57.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0pt 6pt;">Deferred</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:17.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (4,327)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:17.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (1,421)</p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:57.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">Foreign</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"> </p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:17.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"> </p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:17.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">  </p></td></tr><tr><td style="vertical-align:bottom;width:57.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0pt 6pt;">Current</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:17.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:17.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">  </p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:57.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0pt 6pt;">Deferred</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"> </p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:17.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 670</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"> </p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:17.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (404)</p></td></tr><tr><td style="vertical-align:bottom;width:57.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">Change in valuation allowance</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:17.99%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 19,196</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:17.98%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 7,008</p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:57.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">Income tax provision (benefit)</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.5%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:17.99%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> —</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.5%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:17.98%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> —</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">​</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">ASC 740 prescribes a recognition threshold and a measurement attribute for the financial statement recognition and measurement of tax positions taken or expected to be taken in a tax return. For those benefits to be recognized, a tax position must be more-likely-than-not to be sustained upon examination by taxing authorities. As of December 31, 2020, and 2019, there were no uncertain tax positions. The Company’s policy for recording interest and penalties associated with uncertain tax positions is to record such expense as a component of income tax expense. There were no amounts accrued for penalties or interest during the year ended December 31, 2020. Management is currently unaware of any issues under review that could result in significant payments, accruals or material deviations from its position.</p> <p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">The tax effects of temporary differences and tax loss and credit carry forwards that give rise to significant portions of deferred tax assets and liabilities at December 31, 2020 and 2019 are comprised of the following (in thousands):</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">​</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:57.29%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.38%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:18.11%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.46%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:18.02%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:57.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:justify;margin:0pt;"><b style="font-weight:bold;">    </b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:19.5%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">As of December 31, 2020</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:justify;margin:0pt;"><b style="font-weight:bold;">    </b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:19.49%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">As of December 31, 2019</b></p></td></tr><tr><td style="vertical-align:bottom;width:57.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:18.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:18.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">​</span></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:57.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">Deferred tax asset</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"> </p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:18.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">  </p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"> </p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:18.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">  </p></td></tr><tr><td style="vertical-align:bottom;width:57.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0pt 6pt;">Net operating loss carryforward</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:18.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 185,308</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:18.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 176,140</p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:57.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0pt 6pt;">Research and development credit carry forwards</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"> </p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:18.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 18,580</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"> </p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:18.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 16,983</p></td></tr><tr><td style="vertical-align:bottom;width:57.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0pt 6pt;">Stock based compensation and other</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.38%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:18.11%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 22,997</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.46%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:18.02%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 14,565</p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:57.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">Total deferred tax assets</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"> </p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:18.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 226,885</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"> </p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:18.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 207,688</p></td></tr><tr><td style="vertical-align:bottom;width:57.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">Valuation Allowance</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.38%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:18.11%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (226,885)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.46%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:18.02%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (207,688)</p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:57.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">Deferred tax asset, net of allowance</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.38%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:18.11%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> —</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.46%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:18.02%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> —</p></td></tr></table> 185308000 176140000 18580000 16983000 22997000 14565000 226885000 207688000 226885000 207688000 0 0 654500000 547000000.0 107500000 18600000 30000000.0 13300000 16500000 208000 <p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">The expected tax expense (benefit) based on the U.S. federal statutory rate is reconciled with actual tax expense (benefit) as follows:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;text-align:justify;margin:0pt;">(dollars in thousands)</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">​</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:52.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:19.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:19.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.09%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></td></tr><tr><td style="vertical-align:bottom;width:52.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">    </b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:19.5%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">As of December 31, 2020</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:justify;margin:0pt;"><b style="font-weight:bold;">    </b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:19.5%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">As of December 31, 2019</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.09%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:justify;margin:0pt;"><b style="font-weight:bold;"> </b></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:52.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">Statutory federal income tax rate</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"> </p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:19.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 21.0</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:3.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">%  </p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:19.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 21.0</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:3.09%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">%  </p></td></tr><tr><td style="vertical-align:bottom;width:52.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">State taxes, net of federal tax benefit</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:19.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 1.1</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">%  </p></td><td style="vertical-align:bottom;white-space:nowrap;width:19.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 8.9</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.09%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">%  </p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:52.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">Tax rate differential on foreign income</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"> </p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:19.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 0.0</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:3.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">%  </p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:19.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (0.4)</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:3.09%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">%  </p></td></tr><tr><td style="vertical-align:bottom;width:52.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">Derivative gain or loss</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:19.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (17.3)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">%  </p></td><td style="vertical-align:bottom;white-space:nowrap;width:19.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 12.2</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.09%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">%  </p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:52.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">Expiration of net operating losses</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"> </p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:19.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (1.5)</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:3.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">%  </p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:19.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (7.9)</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:3.09%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">%  </p></td></tr><tr><td style="vertical-align:bottom;width:52.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">Other permanent items and true ups</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:19.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (0.1)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">%  </p></td><td style="vertical-align:bottom;white-space:nowrap;width:19.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (2.3)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.09%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">%  </p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:52.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">R&amp;D Credit</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"> </p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:19.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 0.3</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:3.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">%  </p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:19.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 3.0</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:3.09%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">%  </p></td></tr><tr><td style="vertical-align:bottom;width:52.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">Change in valuation allowance</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:19.5%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (3.5)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">%  </p></td><td style="vertical-align:bottom;white-space:nowrap;width:19.5%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (34.5)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.09%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">%  </p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:52.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">Income tax provision (benefit)</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"> </p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:19.5%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 0.0</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:3.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">%  </p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:19.5%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 0.0</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:3.09%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">%  </p></td></tr></table> 0.210 0.210 0.011 0.089 0.000 0.004 -0.173 0.122 0.015 0.079 -0.001 -0.023 0.003 0.030 -0.035 -0.345 0.000 0.000 <p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">​</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:57.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:17.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:17.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></td></tr><tr><td style="vertical-align:bottom;width:57.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">    </b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:19.5%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">As of December 31, 2020</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">    </b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:19.49%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">As of December 31, 2019</b></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:57.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">Federal</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"> </p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:17.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">  </p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"> </p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:17.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">  </p></td></tr><tr><td style="vertical-align:bottom;width:57.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0pt 6pt;">Current</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:17.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> —</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:17.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> —</p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:57.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0pt 6pt;">Deferred</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"> </p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:17.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (15,539)</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"> </p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:17.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (5,183)</p></td></tr><tr><td style="vertical-align:bottom;width:57.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">State</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:17.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:17.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">  </p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:57.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0pt 6pt;">Current</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"> </p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:17.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> —</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"> </p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:17.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> —</p></td></tr><tr><td style="vertical-align:bottom;width:57.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0pt 6pt;">Deferred</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:17.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (4,327)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:17.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (1,421)</p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:57.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">Foreign</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"> </p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:17.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"> </p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:17.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">  </p></td></tr><tr><td style="vertical-align:bottom;width:57.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0pt 6pt;">Current</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:17.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:17.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">  </p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:57.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0pt 6pt;">Deferred</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"> </p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:17.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 670</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"> </p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:17.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (404)</p></td></tr><tr><td style="vertical-align:bottom;width:57.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">Change in valuation allowance</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:17.99%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 19,196</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:17.98%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 7,008</p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:57.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">Income tax provision (benefit)</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.5%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:17.99%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> —</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.5%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:17.98%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> —</p></td></tr></table> 0 0 -15539000 -5183000 0 0 -4327000 -1421000 670000 -404000 -19196000 -7008000 0 0 0 <p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">14. Revision to Prior Period Financial Statements</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">During the course of preparing the quarterly report on Form 10-Q for the three and nine months ended September 30, 2020 and 2019, the Company identified an error in its accrual and capitalization related to the Sawston Facility and research and development costs under the Advent Ancillary Services Agreement. This resulted in an understatement of construction in progress of $1.5 million as of December 31, 2019, and an understatement of accounts payable and accrued expenses to related parties and affiliates of $3.0 million as of December 31, 2019.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">The Company concluded that the error was not material to any prior annual period and the error had no material impact to any prior interim period. Nevertheless, the Company has revised its historical consolidated financial statements to properly reflect research and development expenses, capitalization of construction in progress and accrued liabilities in the prior periods.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">The effect of the revisions to the consolidated financial statements is as follows (amount in thousands):</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><b style="font-weight:bold;">Consolidated Balance Sheet</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">​</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:62.5%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.98%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.27%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.98%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.27%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.98%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:62.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:justify;margin:0pt;"><b style="font-weight:bold;"> </b><span style="font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td colspan="8" style="vertical-align:bottom;white-space:nowrap;width:35.51%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">As of December 31, 2019</b></p></td></tr><tr><td style="vertical-align:bottom;width:62.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:justify;margin:0pt;"><b style="font-weight:bold;"> </b><span style="font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">As Previously</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:justify;margin:0pt;"><b style="font-weight:bold;"> </b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td></tr><tr><td style="vertical-align:bottom;width:62.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:justify;margin:0pt;"><b style="font-weight:bold;"> </b><span style="font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:justify;margin:0pt;"><b style="font-weight:bold;">    </b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.53%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">  Reported </b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:justify;margin:0pt;"><b style="font-weight:bold;">    </b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.53%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Adjustments</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:justify;margin:0pt;"><b style="font-weight:bold;">    </b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.48%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">As Revised</b></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:62.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">Construction in progress</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 171</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 1,514</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 1,685</p></td></tr><tr><td style="vertical-align:bottom;width:62.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0pt 6pt;">Total non-current assets</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 5,929</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 1,514</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 7,443</p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:62.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><b style="font-weight:bold;">TOTAL ASSETS</b></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><b style="font-weight:bold;">$</b></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><b style="font-weight:bold;"> 9,129</b></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><b style="font-weight:bold;">$</b></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><b style="font-weight:bold;"> 1,514</b></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><b style="font-weight:bold;">$</b></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><b style="font-weight:bold;"> 10,643</b></p></td></tr><tr><td style="vertical-align:bottom;width:62.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">  </p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">  </p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">  </p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:62.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">Accounts payable and accrued expenses to related parties and affiliates</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 842</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 3,002</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 3,844</p></td></tr><tr><td style="vertical-align:bottom;width:62.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0pt 6pt;">Total current liabilities</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 41,194</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 3,002</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 44,196</p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:62.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">Total liabilities</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"> </p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 52,696</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"> </p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 3,002</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"> </p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 55,698</p></td></tr><tr><td style="vertical-align:bottom;width:62.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">  </p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">  </p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">  </p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:62.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">Accumulated deficit </p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"> </p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (839,907)</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"> </p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (1,488)</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"> </p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (841,395)</p></td></tr><tr><td style="vertical-align:bottom;width:62.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">Total stockholders' deficit</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (43,567)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (1,488)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (45,055)</p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:62.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><b style="font-weight:bold;">TOTAL LIABILITIES AND STOCKHOLDERS' DEFICIT</b></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><b style="font-weight:bold;">$</b></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><b style="font-weight:bold;"> 9,129</b></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><b style="font-weight:bold;">$</b></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><b style="font-weight:bold;"> 1,514</b></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><b style="font-weight:bold;">$</b></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><b style="font-weight:bold;"> 10,643</b></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">​</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><b style="font-weight:bold;">Consolidated Statement of Operations</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">​</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:56.09%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.45%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.86%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.32%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.46%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.86%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.32%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.46%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.84%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:56.09%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:justify;margin:0pt;"><b style="font-weight:bold;"> </b><span style="font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td colspan="8" style="vertical-align:bottom;white-space:nowrap;width:41.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">For the year ended</b></p></td></tr><tr><td style="vertical-align:bottom;width:56.09%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:justify;margin:0pt;"><b style="font-weight:bold;"> </b><span style="font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td colspan="8" style="vertical-align:bottom;white-space:nowrap;width:41.59%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">December 31, 2019</b></p></td></tr><tr><td style="vertical-align:bottom;width:56.09%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:justify;margin:0pt;"><b style="font-weight:bold;"> </b><span style="font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">As Previously</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:justify;margin:0pt;"><b style="font-weight:bold;"> </b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td></tr><tr><td style="vertical-align:bottom;width:56.09%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:justify;margin:0pt;"><b style="font-weight:bold;"> </b><span style="font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:justify;margin:0pt;"><b style="font-weight:bold;">    </b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.31%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">  Reported </b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:justify;margin:0pt;"><b style="font-weight:bold;">    </b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.32%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Adjustments</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:justify;margin:0pt;"><b style="font-weight:bold;">    </b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.3%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">As Revised</b></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:56.09%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">Research and development expenses</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.45%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 13,590</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 516</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 14,106</p></td></tr><tr><td style="vertical-align:bottom;width:56.09%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0pt 6pt;">Total operating costs and expenses</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.45%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 29,873</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 516</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 30,389</p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:56.09%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0pt 6pt;">Loss from operations</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.45%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"> </p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (27,463)</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"> </p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (516)</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"> </p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (27,979)</p></td></tr><tr><td style="vertical-align:bottom;width:56.09%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><b style="font-weight:bold;">Net loss</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.45%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><b style="font-weight:bold;">$</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><b style="font-weight:bold;"> (20,296)</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><b style="font-weight:bold;">$</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><b style="font-weight:bold;"> (516)</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><b style="font-weight:bold;">$</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><b style="font-weight:bold;"> (20,812)</b></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:56.09%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">Total comprehensive loss</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.45%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (20,460)</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (516)</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (20,976)</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">​</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><b style="font-weight:bold;">Consolidated Statement of Cash Flows</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">​</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:62.5%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.98%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.27%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.98%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.27%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.98%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:62.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:justify;margin:0pt;"><b style="font-weight:bold;"> </b><span style="font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td colspan="8" style="vertical-align:bottom;white-space:nowrap;width:35.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">For the year ended</b></p></td></tr><tr><td style="vertical-align:bottom;width:62.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:justify;margin:0pt;"><b style="font-weight:bold;"> </b><span style="font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td colspan="8" style="vertical-align:bottom;white-space:nowrap;width:35.51%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">December 31, 2019</b></p></td></tr><tr><td style="vertical-align:bottom;width:62.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:justify;margin:0pt;"><b style="font-weight:bold;"> </b><span style="font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">As Previously</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:justify;margin:0pt;"><b style="font-weight:bold;"> </b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td></tr><tr><td style="vertical-align:bottom;width:62.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:justify;margin:0pt;"><b style="font-weight:bold;"> </b><span style="font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:justify;margin:0pt;"><b style="font-weight:bold;">    </b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.53%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">  Reported </b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:justify;margin:0pt;"><b style="font-weight:bold;">    </b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.53%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Adjustments</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:justify;margin:0pt;"><b style="font-weight:bold;">    </b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.48%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">As Revised</b></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:62.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><b style="font-weight:bold;">Cash Flows from Operating Activities:</b></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">  </p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">  </p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">  </p></td></tr><tr><td style="vertical-align:bottom;width:62.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0pt 6pt;">Net loss</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (20,296)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (516)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (20,812)</p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:62.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0pt 6pt;">Related party accounts payable and accrued expenses</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"> </p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (3,746)</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"> </p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 516</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"> </p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (3,230)</p></td></tr><tr><td style="vertical-align:bottom;width:62.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">Net cash used in operating activities</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (31,859)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> —</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (31,859)</p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:62.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><b style="font-weight:bold;">Supplemental schedule of non-cash investing and financing activities:</b></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"> </p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">  </p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"> </p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">  </p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"> </p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">  </p></td></tr><tr><td style="vertical-align:bottom;width:62.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">Capital expenditures included in accounts payable and accrued expenses to related parties and affiliates</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> —</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 947</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 947</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p> 1500000 3000000.0 171000 1514000 1685000 5929000 1514000 7443000 9129000 1514000 10643000 842000 3002000 3844000 41194000 3002000 44196000 52696000 3002000 55698000 -839907000 -1488000 -841395000 -43567000 -1488000 -45055000 9129000 1514000 10643000 13590000 516000 14106000 29873000 516000 30389000 -27463000 -516000 -27979000 -20296000 -516000 -20812000 -20460000 -516000 -20976000 -20296000 -516000 -20812000 -3746000 516000 -3230000 -31859000 -31859000 947000 947000 <p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;text-align:justify;margin:0pt 0pt 12pt 0pt;">15. Subsequent Events</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><span style="text-decoration:underline;text-decoration-color:#000000;">Debt Offering</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">On March 1, 2021, the Company entered into a Commercial Loan Agreement (the “Note”) with an individual investor for an aggregate principal amount of $10 million. The Note bears interest at 8% per annum with a 22-month term. There are no repayments during the first 8 months of the term. The note is amortized in 14 installments starting on November 1, 2021. The Note carries an original issue discount of $1 million and $5,000 legal costs that were reimbursable to the investor.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><span style="text-decoration:underline;text-decoration-color:#000000;">Warrants and Options Suspension</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">On January 15, 2021, the Company further extended the suspension of approximately 256 million warrants and options held by certain officers and directors of the Company until February 28, 2021. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">On February 28, 2021, the Company further extended the suspension of approximately 262 million warrants and options held by certain officers and directors of the Company until April 30, 2021.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">A total 262 million warrants and options will be suspended until April 30, 2021.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><span style="text-decoration:underline;text-decoration-color:#000000;">Warrants Exercised for Cash and Cashless Warrants Exercise</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">Between January and March 2021, the Company received $0.7 million from the exercise of warrants with an exercise price between $0.175 and $0.34. The Company issued approximately 2.6 million shares of common stock upon these warrant exercises.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">Between January and March 2021, certain warrants allowing for cashless exercise were exercised, with exercise prices between $0.22 and $0.52. The Company issued approximately 2.1 million shares of common stock upon 2.6 million warrant exercises.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><span style="text-decoration:underline;text-decoration-color:#000000;">Stock Options Exercised for Cash and Cashless Stock Options Exercise</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">Between January and March 2021, the Company received $46,000 from the exercise of stock options with an exercise price of $0.25. The Company issued approximately 0.2 million shares of common stock upon these options exercises.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">Between January and March 2021, certain stock options holders elected to cashless exercise their options, with exercise prices between $0.25 and $0.34. The Company issued approximately 3.1 million shares of common stock upon 3.7 million options exercises.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><span style="text-decoration:underline;text-decoration-color:#000000;">Debt Conversion</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">Between January and March 2021, the Company converted approximately $4.6 million outstanding debt and interest into approximately 4.5 million shares of common stock.</p> 10000000 0.08 P22M 0 14 1000000 5000 256000000 262000000 262000000 700000 0.175 0.34 2600000 0.22 0.52 2100000 2600000 46000 0.25 200000 0.25 0.34 3100000 3700000 4600000 4500000 As of December 31, 2020, approximately 62.1 million warrants were not exercisable until January 15, 2021. Subsequent to January 15, 2021, the Company suspended 58.8 million warrants until February 28, 2021. XML 20 R1.htm IDEA: XBRL DOCUMENT v3.21.1
Document and Entity Information - USD ($)
12 Months Ended
Dec. 31, 2020
Mar. 26, 2021
Jun. 30, 2020
Document and Entity Information      
Document Type 10-K    
Document Annual Report true    
Document Transition Report false    
Document Period End Date Dec. 31, 2020    
Entity File Number 001-35737    
Entity Registrant Name NORTHWEST BIOTHERAPEUTICS INC    
Entity Central Index Key 0001072379    
Entity Incorporation, State or Country Code DE    
Entity Tax Identification Number 94-3306718    
Entity Address, Address Line One 4800 Montgomery Lane    
Entity Address, Address Line Two Suite 800    
Entity Address, City or Town Bethesda    
Entity Address, State or Province MD    
Entity Address, Postal Zip Code 20814    
City Area Code 240    
Local Phone Number 497-9024    
Trading Symbol NWBO    
Title of 12(b) Security Common Stock, par value $0.001 per share    
Entity Well-known Seasoned Issuer No    
Entity Voluntary Filers No    
Entity Current Reporting Status Yes    
Entity Interactive Data Current Yes    
Entity Filer Category Non-accelerated Filer    
Entity Small Business true    
Entity Emerging Growth Company false    
Document Fiscal Period Focus FY    
Document Fiscal Year Focus 2020    
Current Fiscal Year End Date --12-31    
Entity Shell Company false    
Entity Public Float     $ 234,821,000
Entity Common Stock, Shares Outstanding   842,137,013  
Amendment Flag false    
XML 21 R2.htm IDEA: XBRL DOCUMENT v3.21.1
CONSOLIDATED BALANCE SHEETS - USD ($)
$ in Thousands
Dec. 31, 2020
Dec. 31, 2019
Current assets:    
Cash and cash equivalents $ 9,983 $ 372
Prepaid expenses and other current assets 5,528 2,828
Total current assets 15,511 3,200
Non-current assets:    
Property, plant and equipment, net 1,040 281
Construction in progress 9,074 1,685
Right-of-use asset, net 4,489 4,679
Indefinite-lived intangible asset 1,292 0
Goodwill 626 0
Other assets 867 798
Total non-current assets 17,388 7,443
TOTAL ASSETS 32,899 10,643
Current liabilities:    
Accounts payable and accrued expenses 7,380 6,348
Accounts payable and accrued expenses to related parties and affiliates 5,363 3,844
Convertible notes, net 3,830 568
Notes payable, net 2,437 5,501
Notes payable to related party   66
Contingent payable derivative liability 8,275 7,261
Warrant liability 354,972 20,213
Lease liabilities 167 395
Total current liabilities 382,424 44,196
Non-current liabilities:    
Note payable, net of current portion, net 8,507 6,588
Lease liabilities, net of current portion 4,916 4,914
Total non-current liabilities 13,423 11,502
Total liabilities 395,847 55,698
COMMITMENTS AND CONTINGENCIES (Note 12)
Stockholders' deficit:    
Preferred stock ($0.001 par value); 100,000,000 shares authorized as of December 31, 2020 and 2019, respectively
Common stock ($0.001 par value); 1,200,000,000 shares authorized; 829.6 million and 614.3 million shares issued and outstanding as of December 31, 2020 and 2019, respectively 830 614
Additional paid-in capital 1,008,665 794,900
Stock subscription receivable (79) (10)
Accumulated deficit (1,371,216) (841,395)
Accumulated other comprehensive income (1,148) 836
Total stockholders' deficit (362,948) (45,055)
TOTAL LIABILITIES AND STOCKHOLDERS' DEFICIT $ 32,899 $ 10,643
XML 22 R3.htm IDEA: XBRL DOCUMENT v3.21.1
CONSOLIDATED BALANCE SHEETS (Parenthetical) - $ / shares
Dec. 31, 2020
Dec. 31, 2019
CONSOLIDATED BALANCE SHEETS    
Preferred stock, par value (in dollars per share) $ 0.001 $ 0.001
Preferred Stock, shares authorized 100,000,000 100,000,000
Common stock, par value (in dollars per share) $ 0.001 $ 0.001
Common stock, shares authorized 1,200,000,000 1,200,000,000
Common stock, shares issued 829,600,000 614,300,000
Common stock, shares outstanding 829,600,000 614,300,000
XML 23 R4.htm IDEA: XBRL DOCUMENT v3.21.1
CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS - USD ($)
$ in Thousands
12 Months Ended
Dec. 31, 2020
Dec. 31, 2019
Revenues:    
Research and other $ 1,291 $ 2,410
Total revenues 1,291 2,410
Operating costs and expenses:    
Research and development 33,637 14,106
General and administrative 50,992 12,541
Legal expenses 3,267 3,742
Total operating costs and expenses 87,896 30,389
Loss from operations (86,605) (27,979)
Other income (expense):    
Change in fair value of derivative liabilities (435,351) 11,828
Loss from extinguishment of debt (1,582) (1,941)
Interest expense (8,544) (2,975)
Foreign currency transaction gain 2,261 255
Total other income(expense) (443,216) 7,167
Net loss (529,821) (20,812)
Other comprehensive loss    
Foreign currency translation adjustment (1,984) (164)
Total comprehensive loss $ (531,805) $ (20,976)
Net loss per share applicable to common stockholders - basic and diluted $ (0.73) $ (0.04)
Weighted average shares used in computing basic and diluted loss per share 725,129 564,188
XML 24 R5.htm IDEA: XBRL DOCUMENT v3.21.1
CONSOLIDATED STATEMENTS OF CHANGES IN STOCKHOLDERS' DEFICIT - USD ($)
$ in Thousands
Common Stock
Additional Paid-in Capital
Subscription Receivable
Accumulated Deficit
Cumulative Effect, Period of Adoption, Adjustment
Accumulated Deficit
Accumulated Other Comprehensive Income (Loss)
Cumulative Effect, Period of Adoption, Adjustment
Total
Balance at Dec. 31, 2018 $ 523 $ 775,741 $ (10)   $ (825,385) $ 1,000   $ (48,131)
Balance (in shares) at Dec. 31, 2018 523,232,000              
Issuance of common stock and warrants for cash in a registered direct offering $ 33 4,040           4,073
Issuance of common stock and warrants for cash in a registered direct offering (in shares) 32,708              
Warrants exercised for cash $ 10 2,210           2,220
Warrants exercised for cash (in shares) 9,532              
Reclassification of warrant liabilities related to warrants exercised for cash   1,759           1,759
Issuance of common stock and warrants for conversion of debt and accrued interest $ 35 9,138           9,173
Issuance of common stock and warrants for conversion of debt and accrued interest (in shares) 35,480              
Issuance of common shares in connection with a settlement agreement $ 12 (12)           $ 52,000
Issuance of common shares in connection with a settlement agreement (in shares) 12,000             12,000,000
Stock-based compensation $ 1 1,818           $ 1,819
Stock-based compensation (in shares) 1,340              
Beneficial conversion feature related to amended convertible note   68           68
Reclass between shares payable and additional paid-in capital   138           138
Net loss         (20,812)     (20,812)
Cumulative translation adjustment           (164)   (164)
Balance at Dec. 31, 2019 $ 614 794,900 (10)   (841,395) 836   (45,055)
Balance (in shares) at Dec. 31, 2019 614,292              
Cumulative effect of adopting new accounting standard       $ 4,802     $ 4,802 (841,395)
Issuance of common stock and warrants for cash in a registered direct offering $ 98 16,462 (69)         16,491
Issuance of common stock and warrants for cash in a registered direct offering (in shares) 97,981              
Warrants exercised for cash $ 48 13,867           13,915
Warrants exercised for cash (in shares) 47,511              
Reclassification of warrant liabilities related to warrants exercised for cash   22,701           $ 22,701
Cashless warrants exercise $ 7 (7)            
Cashless warrants exercise (in shares) 7,086              
Cashless option exercise (in shares) 71             94
Issuance of common stock and warrants for conversion of debt and accrued interest $ 58 19,591           $ 19,649
Issuance of common stock and warrants for conversion of debt and accrued interest (in shares) 58,368              
Reclassification of warrant liabilities related to cashless warrants exercise   9,478           9,478
Stock Issued During Period Value Issued For Non Cash Consideration $ 7 (7)            
Issuance of common stock in connection with Flaskworks acquisition $ 1 1,132           1,133
Issuance of common stock in connection with Flaskworks acquisition (in shares) 655              
Reclassification of warrant liabilities related to sequencing policy   78,292           78,292
Stock-based compensation $ 4 52,205 0   0 0   52,209
Stock-based compensation (in shares) 3,667              
Beneficial conversion feature related to amended convertible note   44           44
Net loss         (529,821)     (529,821)
Cumulative translation adjustment           (1,984)   (1,984)
Balance at Dec. 31, 2020 $ 830 $ 1,008,665 $ (79)   $ (1,371,216) $ (1,148)   (362,948)
Balance (in shares) at Dec. 31, 2020 829,631              
Cumulative effect of adopting new accounting standard               $ (1,371,216)
XML 25 R6.htm IDEA: XBRL DOCUMENT v3.21.1
CONSOLIDATED STATEMENTS OF CHANGES IN STOCKHOLDERS' DEFICIT (Parenthetical) - USD ($)
$ in Millions
12 Months Ended
Dec. 31, 2020
Dec. 31, 2019
Payments of Stock Issuance Costs $ 0.6 $ 0.4
Direct Offering [Member]    
Warrant liability $ 10.3 $ 2.7
XML 26 R7.htm IDEA: XBRL DOCUMENT v3.21.1
CONSOLIDATED STATEMENTS OF CASH FLOWS - USD ($)
shares in Thousands, $ in Thousands
12 Months Ended
Dec. 31, 2020
Dec. 31, 2019
Cash Flows from Operating Activities:    
Net loss $ (529,821) $ (20,812)
Reconciliation of net loss to net cash used in operating activities:    
Depreciation and amortization 87 21
Amortization of debt discount 3,013 1,430
Change in fair value of derivatives 435,351 (11,828)
Change in fair value of contingent liability 913  
Loss from extinguishment of debt (1,582) (1,941)
Amortization of operating lease right-of-use asset 338 (322)
Stock-based compensation related to warrants modification   3
Stock-based compensation for services 52,209 1,819
Non-cash interest expense 4,270  
Subtotal of non-cash charges 497,763 (6,936)
Changes in operating assets and liabilities:    
Prepaid expenses and other current assets (2,350) (1,226)
Other non-current assets (31) (11)
Accounts payable and accrued expenses 1,702 30
Related party accounts payable and accrued expenses 431 (3,230)
Lease liabilities 213 326
Net cash used in operating activities (32,093) (31,859)
Cash Flows from Investing Activities:    
Purchase of equipment and construction in progress (6,610) (360)
Acquisition of Flaskworks, net of cash (1,532)  
Net cash used in investing activities (8,142) (360)
Cash Flows from Financing Activities:    
Proceeds from issuance of common stock and warrants in a registered direct offering, net 26,814 6,874
Proceeds from exercise of warrants 13,915 2,220
Proceeds from warrants modification 4 7
Proceeds from issuance of notes payable, net 8,557 7,000
Proceeds from issuance of convertible notes payable, net 5,115  
Proceeds from issuance of convertible notes payable to related party 315  
Repayment of notes payable (1,556) (420)
Repayment of notes payable to related parties (379) (329)
Repayment of convertible notes payable (89)  
Repayment of convertible notes payable to related parties   (5,400)
Net cash provided by financing activities 52,696 9,952
Effect of exchange rate changes on cash and cash equivalents (2,850) 415
Net increase (decrease) in cash and cash equivalents 9,611 (21,852)
Cash and cash equivalents, beginning of the year 372 22,224
Cash and cash equivalents, end of the year $ 9,983 372
Supplemental schedule of non-cash investing and financing activities:    
Issuance of common stock as consideration related to Flaskworks acquisition 220  
Cashless warrants exercise $ 7  
Reclassification of warrant liabilities related to warrants exercised for cash 22,701 1,759
Reclassification of warrant liabilities related to cashless warrants exercise 9,478  
Reclassification of warrant liabilities related to sequencing policy 78,292  
Issuance of common stock and warrants for conversion of debt and accrued interest 8,230 7,313
Offering cost related to warrant liability 4,876 2,693
Deferred offering cost   108
Issuance of warrants in conjunction with convertible note payable 153  
Issuance of warrants in connection with debt modification 395  
Warrant modification in connection with debt amendment 91  
Beneficial conversion feature related to amended convertible note 44 68
Reclass between shares payable and additional paid-in capital   138
Capital expenditures included in accounts payable 1,088 947
Conversion of outstanding accounts payables to note payable and contingent payable   8,560
Issuance of common shares in connection with a settlement agreement   12
Notes payable    
Supplemental disclosure of cash flow information    
Interest payments   (43)
Convertible notes payable    
Supplemental disclosure of cash flow information    
Interest payments (11)  
Related Party | Notes payable    
Supplemental disclosure of cash flow information    
Interest payments (9) (177)
Related Party | Convertible notes payable    
Supplemental disclosure of cash flow information    
Interest payments $ (19) $ (795)
XML 27 R8.htm IDEA: XBRL DOCUMENT v3.21.1
Organization and Description of Business
12 Months Ended
Dec. 31, 2020
Organization and Description of Business  
Organization and Description of Business

1. Organization and Description of Business

Northwest Biotherapeutics, Inc. and its wholly owned subsidiaries NW Bio GmbH, Aracaris Ltd, Aracaris Capital, Ltd, and Northwest Biotherapeutics B.V. (collectively, the “Company”, “we”, “us” and “our”) were organized to discover and develop innovative immunotherapies for cancer. The Company has developed DCVax® platform technologies for both operable and inoperable solid tumor cancers. The Company has wholly owned subsidiaries in the U.K. and on April 25, 2019, the Company established a new wholly owned subsidiary Northwest Biotherapeutics B.V. in the Netherlands, where the European Medicines Agency is relocating.

The Company relies upon contract manufacturers for production of its DCVax products, research and development services, distribution and logistics, and related services, in compliance with the Company’s specifications and the applicable regulatory requirements.

On August 28, 2020, the Company acquired Flaskworks, LLC (“Flaskworks”), a company that has developed a system to close and automate the manufacturing of cell therapy products such as DCVax®.

XML 28 R9.htm IDEA: XBRL DOCUMENT v3.21.1
Financial Condition, Going Concern and Management Plans
12 Months Ended
Dec. 31, 2020
Financial Condition, Going Concern and Management Plans  
Financial Condition, Going Concern and Management Plans

2. Financial Condition, Going Concern and Management Plans

The Company has incurred annual net operating losses since its inception. The Company had a net loss of $529.8 million, which included a cash loss of $32 million and a non-cash loss of $497.8 million, for the year ended December 31, 2020. The increase in net loss for the year ended December 31, 2020 was primarily due to the increased stock price, which resulted in significant non-cash loss from the change on the derivative liability. The Company used approximately $32.1 million of cash in its operating activities for the year ended December 31, 2020. Management believes that the Company has access to capital resources through the sale of equity and debt financing arrangements. However, the Company has not secured any commitments for new financing for this specific purpose at this time.

The Company does not expect to generate material revenue in the near future from the sale of products and is subject to all of the risks and uncertainties that are typically faced by biotechnology companies that devote substantially all of their efforts to R&D and clinical trials and do not yet have commercial products. The Company expects to continue incurring annual losses for the foreseeable future. The Company’s existing liquidity is not sufficient to fund its operations, anticipated capital expenditures, working capital and other financing requirements until the Company reaches significant revenues. Until that time, the Company will need to obtain additional equity and/or debt financing, especially if the Company experiences downturns in its business that are more severe or longer than anticipated, or if the Company experiences significant increases in expense levels resulting from being a publicly-traded company or from expansion of operations. If the Company attempts to obtain additional equity or debt financing, the Company cannot assume that such financing will be available to the Company on favorable terms, or at all. Because of recurring operating losses and operating cash flow deficits, there is substantial doubt about the Company’s ability to continue as a going concern within one year from the date of this filing. The consolidated financial statements have been prepared assuming that the Company will continue as a going concern, and do not include any adjustments to reflect the possible future effects on the recoverability and classification of assets, or the amounts and classification of liabilities that may result from the outcome of this uncertainty.

As also previously reported, coronavirus-related difficulties have impacted most aspects of the process, especially with the successive waves of COVID cases in many areas. The independent service firms have had limited capacity, and restrictions on operations. Key experts at certain specialized service providers have been unavailable for periods of time due to illness in their family.  Other experts have gone on extended leave due to restrictions on operations. Clinical trial site personnel have been unavailable due to being reassigned for COVID, and the limited site personnel have had to work under restrictions. Committee processes and regulatory processes have been similarly focused on COVID matters and delayed on other matters. Firms such as the ones storing the Phase III trial tissue samples that are needed for certain analyses, and the firms conducting the analyses, continue to have only limited operations. Even logistical matters such as the shipping of materials have been, and continue to be, subjected to substantial restrictions and delays.

XML 29 R10.htm IDEA: XBRL DOCUMENT v3.21.1
Summary of Significant Accounting Policies
12 Months Ended
Dec. 31, 2020
Summary of Significant Accounting Policies  
Summary of Significant Accounting Policies

3. Summary of Significant Accounting Policies

Basis of Presentation

The accompanying consolidated financial statements of the Company were prepared in accordance with generally accepted accounting principles in the U.S. (“U.S. GAAP”) and include the assets, liabilities, revenues and expenses of the wholly owned subsidiaries in Germany, United Kingdom and Netherlands. All intercompany transactions and accounts have been eliminated in consolidation.

Consolidation

The Company’s policy is to consolidate all entities in which it can vote a majority of the outstanding voting stock. In addition, the Company consolidates entities that meet the definition of a variable interest entity (VIE) for which the Company is the primary beneficiary, if any. The primary beneficiary is the party who has the power to direct the activities of a VIE that most significantly impact the entity’s economic performance and who has an obligation to absorb losses of the entity or a right to receive benefits from the entity that could potentially be significant to the VIE.

As of December 31, 2020, the Company did not consolidate any VIE's as the Company has concluded that it is not the primary beneficiary.

Use of Estimates

In preparing consolidated financial statements in conformity with U.S. GAAP, management is required to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements, as well as the reported amounts of expenses during the reporting period. Due to inherent uncertainty involved in making estimates, actual results reported in future periods may be affected by changes in these estimates.

On an ongoing basis, the Company evaluates its estimates and judgments, including valuing equity securities in share-based payment arrangements, estimating the fair value of financial instruments recorded as derivative liabilities, useful lives of depreciable assets and whether impairment charges may apply. The Company bases its estimates on historical experience and on various other assumptions that it believes to be reasonable under the circumstances, the results of which form the basis for making judgments about the carrying values of assets and liabilities and the reported amounts of revenues and expenses that are not readily apparent from other sources. Actual results could differ from those estimates, particularly given the significant social and economic disruptions and uncertainties associated with the ongoing coronavirus pandemic ("COVID-19") and the COVID-19 control responses.

Concentration of Credit Risk

Financial instruments that potentially subject the Company to concentration of credit risk consist of cash accounts in a financial institution, which at times may exceed the Federal depository insurance coverage (“FDIC”) of $250,000. As of December 31, 2020, of the total $10 million in cash and cash equivalents, $0.6 million was held by foreign subsidiaries. The Company had not experienced losses on these accounts and management believes the Company is not exposed to significant risks on such accounts.

Property, Plant and Equipment

Property and equipment are stated at cost. Depreciation and amortization are provided for using straight-line methods, in amounts sufficient to charge the cost of depreciable assets to operations over their estimated service lives. Repairs and maintenance costs are charged to operations as incurred.

Costs for capital assets not yet placed into service are capitalized as construction in progress on the consolidated balance sheets and will be depreciated once placed into service.

The Company assesses its long-lived assets for impairment whenever facts and circumstances indicate that the carrying amounts may not be fully recoverable. To analyze recoverability, the Company projects undiscounted net future cash flows over the remaining lives of such assets. If these projected undiscounted net future cash flows are less than the carrying amounts, an impairment loss would be recognized, resulting in a write-down of the assets with a corresponding charge to earnings. The impairment loss is measured based upon the difference between the carrying amounts and the fair values of the assets.

Goodwill and Intangible Assets

Goodwill is the excess of purchase price over the fair value of identified net assets of businesses acquired. The Company's intangible asset with an indefinite life is related to in-process research and development ("IPR&D") programs acquired in the Flaskworks Acquisition, as the Company expects future research and development on these programs to provide the Company with substantial benefit for a period that extends beyond the foreseeable horizon. Intangible assets with indefinite useful lives are measured at their respective fair values as of the acquisition date. The Company does not amortize goodwill and intangible assets with indefinite useful lives. Intangible assets related to IPR&D projects are considered to be indefinite lived until the completion or abandonment of the associated R&D efforts. If and when development is complete, which generally occurs if and when regulatory approval to market a product is obtained, the associated assets would be deemed finite lived and would then be amortized based on their respective estimated useful lives at that point in time.

The Company has one operating segment and one reporting unit. The Company reviews goodwill and indefinite-lived intangible assets at least annually for possible impairment. Goodwill and indefinite-lived intangible assets are reviewed for possible impairment between annual tests if an event occurs or circumstances change that would more likely than not reduce the fair value of the reporting unit or the indefinite-lived intangible assets below their carrying values. No impairment charge was recognized for the year ended December 31, 2020.

Fair Value of Financial Instruments

ASC 820, Fair Value Measurements, provides guidance on the development and disclosure of fair value measurements. Under this accounting guidance, fair value is defined as an exit price, representing the amount that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date. As such, fair value is a market-based measurement that should be determined based on assumptions that market participants would use in pricing an asset or a liability.

The accounting guidance classifies fair value measurements in one of the following three categories for disclosure purposes:

Level 1:    Quoted prices in active markets for identical assets or liabilities.

Level 2:    Inputs other than Level 1 prices for similar assets or liabilities that are directly or indirectly observable in the marketplace.

Level 3:    Unobservable inputs which are supported by little or no market activity and values determined using pricing models, discounted cash flow methodologies, or similar techniques, as well as instruments for which the determination of fair value requires significant judgment or estimation.

The Company accounts for the issuance of common stock purchase warrants issued in connection with the equity offerings in accordance with the provisions of ASC 815, Derivatives and Hedging ("ASC 815"). The Company classifies as equity any contracts that (i) require physical settlement or net-share settlement or (ii) gives the Company a choice of net-cash settlement or settlement in its own shares (physical settlement or net-share settlement). The Company accounts for certain common stock warrants outstanding as a liability at fair value and adjusts the instruments to fair value at each reporting period. This liability is subject to re-measurement at each balance sheet date until exercised, and any change in fair value is recognized in its Consolidated Statements of Operations and Comprehensive Loss. The fair value of the warrants issued by the Company has been estimated using Monte Carlo simulation and or a Black Scholes model. The warrant liabilities are valued using Level 3 valuation inputs (see Note 4).

Embedded Conversion Features

The Company evaluates embedded conversion features within convertible debt instruments to determine whether the embedded conversion feature(s) should be bifurcated from the host instrument and accounted for as a derivative at fair value with changes in fair value recorded in the Statement of Operations. If the conversion feature does not require recognition of a bifurcated derivative, the convertible debt instrument is evaluated for consideration of any beneficial conversion feature (“BCF”) requiring separate recognition. When the Company record a BCF, the intrinsic value of the BCF is recorded as a debt discount against the face amount of the respective debt instrument (offset to additional paid-in capital) and amortized to interest expense over the life of the debt.

Derivative Financial Instruments

The Company has derivative financial instruments that are not hedges and do not qualify for hedge accounting. Changes in the fair value of these instruments are recorded in other income (expense), on a net basis in the Consolidated Statements of Operations and Comprehensive Loss.

Contingent payable derivative liability

During the year ended December 31, 2019, the Company entered into a settlement agreement with Cognate BioServices, resolving past matters and providing for the restart of DCVax®-Direct Production.

As part of this overall settlement, the Company also provided a contingent note payable (the “Contingent Payable Derivative”) of $10 million, which is only payable upon the Company’s first financing after DCVax product approval in or outside the U.S. If such product approval has not been obtained by the seventh anniversary of the agreement, such Contingent Payable Derivative will expire without becoming payable.

On a quarterly basis, management makes estimates for key performance milestones and uses the expected dates as the inputs for valuation. The fair value of the Contingent Payable Derivative has been estimated using Monte Carlo simulation, which are valued using Level 3 valuation inputs.

Leases

Prior to January 1, 2019, the Company recognized rent expense on a straight-line basis over the lease period and accounts for the difference between straight-line rent and actual lease payments as deferred rent.

Subsequent to the adoption of the new leasing standard on January 1, 2019, the Company recognizes a lease asset for its right to use the underlying asset and a lease liability for the corresponding lease obligation. The Company determines whether an arrangement is or contains a lease at contract inception. Operating leases with a duration greater than one year are included in right-of-use assets, lease liabilities, and lease liabilities, net of current portion in the Company’s consolidated balance sheets. Right-of-use assets and liabilities are recognized at the lease commencement date based on the present value of lease payments over the lease term. In determining the net present value of lease payments, the Company uses its incremental borrowing rate based on the information available at the lease commencement date. The incremental borrowing rate represents the interest rate the Company would incur at lease commencement to borrow an amount equal to the lease payments on a collateralized basis over the term of a lease. The Company considers a lease term to be the non-cancelable period that it has the right to use the underlying asset.

The operating lease right-of-use assets also include any lease payments made and exclude lease incentives. Lease expense is recognized on a straight-line basis over the expected lease term. Variable lease expenses are recorded when incurred.

Foreign Currency Translation and Transactions

The Company has operations in Germany, the United Kingdom and Netherlands in addition to the U.S. The Company translated its assets and liabilities into U.S. dollars using end of period exchange rates and revenues and expenses are translated into U.S. dollars using weighted average rates. Foreign currency translation adjustments are reported as a separate component of accumulated other comprehensive income (loss) within stockholders’ equity deficit.

The Company converts receivables and payables denominated in other than the Company’s functional currency at the exchange rate as of the balance sheet date. The resulting transaction exchange gains or losses related to intercompany receivable and payables, are included in other income and expense.

Comprehensive Loss

The Company reports comprehensive loss and its components in its consolidated financial statements. Comprehensive loss consists of net loss and foreign currency translation adjustments, affecting stockholders’ equity deficit that, under U.S, GAAP, is excluded from net loss.

Revenue Recognition

The Company recognizes revenue in accordance with the terms stipulated under the patient service contract. In various situations, the Company receives certain payments for DCVax®-L for patient treatment. These payments are assessed and recognized in accordance with ASC 606 in the period when the performance obligation has been met.

Accrued Outsourcing Costs

Substantial portions of our preclinical studies and clinical trials are performed by third-party laboratories, medical centers, contract research organizations and other vendors (collectively “CROs”). These CROs generally bill monthly or quarterly for services performed, or bill based upon milestones achieved. For clinical studies, expenses are accrued when services are performed. The Company monitors patient enrollment, the progress of clinical studies and related activities through internal reviews of data that is tracked by the CROs under contractual arrangements, correspondence with the CROs and visits to clinical sites.

Research and Development Costs

Research and development costs are charged to operations as incurred and consist primarily of clinical trial related costs (including costs for collection, validation and analysis of trial results), related party manufacturing costs, consulting costs, contract research and development costs, clinical site costs and compensation costs.

Income Taxes

The Company evaluates its tax positions and estimates its current tax exposure along with assessing temporary differences that result from different book to tax treatment of items not currently deductible for tax purposes. These differences result in deferred tax assets and liabilities on the Company’s Consolidated Balance Sheets, which are estimated based upon the difference between the financial statement and tax bases of assets and liabilities using the enacted tax rates that will be in effect when these differences reverse. In general, deferred tax assets represent future tax benefits to be received when certain expenses previously recognized in the Company’s Consolidated Statements of Comprehensive Loss become deductible expenses under applicable income tax laws or loss or credit carryforwards are utilized. Accordingly, realization of the Company’s deferred tax assets is dependent on future taxable income against which these deductions, losses and credits can be utilized.

The Company must assess the likelihood that the Company’s deferred tax assets will be recovered from future taxable income, and to the extent the Company believes that recovery is not more likely than not, the Company must establish a valuation allowance. Management judgment is required in determining the Company’s provision for income taxes, the Company’s deferred tax assets and liabilities and any valuation allowance recorded against the Company’s net deferred tax assets. Excluding foreign operations, the Company recorded a full valuation allowance at each balance sheet date presented because, based on the available evidence, the Company believes it is more likely than not that it will not be able to utilize all of its deferred tax assets in the future. The Company intends to maintain the full valuation allowance until sufficient evidence exists to support the reversal of the valuation allowance.

Stock Based Compensation

The Company measures stock-based compensation to employees, consultants, and Board members at fair value on the grant date of the award. Compensation cost is recognized as expense on a straight-line basis over the requisite service period of the award. For awards that have a performance condition, compensation cost is measured based on the fair value of the award on the grant date, the date performance targets are established, and is expensed over the requisite service period for each separately vesting tranche when achievement of the performance condition becomes probable. The Company assess the probability of the performance conditions being

met on a continuous basis. Forfeitures are recognized when they occur. Prior to January 1, 2019, share-based compensation cost for non-employees was re-measured at every reporting period.

The Company estimates the fair value of stock option grants that do not contain market-based vesting conditions using the Black-Scholes option pricing model and the assumptions used in calculating the fair value of stock-based awards represent management’s best estimates and involve inherent uncertainties and the application of management’s judgment.

Expected Term - The expected term of options represents the period that the Company’s stock-based awards are expected to be outstanding based on the simplified method, which is the half-life from vesting to the end of its contractual term.

Expected Volatility - The Company computes stock price volatility over expected terms based on its historical common stock trading prices.

Risk-Free Interest Rate - The Company bases the risk-free interest rate on the implied yield available on U. S. Treasury zero-coupon issues with an equivalent remaining term.

Expected Dividend - The Company has never declared or paid any cash dividends on its common shares and does not plan to pay cash dividends in the foreseeable future, and, therefore, uses an expected dividend yield of zero in its valuation models.

The Company is also required to make estimates as to the probability of achieving the specific performance conditions. If actual results are not consistent with the Company’s assumptions and judgments used in making these estimates, the Company may be required to increase or decrease compensation expense, which could be material to the Company’s consolidated results of operations.

Debt Extinguishment

The Company accounts for the income or loss from extinguishment of debt by comparing the difference between the reacquisition price and the net carrying amount of the debt being extinguished and recognizes this as gain or loss when the debt is extinguished. The gain or loss from debt extinguishment is recorded in the consolidated statements of operations under “other income (expense)” as loss from extinguishment of convertible debt.

Sequencing

The Company adopted a sequencing policy under ASC 815-40-35 whereby in the event that reclassification of contracts from equity to liabilities is necessary pursuant to ASC 815 due to the Company’s inability to demonstrate it has sufficient authorized shares. This was previously the result of certain financial instruments with a potentially indeterminable number of shares and most recently due to the company committing more shares than authorized. While temporary suspensions are in place to keep the potential exercises beneath the number authorized, certain instruments are classified as liabilities, after allocating available authorized shares on the basis of the earliest grant date of potentially dilutive instruments. Pursuant to ASC 815, issuance of stock based awards to the Company’s employees, nonemployees or directors are not subject to the sequencing policy.

Loss per Share

Basic loss per share is computed on the basis of the weighted average number of shares outstanding for the reporting period. Diluted loss per share is computed on the basis of the weighted average number of common shares plus dilutive potential common shares outstanding using the treasury stock method. Any potentially dilutive securities are anti-dilutive due to the Company’s net losses. For the years presented, there is no difference between the basic and diluted net loss per share.

Recent Accounting Standards

Income Taxes

In December 2019, the FASB issued ASU No. 2019-12, “Income Taxes (Topic 740): Simplifying the Accounting for Income Taxes (“ASU 2019-12”), which is intended to simplify various aspects related to accounting for income taxes. ASU 2019-12 removes certain

exceptions to the general principles in Topic 740 and also clarifies and amends existing guidance to improve consistent application. This guidance is effective for fiscal years, and interim periods within those fiscal years, beginning after December 15, 2020, with early adoption permitted. The Company is currently evaluating the impact of this standard on its consolidated financial statements and related disclosures.

Debt

In August 2020, the FASB issued ASU No. 2020-06, Debt—Debt with Conversion and Other Options (Subtopic 470-20) and Derivatives and Hedging—Contracts in Entity’s Own Equity (Subtopic 815-40): Accounting for Convertible Instruments and Contracts in an Entity’s Own Equity, which simplifies accounting for convertible instruments by removing major separation models required under current GAAP. The ASU removes certain settlement conditions that are required for equity contracts to qualify for the derivative scope exception and it also simplifies the diluted earnings per share calculation in certain areas. This ASU is effective for annual reporting periods beginning after December 15, 2021, including interim periods within those fiscal years. Early adoption is permitted, but no earlier than fiscal years beginning after December 15, 2020. This update permits the use of either the modified retrospective or fully retrospective method of transition. The Company is currently evaluating the impact this ASU will have on the its consolidated financial statements and related disclosures.

XML 30 R11.htm IDEA: XBRL DOCUMENT v3.21.1
Fair Value Measurements
12 Months Ended
Dec. 31, 2020
Fair Value Measurements  
Fair Value Measurements

4. Fair Value Measurements

In accordance with ASC 820 (Fair Value Measurements and Disclosures), the Company uses various inputs to measure the outstanding warrants, certain embedded conversion feature associated with convertible debt and contingent payable to Cognate BioServices on a recurring basis to determine the fair value of the liability.

Fair value measured at December 31, 2020

    

    

Quoted prices in active

    

Significant other

    

Significant

Fair value at

markets

observable inputs

unobservable inputs

December 31, 2020

(Level 1)

(Level 2)

(Level 3)

Warrant liability

$

354,972

$

$

$

354,972

Embedded conversion option

2,507

2,507

Contingent payable derivative liability

 

8,275

 

 

 

8,275

Total fair value

$

365,754

$

$

$

365,754

Fair value measured at December 31, 2019

    

    

Quoted prices in active

    

Significant other

    

Significant

Fair value at

markets

observable inputs

unobservable inputs

December 31, 2019

(Level 1)

(Level 2)

(Level 3)

Warrant liability

$

20,213

$

$

$

20,213

Contingent payable derivative liability

 

7,261

 

 

 

7,261

Total fair value

$

27,474

$

$

$

27,474

There were no transfers between Level 1, 2 or 3 during the years ended December 31, 2020 and 2019.

The following table presents changes in Level 3 liabilities measured at fair value for the years ended December 31, 2020 and 2019. Both observable and unobservable inputs were used to determine the fair value of positions that the Company has classified within the Level 3 category. Unrealized gains and losses associated with liabilities within the Level 3 category include changes in fair value that were attributable to both observable (e.g., changes in market interest rates) and unobservable (e.g., changes in unobservable long- dated volatilities) inputs (in thousands).

Contingent

Embedded

Payable

Warrant

Conversion

Derivative

    

Liability

    

Option

    

Liability

    

Total

Balance - January 1, 2019

$

29,995

$

357

$

$

30,352

Additional contingent liability in connection with a settlement agreement

6,602

6,602

Additional warrant liability

4,110

4,110

Extinguishment of derivative liabilities

(3)

(3)

Extinguishment of warrant liabilities related to warrants exercised for cash

(1,759)

(1,759)

Change in fair value

(12,133)

(354)

659

(11,828)

Balance - December 31, 2019

20,213

7,261

27,474

Additional warrant liability

18,864

18,864

Reclassification of warrant liabilities

(110,471)

(110,471)

Extinguishment of embedded conversion option due to debt conversion and debt repayment

(8,271)

(8,271)

Additional embedded conversion option

2,807

2,807

Change in fair value

426,366

7,971

1,014

435,351

Balance - December 31, 2020

$

354,972

$

2,507

$

8,275

$

365,754

A summary of the weighted average (in aggregate) significant unobservable inputs (Level 3 inputs) used in measuring the Company’s warrant liabilities and embedded conversion feature that are categorized within Level 3 of the fair value hierarchy as of December 31, 2020 and 2019 is as follows:

    

As of December 31, 2020

 

Warrant

Embedded

Contingent Payable

 

Liability

Conversion Option

Derivative Liability

 

Strike price

$

0.28

$

0.59

$

1.53

Contractual term (years)

 

1.6

 

0.9

 

1.4

Volatility (annual)

 

116

%  

 

106

%  

 

126

%

Risk-free rate

 

0.2

%  

 

0.1

%  

 

0.1

%

Dividend yield (per share)

 

0

%  

 

0

%  

 

0

%

As of December 31, 2019

 

    

Warrant

    

Contingent Payable

 

Liability

Derivative Liability

 

Strike price

$

0.21

$

0.21

Contractual term (years)

 

1.4

 

1.0

Volatility (annual)

 

74

%  

 

62

%  

Risk-free rate

 

2

%  

 

2

%  

Dividend yield (per share)

 

0

%  

 

0

%  

* contingent payable derivative liability based on stock price as of December 31, 2020 and December 31, 2019

XML 31 R12.htm IDEA: XBRL DOCUMENT v3.21.1
Flaskworks Acquisition
12 Months Ended
Dec. 31, 2020
Flaskworks Acquisition  
Flaskworks Acquisition

5. Flaskworks Acquisition

On August 28, 2020, the Company completed the acquisition of Flaskworks (the “Acquisition”), whereby Flaskworks became a wholly-owned subsidiary of the Company.

The Unit Purchase Agreement was executed and closed on August 28, 2020. The Company acquired 100% of the ownership units of Flaskworks. Flaskworks was previously owned by its technical founders and Corning Inc. The technical team from Flaskworks has joined the Company as part of the Acquisition. It is anticipated that the Flaskworks system will enable substantial scale-up of production volumes of DCVax products and substantial reduction of production costs. The Company’s buildout of the Sawston, UK facility has been designed to proceed in phases, as modules, both for efficiency in the timing of capital costs and to allow flexibility in operations and usage. The Company anticipates that implementation of the Flaskworks system will enable certain phases of the buildout to be simplified and streamlined.

The total purchase price was approximately $4.3 million, of which $1.7 million was paid in cash at closing, up to $2.01 million will be paid in stock subject to milestone-based vesting (see Note 6), and $0.7 million was paid in either cash or stock, or a combination thereof, within 120 days after the closing. Between October and December 2020, $0.5 million was paid in cash upon the seller’s election.

In addition to the $0.5 million cash payment, on December 25, 2020, upon the seller’s election, the Company issued 654,762 shares in equivalent of $0.2 million special consideration payment pursuant to the Unit Purchase Agreement. The $0.336 per share price was established by the Unit Purchase Agreement. The incremental change in fair value of the shares resulting from market price increase was approximately $0.9 million, which was recognized as a component of general and administrative expense in the consolidated statement of operations.

Based on the Company's preliminary valuation, the total estimated consideration of $2.1 million has been allocated to assets acquired and liabilities assumed as of the acquisition date as follows (amount in thousands):

Cash

    

$

146

Current assets

 

135

Fixed assets, net

 

188

Indefinite-lived intangible asset

 

1,292

Security deposits

 

8

Total assets acquired

 

1,769

Accounts payable

 

(12)

Accrued expenses

 

(240)

Total liabilities assumed

 

(252)

Net identifiable assets acquired

 

1,517

Goodwill

 

626

Total estimated consideration (1)

$

2,143

Less special consideration paid in cash and stock

$

(465)

Less cash acquired

 

(146)

Total consideration paid, net of cash acquired

$

1,532

(1)The purchase price allocation excludes $2.01 million stock consideration, which was recorded as stock-based compensation for accounting purposes, although the treatment for tax purposes is anticipated to be different (see Note 6), and $0.2 million payable for services not related to the Acquisition in either cash or stock within 120 days after the closing.

The Acquisition was accounted for under the acquisition method of accounting in accordance with US GAAP. As such, results of operations for Flaskworks are included in the accompanying consolidated statements of operations since the Acquisition date, and the assets acquired and liabilities assumed were recorded at their fair value as of the Acquisition date.

Accordingly, goodwill has been measured as the excess of the total consideration over the amounts assigned to the identifiable assets acquired and liabilities assumed. Based on the Company's preliminary valuation, the Company recorded goodwill of approximately $0.6 million, which was primarily related to the acquisition of the assembled workforce and other indefinite-lived intangible asset of approximate $1.3 million in connection with the Acquisition. The $0.6 million of goodwill is expected to be deductible for tax purposes.

The acquired Licensed IP Agreement was identified as an intangible asset and valued separate and apart from goodwill. Specifically, the Company used the Relief-from-Royalty Method, a form of the Income Approach, to estimate the fair value of the Licensed IP Agreement based on projected sales and cash flow. In application of the Relief-from-Royalty Method, we estimate the value of the Licensed IP Agreement by capitalizing the royalties saved because the Company owns the specific technology and the owner of the technology realizes a benefit from owning the intangible asset rather than paying a rent or royalty for the use of the asset.

The royalty rate used for this Licensed IP Agreement was based on the rate and terms indicated in the license agreement that was corroborated with the Company’s external research of third-party royalty rates for technology and patents in the pharma, healthcare, and medical industries. The estimation of fair value was determined based on the projected sales assuming commercialization of Flaskworks’ products and the respective royalty rate, tax affected and discounted to the present using a discount rate based on Flaskworks’ weighted average cost of capital.

The preliminary purchase price allocation is adjusted, as necessary, up to one year after the acquisition closing date if management obtains more information regarding asset valuations and liabilities assumed.

XML 32 R13.htm IDEA: XBRL DOCUMENT v3.21.1
Stock-based Compensation
12 Months Ended
Dec. 31, 2020
Stock-based Compensation  
Stock-based Compensation

6. Stock-based Compensation

The following table summarizes total stock-based compensation expense recognized for the years ended December 31, 2020 and 2019 (in thousands):

    

For the years ended

December 31,

 

2020

 

2019

Research and development

$

19,792

$

471

General and administrative (1)

 

32,163

 

1,350

Total stock-based compensation expense

$

51,955

$

1,821

(1)The general and administrative expense during the years ended December 31, 2020 and 2019 is related to the applicable vesting portion of stock options awards made in the past and new options granted during the year ended December 31, 2020 to directors, employees and external consultants.

The Black-Scholes option pricing model is used to estimate the fair value of stock options granted. The weighted average assumptions used in calculating the fair values of stock options that were granted during the years ended December 31, 2020 and 2019:

    

For the years ended

 

December 31,

 

Grant Date

2020

2019

 

Exercise price

$

0.26

$

0.20

Expected term (years)

 

5.2

 

5.6

Expected stock price volatility

 

98

%  

 

86

%

Risk-free rate of interest

 

0

%  

 

1

%

The total unrecognized compensation cost was approximately $17 million as of December 31, 2020, and will be recognized over the next 1.8 years.

Stock Options

Equity Compensation Plan

On May 29, 2020, the Board of Directors of the Company approved a new equity compensation plan (the “Plan”). The Company’s prior plan was adopted in 2007, was updated in amended and restated plans that were approved by shareholders in 2012 and 2013, and expired in 2017 (the “Prior Plan”).

The Plan is substantially similar to the Prior Plan. The Plan has a 10-year life, and allows for awards to employees, directors and consultants of the Company, as did the Prior Plan. The Plan allows for any type of equity security to be awarded, as did the Prior Plan. The awards and their terms (including vesting) will be determined by the Board and applicable Committees, as was the case under the Prior Plan. The Plan establishes a pool of potential equity compensation equal to twenty percent of the outstanding securities of the Company, which is on an evergreen basis as under the Prior Plan.

The following table summarizes stock option activity for the Company’s option plans during the years ended December 31, 2020 and 2019 (amount in thousands, except per share number):

    

    

    

Weighted

    

Average

Weighted

Remaining

Number of

Average Exercise

Contractual Life

Total Intrinsic

Shares

Price

(in years)

Value

Outstanding as of January 1, 2019

 

100,159

0.24

 

9.3

Granted

4,500

0.22

10.4

Outstanding as of December 31, 2019

104,659

$

0.24

8.4

$

Granted (Approved 2018-2020) (1)

208,525

0.37

(3)

10.0

Cashless exercise

 

(94)

 

0.34

 

Forfeited/expired

 

(4,250)

 

0.22

 

 

Outstanding as of December 31, 2020

 

308,840

$

0.33

 

8.9

$

372,219

Options vested (2)

 

223,720

$

0.30

 

8.7

$

276,432

(1)The options granted during the year ended December 31, 2020 included options already approved at various times during the 3 years 2018 - 2020 but not issued until Q3 2020, and also included options that will vest for performance and milestones going forward over the next 2 years. The options included awards to key external consultants and vendors in addition to internal parties.
(2)Approximately 128 million vested options as of December 31, 2020 are not exercisable until January 15, 2021. See Note 15 below under Subsequent Events for more information about additional options suspensions for further periods.
(3)The weighted average exercise price of the Q3 2020 options was initially $0.25. However, subsequently, the exercise price was amended to a weighted average exercise price of $0.36.

Stock Options Modification

On April 30, 2020, the Company's CEO, Linda Powers agreed to not exercise approximately 39.2 million existing options held by her for 6 months, until November 1, 2020 and correspondingly extended the contractual term for 6 months. The Company recognized approximately $78,000 of incremental stock-based compensation for this modification during the year ended December 31, 2020, based on the following weighted average assumptions:

    

Post Modification

    

Pre Modification

 

Exercise price

$

0.23

$

0.23

Expected term (years)

 

4.3

 

4.0

Expected stock price volatility

 

97

%

 

97

%

Risk-free rate of interest

 

0

%  

 

0

%

For another officer, on August 5, 2020, the Company cancelled 1.75 million options which were originally issued in December 2019 and issued 3 million options (the “Replacement Options”) with an exercise price of $0.22 and vesting of 1/3 immediately and the remaining 2/3 vesting ratably over the following 24 months from the grant date. The incremental stock-based compensation for this modification was approximately $0.3 million based on the following weighted average assumptions, which will be amortized over the new vesting terms.

    

Post Modification

    

Pre Modification

 

Exercise price

$

0.22

$

0.22

Expected term (years)

 

5.3

 

4.7

Expected stock price volatility

 

96

%  

 

97

%

Risk-free rate of interest

 

0

%  

 

0

%

Flaskworks Acquisition

On August 28, 2020, the Company entered into a Unit Purchase Agreement (the “Agreement”) to acquire Flaskworks. Included in the consideration pursuant to the Agreement was Stock Consideration in the amount of approximately $2 million. This Stock Consideration is issued in the form of Rights to receive such value in shares issued pursuant to and subject to the vesting criteria set forth in a Rights Issuance Agreement entered into in connection with the closing of Flaskworks Acquisition. Because the Rights were subject to future employment and performance conditions, the Stock Consideration was not included in consideration payable for the Flaskworks Acquisition but rather was recorded as contingent consideration payable to employees for accounting purposes. The Company anticipates that the treatment of this Stock Consideration for tax purposes may be different than for accounting purposes, and will reflect the fact that this Stock Consideration was payment for acquisition of the ownership interests of certain shareholders of Flaskworks.

On December 1, 2020, the Company issued 1.5 million shares of common stock based upon the Flaskworks team having completed a significant milestone, in accordance with the Rights Issuance Agreement entered on August 28, 2020. During the year ended December 31, 2020, the Company recognized approximately $1.0 million stock-based compensation related to the Flaskworks Acquisition. Approximate $0.5 million was recognized in general and administrative and $0.5 million was recognized in research and development.

XML 33 R14.htm IDEA: XBRL DOCUMENT v3.21.1
Property, Plant and Equipment
12 Months Ended
Dec. 31, 2020
Property, Plant and Equipment  
Property, Plant and Equipment

7. Property, Plant and Equipment

Property, plant and equipment consist of the following at December 31, 2020 and 2019 (in thousands):

    

December 31, 

    

December 31, 

    

Estimated

2020

2019

Useful Life

Leasehold improvements

$

81

$

186

 

Lesser of lease term or estimated useful life

Office furniture and equipment

 

219

 

59

 

3-5 years

Computer equipment and software

 

1,403

 

611

 

3-5 years

Land in the United Kingdom

93

90

NA

 

1,796

 

946

Less: accumulated depreciation

 

(756)

 

(665)

 

  

Total property, plant and equipment, net

$

1,040

$

281

 

  

Construction in progress

$

9,074

$

1,685

 

  

Depreciation expense was approximately $87,000 and $21,000 for the years ended December 31, 2020 and 2019, respectively.

Construction in Progress

In connection with the Company’s manufacturing facility in U.K, the Company has incurred and is incurring costs with certain vendors to design and build out certain stages of the facility. Additionally, the Company purchased certain manufacturing equipment that has been or will be installed in connection with the buildout. These costs were all capitalized and recorded as part of construction in progress as of December 31, 2020 and 2019. Upon completion of the buildout, all costs associated with the buildout will be recorded as manufacturing equipment or leasehold improvement, and amortized over the estimated useful life of the facility.

XML 34 R15.htm IDEA: XBRL DOCUMENT v3.21.1
Notes Payable
12 Months Ended
Dec. 31, 2020
Notes Payable  
Notes Payable

8. Notes Payable

The following two tables summarize outstanding debt as of December 31, 2020 and December 31, 2019, respectively (amount in thousands):

    

    

Stated

    

    

    

    

Embedded

    

Interest

Conversion

Remaining

Conversion

Carrying

Maturity Date

Rate

Price

Face Value

Debt Discount

Option

Value

Short term convertible notes payable

 

  

 

  

 

  

 

  

 

  

 

  

 

  

6% unsecured (1)

 

Due

 

6

%  

$

3.09

$

135

$

$

$

135

8% unsecured (3) (4)

 

4/30/2021

 

8

%  

$

0.85

 

2,125

 

(937)

 

2,507

 

3,695

2,260

(937)

2,507

3,830

Short term notes payable

 

  

 

  

 

  

 

  

 

  

 

  

 

  

8% unsecured (5)

 

Various

 

8

%  

 

N/A

 

1,785

 

(51)

 

 

1,734

10% unsecured (6)

 

Various

 

10

%  

 

N/A

 

263

 

 

 

263

12% unsecured (7)

 

On Demand

 

12

%  

 

N/A

 

440

 

 

 

440

 

2,488

 

(51)

 

 

2,437

Long term notes payable

 

  

 

  

 

  

 

  

 

  

 

  

 

  

8% unsecured (10)

 

Various

 

8

%  

 

N/A

 

7,160

 

(496)

 

 

6,664

6% secured (11)

 

3/25/2025

 

6

%  

 

N/A

 

1,843

 

 

 

1,843

 

9,003

 

(496)

 

 

8,507

Ending balance as of December 31, 2020

$

13,751

$

(1,484)

$

2,507

$

14,774

    

    

Stated

    

    

    

    

Interest

Conversion

Remaining

Carrying

Maturity Date

Rate

Price

Face Value

Debt Discount

Value

Short term convertible notes payable

 

  

 

  

 

  

 

  

 

  

 

  

6% unsecured (1)

 

Due

 

6

%  

$

3.09

$

135

$

$

135

10% unsecured (2)

 

4/18/2020

 

10

%  

$

0.22

 

500

 

(67)

 

433

 

635

(67)

 

568

Short term notes payable

 

  

 

  

 

  

 

  

 

  

 

  

8% unsecured (5)

 

Various

 

8

%  

 

N/A

 

555

 

(43)

 

512

10% unsecured (6)

 

Various

 

10

%  

 

N/A

 

3,551

 

(73)

 

3,478

12% unsecured (7)

 

On Demand

 

12

%  

 

N/A

 

440

 

 

440

0% unsecured (8)

 

8/1/2020

 

0

%  

 

N/A

 

1,156

 

(85)

 

1,071

 

5,702

 

(201)

 

 

5,501

Short term notes payable - related parties

 

  

 

  

 

  

 

  

 

  

 

  

10% unsecured - Related Parties (9)

 

On Demand

 

10

%  

 

N/A

 

66

 

 

66

 

66

 

 

 

66

Long term notes payable

 

  

 

  

 

  

 

  

 

  

 

  

8% unsecured (5)

 

Various

 

8

%  

 

N/A

 

7,008

 

(420)

 

6,588

 

7,008

 

(420)

 

 

6,588

Ending balance as of December 31, 2019

$

13,411

$

(688)

$

12,723

(1)This $135,000 note as of December 31, 2020 and 2019 consists of two separate 6% notes in the amounts of $110,000 and $25,000. In regard to the $110,000 note, the Company has made ongoing attempts to locate the creditor to repay or convert this note, but has been unable to locate the creditor to date. In regard to the $25,000 note, the holder has elected to convert these notes into equity, the Company has delivered the applicable conversion documents to the holder, and the Company is waiting for the holder to execute and return the documents.
(2)In February 2020, the Company entered into multiple one-year convertible notes (the “February Notes”) with multiple holders (the “Holders”) for an aggregate principal amount of $1.0 million. The Notes are convertible into common shares of the Company at $0.21 per share and bear interest at the rate of 10% per annum. Upon issuance of the February Notes, the Holders also received a 2-year warrant to purchase a total of 1.4 million common shares of the Company at an exercise price of $0.35 per share. The fair value of the warrants was approximately $79,000 on the grant date.

During the year ended December 31, 2020, the Company converted the entire February Notes, including $68,000 accrued interest into approximate 5.1 million shares of the Company's common stock.

In April 2020, the Company entered into a six-month convertible note (the “April Note”) with an individual investor (the “Holder”) with an aggregate principal amount of $0.8 million for cash proceeds of $0.7 million. The Company also incurred approximately $69,000 placement agent costs, including both a cash fee and the fair value of common stock warrants issued to the placement agent, which was recognized as additional debt discount.

The April Note bears interest at the rate of 10% per annum and is convertible into common shares of the Company at $0.17 per share plus a warrant to purchase a number of exercise shares equal to 50% of the number of common shares issued upon conversion (the “Conversion Warrants”). The Conversion Warrants will be exercisable until April 9, 2022 beginning on November 1, 2020, with an exercise price of $0.20 per share. The conversion option within the April Note is required to be bifurcated at fair value, which was approximately $0.4 million on the issuance date, resulting in additional debt discount to the April Note.

As consideration for entering into the April Note, the Company also agreed to amend the Holder’s existing outstanding warrants to purchase 5.1 million common shares of the Company. The exercise price of the warrants was amended from $0.25 per share to $0.20 per share. The incremental change in fair value resulting from the amendment was approximately $51,000, which was recognized as additional debt discount to the April Note.

On August 3, 2020, the Company converted approximately $0.8 million of outstanding principal and $26,000 of accrued interest of the April Note into approximately 5.1 million shares of common stock and 2.5 million warrants with fair value of approximately $2.4 million. The Company also extinguished $1.5 million embedded derivative liability and $0.2 million unamortized debt discount upon the conversion. The Company recorded approximately $0.3 million debt extinguishment loss.

In April 2020, the Company entered into a Note Amendment Agreement (the “Amendment”) with an individual holder of a short-term convertible note, primarily to agree on the following changes:

-Reclassed $75,000 accrued interest as of amendment date to the outstanding principal amount;
-Extended the maturity date of a convertible note with approximately $0.6 million of principal outstanding, as of the amendment date, to October 18, 2020 (the “Amended Note”);
-Reduced the conversion price from $0.22 to $0.181
-Issued a new 2-year warrant for up to 2.3 million shares of the Company’s common stock at an exercise price of $0.25 per share valued at $115,000 on the amendment date;

The amendment was recognized as a debt extinguishment, resulting in a loss on debt extinguishment of approximately $70,000.

During the year ended December 31, 2020, the Company converted the entire Amended Note of approximately $0.6 million, including $28,000 accrued interest into approximately 3.3 million shares of common stock.

(3)In May 2020, the Company entered into a six-month convertible note (the “May Note”) with an individual investor (the “Holder”) with an aggregate principal amount of $0.6 million. The May Note contains an original issue discount (“OID”) in the amount of $50,000.

The May Note bears interest at the rate of 8% per annum and is convertible into common shares of the Company at $0.25 plus a warrant to purchase a number of exercise shares equal to 40% of the number of common shares issued upon conversion (the “Conversion Warrants”). The Conversion Warrants will be exercisable until November 28, 2022 beginning on November 1, 2020 with exercise price of $0.25 per share. The conversion option within the May Note required bifurcation at fair value, which was approximately $0.5 million on the issuance date, resulting in additional debt discount to the May Note.

On October 1, 2020, the Company converted the entire $0.6 million of the May Note including $19,000 accrued interest, into approximately 2.3 million shares of the Company's common stock and 0.9 million warrants with fair value of approximate $3.4 million. The Company also extinguished $2.8 million embedded derivative liability upon the conversion.

In August 2020, the Company entered into another convertible note (the "August Note") with the same investor as the May Note (the "Holder") with an aggregate principal amount of $1.1 million. The August Note contains OID in the amount of $110,000.

The August Note bears interest at the rate of 8% per annum and is convertible into common shares of the Company at $0.345 plus a warrant to purchase a number of exercise shares equal to 35% of the number of common shares issued upon conversion (the "Conversion Warrants"). The Conversion Warrants will be exercisable until February 4, 2023 beginning on December 15, 2020 with exercise price of $0.34 per share. The conversion option within the August Note is required to be bifurcated at fair value, which was approximately $0.6 million on the issuance date, resulting in additional debt discount to the August Note.

On September 29, 2020, the Company converted entire $1.1 million of August Note into approximately 3.3 million shares of the Company's common stock and 1.1 million warrants with fair value of approximate $3.3 million. The Company also extinguished $2.3 million embedded derivative liability and $0.5 million unamortized debt discount upon the conversion. The company recorded approximately $0.4 million debt extinguishment loss.

(4)In October 2020, the Company entered into a convertible note (the "October Note") with the same investor as the August Note (the "Holder") with an aggregate principal amount of $2.1 million. The October Note contains OID in the amount of $200,000.

The October Note bears interest at the rate of 8% per annum and is convertible into common shares of the Company at $0.85 plus a warrant to purchase a number of exercise shares equal to 30% of the number of common shares issued upon conversion (the "Conversion Warrants"). The Conversion Warrants will be exercisable until January 12, 2022 beginning on January 15, 2021 with exercise price of $2.00 per share. The conversion option within the October Note is required to be bifurcated at fair value, which was approximately $1.4 million on the issuance date, resulting in additional debt discount of $1.4 million to the October Note.

(5)During the year ended December 31, 2020, the Company converted approximately $5.8 million of outstanding principal and $0.6 million of accrued interest into approximately 29.1 million shares of the Company’s common stock with a fair value of $7.6 million. The Company recognized approximately $1.2 million in debt extinguishment loss from this conversion.
(6)In May 2020, the Company converted approximately $0.3 million of outstanding principal and accrued interest into approximately 1.3 million shares of the Company’s common stock with a fair value of $0.5 million. The Company recognized approximately $0.2 million in debt extinguishment loss from this conversion.

In August 2020, the Company extinguished approximately $1.5 million of outstanding principal and accrued interest into approximately 4.8 million shares of the Company's common stock and 1.7 million warrants. The Company also modified certain existing warrants and issued additional 6.5 million warrants consideration for certain suspension. The Company also agreed to amend the remaining outstanding $1.5 million outstanding debt. The note became convertible at a conversion price of $0.34 (the “Amended August Note”). The amendment was accounted as debt extinguishment and the Company recognized approximately $1.6 million in debt extinguishment loss from this transaction.

During the year ended December 31, 2020, the Company made $0.1 million cash payment and converted approximate $1.4 million outstanding debt including $15,000 accrued interest into approximately 4.1 million shares of the Company’s common stock.

During the year ended December 31, 2020, the Company entered into multiple Note Extension Agreements with multiple holders, primarily resulting in the following changes:

-Extended the maturity dates of promissory notes with outstanding principal balances aggregating approximately $3.3 million for an additional 6 to 12 months from the original maturity date;
-Issued new 2-year warrants to purchase up to 10.3 million shares of the Company’s common stock at an exercise prices ranging from $0.20 and $0.23 per share valued at approximately $0.5 million on the amendment date;

The Note Extension Agreements for approximately $2.3 million of outstanding principal of promissory notes was recognized as a debt modification, while the amendments for approximately $1.0 million of outstanding principal of promissory notes was recognized as a debt extinguishment, resulting in a loss on extinguishment of debt of approximately $0.1 million.

(7)The $440,000 balance of outstanding principal as of December 31, 2020 and 2019 consists of two separate 12% demand notes in the amounts of $300,000 and $140,000.
(8)On May 28, 2019, the Company issued a deferred note to a third-party vendor pursuant to a settlement agreement resolving past matters and providing for the restart of DCVax®-Direct Production. During the year ended December 31, 2020, the Company made full repayment of $1.2 million to the note holder.
(9)On September 26, 2018, Advent BioServices (“Advent”), a related party of the Company, provided a short-term loan in the amount of $65,000. The loan bore interest at 10% per annum, and is payable upon demand, with 7 days’ prior written notice to the Company. During the year ended December 31, 2020, the Company made full repayment to Advent, including all outstanding interest.

Between February and May 2020, the Company entered into multiple demand loan agreements with Leslie Goldman, the Company’s Senior Vice President, General Counsel, for an aggregate principal amount of $0.3 million (the “Goldman Notes”). The Goldman Notes bear interest rate at 10% per annum, and are repayable upon 15 days' notice from Mr. Goldman.

The Goldman Notes are convertible into common shares of the Company at conversion prices ranging from $0.23 to $0.25 per share. Additionally, the Company agreed to issue warrants to Mr. Goldman to purchase 0.6 million shares of the Company’s common stock (the “Initial Warrants”) in conjunction with the Goldman Notes. The Initial Warrants have a five - year term and are exercisable at prices ranging from $0.23 and $0.25 per share. The fair value of the Initial Warrants was approximately $66,000, which was recognized as debt discount to the Goldman Notes at the issuance date. The conversion option within the Goldman Notes were required to be bifurcated at fair value, which was approximately $36,000 on the issuance date, resulting in additional debt discount to the Goldman Notes.

Upon conversion, Mr. Goldman would also receive a five-year term warrant to purchase a number of the Company’s common shares equal to 50% of the number of common shares issued upon conversion of the Goldman Notes (the “Conversion Warrants”). The Conversion Warrants will be exercisable at $0.25 per share.

During the year ended December 31, 2020, the Company made full repayment of $0.3 million to Mr. Goldman, including all outstanding interest. Upon the repayment, the Company also extinguished $1.6 million embedded derivative liability, which was recorded as debt extinguishment gain.

(10)During the year ended December 31, 2020, the Company entered into two note purchase agreements (the “Notes”) with same investor for an aggregate principal amount of approximate $7.2 million. The Notes bear interest at 8% per annum with 21-month term. There are no repayments during the first 7 months of the term. The Notes are amortized in 14 installments starting in month 8. The Notes carry an original issue discount of $650,000 and $10,000 legal costs that were reimbursable to the investor.
(11)Cambridge Loan

On March 26, 2020, the Company entered into a Loan Agreement (the “Loan Agreement”) with Cambridge & Peterborough Combined Authority (the “Lender”) for a loan of £1.35 million (approximately $1.7 million) (the “Loan”) for the current phase of buildout of the Sawston facility. The Company received funds on April 6, 2020. The Lender provides funding for selected economic development projects in the Cambridge region through a competitive selection process.

Under the Loan Agreement, there will be no repayments during the first year of the Loan term, although interest will accrue. Following the first anniversary, repayment of the Loan principal and interest will take place over 4 years, for a total term of 5 years.  The interest rate on the Loan is 6.25% per annum.

In conjunction with the Loan, the Company agreed to enter into a Security Agreement with the Lender under which the Company granted a security interest in the Company’s 17-acre property in Sawston, U.K. to secure the Loan.  No other tangible or intangible assets of the Company or its subsidiaries are subject to any security interest. Such security interest on the 17-acre property will be released upon completion of repayment

PPP Loan

The Company received a loan under the Coronavirus Aid, Relief and Economic Security (“CARES”) Act’s Paycheck Protection Program (“PPP”). The PPP loan was received on May 20, 2020 in the amount of $0.4 million. The current terms of the PPP loan is two years with a maturity date of May 20, 2022 and it contains a favorable fixed annual interest rate of 1.00%. Payments of principal and interest on the PPP Loan are deferred for the first six months of the term of the PPP Loan until November 20, 2020. The Company used the loan to make payments for payroll, health and disability insurance and rent.

The Company submitted a PPP loan forgiveness application to the Lender on October 26, 2020, with the amount which may be forgiven equal to the sum of qualifying expenses, including payroll costs, covered rent obligations, and covered utility payments incurred by the Company during the twenty-four week period beginning on May 20, 2020, calculated in accordance with the terms of the CARES Act. The forgiveness application was approved on December 7, 2020. The Company recorded approximate $0.4 million debt extinguishment gain from the forgiveness of PPP Loan.

The following table summarizes total interest expenses related to outstanding debt for the years ended December 31, 2020 and 2019, respectively (in thousands):

For the year ended

December 31, 

    

2020

    

2019

Interest expenses related to outstanding notes:

  

 

  

Contractual interest

$

1,231

$

1,168

Amortization of debt discount

 

2,891

 

1,430

Total interest expenses related to outstanding notes

 

4,122

 

2,598

Interest expenses related to outstanding notes to related parties:

 

 

Contractual interest

 

20

 

366

Amortization of debt discount

 

122

 

Total interest expenses related to outstanding notes to related parties

 

142

 

366

Interest expenses related to forbearance of debt to related parties

4,270

Other interest expenses

 

10

 

11

Total interest expense

$

8,544

$

2,975

The following table summarizes the principal amounts of the Company’s debt obligations as of December 31, 2020 (amount in thousands):

Payment Due by Period

Less than

1 to 2

3 to 5

    

Total

    

1 Year

    

Years

    

Years

Short term convertible notes payable

6% unsecured

$

135

$

135

$

$

8% unsecured

2,125

2,125

Short term notes payable

8% unsecured

1,785

1,785

10% unsecured

263

263

12% unsecured

440

440

Long term notes payable

8% unsecured

7,160

7,160

6% secured

1,843

1,843

Total

$

13,751

$

4,748

$

7,160

$

1,843

XML 35 R16.htm IDEA: XBRL DOCUMENT v3.21.1
Net Loss per Share Applicable to Common Stockholders
12 Months Ended
Dec. 31, 2020
Net Loss per Share Applicable to Common Stockholders  
Net Loss per Share Applicable to Common Stockholders

9. Net Loss per Share Applicable to Common Stockholders

Basic loss per common share is computed by dividing net loss by the weighted average number of common shares outstanding during the reporting period. Diluted loss per common share is computed similar to basic loss per common share except that it reflects the potential dilution that could occur if dilutive securities or other obligations to issue common stock were exercised or converted into common stock.

The following securities were not included in the diluted net loss per share calculation because their effect was anti-dilutive as of the periods presented (in thousands):

For the year ended

December 31, 

    

2020

    

2019

Common stock options

 

308,840

 

104,659

Common stock warrants

 

328,979

 

347,734

Contingently issuable warrants

 

2,774

 

11,739

Convertible notes and accrued interest

 

2,617

 

2,617

Potentially dilutive securities

 

643,210

 

466,749

XML 36 R17.htm IDEA: XBRL DOCUMENT v3.21.1
Related Party Transactions
12 Months Ended
Dec. 31, 2020
Related Party Transactions  
Related Party Transactions

10. Related Party Transactions

Advent BioServices Agreement

The Company has a Manufacturing Services Agreement with Advent BioServices for manufacture of DCVax-L products at an existing facility in London, as previously reported. The Company also has an Ancillary Services Agreement with Advent, which establishes a structure under which Advent will submit Statements of Work (“SOWs”) for activities related to the development of the Sawston facility and the compassionate use activities in the UK, as previously reported. The Ancillary Services Agreement had an original term of 8 months, which ended in July 2020. The Company extended the term by 12 months, and did not make any other changes.

Related Party Expenses and Accounts Payable

The following table summarizes expenses incurred to related parties (i.e., amounts invoiced) during the year ended December 31, 2020 and 2019 (amount in thousands) (some of which were for previous periods’ services and remain unpaid as noted in the second table below):

For the year ended

December 31, 

2020

    

2019

(As revised) (Note 14)

Advent BioServices

$

7,543

 

$

5,735

During the years ended December 31, 2020 and 2019, the Company capitalized $3.6 million and $0.9 million costs related to Sawston buildout in addition to the costs disclosed in the above table.

The following table summarizes outstanding unpaid accounts payable and the accrued amount under the SOWs relating to the Sawston Facility and the compassionate use programs held by related parties as of December 31, 2020 and outstanding unpaid accounts payable

as of December 31, 2019 (amount in thousands). These unpaid amounts include part of the expenses reported in the table above and also certain expenses incurred in prior periods.

    

December 31, 2020

    

December 31, 2019

(As revised) (Note 14)

Advent BioServices – amount invoiced

$

3,734

$

834

Advent BioServices – amount accrued

1,629

3,002

Accounts payable and accrued expenses to Advent BioServices

$

5,363

$

3,836

Related Parties Loans

Linda F. Powers - Demand Loans

Between February 2018 and April 2018, the Company’s Chief Executive Officer, Linda Powers, loaned the Company aggregate funding of $5.4 million pursuant to convertible Notes. The Notes were 15-day demand notes, for loans provided as short-term bridge loans. However, repayment was not completed for nearly 1-1/2 years.

During the year ended December 31, 2019, the Company repaid the $5.4 million principal and approximately $0.8 million interest.

Loan from Advent BioServices

Advent BioServices provided a short-term loan to the Company in the amount of $65,000 on September 26, 2018. The loan bore interest at 10% per annum, and is payable upon demand, with 7 days’ prior written notice to the Company.

During the year ended December 31, 2020, the Company made full repayment of $73,000 to Advent, including all outstanding interest.

Loan from Leslie Goldman

During the year ended December 31, 2020, the Company's Senior Vice President, General Counsel, Leslie Goldman, loaned the Company $315,000 pursuant to various convertible notes (the “Notes”). The Notes bore interest rate at 10% per annum and fifty percent warrant coverage, and are repayable upon 15 days' notice from the holder. The Notes were convertible, in whole or in part, into stock together with warrants.

During the year ended December 31, 2020, the Company made full repayment of $0.3 million to Mr. Goldman, including all outstanding interest.

Warrants issued to Linda Powers

On July 2, 2020, the Company issued approximately 15.2 million warrants (the "Forbearance Warrants") to Ms. Powers in consideration for Ms. Powers' previously reported forbearance and extension of loans of $5.4 million from Ms. Powers to the Company. These warrants were approved by the Board in November 2018 when the loans were long overdue, as previously reported, and the warrants were re-approved in January 2020, but were not issued until July 2, 2020.

The Forbearance Warrants have an exercise price of $0.21 per share with 5-year contractual term. The fair value of the Forbearance Warrants was approximately $4.3 million on the grant date, which was recognized as an additional interest expense.

The following table summarizes total interest expenses related to outstanding notes to related parties for the three months and nine months ended December 31, 2020 and 2019, respectively (in thousands):

For the year ended

December 31, 2020

    

2020

    

2019

Interest expenses related to outstanding notes to related parties:

 

  

 

  

Contractual interest

$

20

$

366

Amortization of debt discount

 

122

 

Interest expenses related to forbearance of debt to related parties

4,270

Total interest expense

$

4,412

$

366

XML 37 R18.htm IDEA: XBRL DOCUMENT v3.21.1
Stockholders' Deficit
12 Months Ended
Dec. 31, 2020
Stockholders' Deficit  
Stockholders' Deficit

11. Stockholders’ Deficit

2020 Activities

Registered Direct Offering

Between January and February 2020, the Company issued an aggregate of 34.5 million shares of its common stock in a registered direct offering (the “Offering”). The net proceeds from the Offering were approximately $5.7 million, after deducting offering costs of $0.4 million paid by the Company.

In connection with the Offering, the Company also issued approximately 8.5 million 2-year term warrants with an exercise price of $0.25 per share to the investors and approximately 0.8 million 2-year term warrants with an exercise price between $0.17 and $0.21 per share to placement agent in this direct offering. The fair value of these new issued warrants was approximately $1.0 million. Additionally, the Company agreed to extend by twelve months the maturity date of certain existing warrants already held by some of those investors. The Company recorded an incremental change of approximately $2.5 million on the fair value of warrants due to the modifications, which was recorded as part of offering cost during the year ended December 31, 2020.

During April 2020, the Company issued an aggregate of 19.9 million shares of its common stock and 11.3 million new issued warrants in a registered direct offering (the "April Financing"). The common stock was offered at a price of $0.153 per share. The warrants are exercisable at $0.20 per share. The net proceeds from the April Financing were approximately $3.0 million, after deducting offering costs of $68,000 paid by the Company. An approximate $0.8 million of proceeds were allocated to warrant liabilities.

During May 2020, the Company issued an aggregate 14.2 million shares of its common stock and 5.6 million new issued warrants in a registered direct offering (the "May Financing"). The common stock was offered at a price between $0.17 and $0.225 per share. The warrants have an exercise price between $0.22 and $0.23 per share and an exercise period between 1.5-2.5 years. The Company received approximately $2.9 million from the May Financing. An approximate $0.9 million of proceeds were allocated to warrant liabilities.

All of the warrants issued in the May Financings were not exercisable until November 1, 2020. In addition, as part of these agreements, the investors who have existing outstanding warrants that had not already been suspended until November 1, suspended approximately 14.6 million existing warrants until November 1, 2020.

On August 5, 2020, the Company entered into financings totaling approximately $8 million (the "August Financing"). The financings were comprised of:

Approximately $7 million from an offering at $0.32 per share of newly registered common stock of approximately 21.8 million shares with 20-35% warrants coverage. The warrants are exercisable at $0.34 per share for approximately 5.3 million shares, with an exercise period of 18 to 30 months. The fair value of these 5.3 million warrants was approximately $1.5 million.
$1 million from a convertible note (the "August Note") which is convertible at $0.345 per share. The August Note carries no warrants unless it is converted. If, and only to the extent, the note is converted it will carry 35% warrants exercisable at $0.34 per share.
All of the new warrants issued in the August Financing were suspended until December 15, 2020.
In addition, as part of these agreements, the investors who have existing outstanding warrants that had not yet been suspended, suspended approximately 75.5 million additional existing warrant exercise shares until December 15, 2020. In consideration for the suspension of the 75.5 million existing warrant shares as part of the August Financing, the Company issued approximately 12.5 million warrants with an exercise price of $0.34 per share and an exercise period ranging from approximately 13.5 to 25.5 months following the termination of the suspensions. These suspension consideration warrants were also suspended until the same December date.
Only the common stock sold directly or underlying the warrants and convertible note were registered in this transaction.

On October 12, 2020, the Company entered into financings totaling approximately $11.9 million (the “Offering”). The financings were comprised of:

Approximately $10 million from an offering at $0.816 per share (based upon the average 10 day closing price ending on October 12, 2020) of newly registered common stock of approximately 12.2 million shares with 30% warrants coverage. The warrants are exercisable at an exercise price of $2.00 per share for approximately 3.6 million shares, with an exercise period of 12 months (following a 3-month suspension after issuance). The fair value of these 3.6 million warrants was approximately $1.2 million.
Approximately $1.9 million from a convertible note which is convertible at $0.85 per share (the “Note”). The Note carries no warrants unless it is converted. If, and only to the extent, the Note is converted it will carry 30% warrants with an exercise price of $2.00 per share and an exercise period of 12 months (following a 3-month suspension after issuance).
All of the new warrants issued in the Offering are suspended until January 15, 2021.

In addition, as part of these agreements, certain investors who have existing outstanding warrants that have not yet been suspended are now suspending approximately 3.5 million additional existing warrant exercise shares until January 15, 2021.

In consideration for the suspension of the 3.5 million existing warrant shares as part of the Offering, the Company issued approximately 261,000 warrants with an exercise price of $2.00 per share and an exercise period of 12 months (following a 3-month suspension after issuance). These suspension consideration warrants are also suspended until the same January date.

Warrants Exercised for Cash

During the year ended December 31, 2020, the Company issued 47.5 million shares of its common stock from warrants exercised for cash. The Company received $13.9 million in cash.

Cashless Warrants Exercise

During the year ended December 31, 2020, The Company issued approximately 7.1 million shares of common stock upon 8.6 million warrant cashless exercises with weighted average exercise price of $0.22.

Debt Conversion

During the year ended December 31, 2020, the Company converted approximately $13.9 million outstanding debt and interest into 58.4 million shares of common stock and 6.2 million warrants, see Note 8 for further details.

Flaskworks Shares Issuance

On December 1, 2020, the Company issued 1.5 million shares of common stock based upon the Flaskworks team having completed a significant milestone, in accordance with the Rights Issuance Agreement entered on August 28, 2020.

On December 25, 2020, upon the seller’s election, the Company issued 0.7 million shares in equivalent of $0.2 million special consideration payment pursuant to the Unit Purchase Agreement. The $0.336 per share price was established by the Unit Purchase Agreement. The incremental change in fair value of the shares resulting from market price increase was approximately $0.9 million, which was recognized as additional general and administrative expense on the consolidated statement of operations.

2019 Activities

Registered Direct Offering

During the year ended December 31, 2019, the Company issued an aggregate of 32.7 million shares of its common stock at a purchase price between $0.19 and $0.23 per share to certain institutional investors in multiple registered direct offerings (the “Offering”). Included with the Offering were 1.3 million shares of common stock which were issued from the conversion of an existing loan and the related accrued interest totaling $306,000. The net proceeds from the Offering were approximately $6.9 million, after deducting offering costs of $0.3 million paid by the Company.

In connection with the Offering, the Company did not issue any additional warrants for the new investment by the investors, but the Company, in effect, agreed to modify certain existing warrants already held by some of those investors. The Company extended the expiration date for additional 12 to 18 months after the original expiration date and the weighted average exercise price of warrants was reduced by an amount ranging from 2 to 8 cents as well. The Company recorded an incremental change of $2.5 million on the fair value of warrants due to the modification and recorded it as part of offering cost during the year ended December 31, 2019.

Debt Conversion

During the year ended December 31, 2019, the Company converted debt of approximately $6.8 million of principal and $0.7 million of accrued interest into approximately 35.5 million shares of the Company’s common stock at a fair value of $9.2 million. The Company recorded approximately $1.7 million of debt extinguishment loss from the conversion.

Warrants Exercised for Cash

During the year ended December 31, 2019, the Company issued 9.5 million shares of its common stock from warrants exercised for cash. The Company received $2.2 million in cash.

Shares Settlement

On May 28, 2019, the Company entered into a settlement agreement with Cognate BioServices, resolving past matters and providing for the restart of DCVax®-Direct Production (see Note 8).

As part of the settlement agreement, the number of shares of the Company’s common stock which the Company was to issue to Cognate was substantially reduced: 52 million shares of the Company’s common stock which the Company had previously agreed to issue to Cognate were reduced to 12 million shares. The Company considers the reduction in shares owed to Cognate a modification. Because the 52 million shares were never issued and the modification, which resulted in a decrease in fair value, is not a forfeiture, previously recognized expense related to services performed by Cognate is not reversed in connection with this modification. During the year ended December 31, 2019, the Company recorded $12,000 in its common stock par and reduced same amount in additional paid-in capital.

Stock Purchase Warrants

The following is a summary of warrant activity for the years ended December 31, 2020 and 2019 (dollars in thousands, except per share data):

    

Number of

    

Weighted Average

    

Remaining

Warrants

Exercise Price

Contractual Term

Outstanding as of January 1, 2019

 

372,153

$

0.29

 

1.97

Warrants granted

 

8,067

 

0.23

 

  

Warrants exercised for cash

 

(9,532)

 

0.23

 

  

Warrants expired and cancelled

 

(11,215)

 

0.62

 

  

Outstanding as of December 31, 2019

 

359,473

$

0.27

 

1.42

Warrants granted

88,658

0.22

Contingently issuable warrants (1)

 

2,774

 

1.48

 

  

Warrants exercised for cash

 

(47,511)

 

0.29

 

  

Cashless warrants exercise

(8,631)

0.22

Warrants expired and cancelled

 

(63,010)

 

0.32

 

  

Outstanding as of December 31, 2020 (2)

 

331,753

$

0.28

 

1.61

(1)The approximately 2.8 million warrants represent compensation warrants to be issued to the Company’s CEO, Linda Powers, in accordance with her warrants and options suspension agreement dated November 1, 2020.
(2)As of December 31, 2020, approximately 62.1 million warrants were not exercisable until January 15, 2021. Subsequent to January 15, 2021, the Company suspended 58.8 million warrants until February 28, 2021.

As of December 31, 2020, approximately 272.8 million warrants were treated as liability warrants due to the sequencing policy (see note 3).

Warrant Adjustments

Between April and August 2020, the Company undertook negotiations related to certain warrant adjustments, including suspending certain outstanding warrants, making them unexercisable for a defined period, and suspending extensions of the warrants during that period.

As previously reported, on May 10, 2020, for a number of unrelated warrant holders, the Company agreed to issue 17.5% new warrants and extend the investors' current warrant terms by six months, in consideration of the investor's suspension of the current and newly issued warrants until November 1, 2020. The unrelated investors suspended warrants for the purchase of approximately 81 million shares of the Company’s common stock. The Company agreed to issue new warrants to purchase 14.2 million shares of the Company’s common stock to these investors under the suspension agreements, and these additional warrants were also suspended until November 1, 2020.

On August 5, 2020, the investors who had existing outstanding warrants, that had not yet been suspended, suspended approximately 75.5 million additional existing warrant exercise shares until December 15, 2020. In consideration for the suspension of the 75.5 million existing warrant shares as part of the August Financing, the Company issued approximately 12.5 million warrants with an exercise price of $0.34 per share and an exercise period ranging from approximately 13.5 to 25.5 months following the termination of the suspensions. These suspension consideration warrants were also suspended until December 15, 2020.

On April 30, 2020, the Company entered into an agreement with its CEO, Linda Powers, in regard to approximately 90 million warrants and options held by Ms. Powers. She agreed to suspend approximately 60 million existing warrants and options held or due to her until November 1, 2020, making them unexercisable during this period. In consideration, the Company extended the exercise period of a separate 29 million existing warrants held by Ms. Powers (not part of the 60 million warrants and options), and Ms. Powers also agreed to suspend those 29 million warrants until November 1, 2020. The extension of the 29 million warrants provides an exercise period of 2-1/2 years after the suspension period.

On October 31, 2020, the Company further extended the suspension of approximately 157 million of those 171 million warrants and options through December 15, 2020. Furthermore, other holders agreed to new suspensions of approximately 21 million additional warrants (in addition to the 157 million suspended) through December 15, 2020, making for a total of approximately 178 million suspensions through December 15, 2020.

Still another 96 million warrants (beyond the 178 million described above) were also suspended earlier in connection with other new share purchases. Consequently, a total of approximately 274 million warrants and options were suspended through December 15, 2020.

On December 15, 2020, the Company further extended the suspension of approximately 183 million warrants and options held by the Company’s certain officers and board of directors until January 15, 2021. Total warrants and options suspended until January 15, 2021 were approximately 190 million. See Note 15 below under Subsequent Events for more information about additional suspensions of warrants and options suspensions for further periods.

XML 38 R19.htm IDEA: XBRL DOCUMENT v3.21.1
Commitments and Contingencies
12 Months Ended
Dec. 31, 2020
Commitments and Contingencies.  
Commitments and Contingencies

12. Commitments and Contingencies

Operating Lease

The Company adopted ASC Topic 842 - Leases as of January 1, 2019, using the transition method per ASU No. 2018-11 issued on July 2018 wherein entities were allowed to initially apply the new leases standard at adoption date and recognize a cumulative-effect adjustment to the opening balance of retained earnings in the period of adoption. Accordingly, all periods prior to January 1, 2019 were presented in accordance with the previous ASC Topic 840, Leases, and no retrospective adjustments were made to the comparative periods presented. Adoption of ASC 842 resulted in an increase to total assets and liabilities due to the recording of operating lease right-of-use assets ("ROU") and operating lease liabilities of approximately $4.3 million, as of January 1, 2019.  On March 4, 2019, the Company recognized additional $0.6 million ROU and lease liabilities to its amended office lease in the U.S. The adoption did not materially impact the Company’s consolidated statements of operations or cash flows.

The Company has operating leases for corporate offices in the U.S., U.K., Germany and the Netherlands, and for manufacturing facilities in the U.K. Leases with an initial term of 12 months or less are not recorded in the balance sheet. The Company has elected the practical expedient to account for each separate lease component of a contract and its associated non-lease components as a single lease component, thus causing all fixed payments to be capitalized. The Company also elected the package of practical expedients permitted within the new standard, which among other things, allows the Company to carry forward historical lease classification. The renewal options have not been included in the calculation of the lease liabilities and ROU as the Company is not reasonably certain to exercise the options. Variable lease payment amounts that cannot be determined at the commencement of the lease such as increases in lease payments based on changes in index rates or usage, are not included in the ROU assets or liabilities. These are expensed as incurred and recorded as variable lease expense.

At December 31, 2020, the Company had operating lease liabilities of approximately $5.1 million for both the 20-year lease of the building for the manufacturing facility in Sawston, U.K., and the current office lease in the U.S. and ROU of approximately $4.5 million for the Sawston lease and US office lease, which were included in the consolidated balance sheet.

The following summarizes quantitative information about the Company’s operating leases (amount in thousands):

For the Year ended

December 31, 2020

    

U.K

    

U.S

    

Total

Lease cost

Operating lease cost

$

610

$

330

$

940

Short-term lease cost

44

44

Variable lease cost

45

20

65

Total

$

699

$

350

$

1,049

Other information

Operating cash flows from operating leases

$

(661)

$

(332)

$

(993)

Weighted-average remaining lease term - operating leases

9.1

0.2

Weighted-average discount rate - operating leases

12

%

12

%

For the Year ended

December 31, 2019

    

U.K

    

U.S

    

Total

Lease cost

 

  

 

  

 

  

Operating lease cost

$

607

$

247

$

854

Short-term lease cost

 

50

 

81

 

131

Variable lease cost

 

 

15

 

15

Total

$

657

$

343

$

1,000

Other information

 

 

 

Operating cash flows from operating leases

$

$

(244)

$

(244)

Weighted-average remaining lease term – operating leases

 

10.0

 

0.9

 

  

Weighted-average discount rate – operating leases

 

12

%  

 

12

%  

 

  

The Company recorded lease costs as a component of general and administrative expense during the years ended December 31, 2020 and 2019.

Maturities of our operating leases, excluding short-term leases, are as follows:

    

U.K

    

U.S

    

Total

Year ended December 31, 2021

$

644

$

84

$

728

Year ended December 31, 2022

644

644

Year ended December 31, 2023

644

644

Year ended December 31, 2024

644

644

Thereafter

8,990

8,990

Total

11,566

84

11,650

Less present value discount

(6,565)

(2)

(6,567)

Operating lease liabilities included in the Consolidated Balance Sheet at December 31, 2020

$

5,001

$

82

$

5,083

Manufacturing Services Agreements

The Company has a manufacturing services agreement with Advent BioServices in the U.K.

Advent BioServices

On May 14, 2018, the Company entered into a DCVax®-L Manufacturing and Services Agreement (“MSA”) with Advent BioServices, a related party which was formerly part of Cognate BioServices and was spun off separately as part of an institutional financing of Cognate. The Advent Agreement provides for manufacturing of DCVax-L products at an existing facility in London. The Agreement is structured in the same manner as the Company’s prior agreements with Cognate BioServices. The Advent Agreement provides for a program initiation payment of approximately $1.0 million (which was fully paid in 2018), in connection with technology transfer and operations to the U.K. from Germany, development of new Standard Operating Procedures (SOPs) for the London facility, selection of new suppliers and auditing for GMP compliance, and other preparatory activities. The Advent Agreement provides for certain payments for achievement of milestones and, as was the case under the prior agreement with Cognate BioServices, the Company is required to pay certain fees for dedicated production capacity reserved exclusively for DCVax production, and pay for manufacturing of DCVax-L products for a certain minimum number of patients, whether or not the Company fully utilizes the dedicated capacity and number of patients. Either party may terminate the MSA on twelve months’ notice, to allow for transition arrangements by both parties.

On November 8, 2019, the Company and Advent entered into an Ancillary Services Agreement with an 8-month Term for U.K. Facility Development Activities and Compassionate Use Program Activities. The Ancillary Services Agreement establishes a structure under which Advent will develop Statements of Work (“SOWs”) for each portion of the U.K. Facility Development Activities and Compassionate Use Program Activities, and will deliver those SOWs to the Company for review and approval. After an SOW is approved by the Company, Advent will proceed with or continue the applicable services and will invoice the Company pursuant to the SOW. Since both the U.K. Facility Development and the Compassionate Use Program involve pioneering and uncertainties in most aspects, the invoicing under the Ancillary Services Agreement is on the basis of costs incurred plus fifteen percent. The Ancillary Services Agreement had an original term of 8 months, which ended in July 2020. The Company extended the term by 12 months, and did not make any other changes.

German Tax Matter

The German tax authorities have audited our wholly owned subsidiary, NW Bio GmbH, for 2013-2015. During those years, NWBio, Inc. sent funds to NWBio GmbH to pay for operating expenses and costs associated with the Phase III clinical trial. The German tax authorities have asserted that the subsidiary should have charged NWBio parent company a  profit margin on top of these costs, that they will deem that such a profit margin was charged by the subsidiary (even though it was not) and that they will tax this deemed profit margin, although neither NW Bio, Inc. nor NW Bio GmbH made any profit during the period in question (or at any other time), and even though the funds provided by NW Bio, Inc. were used by NW Bio GmbH entirely for operating expenses and clinical trial costs.   They have also made claims for other taxes including penalties and interest.

In July, NW Bio GmbH submitted substantial documentation to refute the assessments of the German tax authorities.  The authorities responded in December that they were open to settlement negotiations.

On February 12, 2021, the German tax authorities agreed in principle with the Company’s settlement offer. The Company has accrued for the Company approved tax settlement offer of €351,000 (approximately $421,000 as of December 31, 2020) for the years under audit, with an addition of €156,000 (approximately $187,000) for the more recent years to date.  Penalties and interest are still under negotiation. After considering further negotiations, under its evaluation under ASC 740, it is the view of the Company currently that it is not more likely than not that the resolution of these tax matters will ultimately result in a net material charge to the Company.

XML 39 R20.htm IDEA: XBRL DOCUMENT v3.21.1
Income Taxes
12 Months Ended
Dec. 31, 2020
Income Taxes  
Income Taxes

13. Income Taxes

No provision was made for U.S. taxes on undistributed foreign earning as such earnings are considered to be permanently reinvested. It is not practicable to determine the amount of additional tax, if any that might be payable on those earnings if repatriated.

The tax effects of temporary differences and tax loss and credit carry forwards that give rise to significant portions of deferred tax assets and liabilities at December 31, 2020 and 2019 are comprised of the following (in thousands):

    

As of December 31, 2020

    

As of December 31, 2019

Deferred tax asset

 

  

 

  

Net operating loss carryforward

$

185,308

$

176,140

Research and development credit carry forwards

 

18,580

 

16,983

Stock based compensation and other

 

22,997

 

14,565

Total deferred tax assets

 

226,885

 

207,688

Valuation Allowance

 

(226,885)

 

(207,688)

Deferred tax asset, net of allowance

$

$

The Company has identified the United States, Maryland, Germany and United Kingdom as significant tax jurisdictions.

The Company’s U.S. net operating loss (“NOL”) carryforwards for tax purposes as of December 31, 2020, are approximately $654.5 million. Unused NOL carryforwards from years prior to 2018 of $547.0 million will begin to expire in 2020 through 2037. NOL incurred in 2018 and later amount to $107.5 million and shall carryforward indefinitely. NOL carryforwards are generally available to offset future taxable income; however, the utilization of NOL may be limited under the Internal Revenue Code Section 382 as a result of changes in ownership of the Company’s stock over the loss periods and prior to utilization of the carryforwards. The Company also has approximately $18.6 million in research and development tax credits available to offset federal income tax in future periods. If unused, these credits expire through 2037. The Company’s NOL carryforwards for foreign tax purposes as of December 31, 2020 are $30.0 million. NOL in the United Kingdom and Germany of $13.3 million and $16.5 million respectively do not expire over time. NOL in the Netherlands of $208,000 will begin to expire in 2025 through 2031. The Company’s tax years are still open under statute from 2016 to present, although NOL carryovers from prior tax years are subject to examination and adjustments to the extent utilized in future years.

In assessing the realization of deferred tax assets, management considers whether it is more likely than not that some portion or all of the deferred tax assets will be realized. The ultimate realization of deferred tax assets is dependent upon the generation of future taxable income during the period in which those temporary differences become deductible. Management considers the scheduled reversal of deferred tax liabilities, projected future taxable income and taxing strategies in making this assessment. In case the deferred tax assets will not be realized in future periods, the Company has provided a valuation allowance for the full amount of the deferred tax assets at December 31, 2020 and 2019.

The expected tax expense (benefit) based on the U.S. federal statutory rate is reconciled with actual tax expense (benefit) as follows:

(dollars in thousands)

    

As of December 31, 2020

    

As of December 31, 2019

 

Statutory federal income tax rate

 

21.0

%  

21.0

%  

State taxes, net of federal tax benefit

 

1.1

%  

8.9

%  

Tax rate differential on foreign income

 

0.0

%  

(0.4)

%  

Derivative gain or loss

 

(17.3)

%  

12.2

%  

Expiration of net operating losses

 

(1.5)

%  

(7.9)

%  

Other permanent items and true ups

 

(0.1)

%  

(2.3)

%  

R&D Credit

 

0.3

%  

3.0

%  

Change in valuation allowance

 

(3.5)

%  

(34.5)

%  

Income tax provision (benefit)

 

0.0

%  

0.0

%  

    

As of December 31, 2020

    

As of December 31, 2019

Federal

 

  

 

  

Current

$

$

Deferred

 

(15,539)

 

(5,183)

State

 

 

  

Current

 

 

Deferred

 

(4,327)

 

(1,421)

Foreign

 

 

  

Current

 

 

  

Deferred

 

670

 

(404)

Change in valuation allowance

 

19,196

 

7,008

Income tax provision (benefit)

$

$

ASC 740 prescribes a recognition threshold and a measurement attribute for the financial statement recognition and measurement of tax positions taken or expected to be taken in a tax return. For those benefits to be recognized, a tax position must be more-likely-than-not to be sustained upon examination by taxing authorities. As of December 31, 2020, and 2019, there were no uncertain tax positions. The Company’s policy for recording interest and penalties associated with uncertain tax positions is to record such expense as a component of income tax expense. There were no amounts accrued for penalties or interest during the year ended December 31, 2020. Management is currently unaware of any issues under review that could result in significant payments, accruals or material deviations from its position.

XML 40 R21.htm IDEA: XBRL DOCUMENT v3.21.1
Revision to Prior Period Financial Statements
12 Months Ended
Dec. 31, 2020
Revision to Prior Period Financial Statements  
Revision to Prior Period Financial Statements

14. Revision to Prior Period Financial Statements

During the course of preparing the quarterly report on Form 10-Q for the three and nine months ended September 30, 2020 and 2019, the Company identified an error in its accrual and capitalization related to the Sawston Facility and research and development costs under the Advent Ancillary Services Agreement. This resulted in an understatement of construction in progress of $1.5 million as of December 31, 2019, and an understatement of accounts payable and accrued expenses to related parties and affiliates of $3.0 million as of December 31, 2019.

The Company concluded that the error was not material to any prior annual period and the error had no material impact to any prior interim period. Nevertheless, the Company has revised its historical consolidated financial statements to properly reflect research and development expenses, capitalization of construction in progress and accrued liabilities in the prior periods.

The effect of the revisions to the consolidated financial statements is as follows (amount in thousands):

Consolidated Balance Sheet

As of December 31, 2019

As Previously

 

    

  Reported 

    

Adjustments

    

As Revised

Construction in progress

$

171

$

1,514

$

1,685

Total non-current assets

 

5,929

 

1,514

 

7,443

TOTAL ASSETS

$

9,129

$

1,514

$

10,643

 

  

 

  

 

  

Accounts payable and accrued expenses to related parties and affiliates

$

842

$

3,002

$

3,844

Total current liabilities

 

41,194

 

3,002

 

44,196

Total liabilities

 

52,696

 

3,002

 

55,698

 

  

 

  

 

  

Accumulated deficit

 

(839,907)

 

(1,488)

 

(841,395)

Total stockholders' deficit

 

(43,567)

 

(1,488)

 

(45,055)

TOTAL LIABILITIES AND STOCKHOLDERS' DEFICIT

$

9,129

$

1,514

$

10,643

Consolidated Statement of Operations

For the year ended

December 31, 2019

As Previously

 

    

  Reported 

    

Adjustments

    

As Revised

Research and development expenses

$

13,590

$

516

$

14,106

Total operating costs and expenses

 

29,873

 

516

 

30,389

Loss from operations

 

(27,463)

 

(516)

 

(27,979)

Net loss

$

(20,296)

$

(516)

$

(20,812)

Total comprehensive loss

$

(20,460)

$

(516)

$

(20,976)

Consolidated Statement of Cash Flows

For the year ended

December 31, 2019

As Previously

 

    

  Reported 

    

Adjustments

    

As Revised

Cash Flows from Operating Activities:

  

  

  

Net loss

$

(20,296)

$

(516)

$

(20,812)

Related party accounts payable and accrued expenses

 

(3,746)

 

516

 

(3,230)

Net cash used in operating activities

$

(31,859)

$

$

(31,859)

Supplemental schedule of non-cash investing and financing activities:

 

  

 

  

 

  

Capital expenditures included in accounts payable and accrued expenses to related parties and affiliates

$

$

947

$

947

XML 41 R22.htm IDEA: XBRL DOCUMENT v3.21.1
Subsequent Events
12 Months Ended
Dec. 31, 2020
Subsequent Events  
Subsequent Events

15. Subsequent Events

Debt Offering

On March 1, 2021, the Company entered into a Commercial Loan Agreement (the “Note”) with an individual investor for an aggregate principal amount of $10 million. The Note bears interest at 8% per annum with a 22-month term. There are no repayments during the first 8 months of the term. The note is amortized in 14 installments starting on November 1, 2021. The Note carries an original issue discount of $1 million and $5,000 legal costs that were reimbursable to the investor.

Warrants and Options Suspension

On January 15, 2021, the Company further extended the suspension of approximately 256 million warrants and options held by certain officers and directors of the Company until February 28, 2021.

On February 28, 2021, the Company further extended the suspension of approximately 262 million warrants and options held by certain officers and directors of the Company until April 30, 2021.

A total 262 million warrants and options will be suspended until April 30, 2021.

Warrants Exercised for Cash and Cashless Warrants Exercise

Between January and March 2021, the Company received $0.7 million from the exercise of warrants with an exercise price between $0.175 and $0.34. The Company issued approximately 2.6 million shares of common stock upon these warrant exercises.

Between January and March 2021, certain warrants allowing for cashless exercise were exercised, with exercise prices between $0.22 and $0.52. The Company issued approximately 2.1 million shares of common stock upon 2.6 million warrant exercises.

Stock Options Exercised for Cash and Cashless Stock Options Exercise

Between January and March 2021, the Company received $46,000 from the exercise of stock options with an exercise price of $0.25. The Company issued approximately 0.2 million shares of common stock upon these options exercises.

Between January and March 2021, certain stock options holders elected to cashless exercise their options, with exercise prices between $0.25 and $0.34. The Company issued approximately 3.1 million shares of common stock upon 3.7 million options exercises.

Debt Conversion

Between January and March 2021, the Company converted approximately $4.6 million outstanding debt and interest into approximately 4.5 million shares of common stock.

XML 42 R23.htm IDEA: XBRL DOCUMENT v3.21.1
Summary of Significant Accounting Policies (Policies)
12 Months Ended
Dec. 31, 2020
Summary of Significant Accounting Policies  
Basis of Presentation

Basis of Presentation

The accompanying consolidated financial statements of the Company were prepared in accordance with generally accepted accounting principles in the U.S. (“U.S. GAAP”) and include the assets, liabilities, revenues and expenses of the wholly owned subsidiaries in Germany, United Kingdom and Netherlands. All intercompany transactions and accounts have been eliminated in consolidation.

Consolidation

Consolidation

The Company’s policy is to consolidate all entities in which it can vote a majority of the outstanding voting stock. In addition, the Company consolidates entities that meet the definition of a variable interest entity (VIE) for which the Company is the primary beneficiary, if any. The primary beneficiary is the party who has the power to direct the activities of a VIE that most significantly impact the entity’s economic performance and who has an obligation to absorb losses of the entity or a right to receive benefits from the entity that could potentially be significant to the VIE.

As of December 31, 2020, the Company did not consolidate any VIE's as the Company has concluded that it is not the primary beneficiary.

Use of Estimates

Use of Estimates

In preparing consolidated financial statements in conformity with U.S. GAAP, management is required to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements, as well as the reported amounts of expenses during the reporting period. Due to inherent uncertainty involved in making estimates, actual results reported in future periods may be affected by changes in these estimates.

On an ongoing basis, the Company evaluates its estimates and judgments, including valuing equity securities in share-based payment arrangements, estimating the fair value of financial instruments recorded as derivative liabilities, useful lives of depreciable assets and whether impairment charges may apply. The Company bases its estimates on historical experience and on various other assumptions that it believes to be reasonable under the circumstances, the results of which form the basis for making judgments about the carrying values of assets and liabilities and the reported amounts of revenues and expenses that are not readily apparent from other sources. Actual results could differ from those estimates, particularly given the significant social and economic disruptions and uncertainties associated with the ongoing coronavirus pandemic ("COVID-19") and the COVID-19 control responses.

Concentration of Credit Risk

Concentration of Credit Risk

Financial instruments that potentially subject the Company to concentration of credit risk consist of cash accounts in a financial institution, which at times may exceed the Federal depository insurance coverage (“FDIC”) of $250,000. As of December 31, 2020, of the total $10 million in cash and cash equivalents, $0.6 million was held by foreign subsidiaries. The Company had not experienced losses on these accounts and management believes the Company is not exposed to significant risks on such accounts.

Property, Plant and Equipment

Property, Plant and Equipment

Property and equipment are stated at cost. Depreciation and amortization are provided for using straight-line methods, in amounts sufficient to charge the cost of depreciable assets to operations over their estimated service lives. Repairs and maintenance costs are charged to operations as incurred.

Costs for capital assets not yet placed into service are capitalized as construction in progress on the consolidated balance sheets and will be depreciated once placed into service.

The Company assesses its long-lived assets for impairment whenever facts and circumstances indicate that the carrying amounts may not be fully recoverable. To analyze recoverability, the Company projects undiscounted net future cash flows over the remaining lives of such assets. If these projected undiscounted net future cash flows are less than the carrying amounts, an impairment loss would be recognized, resulting in a write-down of the assets with a corresponding charge to earnings. The impairment loss is measured based upon the difference between the carrying amounts and the fair values of the assets.

Goodwill and Intangible Assets

Goodwill and Intangible Assets

Goodwill is the excess of purchase price over the fair value of identified net assets of businesses acquired. The Company's intangible asset with an indefinite life is related to in-process research and development ("IPR&D") programs acquired in the Flaskworks Acquisition, as the Company expects future research and development on these programs to provide the Company with substantial benefit for a period that extends beyond the foreseeable horizon. Intangible assets with indefinite useful lives are measured at their respective fair values as of the acquisition date. The Company does not amortize goodwill and intangible assets with indefinite useful lives. Intangible assets related to IPR&D projects are considered to be indefinite lived until the completion or abandonment of the associated R&D efforts. If and when development is complete, which generally occurs if and when regulatory approval to market a product is obtained, the associated assets would be deemed finite lived and would then be amortized based on their respective estimated useful lives at that point in time.

The Company has one operating segment and one reporting unit. The Company reviews goodwill and indefinite-lived intangible assets at least annually for possible impairment. Goodwill and indefinite-lived intangible assets are reviewed for possible impairment between annual tests if an event occurs or circumstances change that would more likely than not reduce the fair value of the reporting unit or the indefinite-lived intangible assets below their carrying values. No impairment charge was recognized for the year ended December 31, 2020.

Fair Value of Financial Instruments

Fair Value of Financial Instruments

ASC 820, Fair Value Measurements, provides guidance on the development and disclosure of fair value measurements. Under this accounting guidance, fair value is defined as an exit price, representing the amount that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date. As such, fair value is a market-based measurement that should be determined based on assumptions that market participants would use in pricing an asset or a liability.

The accounting guidance classifies fair value measurements in one of the following three categories for disclosure purposes:

Level 1:    Quoted prices in active markets for identical assets or liabilities.

Level 2:    Inputs other than Level 1 prices for similar assets or liabilities that are directly or indirectly observable in the marketplace.

Level 3:    Unobservable inputs which are supported by little or no market activity and values determined using pricing models, discounted cash flow methodologies, or similar techniques, as well as instruments for which the determination of fair value requires significant judgment or estimation.

The Company accounts for the issuance of common stock purchase warrants issued in connection with the equity offerings in accordance with the provisions of ASC 815, Derivatives and Hedging ("ASC 815"). The Company classifies as equity any contracts that (i) require physical settlement or net-share settlement or (ii) gives the Company a choice of net-cash settlement or settlement in its own shares (physical settlement or net-share settlement). The Company accounts for certain common stock warrants outstanding as a liability at fair value and adjusts the instruments to fair value at each reporting period. This liability is subject to re-measurement at each balance sheet date until exercised, and any change in fair value is recognized in its Consolidated Statements of Operations and Comprehensive Loss. The fair value of the warrants issued by the Company has been estimated using Monte Carlo simulation and or a Black Scholes model. The warrant liabilities are valued using Level 3 valuation inputs (see Note 4).

Embedded Conversion Features

Embedded Conversion Features

The Company evaluates embedded conversion features within convertible debt instruments to determine whether the embedded conversion feature(s) should be bifurcated from the host instrument and accounted for as a derivative at fair value with changes in fair value recorded in the Statement of Operations. If the conversion feature does not require recognition of a bifurcated derivative, the convertible debt instrument is evaluated for consideration of any beneficial conversion feature (“BCF”) requiring separate recognition. When the Company record a BCF, the intrinsic value of the BCF is recorded as a debt discount against the face amount of the respective debt instrument (offset to additional paid-in capital) and amortized to interest expense over the life of the debt.

Derivative Financial Instruments

Derivative Financial Instruments

The Company has derivative financial instruments that are not hedges and do not qualify for hedge accounting. Changes in the fair value of these instruments are recorded in other income (expense), on a net basis in the Consolidated Statements of Operations and Comprehensive Loss.

Contingent payable derivative liability

During the year ended December 31, 2019, the Company entered into a settlement agreement with Cognate BioServices, resolving past matters and providing for the restart of DCVax®-Direct Production.

As part of this overall settlement, the Company also provided a contingent note payable (the “Contingent Payable Derivative”) of $10 million, which is only payable upon the Company’s first financing after DCVax product approval in or outside the U.S. If such product approval has not been obtained by the seventh anniversary of the agreement, such Contingent Payable Derivative will expire without becoming payable.

On a quarterly basis, management makes estimates for key performance milestones and uses the expected dates as the inputs for valuation. The fair value of the Contingent Payable Derivative has been estimated using Monte Carlo simulation, which are valued using Level 3 valuation inputs.

Leases

Leases

Prior to January 1, 2019, the Company recognized rent expense on a straight-line basis over the lease period and accounts for the difference between straight-line rent and actual lease payments as deferred rent.

Subsequent to the adoption of the new leasing standard on January 1, 2019, the Company recognizes a lease asset for its right to use the underlying asset and a lease liability for the corresponding lease obligation. The Company determines whether an arrangement is or contains a lease at contract inception. Operating leases with a duration greater than one year are included in right-of-use assets, lease liabilities, and lease liabilities, net of current portion in the Company’s consolidated balance sheets. Right-of-use assets and liabilities are recognized at the lease commencement date based on the present value of lease payments over the lease term. In determining the net present value of lease payments, the Company uses its incremental borrowing rate based on the information available at the lease commencement date. The incremental borrowing rate represents the interest rate the Company would incur at lease commencement to borrow an amount equal to the lease payments on a collateralized basis over the term of a lease. The Company considers a lease term to be the non-cancelable period that it has the right to use the underlying asset.

The operating lease right-of-use assets also include any lease payments made and exclude lease incentives. Lease expense is recognized on a straight-line basis over the expected lease term. Variable lease expenses are recorded when incurred.

Foreign Currency Translation and Transactions

Foreign Currency Translation and Transactions

The Company has operations in Germany, the United Kingdom and Netherlands in addition to the U.S. The Company translated its assets and liabilities into U.S. dollars using end of period exchange rates and revenues and expenses are translated into U.S. dollars using weighted average rates. Foreign currency translation adjustments are reported as a separate component of accumulated other comprehensive income (loss) within stockholders’ equity deficit.

The Company converts receivables and payables denominated in other than the Company’s functional currency at the exchange rate as of the balance sheet date. The resulting transaction exchange gains or losses related to intercompany receivable and payables, are included in other income and expense.

Comprehensive Loss

Comprehensive Loss

The Company reports comprehensive loss and its components in its consolidated financial statements. Comprehensive loss consists of net loss and foreign currency translation adjustments, affecting stockholders’ equity deficit that, under U.S, GAAP, is excluded from net loss.

Revenue Recognition

Revenue Recognition

The Company recognizes revenue in accordance with the terms stipulated under the patient service contract. In various situations, the Company receives certain payments for DCVax®-L for patient treatment. These payments are assessed and recognized in accordance with ASC 606 in the period when the performance obligation has been met.

Accrued Outsourcing Costs

Accrued Outsourcing Costs

Substantial portions of our preclinical studies and clinical trials are performed by third-party laboratories, medical centers, contract research organizations and other vendors (collectively “CROs”). These CROs generally bill monthly or quarterly for services performed, or bill based upon milestones achieved. For clinical studies, expenses are accrued when services are performed. The Company monitors patient enrollment, the progress of clinical studies and related activities through internal reviews of data that is tracked by the CROs under contractual arrangements, correspondence with the CROs and visits to clinical sites.

Research and Development Costs

Research and Development Costs

Research and development costs are charged to operations as incurred and consist primarily of clinical trial related costs (including costs for collection, validation and analysis of trial results), related party manufacturing costs, consulting costs, contract research and development costs, clinical site costs and compensation costs.

Income Taxes

Income Taxes

The Company evaluates its tax positions and estimates its current tax exposure along with assessing temporary differences that result from different book to tax treatment of items not currently deductible for tax purposes. These differences result in deferred tax assets and liabilities on the Company’s Consolidated Balance Sheets, which are estimated based upon the difference between the financial statement and tax bases of assets and liabilities using the enacted tax rates that will be in effect when these differences reverse. In general, deferred tax assets represent future tax benefits to be received when certain expenses previously recognized in the Company’s Consolidated Statements of Comprehensive Loss become deductible expenses under applicable income tax laws or loss or credit carryforwards are utilized. Accordingly, realization of the Company’s deferred tax assets is dependent on future taxable income against which these deductions, losses and credits can be utilized.

The Company must assess the likelihood that the Company’s deferred tax assets will be recovered from future taxable income, and to the extent the Company believes that recovery is not more likely than not, the Company must establish a valuation allowance. Management judgment is required in determining the Company’s provision for income taxes, the Company’s deferred tax assets and liabilities and any valuation allowance recorded against the Company’s net deferred tax assets. Excluding foreign operations, the Company recorded a full valuation allowance at each balance sheet date presented because, based on the available evidence, the Company believes it is more likely than not that it will not be able to utilize all of its deferred tax assets in the future. The Company intends to maintain the full valuation allowance until sufficient evidence exists to support the reversal of the valuation allowance.

Stock Based Compensation

Stock Based Compensation

The Company measures stock-based compensation to employees, consultants, and Board members at fair value on the grant date of the award. Compensation cost is recognized as expense on a straight-line basis over the requisite service period of the award. For awards that have a performance condition, compensation cost is measured based on the fair value of the award on the grant date, the date performance targets are established, and is expensed over the requisite service period for each separately vesting tranche when achievement of the performance condition becomes probable. The Company assess the probability of the performance conditions being

met on a continuous basis. Forfeitures are recognized when they occur. Prior to January 1, 2019, share-based compensation cost for non-employees was re-measured at every reporting period.

The Company estimates the fair value of stock option grants that do not contain market-based vesting conditions using the Black-Scholes option pricing model and the assumptions used in calculating the fair value of stock-based awards represent management’s best estimates and involve inherent uncertainties and the application of management’s judgment.

Expected Term - The expected term of options represents the period that the Company’s stock-based awards are expected to be outstanding based on the simplified method, which is the half-life from vesting to the end of its contractual term.

Expected Volatility - The Company computes stock price volatility over expected terms based on its historical common stock trading prices.

Risk-Free Interest Rate - The Company bases the risk-free interest rate on the implied yield available on U. S. Treasury zero-coupon issues with an equivalent remaining term.

Expected Dividend - The Company has never declared or paid any cash dividends on its common shares and does not plan to pay cash dividends in the foreseeable future, and, therefore, uses an expected dividend yield of zero in its valuation models.

The Company is also required to make estimates as to the probability of achieving the specific performance conditions. If actual results are not consistent with the Company’s assumptions and judgments used in making these estimates, the Company may be required to increase or decrease compensation expense, which could be material to the Company’s consolidated results of operations.

Debt Extinguishment

Debt Extinguishment

The Company accounts for the income or loss from extinguishment of debt by comparing the difference between the reacquisition price and the net carrying amount of the debt being extinguished and recognizes this as gain or loss when the debt is extinguished. The gain or loss from debt extinguishment is recorded in the consolidated statements of operations under “other income (expense)” as loss from extinguishment of convertible debt.

Sequencing

Sequencing

The Company adopted a sequencing policy under ASC 815-40-35 whereby in the event that reclassification of contracts from equity to liabilities is necessary pursuant to ASC 815 due to the Company’s inability to demonstrate it has sufficient authorized shares. This was previously the result of certain financial instruments with a potentially indeterminable number of shares and most recently due to the company committing more shares than authorized. While temporary suspensions are in place to keep the potential exercises beneath the number authorized, certain instruments are classified as liabilities, after allocating available authorized shares on the basis of the earliest grant date of potentially dilutive instruments. Pursuant to ASC 815, issuance of stock based awards to the Company’s employees, nonemployees or directors are not subject to the sequencing policy.

Loss per Share

Loss per Share

Basic loss per share is computed on the basis of the weighted average number of shares outstanding for the reporting period. Diluted loss per share is computed on the basis of the weighted average number of common shares plus dilutive potential common shares outstanding using the treasury stock method. Any potentially dilutive securities are anti-dilutive due to the Company’s net losses. For the years presented, there is no difference between the basic and diluted net loss per share.

Recent Accounting Standards

Recent Accounting Standards

Income Taxes

In December 2019, the FASB issued ASU No. 2019-12, “Income Taxes (Topic 740): Simplifying the Accounting for Income Taxes (“ASU 2019-12”), which is intended to simplify various aspects related to accounting for income taxes. ASU 2019-12 removes certain

exceptions to the general principles in Topic 740 and also clarifies and amends existing guidance to improve consistent application. This guidance is effective for fiscal years, and interim periods within those fiscal years, beginning after December 15, 2020, with early adoption permitted. The Company is currently evaluating the impact of this standard on its consolidated financial statements and related disclosures.

Debt

Debt

In August 2020, the FASB issued ASU No. 2020-06, Debt—Debt with Conversion and Other Options (Subtopic 470-20) and Derivatives and Hedging—Contracts in Entity’s Own Equity (Subtopic 815-40): Accounting for Convertible Instruments and Contracts in an Entity’s Own Equity, which simplifies accounting for convertible instruments by removing major separation models required under current GAAP. The ASU removes certain settlement conditions that are required for equity contracts to qualify for the derivative scope exception and it also simplifies the diluted earnings per share calculation in certain areas. This ASU is effective for annual reporting periods beginning after December 15, 2021, including interim periods within those fiscal years. Early adoption is permitted, but no earlier than fiscal years beginning after December 15, 2020. This update permits the use of either the modified retrospective or fully retrospective method of transition. The Company is currently evaluating the impact this ASU will have on the its consolidated financial statements and related disclosures.

XML 43 R24.htm IDEA: XBRL DOCUMENT v3.21.1
Fair Value Measurements (Tables)
12 Months Ended
Dec. 31, 2020
Fair Value Measurements  
Schedule of fair value assets and liabilities measured on recurring basis

Fair value measured at December 31, 2020

    

    

Quoted prices in active

    

Significant other

    

Significant

Fair value at

markets

observable inputs

unobservable inputs

December 31, 2020

(Level 1)

(Level 2)

(Level 3)

Warrant liability

$

354,972

$

$

$

354,972

Embedded conversion option

2,507

2,507

Contingent payable derivative liability

 

8,275

 

 

 

8,275

Total fair value

$

365,754

$

$

$

365,754

Fair value measured at December 31, 2019

    

    

Quoted prices in active

    

Significant other

    

Significant

Fair value at

markets

observable inputs

unobservable inputs

December 31, 2019

(Level 1)

(Level 2)

(Level 3)

Warrant liability

$

20,213

$

$

$

20,213

Contingent payable derivative liability

 

7,261

 

 

 

7,261

Total fair value

$

27,474

$

$

$

27,474

Schedule of Fair Value Liabilities Measured On Recurring Basis Unobservable Input Reconciliation

The following table presents changes in Level 3 liabilities measured at fair value for the years ended December 31, 2020 and 2019. Both observable and unobservable inputs were used to determine the fair value of positions that the Company has classified within the Level 3 category. Unrealized gains and losses associated with liabilities within the Level 3 category include changes in fair value that were attributable to both observable (e.g., changes in market interest rates) and unobservable (e.g., changes in unobservable long- dated volatilities) inputs (in thousands).

Contingent

Embedded

Payable

Warrant

Conversion

Derivative

    

Liability

    

Option

    

Liability

    

Total

Balance - January 1, 2019

$

29,995

$

357

$

$

30,352

Additional contingent liability in connection with a settlement agreement

6,602

6,602

Additional warrant liability

4,110

4,110

Extinguishment of derivative liabilities

(3)

(3)

Extinguishment of warrant liabilities related to warrants exercised for cash

(1,759)

(1,759)

Change in fair value

(12,133)

(354)

659

(11,828)

Balance - December 31, 2019

20,213

7,261

27,474

Additional warrant liability

18,864

18,864

Reclassification of warrant liabilities

(110,471)

(110,471)

Extinguishment of embedded conversion option due to debt conversion and debt repayment

(8,271)

(8,271)

Additional embedded conversion option

2,807

2,807

Change in fair value

426,366

7,971

1,014

435,351

Balance - December 31, 2020

$

354,972

$

2,507

$

8,275

$

365,754

Schedule of Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis Valuation Techniques

A summary of the weighted average (in aggregate) significant unobservable inputs (Level 3 inputs) used in measuring the Company’s warrant liabilities and embedded conversion feature that are categorized within Level 3 of the fair value hierarchy as of December 31, 2020 and 2019 is as follows:

    

As of December 31, 2020

 

Warrant

Embedded

Contingent Payable

 

Liability

Conversion Option

Derivative Liability

 

Strike price

$

0.28

$

0.59

$

1.53

Contractual term (years)

 

1.6

 

0.9

 

1.4

Volatility (annual)

 

116

%  

 

106

%  

 

126

%

Risk-free rate

 

0.2

%  

 

0.1

%  

 

0.1

%

Dividend yield (per share)

 

0

%  

 

0

%  

 

0

%

As of December 31, 2019

 

    

Warrant

    

Contingent Payable

 

Liability

Derivative Liability

 

Strike price

$

0.21

$

0.21

Contractual term (years)

 

1.4

 

1.0

Volatility (annual)

 

74

%  

 

62

%  

Risk-free rate

 

2

%  

 

2

%  

Dividend yield (per share)

 

0

%  

 

0

%  

* contingent payable derivative liability based on stock price as of December 31, 2020 and December 31, 2019

XML 44 R25.htm IDEA: XBRL DOCUMENT v3.21.1
Flaskworks Acquisition (Tables)
12 Months Ended
Dec. 31, 2020
Flaskworks Acquisition  
Schedule of assets acquired and liabilities assumed

Based on the Company's preliminary valuation, the total estimated consideration of $2.1 million has been allocated to assets acquired and liabilities assumed as of the acquisition date as follows (amount in thousands):

Cash

    

$

146

Current assets

 

135

Fixed assets, net

 

188

Indefinite-lived intangible asset

 

1,292

Security deposits

 

8

Total assets acquired

 

1,769

Accounts payable

 

(12)

Accrued expenses

 

(240)

Total liabilities assumed

 

(252)

Net identifiable assets acquired

 

1,517

Goodwill

 

626

Total estimated consideration (1)

$

2,143

Less special consideration paid in cash and stock

$

(465)

Less cash acquired

 

(146)

Total consideration paid, net of cash acquired

$

1,532

XML 45 R26.htm IDEA: XBRL DOCUMENT v3.21.1
Stock-based Compensation (Tables)
12 Months Ended
Dec. 31, 2020
Stock-based Compensation  
Schedule of stock-based compensation expense

The following table summarizes stock option activity for the Company’s option plans during the years ended December 31, 2020 and 2019 (amount in thousands, except per share number):

    

    

    

Weighted

    

Average

Weighted

Remaining

Number of

Average Exercise

Contractual Life

Total Intrinsic

Shares

Price

(in years)

Value

Outstanding as of January 1, 2019

 

100,159

0.24

 

9.3

Granted

4,500

0.22

10.4

Outstanding as of December 31, 2019

104,659

$

0.24

8.4

$

Granted (Approved 2018-2020) (1)

208,525

0.37

(3)

10.0

Cashless exercise

 

(94)

 

0.34

 

Forfeited/expired

 

(4,250)

 

0.22

 

 

Outstanding as of December 31, 2020

 

308,840

$

0.33

 

8.9

$

372,219

Options vested (2)

 

223,720

$

0.30

 

8.7

$

276,432

(1)The options granted during the year ended December 31, 2020 included options already approved at various times during the 3 years 2018 - 2020 but not issued until Q3 2020, and also included options that will vest for performance and milestones going forward over the next 2 years. The options included awards to key external consultants and vendors in addition to internal parties.
(2)Approximately 128 million vested options as of December 31, 2020 are not exercisable until January 15, 2021. See Note 15 below under Subsequent Events for more information about additional options suspensions for further periods.
(3)The weighted average exercise price of the Q3 2020 options was initially $0.25. However, subsequently, the exercise price was amended to a weighted average exercise price of $0.36.
Schedule of weighted average assumptions for stock options modification

    

For the years ended

 

December 31,

 

Grant Date

2020

2019

 

Exercise price

$

0.26

$

0.20

Expected term (years)

 

5.2

 

5.6

Expected stock price volatility

 

98

%  

 

86

%

Risk-free rate of interest

 

0

%  

 

1

%

    

Post Modification

    

Pre Modification

 

Exercise price

$

0.23

$

0.23

Expected term (years)

 

4.3

 

4.0

Expected stock price volatility

 

97

%

 

97

%

Risk-free rate of interest

 

0

%  

 

0

%

    

Post Modification

    

Pre Modification

 

Exercise price

$

0.22

$

0.22

Expected term (years)

 

5.3

 

4.7

Expected stock price volatility

 

96

%  

 

97

%

Risk-free rate of interest

 

0

%  

 

0

%

Schedule of stock based compensation

The following table summarizes total stock-based compensation expense recognized for the years ended December 31, 2020 and 2019 (in thousands):

    

For the years ended

December 31,

 

2020

 

2019

Research and development

$

19,792

$

471

General and administrative (1)

 

32,163

 

1,350

Total stock-based compensation expense

$

51,955

$

1,821

(1)The general and administrative expense during the years ended December 31, 2020 and 2019 is related to the applicable vesting portion of stock options awards made in the past and new options granted during the year ended December 31, 2020 to directors, employees and external consultants.
XML 46 R27.htm IDEA: XBRL DOCUMENT v3.21.1
Property, Plant and Equipment (Tables)
12 Months Ended
Dec. 31, 2020
Property, Plant and Equipment  
Schedule of property and equipment

Property, plant and equipment consist of the following at December 31, 2020 and 2019 (in thousands):

    

December 31, 

    

December 31, 

    

Estimated

2020

2019

Useful Life

Leasehold improvements

$

81

$

186

 

Lesser of lease term or estimated useful life

Office furniture and equipment

 

219

 

59

 

3-5 years

Computer equipment and software

 

1,403

 

611

 

3-5 years

Land in the United Kingdom

93

90

NA

 

1,796

 

946

Less: accumulated depreciation

 

(756)

 

(665)

 

  

Total property, plant and equipment, net

$

1,040

$

281

 

  

Construction in progress

$

9,074

$

1,685

 

  

XML 47 R28.htm IDEA: XBRL DOCUMENT v3.21.1
Notes Payable (Tables)
12 Months Ended
Dec. 31, 2020
Notes Payable  
Schedule of outstanding debt

    

    

Stated

    

    

    

    

Embedded

    

Interest

Conversion

Remaining

Conversion

Carrying

Maturity Date

Rate

Price

Face Value

Debt Discount

Option

Value

Short term convertible notes payable

 

  

 

  

 

  

 

  

 

  

 

  

 

  

6% unsecured (1)

 

Due

 

6

%  

$

3.09

$

135

$

$

$

135

8% unsecured (3) (4)

 

4/30/2021

 

8

%  

$

0.85

 

2,125

 

(937)

 

2,507

 

3,695

2,260

(937)

2,507

3,830

Short term notes payable

 

  

 

  

 

  

 

  

 

  

 

  

 

  

8% unsecured (5)

 

Various

 

8

%  

 

N/A

 

1,785

 

(51)

 

 

1,734

10% unsecured (6)

 

Various

 

10

%  

 

N/A

 

263

 

 

 

263

12% unsecured (7)

 

On Demand

 

12

%  

 

N/A

 

440

 

 

 

440

 

2,488

 

(51)

 

 

2,437

Long term notes payable

 

  

 

  

 

  

 

  

 

  

 

  

 

  

8% unsecured (10)

 

Various

 

8

%  

 

N/A

 

7,160

 

(496)

 

 

6,664

6% secured (11)

 

3/25/2025

 

6

%  

 

N/A

 

1,843

 

 

 

1,843

 

9,003

 

(496)

 

 

8,507

Ending balance as of December 31, 2020

$

13,751

$

(1,484)

$

2,507

$

14,774

    

    

Stated

    

    

    

    

Interest

Conversion

Remaining

Carrying

Maturity Date

Rate

Price

Face Value

Debt Discount

Value

Short term convertible notes payable

 

  

 

  

 

  

 

  

 

  

 

  

6% unsecured (1)

 

Due

 

6

%  

$

3.09

$

135

$

$

135

10% unsecured (2)

 

4/18/2020

 

10

%  

$

0.22

 

500

 

(67)

 

433

 

635

(67)

 

568

Short term notes payable

 

  

 

  

 

  

 

  

 

  

 

  

8% unsecured (5)

 

Various

 

8

%  

 

N/A

 

555

 

(43)

 

512

10% unsecured (6)

 

Various

 

10

%  

 

N/A

 

3,551

 

(73)

 

3,478

12% unsecured (7)

 

On Demand

 

12

%  

 

N/A

 

440

 

 

440

0% unsecured (8)

 

8/1/2020

 

0

%  

 

N/A

 

1,156

 

(85)

 

1,071

 

5,702

 

(201)

 

 

5,501

Short term notes payable - related parties

 

  

 

  

 

  

 

  

 

  

 

  

10% unsecured - Related Parties (9)

 

On Demand

 

10

%  

 

N/A

 

66

 

 

66

 

66

 

 

 

66

Long term notes payable

 

  

 

  

 

  

 

  

 

  

 

  

8% unsecured (5)

 

Various

 

8

%  

 

N/A

 

7,008

 

(420)

 

6,588

 

7,008

 

(420)

 

 

6,588

Ending balance as of December 31, 2019

$

13,411

$

(688)

$

12,723

(1)This $135,000 note as of December 31, 2020 and 2019 consists of two separate 6% notes in the amounts of $110,000 and $25,000. In regard to the $110,000 note, the Company has made ongoing attempts to locate the creditor to repay or convert this note, but has been unable to locate the creditor to date. In regard to the $25,000 note, the holder has elected to convert these notes into equity, the Company has delivered the applicable conversion documents to the holder, and the Company is waiting for the holder to execute and return the documents.
(2)In February 2020, the Company entered into multiple one-year convertible notes (the “February Notes”) with multiple holders (the “Holders”) for an aggregate principal amount of $1.0 million. The Notes are convertible into common shares of the Company at $0.21 per share and bear interest at the rate of 10% per annum. Upon issuance of the February Notes, the Holders also received a 2-year warrant to purchase a total of 1.4 million common shares of the Company at an exercise price of $0.35 per share. The fair value of the warrants was approximately $79,000 on the grant date.

During the year ended December 31, 2020, the Company converted the entire February Notes, including $68,000 accrued interest into approximate 5.1 million shares of the Company's common stock.

In April 2020, the Company entered into a six-month convertible note (the “April Note”) with an individual investor (the “Holder”) with an aggregate principal amount of $0.8 million for cash proceeds of $0.7 million. The Company also incurred approximately $69,000 placement agent costs, including both a cash fee and the fair value of common stock warrants issued to the placement agent, which was recognized as additional debt discount.

The April Note bears interest at the rate of 10% per annum and is convertible into common shares of the Company at $0.17 per share plus a warrant to purchase a number of exercise shares equal to 50% of the number of common shares issued upon conversion (the “Conversion Warrants”). The Conversion Warrants will be exercisable until April 9, 2022 beginning on November 1, 2020, with an exercise price of $0.20 per share. The conversion option within the April Note is required to be bifurcated at fair value, which was approximately $0.4 million on the issuance date, resulting in additional debt discount to the April Note.

As consideration for entering into the April Note, the Company also agreed to amend the Holder’s existing outstanding warrants to purchase 5.1 million common shares of the Company. The exercise price of the warrants was amended from $0.25 per share to $0.20 per share. The incremental change in fair value resulting from the amendment was approximately $51,000, which was recognized as additional debt discount to the April Note.

On August 3, 2020, the Company converted approximately $0.8 million of outstanding principal and $26,000 of accrued interest of the April Note into approximately 5.1 million shares of common stock and 2.5 million warrants with fair value of approximately $2.4 million. The Company also extinguished $1.5 million embedded derivative liability and $0.2 million unamortized debt discount upon the conversion. The Company recorded approximately $0.3 million debt extinguishment loss.

In April 2020, the Company entered into a Note Amendment Agreement (the “Amendment”) with an individual holder of a short-term convertible note, primarily to agree on the following changes:

-Reclassed $75,000 accrued interest as of amendment date to the outstanding principal amount;
-Extended the maturity date of a convertible note with approximately $0.6 million of principal outstanding, as of the amendment date, to October 18, 2020 (the “Amended Note”);
-Reduced the conversion price from $0.22 to $0.181
-Issued a new 2-year warrant for up to 2.3 million shares of the Company’s common stock at an exercise price of $0.25 per share valued at $115,000 on the amendment date;

The amendment was recognized as a debt extinguishment, resulting in a loss on debt extinguishment of approximately $70,000.

During the year ended December 31, 2020, the Company converted the entire Amended Note of approximately $0.6 million, including $28,000 accrued interest into approximately 3.3 million shares of common stock.

(3)In May 2020, the Company entered into a six-month convertible note (the “May Note”) with an individual investor (the “Holder”) with an aggregate principal amount of $0.6 million. The May Note contains an original issue discount (“OID”) in the amount of $50,000.

The May Note bears interest at the rate of 8% per annum and is convertible into common shares of the Company at $0.25 plus a warrant to purchase a number of exercise shares equal to 40% of the number of common shares issued upon conversion (the “Conversion Warrants”). The Conversion Warrants will be exercisable until November 28, 2022 beginning on November 1, 2020 with exercise price of $0.25 per share. The conversion option within the May Note required bifurcation at fair value, which was approximately $0.5 million on the issuance date, resulting in additional debt discount to the May Note.

On October 1, 2020, the Company converted the entire $0.6 million of the May Note including $19,000 accrued interest, into approximately 2.3 million shares of the Company's common stock and 0.9 million warrants with fair value of approximate $3.4 million. The Company also extinguished $2.8 million embedded derivative liability upon the conversion.

In August 2020, the Company entered into another convertible note (the "August Note") with the same investor as the May Note (the "Holder") with an aggregate principal amount of $1.1 million. The August Note contains OID in the amount of $110,000.

The August Note bears interest at the rate of 8% per annum and is convertible into common shares of the Company at $0.345 plus a warrant to purchase a number of exercise shares equal to 35% of the number of common shares issued upon conversion (the "Conversion Warrants"). The Conversion Warrants will be exercisable until February 4, 2023 beginning on December 15, 2020 with exercise price of $0.34 per share. The conversion option within the August Note is required to be bifurcated at fair value, which was approximately $0.6 million on the issuance date, resulting in additional debt discount to the August Note.

On September 29, 2020, the Company converted entire $1.1 million of August Note into approximately 3.3 million shares of the Company's common stock and 1.1 million warrants with fair value of approximate $3.3 million. The Company also extinguished $2.3 million embedded derivative liability and $0.5 million unamortized debt discount upon the conversion. The company recorded approximately $0.4 million debt extinguishment loss.

(4)In October 2020, the Company entered into a convertible note (the "October Note") with the same investor as the August Note (the "Holder") with an aggregate principal amount of $2.1 million. The October Note contains OID in the amount of $200,000.

The October Note bears interest at the rate of 8% per annum and is convertible into common shares of the Company at $0.85 plus a warrant to purchase a number of exercise shares equal to 30% of the number of common shares issued upon conversion (the "Conversion Warrants"). The Conversion Warrants will be exercisable until January 12, 2022 beginning on January 15, 2021 with exercise price of $2.00 per share. The conversion option within the October Note is required to be bifurcated at fair value, which was approximately $1.4 million on the issuance date, resulting in additional debt discount of $1.4 million to the October Note.

(5)During the year ended December 31, 2020, the Company converted approximately $5.8 million of outstanding principal and $0.6 million of accrued interest into approximately 29.1 million shares of the Company’s common stock with a fair value of $7.6 million. The Company recognized approximately $1.2 million in debt extinguishment loss from this conversion.
(6)In May 2020, the Company converted approximately $0.3 million of outstanding principal and accrued interest into approximately 1.3 million shares of the Company’s common stock with a fair value of $0.5 million. The Company recognized approximately $0.2 million in debt extinguishment loss from this conversion.

In August 2020, the Company extinguished approximately $1.5 million of outstanding principal and accrued interest into approximately 4.8 million shares of the Company's common stock and 1.7 million warrants. The Company also modified certain existing warrants and issued additional 6.5 million warrants consideration for certain suspension. The Company also agreed to amend the remaining outstanding $1.5 million outstanding debt. The note became convertible at a conversion price of $0.34 (the “Amended August Note”). The amendment was accounted as debt extinguishment and the Company recognized approximately $1.6 million in debt extinguishment loss from this transaction.

During the year ended December 31, 2020, the Company made $0.1 million cash payment and converted approximate $1.4 million outstanding debt including $15,000 accrued interest into approximately 4.1 million shares of the Company’s common stock.

During the year ended December 31, 2020, the Company entered into multiple Note Extension Agreements with multiple holders, primarily resulting in the following changes:

-Extended the maturity dates of promissory notes with outstanding principal balances aggregating approximately $3.3 million for an additional 6 to 12 months from the original maturity date;
-Issued new 2-year warrants to purchase up to 10.3 million shares of the Company’s common stock at an exercise prices ranging from $0.20 and $0.23 per share valued at approximately $0.5 million on the amendment date;

The Note Extension Agreements for approximately $2.3 million of outstanding principal of promissory notes was recognized as a debt modification, while the amendments for approximately $1.0 million of outstanding principal of promissory notes was recognized as a debt extinguishment, resulting in a loss on extinguishment of debt of approximately $0.1 million.

(7)The $440,000 balance of outstanding principal as of December 31, 2020 and 2019 consists of two separate 12% demand notes in the amounts of $300,000 and $140,000.
(8)On May 28, 2019, the Company issued a deferred note to a third-party vendor pursuant to a settlement agreement resolving past matters and providing for the restart of DCVax®-Direct Production. During the year ended December 31, 2020, the Company made full repayment of $1.2 million to the note holder.
(9)On September 26, 2018, Advent BioServices (“Advent”), a related party of the Company, provided a short-term loan in the amount of $65,000. The loan bore interest at 10% per annum, and is payable upon demand, with 7 days’ prior written notice to the Company. During the year ended December 31, 2020, the Company made full repayment to Advent, including all outstanding interest.

Between February and May 2020, the Company entered into multiple demand loan agreements with Leslie Goldman, the Company’s Senior Vice President, General Counsel, for an aggregate principal amount of $0.3 million (the “Goldman Notes”). The Goldman Notes bear interest rate at 10% per annum, and are repayable upon 15 days' notice from Mr. Goldman.

The Goldman Notes are convertible into common shares of the Company at conversion prices ranging from $0.23 to $0.25 per share. Additionally, the Company agreed to issue warrants to Mr. Goldman to purchase 0.6 million shares of the Company’s common stock (the “Initial Warrants”) in conjunction with the Goldman Notes. The Initial Warrants have a five - year term and are exercisable at prices ranging from $0.23 and $0.25 per share. The fair value of the Initial Warrants was approximately $66,000, which was recognized as debt discount to the Goldman Notes at the issuance date. The conversion option within the Goldman Notes were required to be bifurcated at fair value, which was approximately $36,000 on the issuance date, resulting in additional debt discount to the Goldman Notes.

Upon conversion, Mr. Goldman would also receive a five-year term warrant to purchase a number of the Company’s common shares equal to 50% of the number of common shares issued upon conversion of the Goldman Notes (the “Conversion Warrants”). The Conversion Warrants will be exercisable at $0.25 per share.

During the year ended December 31, 2020, the Company made full repayment of $0.3 million to Mr. Goldman, including all outstanding interest. Upon the repayment, the Company also extinguished $1.6 million embedded derivative liability, which was recorded as debt extinguishment gain.

(10)During the year ended December 31, 2020, the Company entered into two note purchase agreements (the “Notes”) with same investor for an aggregate principal amount of approximate $7.2 million. The Notes bear interest at 8% per annum with 21-month term. There are no repayments during the first 7 months of the term. The Notes are amortized in 14 installments starting in month 8. The Notes carry an original issue discount of $650,000 and $10,000 legal costs that were reimbursable to the investor.
(11)Cambridge Loan

On March 26, 2020, the Company entered into a Loan Agreement (the “Loan Agreement”) with Cambridge & Peterborough Combined Authority (the “Lender”) for a loan of £1.35 million (approximately $1.7 million) (the “Loan”) for the current phase of buildout of the Sawston facility. The Company received funds on April 6, 2020. The Lender provides funding for selected economic development projects in the Cambridge region through a competitive selection process.

Under the Loan Agreement, there will be no repayments during the first year of the Loan term, although interest will accrue. Following the first anniversary, repayment of the Loan principal and interest will take place over 4 years, for a total term of 5 years.  The interest rate on the Loan is 6.25% per annum.

In conjunction with the Loan, the Company agreed to enter into a Security Agreement with the Lender under which the Company granted a security interest in the Company’s 17-acre property in Sawston, U.K. to secure the Loan.  No other tangible or intangible assets of the Company or its subsidiaries are subject to any security interest. Such security interest on the 17-acre property will be released upon completion of repayment

Schedule of total interest expenses related to outstanding notes and mortgage loan

The following table summarizes total interest expenses related to outstanding debt for the years ended December 31, 2020 and 2019, respectively (in thousands):

For the year ended

December 31, 

    

2020

    

2019

Interest expenses related to outstanding notes:

  

 

  

Contractual interest

$

1,231

$

1,168

Amortization of debt discount

 

2,891

 

1,430

Total interest expenses related to outstanding notes

 

4,122

 

2,598

Interest expenses related to outstanding notes to related parties:

 

 

Contractual interest

 

20

 

366

Amortization of debt discount

 

122

 

Total interest expenses related to outstanding notes to related parties

 

142

 

366

Interest expenses related to forbearance of debt to related parties

4,270

Other interest expenses

 

10

 

11

Total interest expense

$

8,544

$

2,975

Schedule of the company's contractual obligations on debt principal

The following table summarizes the principal amounts of the Company’s debt obligations as of December 31, 2020 (amount in thousands):

Payment Due by Period

Less than

1 to 2

3 to 5

    

Total

    

1 Year

    

Years

    

Years

Short term convertible notes payable

6% unsecured

$

135

$

135

$

$

8% unsecured

2,125

2,125

Short term notes payable

8% unsecured

1,785

1,785

10% unsecured

263

263

12% unsecured

440

440

Long term notes payable

8% unsecured

7,160

7,160

6% secured

1,843

1,843

Total

$

13,751

$

4,748

$

7,160

$

1,843

XML 48 R29.htm IDEA: XBRL DOCUMENT v3.21.1
Net Loss per Share Applicable to Common Stockholders (Tables)
12 Months Ended
Dec. 31, 2020
Net Loss per Share Applicable to Common Stockholders  
Schedule of antidilutive securities excluded from computation of earnings per share

The following securities were not included in the diluted net loss per share calculation because their effect was anti-dilutive as of the periods presented (in thousands):

For the year ended

December 31, 

    

2020

    

2019

Common stock options

 

308,840

 

104,659

Common stock warrants

 

328,979

 

347,734

Contingently issuable warrants

 

2,774

 

11,739

Convertible notes and accrued interest

 

2,617

 

2,617

Potentially dilutive securities

 

643,210

 

466,749

XML 49 R30.htm IDEA: XBRL DOCUMENT v3.21.1
Related Party Transactions (Tables)
12 Months Ended
Dec. 31, 2020
Related Party Transactions  
Schedule of expenses incurred to related parties and amounts invoiced some of which remain unpaid

The following table summarizes expenses incurred to related parties (i.e., amounts invoiced) during the year ended December 31, 2020 and 2019 (amount in thousands) (some of which were for previous periods’ services and remain unpaid as noted in the second table below):

For the year ended

December 31, 

2020

    

2019

(As revised) (Note 14)

Advent BioServices

$

7,543

 

$

5,735

Schedule of outstanding unpaid accounts payable held by related parties

The following table summarizes outstanding unpaid accounts payable and the accrued amount under the SOWs relating to the Sawston Facility and the compassionate use programs held by related parties as of December 31, 2020 and outstanding unpaid accounts payable

as of December 31, 2019 (amount in thousands). These unpaid amounts include part of the expenses reported in the table above and also certain expenses incurred in prior periods.

    

December 31, 2020

    

December 31, 2019

(As revised) (Note 14)

Advent BioServices – amount invoiced

$

3,734

$

834

Advent BioServices – amount accrued

1,629

3,002

Accounts payable and accrued expenses to Advent BioServices

$

5,363

$

3,836

XML 50 R31.htm IDEA: XBRL DOCUMENT v3.21.1
Stockholders' Deficit (Tables)
12 Months Ended
Dec. 31, 2020
Stockholders' Deficit  
Schedule of warrant activity

The following is a summary of warrant activity for the years ended December 31, 2020 and 2019 (dollars in thousands, except per share data):

    

Number of

    

Weighted Average

    

Remaining

Warrants

Exercise Price

Contractual Term

Outstanding as of January 1, 2019

 

372,153

$

0.29

 

1.97

Warrants granted

 

8,067

 

0.23

 

  

Warrants exercised for cash

 

(9,532)

 

0.23

 

  

Warrants expired and cancelled

 

(11,215)

 

0.62

 

  

Outstanding as of December 31, 2019

 

359,473

$

0.27

 

1.42

Warrants granted

88,658

0.22

Contingently issuable warrants (1)

 

2,774

 

1.48

 

  

Warrants exercised for cash

 

(47,511)

 

0.29

 

  

Cashless warrants exercise

(8,631)

0.22

Warrants expired and cancelled

 

(63,010)

 

0.32

 

  

Outstanding as of December 31, 2020 (2)

 

331,753

$

0.28

 

1.61

XML 51 R32.htm IDEA: XBRL DOCUMENT v3.21.1
Commitments and Contingencies (Tables)
12 Months Ended
Dec. 31, 2020
Commitments and Contingencies.  
Schedule of quantitative information about the company's operating leases

The following summarizes quantitative information about the Company’s operating leases (amount in thousands):

For the Year ended

December 31, 2020

    

U.K

    

U.S

    

Total

Lease cost

Operating lease cost

$

610

$

330

$

940

Short-term lease cost

44

44

Variable lease cost

45

20

65

Total

$

699

$

350

$

1,049

Other information

Operating cash flows from operating leases

$

(661)

$

(332)

$

(993)

Weighted-average remaining lease term - operating leases

9.1

0.2

Weighted-average discount rate - operating leases

12

%

12

%

Schedule of maturities of our operating leases, excluding short-term leases

Maturities of our operating leases, excluding short-term leases, are as follows:

    

U.K

    

U.S

    

Total

Year ended December 31, 2021

$

644

$

84

$

728

Year ended December 31, 2022

644

644

Year ended December 31, 2023

644

644

Year ended December 31, 2024

644

644

Thereafter

8,990

8,990

Total

11,566

84

11,650

Less present value discount

(6,565)

(2)

(6,567)

Operating lease liabilities included in the Consolidated Balance Sheet at December 31, 2020

$

5,001

$

82

$

5,083

XML 52 R33.htm IDEA: XBRL DOCUMENT v3.21.1
Income Taxes (Tables)
12 Months Ended
Dec. 31, 2020
Income Taxes  
Schedule of Deferred Tax Assets and Liabilities

The tax effects of temporary differences and tax loss and credit carry forwards that give rise to significant portions of deferred tax assets and liabilities at December 31, 2020 and 2019 are comprised of the following (in thousands):

    

As of December 31, 2020

    

As of December 31, 2019

Deferred tax asset

 

  

 

  

Net operating loss carryforward

$

185,308

$

176,140

Research and development credit carry forwards

 

18,580

 

16,983

Stock based compensation and other

 

22,997

 

14,565

Total deferred tax assets

 

226,885

 

207,688

Valuation Allowance

 

(226,885)

 

(207,688)

Deferred tax asset, net of allowance

$

$

Schedule of Effective Income Tax Rate Reconciliation

The expected tax expense (benefit) based on the U.S. federal statutory rate is reconciled with actual tax expense (benefit) as follows:

(dollars in thousands)

    

As of December 31, 2020

    

As of December 31, 2019

 

Statutory federal income tax rate

 

21.0

%  

21.0

%  

State taxes, net of federal tax benefit

 

1.1

%  

8.9

%  

Tax rate differential on foreign income

 

0.0

%  

(0.4)

%  

Derivative gain or loss

 

(17.3)

%  

12.2

%  

Expiration of net operating losses

 

(1.5)

%  

(7.9)

%  

Other permanent items and true ups

 

(0.1)

%  

(2.3)

%  

R&D Credit

 

0.3

%  

3.0

%  

Change in valuation allowance

 

(3.5)

%  

(34.5)

%  

Income tax provision (benefit)

 

0.0

%  

0.0

%  

Schedule of Components of Income Tax Expense (Benefit)

    

As of December 31, 2020

    

As of December 31, 2019

Federal

 

  

 

  

Current

$

$

Deferred

 

(15,539)

 

(5,183)

State

 

 

  

Current

 

 

Deferred

 

(4,327)

 

(1,421)

Foreign

 

 

  

Current

 

 

  

Deferred

 

670

 

(404)

Change in valuation allowance

 

19,196

 

7,008

Income tax provision (benefit)

$

$

XML 53 R34.htm IDEA: XBRL DOCUMENT v3.21.1
Financial Condition, Going Concern and Management Plans (Details Textual) - USD ($)
$ in Thousands
12 Months Ended
Dec. 31, 2020
Dec. 31, 2019
Organization and Description of Business    
Net Cash Provided by (Used in) Operating Activities $ (32,093) $ (31,859)
Net Income (Loss) Attributable to Parent (529,821) $ (20,812)
Net Cash Loss 32,000  
Net Non-cash Loss $ 497,800  
XML 54 R35.htm IDEA: XBRL DOCUMENT v3.21.1
Summary of Significant Accounting Policies (Details)
12 Months Ended
Dec. 31, 2020
USD ($)
segment
Dec. 31, 2019
USD ($)
Jan. 01, 2019
USD ($)
Cumulative effect of adopting new accounting standard $ (1,371,216,000) $ (841,395,000)  
Operating Lease, Right-of-Use Asset 4,489,000 4,679,000 $ 4,300,000
Operating Lease, Liability 5,083,000   $ 4,300,000
Federal depository insurance coverage 250,000    
Cash and cash equivalents uninsured amount 10,000,000    
Cash and cash equivalents held by foreign subsidiaries $ 600,000    
Number of Operating Segments | segment 1    
Number of reporting segments | segment 1    
Impairment charge $ 0    
Cumulative Effect, Period of Adoption, Adjustment      
Cumulative effect of adopting new accounting standard   $ 4,802,000  
UNITED KINGDOM      
Operating Lease, Right-of-Use Asset 4,500,000    
Operating Lease, Liability 5,001,000    
Short term contingent note | Cognate Bio Services Notes [Member]      
Deferred Accounts Payable $ 10,000,000    
XML 55 R36.htm IDEA: XBRL DOCUMENT v3.21.1
Fair Value Measurements (Details) - USD ($)
$ in Thousands
Dec. 31, 2020
Dec. 31, 2019
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Warrant liability $ 354,972 $ 20,213
Embedded conversion option 2,507  
Contingent payable derivative liability 8,275 7,261
Total fair value 365,754 27,474
Fair Value, Inputs, Level 1 [Member]    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Warrant liability 0 0
Embedded conversion option 0  
Contingent payable derivative liability 0 0
Total fair value 0 0
Fair Value, Inputs, Level 2 [Member]    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Warrant liability 0 0
Embedded conversion option 0  
Contingent payable derivative liability 0 0
Total fair value 0 0
Fair Value, Inputs, Level 3 [Member]    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Warrant liability 354,972 20,213
Embedded conversion option 2,507  
Contingent payable derivative liability 8,275 7,261
Total fair value $ 365,754 $ 27,474
XML 56 R37.htm IDEA: XBRL DOCUMENT v3.21.1
Fair Value Measurements - Changes in Level 3 liabilities (Details) - USD ($)
$ in Thousands
12 Months Ended
Dec. 31, 2020
Dec. 31, 2019
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Balance $ 27,474 $ 30,352
Additional contingent liability in connection with a settlement agreement   6,602
Additional warrant liability 18,864 4,110
Reclassification of warrant liabilities (110,471)  
Extinguishment of derivative liabilities   (3)
Additional embedded conversion option 2,807  
Extinguishment of warrant liabilities related to warrants exercised for cash   (1,759)
Extinguishement of embedded conversion option due to debt conversion and debt repayment (8,271)  
Change in fair value 435,351 (11,828)
Balance 365,754 27,474
Warrant Liability [Member]    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Balance 20,213 29,995
Additional warrant liability 18,864 4,110
Reclassification of warrant liabilities (110,471)  
Extinguishment of warrant liabilities related to warrants exercised for cash   (1,759)
Change in fair value 426,366 (12,133)
Balance 354,972 20,213
Contingent Payable Derivative Liability [Member]    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Balance 7,261  
Additional contingent liability in connection with a settlement agreement   6,602
Change in fair value 1,014 659
Balance 8,275 7,261
Embedded Conversion Option [Member]    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Balance   357
Extinguishment of derivative liabilities   (3)
Additional embedded conversion option 2,807  
Extinguishement of embedded conversion option due to debt conversion and debt repayment (8,271)  
Change in fair value 7,971 $ (354)
Balance $ 2,507  
XML 57 R38.htm IDEA: XBRL DOCUMENT v3.21.1
Fair Value Measurements - Weighted average (in aggregate) significant unobservable inputs (Details) - $ / shares
12 Months Ended
Dec. 31, 2020
Dec. 31, 2019
Warrant Liability [Member]    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Strike price $ 0.28  
Contractual term (years) 1 year 7 months 6 days  
Volatility (annual) 116.00%  
Risk-free rate 0.20%  
Dividend yield (per share) 0.00%  
Contingent Payable Derivative Liability [Member]    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Strike price $ 1.53  
Contractual term (years) 1 year 4 months 24 days  
Volatility (annual) 126.00%  
Risk-free rate 0.10%  
Dividend yield (per share) 0.00%  
Embedded Conversion Option [Member]    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Strike price $ 0.59  
Contractual term (years) 10 months 24 days  
Volatility (annual) 106.00%  
Risk-free rate 0.10%  
Dividend yield (per share) 0.00%  
Fair Value, Inputs, Level 3 [Member] | Warrant Liability [Member]    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Strike price   $ 0.21
Contractual term (years)   1 year 4 months 24 days
Volatility (annual)   74.00%
Risk-free rate   2.00%
Dividend yield (per share)   0.00%
Fair Value, Inputs, Level 3 [Member] | Embedded Conversion Option [Member]    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Strike price   $ 0.21
Contractual term (years)   1 year
Volatility (annual)   62.00%
Risk-free rate   2.00%
Dividend yield (per share)   0.00%
XML 58 R39.htm IDEA: XBRL DOCUMENT v3.21.1
Flaskworks Acquisition (Details) - USD ($)
$ / shares in Units, $ in Thousands
3 Months Ended
Dec. 25, 2020
Dec. 01, 2020
Aug. 28, 2020
Dec. 31, 2020
Dec. 31, 2019
Business Acquisition [Line Items]          
Purchase price paid in cash     $ 200    
Purchase price paid in cash     $ 200    
Assets acquired and liabilities assumed          
Goodwill       $ 626 $ 0
Acquisition          
Business Acquisition [Line Items]          
Acquired ownership units percentage     100.00%    
Total purchase price     $ 4,300    
Purchase price paid in cash $ 500   1,700    
Purchase price paid in stock 200   2,010    
Purchase price to be paid in either cash or stock, or a combination     700    
Business Combination, Consideration Transferred, Other     2,010 $ 500  
Purchase price paid in cash $ 500   1,700    
Issuance of common stock in acquisition (in shares) 654,762 1,500,000      
Special consideration $ 200   2,010    
Business Acquisition, Share Price $ 0.336        
Incremental change in fair value of the shares $ 900        
Assets acquired and liabilities assumed          
Cash     146    
Current assets     135    
Fixed assets, net     188    
Indefinite-lived intangible asset     1,292    
Security deposits     8    
Total assets acquired     1,769    
Accounts payable     (12)    
Accrued expenses     (240)    
Total liabilities assumed     (252)    
Net identifiable assets acquired     1,517    
Goodwill     626    
Total estimated consideration     2,143    
Less special consideration paid in cash and stock     (465)    
Less cash acquired     (146)    
Total consideration paid, net of cash acquired     $ 1,532    
XML 59 R40.htm IDEA: XBRL DOCUMENT v3.21.1
Stock-based Compensation - Stock option activity (Details) - USD ($)
$ / shares in Units, $ in Thousands
12 Months Ended
Dec. 31, 2020
Dec. 31, 2019
Dec. 31, 2018
Stock-based Compensation      
Number of Shares, Outstanding 104,659 100,159  
Number of Shares, Granted 208,525 4,500  
Number of Shares, Cashless exercise (94)    
Number of Shares, Forfeited/expired (4,250)    
Number of Shares, Outstanding 308,840 104,659 100,159
Number of Shares, Options vested 223,720    
Weighted Average Exercise Price, Outstanding $ 0.24 $ 0.24  
Weighted Average Exercise Price, Granted 0.37 0.22  
Weighted Average Exercise Price, Cashless exercise 0.34    
Weighted Average Exercise Price, Forfeited/expired 0.22    
Weighted Average Exercise Price, Outstanding 0.33 $ 0.24 $ 0.24
Weighted Average Exercise Price, Options vested $ 0.30    
Weighted Average Remaining Contractual Life (in years), Outstanding 8 years 10 months 24 days 8 years 4 months 24 days 9 years 3 months 18 days
Weighted Average Remaining Contractual Life (in years), Granted 10 years 10 years 4 months 24 days  
Weighted Average Remaining Contractual Life (in years), Options vested 8 years 8 months 12 days    
Total Intrinsic Value, Outstanding      
Total Intrinsic Value, Outstanding $ 372,219    
Total Intrinsic Value, Options vested $ 276,432    
XML 60 R41.htm IDEA: XBRL DOCUMENT v3.21.1
Stock-based Compensation - Assumptions (Details) - $ / shares
12 Months Ended
Aug. 05, 2020
Dec. 31, 2020
Dec. 31, 2019
Exercise price   $ 0.26 $ 0.20
Expected term (years)   5 years 2 months 12 days 5 years 7 months 6 days
Expected stock price volatility   98.00% 86.00%
Risk-free rate of interest   0.00% 1.00%
Post Modification      
Exercise price $ 0.22 $ 0.23  
Expected term (years) 5 years 3 months 18 days 4 years 3 months 18 days  
Expected stock price volatility 96.00% 97.00%  
Risk-free rate of interest 0.00% 0.00%  
Pre Modification      
Exercise price $ 0.22 $ 0.23  
Expected term (years) 4 years 8 months 12 days 4 years  
Expected stock price volatility 97.00% 97.00%  
Risk-free rate of interest 0.00% 0.00%  
XML 61 R42.htm IDEA: XBRL DOCUMENT v3.21.1
Stock-based Compensation - Summary of stock-based compensation expense (Details) - USD ($)
$ in Thousands
12 Months Ended
Dec. 01, 2020
Dec. 31, 2020
Dec. 31, 2019
Total stock-based compensation expense   $ 51,955 $ 1,821
Research and development      
Total stock-based compensation expense $ 500 19,792 471
General and administrative      
Total stock-based compensation expense $ 500 $ 32,163 $ 1,350
XML 62 R43.htm IDEA: XBRL DOCUMENT v3.21.1
Stock-based Compensation - Additional Information (Details) - USD ($)
1 Months Ended 12 Months Ended
Dec. 01, 2020
Aug. 05, 2020
Apr. 30, 2020
Dec. 31, 2020
Dec. 31, 2019
Dec. 31, 2018
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]            
Employee Service Share-based Compensation, Nonvested Awards, Compensation Cost Not yet Recognized       $ 17,000,000    
Employee Service Share-based Compensation, Nonvested Awards, Compensation Cost Not yet Recognized, Period for Recognition       1 year 9 months 18 days    
Share-based compensation arrangement by share-based payment award, options, cancelled in period   1,750,000        
Number of Shares, Outstanding   3,000,000   308,840 104,659 100,159
Incremental stock-based compensation for stock options modification   $ 300,000   $ 78,000,000    
Weighted Average Exercise Price, Granted       $ 0.37 $ 0.22  
Existing options that the Company's CEO has agreed to not exercise until the specified period (in shares)     39,200,000      
Period during which the Company's CEO has agreed to not exercise the options     6 months      
Extended contractual term of the options held by the Company's CEO     6 months      
Allocated Share-based Compensation Expense       $ 51,955,000 $ 1,821,000  
Acquisition            
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]            
Share-based Compensation   $ 2,000,000        
Allocated Share-based Compensation Expense       $ 1,000,000.0    
Stock options            
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]            
Number of shares, Vested       128,000,000    
Weighted Average Exercise Price, Granted       $ 0.36    
General and administrative            
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]            
Allocated Share-based Compensation Expense $ 500,000     $ 32,163,000 1,350,000  
Research and development            
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]            
Allocated Share-based Compensation Expense $ 500,000     $ 19,792,000 $ 471,000  
XML 63 R44.htm IDEA: XBRL DOCUMENT v3.21.1
Property, Plant and Equipment (Details) - USD ($)
$ in Thousands
12 Months Ended
Dec. 31, 2020
Dec. 31, 2019
Construction in progress $ 9,074 $ 1,685
Total property, plant and equipment, net 1,040 281
Domestic [Member]    
Property, Plant and Equipment, Gross 1,796 946
Less: accumulated depreciation (756) (665)
Construction in progress $ 9,074 1,685
Leasehold improvements [Member]    
Leasehold Improvements Useful Life Lesser of lease term or estimated useful life  
Leasehold improvements [Member] | Domestic [Member]    
Property, Plant and Equipment, Gross $ 81 186
Office furniture and equipment [Member] | Maximum    
Property, Plant and Equipment, Useful Life 5 years  
Office furniture and equipment [Member] | Minimum    
Property, Plant and Equipment, Useful Life 3 years  
Office furniture and equipment [Member] | Domestic [Member]    
Property, Plant and Equipment, Gross $ 219 59
Computer equipment and software [Member] | Maximum    
Property, Plant and Equipment, Useful Life 5 years  
Computer equipment and software [Member] | Minimum    
Property, Plant and Equipment, Useful Life 3 years  
Computer equipment and software [Member] | Domestic [Member]    
Property, Plant and Equipment, Gross $ 1,403 611
Land [Member] | UNITED KINGDOM    
Property, Plant and Equipment, Gross $ 93 $ 90
XML 64 R45.htm IDEA: XBRL DOCUMENT v3.21.1
Property, Plant and Equipment - Additional Information (Details) - USD ($)
12 Months Ended
Dec. 31, 2020
Dec. 31, 2019
Property, Plant and Equipment    
Depreciation $ 87,000 $ 21,000
XML 65 R46.htm IDEA: XBRL DOCUMENT v3.21.1
Notes Payable (Details) - USD ($)
12 Months Ended
Dec. 31, 2020
Dec. 31, 2019
Aug. 31, 2020
May 31, 2020
Dec. 31, 2018
Debt Instrument, Stated Interest Rate         10.00%
Debt Instrument, Face Value $ 13,751,000 $ 13,411,000      
Debt Instrument, Remaining Debt Discount (1,484,000) (688,000)      
Debt Instrument, Embedded Conversion Option (2,507,000)        
Debt Instrument, Carrying Value $ 14,774,000 $ 12,723,000      
6% Unsecurble [Member]          
Debt Instrument, Stated Interest Rate 6.00%        
8% unsecured [Member]          
Debt Instrument, Face Value $ 5,800,000        
10% unsecured [Member]          
Debt Instrument, Conversion Price     $ 0.34    
Debt Instrument, Face Value $ 3,300,000   $ 1,500,000 $ 300,000  
12% unsecured [Member]          
Debt Instrument, Stated Interest Rate 12.00% 12.00%      
Debt Instrument, Face Value $ 440,000 $ 440,000      
Short term convertible notes payable [Member]          
Debt Instrument, Face Value 2,260,000 635,000      
Debt Instrument, Remaining Debt Discount (937,000) (67,000)      
Debt Instrument, Embedded Conversion Option (2,507,000)        
Debt Instrument, Carrying Value $ 3,830,000 $ 568,000      
Short term convertible notes payable [Member] | 6% Unsecurble [Member]          
Debt Instrument, Maturity Date, Description Due Due      
Debt Instrument, Stated Interest Rate 6.00% 6.00%      
Debt Instrument, Conversion Price $ 3.09 $ 3.09      
Debt Instrument, Face Value $ 135,000 $ 135,000      
Debt Instrument, Carrying Value $ 135,000 $ 135,000      
Short term convertible notes payable [Member] | 8% unsecured [Member]          
Debt Instrument, Maturity Date, Description 4/30/2021        
Debt Instrument, Stated Interest Rate 8.00%        
Debt Instrument, Conversion Price $ 0.85        
Debt Instrument, Face Value $ 2,125,000        
Debt Instrument, Remaining Debt Discount (937,000)        
Debt Instrument, Embedded Conversion Option (2,507,000)        
Debt Instrument, Carrying Value 3,695,000        
Short term convertible notes payable [Member] | 10% unsecured [Member]          
Debt Instrument, Maturity Date, Description   4/18/2020      
Debt Instrument, Stated Interest Rate   10.00%      
Debt Instrument, Conversion Price   $ 0.22      
Debt Instrument, Face Value   $ 500,000      
Debt Instrument, Remaining Debt Discount   (67,000)      
Debt Instrument, Carrying Value   433,000      
Short Term Notes Payable [Member]          
Debt Instrument, Face Value 2,488,000 5,702,000      
Debt Instrument, Remaining Debt Discount (51,000) (201,000)      
Debt Instrument, Carrying Value $ 2,437,000 $ 5,501,000      
Short Term Notes Payable [Member] | 8% unsecured [Member]          
Debt Instrument, Maturity Date, Description Various Various      
Debt Instrument, Stated Interest Rate 8.00% 8.00%      
Debt Instrument, Face Value $ 1,785,000 $ 555,000      
Debt Instrument, Remaining Debt Discount (51,000) (43,000)      
Debt Instrument, Carrying Value $ 1,734,000 $ 512,000      
Short Term Notes Payable [Member] | 10% unsecured [Member]          
Debt Instrument, Maturity Date, Description Various Various      
Debt Instrument, Stated Interest Rate 10.00% 10.00%      
Debt Instrument, Face Value $ 263,000 $ 3,551,000      
Debt Instrument, Remaining Debt Discount   (73,000)      
Debt Instrument, Carrying Value $ 263,000 $ 3,478,000      
Short Term Notes Payable [Member] | 12% unsecured [Member]          
Debt Instrument, Maturity Date, Description On Demand On Demand      
Debt Instrument, Stated Interest Rate 12.00% 12.00%      
Debt Instrument, Face Value $ 440,000 $ 440,000      
Debt Instrument, Carrying Value 440,000 $ 440,000      
Short Term Notes Payable [Member] | 0% unsecured [Member]          
Debt Instrument, Maturity Date, Description   8/1/2020      
Debt Instrument, Stated Interest Rate   0.00%      
Debt Instrument, Face Value   $ 1,156,000      
Debt Instrument, Remaining Debt Discount   (85,000)      
Debt Instrument, Carrying Value   1,071,000      
Short term convertible notes payable - related parties [Member]          
Debt Instrument, Face Value   66,000      
Debt Instrument, Carrying Value   $ 66,000      
Short term convertible notes payable - related parties [Member] | 10% unsecured [Member]          
Debt Instrument, Maturity Date, Description   On Demand      
Debt Instrument, Stated Interest Rate   10.00%      
Debt Instrument, Face Value   $ 66,000      
Debt Instrument, Carrying Value   66,000      
Long Term Notes Payable [Member]          
Debt Instrument, Face Value 9,003,000 7,008,000      
Debt Instrument, Remaining Debt Discount (496,000) (420,000)      
Debt Instrument, Carrying Value $ 8,507,000 $ 6,588,000      
Long Term Notes Payable [Member] | 8% unsecured [Member]          
Debt Instrument, Maturity Date, Description Various Various      
Debt Instrument, Stated Interest Rate 8.00% 8.00%      
Debt Instrument, Face Value $ 7,160,000 $ 7,008,000      
Debt Instrument, Remaining Debt Discount (496,000) (420,000)      
Debt Instrument, Carrying Value $ 6,664,000 $ 6,588,000      
Long Term Notes Payable [Member] | 6% secured [Member]          
Debt Instrument, Maturity Date, Description 3/25/2025        
Debt Instrument, Stated Interest Rate 6.00%        
Debt Instrument, Face Value $ 1,843,000        
Debt Instrument, Carrying Value $ 1,843,000        
XML 66 R47.htm IDEA: XBRL DOCUMENT v3.21.1
Notes Payable - Mortgage Loan (Details) - USD ($)
$ in Thousands
12 Months Ended
Dec. 31, 2020
Dec. 31, 2019
Contractual interest $ 20 $ 366
Amortization of Debt Discount 3,013 1,430
Amortization of debt discount 122 0
Interest Expense, Debt 8,544 2,975
Interest and Debt Expense 4,412 366
Other interest expenses 10 11
Total interest expense 8,544 2,975
Short term convertible notes payable - related parties [Member]    
Contractual interest 20 366
Amortization of Debt Discount (Premium) 122  
Interest Expense, Debt 142 366
Forbearance of debt to related parties    
Interest Expense, Debt 4,270  
Notes payable    
Contractual interest 1,231 1,168
Amortization of debt discount 2,891 1,430
Interest and Debt Expense $ 4,122 $ 2,598
XML 67 R48.htm IDEA: XBRL DOCUMENT v3.21.1
Notes Payable - summary of the company's contractual obligations on debt principal (Details) - USD ($)
Dec. 31, 2020
Aug. 31, 2020
May 31, 2020
Dec. 31, 2019
Debt Instrument, Face Amount $ 13,751,000     $ 13,411,000
10% unsecured [Member]        
Debt Instrument, Face Amount 3,300,000 $ 1,500,000 $ 300,000  
8% unsecured [Member]        
Debt Instrument, Face Amount 5,800,000      
12% unsecured [Member]        
Debt Instrument, Face Amount 440,000     440,000
Short term convertible note | 6% unsecured [Member]        
Debt Instrument, Face Amount 135,000      
Short term convertible note | 8% unsecured [Member]        
Debt Instrument, Face Amount 2,125,000      
Short Term Notes Payable [Member]        
Debt Instrument, Face Amount 2,488,000     5,702,000
Short Term Notes Payable [Member] | 10% unsecured [Member]        
Debt Instrument, Face Amount 263,000     3,551,000
Short Term Notes Payable [Member] | 8% unsecured [Member]        
Debt Instrument, Face Amount 1,785,000     555,000
Short Term Notes Payable [Member] | 12% unsecured [Member]        
Debt Instrument, Face Amount 440,000     440,000
Short Term Notes Payable [Member] | 0% unsecured [Member]        
Debt Instrument, Face Amount       1,156,000
Short term convertible notes payable - related parties [Member]        
Debt Instrument, Face Amount       66,000
Short term convertible notes payable - related parties [Member] | 10% unsecured [Member]        
Debt Instrument, Face Amount       66,000
Long Term Notes Payable [Member]        
Debt Instrument, Face Amount 9,003,000     7,008,000
Long Term Notes Payable [Member] | 8% unsecured [Member]        
Debt Instrument, Face Amount 7,160,000     $ 7,008,000
Long Term Notes Payable [Member] | 6% secured [Member]        
Debt Instrument, Face Amount 1,843,000      
Less than 1 Year [Member]        
Debt Instrument, Face Amount 4,748,000      
Less than 1 Year [Member] | Short term convertible note | 6% unsecured [Member]        
Debt Instrument, Face Amount 135,000      
Less than 1 Year [Member] | Short term convertible note | 8% unsecured [Member]        
Debt Instrument, Face Amount 2,125,000      
Less than 1 Year [Member] | Short Term Notes Payable [Member] | 10% unsecured [Member]        
Debt Instrument, Face Amount 263,000      
Less than 1 Year [Member] | Short Term Notes Payable [Member] | 8% unsecured [Member]        
Debt Instrument, Face Amount 1,785,000      
Less than 1 Year [Member] | Short Term Notes Payable [Member] | 12% unsecured [Member]        
Debt Instrument, Face Amount 440,000      
1 to 2 Years [Member]        
Debt Instrument, Face Amount 7,160,000      
1 to 2 Years [Member] | Long Term Notes Payable [Member] | 8% unsecured [Member]        
Debt Instrument, Face Amount 7,160,000      
3 to 5 Years [Member]        
Debt Instrument, Face Amount 1,843,000      
3 to 5 Years [Member] | Long Term Notes Payable [Member] | 6% secured [Member]        
Debt Instrument, Face Amount $ 1,843,000      
XML 68 R49.htm IDEA: XBRL DOCUMENT v3.21.1
Notes Payable - Additional Information (Details)
$ / shares in Units, £ in Thousands
1 Months Ended 3 Months Ended 4 Months Ended 12 Months Ended
Jan. 15, 2021
USD ($)
$ / shares
shares
Oct. 18, 2020
USD ($)
Oct. 01, 2020
USD ($)
shares
Sep. 29, 2020
USD ($)
shares
Aug. 03, 2020
USD ($)
shares
May 20, 2020
USD ($)
Mar. 26, 2020
USD ($)
May 28, 2019
USD ($)
Sep. 26, 2018
USD ($)
Oct. 31, 2020
USD ($)
$ / shares
Aug. 31, 2020
USD ($)
$ / shares
shares
May 31, 2020
USD ($)
$ / shares
Apr. 30, 2020
USD ($)
$ / shares
shares
Feb. 29, 2020
USD ($)
$ / shares
shares
Mar. 31, 2021
USD ($)
$ / shares
shares
May 31, 2020
USD ($)
$ / shares
shares
Dec. 31, 2020
USD ($)
$ / shares
shares
Dec. 31, 2019
USD ($)
$ / shares
Nov. 01, 2020
Mar. 26, 2020
GBP (£)
Dec. 31, 2018
Debt Instrument, Face Amount                                 $ 13,751,000 $ 13,411,000      
Debt Instrument, Unamortized Discount                                 1,484,000 688,000      
Embedded Conversion Option                                 (2,507,000)        
Carrying Value                                 14,774,000 12,723,000      
Notes Payable                                 135,000 135,000      
Legal Fees                                 3,267,000 3,742,000      
Embedded Derivative, Fair Value of Embedded Derivative Liability                                 2,507,000        
Debt Instrument, Interest Rate, Stated Percentage                                         10.00%
Repayments of Debt               $ 1,200,000                          
Interest Expense, Debt                                 8,544,000 2,975,000      
Repayments of Related Party Debt                                 $ 379,000 329,000      
Interest Payable                                   800,000      
Short-term Debt                 $ 65,000                        
Warrants and Rights Outstanding, Term                                     2 years 6 months    
Class of Warrant or Right, Number of Securities Called by Warrants or Rights | shares                                 8,500,000        
Loss (gain) from extinguishment of debt                                 $ 1,582,000 1,941,000      
Short term convertible notes payable [Member]                                          
Debt Instrument, Face Amount                                 2,260,000 635,000      
Debt Instrument, Unamortized Discount                                 937,000 67,000      
Embedded Conversion Option                                 (2,507,000)        
Carrying Value                                 3,830,000 568,000      
Short Term Notes Payable [Member]                                          
Debt Instrument, Face Amount                                 2,488,000 5,702,000      
Debt Instrument, Unamortized Discount                                 51,000 201,000      
Carrying Value                                 2,437,000 5,501,000      
Advent BioServices [Member]                                          
Debt Instrument, Interest Rate, Stated Percentage                 10.00%                        
Short-term Debt                 $ 65,000                        
Debt Instrument, Term.                 7 days                        
10% unsecured [Member]                                          
Debt Conversion, Converted Instrument, Amount                                 $ 1,400,000        
Debt Conversion, Converted Instrument, Shares Issued | shares                     4,800,000           4,100,000        
Debt Instrument, Face Amount                     $ 1,500,000 $ 300,000       $ 300,000 $ 3,300,000        
Det converted to warrants (in shares) | shares                     1,700,000                    
Debt Instrument, Convertible, Conversion Price | $ / shares                     $ 0.34                    
Repayments of Debt                                 100,000        
Number of existing warrants | shares                     6,500,000                    
Accrued interest amount converted                       1,300,000         15,000        
Fair value of debt converted                       500,000       500,000          
Embedded derivative liability extinguished                     $ 1,500,000                    
Loss (gain) from extinguishment of debt                     1,600,000 200,000                  
10% unsecured [Member] | Short term convertible notes payable [Member]                                          
Debt Conversion, Converted Instrument, Amount   $ 600,000                     $ 75,000                
Debt Instrument, Face Amount                                   500,000      
Debt Instrument, Unamortized Discount                                   67,000      
Carrying Value                                   $ 433,000      
Debt Instrument, Interest Rate, Stated Percentage                                   10.00%      
Debt Instrument, Convertible, Conversion Price | $ / shares                                   $ 0.22      
Class of Warrant or Right, Exercise Price of Warrants or Rights | $ / shares                         $ 0.25                
Warrants and Rights Outstanding, Term                         2 years                
Class of Warrant or Right, Number of Securities Called by Warrants or Rights | shares                         2,300,000                
Warrants issued at fair value                         $ 115,000                
10% unsecured [Member] | Short Term Notes Payable [Member]                                          
Debt Instrument, Face Amount                                 263,000 $ 3,551,000      
Debt Instrument, Unamortized Discount                                   73,000      
Carrying Value                                 $ 263,000 $ 3,478,000      
Debt Instrument, Interest Rate, Stated Percentage                                 10.00% 10.00%      
8% unsecured [Member]                                          
Debt Conversion, Converted Instrument, Shares Issued | shares                                 29,100,000        
Debt Instrument, Face Amount                                 $ 5,800,000        
Accrued interest amount converted                                 600,000        
Fair value of debt converted                                 7,600,000        
Loss (gain) from extinguishment of debt                                 1,200,000        
8% unsecured [Member] | Short term convertible notes payable [Member]                                          
Debt Instrument, Face Amount                                 2,125,000        
Debt Instrument, Unamortized Discount                                 937,000        
Embedded Conversion Option                                 (2,507,000)        
Carrying Value                                 $ 3,695,000        
Debt Instrument, Interest Rate, Stated Percentage                                 8.00%        
Debt Instrument, Convertible, Conversion Price | $ / shares                                 $ 0.85        
8% unsecured [Member] | Short Term Notes Payable [Member]                                          
Debt Instrument, Face Amount                                 $ 1,785,000 $ 555,000      
Debt Instrument, Unamortized Discount                                 51,000 43,000      
Carrying Value                                 $ 1,734,000 $ 512,000      
Debt Instrument, Interest Rate, Stated Percentage                                 8.00% 8.00%      
12% unsecured [Member]                                          
Debt Conversion, Converted Instrument, Amount                                 $ 300,000 $ 140,000      
Debt Instrument, Face Amount                                 $ 440,000 $ 440,000      
Debt Instrument, Interest Rate, Stated Percentage                                 12.00% 12.00%      
12% unsecured [Member] | Short Term Notes Payable [Member]                                          
Debt Instrument, Face Amount                                 $ 440,000 $ 440,000      
Carrying Value                                 $ 440,000 $ 440,000      
Debt Instrument, Interest Rate, Stated Percentage                                 12.00% 12.00%      
Short term contingent note | Cognate Bio Services Notes [Member]                                          
Deferred Accounts Payable                                 $ 10,000,000        
Subsequent Event                                          
Debt Conversion, Converted Instrument, Shares Issued | shares                             4,500,000            
Det converted to warrants (in shares) | shares 261,000                                        
Class of Warrant or Right, Exercise Price of Warrants or Rights | $ / shares $ 2.00                                        
Debt Conversion, Original Debt, Amount                             $ 4,600,000            
Fair value of warrants $ 62,100,000                                        
Minimum | 10% unsecured [Member]                                          
Debt Instrument, Term.                                 6 months        
Minimum | 10% unsecured [Member] | Short term convertible notes payable [Member]                                          
Debt Instrument, Convertible, Conversion Price | $ / shares                         $ 0.181                
Minimum | Subsequent Event                                          
Class of Warrant or Right, Exercise Price of Warrants or Rights | $ / shares                             $ 0.175            
Maximum | 10% unsecured [Member]                                          
Debt Instrument, Term.                                 12 months        
Maximum | 10% unsecured [Member] | Short term convertible notes payable [Member]                                          
Debt Instrument, Convertible, Conversion Price | $ / shares                         $ 0.22                
Maximum | Subsequent Event                                          
Class of Warrant or Right, Exercise Price of Warrants or Rights | $ / shares                             $ 0.34            
Goldman Note [Member]                                          
Debt Instrument, Face Amount                       $ 300,000       $ 300,000          
Det converted to warrants (in shares) | shares                               600,000          
Embedded Derivative, Fair Value of Embedded Derivative Liability                                 $ 1,600,000        
Debt Instrument, Interest Rate, Stated Percentage                       10.00%       10.00%          
Class of Warrant or Right, Exercise Price of Warrants or Rights | $ / shares                       $ 0.25       $ 0.25          
Repayments of Debt                                 300,000        
Warrants and Rights Outstanding, Term                       5 years       5 years          
Warrants issued as a percentage of common shares issued upon conversion                               50.00%          
Fair value of warrants                       $ 66,000       $ 66,000          
Amortization of Debt Discount (Premium)                               $ 36,000          
Debt Instrument, Term.                               15 days          
Goldman Note [Member] | Minimum                                          
Debt Instrument, Convertible, Conversion Price | $ / shares                       $ 0.23       $ 0.23          
Goldman Note [Member] | Maximum                                          
Debt Instrument, Convertible, Conversion Price | $ / shares                       $ 0.25       $ 0.25          
Promissory Note [Member] | 10% unsecured [Member]                                          
Debt Instrument, Face Amount                                 2,300,000        
Extinguishment of Debt, Amount                                 1,000,000.0        
Loss (gain) from extinguishment of debt                                 100,000        
Note Due In 2011 [Member]                                          
Notes Payable                                 110,000 $ 25,000      
Notes [Member]                                          
Debt Instrument, Face Amount                                 $ 7,200,000        
Number of installments for amortization                                 14        
Debt Instrument, Interest Rate, Stated Percentage                                 8.00%        
Legal fees                                 $ 10,000        
Amortization of Debt Discount (Premium)                                 $ 650,000        
Debt Instrument, Term.                                 21 months        
Paycheck Protection Program loan                                          
Proceeds from issuance of debt           $ 400,000                              
Debt Instrument, Interest Rate, Stated Percentage           1.00%                              
Loss (gain) from extinguishment of debt           $ 400,000                              
Debt Instrument, Term.           2 years                              
Proceeds from Issuance of Debt           $ 400,000                              
Six Percentage Note Payable One [Member]                                          
Notes Payable                                 $ 110,000 $ 25,000      
February Notes | 10% unsecured [Member]                                          
Debt Conversion, Converted Instrument, Shares Issued | shares                                 5,100,000        
Accrued interest amount converted                                 $ 68,000        
February Notes | 10% unsecured [Member] | Short term convertible notes payable [Member]                                          
Debt Instrument, Face Amount                           $ 1,000,000.0              
Debt Instrument, Interest Rate, Stated Percentage                           10.00%              
Debt Instrument, Convertible, Conversion Price | $ / shares                           $ 0.21              
Warrants exercise, Number | shares                           1,400,000              
Class of Warrant or Right, Exercise Price of Warrants or Rights | $ / shares                           $ 0.35              
Fair value of warrants                           $ 79,000              
Debt Instrument, Term.                           2 years              
April Note | Short term convertible notes payable [Member]                                          
Placement agent cost                         $ 69,000                
April Note | 10% unsecured [Member]                                          
Debt Conversion, Converted Instrument, Amount                                 $ 600,000        
Debt Conversion, Converted Instrument, Shares Issued | shares         5,100,000                       3,300,000        
Debt Instrument, Face Amount         $ 800,000                                
Det converted to warrants (in shares) | shares         2,500,000                                
Debt Instrument, Unamortized Discount         $ 200,000                                
Debt Instrument, Interest Rate, Stated Percentage                         10.00%                
Debt Instrument, Convertible, Conversion Price | $ / shares                         $ 0.17                
Class of Warrant or Right, Exercise Price of Warrants or Rights | $ / shares                         $ 0.20                
Extinguishment of Debt, Amount         1,500,000                                
Fair Value Adjustment of Warrants                         $ 51,000                
Number of existing warrants | shares                         5,100,000                
Accrued interest amount converted         26,000                       $ 28,000        
Warrants issued as a percentage of common shares issued upon conversion                         50.00%                
Fair value of debt converted         2,400,000               $ 400,000                
Loss (gain) from extinguishment of debt         $ 300,000               70,000                
April Note | 10% unsecured [Member] | Short term convertible notes payable [Member]                                          
Debt Instrument, Face Amount                         800,000                
Proceeds from issuance of debt                         700,000                
Proceeds from Issuance of Debt                         $ 700,000                
April Note | Minimum | 10% unsecured [Member]                                          
Class of Warrant or Right, Exercise Price of Warrants or Rights | $ / shares                         $ 0.25                
April Note | Maximum | 10% unsecured [Member]                                          
Class of Warrant or Right, Exercise Price of Warrants or Rights | $ / shares                         $ 0.20                
May Note                                          
Debt Conversion, Converted Instrument, Amount     $ 600,000                 $ 500,000                  
Debt Conversion, Converted Instrument, Shares Issued | shares     2,300,000                                    
Debt Instrument, Face Amount                       $ 600,000       $ 600,000          
Det converted to warrants (in shares) | shares     900,000                                    
Embedded Derivative, Fair Value of Embedded Derivative Liability     $ 2,800,000                                    
Debt Instrument, Interest Rate, Stated Percentage                       8.00%       8.00%          
Class of Warrant or Right, Exercise Price of Warrants or Rights | $ / shares                       $ 0.25       $ 0.25          
Debt Conversion, Original Debt, Amount                       $ 50,000                  
Accrued interest amount converted     19,000                                    
Warrants issued as a percentage of common shares issued upon conversion                       40.00%                  
Fair value of debt converted     $ 3,400,000                                    
October Note                                          
Debt Instrument, Face Amount                   $ 2,100,000                      
Original issue discount                   $ 200,000                      
Debt Instrument, Interest Rate, Stated Percentage                   8.00%                      
Debt Instrument, Convertible, Conversion Price | $ / shares                   $ 0.85                      
Class of Warrant or Right, Exercise Price of Warrants or Rights | $ / shares                   $ 2.00                      
Warrants issued as a percentage of common shares issued upon conversion                   30.00%                      
Fair value of debt converted                   $ 1,400,000                      
August Note                                          
Debt Conversion, Converted Instrument, Amount       $ 1,100,000                                  
Debt Conversion, Converted Instrument, Shares Issued | shares       3,300,000                                  
Debt Instrument, Face Amount                     1,100,000                    
Det converted to warrants (in shares) | shares       1,100,000                                  
Original issue discount                     $ 110,000                    
Debt Instrument, Unamortized Discount       $ 500,000                                  
Embedded Derivative, Fair Value of Embedded Derivative Liability       2,300,000                                  
Debt Instrument, Interest Rate, Stated Percentage                     8.00%                    
Debt Instrument, Convertible, Conversion Price | $ / shares                     $ 0.345                    
Class of Warrant or Right, Exercise Price of Warrants or Rights | $ / shares                     $ 0.34                    
Warrants issued as a percentage of common shares issued upon conversion                     35.00%                    
Fair value of debt converted       3,300,000             $ 600,000                    
Loss (gain) from extinguishment of debt       $ 400,000                                  
Amended | 10% unsecured [Member]                                          
Det converted to warrants (in shares) | shares                                 10,300,000        
Warrants and Rights Outstanding, Term                                 2 years        
Fair value of debt converted                                 $ 500,000        
Amended | Minimum | 10% unsecured [Member]                                          
Class of Warrant or Right, Exercise Price of Warrants or Rights | $ / shares                                 $ 0.20        
Amended | Maximum | 10% unsecured [Member]                                          
Class of Warrant or Right, Exercise Price of Warrants or Rights | $ / shares                                 $ 0.23        
Lender                                          
Debt Instrument, Face Amount             $ 1,700,000                         £ 1,350  
Debt Instrument, Interest Rate, Stated Percentage             6.25%                         6.25%  
Debt Instrument, Term.             5 years                            
Debt Instrument, Term For Repayment Of The Loan Principal And Interest             4 years                            
XML 69 R50.htm IDEA: XBRL DOCUMENT v3.21.1
Net Earnings (Loss) per Share Applicable to Common Stockholders (Details) - shares
shares in Thousands
12 Months Ended
Dec. 31, 2020
Dec. 31, 2019
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]    
Potentially dilutive securities 643,210 466,749
Common stock options [Member]    
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]    
Potentially dilutive securities 308,840 104,659
Common stock warrants - liability treatment [Member]    
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]    
Potentially dilutive securities 328,979 347,734
Warrants [Member]    
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]    
Potentially dilutive securities 2,774 11,739
Convertible notes and accrued interest [Member]    
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]    
Potentially dilutive securities 2,617 2,617
XML 70 R51.htm IDEA: XBRL DOCUMENT v3.21.1
Related Party Transactions - Summary of outstanding unpaid accounts payable held by related parties (Details) - USD ($)
$ in Thousands
12 Months Ended
Dec. 31, 2020
Dec. 31, 2019
Advent BioServices [Member]    
Related Party Transaction, Expenses from Transactions with Related Party $ 7,543 $ 5,735
XML 71 R52.htm IDEA: XBRL DOCUMENT v3.21.1
Related Party Transactions - Total interest expenses (Details) - USD ($)
$ in Thousands
12 Months Ended
Dec. 31, 2020
Dec. 31, 2019
Related Party Transactions    
Contractual interest $ 20 $ 366
Amortization of debt discount 122 0
Interest expenses related to forbearance of debt to related parties 4,270 0
Total interest expense $ 4,412 $ 366
XML 72 R53.htm IDEA: XBRL DOCUMENT v3.21.1
Related Party Transactions - Additional Information (Details) - USD ($)
$ / shares in Units, shares in Millions
12 Months Ended
Jul. 02, 2020
Nov. 08, 2019
Dec. 31, 2020
Dec. 31, 2019
Mar. 31, 2021
Jan. 15, 2021
Dec. 31, 2018
Sep. 26, 2018
Apr. 30, 2018
Related Party Transaction [Line Items]                  
Short-term Debt               $ 65,000  
Repayments of notes     $ 379,000 $ 329,000          
Interest rate             10.00%    
Interest expenses related to forbearance of debt to related parties     4,270,000 0          
Interest Expense, Debt     $ 8,544,000 2,975,000          
Extended term of the Ancillary Services agreement     12 months            
Interest Payable       800,000          
Subsequent Event                  
Related Party Transaction [Line Items]                  
Class of Warrant or Right, Exercise Price of Warrants or Rights           $ 2.00      
Forbearance Warrants [Member]                  
Related Party Transaction [Line Items]                  
Class of Warrant or Right, Exercise Price of Warrants or Rights     $ 0.21            
Class of Warrant or Right, Warrants Issued 15.2                
Debt instrument term     5 years            
Interest Payable     $ 4,300,000            
Extension of Loans $ 5,400,000                
Minimum | Subsequent Event                  
Related Party Transaction [Line Items]                  
Class of Warrant or Right, Exercise Price of Warrants or Rights         $ 0.175        
Maximum | Subsequent Event                  
Related Party Transaction [Line Items]                  
Class of Warrant or Right, Exercise Price of Warrants or Rights         $ 0.34        
Advent BioServices Invoiced [Member]                  
Related Party Transaction [Line Items]                  
Accounts Payable, Related Parties     3,734,000 834,000          
Advent Bioscience Accrued                  
Related Party Transaction [Line Items]                  
Accounts Payable, Related Parties     $ 1,629,000 3,002,000          
Term (in months)   8 months              
Extended term of the Ancillary Services agreement     12 months            
Advent BioServices [Member]                  
Related Party Transaction [Line Items]                  
Accounts Payable, Related Parties     $ 5,363,000 3,836,000          
Repayments of notes     73,000            
Sawston buildout [Member]                  
Related Party Transaction [Line Items]                  
Capitalized costs to related party     3,600,000 $ 900,000          
Mr. Goldman [Member]                  
Related Party Transaction [Line Items]                  
Repayments of notes     $ 300,000            
Senior Vice President                  
Related Party Transaction [Line Items]                  
Percentage of Warrant Coverage     50.00%            
Convertible notes payable     $ 315,000           $ 5,400,000
Senior Vice President | Advent BioServices [Member]                  
Related Party Transaction [Line Items]                  
Interest rate     10.00%            
XML 73 R54.htm IDEA: XBRL DOCUMENT v3.21.1
Stockholders' Deficit (Details) - $ / shares
12 Months Ended
Dec. 31, 2020
Dec. 31, 2019
Dec. 31, 2018
Stockholders' Deficit      
Number of Warrants, Outstanding 359,473 372,153  
Number of Warrants, Warrants granted 88,658 8,067  
Number of Warrants, Contingently issuable warrants 2,774    
Number of Warrants, Warrants exercised for cash (47,511) (9,532)  
Number of Warrants, Cashless warrants exercise (8,631)    
Number of Warrants, Warrants expired and cancellation (63,010) (11,215)  
Number of Warrants, Outstanding 331,753 [1] 359,473 372,153
Weighted Average Exercise Price - Outstanding $ 0.27 $ 0.29  
Weighted Average Exercise Price - Warrants granted 0.22 0.23  
Weighted Average Exercise Price - Contingently issuable warrants 1.48    
Weighted Average Exercise Price - Warrants exercised for cash 0.29 $ 0.23  
Weighted Average Exercise Price, Cashless warrants exercise $ 0.22    
Weighted Average Exercise Price, Warrants expired and cancellation 0.32% 0.62%  
Weighted Average Exercise Price - Outstanding $ 0.28 [1] $ 0.27 $ 0.29
Remaining Contractual Term 1 year 7 months 9 days [1] 1 year 5 months 1 day 1 year 11 months 19 days
[1] As of December 31, 2020, approximately 62.1 million warrants were not exercisable until January 15, 2021. Subsequent to January 15, 2021, the Company suspended 58.8 million warrants until February 28, 2021.
XML 74 R55.htm IDEA: XBRL DOCUMENT v3.21.1
Stockholders' Deficit - Additional Information (Details - USD ($)
1 Months Ended 3 Months Ended 12 Months Ended
Feb. 28, 2021
Jan. 15, 2021
Dec. 25, 2020
Dec. 01, 2020
Oct. 31, 2020
Oct. 12, 2020
Aug. 05, 2020
May 10, 2020
Aug. 31, 2020
May 31, 2020
Apr. 30, 2020
Mar. 31, 2021
Dec. 31, 2020
Dec. 31, 2019
Apr. 30, 2021
Dec. 15, 2020
Nov. 01, 2020
Dec. 31, 2018
Shareholders Deficit [Line Items]                                    
Proceeds from Warrant Exercises                         $ 13,915,000 $ 2,220,000        
Gain (Loss) on Extinguishment of Debt                         $ (1,582,000) $ (1,941,000)        
Shares Issued During Period Shares, Upon Exercise Of warrants                         47,500,000 9,500,000        
Class of Warrant or Right, Outstanding                         331,753 [1] 359,473       372,153
Common Stock, Shares Authorized                         1,200,000,000 1,200,000,000        
Common Stock, Par or Stated Value Per Share                         $ 0.001 $ 0.001        
Preferred Stock, Shares Authorized                         100,000,000 100,000,000        
Preferred Stock, Par or Stated Value Per Share                         $ 0.001 $ 0.001        
Class of Warrant or Right, Number of Securities Called by Warrants or Rights                         8,500,000          
Research and Development Expense                         $ 33,637,000 $ 14,106,000        
Debt Instrument, Face Amount                         13,751,000 13,411,000        
Warrants Not Settleable in Cash, Fair Value Disclosure             $ 5,300,000           $ 272,800,000 5,400,000     $ 2,800,000  
Class of Warrant or Right, Warrant Term                         2 years          
Value of Warrants Exercised For Cash                         $ 13,915,000 2,220,000        
Interest Payable                           800,000        
Proceeds from Issuance Initial Public Offering                           6,900,000        
Payments for Repurchase of Initial Public Offering                           $ 300,000        
Common Stock, Shares, Issued                         829,600,000 614,300,000        
Common Stock Shares Issued Upon Existing Loan Conversion                           1,300,000        
Issuance Of Common Shares In Settlement Agreement                           $ 52,000,000        
Issuance Of Common Shares In Settlement Agreement (in shares)                           12,000,000        
Proceeds from issuance of common stock and warrants in a registered direct offering, net                         $ 26,814,000 $ 6,874,000        
Payments of stock issuance costs                         $ 600,000 400,000        
Class of warrant or right, agreed to be suspended               14,200,000         14,600,000          
Proceeds from issuance of convertible notes payable, net                         $ 5,115,000          
Class of Warrant or Right, Agreed to be Suspended And Unexercisable                     90,000,000           60,000,000  
Class of Warrant or Right, Percentage Of Warrants Issued On Conversion               17.50%                    
Number of warrants suspended           274,000,000   81,000,000               183,000,000 29,000,000  
Number of common stock issued                         7,100,000          
Number of Warrants, cashless warrants exercise                         8,631          
Weighted Average Exercise Price, Cashless warrants exercise                         $ 0.22          
General and administrative expenses                         $ 50,992,000 $ 12,541,000        
Class of Warrant or Right, Extended in Suspension         157,000,000                          
Class of Warrant or Right, Suspended And Unexercisable         171,000,000                          
Subsequent Event                                    
Shareholders Deficit [Line Items]                                    
Proceeds from Warrant Exercises                       $ 700,000            
Debt Conversion, Converted Instrument, Shares Issued                       4,500,000            
Warrants exercise price   $ 2.00                                
Warrants Not Settleable in Cash, Fair Value Disclosure $ 58,800,000                                  
Warrants and Rights Outstanding   $ 62,100,000                                
Class of warrant or right, agreed to be suspended   3,500,000                                
Warrants exercise period   12 months                                
Number of warrants suspended                             262,000,000      
Number of warrants issued   261,000                                
Debt amount converted                       $ 4,600,000            
Class of Warrant or Right, Extended in Suspension 262,000,000 256,000,000                                
Class of Warrant or Right, Suspended And Unexercisable   190,000,000                                
Acquisition                                    
Shareholders Deficit [Line Items]                                    
Stock Issued During Period, Shares, Acquisitions     654,762 1,500,000                            
Weighted Average Exercise Price, Cashless warrants exercise     $ 0.336                              
Special consideration payment     $ 200,000                              
General and administrative expenses     $ 900,000                              
Share Settlement Agreement [Member]                                    
Shareholders Deficit [Line Items]                                    
Issuance Of Common Shares In Settlement Agreement (in shares)                           52,000,000        
Convertible Preferred Stock [Member]                                    
Shareholders Deficit [Line Items]                                    
Debt Conversion, Converted Instrument, Shares Issued                           35,500,000        
Gain (Loss) on Extinguishment of Debt                           $ 1,700,000        
Debt Instrument, Fair Value Disclosure                           6,800,000        
Debt Instrument, Increase, Accrued Interest                           700,000        
Warrants issued as consideration for warrants suspension                                    
Shareholders Deficit [Line Items]                                    
Class of Warrant or Right, Agreed to be Suspended And Unexercisable         21,000,000                          
Number of warrants suspended         178,000,000                          
Warrants through December 15, 2020                                    
Shareholders Deficit [Line Items]                                    
Class of Warrant or Right, Suspended And Unexercisable           178,000,000                        
Warrants Oher New Share Purchases                                    
Shareholders Deficit [Line Items]                                    
Class of Warrant or Right, Suspended And Unexercisable           96,000,000                        
Convertible Debt Securities [Member]                                    
Shareholders Deficit [Line Items]                                    
Debt Conversion, Converted Instrument, Shares Issued                         58,400,000          
Number of warrants issued                         6,200,000          
Debt amount converted                         $ 13,900,000          
Registered Direct Offering [Member]                                    
Shareholders Deficit [Line Items]                                    
Warrants exercise price                         $ 0.25          
Interest Payable                           $ 306,000,000        
Proceeds from Issuance Initial Public Offering                         $ 5,700,000          
Payments for Repurchase of Initial Public Offering                         $ 400,000          
Common Stock, Shares, Issued                         34,500,000 32,700,000        
April Financing                                    
Shareholders Deficit [Line Items]                                    
Warrants exercise price                     $ 0.20              
Shares issued                     19,900,000              
Class of Warrant or Right, Number of Securities Called by Warrants or Rights                     11,300,000              
Share Price                     $ 0.153              
Proceeds from issuance of common stock and warrants in a registered direct offering, net                         $ 3,000,000.0          
Payments of stock issuance costs                         68,000          
Proceeds from issuance of warrants                         $ 800,000          
May Financing                                    
Shareholders Deficit [Line Items]                                    
Shares issued                   14,200,000                
Class of Warrant or Right, Number of Securities Called by Warrants or Rights                   5,600,000                
Proceeds from issuance of common stock and warrants in a registered direct offering, net                   $ 2,900,000                
Proceeds from issuance of warrants                   $ 900,000                
August Financing                                    
Shareholders Deficit [Line Items]                                    
Amount of financing                 $ 8,000,000                  
Number of warrants suspended             75,500,000                      
Number of warrants issued             12,500,000                      
August Financing | Warrants issued as consideration for warrants suspension                                    
Shareholders Deficit [Line Items]                                    
Warrants exercise price             $ 0.34                      
August Financing | Convertible notes payable                                    
Shareholders Deficit [Line Items]                                    
Warrants exercise price             $ 0.34                      
Proceeds from issuance of convertible notes payable, net             $ 1,000,000                      
Conversion price             $ 0.345                      
Class of Warrant or Right, Percentage Of Warrants Issued On Conversion             35.00%                      
October Financing [Member]                                    
Shareholders Deficit [Line Items]                                    
Class of Warrant or Right, Number of Securities Called by Warrants or Rights           3,600,000                        
Incremental change in fair value of warrants           $ 1,200,000                        
Share Price           $ 0.816                        
Class of warrant or right, agreed to be suspended           3,600,000                        
Amount of financing           $ 11,900,000                        
Warrants exercise period           3 months                        
Debt amount converted           $ 10,000,000                        
October Financing [Member] | Convertible notes payable                                    
Shareholders Deficit [Line Items]                                    
Warrants exercise price           $ 2.00                        
Warrants exercise period           12 months                        
Proceeds from issuance of convertible notes payable, net           $ 1,900,000                        
Conversion price           $ 0.85                        
Class of Warrant or Right, Percentage Of Warrants Issued On Conversion           30.00%                        
Placement Agent                                    
Shareholders Deficit [Line Items]                                    
Warrants exercise price                         $ 0.21          
Class of Warrant or Right, Number of Securities Called by Warrants or Rights                         800,000          
Class of Warrant or Right, Warrant Term                         2 years          
Warrants [Member] | Registered Direct Offering [Member]                                    
Shareholders Deficit [Line Items]                                    
Incremental change in fair value of warrants                         $ 2,500,000          
Warrants [Member] | Placement Agent                                    
Shareholders Deficit [Line Items]                                    
Incremental change in fair value of warrants                         $ 1,000,000.0          
Common Stock                                    
Shareholders Deficit [Line Items]                                    
Debt Conversion, Converted Instrument, Amount                           $ 9,200,000        
Stock Issued During Period, Shares, Acquisitions                         655          
Stock Issued During Period, Shares, Other                         97,981 32,708        
Stock Issued During Period Shares Issued For Non Cash Consideration 1                         7,086          
Value of Warrants Exercised For Cash                         $ 48,000 $ 10,000        
Issuance Of Common Shares In Settlement Agreement                           $ 12,000        
Issuance Of Common Shares In Settlement Agreement (in shares)                           12,000        
Incremental change in fair value of warrants                           $ 2,500,000        
Percentage of warrants exercisable           30.00%                        
Number of Warrants, cashless warrants exercise                         8,600,000          
Common Stock | August Financing                                    
Shareholders Deficit [Line Items]                                    
Warrants exercise price             $ 0.34                      
Shares issued             21,800,000                      
Incremental change in fair value of warrants             $ 1,500,000                      
Share Price             $ 0.32                      
Amount from offering of newly registered common stock             $ 7,000,000                      
Number of warrants exercisable             5,300,000                      
Common Stock | October Financing [Member]                                    
Shareholders Deficit [Line Items]                                    
Warrants exercise price           $ 2.00                        
Shares issued           12,200,000                        
Warrants exercise period           12 months                        
Additional Paid-in Capital                                    
Shareholders Deficit [Line Items]                                    
Value of Warrants Exercised For Cash                         $ 13,867,000 2,210,000        
Issuance Of Common Shares In Settlement Agreement                           $ (12,000)        
Minimum                                    
Shareholders Deficit [Line Items]                                    
Sale of Stock, Price Per Share                           $ 0.19        
Minimum | Subsequent Event                                    
Shareholders Deficit [Line Items]                                    
Warrants exercise price                       $ 0.175            
Minimum | May Financing                                    
Shareholders Deficit [Line Items]                                    
Warrants exercise price                   $ 0.22                
Class of Warrant or Right, Warrant Term                   1 year 6 months                
Share Price                   $ 0.17                
Minimum | August Financing | Warrants issued as consideration for warrants suspension                                    
Shareholders Deficit [Line Items]                                    
Warrants exercise period             13 months 15 days                      
Minimum | Placement Agent                                    
Shareholders Deficit [Line Items]                                    
Warrants exercise price                         $ 0.17          
Minimum | Common Stock | August Financing                                    
Shareholders Deficit [Line Items]                                    
Percentage of warrants exercisable             20.00%                      
Warrants exercise period             18 years                      
Maximum                                    
Shareholders Deficit [Line Items]                                    
Sale of Stock, Price Per Share                           $ 0.23        
Maximum | Subsequent Event                                    
Shareholders Deficit [Line Items]                                    
Warrants exercise price                       $ 0.34            
Maximum | May Financing                                    
Shareholders Deficit [Line Items]                                    
Warrants exercise price                   $ 0.23                
Class of Warrant or Right, Warrant Term                   2 years 6 months                
Share Price                   $ 0.225                
Maximum | August Financing | Warrants issued as consideration for warrants suspension                                    
Shareholders Deficit [Line Items]                                    
Warrants exercise period             25 months 15 days                      
Maximum | Common Stock | August Financing                                    
Shareholders Deficit [Line Items]                                    
Percentage of warrants exercisable             35.00%                      
Warrants exercise period             30 months                      
[1] As of December 31, 2020, approximately 62.1 million warrants were not exercisable until January 15, 2021. Subsequent to January 15, 2021, the Company suspended 58.8 million warrants until February 28, 2021.
XML 75 R56.htm IDEA: XBRL DOCUMENT v3.21.1
Commitments and Contingencies (Details) - USD ($)
$ in Thousands
12 Months Ended
Dec. 31, 2020
Dec. 31, 2019
Lease cost    
Operating lease cost $ 940 $ 854
Short-term lease cost 44 131
Variable lease cost 65 15
Total 1,049 1,000
Other information    
Operating cash flows from operating leases (993) (244)
UNITED KINGDOM    
Lease cost    
Operating lease cost 610 607
Short-term lease cost 44 50
Variable lease cost 45  
Total 699 $ 657
Other information    
Operating cash flows from operating leases $ (661)  
Weighted-average remaining lease term - operating leases 9 years 1 month 6 days 10 years
Weighted-average discount rate - operating leases 12.00% 12.00%
UNITED STATES    
Lease cost    
Operating lease cost $ 330 $ 247
Short-term lease cost 0 81
Variable lease cost 20 15
Total 350 343
Other information    
Operating cash flows from operating leases $ (332) $ (244)
Weighted-average remaining lease term - operating leases 2 months 12 days 10 months 24 days
Weighted-average discount rate - operating leases 12.00% 12.00%
XML 76 R57.htm IDEA: XBRL DOCUMENT v3.21.1
Commitments and Contingencies - maturities of our operating leases (Details) - USD ($)
$ in Thousands
Dec. 31, 2020
Mar. 04, 2019
Jan. 01, 2019
Year ended December 31, 2021 $ 728    
Year ended December 31, 2022 644    
Year ended December 31, 2023 644    
Year ended December 31, 2024 644    
Therafter 8,990    
Total 11,650    
Less present value discount (6,567)    
Operating lease liabilities included in the Consolidated Balance Sheet at December 31, 2020 5,083   $ 4,300
UNITED STATES      
Year ended December 31, 2021 84    
Year ended December 31, 2022 0    
Year ended December 31, 2023 0    
Year ended December 31, 2024 0    
Therafter 0    
Total 84    
Less present value discount (2)    
Operating lease liabilities included in the Consolidated Balance Sheet at December 31, 2020 82 $ 600  
UNITED KINGDOM      
Year ended December 31, 2021 644    
Year ended December 31, 2022 644    
Year ended December 31, 2023 644    
Year ended December 31, 2024 644    
Therafter 8,990    
Total 11,566    
Less present value discount (6,565)    
Operating lease liabilities included in the Consolidated Balance Sheet at December 31, 2020 $ 5,001    
XML 77 R58.htm IDEA: XBRL DOCUMENT v3.21.1
Commitments and Contingencies - Additional Information (Details)
12 Months Ended
Feb. 12, 2021
USD ($)
Feb. 12, 2021
EUR (€)
May 14, 2018
USD ($)
Dec. 31, 2020
USD ($)
Dec. 31, 2019
USD ($)
Mar. 04, 2019
USD ($)
Jan. 01, 2019
USD ($)
Lease, Practical Expedient, Lessor Single Lease Component [true false]       true      
Operating Lease, Liability       $ 5,083,000     $ 4,300,000
Lessee, Operating Lease, Term of Contract       20 years      
Operating Lease, Right-of-Use Asset       $ 4,489,000 $ 4,679,000   $ 4,300,000
Original term of the agreement       8 months      
Extended term of the Ancillary Services agreement       12 months      
Foreign Tax Authorities              
Approved tax settlement offer $ 421,000 € 351,000          
Tax settlement offer for more recent years $ 187,000 € 156,000          
Advent BioSerivices [Member]              
Program Initiation Payment     $ 1,000,000.0        
UNITED STATES              
Operating Lease, Liability       $ 82,000   $ 600,000  
Operating Lease, Right-of-Use Asset           $ 600,000  
XML 78 R59.htm IDEA: XBRL DOCUMENT v3.21.1
Income Taxes - Summary of Deferred Tax Assets and Liabilities (Details) - USD ($)
$ in Thousands
Dec. 31, 2020
Dec. 31, 2019
Deferred tax asset    
Net operating loss carryforward $ 185,308 $ 176,140
Research and development credit carry forwards 18,580 16,983
Stock based compensation and other 22,997 14,565
Total deferred tax assets 226,885 207,688
Valuation Allowance (226,885) (207,688)
Deferred tax asset, net of allowance $ 0 $ 0
XML 79 R60.htm IDEA: XBRL DOCUMENT v3.21.1
Income Taxes - Reconcilation of U.S. Federal Statutory Tax Expense (Benefit) (Details)
12 Months Ended
Dec. 31, 2020
Dec. 31, 2019
Income Taxes    
Statutory federal income tax rate 21.00% 21.00%
State taxes, net of federal tax benefit 1.10% 8.90%
Tax rate differential on foreign income (0.00%) (0.40%)
Derivative gain or loss (17.30%) 12.20%
Expiration of net operating losses (1.50%) (7.90%)
Other permanent items and true ups (0.10%) (2.30%)
R&D Credit 0.30% 3.00%
Change in valuation allowance (3.50%) (34.50%)
Income tax provision (benefit) 0.00% 0.00%
XML 80 R61.htm IDEA: XBRL DOCUMENT v3.21.1
Income Taxes - Summary of Tax Provision Benefit (Details) - USD ($)
$ in Thousands
12 Months Ended
Dec. 31, 2020
Dec. 31, 2019
Federal    
Current $ 0 $ 0
Deferred (15,539) (5,183)
State    
Current 0 0
Deferred (4,327) (1,421)
Foreign    
Deferred 670 (404)
Change in valuation allowance 19,196 7,008
Income tax provision (benefit) $ 0 $ 0
XML 81 R62.htm IDEA: XBRL DOCUMENT v3.21.1
Income Taxes - Additional information (Details)
Dec. 31, 2020
USD ($)
Income Taxes [Line Items]  
Operating Loss Carryforwards $ 654,500,000
Deferred Tax Assets Tax Credit Carry Forward Unused Research And Development 547,000,000.0
Deferred Tax Assets, Tax Credit Carryforwards, Research 18,600,000
Deferred Tax Assets, Tax Credit Carryforwards, Foreign 30,000,000.0
Amounts accrued for penalties or interest 0
UNITED KINGDOM  
Income Taxes [Line Items]  
Deferred Tax Assets, Tax Credit Carryforwards, Foreign 13,300,000
Germany  
Income Taxes [Line Items]  
Deferred Tax Assets, Tax Credit Carryforwards, Foreign 16,500,000
Netherland  
Income Taxes [Line Items]  
Deferred Tax Assets, Tax Credit Carryforwards, Foreign 208,000
Foreign Tax Authorities | Germany  
Income Taxes [Line Items]  
Operating Loss Carryforwards $ 107,500,000
XML 82 R63.htm IDEA: XBRL DOCUMENT v3.21.1
Revision to Prior Period Financial Statements -Consolidated Balance Sheet (Details) - USD ($)
$ in Thousands
Dec. 31, 2020
Dec. 31, 2019
Dec. 31, 2018
Error Corrections and Prior Period Adjustments Restatement [Line Items]      
Construction in progress $ 9,074 $ 1,685  
Total non-current assets 17,388 7,443  
TOTAL ASSETS 32,899 10,643  
Accounts payable and accrued expenses to related parties and affiliates 5,363 3,844  
Total current liabilities 382,424 44,196  
Total liabilities 395,847 55,698  
Accumulated deficit (1,371,216) (841,395)  
Total stockholders' deficit (362,948) (45,055) $ (48,131)
TOTAL LIABILITIES AND STOCKHOLDERS' DEFICIT $ 32,899 10,643  
As Previously Reported      
Error Corrections and Prior Period Adjustments Restatement [Line Items]      
Construction in progress   171  
Total non-current assets   5,929  
TOTAL ASSETS   9,129  
Accounts payable and accrued expenses to related parties and affiliates   842  
Total current liabilities   41,194  
Total liabilities   52,696  
Accumulated deficit   (839,907)  
Total stockholders' deficit   (43,567)  
TOTAL LIABILITIES AND STOCKHOLDERS' DEFICIT   9,129  
Adjustments      
Error Corrections and Prior Period Adjustments Restatement [Line Items]      
Construction in progress   1,500  
Accounts payable and accrued expenses to related parties and affiliates   3,000  
Adjustments | Accrual and capitalization error correction      
Error Corrections and Prior Period Adjustments Restatement [Line Items]      
Construction in progress   1,514  
Total non-current assets   1,514  
TOTAL ASSETS   1,514  
Accounts payable and accrued expenses to related parties and affiliates   3,002  
Total current liabilities   3,002  
Total liabilities   3,002  
Accumulated deficit   (1,488)  
Total stockholders' deficit   (1,488)  
TOTAL LIABILITIES AND STOCKHOLDERS' DEFICIT   $ 1,514  
XML 83 R64.htm IDEA: XBRL DOCUMENT v3.21.1
Revision to Prior Period Financial Statements - Consolidated Statement of Operations (Detaills) - USD ($)
$ in Thousands
12 Months Ended
Dec. 31, 2020
Dec. 31, 2019
Error Corrections and Prior Period Adjustments Restatement [Line Items]    
Research and development expenses $ 33,637 $ 14,106
Total operating costs and expenses 87,896 30,389
Loss from operations (86,605) (27,979)
Net loss (529,821) (20,812)
Total comprehensive loss $ (531,805) (20,976)
As Previously Reported    
Error Corrections and Prior Period Adjustments Restatement [Line Items]    
Research and development expenses   13,590
Total operating costs and expenses   29,873
Loss from operations   (27,463)
Net loss   (20,296)
Total comprehensive loss   (20,460)
Adjustments | Accrual and capitalization error correction    
Error Corrections and Prior Period Adjustments Restatement [Line Items]    
Research and development expenses   516
Total operating costs and expenses   516
Loss from operations   (516)
Net loss   (516)
Total comprehensive loss   $ (516)
XML 84 R65.htm IDEA: XBRL DOCUMENT v3.21.1
Revision to Prior Period Financial Statements - Consolidated Statement of Cash Flows (Detaills) - USD ($)
$ in Thousands
12 Months Ended
Dec. 31, 2020
Dec. 31, 2019
Cash Flows from Operating Activities:    
Net loss $ (529,821) $ (20,812)
Related party accounts payable and accrued expenses 431 (3,230)
Net cash used in operating activities $ (32,093) (31,859)
Supplemental schedule of non-cash investing and financing activities:    
Capital expenditures included in accounts payable and accrued expenses to related parties and affiliates   947
As Previously Reported    
Cash Flows from Operating Activities:    
Net loss   (20,296)
Related party accounts payable and accrued expenses   (3,746)
Net cash used in operating activities   (31,859)
Accrual and capitalization error correction | Adjustments    
Cash Flows from Operating Activities:    
Net loss   (516)
Related party accounts payable and accrued expenses   516
Supplemental schedule of non-cash investing and financing activities:    
Capital expenditures included in accounts payable and accrued expenses to related parties and affiliates   $ 947
XML 85 R66.htm IDEA: XBRL DOCUMENT v3.21.1
Subsequent Events (Details)
3 Months Ended 12 Months Ended
Nov. 01, 2021
installment
Mar. 01, 2021
USD ($)
Feb. 28, 2021
shares
Jan. 15, 2021
$ / shares
shares
Oct. 31, 2020
shares
Oct. 12, 2020
shares
May 28, 2019
USD ($)
Mar. 31, 2021
USD ($)
$ / shares
shares
Dec. 31, 2020
USD ($)
$ / shares
shares
Dec. 31, 2019
USD ($)
Apr. 30, 2021
shares
Dec. 15, 2020
shares
Nov. 01, 2020
shares
May 10, 2020
shares
Dec. 31, 2018
Subsequent Event [Line Items]                              
Principal amount | $                 $ 13,751,000 $ 13,411,000          
Interest rate                             10.00%
Repayments of Debt | $             $ 1,200,000                
Class of Warrant or Right, Agreed to be Suspended                 14,600,000         14,200,000  
Class of warrant or right,extended in suspension         157,000,000                    
Number of warrants suspended           274,000,000           183,000,000 29,000,000 81,000,000  
Aggregate proceeds from exercise of warrants | $                 $ 13,915,000 $ 2,220,000          
Number of Warrants, cashless warrants exercise                 8,631            
Exercise price of stock options | $ / shares                 $ 0.34            
Number of Shares, Cashless exercise                 94            
Warrants and options were previously suspended and not exercisable         171,000,000                    
Warrants to be issued to holder                 8,500,000            
Subsequent Event                              
Subsequent Event [Line Items]                              
Exercise period       12 months                      
Class of Warrant or Right, Agreed to be Suspended       3,500,000                      
Number of warrants issued       261,000                      
Class of warrant or right,extended in suspension     262,000,000 256,000,000                      
Number of warrants suspended                     262,000,000        
Aggregate proceeds from exercise of warrants | $               $ 700,000              
Class of Warrant or Right, Exercise Price of Warrants or Rights | $ / shares       $ 2.00                      
Stock issued on exercise of warrants               2,600,000              
Proceeds from exercise of stock options | $               $ 46,000              
Exercise price of stock options | $ / shares               $ 0.25              
Number of Shares, Cashless exercise               200,000              
Amount of debt converted | $               $ 4,600,000              
Shares issued upon conversion               4,500,000              
Warrants and options were previously suspended and not exercisable       190,000,000                      
Convertible Debt Securities [Member]                              
Subsequent Event [Line Items]                              
Number of warrants issued                 6,200,000            
Amount of debt converted | $                 $ 13,900,000            
Shares issued upon conversion                 58,400,000            
Cashless options exercise | Subsequent Event                              
Subsequent Event [Line Items]                              
Number of shares issued for exercise of stock options, cashless               3,100,000              
Number of Shares, Cashless exercise               3,700,000              
Warrants Oher New Share Purchases                              
Subsequent Event [Line Items]                              
Warrants and options were previously suspended and not exercisable           96,000,000                  
Cashless Warrants Exercise | Subsequent Event                              
Subsequent Event [Line Items]                              
Stock issued on exercise of warrants               2,100,000              
Number of Warrants, cashless warrants exercise               2,600,000              
Warrants through December 15, 2020                              
Subsequent Event [Line Items]                              
Warrants and options were previously suspended and not exercisable           178,000,000                  
Minimum | Subsequent Event                              
Subsequent Event [Line Items]                              
Class of Warrant or Right, Exercise Price of Warrants or Rights | $ / shares               $ 0.175              
Minimum | Cashless options exercise | Subsequent Event                              
Subsequent Event [Line Items]                              
Exercise price of stock options | $ / shares               0.25              
Minimum | Cashless Warrants Exercise | Subsequent Event                              
Subsequent Event [Line Items]                              
Class of Warrant or Right, Exercise Price of Warrants or Rights | $ / shares               0.22              
Maximum | Subsequent Event                              
Subsequent Event [Line Items]                              
Class of Warrant or Right, Exercise Price of Warrants or Rights | $ / shares               0.34              
Maximum | Cashless options exercise | Subsequent Event                              
Subsequent Event [Line Items]                              
Exercise price of stock options | $ / shares               0.34              
Maximum | Cashless Warrants Exercise | Subsequent Event                              
Subsequent Event [Line Items]                              
Class of Warrant or Right, Exercise Price of Warrants or Rights | $ / shares               $ 0.52              
Note [Member] | Subsequent Event                              
Subsequent Event [Line Items]                              
Principal amount | $   $ 10,000,000                          
Interest rate   8.00%                          
Repayments of Debt | $   $ 0                          
Number of installments for amortization | installment 14                            
Investor [Member] | Note [Member] | Subsequent Event                              
Subsequent Event [Line Items]                              
Debt instrument term   22 months                          
Original issue discount | $   $ 1,000,000                          
Legal fees | $   $ 5,000                          
EXCEL 86 Financial_Report.xlsx IDEA: XBRL DOCUMENT begin 644 Financial_Report.xlsx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end XML 87 Show.js IDEA: XBRL DOCUMENT // Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission. Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105. var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0); e.removeAttribute('id');a.parentNode.appendChild(e)}} if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'} e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}} XML 88 report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ ..report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } ..report table.authRefData a { display: block; font-weight: bold; } ..report table.authRefData p { margin-top: 0px; } ..report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } ..report table.authRefData .hide a:hover { background-color: #2F4497; } ..report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } ..report table.authRefData table{ font-size: 1em; } /* Report Styles */ ..pl a, .pl a:visited { color: black; text-decoration: none; } /* table */ ..report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } ..report hr { border: 1px solid #acf; } /* Top labels */ ..report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } ..report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } ..report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; white-space: normal; /* word-wrap: break-word; */ } ..report td.pl a.a { cursor: pointer; display: block; width: 200px; overflow: hidden; } ..report td.pl div.a { width: 200px; } ..report td.pl a:hover { background-color: #ffc; } /* Header rows... */ ..report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ ..report .rc { background-color: #f0f0f0; } /* Even rows... */ ..report .re, .report .reu { background-color: #def; } ..report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ ..report .ro, .report .rou { background-color: white; } ..report .rou td { border-bottom: 1px solid black; } ..report .rou table td, .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */ ..report .fn { white-space: nowrap; } /* styles for numeric types */ ..report .num, .report .nump { text-align: right; white-space: nowrap; } ..report .nump { padding-left: 2em; } ..report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */ ..report .text { text-align: left; white-space: normal; } ..report .text .big { margin-bottom: 1em; width: 17em; } ..report .text .more { display: none; } ..report .text .note { font-style: italic; font-weight: bold; } ..report .text .small { width: 10em; } ..report sup { font-style: italic; } ..report .outerFootnotes { font-size: 1em; } XML 89 FilingSummary.xml IDEA: XBRL DOCUMENT 3.21.1 html 350 499 1 true 101 0 false 8 false false R1.htm 00090 - Document - Document and Entity Information Sheet http://www.nwbio.com/role/DocumentDocumentAndEntityInformation Document and Entity Information Cover 1 false false R2.htm 00100 - Statement - CONSOLIDATED BALANCE SHEETS Sheet http://www.nwbio.com/role/StatementConsolidatedBalanceSheets CONSOLIDATED BALANCE SHEETS Statements 2 false false R3.htm 00105 - Statement - CONSOLIDATED BALANCE SHEETS (Parenthetical) Sheet http://www.nwbio.com/role/StatementConsolidatedBalanceSheetsParenthetical CONSOLIDATED BALANCE SHEETS (Parenthetical) Statements 3 false false R4.htm 00200 - Statement - CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS Sheet http://www.nwbio.com/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS Statements 4 false false R5.htm 00300 - Statement - CONSOLIDATED STATEMENTS OF CHANGES IN STOCKHOLDERS' DEFICIT Sheet http://www.nwbio.com/role/StatementConsolidatedStatementsOfChangesInStockholdersDeficit CONSOLIDATED STATEMENTS OF CHANGES IN STOCKHOLDERS' DEFICIT Statements 5 false false R6.htm 00305 - Statement - CONSOLIDATED STATEMENTS OF CHANGES IN STOCKHOLDERS' DEFICIT (Parenthetical) Sheet http://www.nwbio.com/role/StatementConsolidatedStatementsOfChangesInStockholdersDeficitParenthetical CONSOLIDATED STATEMENTS OF CHANGES IN STOCKHOLDERS' DEFICIT (Parenthetical) Statements 6 false false R7.htm 00400 - Statement - CONSOLIDATED STATEMENTS OF CASH FLOWS Sheet http://www.nwbio.com/role/StatementConsolidatedStatementsOfCashFlows CONSOLIDATED STATEMENTS OF CASH FLOWS Statements 7 false false R8.htm 10101 - Disclosure - Organization and Description of Business Sheet http://www.nwbio.com/role/DisclosureOrganizationAndDescriptionOfBusiness Organization and Description of Business Notes 8 false false R9.htm 10201 - Disclosure - Financial Condition, Going Concern and Management Plans Sheet http://www.nwbio.com/role/DisclosureFinancialConditionGoingConcernAndManagementPlans Financial Condition, Going Concern and Management Plans Notes 9 false false R10.htm 10301 - Disclosure - Summary of Significant Accounting Policies Sheet http://www.nwbio.com/role/DisclosureSummaryOfSignificantAccountingPolicies Summary of Significant Accounting Policies Notes 10 false false R11.htm 10401 - Disclosure - Fair Value Measurements Sheet http://www.nwbio.com/role/DisclosureFairValueMeasurements Fair Value Measurements Notes 11 false false R12.htm 10501 - Disclosure - Flaskworks Acquisition Sheet http://www.nwbio.com/role/DisclosureFlaskworksAcquisition Flaskworks Acquisition Notes 12 false false R13.htm 10601 - Disclosure - Stock-based Compensation Sheet http://www.nwbio.com/role/DisclosureStockBasedCompensation Stock-based Compensation Notes 13 false false R14.htm 10701 - Disclosure - Property, Plant and Equipment Sheet http://www.nwbio.com/role/DisclosurePropertyPlantAndEquipment Property, Plant and Equipment Notes 14 false false R15.htm 10801 - Disclosure - Notes Payable Notes http://www.nwbio.com/role/DisclosureNotesPayable Notes Payable Notes 15 false false R16.htm 10901 - Disclosure - Net Loss per Share Applicable to Common Stockholders Sheet http://www.nwbio.com/role/DisclosureNetLossPerShareApplicableToCommonStockholders Net Loss per Share Applicable to Common Stockholders Notes 16 false false R17.htm 11001 - Disclosure - Related Party Transactions Sheet http://www.nwbio.com/role/DisclosureRelatedPartyTransactions Related Party Transactions Notes 17 false false R18.htm 11101 - Disclosure - Stockholders' Deficit Sheet http://www.nwbio.com/role/DisclosureStockholdersDeficit Stockholders' Deficit Notes 18 false false R19.htm 11201 - Disclosure - Commitments and Contingencies Sheet http://www.nwbio.com/role/DisclosureCommitmentsAndContingencies Commitments and Contingencies Notes 19 false false R20.htm 11301 - Disclosure - Income Taxes Sheet http://www.nwbio.com/role/DisclosureIncomeTaxes Income Taxes Notes 20 false false R21.htm 11401 - Disclosure - Revision to Prior Period Financial Statements Sheet http://www.nwbio.com/role/DisclosureRevisionToPriorPeriodFinancialStatements Revision to Prior Period Financial Statements Notes 21 false false R22.htm 11501 - Disclosure - Subsequent Events Sheet http://www.nwbio.com/role/DisclosureSubsequentEvents Subsequent Events Notes 22 false false R23.htm 20302 - Disclosure - Summary of Significant Accounting Policies (Policies) Sheet http://www.nwbio.com/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies Summary of Significant Accounting Policies (Policies) Policies http://www.nwbio.com/role/DisclosureSummaryOfSignificantAccountingPolicies 23 false false R24.htm 30403 - Disclosure - Fair Value Measurements (Tables) Sheet http://www.nwbio.com/role/DisclosureFairValueMeasurementsTables Fair Value Measurements (Tables) Tables http://www.nwbio.com/role/DisclosureFairValueMeasurements 24 false false R25.htm 30503 - Disclosure - Flaskworks Acquisition (Tables) Sheet http://www.nwbio.com/role/DisclosureFlaskworksAcquisitionTables Flaskworks Acquisition (Tables) Tables http://www.nwbio.com/role/DisclosureFlaskworksAcquisition 25 false false R26.htm 30603 - Disclosure - Stock-based Compensation (Tables) Sheet http://www.nwbio.com/role/DisclosureStockBasedCompensationTables Stock-based Compensation (Tables) Tables http://www.nwbio.com/role/DisclosureStockBasedCompensation 26 false false R27.htm 30703 - Disclosure - Property, Plant and Equipment (Tables) Sheet http://www.nwbio.com/role/DisclosurePropertyPlantAndEquipmentTables Property, Plant and Equipment (Tables) Tables http://www.nwbio.com/role/DisclosurePropertyPlantAndEquipment 27 false false R28.htm 30803 - Disclosure - Notes Payable (Tables) Notes http://www.nwbio.com/role/DisclosureNotesPayableTables Notes Payable (Tables) Tables http://www.nwbio.com/role/DisclosureNotesPayable 28 false false R29.htm 30903 - Disclosure - Net Loss per Share Applicable to Common Stockholders (Tables) Sheet http://www.nwbio.com/role/DisclosureNetLossPerShareApplicableToCommonStockholdersTables Net Loss per Share Applicable to Common Stockholders (Tables) Tables http://www.nwbio.com/role/DisclosureNetLossPerShareApplicableToCommonStockholders 29 false false R30.htm 31003 - Disclosure - Related Party Transactions (Tables) Sheet http://www.nwbio.com/role/DisclosureRelatedPartyTransactionsTables Related Party Transactions (Tables) Tables http://www.nwbio.com/role/DisclosureRelatedPartyTransactions 30 false false R31.htm 31103 - Disclosure - Stockholders' Deficit (Tables) Sheet http://www.nwbio.com/role/DisclosureStockholdersDeficitTables Stockholders' Deficit (Tables) Tables http://www.nwbio.com/role/DisclosureStockholdersDeficit 31 false false R32.htm 31203 - Disclosure - Commitments and Contingencies (Tables) Sheet http://www.nwbio.com/role/DisclosureCommitmentsAndContingenciesTables Commitments and Contingencies (Tables) Tables http://www.nwbio.com/role/DisclosureCommitmentsAndContingencies 32 false false R33.htm 31303 - Disclosure - Income Taxes (Tables) Sheet http://www.nwbio.com/role/DisclosureIncomeTaxesTables Income Taxes (Tables) Tables http://www.nwbio.com/role/DisclosureIncomeTaxes 33 false false R34.htm 40201 - Disclosure - Financial Condition, Going Concern and Management Plans (Details Textual) Sheet http://www.nwbio.com/role/DisclosureFinancialConditionGoingConcernAndManagementPlansDetailsTextual Financial Condition, Going Concern and Management Plans (Details Textual) Details http://www.nwbio.com/role/DisclosureFinancialConditionGoingConcernAndManagementPlans 34 false false R35.htm 40301 - Disclosure - Summary of Significant Accounting Policies (Details) Sheet http://www.nwbio.com/role/DisclosureSummaryOfSignificantAccountingPoliciesDetails Summary of Significant Accounting Policies (Details) Details http://www.nwbio.com/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies 35 false false R36.htm 40401 - Disclosure - Fair Value Measurements (Details) Sheet http://www.nwbio.com/role/DisclosureFairValueMeasurementsDetails Fair Value Measurements (Details) Details http://www.nwbio.com/role/DisclosureFairValueMeasurementsTables 36 false false R37.htm 40402 - Disclosure - Fair Value Measurements - Changes in Level 3 liabilities (Details) Sheet http://www.nwbio.com/role/DisclosureFairValueMeasurementsChangesInLevel3LiabilitiesDetails Fair Value Measurements - Changes in Level 3 liabilities (Details) Details 37 false false R38.htm 40403 - Disclosure - Fair Value Measurements - Weighted average (in aggregate) significant unobservable inputs (Details) Sheet http://www.nwbio.com/role/DisclosureFairValueMeasurementsWeightedAverageInAggregateSignificantUnobservableInputsDetails Fair Value Measurements - Weighted average (in aggregate) significant unobservable inputs (Details) Details 38 false false R39.htm 40501 - Disclosure - Flaskworks Acquisition (Details) Sheet http://www.nwbio.com/role/DisclosureFlaskworksAcquisitionDetails Flaskworks Acquisition (Details) Details http://www.nwbio.com/role/DisclosureFlaskworksAcquisitionTables 39 false false R40.htm 40601 - Disclosure - Stock-based Compensation - Stock option activity (Details) Sheet http://www.nwbio.com/role/DisclosureStockBasedCompensationStockOptionActivityDetails Stock-based Compensation - Stock option activity (Details) Details 40 false false R41.htm 40602 - Disclosure - Stock-based Compensation - Assumptions (Details) Sheet http://www.nwbio.com/role/DisclosureStockBasedCompensationAssumptionsDetails Stock-based Compensation - Assumptions (Details) Details 41 false false R42.htm 40603 - Disclosure - Stock-based Compensation - Summary of stock-based compensation expense (Details) Sheet http://www.nwbio.com/role/DisclosureStockBasedCompensationSummaryOfStockBasedCompensationExpenseDetails Stock-based Compensation - Summary of stock-based compensation expense (Details) Details 42 false false R43.htm 40604 - Disclosure - Stock-based Compensation - Additional Information (Details) Sheet http://www.nwbio.com/role/DisclosureStockBasedCompensationAdditionalInformationDetails Stock-based Compensation - Additional Information (Details) Details 43 false false R44.htm 40701 - Disclosure - Property, Plant and Equipment (Details) Sheet http://www.nwbio.com/role/DisclosurePropertyPlantAndEquipmentDetails Property, Plant and Equipment (Details) Details http://www.nwbio.com/role/DisclosurePropertyPlantAndEquipmentTables 44 false false R45.htm 40702 - Disclosure - Property, Plant and Equipment - Additional Information (Details) Sheet http://www.nwbio.com/role/DisclosurePropertyPlantAndEquipmentAdditionalInformationDetails Property, Plant and Equipment - Additional Information (Details) Details 45 false false R46.htm 40801 - Disclosure - Notes Payable (Details) Notes http://www.nwbio.com/role/DisclosureNotesPayableDetails Notes Payable (Details) Details http://www.nwbio.com/role/DisclosureNotesPayableTables 46 false false R47.htm 40803 - Disclosure - Notes Payable - Mortgage Loan (Details) Notes http://www.nwbio.com/role/DisclosureNotesPayableMortgageLoanDetails Notes Payable - Mortgage Loan (Details) Details 47 false false R48.htm 40804 - Disclosure - Notes Payable - summary of the company's contractual obligations on debt principal (Details) Notes http://www.nwbio.com/role/DisclosureNotesPayableSummaryOfCompanySContractualObligationsOnDebtPrincipalDetails Notes Payable - summary of the company's contractual obligations on debt principal (Details) Details 48 false false R49.htm 40805 - Disclosure - Notes Payable - Additional Information (Details) Notes http://www.nwbio.com/role/DisclosureNotesPayableAdditionalInformationDetails Notes Payable - Additional Information (Details) Details 49 false false R50.htm 40901 - Disclosure - Net Earnings (Loss) per Share Applicable to Common Stockholders (Details) Sheet http://www.nwbio.com/role/DisclosureNetEarningsLossPerShareApplicableToCommonStockholdersDetails Net Earnings (Loss) per Share Applicable to Common Stockholders (Details) Details 50 false false R51.htm 41001 - Disclosure - Related Party Transactions - Summary of outstanding unpaid accounts payable held by related parties (Details) Sheet http://www.nwbio.com/role/DisclosureRelatedPartyTransactionsSummaryOfOutstandingUnpaidAccountsPayableHeldByRelatedPartiesDetails Related Party Transactions - Summary of outstanding unpaid accounts payable held by related parties (Details) Details 51 false false R52.htm 41002 - Disclosure - Related Party Transactions - Total interest expenses (Details) Sheet http://www.nwbio.com/role/DisclosureRelatedPartyTransactionsTotalInterestExpensesDetails Related Party Transactions - Total interest expenses (Details) Details 52 false false R53.htm 41003 - Disclosure - Related Party Transactions - Additional Information (Details) Sheet http://www.nwbio.com/role/DisclosureRelatedPartyTransactionsAdditionalInformationDetails Related Party Transactions - Additional Information (Details) Details 53 false false R54.htm 41101 - Disclosure - Stockholders' Deficit (Details) Sheet http://www.nwbio.com/role/DisclosureStockholdersDeficitDetails Stockholders' Deficit (Details) Details http://www.nwbio.com/role/DisclosureStockholdersDeficitTables 54 false false R55.htm 41102 - Disclosure - Stockholders' Deficit - Additional Information (Details Sheet http://www.nwbio.com/role/DisclosureStockholdersDeficitAdditionalInformationDetails Stockholders' Deficit - Additional Information (Details Uncategorized 55 false false R56.htm 41201 - Disclosure - Commitments and Contingencies (Details) Sheet http://www.nwbio.com/role/DisclosureCommitmentsAndContingenciesDetails Commitments and Contingencies (Details) Details http://www.nwbio.com/role/DisclosureCommitmentsAndContingenciesTables 56 false false R57.htm 41202 - Disclosure - Commitments and Contingencies - maturities of our operating leases (Details) Sheet http://www.nwbio.com/role/DisclosureCommitmentsAndContingenciesMaturitiesOfOurOperatingLeasesDetails Commitments and Contingencies - maturities of our operating leases (Details) Details 57 false false R58.htm 41203 - Disclosure - Commitments and Contingencies - Additional Information (Details) Sheet http://www.nwbio.com/role/DisclosureCommitmentsAndContingenciesAdditionalInformationDetails Commitments and Contingencies - Additional Information (Details) Details 58 false false R59.htm 41301 - Disclosure - Income Taxes - Summary of Deferred Tax Assets and Liabilities (Details) Sheet http://www.nwbio.com/role/DisclosureIncomeTaxesSummaryOfDeferredTaxAssetsAndLiabilitiesDetails Income Taxes - Summary of Deferred Tax Assets and Liabilities (Details) Details 59 false false R60.htm 41302 - Disclosure - Income Taxes - Reconcilation of U.S. Federal Statutory Tax Expense (Benefit) (Details) Sheet http://www.nwbio.com/role/DisclosureIncomeTaxesReconcilationOfUsFederalStatutoryTaxExpenseBenefitDetails Income Taxes - Reconcilation of U.S. Federal Statutory Tax Expense (Benefit) (Details) Details 60 false false R61.htm 41303 - Disclosure - Income Taxes - Summary of Tax Provision Benefit (Details) Sheet http://www.nwbio.com/role/DisclosureIncomeTaxesSummaryOfTaxProvisionBenefitDetails Income Taxes - Summary of Tax Provision Benefit (Details) Details 61 false false R62.htm 41304 - Disclosure - Income Taxes - Additional information (Details) Sheet http://www.nwbio.com/role/DisclosureIncomeTaxesAdditionalInformationDetails Income Taxes - Additional information (Details) Details 62 false false R63.htm 41401 - Disclosure - Revision to Prior Period Financial Statements -Consolidated Balance Sheet (Details) Sheet http://www.nwbio.com/role/DisclosureRevisionToPriorPeriodFinancialStatementsConsolidatedBalanceSheetDetails Revision to Prior Period Financial Statements -Consolidated Balance Sheet (Details) Details 63 false false R64.htm 41402 - Disclosure - Revision to Prior Period Financial Statements - Consolidated Statement of Operations (Detaills) Sheet http://www.nwbio.com/role/DisclosureRevisionToPriorPeriodFinancialStatementsConsolidatedStatementOfOperationsDetaills Revision to Prior Period Financial Statements - Consolidated Statement of Operations (Detaills) Details 64 false false R65.htm 41403 - Disclosure - Revision to Prior Period Financial Statements - Consolidated Statement of Cash Flows (Detaills) Sheet http://www.nwbio.com/role/DisclosureRevisionToPriorPeriodFinancialStatementsConsolidatedStatementOfCashFlowsDetaills Revision to Prior Period Financial Statements - Consolidated Statement of Cash Flows (Detaills) Details 65 false false R66.htm 41501 - Disclosure - Subsequent Events (Details) Sheet http://www.nwbio.com/role/DisclosureSubsequentEventsDetails Subsequent Events (Details) Details http://www.nwbio.com/role/DisclosureSubsequentEvents 66 false false All Reports Book All Reports nwbo-20201231x10k.htm nwbo-20201231.xsd nwbo-20201231_cal.xml nwbo-20201231_def.xml nwbo-20201231_lab.xml nwbo-20201231_pre.xml nwbo-20201231xex10d81.htm nwbo-20201231xex10d82.htm nwbo-20201231xex10d83.htm nwbo-20201231xex10d85.htm nwbo-20201231xex21d1.htm nwbo-20201231xex23d1.htm nwbo-20201231xex31d1.htm nwbo-20201231xex32d1.htm nwbo-20201231xex4d1.htm http://fasb.org/us-gaap/2020-01-31 http://xbrl.sec.gov/country/2020-01-31 http://xbrl.sec.gov/dei/2020-01-31 http://fasb.org/srt/2020-01-31 true true JSON 92 MetaLinks.json IDEA: XBRL DOCUMENT { "instance": { "nwbo-20201231x10k.htm": { "axisCustom": 1, "axisStandard": 30, "contextCount": 350, "dts": { "calculationLink": { "local": [ "nwbo-20201231_cal.xml" ] }, "definitionLink": { "local": [ "nwbo-20201231_def.xml" ], "remote": [ "http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-eedm-def-2020-01-31.xml", "http://xbrl.fasb.org/srt/2020/elts/srt-eedm1-def-2020-01-31.xml" ] }, "inline": { "local": [ "nwbo-20201231x10k.htm" ] }, "labelLink": { "local": [ "nwbo-20201231_lab.xml" ], "remote": [ "http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-doc-2020-01-31.xml", "https://xbrl.sec.gov/dei/2020/dei-doc-2020-01-31.xml" ] }, "presentationLink": { "local": [ "nwbo-20201231_pre.xml" ] }, "referenceLink": { "remote": [ "http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-ref-2020-01-31.xml", "https://xbrl.sec.gov/dei/2020/dei-ref-2020-01-31.xml" ] }, "schema": { "local": [ "nwbo-20201231.xsd" ], "remote": [ "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd", "http://www.xbrl.org/2003/xl-2003-12-31.xsd", "http://www.xbrl.org/2003/xlink-2003-12-31.xsd", "https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd", "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd", "http://www.xbrl.org/2005/xbrldt-2005.xsd", "http://www.xbrl.org/dtr/type/nonNumeric-2009-12-16.xsd", "http://www.xbrl.org/dtr/type/numeric-2009-12-16.xsd", "http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd", "http://xbrl.fasb.org/us-gaap/2020/elts/us-roles-2020-01-31.xsd", "http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd", "http://www.xbrl.org/2006/ref-2006-02-27.xsd", "http://xbrl.fasb.org/srt/2020/elts/srt-types-2020-01-31.xsd", "http://xbrl.fasb.org/srt/2020/elts/srt-roles-2020-01-31.xsd", "https://xbrl.sec.gov/country/2020/country-2020-01-31.xsd", "http://xbrl.fasb.org/us-gaap/2020/elts/us-types-2020-01-31.xsd", "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/reference-2009-12-16.xsd", "http://xbrl.fasb.org/us-gaap/2020/elts/us-parts-codification-2020-01-31.xsd", "http://www.xbrl.org/lrr/role/deprecated-2009-12-16.xsd" ] } }, "elementCount": 660, "entityCount": 1, "hidden": { "http://fasb.org/us-gaap/2020-01-31": 14, "http://www.nwbio.com/20201231": 10, "http://xbrl.sec.gov/dei/2020-01-31": 7, "total": 31 }, "keyCustom": 127, "keyStandard": 372, "memberCustom": 62, "memberStandard": 36, "nsprefix": "nwbo", "nsuri": "http://www.nwbio.com/20201231", "report": { "R1": { "firstAnchor": { "ancestors": [ "p", "div", "div", "body", "html" ], "baseRef": "nwbo-20201231x10k.htm", "contextRef": "Duration_1_1_2020_To_12_31_2020_nxgPv_TR5kW7h-rGR5n91A", "decimals": null, "first": true, "lang": "en-US", "name": "dei:DocumentType", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "document", "isDefault": "true", "longName": "00090 - Document - Document and Entity Information", "role": "http://www.nwbio.com/role/DocumentDocumentAndEntityInformation", "shortName": "Document and Entity Information", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "p", "div", "div", "body", "html" ], "baseRef": "nwbo-20201231x10k.htm", "contextRef": "Duration_1_1_2020_To_12_31_2020_nxgPv_TR5kW7h-rGR5n91A", "decimals": null, "first": true, "lang": "en-US", "name": "dei:DocumentType", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R10": { "firstAnchor": { "ancestors": [ "div", "div", "body", "html" ], "baseRef": "nwbo-20201231x10k.htm", "contextRef": "Duration_1_1_2020_To_12_31_2020_nxgPv_TR5kW7h-rGR5n91A", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:SignificantAccountingPoliciesTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "10301 - Disclosure - Summary of Significant Accounting Policies", "role": "http://www.nwbio.com/role/DisclosureSummaryOfSignificantAccountingPolicies", "shortName": "Summary of Significant Accounting Policies", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "div", "div", "body", "html" ], "baseRef": "nwbo-20201231x10k.htm", "contextRef": "Duration_1_1_2020_To_12_31_2020_nxgPv_TR5kW7h-rGR5n91A", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:SignificantAccountingPoliciesTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R11": { "firstAnchor": { "ancestors": [ "div", "div", "body", "html" ], "baseRef": "nwbo-20201231x10k.htm", "contextRef": "Duration_1_1_2020_To_12_31_2020_nxgPv_TR5kW7h-rGR5n91A", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:FairValueDisclosuresTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "10401 - Disclosure - Fair Value Measurements", "role": "http://www.nwbio.com/role/DisclosureFairValueMeasurements", "shortName": "Fair Value Measurements", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "div", "div", "body", "html" ], "baseRef": "nwbo-20201231x10k.htm", "contextRef": "Duration_1_1_2020_To_12_31_2020_nxgPv_TR5kW7h-rGR5n91A", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:FairValueDisclosuresTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R12": { "firstAnchor": { "ancestors": [ "div", "div", "body", "html" ], "baseRef": "nwbo-20201231x10k.htm", "contextRef": "Duration_1_1_2020_To_12_31_2020_nxgPv_TR5kW7h-rGR5n91A", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:BusinessCombinationDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "10501 - Disclosure - Flaskworks Acquisition", "role": "http://www.nwbio.com/role/DisclosureFlaskworksAcquisition", "shortName": "Flaskworks Acquisition", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "div", "div", "body", "html" ], "baseRef": "nwbo-20201231x10k.htm", "contextRef": "Duration_1_1_2020_To_12_31_2020_nxgPv_TR5kW7h-rGR5n91A", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:BusinessCombinationDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R13": { "firstAnchor": { "ancestors": [ "div", "div", "body", "html" ], "baseRef": "nwbo-20201231x10k.htm", "contextRef": "Duration_1_1_2020_To_12_31_2020_nxgPv_TR5kW7h-rGR5n91A", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "10601 - Disclosure - Stock-based Compensation", "role": "http://www.nwbio.com/role/DisclosureStockBasedCompensation", "shortName": "Stock-based Compensation", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "div", "div", "body", "html" ], "baseRef": "nwbo-20201231x10k.htm", "contextRef": "Duration_1_1_2020_To_12_31_2020_nxgPv_TR5kW7h-rGR5n91A", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R14": { "firstAnchor": { "ancestors": [ "div", "div", "body", "html" ], "baseRef": "nwbo-20201231x10k.htm", "contextRef": "Duration_1_1_2020_To_12_31_2020_nxgPv_TR5kW7h-rGR5n91A", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "10701 - Disclosure - Property, Plant and Equipment", "role": "http://www.nwbio.com/role/DisclosurePropertyPlantAndEquipment", "shortName": "Property, Plant and Equipment", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "div", "div", "body", "html" ], "baseRef": "nwbo-20201231x10k.htm", "contextRef": "Duration_1_1_2020_To_12_31_2020_nxgPv_TR5kW7h-rGR5n91A", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R15": { "firstAnchor": { "ancestors": [ "div", "div", "body", "html" ], "baseRef": "nwbo-20201231x10k.htm", "contextRef": "Duration_1_1_2020_To_12_31_2020_nxgPv_TR5kW7h-rGR5n91A", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:DebtDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "10801 - Disclosure - Notes Payable", "role": "http://www.nwbio.com/role/DisclosureNotesPayable", "shortName": "Notes Payable", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "div", "div", "body", "html" ], "baseRef": "nwbo-20201231x10k.htm", "contextRef": "Duration_1_1_2020_To_12_31_2020_nxgPv_TR5kW7h-rGR5n91A", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:DebtDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R16": { "firstAnchor": { "ancestors": [ "div", "div", "body", "html" ], "baseRef": "nwbo-20201231x10k.htm", "contextRef": "Duration_1_1_2020_To_12_31_2020_nxgPv_TR5kW7h-rGR5n91A", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:EarningsPerShareTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "10901 - Disclosure - Net Loss per Share Applicable to Common Stockholders", "role": "http://www.nwbio.com/role/DisclosureNetLossPerShareApplicableToCommonStockholders", "shortName": "Net Loss per Share Applicable to Common Stockholders", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "div", "div", "body", "html" ], "baseRef": "nwbo-20201231x10k.htm", "contextRef": "Duration_1_1_2020_To_12_31_2020_nxgPv_TR5kW7h-rGR5n91A", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:EarningsPerShareTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R17": { "firstAnchor": { "ancestors": [ "div", "div", "body", "html" ], "baseRef": "nwbo-20201231x10k.htm", "contextRef": "Duration_1_1_2020_To_12_31_2020_nxgPv_TR5kW7h-rGR5n91A", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:RelatedPartyTransactionsDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "11001 - Disclosure - Related Party Transactions", "role": "http://www.nwbio.com/role/DisclosureRelatedPartyTransactions", "shortName": "Related Party Transactions", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "div", "div", "body", "html" ], "baseRef": "nwbo-20201231x10k.htm", "contextRef": "Duration_1_1_2020_To_12_31_2020_nxgPv_TR5kW7h-rGR5n91A", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:RelatedPartyTransactionsDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R18": { "firstAnchor": { "ancestors": [ "div", "div", "body", "html" ], "baseRef": "nwbo-20201231x10k.htm", "contextRef": "Duration_1_1_2020_To_12_31_2020_nxgPv_TR5kW7h-rGR5n91A", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:StockholdersEquityNoteDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "11101 - Disclosure - Stockholders' Deficit", "role": "http://www.nwbio.com/role/DisclosureStockholdersDeficit", "shortName": "Stockholders' Deficit", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "div", "div", "body", "html" ], "baseRef": "nwbo-20201231x10k.htm", "contextRef": "Duration_1_1_2020_To_12_31_2020_nxgPv_TR5kW7h-rGR5n91A", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:StockholdersEquityNoteDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R19": { "firstAnchor": { "ancestors": [ "div", "div", "body", "html" ], "baseRef": "nwbo-20201231x10k.htm", "contextRef": "Duration_1_1_2020_To_12_31_2020_nxgPv_TR5kW7h-rGR5n91A", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "11201 - Disclosure - Commitments and Contingencies", "role": "http://www.nwbio.com/role/DisclosureCommitmentsAndContingencies", "shortName": "Commitments and Contingencies", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "div", "div", "body", "html" ], "baseRef": "nwbo-20201231x10k.htm", "contextRef": "Duration_1_1_2020_To_12_31_2020_nxgPv_TR5kW7h-rGR5n91A", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R2": { "firstAnchor": { "ancestors": [ "p", "td", "tr", "table", "div", "div", "body", "html" ], "baseRef": "nwbo-20201231x10k.htm", "contextRef": "As_Of_12_31_2020_PD0VNgTHr0-8kHUggoZKhQ", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue", "reportCount": 1, "unitRef": "Unit_Standard_USD_SP4J7mnD6kCeIOWPHSnMBQ", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "00100 - Statement - CONSOLIDATED BALANCE SHEETS", "role": "http://www.nwbio.com/role/StatementConsolidatedBalanceSheets", "shortName": "CONSOLIDATED BALANCE SHEETS", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "p", "td", "tr", "table", "div", "div", "body", "html" ], "baseRef": "nwbo-20201231x10k.htm", "contextRef": "As_Of_12_31_2020_PD0VNgTHr0-8kHUggoZKhQ", "decimals": "-3", "lang": null, "name": "us-gaap:PrepaidExpenseAndOtherAssetsCurrent", "reportCount": 1, "unique": true, "unitRef": "Unit_Standard_USD_SP4J7mnD6kCeIOWPHSnMBQ", "xsiNil": "false" } }, "R20": { "firstAnchor": { "ancestors": [ "div", "div", "body", "html" ], "baseRef": "nwbo-20201231x10k.htm", "contextRef": "Duration_1_1_2020_To_12_31_2020_nxgPv_TR5kW7h-rGR5n91A", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:IncomeTaxDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "11301 - Disclosure - Income Taxes", "role": "http://www.nwbio.com/role/DisclosureIncomeTaxes", "shortName": "Income Taxes", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "div", "div", "body", "html" ], "baseRef": "nwbo-20201231x10k.htm", "contextRef": "Duration_1_1_2020_To_12_31_2020_nxgPv_TR5kW7h-rGR5n91A", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:IncomeTaxDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R21": { "firstAnchor": { "ancestors": [ "div", "div", "body", "html" ], "baseRef": "nwbo-20201231x10k.htm", "contextRef": "Duration_1_1_2020_To_12_31_2020_nxgPv_TR5kW7h-rGR5n91A", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:AccountingChangesAndErrorCorrectionsTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "11401 - Disclosure - Revision to Prior Period Financial Statements", "role": "http://www.nwbio.com/role/DisclosureRevisionToPriorPeriodFinancialStatements", "shortName": "Revision to Prior Period Financial Statements", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "div", "div", "body", "html" ], "baseRef": "nwbo-20201231x10k.htm", "contextRef": "Duration_1_1_2020_To_12_31_2020_nxgPv_TR5kW7h-rGR5n91A", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:AccountingChangesAndErrorCorrectionsTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R22": { "firstAnchor": { "ancestors": [ "div", "div", "body", "html" ], "baseRef": "nwbo-20201231x10k.htm", "contextRef": "Duration_1_1_2020_To_12_31_2020_nxgPv_TR5kW7h-rGR5n91A", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:SubsequentEventsTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "11501 - Disclosure - Subsequent Events", "role": "http://www.nwbio.com/role/DisclosureSubsequentEvents", "shortName": "Subsequent Events", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "div", "div", "body", "html" ], "baseRef": "nwbo-20201231x10k.htm", "contextRef": "Duration_1_1_2020_To_12_31_2020_nxgPv_TR5kW7h-rGR5n91A", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:SubsequentEventsTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R23": { "firstAnchor": { "ancestors": [ "us-gaap:SignificantAccountingPoliciesTextBlock", "div", "div", "body", "html" ], "baseRef": "nwbo-20201231x10k.htm", "contextRef": "Duration_1_1_2020_To_12_31_2020_nxgPv_TR5kW7h-rGR5n91A", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:BasisOfAccountingPolicyPolicyTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "20302 - Disclosure - Summary of Significant Accounting Policies (Policies)", "role": "http://www.nwbio.com/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies", "shortName": "Summary of Significant Accounting Policies (Policies)", "subGroupType": "policies", "uniqueAnchor": { "ancestors": [ "us-gaap:SignificantAccountingPoliciesTextBlock", "div", "div", "body", "html" ], "baseRef": "nwbo-20201231x10k.htm", "contextRef": "Duration_1_1_2020_To_12_31_2020_nxgPv_TR5kW7h-rGR5n91A", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:BasisOfAccountingPolicyPolicyTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R24": { "firstAnchor": { "ancestors": [ "us-gaap:FairValueDisclosuresTextBlock", "div", "div", "body", "html" ], "baseRef": "nwbo-20201231x10k.htm", "contextRef": "Duration_1_1_2020_To_12_31_2020_nxgPv_TR5kW7h-rGR5n91A", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "30403 - Disclosure - Fair Value Measurements (Tables)", "role": "http://www.nwbio.com/role/DisclosureFairValueMeasurementsTables", "shortName": "Fair Value Measurements (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "us-gaap:FairValueDisclosuresTextBlock", "div", "div", "body", "html" ], "baseRef": "nwbo-20201231x10k.htm", "contextRef": "Duration_1_1_2020_To_12_31_2020_nxgPv_TR5kW7h-rGR5n91A", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R25": { "firstAnchor": { "ancestors": [ "ix:continuation", "div", "div", "body", "html" ], "baseRef": "nwbo-20201231x10k.htm", "contextRef": "Duration_1_1_2020_To_12_31_2020_nxgPv_TR5kW7h-rGR5n91A", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfBusinessAcquisitionsByAcquisitionTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "30503 - Disclosure - Flaskworks Acquisition (Tables)", "role": "http://www.nwbio.com/role/DisclosureFlaskworksAcquisitionTables", "shortName": "Flaskworks Acquisition (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "ix:continuation", "div", "div", "body", "html" ], "baseRef": "nwbo-20201231x10k.htm", "contextRef": "Duration_1_1_2020_To_12_31_2020_nxgPv_TR5kW7h-rGR5n91A", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfBusinessAcquisitionsByAcquisitionTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R26": { "firstAnchor": { "ancestors": [ "ix:continuation", "div", "div", "body", "html" ], "baseRef": "nwbo-20201231x10k.htm", "contextRef": "Duration_1_1_2020_To_12_31_2020_nxgPv_TR5kW7h-rGR5n91A", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "30603 - Disclosure - Stock-based Compensation (Tables)", "role": "http://www.nwbio.com/role/DisclosureStockBasedCompensationTables", "shortName": "Stock-based Compensation (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "ix:continuation", "div", "div", "body", "html" ], "baseRef": "nwbo-20201231x10k.htm", "contextRef": "Duration_1_1_2020_To_12_31_2020_nxgPv_TR5kW7h-rGR5n91A", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R27": { "firstAnchor": { "ancestors": [ "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock", "div", "div", "body", "html" ], "baseRef": "nwbo-20201231x10k.htm", "contextRef": "Duration_1_1_2020_To_12_31_2020_nxgPv_TR5kW7h-rGR5n91A", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:PropertyPlantAndEquipmentTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "30703 - Disclosure - Property, Plant and Equipment (Tables)", "role": "http://www.nwbio.com/role/DisclosurePropertyPlantAndEquipmentTables", "shortName": "Property, Plant and Equipment (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock", "div", "div", "body", "html" ], "baseRef": "nwbo-20201231x10k.htm", "contextRef": "Duration_1_1_2020_To_12_31_2020_nxgPv_TR5kW7h-rGR5n91A", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:PropertyPlantAndEquipmentTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R28": { "firstAnchor": { "ancestors": [ "us-gaap:DebtDisclosureTextBlock", "div", "div", "body", "html" ], "baseRef": "nwbo-20201231x10k.htm", "contextRef": "Duration_1_1_2020_To_12_31_2020_nxgPv_TR5kW7h-rGR5n91A", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfDebtTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "30803 - Disclosure - Notes Payable (Tables)", "role": "http://www.nwbio.com/role/DisclosureNotesPayableTables", "shortName": "Notes Payable (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "us-gaap:DebtDisclosureTextBlock", "div", "div", "body", "html" ], "baseRef": "nwbo-20201231x10k.htm", "contextRef": "Duration_1_1_2020_To_12_31_2020_nxgPv_TR5kW7h-rGR5n91A", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfDebtTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R29": { "firstAnchor": { "ancestors": [ "us-gaap:EarningsPerShareTextBlock", "div", "div", "body", "html" ], "baseRef": "nwbo-20201231x10k.htm", "contextRef": "Duration_1_1_2020_To_12_31_2020_nxgPv_TR5kW7h-rGR5n91A", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "30903 - Disclosure - Net Loss per Share Applicable to Common Stockholders (Tables)", "role": "http://www.nwbio.com/role/DisclosureNetLossPerShareApplicableToCommonStockholdersTables", "shortName": "Net Loss per Share Applicable to Common Stockholders (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "us-gaap:EarningsPerShareTextBlock", "div", "div", "body", "html" ], "baseRef": "nwbo-20201231x10k.htm", "contextRef": "Duration_1_1_2020_To_12_31_2020_nxgPv_TR5kW7h-rGR5n91A", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R3": { "firstAnchor": { "ancestors": [ "us-gaap:PreferredStockParOrStatedValuePerShare", "p", "td", "tr", "table", "div", "div", "body", "html" ], "baseRef": "nwbo-20201231x10k.htm", "contextRef": "As_Of_12_31_2020_PD0VNgTHr0-8kHUggoZKhQ", "decimals": "INF", "first": true, "lang": null, "name": "us-gaap:PreferredStockParOrStatedValuePerShare", "reportCount": 1, "unitRef": "Unit_Divide_USD_shares_32eNyMKIhUuTmxYRiM-fcA", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "00105 - Statement - CONSOLIDATED BALANCE SHEETS (Parenthetical)", "role": "http://www.nwbio.com/role/StatementConsolidatedBalanceSheetsParenthetical", "shortName": "CONSOLIDATED BALANCE SHEETS (Parenthetical)", "subGroupType": "parenthetical", "uniqueAnchor": null }, "R30": { "firstAnchor": { "ancestors": [ "us-gaap:RelatedPartyTransactionsDisclosureTextBlock", "div", "div", "body", "html" ], "baseRef": "nwbo-20201231x10k.htm", "contextRef": "Duration_1_1_2020_To_12_31_2020_nxgPv_TR5kW7h-rGR5n91A", "decimals": null, "first": true, "lang": "en-US", "name": "nwbo:ScheduleOfSettlementObligationsTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "31003 - Disclosure - Related Party Transactions (Tables)", "role": "http://www.nwbio.com/role/DisclosureRelatedPartyTransactionsTables", "shortName": "Related Party Transactions (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "us-gaap:RelatedPartyTransactionsDisclosureTextBlock", "div", "div", "body", "html" ], "baseRef": "nwbo-20201231x10k.htm", "contextRef": "Duration_1_1_2020_To_12_31_2020_nxgPv_TR5kW7h-rGR5n91A", "decimals": null, "first": true, "lang": "en-US", "name": "nwbo:ScheduleOfSettlementObligationsTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R31": { "firstAnchor": { "ancestors": [ "ix:continuation", "div", "div", "body", "html" ], "baseRef": "nwbo-20201231x10k.htm", "contextRef": "Duration_1_1_2020_To_12_31_2020_nxgPv_TR5kW7h-rGR5n91A", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "31103 - Disclosure - Stockholders' Deficit (Tables)", "role": "http://www.nwbio.com/role/DisclosureStockholdersDeficitTables", "shortName": "Stockholders' Deficit (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "ix:continuation", "div", "div", "body", "html" ], "baseRef": "nwbo-20201231x10k.htm", "contextRef": "Duration_1_1_2020_To_12_31_2020_nxgPv_TR5kW7h-rGR5n91A", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R32": { "firstAnchor": { "ancestors": [ "ix:continuation", "div", "div", "body", "html" ], "baseRef": "nwbo-20201231x10k.htm", "contextRef": "Duration_1_1_2020_To_12_31_2020_nxgPv_TR5kW7h-rGR5n91A", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:LeaseCostTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "31203 - Disclosure - Commitments and Contingencies (Tables)", "role": "http://www.nwbio.com/role/DisclosureCommitmentsAndContingenciesTables", "shortName": "Commitments and Contingencies (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "ix:continuation", "div", "div", "body", "html" ], "baseRef": "nwbo-20201231x10k.htm", "contextRef": "Duration_1_1_2020_To_12_31_2020_nxgPv_TR5kW7h-rGR5n91A", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:LeaseCostTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R33": { "firstAnchor": { "ancestors": [ "ix:continuation", "div", "div", "body", "html" ], "baseRef": "nwbo-20201231x10k.htm", "contextRef": "Duration_1_1_2020_To_12_31_2020_nxgPv_TR5kW7h-rGR5n91A", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "31303 - Disclosure - Income Taxes (Tables)", "role": "http://www.nwbio.com/role/DisclosureIncomeTaxesTables", "shortName": "Income Taxes (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "ix:continuation", "div", "div", "body", "html" ], "baseRef": "nwbo-20201231x10k.htm", "contextRef": "Duration_1_1_2020_To_12_31_2020_nxgPv_TR5kW7h-rGR5n91A", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R34": { "firstAnchor": { "ancestors": [ "p", "td", "tr", "table", "div", "div", "body", "html" ], "baseRef": "nwbo-20201231x10k.htm", "contextRef": "Duration_1_1_2020_To_12_31_2020_nxgPv_TR5kW7h-rGR5n91A", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:NetCashProvidedByUsedInOperatingActivities", "reportCount": 1, "unitRef": "Unit_Standard_USD_SP4J7mnD6kCeIOWPHSnMBQ", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "40201 - Disclosure - Financial Condition, Going Concern and Management Plans (Details Textual)", "role": "http://www.nwbio.com/role/DisclosureFinancialConditionGoingConcernAndManagementPlansDetailsTextual", "shortName": "Financial Condition, Going Concern and Management Plans (Details Textual)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "p", "nwbo:FinancialConditionGoingConcernAndManagementPlansTextBlock", "div", "div", "body", "html" ], "baseRef": "nwbo-20201231x10k.htm", "contextRef": "Duration_1_1_2020_To_12_31_2020_nxgPv_TR5kW7h-rGR5n91A", "decimals": "-6", "lang": null, "name": "nwbo:NetCashLoss", "reportCount": 1, "unique": true, "unitRef": "Unit_Standard_USD_SP4J7mnD6kCeIOWPHSnMBQ", "xsiNil": "false" } }, "R35": { "firstAnchor": { "ancestors": [ "p", "td", "tr", "table", "div", "div", "body", "html" ], "baseRef": "nwbo-20201231x10k.htm", "contextRef": "As_Of_12_31_2020_PD0VNgTHr0-8kHUggoZKhQ", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:RetainedEarningsAccumulatedDeficit", "reportCount": 1, "unitRef": "Unit_Standard_USD_SP4J7mnD6kCeIOWPHSnMBQ", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "40301 - Disclosure - Summary of Significant Accounting Policies (Details)", "role": "http://www.nwbio.com/role/DisclosureSummaryOfSignificantAccountingPoliciesDetails", "shortName": "Summary of Significant Accounting Policies (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "p", "us-gaap:ConcentrationRiskCreditRisk", "ix:continuation", "div", "div", "body", "html" ], "baseRef": "nwbo-20201231x10k.htm", "contextRef": "As_Of_12_31_2020_PD0VNgTHr0-8kHUggoZKhQ", "decimals": "0", "lang": null, "name": "us-gaap:CashFDICInsuredAmount", "reportCount": 1, "unique": true, "unitRef": "Unit_Standard_USD_SP4J7mnD6kCeIOWPHSnMBQ", "xsiNil": "false" } }, "R36": { "firstAnchor": { "ancestors": [ "p", "td", "tr", "table", "div", "div", "body", "html" ], "baseRef": "nwbo-20201231x10k.htm", "contextRef": "As_Of_12_31_2020_PD0VNgTHr0-8kHUggoZKhQ", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:DerivativeLiabilitiesCurrent", "reportCount": 1, "unitRef": "Unit_Standard_USD_SP4J7mnD6kCeIOWPHSnMBQ", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "40401 - Disclosure - Fair Value Measurements (Details)", "role": "http://www.nwbio.com/role/DisclosureFairValueMeasurementsDetails", "shortName": "Fair Value Measurements (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "p", "td", "tr", "table", "us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock", "us-gaap:FairValueDisclosuresTextBlock", "div", "div", "body", "html" ], "baseRef": "nwbo-20201231x10k.htm", "contextRef": "As_Of_12_31_2020_PD0VNgTHr0-8kHUggoZKhQ", "decimals": "-3", "lang": null, "name": "nwbo:ContingentPayableDerivativeLiability", "reportCount": 1, "unique": true, "unitRef": "Unit_Standard_USD_SP4J7mnD6kCeIOWPHSnMBQ", "xsiNil": "false" } }, "R37": { "firstAnchor": { "ancestors": [ "p", "td", "tr", "table", "us-gaap:FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock", "ix:continuation", "div", "div", "body", "html" ], "baseRef": "nwbo-20201231x10k.htm", "contextRef": "As_Of_12_31_2019_FthWjoGov0yYs91CHK22cA", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue", "reportCount": 1, "unitRef": "Unit_Standard_USD_SP4J7mnD6kCeIOWPHSnMBQ", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "40402 - Disclosure - Fair Value Measurements - Changes in Level 3 liabilities (Details)", "role": "http://www.nwbio.com/role/DisclosureFairValueMeasurementsChangesInLevel3LiabilitiesDetails", "shortName": "Fair Value Measurements - Changes in Level 3 liabilities (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "b", "p", "td", "tr", "table", "us-gaap:FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock", "ix:continuation", "div", "div", "body", "html" ], "baseRef": "nwbo-20201231x10k.htm", "contextRef": "As_Of_12_31_2018_02NXw6S5U06C-xF75mRE9g", "decimals": "-3", "lang": null, "name": "us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue", "reportCount": 1, "unique": true, "unitRef": "Unit_Standard_USD_SP4J7mnD6kCeIOWPHSnMBQ", "xsiNil": "false" } }, "R38": { "firstAnchor": { "ancestors": [ "p", "td", "tr", "table", "us-gaap:FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock", "ix:continuation", "div", "div", "body", "html" ], "baseRef": "nwbo-20201231x10k.htm", "contextRef": "As_Of_12_31_2020_us-gaap_DerivativeInstrumentRiskAxis_nwbo_WarrantLiabilityMember_W8-vnodUvk63nLHMpXjs4w", "decimals": "INF", "first": true, "lang": null, "name": "us-gaap:SharePrice", "reportCount": 1, "unique": true, "unitRef": "Unit_Divide_USD_shares_32eNyMKIhUuTmxYRiM-fcA", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "40403 - Disclosure - Fair Value Measurements - Weighted average (in aggregate) significant unobservable inputs (Details)", "role": "http://www.nwbio.com/role/DisclosureFairValueMeasurementsWeightedAverageInAggregateSignificantUnobservableInputsDetails", "shortName": "Fair Value Measurements - Weighted average (in aggregate) significant unobservable inputs (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "p", "td", "tr", "table", "us-gaap:FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock", "ix:continuation", "div", "div", "body", "html" ], "baseRef": "nwbo-20201231x10k.htm", "contextRef": "As_Of_12_31_2020_us-gaap_DerivativeInstrumentRiskAxis_nwbo_WarrantLiabilityMember_W8-vnodUvk63nLHMpXjs4w", "decimals": "INF", "first": true, "lang": null, "name": "us-gaap:SharePrice", "reportCount": 1, "unique": true, "unitRef": "Unit_Divide_USD_shares_32eNyMKIhUuTmxYRiM-fcA", "xsiNil": "false" } }, "R39": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "ix:continuation", "div", "div", "body", "html" ], "baseRef": "nwbo-20201231x10k.htm", "contextRef": "Duration_8_28_2020_To_8_28_2020_sFBp1YqKAUCJtmnnCSSwyg", "decimals": "-5", "first": true, "lang": null, "name": "us-gaap:PaymentsToAcquireBusinessesGross", "reportCount": 1, "unitRef": "Unit_Standard_USD_SP4J7mnD6kCeIOWPHSnMBQ", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "40501 - Disclosure - Flaskworks Acquisition (Details)", "role": "http://www.nwbio.com/role/DisclosureFlaskworksAcquisitionDetails", "shortName": "Flaskworks Acquisition (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "p", "ix:continuation", "div", "div", "body", "html" ], "baseRef": "nwbo-20201231x10k.htm", "contextRef": "As_Of_8_28_2020_us-gaap_BusinessAcquisitionAxis_nwbo_FlaskworksMember_tO_tx1nSlkuLvF0opwu_hg", "decimals": "2", "lang": null, "name": "us-gaap:BusinessAcquisitionPercentageOfVotingInterestsAcquired", "reportCount": 1, "unique": true, "unitRef": "Unit_Standard_pure_xOJ50rF1aEWVcaiPi-ewlQ", "xsiNil": "false" } }, "R4": { "firstAnchor": { "ancestors": [ "p", "td", "tr", "table", "div", "div", "body", "html" ], "baseRef": "nwbo-20201231x10k.htm", "contextRef": "Duration_1_1_2020_To_12_31_2020_nxgPv_TR5kW7h-rGR5n91A", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax", "reportCount": 1, "unique": true, "unitRef": "Unit_Standard_USD_SP4J7mnD6kCeIOWPHSnMBQ", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "00200 - Statement - CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS", "role": "http://www.nwbio.com/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss", "shortName": "CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "p", "td", "tr", "table", "div", "div", "body", "html" ], "baseRef": "nwbo-20201231x10k.htm", "contextRef": "Duration_1_1_2020_To_12_31_2020_nxgPv_TR5kW7h-rGR5n91A", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax", "reportCount": 1, "unique": true, "unitRef": "Unit_Standard_USD_SP4J7mnD6kCeIOWPHSnMBQ", "xsiNil": "false" } }, "R40": { "firstAnchor": { "ancestors": [ "p", "td", "tr", "table", "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock", "ix:continuation", "div", "div", "body", "html" ], "baseRef": "nwbo-20201231x10k.htm", "contextRef": "As_Of_12_31_2019_FthWjoGov0yYs91CHK22cA", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber", "reportCount": 1, "unitRef": "Unit_Standard_shares_JGINntETFEOmfZdvpym0WQ", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "40601 - Disclosure - Stock-based Compensation - Stock option activity (Details)", "role": "http://www.nwbio.com/role/DisclosureStockBasedCompensationStockOptionActivityDetails", "shortName": "Stock-based Compensation - Stock option activity (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "p", "td", "tr", "table", "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock", "ix:continuation", "div", "div", "body", "html" ], "baseRef": "nwbo-20201231x10k.htm", "contextRef": "Duration_1_1_2020_To_12_31_2020_nxgPv_TR5kW7h-rGR5n91A", "decimals": "0", "lang": null, "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross", "reportCount": 1, "unique": true, "unitRef": "Unit_Standard_shares_JGINntETFEOmfZdvpym0WQ", "xsiNil": "false" } }, "R41": { "firstAnchor": { "ancestors": [ "p", "td", "tr", "table", "us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock", "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "div", "div", "body", "html" ], "baseRef": "nwbo-20201231x10k.htm", "contextRef": "As_Of_12_31_2020_PD0VNgTHr0-8kHUggoZKhQ", "decimals": "2", "first": true, "lang": null, "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice", "reportCount": 1, "unique": true, "unitRef": "Unit_Divide_USD_shares_32eNyMKIhUuTmxYRiM-fcA", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "40602 - Disclosure - Stock-based Compensation - Assumptions (Details)", "role": "http://www.nwbio.com/role/DisclosureStockBasedCompensationAssumptionsDetails", "shortName": "Stock-based Compensation - Assumptions (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "p", "td", "tr", "table", "us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock", "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "div", "div", "body", "html" ], "baseRef": "nwbo-20201231x10k.htm", "contextRef": "As_Of_12_31_2020_PD0VNgTHr0-8kHUggoZKhQ", "decimals": "2", "first": true, "lang": null, "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice", "reportCount": 1, "unique": true, "unitRef": "Unit_Divide_USD_shares_32eNyMKIhUuTmxYRiM-fcA", "xsiNil": "false" } }, "R42": { "firstAnchor": { "ancestors": [ "p", "td", "tr", "table", "us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock", "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "div", "div", "body", "html" ], "baseRef": "nwbo-20201231x10k.htm", "contextRef": "Duration_1_1_2020_To_12_31_2020_nxgPv_TR5kW7h-rGR5n91A", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:AllocatedShareBasedCompensationExpense", "reportCount": 1, "unitRef": "Unit_Standard_USD_SP4J7mnD6kCeIOWPHSnMBQ", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "40603 - Disclosure - Stock-based Compensation - Summary of stock-based compensation expense (Details)", "role": "http://www.nwbio.com/role/DisclosureStockBasedCompensationSummaryOfStockBasedCompensationExpenseDetails", "shortName": "Stock-based Compensation - Summary of stock-based compensation expense (Details)", "subGroupType": "details", "uniqueAnchor": null }, "R43": { "firstAnchor": { "ancestors": [ "p", "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "div", "div", "body", "html" ], "baseRef": "nwbo-20201231x10k.htm", "contextRef": "As_Of_12_31_2020_PD0VNgTHr0-8kHUggoZKhQ", "decimals": "-6", "first": true, "lang": null, "name": "us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized", "reportCount": 1, "unique": true, "unitRef": "Unit_Standard_USD_SP4J7mnD6kCeIOWPHSnMBQ", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "40604 - Disclosure - Stock-based Compensation - Additional Information (Details)", "role": "http://www.nwbio.com/role/DisclosureStockBasedCompensationAdditionalInformationDetails", "shortName": "Stock-based Compensation - Additional Information (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "p", "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "div", "div", "body", "html" ], "baseRef": "nwbo-20201231x10k.htm", "contextRef": "As_Of_12_31_2020_PD0VNgTHr0-8kHUggoZKhQ", "decimals": "-6", "first": true, "lang": null, "name": "us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized", "reportCount": 1, "unique": true, "unitRef": "Unit_Standard_USD_SP4J7mnD6kCeIOWPHSnMBQ", "xsiNil": "false" } }, "R44": { "firstAnchor": { "ancestors": [ "p", "td", "tr", "table", "div", "div", "body", "html" ], "baseRef": "nwbo-20201231x10k.htm", "contextRef": "As_Of_12_31_2020_PD0VNgTHr0-8kHUggoZKhQ", "decimals": "-3", "first": true, "lang": null, "name": "nwbo:ConstructionsInProgressNet", "reportCount": 1, "unitRef": "Unit_Standard_USD_SP4J7mnD6kCeIOWPHSnMBQ", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "40701 - Disclosure - Property, Plant and Equipment (Details)", "role": "http://www.nwbio.com/role/DisclosurePropertyPlantAndEquipmentDetails", "shortName": "Property, Plant and Equipment (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "p", "td", "tr", "table", "us-gaap:PropertyPlantAndEquipmentTextBlock", "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock", "div", "div", "body", "html" ], "baseRef": "nwbo-20201231x10k.htm", "contextRef": "As_Of_12_31_2020_us-gaap_GeographicDistributionAxis_us-gaap_GeographicDistributionDomesticMember_0QMgfHyeo0uK9YGndRaVbQ", "decimals": "-3", "lang": null, "name": "us-gaap:PropertyPlantAndEquipmentGross", "reportCount": 1, "unique": true, "unitRef": "Unit_Standard_USD_SP4J7mnD6kCeIOWPHSnMBQ", "xsiNil": "false" } }, "R45": { "firstAnchor": { "ancestors": [ "p", "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock", "div", "div", "body", "html" ], "baseRef": "nwbo-20201231x10k.htm", "contextRef": "Duration_1_1_2020_To_12_31_2020_nxgPv_TR5kW7h-rGR5n91A", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:Depreciation", "reportCount": 1, "unique": true, "unitRef": "Unit_Standard_USD_SP4J7mnD6kCeIOWPHSnMBQ", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "40702 - Disclosure - Property, Plant and Equipment - Additional Information (Details)", "role": "http://www.nwbio.com/role/DisclosurePropertyPlantAndEquipmentAdditionalInformationDetails", "shortName": "Property, Plant and Equipment - Additional Information (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "p", "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock", "div", "div", "body", "html" ], "baseRef": "nwbo-20201231x10k.htm", "contextRef": "Duration_1_1_2020_To_12_31_2020_nxgPv_TR5kW7h-rGR5n91A", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:Depreciation", "reportCount": 1, "unique": true, "unitRef": "Unit_Standard_USD_SP4J7mnD6kCeIOWPHSnMBQ", "xsiNil": "false" } }, "R46": { "firstAnchor": { "ancestors": [ "p", "ix:continuation", "div", "div", "body", "html" ], "baseRef": "nwbo-20201231x10k.htm", "contextRef": "As_Of_12_31_2018_02NXw6S5U06C-xF75mRE9g", "decimals": "2", "first": true, "lang": null, "name": "us-gaap:DebtInstrumentInterestRateStatedPercentage", "reportCount": 1, "unitRef": "Unit_Standard_pure_xOJ50rF1aEWVcaiPi-ewlQ", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "40801 - Disclosure - Notes Payable (Details)", "role": "http://www.nwbio.com/role/DisclosureNotesPayableDetails", "shortName": "Notes Payable (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "us-gaap:ScheduleOfDebtTableTextBlock", "us-gaap:DebtDisclosureTextBlock", "div", "div", "body", "html" ], "baseRef": "nwbo-20201231x10k.htm", "contextRef": "As_Of_12_31_2020_us-gaap_ShortTermDebtTypeAxis_nwbo_SixPercentUnsecurbleMember_xB3YHZ8iS0er2F6O8NIf4g", "decimals": "2", "lang": null, "name": "us-gaap:DebtInstrumentInterestRateStatedPercentage", "reportCount": 1, "unique": true, "unitRef": "Unit_Standard_pure_xOJ50rF1aEWVcaiPi-ewlQ", "xsiNil": "false" } }, "R47": { "firstAnchor": { "ancestors": [ "p", "td", "tr", "table", "ix:continuation", "div", "div", "body", "html" ], "baseRef": "nwbo-20201231x10k.htm", "contextRef": "Duration_1_1_2020_To_12_31_2020_nxgPv_TR5kW7h-rGR5n91A", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:ContractualInterestExpenseOnPrepetitionLiabilitiesNotRecognizedInStatementOfOperations", "reportCount": 1, "unitRef": "Unit_Standard_USD_SP4J7mnD6kCeIOWPHSnMBQ", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "40803 - Disclosure - Notes Payable - Mortgage Loan (Details)", "role": "http://www.nwbio.com/role/DisclosureNotesPayableMortgageLoanDetails", "shortName": "Notes Payable - Mortgage Loan (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "p", "td", "tr", "table", "us-gaap:InterestIncomeAndInterestExpenseDisclosureTableTextBlock", "ix:continuation", "div", "div", "body", "html" ], "baseRef": "nwbo-20201231x10k.htm", "contextRef": "Duration_1_1_2020_To_12_31_2020_nxgPv_TR5kW7h-rGR5n91A", "decimals": "-3", "lang": null, "name": "us-gaap:InterestExpenseOther", "reportCount": 1, "unique": true, "unitRef": "Unit_Standard_USD_SP4J7mnD6kCeIOWPHSnMBQ", "xsiNil": "false" } }, "R48": { "firstAnchor": { "ancestors": [ "b", "p", "td", "tr", "table", "us-gaap:ScheduleOfDebtTableTextBlock", "us-gaap:DebtDisclosureTextBlock", "div", "div", "body", "html" ], "baseRef": "nwbo-20201231x10k.htm", "contextRef": "As_Of_12_31_2020_PD0VNgTHr0-8kHUggoZKhQ", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:DebtInstrumentFaceAmount", "reportCount": 1, "unitRef": "Unit_Standard_USD_SP4J7mnD6kCeIOWPHSnMBQ", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "40804 - Disclosure - Notes Payable - summary of the company's contractual obligations on debt principal (Details)", "role": "http://www.nwbio.com/role/DisclosureNotesPayableSummaryOfCompanySContractualObligationsOnDebtPrincipalDetails", "shortName": "Notes Payable - summary of the company's contractual obligations on debt principal (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "p", "td", "tr", "table", "nwbo:ScheduleOfContractualObligationsOnDebtPrincipalTableTextBlock", "ix:continuation", "div", "div", "body", "html" ], "baseRef": "nwbo-20201231x10k.htm", "contextRef": "As_Of_12_31_2020_us-gaap_ExtinguishmentOfDebtAxis_nwbo_ShortTermConvertibleNoteMember_us-gaap_ShortTermDebtTypeAxis_nwbo_SixPercentUnsecuredMember_-7NeyGC_qEa73dbLSVOWPQ", "decimals": "-3", "lang": null, "name": "us-gaap:DebtInstrumentFaceAmount", "reportCount": 1, "unique": true, "unitRef": "Unit_Standard_USD_SP4J7mnD6kCeIOWPHSnMBQ", "xsiNil": "false" } }, "R49": { "firstAnchor": { "ancestors": [ "b", "p", "td", "tr", "table", "us-gaap:ScheduleOfDebtTableTextBlock", "us-gaap:DebtDisclosureTextBlock", "div", "div", "body", "html" ], "baseRef": "nwbo-20201231x10k.htm", "contextRef": "As_Of_12_31_2020_PD0VNgTHr0-8kHUggoZKhQ", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:DebtInstrumentFaceAmount", "reportCount": 1, "unitRef": "Unit_Standard_USD_SP4J7mnD6kCeIOWPHSnMBQ", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "40805 - Disclosure - Notes Payable - Additional Information (Details)", "role": "http://www.nwbio.com/role/DisclosureNotesPayableAdditionalInformationDetails", "shortName": "Notes Payable - Additional Information (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "us-gaap:NotesPayable", "span", "td", "tr", "table", "us-gaap:ScheduleOfDebtTableTextBlock", "us-gaap:DebtDisclosureTextBlock", "div", "div", "body", "html" ], "baseRef": "nwbo-20201231x10k.htm", "contextRef": "As_Of_12_31_2020_PD0VNgTHr0-8kHUggoZKhQ", "decimals": "-3", "lang": null, "name": "us-gaap:NotesPayable", "reportCount": 1, "unique": true, "unitRef": "Unit_Standard_USD_SP4J7mnD6kCeIOWPHSnMBQ", "xsiNil": "false" } }, "R5": { "firstAnchor": { "ancestors": [ "b", "p", "td", "tr", "table", "div", "div", "body", "html" ], "baseRef": "nwbo-20201231x10k.htm", "contextRef": "As_Of_12_31_2018_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_VZ3XDaPDxUeAqKGUrUGnxQ", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:StockholdersEquity", "reportCount": 1, "unique": true, "unitRef": "Unit_Standard_USD_SP4J7mnD6kCeIOWPHSnMBQ", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "00300 - Statement - CONSOLIDATED STATEMENTS OF CHANGES IN STOCKHOLDERS' DEFICIT", "role": "http://www.nwbio.com/role/StatementConsolidatedStatementsOfChangesInStockholdersDeficit", "shortName": "CONSOLIDATED STATEMENTS OF CHANGES IN STOCKHOLDERS' DEFICIT", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "b", "p", "td", "tr", "table", "div", "div", "body", "html" ], "baseRef": "nwbo-20201231x10k.htm", "contextRef": "As_Of_12_31_2018_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_VZ3XDaPDxUeAqKGUrUGnxQ", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:StockholdersEquity", "reportCount": 1, "unique": true, "unitRef": "Unit_Standard_USD_SP4J7mnD6kCeIOWPHSnMBQ", "xsiNil": "false" } }, "R50": { "firstAnchor": { "ancestors": [ "b", "p", "td", "tr", "table", "us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock", "us-gaap:EarningsPerShareTextBlock", "div", "div", "body", "html" ], "baseRef": "nwbo-20201231x10k.htm", "contextRef": "Duration_1_1_2020_To_12_31_2020_nxgPv_TR5kW7h-rGR5n91A", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount", "reportCount": 1, "unique": true, "unitRef": "Unit_Standard_shares_JGINntETFEOmfZdvpym0WQ", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "40901 - Disclosure - Net Earnings (Loss) per Share Applicable to Common Stockholders (Details)", "role": "http://www.nwbio.com/role/DisclosureNetEarningsLossPerShareApplicableToCommonStockholdersDetails", "shortName": "Net Earnings (Loss) per Share Applicable to Common Stockholders (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "b", "p", "td", "tr", "table", "us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock", "us-gaap:EarningsPerShareTextBlock", "div", "div", "body", "html" ], "baseRef": "nwbo-20201231x10k.htm", "contextRef": "Duration_1_1_2020_To_12_31_2020_nxgPv_TR5kW7h-rGR5n91A", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount", "reportCount": 1, "unique": true, "unitRef": "Unit_Standard_shares_JGINntETFEOmfZdvpym0WQ", "xsiNil": "false" } }, "R51": { "firstAnchor": { "ancestors": [ "p", "td", "tr", "table", "nwbo:ScheduleOfSettlementObligationsTableTextBlock", "us-gaap:RelatedPartyTransactionsDisclosureTextBlock", "div", "div", "body", "html" ], "baseRef": "nwbo-20201231x10k.htm", "contextRef": "Duration_1_1_2020_To_12_31_2020_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_nwbo_AdventBioservicesMember_jOwwhdNZLka13954EFBXhg", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty", "reportCount": 1, "unique": true, "unitRef": "Unit_Standard_USD_SP4J7mnD6kCeIOWPHSnMBQ", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "41001 - Disclosure - Related Party Transactions - Summary of outstanding unpaid accounts payable held by related parties (Details)", "role": "http://www.nwbio.com/role/DisclosureRelatedPartyTransactionsSummaryOfOutstandingUnpaidAccountsPayableHeldByRelatedPartiesDetails", "shortName": "Related Party Transactions - Summary of outstanding unpaid accounts payable held by related parties (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "p", "td", "tr", "table", "nwbo:ScheduleOfSettlementObligationsTableTextBlock", "us-gaap:RelatedPartyTransactionsDisclosureTextBlock", "div", "div", "body", "html" ], "baseRef": "nwbo-20201231x10k.htm", "contextRef": "Duration_1_1_2020_To_12_31_2020_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_nwbo_AdventBioservicesMember_jOwwhdNZLka13954EFBXhg", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty", "reportCount": 1, "unique": true, "unitRef": "Unit_Standard_USD_SP4J7mnD6kCeIOWPHSnMBQ", "xsiNil": "false" } }, "R52": { "firstAnchor": { "ancestors": [ "p", "td", "tr", "table", "ix:continuation", "div", "div", "body", "html" ], "baseRef": "nwbo-20201231x10k.htm", "contextRef": "Duration_1_1_2020_To_12_31_2020_nxgPv_TR5kW7h-rGR5n91A", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:ContractualInterestExpenseOnPrepetitionLiabilitiesNotRecognizedInStatementOfOperations", "reportCount": 1, "unitRef": "Unit_Standard_USD_SP4J7mnD6kCeIOWPHSnMBQ", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "41002 - Disclosure - Related Party Transactions - Total interest expenses (Details)", "role": "http://www.nwbio.com/role/DisclosureRelatedPartyTransactionsTotalInterestExpensesDetails", "shortName": "Related Party Transactions - Total interest expenses (Details)", "subGroupType": "details", "uniqueAnchor": null }, "R53": { "firstAnchor": { "ancestors": [ "p", "ix:continuation", "div", "div", "body", "html" ], "baseRef": "nwbo-20201231x10k.htm", "contextRef": "As_Of_9_26_2018_M8kU1aPITUK7fmFMsoWYkQ", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:ShortTermBorrowings", "reportCount": 1, "unitRef": "Unit_Standard_USD_SP4J7mnD6kCeIOWPHSnMBQ", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "41003 - Disclosure - Related Party Transactions - Additional Information (Details)", "role": "http://www.nwbio.com/role/DisclosureRelatedPartyTransactionsAdditionalInformationDetails", "shortName": "Related Party Transactions - Additional Information (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "p", "ix:continuation", "div", "div", "body", "html" ], "baseRef": "nwbo-20201231x10k.htm", "contextRef": "As_Of_12_31_2020_us-gaap_AwardTypeAxis_nwbo_ForbearanceWarrantsMember_rkQSh5i19UmlCJUUJQT-HQ", "decimals": "2", "lang": null, "name": "us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1", "reportCount": 1, "unique": true, "unitRef": "Unit_Divide_USD_shares_32eNyMKIhUuTmxYRiM-fcA", "xsiNil": "false" } }, "R54": { "firstAnchor": { "ancestors": [ "b", "p", "td", "tr", "table", "us-gaap:ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock", "ix:continuation", "div", "div", "body", "html" ], "baseRef": "nwbo-20201231x10k.htm", "contextRef": "As_Of_12_31_2019_FthWjoGov0yYs91CHK22cA", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:ClassOfWarrantOrRightOutstanding", "reportCount": 1, "unitRef": "Unit_Standard_shares_JGINntETFEOmfZdvpym0WQ", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "41101 - Disclosure - Stockholders' Deficit (Details)", "role": "http://www.nwbio.com/role/DisclosureStockholdersDeficitDetails", "shortName": "Stockholders' Deficit (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "p", "td", "tr", "table", "us-gaap:ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock", "ix:continuation", "div", "div", "body", "html" ], "baseRef": "nwbo-20201231x10k.htm", "contextRef": "Duration_1_1_2020_To_12_31_2020_nxgPv_TR5kW7h-rGR5n91A", "decimals": "0", "lang": null, "name": "nwbo:ClassOfWarrantOrRightGranted", "reportCount": 1, "unique": true, "unitRef": "Unit_Standard_shares_JGINntETFEOmfZdvpym0WQ", "xsiNil": "false" } }, "R55": { "firstAnchor": { "ancestors": [ "p", "td", "tr", "table", "div", "div", "body", "html" ], "baseRef": "nwbo-20201231x10k.htm", "contextRef": "Duration_1_1_2020_To_12_31_2020_nxgPv_TR5kW7h-rGR5n91A", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:ProceedsFromWarrantExercises", "reportCount": 1, "unitRef": "Unit_Standard_USD_SP4J7mnD6kCeIOWPHSnMBQ", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "41102 - Disclosure - Stockholders' Deficit - Additional Information (Details", "role": "http://www.nwbio.com/role/DisclosureStockholdersDeficitAdditionalInformationDetails", "shortName": "Stockholders' Deficit - Additional Information (Details", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "p", "ix:continuation", "div", "div", "body", "html" ], "baseRef": "nwbo-20201231x10k.htm", "contextRef": "As_Of_12_31_2020_PD0VNgTHr0-8kHUggoZKhQ", "decimals": "-5", "lang": null, "name": "nwbo:SharesIssuedDuringPeriodSharesUponExerciseOfWarrants", "reportCount": 1, "unique": true, "unitRef": "Unit_Standard_shares_JGINntETFEOmfZdvpym0WQ", "xsiNil": "false" } }, "R56": { "firstAnchor": { "ancestors": [ "p", "td", "tr", "table", "us-gaap:LeaseCostTableTextBlock", "ix:continuation", "div", "div", "body", "html" ], "baseRef": "nwbo-20201231x10k.htm", "contextRef": "Duration_1_1_2020_To_12_31_2020_nxgPv_TR5kW7h-rGR5n91A", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:OperatingLeaseCost", "reportCount": 1, "unique": true, "unitRef": "Unit_Standard_USD_SP4J7mnD6kCeIOWPHSnMBQ", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "41201 - Disclosure - Commitments and Contingencies (Details)", "role": "http://www.nwbio.com/role/DisclosureCommitmentsAndContingenciesDetails", "shortName": "Commitments and Contingencies (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "p", "td", "tr", "table", "us-gaap:LeaseCostTableTextBlock", "ix:continuation", "div", "div", "body", "html" ], "baseRef": "nwbo-20201231x10k.htm", "contextRef": "Duration_1_1_2020_To_12_31_2020_nxgPv_TR5kW7h-rGR5n91A", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:OperatingLeaseCost", "reportCount": 1, "unique": true, "unitRef": "Unit_Standard_USD_SP4J7mnD6kCeIOWPHSnMBQ", "xsiNil": "false" } }, "R57": { "firstAnchor": { "ancestors": [ "p", "td", "tr", "table", "us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock", "ix:continuation", "div", "div", "body", "html" ], "baseRef": "nwbo-20201231x10k.htm", "contextRef": "As_Of_12_31_2020_PD0VNgTHr0-8kHUggoZKhQ", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths", "reportCount": 1, "unique": true, "unitRef": "Unit_Standard_USD_SP4J7mnD6kCeIOWPHSnMBQ", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "41202 - Disclosure - Commitments and Contingencies - maturities of our operating leases (Details)", "role": "http://www.nwbio.com/role/DisclosureCommitmentsAndContingenciesMaturitiesOfOurOperatingLeasesDetails", "shortName": "Commitments and Contingencies - maturities of our operating leases (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "p", "td", "tr", "table", "us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock", "ix:continuation", "div", "div", "body", "html" ], "baseRef": "nwbo-20201231x10k.htm", "contextRef": "As_Of_12_31_2020_PD0VNgTHr0-8kHUggoZKhQ", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths", "reportCount": 1, "unique": true, "unitRef": "Unit_Standard_USD_SP4J7mnD6kCeIOWPHSnMBQ", "xsiNil": "false" } }, "R58": { "firstAnchor": { "ancestors": [ "p", "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock", "div", "div", "body", "html" ], "baseRef": "nwbo-20201231x10k.htm", "contextRef": "As_Of_12_31_2020_PD0VNgTHr0-8kHUggoZKhQ", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:LeasePracticalExpedientLessorSingleLeaseComponent", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "41203 - Disclosure - Commitments and Contingencies - Additional Information (Details)", "role": "http://www.nwbio.com/role/DisclosureCommitmentsAndContingenciesAdditionalInformationDetails", "shortName": "Commitments and Contingencies - Additional Information (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "p", "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock", "div", "div", "body", "html" ], "baseRef": "nwbo-20201231x10k.htm", "contextRef": "As_Of_12_31_2020_PD0VNgTHr0-8kHUggoZKhQ", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:LeasePracticalExpedientLessorSingleLeaseComponent", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R59": { "firstAnchor": { "ancestors": [ "p", "td", "tr", "table", "us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock", "ix:continuation", "div", "div", "body", "html" ], "baseRef": "nwbo-20201231x10k.htm", "contextRef": "As_Of_12_31_2020_PD0VNgTHr0-8kHUggoZKhQ", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:DeferredTaxAssetsOperatingLossCarryforwards", "reportCount": 1, "unique": true, "unitRef": "Unit_Standard_USD_SP4J7mnD6kCeIOWPHSnMBQ", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "41301 - Disclosure - Income Taxes - Summary of Deferred Tax Assets and Liabilities (Details)", "role": "http://www.nwbio.com/role/DisclosureIncomeTaxesSummaryOfDeferredTaxAssetsAndLiabilitiesDetails", "shortName": "Income Taxes - Summary of Deferred Tax Assets and Liabilities (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "p", "td", "tr", "table", "us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock", "ix:continuation", "div", "div", "body", "html" ], "baseRef": "nwbo-20201231x10k.htm", "contextRef": "As_Of_12_31_2020_PD0VNgTHr0-8kHUggoZKhQ", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:DeferredTaxAssetsOperatingLossCarryforwards", "reportCount": 1, "unique": true, "unitRef": "Unit_Standard_USD_SP4J7mnD6kCeIOWPHSnMBQ", "xsiNil": "false" } }, "R6": { "firstAnchor": { "ancestors": [ "p", "td", "tr", "table", "div", "div", "body", "html" ], "baseRef": "nwbo-20201231x10k.htm", "contextRef": "Duration_1_1_2020_To_12_31_2020_nxgPv_TR5kW7h-rGR5n91A", "decimals": "-5", "first": true, "lang": null, "name": "us-gaap:PaymentsOfStockIssuanceCosts", "reportCount": 1, "unitRef": "Unit_Standard_USD_SP4J7mnD6kCeIOWPHSnMBQ", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "00305 - Statement - CONSOLIDATED STATEMENTS OF CHANGES IN STOCKHOLDERS' DEFICIT (Parenthetical)", "role": "http://www.nwbio.com/role/StatementConsolidatedStatementsOfChangesInStockholdersDeficitParenthetical", "shortName": "CONSOLIDATED STATEMENTS OF CHANGES IN STOCKHOLDERS' DEFICIT (Parenthetical)", "subGroupType": "parenthetical", "uniqueAnchor": { "ancestors": [ "p", "td", "tr", "table", "div", "div", "body", "html" ], "baseRef": "nwbo-20201231x10k.htm", "contextRef": "Duration_1_1_2020_To_12_31_2020_us-gaap_SubsidiarySaleOfStockAxis_nwbo_DirectOfferingMember_yobIUP_SNk6yoLcGsyjb4Q", "decimals": "-5", "lang": null, "name": "us-gaap:FairValueAdjustmentOfWarrants", "reportCount": 1, "unique": true, "unitRef": "Unit_Standard_USD_SP4J7mnD6kCeIOWPHSnMBQ", "xsiNil": "false" } }, "R60": { "firstAnchor": { "ancestors": [ "p", "td", "tr", "table", "us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock", "ix:continuation", "div", "div", "body", "html" ], "baseRef": "nwbo-20201231x10k.htm", "contextRef": "Duration_1_1_2020_To_12_31_2020_nxgPv_TR5kW7h-rGR5n91A", "decimals": "3", "first": true, "lang": null, "name": "us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate", "reportCount": 1, "unique": true, "unitRef": "Unit_Standard_pure_xOJ50rF1aEWVcaiPi-ewlQ", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "41302 - Disclosure - Income Taxes - Reconcilation of U.S. Federal Statutory Tax Expense (Benefit) (Details)", "role": "http://www.nwbio.com/role/DisclosureIncomeTaxesReconcilationOfUsFederalStatutoryTaxExpenseBenefitDetails", "shortName": "Income Taxes - Reconcilation of U.S. Federal Statutory Tax Expense (Benefit) (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "p", "td", "tr", "table", "us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock", "ix:continuation", "div", "div", "body", "html" ], "baseRef": "nwbo-20201231x10k.htm", "contextRef": "Duration_1_1_2020_To_12_31_2020_nxgPv_TR5kW7h-rGR5n91A", "decimals": "3", "first": true, "lang": null, "name": "us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate", "reportCount": 1, "unique": true, "unitRef": "Unit_Standard_pure_xOJ50rF1aEWVcaiPi-ewlQ", "xsiNil": "false" } }, "R61": { "firstAnchor": { "ancestors": [ "p", "td", "tr", "table", "us-gaap:ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock", "ix:continuation", "div", "div", "body", "html" ], "baseRef": "nwbo-20201231x10k.htm", "contextRef": "Duration_1_1_2020_To_12_31_2020_nxgPv_TR5kW7h-rGR5n91A", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:CurrentFederalTaxExpenseBenefit", "reportCount": 1, "unique": true, "unitRef": "Unit_Standard_USD_SP4J7mnD6kCeIOWPHSnMBQ", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "41303 - Disclosure - Income Taxes - Summary of Tax Provision Benefit (Details)", "role": "http://www.nwbio.com/role/DisclosureIncomeTaxesSummaryOfTaxProvisionBenefitDetails", "shortName": "Income Taxes - Summary of Tax Provision Benefit (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "p", "td", "tr", "table", "us-gaap:ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock", "ix:continuation", "div", "div", "body", "html" ], "baseRef": "nwbo-20201231x10k.htm", "contextRef": "Duration_1_1_2020_To_12_31_2020_nxgPv_TR5kW7h-rGR5n91A", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:CurrentFederalTaxExpenseBenefit", "reportCount": 1, "unique": true, "unitRef": "Unit_Standard_USD_SP4J7mnD6kCeIOWPHSnMBQ", "xsiNil": "false" } }, "R62": { "firstAnchor": { "ancestors": [ "p", "ix:continuation", "div", "div", "body", "html" ], "baseRef": "nwbo-20201231x10k.htm", "contextRef": "As_Of_12_31_2020_PD0VNgTHr0-8kHUggoZKhQ", "decimals": "-5", "first": true, "lang": null, "name": "us-gaap:OperatingLossCarryforwards", "reportCount": 1, "unique": true, "unitRef": "Unit_Standard_USD_SP4J7mnD6kCeIOWPHSnMBQ", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "41304 - Disclosure - Income Taxes - Additional information (Details)", "role": "http://www.nwbio.com/role/DisclosureIncomeTaxesAdditionalInformationDetails", "shortName": "Income Taxes - Additional information (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "p", "ix:continuation", "div", "div", "body", "html" ], "baseRef": "nwbo-20201231x10k.htm", "contextRef": "As_Of_12_31_2020_PD0VNgTHr0-8kHUggoZKhQ", "decimals": "-5", "first": true, "lang": null, "name": "us-gaap:OperatingLossCarryforwards", "reportCount": 1, "unique": true, "unitRef": "Unit_Standard_USD_SP4J7mnD6kCeIOWPHSnMBQ", "xsiNil": "false" } }, "R63": { "firstAnchor": { "ancestors": [ "p", "td", "tr", "table", "div", "div", "body", "html" ], "baseRef": "nwbo-20201231x10k.htm", "contextRef": "As_Of_12_31_2020_PD0VNgTHr0-8kHUggoZKhQ", "decimals": "-3", "first": true, "lang": null, "name": "nwbo:ConstructionsInProgressNet", "reportCount": 1, "unitRef": "Unit_Standard_USD_SP4J7mnD6kCeIOWPHSnMBQ", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "41401 - Disclosure - Revision to Prior Period Financial Statements -Consolidated Balance Sheet (Details)", "role": "http://www.nwbio.com/role/DisclosureRevisionToPriorPeriodFinancialStatementsConsolidatedBalanceSheetDetails", "shortName": "Revision to Prior Period Financial Statements -Consolidated Balance Sheet (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "p", "td", "tr", "table", "ix:continuation", "div", "div", "body", "html" ], "baseRef": "nwbo-20201231x10k.htm", "contextRef": "As_Of_12_31_2019_srt_RestatementAxis_srt_ScenarioPreviouslyReportedMember_nBUCZpwg3EmGmty0I2IF-w", "decimals": "-3", "lang": null, "name": "nwbo:ConstructionsInProgressNet", "reportCount": 1, "unique": true, "unitRef": "Unit_Standard_USD_SP4J7mnD6kCeIOWPHSnMBQ", "xsiNil": "false" } }, "R64": { "firstAnchor": { "ancestors": [ "p", "td", "tr", "table", "div", "div", "body", "html" ], "baseRef": "nwbo-20201231x10k.htm", "contextRef": "Duration_1_1_2020_To_12_31_2020_nxgPv_TR5kW7h-rGR5n91A", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:ResearchAndDevelopmentExpense", "reportCount": 1, "unitRef": "Unit_Standard_USD_SP4J7mnD6kCeIOWPHSnMBQ", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "41402 - Disclosure - Revision to Prior Period Financial Statements - Consolidated Statement of Operations (Detaills)", "role": "http://www.nwbio.com/role/DisclosureRevisionToPriorPeriodFinancialStatementsConsolidatedStatementOfOperationsDetaills", "shortName": "Revision to Prior Period Financial Statements - Consolidated Statement of Operations (Detaills)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "p", "td", "tr", "table", "ix:continuation", "div", "div", "body", "html" ], "baseRef": "nwbo-20201231x10k.htm", "contextRef": "Duration_1_1_2019_To_12_31_2019_srt_RestatementAxis_srt_ScenarioPreviouslyReportedMember_R92YhJ8FdUGzAbgxA5iS3w", "decimals": "-3", "lang": null, "name": "us-gaap:ResearchAndDevelopmentExpense", "reportCount": 1, "unique": true, "unitRef": "Unit_Standard_USD_SP4J7mnD6kCeIOWPHSnMBQ", "xsiNil": "false" } }, "R65": { "firstAnchor": { "ancestors": [ "p", "td", "tr", "table", "div", "div", "body", "html" ], "baseRef": "nwbo-20201231x10k.htm", "contextRef": "Duration_1_1_2020_To_12_31_2020_nxgPv_TR5kW7h-rGR5n91A", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:NetIncomeLoss", "reportCount": 1, "unitRef": "Unit_Standard_USD_SP4J7mnD6kCeIOWPHSnMBQ", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "41403 - Disclosure - Revision to Prior Period Financial Statements - Consolidated Statement of Cash Flows (Detaills)", "role": "http://www.nwbio.com/role/DisclosureRevisionToPriorPeriodFinancialStatementsConsolidatedStatementOfCashFlowsDetaills", "shortName": "Revision to Prior Period Financial Statements - Consolidated Statement of Cash Flows (Detaills)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "p", "td", "tr", "table", "ix:continuation", "div", "div", "body", "html" ], "baseRef": "nwbo-20201231x10k.htm", "contextRef": "Duration_1_1_2019_To_12_31_2019_xAxEFd56NkqnpXDYVfXO_A", "decimals": "-3", "lang": null, "name": "nwbo:CapitalExpendituresIncludedInAccountsPayableAndAccruedExpensesToRelatedPartiesAndAffiliates", "reportCount": 1, "unique": true, "unitRef": "Unit_Standard_USD_SP4J7mnD6kCeIOWPHSnMBQ", "xsiNil": "false" } }, "R66": { "firstAnchor": { "ancestors": [ "b", "p", "td", "tr", "table", "us-gaap:ScheduleOfDebtTableTextBlock", "us-gaap:DebtDisclosureTextBlock", "div", "div", "body", "html" ], "baseRef": "nwbo-20201231x10k.htm", "contextRef": "As_Of_12_31_2020_PD0VNgTHr0-8kHUggoZKhQ", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:DebtInstrumentFaceAmount", "reportCount": 1, "unitRef": "Unit_Standard_USD_SP4J7mnD6kCeIOWPHSnMBQ", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "41501 - Disclosure - Subsequent Events (Details)", "role": "http://www.nwbio.com/role/DisclosureSubsequentEventsDetails", "shortName": "Subsequent Events (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "p", "ix:continuation", "div", "div", "body", "html" ], "baseRef": "nwbo-20201231x10k.htm", "contextRef": "Duration_1_1_2021_To_3_31_2021_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember_agVHvrb0K0epES80HXIqtw", "decimals": "-5", "lang": null, "name": "nwbo:StockIssuedDuringPeriodSharesWarrantExercises", "reportCount": 1, "unique": true, "unitRef": "Unit_Standard_shares_JGINntETFEOmfZdvpym0WQ", "xsiNil": "false" } }, "R7": { "firstAnchor": { "ancestors": [ "p", "td", "tr", "table", "div", "div", "body", "html" ], "baseRef": "nwbo-20201231x10k.htm", "contextRef": "Duration_1_1_2020_To_12_31_2020_nxgPv_TR5kW7h-rGR5n91A", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:NetIncomeLoss", "reportCount": 1, "unitRef": "Unit_Standard_USD_SP4J7mnD6kCeIOWPHSnMBQ", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "00400 - Statement - CONSOLIDATED STATEMENTS OF CASH FLOWS", "role": "http://www.nwbio.com/role/StatementConsolidatedStatementsOfCashFlows", "shortName": "CONSOLIDATED STATEMENTS OF CASH FLOWS", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "p", "td", "tr", "table", "div", "div", "body", "html" ], "baseRef": "nwbo-20201231x10k.htm", "contextRef": "Duration_1_1_2020_To_12_31_2020_nxgPv_TR5kW7h-rGR5n91A", "decimals": "-3", "lang": null, "name": "us-gaap:DepreciationAndAmortization", "reportCount": 1, "unique": true, "unitRef": "Unit_Standard_USD_SP4J7mnD6kCeIOWPHSnMBQ", "xsiNil": "false" } }, "R8": { "firstAnchor": { "ancestors": [ "div", "div", "body", "html" ], "baseRef": "nwbo-20201231x10k.htm", "contextRef": "Duration_1_1_2020_To_12_31_2020_nxgPv_TR5kW7h-rGR5n91A", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "10101 - Disclosure - Organization and Description of Business", "role": "http://www.nwbio.com/role/DisclosureOrganizationAndDescriptionOfBusiness", "shortName": "Organization and Description of Business", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "div", "div", "body", "html" ], "baseRef": "nwbo-20201231x10k.htm", "contextRef": "Duration_1_1_2020_To_12_31_2020_nxgPv_TR5kW7h-rGR5n91A", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R9": { "firstAnchor": { "ancestors": [ "div", "div", "body", "html" ], "baseRef": "nwbo-20201231x10k.htm", "contextRef": "Duration_1_1_2020_To_12_31_2020_nxgPv_TR5kW7h-rGR5n91A", "decimals": null, "first": true, "lang": "en-US", "name": "nwbo:FinancialConditionGoingConcernAndManagementPlansTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "10201 - Disclosure - Financial Condition, Going Concern and Management Plans", "role": "http://www.nwbio.com/role/DisclosureFinancialConditionGoingConcernAndManagementPlans", "shortName": "Financial Condition, Going Concern and Management Plans", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "div", "div", "body", "html" ], "baseRef": "nwbo-20201231x10k.htm", "contextRef": "Duration_1_1_2020_To_12_31_2020_nxgPv_TR5kW7h-rGR5n91A", "decimals": null, "first": true, "lang": "en-US", "name": "nwbo:FinancialConditionGoingConcernAndManagementPlansTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } } }, "segmentCount": 101, "tag": { "country_DE": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "D [E]", "terseLabel": "Germany" } } }, "localname": "DE", "nsuri": "http://xbrl.sec.gov/country/2020-01-31", "presentation": [ "http://www.nwbio.com/role/DisclosureIncomeTaxesAdditionalInformationDetails" ], "xbrltype": "domainItemType" }, "country_GB": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "G [B]", "terseLabel": "UNITED KINGDOM" } } }, "localname": "GB", "nsuri": "http://xbrl.sec.gov/country/2020-01-31", "presentation": [ "http://www.nwbio.com/role/DisclosureCommitmentsAndContingenciesDetails", "http://www.nwbio.com/role/DisclosureCommitmentsAndContingenciesMaturitiesOfOurOperatingLeasesDetails", "http://www.nwbio.com/role/DisclosureIncomeTaxesAdditionalInformationDetails", "http://www.nwbio.com/role/DisclosurePropertyPlantAndEquipmentDetails", "http://www.nwbio.com/role/DisclosureSummaryOfSignificantAccountingPoliciesDetails" ], "xbrltype": "domainItemType" }, "country_NL": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "N [L]", "terseLabel": "Netherland" } } }, "localname": "NL", "nsuri": "http://xbrl.sec.gov/country/2020-01-31", "presentation": [ "http://www.nwbio.com/role/DisclosureIncomeTaxesAdditionalInformationDetails" ], "xbrltype": "domainItemType" }, "country_US": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "U [S]", "terseLabel": "UNITED STATES" } } }, "localname": "US", "nsuri": "http://xbrl.sec.gov/country/2020-01-31", "presentation": [ "http://www.nwbio.com/role/DisclosureCommitmentsAndContingenciesAdditionalInformationDetails", "http://www.nwbio.com/role/DisclosureCommitmentsAndContingenciesDetails", "http://www.nwbio.com/role/DisclosureCommitmentsAndContingenciesMaturitiesOfOurOperatingLeasesDetails" ], "xbrltype": "domainItemType" }, "dei_AmendmentFlag": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.", "label": "Amendment Flag" } } }, "localname": "AmendmentFlag", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://www.nwbio.com/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_CityAreaCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Area code of city", "label": "City Area Code" } } }, "localname": "CityAreaCode", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://www.nwbio.com/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_CoverAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Cover page.", "label": "Document and Entity Information" } } }, "localname": "CoverAbstract", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "xbrltype": "stringItemType" }, "dei_CurrentFiscalYearEndDate": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "End date of current fiscal year in the format --MM-DD.", "label": "Current Fiscal Year End Date" } } }, "localname": "CurrentFiscalYearEndDate", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://www.nwbio.com/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "gMonthDayItemType" }, "dei_DocumentAnnualReport": { "auth_ref": [ "r484", "r485", "r486" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true only for a form used as an annual report.", "label": "Document Annual Report" } } }, "localname": "DocumentAnnualReport", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://www.nwbio.com/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_DocumentFiscalPeriodFocus": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Fiscal period values are FY, Q1, Q2, and Q3. 1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.", "label": "Document Fiscal Period Focus" } } }, "localname": "DocumentFiscalPeriodFocus", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://www.nwbio.com/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "fiscalPeriodItemType" }, "dei_DocumentFiscalYearFocus": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.", "label": "Document Fiscal Year Focus" } } }, "localname": "DocumentFiscalYearFocus", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://www.nwbio.com/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "gYearItemType" }, "dei_DocumentPeriodEndDate": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The end date of the period reflected on the cover page if a periodic report. For all other reports and registration statements containing historical data, it is the date up through which that historical data is presented. If there is no historical data in the report, use the filing date. The format of the date is YYYY-MM-DD.", "label": "Document Period End Date" } } }, "localname": "DocumentPeriodEndDate", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://www.nwbio.com/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "dateItemType" }, "dei_DocumentTransitionReport": { "auth_ref": [ "r487" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true only for a form used as a transition report.", "label": "Document Transition Report" } } }, "localname": "DocumentTransitionReport", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://www.nwbio.com/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_DocumentType": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.", "label": "Document Type" } } }, "localname": "DocumentType", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://www.nwbio.com/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "submissionTypeItemType" }, "dei_EntityAddressAddressLine1": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Address Line 1 such as Attn, Building Name, Street Name", "label": "Entity Address, Address Line One" } } }, "localname": "EntityAddressAddressLine1", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://www.nwbio.com/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressAddressLine2": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Address Line 2 such as Street or Suite number", "label": "Entity Address, Address Line Two" } } }, "localname": "EntityAddressAddressLine2", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://www.nwbio.com/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressCityOrTown": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Name of the City or Town", "label": "Entity Address, City or Town" } } }, "localname": "EntityAddressCityOrTown", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://www.nwbio.com/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressPostalZipCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Code for the postal or zip code", "label": "Entity Address, Postal Zip Code" } } }, "localname": "EntityAddressPostalZipCode", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://www.nwbio.com/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressStateOrProvince": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Name of the state or province.", "label": "Entity Address, State or Province" } } }, "localname": "EntityAddressStateOrProvince", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://www.nwbio.com/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "stateOrProvinceItemType" }, "dei_EntityCentralIndexKey": { "auth_ref": [ "r488" ], "lang": { "en-us": { "role": { "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.", "label": "Entity Central Index Key" } } }, "localname": "EntityCentralIndexKey", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://www.nwbio.com/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "centralIndexKeyItemType" }, "dei_EntityCommonStockSharesOutstanding": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.", "label": "Entity Common Stock, Shares Outstanding" } } }, "localname": "EntityCommonStockSharesOutstanding", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://www.nwbio.com/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "sharesItemType" }, "dei_EntityCurrentReportingStatus": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.", "label": "Entity Current Reporting Status" } } }, "localname": "EntityCurrentReportingStatus", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://www.nwbio.com/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "yesNoItemType" }, "dei_EntityEmergingGrowthCompany": { "auth_ref": [ "r488" ], "lang": { "en-us": { "role": { "documentation": "Indicate if registrant meets the emerging growth company criteria.", "label": "Entity Emerging Growth Company" } } }, "localname": "EntityEmergingGrowthCompany", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://www.nwbio.com/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_EntityFileNumber": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.", "label": "Entity File Number" } } }, "localname": "EntityFileNumber", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://www.nwbio.com/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "fileNumberItemType" }, "dei_EntityFilerCategory": { "auth_ref": [ "r488" ], "lang": { "en-us": { "role": { "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.", "label": "Entity Filer Category" } } }, "localname": "EntityFilerCategory", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://www.nwbio.com/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "filerCategoryItemType" }, "dei_EntityIncorporationStateCountryCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Two-character EDGAR code representing the state or country of incorporation.", "label": "Entity Incorporation, State or Country Code" } } }, "localname": "EntityIncorporationStateCountryCode", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://www.nwbio.com/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "edgarStateCountryItemType" }, "dei_EntityInteractiveDataCurrent": { "auth_ref": [ "r489" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).", "label": "Entity Interactive Data Current" } } }, "localname": "EntityInteractiveDataCurrent", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://www.nwbio.com/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "yesNoItemType" }, "dei_EntityPublicFloat": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The aggregate market value of the voting and non-voting common equity held by non-affiliates computed by reference to the price at which the common equity was last sold, or the average bid and asked price of such common equity, as of the last business day of the registrant's most recently completed second fiscal quarter.", "label": "Entity Public Float" } } }, "localname": "EntityPublicFloat", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://www.nwbio.com/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "monetaryItemType" }, "dei_EntityRegistrantName": { "auth_ref": [ "r488" ], "lang": { "en-us": { "role": { "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.", "label": "Entity Registrant Name" } } }, "localname": "EntityRegistrantName", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://www.nwbio.com/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityShellCompany": { "auth_ref": [ "r488" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.", "label": "Entity Shell Company" } } }, "localname": "EntityShellCompany", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://www.nwbio.com/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_EntitySmallBusiness": { "auth_ref": [ "r488" ], "lang": { "en-us": { "role": { "documentation": "Indicates that the company is a Smaller Reporting Company (SRC).", "label": "Entity Small Business" } } }, "localname": "EntitySmallBusiness", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://www.nwbio.com/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_EntityTaxIdentificationNumber": { "auth_ref": [ "r488" ], "lang": { "en-us": { "role": { "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.", "label": "Entity Tax Identification Number" } } }, "localname": "EntityTaxIdentificationNumber", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://www.nwbio.com/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "employerIdItemType" }, "dei_EntityVoluntaryFilers": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Indicate 'Yes' or 'No' if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act.", "label": "Entity Voluntary Filers" } } }, "localname": "EntityVoluntaryFilers", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://www.nwbio.com/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "yesNoItemType" }, "dei_EntityWellKnownSeasonedIssuer": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Indicate 'Yes' or 'No' if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Is used on Form Type: 10-K, 10-Q, 8-K, 20-F, 6-K, 10-K/A, 10-Q/A, 20-F/A, 6-K/A, N-CSR, N-Q, N-1A.", "label": "Entity Well-known Seasoned Issuer" } } }, "localname": "EntityWellKnownSeasonedIssuer", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://www.nwbio.com/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "yesNoItemType" }, "dei_LocalPhoneNumber": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Local phone number for entity.", "label": "Local Phone Number" } } }, "localname": "LocalPhoneNumber", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://www.nwbio.com/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_Security12bTitle": { "auth_ref": [ "r483" ], "lang": { "en-us": { "role": { "documentation": "Title of a 12(b) registered security.", "label": "Title of 12(b) Security" } } }, "localname": "Security12bTitle", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://www.nwbio.com/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "securityTitleItemType" }, "dei_TradingSymbol": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Trading symbol of an instrument as listed on an exchange.", "label": "Trading Symbol" } } }, "localname": "TradingSymbol", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://www.nwbio.com/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "tradingSymbolItemType" }, "nwbo_AccountsPayableAndAccruedLiabilitiesRelatedPartiesCurrent": { "auth_ref": [], "calculation": { "http://www.nwbio.com/role/StatementConsolidatedBalanceSheets": { "order": 2.0, "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount for accounts payable and accrued liabilities to related parties.", "label": "Accounts Payable And Accrued Liabilities Related Parties Current", "terseLabel": "Accounts payable and accrued expenses to related parties and affiliates", "verboseLabel": "Accounts payable and accrued expenses to related parties and affiliates" } } }, "localname": "AccountsPayableAndAccruedLiabilitiesRelatedPartiesCurrent", "nsuri": "http://www.nwbio.com/20201231", "presentation": [ "http://www.nwbio.com/role/DisclosureRevisionToPriorPeriodFinancialStatementsConsolidatedBalanceSheetDetails", "http://www.nwbio.com/role/StatementConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "nwbo_AccruedOutsourcingCostsPolicyTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for accruing cost on outsourcing with third-party.", "label": "Accrued Outsourcing Costs [Policy Text Block]", "terseLabel": "Accrued Outsourcing Costs" } } }, "localname": "AccruedOutsourcingCostsPolicyTextBlock", "nsuri": "http://www.nwbio.com/20201231", "presentation": [ "http://www.nwbio.com/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "nwbo_AdjustmentToAdditionalPaidInCapitalReclassificationOfCashlessWarrantsExercised": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of increase (decrease) in additional paid in capital (APIC) resulting from reclassification of warrant liabilities related to cashless warrants exercised.", "label": "Adjustment to Additional Paid In Capital, Reclassification of Cashless Warrants Exercised", "terseLabel": "Reclassification of warrant liabilities related to cashless warrants exercise" } } }, "localname": "AdjustmentToAdditionalPaidInCapitalReclassificationOfCashlessWarrantsExercised", "nsuri": "http://www.nwbio.com/20201231", "presentation": [ "http://www.nwbio.com/role/StatementConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "nwbo_AdjustmentsToAdditionalPaidInCapitalBeneficialConversionFeatureOfSeriesAConvertiblePreferredStock": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of increase (decrease) in additional paid in capital (APIC) resulting from beneficial conversion feature of Series A convertible preferred stock.", "label": "Adjustments To Additional Paid In Capital Beneficial Conversion Feature Of Series A Convertible Preferred Stock", "verboseLabel": "Beneficial conversion feature related to amended convertible note" } } }, "localname": "AdjustmentsToAdditionalPaidInCapitalBeneficialConversionFeatureOfSeriesAConvertiblePreferredStock", "nsuri": "http://www.nwbio.com/20201231", "presentation": [ "http://www.nwbio.com/role/StatementConsolidatedStatementsOfCashFlows", "http://www.nwbio.com/role/StatementConsolidatedStatementsOfChangesInStockholdersDeficit" ], "xbrltype": "monetaryItemType" }, "nwbo_AdjustmentsToAdditionalPaidInCapitalReclassification": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of increase (decrease) in additional paid in capital (APIC) resulting from reclassification of warrant liabilities related to warrants exercised.", "label": "Adjustments To Additional Paid In Capital Reclassification", "terseLabel": "Reclassification of warrant liabilities related to warrants exercised for cash", "verboseLabel": "Reclassification of warrant liabilities related to warrants exercised for cash" } } }, "localname": "AdjustmentsToAdditionalPaidInCapitalReclassification", "nsuri": "http://www.nwbio.com/20201231", "presentation": [ "http://www.nwbio.com/role/StatementConsolidatedStatementsOfCashFlows", "http://www.nwbio.com/role/StatementConsolidatedStatementsOfChangesInStockholdersDeficit" ], "xbrltype": "monetaryItemType" }, "nwbo_AdjustmentsToAdditionalPaidInCapitalReclassificationOfWarrantLiabilitiesRelatedToCashlessWarrantsExercise": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of increase (decrease) in additional paid in capital (APIC) resulting from reclassification of warrant liabilities related to cashless warrants exercise during the reporting period.", "label": "Adjustments To Additional Paid In Capital Reclassification Of Warrant Liabilities Related To Cashless Warrants Exercise", "verboseLabel": "Reclassification of warrant liabilities related to cashless warrants exercise" } } }, "localname": "AdjustmentsToAdditionalPaidInCapitalReclassificationOfWarrantLiabilitiesRelatedToCashlessWarrantsExercise", "nsuri": "http://www.nwbio.com/20201231", "presentation": [ "http://www.nwbio.com/role/StatementConsolidatedStatementsOfChangesInStockholdersDeficit" ], "xbrltype": "monetaryItemType" }, "nwbo_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationRequisiteServicePeriodRecognitionShares": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Amount of increase to additional paid-in capital (APIC) from recognition of equity share-based compensation during the reporting period.", "label": "Adjustments To Additional Paid In Capital Share Based Compensation Requisite Service Period Recognition Shares", "terseLabel": "Stock-based compensation (in shares)" } } }, "localname": "AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationRequisiteServicePeriodRecognitionShares", "nsuri": "http://www.nwbio.com/20201231", "presentation": [ "http://www.nwbio.com/role/StatementConsolidatedStatementsOfChangesInStockholdersDeficit" ], "xbrltype": "sharesItemType" }, "nwbo_AdventBioServicesAgreementMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Advent BioServices Agreement", "label": "Advent Bio Services Agreement [Member]", "terseLabel": "Advent BioServices Invoiced [Member]" } } }, "localname": "AdventBioServicesAgreementMember", "nsuri": "http://www.nwbio.com/20201231", "presentation": [ "http://www.nwbio.com/role/DisclosureRelatedPartyTransactionsAdditionalInformationDetails" ], "xbrltype": "domainItemType" }, "nwbo_AdventBioServicesNotesMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Advent Bio Services Notes", "label": "Advent Bio Services Notes [Member]", "terseLabel": "Advent BioServices [Member]" } } }, "localname": "AdventBioServicesNotesMember", "nsuri": "http://www.nwbio.com/20201231", "presentation": [ "http://www.nwbio.com/role/DisclosureNotesPayableAdditionalInformationDetails", "http://www.nwbio.com/role/DisclosureRelatedPartyTransactionsAdditionalInformationDetails" ], "xbrltype": "domainItemType" }, "nwbo_AdventBioserivicesMember": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Advent Bioserivices [Member]", "terseLabel": "Advent BioSerivices [Member]" } } }, "localname": "AdventBioserivicesMember", "nsuri": "http://www.nwbio.com/20201231", "presentation": [ "http://www.nwbio.com/role/DisclosureCommitmentsAndContingenciesAdditionalInformationDetails" ], "xbrltype": "domainItemType" }, "nwbo_AdventBioservicesMember": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Advent Bioservices [Member]", "terseLabel": "Advent BioServices [Member]" } } }, "localname": "AdventBioservicesMember", "nsuri": "http://www.nwbio.com/20201231", "presentation": [ "http://www.nwbio.com/role/DisclosureRelatedPartyTransactionsSummaryOfOutstandingUnpaidAccountsPayableHeldByRelatedPartiesDetails" ], "xbrltype": "domainItemType" }, "nwbo_AfterAmendmentMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Represents the information pertaining to, after amendment.", "label": "After Amendment [Member]", "terseLabel": "Amended" } } }, "localname": "AfterAmendmentMember", "nsuri": "http://www.nwbio.com/20201231", "presentation": [ "http://www.nwbio.com/role/DisclosureNotesPayableAdditionalInformationDetails" ], "xbrltype": "domainItemType" }, "nwbo_AgreementAxis": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "No definition available.", "label": "Agreement [Axis]" } } }, "localname": "AgreementAxis", "nsuri": "http://www.nwbio.com/20201231", "presentation": [ "http://www.nwbio.com/role/DisclosureStockholdersDeficitAdditionalInformationDetails" ], "xbrltype": "stringItemType" }, "nwbo_AgreementDomain": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "No definition available.", "label": "Agreement [Domain]", "terseLabel": "Agreement [Domain]" } } }, "localname": "AgreementDomain", "nsuri": "http://www.nwbio.com/20201231", "presentation": [ "http://www.nwbio.com/role/DisclosureStockholdersDeficitAdditionalInformationDetails" ], "xbrltype": "domainItemType" }, "nwbo_AgreementTerm": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Represents the period of agreement term.", "label": "Agreement Term", "terseLabel": "Term (in months)" } } }, "localname": "AgreementTerm", "nsuri": "http://www.nwbio.com/20201231", "presentation": [ "http://www.nwbio.com/role/DisclosureRelatedPartyTransactionsAdditionalInformationDetails" ], "xbrltype": "durationItemType" }, "nwbo_AmortizationOfDebtDiscount": { "auth_ref": [], "calculation": { "http://www.nwbio.com/role/StatementConsolidatedStatementsOfCashFlows": { "order": 2.0, "parentTag": "us-gaap_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of noncash expense included in interest expense to amortize debt discount associated with the related debt instruments.", "label": "Amortization of Debt Discount", "terseLabel": "Amortization of debt discount" } } }, "localname": "AmortizationOfDebtDiscount", "nsuri": "http://www.nwbio.com/20201231", "presentation": [ "http://www.nwbio.com/role/DisclosureNotesPayableMortgageLoanDetails", "http://www.nwbio.com/role/StatementConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "nwbo_AncillaryServicesAgreementMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Represents the information pertaining to Ancillary Services Agreement.", "label": "Ancillary Services Agreement [Member]", "terseLabel": "Advent Bioscience Accrued" } } }, "localname": "AncillaryServicesAgreementMember", "nsuri": "http://www.nwbio.com/20201231", "presentation": [ "http://www.nwbio.com/role/DisclosureRelatedPartyTransactionsAdditionalInformationDetails" ], "xbrltype": "domainItemType" }, "nwbo_AprilFinancingMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Represents the information pertaining to April Financing.", "label": "April Financing [Member]", "terseLabel": "April Financing" } } }, "localname": "AprilFinancingMember", "nsuri": "http://www.nwbio.com/20201231", "presentation": [ "http://www.nwbio.com/role/DisclosureStockholdersDeficitAdditionalInformationDetails" ], "xbrltype": "domainItemType" }, "nwbo_AprilNotesMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "This member stands for April Notes.", "label": "April Notes [Member]", "terseLabel": "April Note" } } }, "localname": "AprilNotesMember", "nsuri": "http://www.nwbio.com/20201231", "presentation": [ "http://www.nwbio.com/role/DisclosureNotesPayableAdditionalInformationDetails" ], "xbrltype": "domainItemType" }, "nwbo_AugustFinancingMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Represents the information pertaining to August Financing.", "label": "August Financing [Member]", "terseLabel": "August Financing" } } }, "localname": "AugustFinancingMember", "nsuri": "http://www.nwbio.com/20201231", "presentation": [ "http://www.nwbio.com/role/DisclosureStockholdersDeficitAdditionalInformationDetails" ], "xbrltype": "domainItemType" }, "nwbo_AugustNoteMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Represents the information pertaining to August Note.", "label": "August Note [Member]", "terseLabel": "August Note" } } }, "localname": "AugustNoteMember", "nsuri": "http://www.nwbio.com/20201231", "presentation": [ "http://www.nwbio.com/role/DisclosureNotesPayableAdditionalInformationDetails" ], "xbrltype": "domainItemType" }, "nwbo_BifurcatedEmbeddedDerivativeFairValueOfEmbeddedDerivativeLiability1": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Fair value as of the balance sheet date of the bifurcated embedded derivative or group of embedded derivatives classified as a liability.", "label": "Bifurcated Embedded Derivative Fair Value Of Embedded Derivative Liability1", "terseLabel": "Additional embedded conversion option" } } }, "localname": "BifurcatedEmbeddedDerivativeFairValueOfEmbeddedDerivativeLiability1", "nsuri": "http://www.nwbio.com/20201231", "presentation": [ "http://www.nwbio.com/role/DisclosureFairValueMeasurementsChangesInLevel3LiabilitiesDetails" ], "xbrltype": "monetaryItemType" }, "nwbo_BusinessCombinationCashAcquired": { "auth_ref": [], "calculation": { "http://www.nwbio.com/role/DisclosureFlaskworksAcquisitionDetails": { "order": 1.0, "parentTag": "nwbo_BusinessCombinationConsiderationTransferredNetOfCashAcquired", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The amount of cash acquired in business combination.", "label": "Business Combination, Cash Acquired", "negatedLabel": "Less cash acquired" } } }, "localname": "BusinessCombinationCashAcquired", "nsuri": "http://www.nwbio.com/20201231", "presentation": [ "http://www.nwbio.com/role/DisclosureFlaskworksAcquisitionDetails" ], "xbrltype": "monetaryItemType" }, "nwbo_BusinessCombinationConsiderationTransferredEitherInCashOrStockOrCombinationOfCashAndStock": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of consideration transferred, payable consisting of cash or stock or combination of both cash and stock.", "label": "Business Combination, Consideration Transferred, Either in Cash or Stock or Combination of Cash and Stock", "terseLabel": "Purchase price to be paid in either cash or stock, or a combination" } } }, "localname": "BusinessCombinationConsiderationTransferredEitherInCashOrStockOrCombinationOfCashAndStock", "nsuri": "http://www.nwbio.com/20201231", "presentation": [ "http://www.nwbio.com/role/DisclosureFlaskworksAcquisitionDetails" ], "xbrltype": "monetaryItemType" }, "nwbo_BusinessCombinationConsiderationTransferredNetOfCashAcquired": { "auth_ref": [], "calculation": { "http://www.nwbio.com/role/DisclosureFlaskworksAcquisitionDetails": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount recognized net of cash acquired.", "label": "Business Combination, Consideration Transferred, Net of Cash Acquired", "totalLabel": "Total consideration paid, net of cash acquired" } } }, "localname": "BusinessCombinationConsiderationTransferredNetOfCashAcquired", "nsuri": "http://www.nwbio.com/20201231", "presentation": [ "http://www.nwbio.com/role/DisclosureFlaskworksAcquisitionDetails" ], "xbrltype": "monetaryItemType" }, "nwbo_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccruedExpenses": { "auth_ref": [], "calculation": { "http://www.nwbio.com/role/DisclosureFlaskworksAcquisitionDetails": { "order": 2.0, "parentTag": "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of accrued expenses, assumed at the acquisition date.", "label": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Current Liabilities, Accrued Expenses", "negatedLabel": "Accrued expenses" } } }, "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccruedExpenses", "nsuri": "http://www.nwbio.com/20201231", "presentation": [ "http://www.nwbio.com/role/DisclosureFlaskworksAcquisitionDetails" ], "xbrltype": "monetaryItemType" }, "nwbo_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedSecurityDeposits": { "auth_ref": [], "calculation": { "http://www.nwbio.com/role/DisclosureFlaskworksAcquisitionDetails": { "order": 5.0, "parentTag": "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The amount of security deposits recognized as of the acquisition date.", "label": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Security Deposits", "terseLabel": "Security deposits" } } }, "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedSecurityDeposits", "nsuri": "http://www.nwbio.com/20201231", "presentation": [ "http://www.nwbio.com/role/DisclosureFlaskworksAcquisitionDetails" ], "xbrltype": "monetaryItemType" }, "nwbo_BusinessCombinationUnpaidConsideration": { "auth_ref": [], "calculation": { "http://www.nwbio.com/role/DisclosureFlaskworksAcquisitionDetails": { "order": 2.0, "parentTag": "nwbo_BusinessCombinationConsiderationTransferredNetOfCashAcquired", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The amount of unpaid consideration in business combination.", "label": "Business Combination, Unpaid Consideration", "negatedLabel": "Less special consideration paid in cash and stock" } } }, "localname": "BusinessCombinationUnpaidConsideration", "nsuri": "http://www.nwbio.com/20201231", "presentation": [ "http://www.nwbio.com/role/DisclosureFlaskworksAcquisitionDetails" ], "xbrltype": "monetaryItemType" }, "nwbo_CambridgePeterboroughCombinedAuthorityMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Represents the information pertaining to Cambridge & Peterborough Combined Authority.", "label": "Cambridge Peterborough Combined Authority [Member]", "terseLabel": "Lender" } } }, "localname": "CambridgePeterboroughCombinedAuthorityMember", "nsuri": "http://www.nwbio.com/20201231", "presentation": [ "http://www.nwbio.com/role/DisclosureNotesPayableAdditionalInformationDetails" ], "xbrltype": "domainItemType" }, "nwbo_CapitalExpendituresIncludedInAccountsPayable": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The value of the capital expenditures included in accounts payable.", "label": "Capital Expenditures included in Accounts Payable", "terseLabel": "Capital expenditures included in accounts payable" } } }, "localname": "CapitalExpendituresIncludedInAccountsPayable", "nsuri": "http://www.nwbio.com/20201231", "presentation": [ "http://www.nwbio.com/role/StatementConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "nwbo_CapitalExpendituresIncludedInAccountsPayableAndAccruedExpensesToRelatedPartiesAndAffiliates": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The value of the capital expenditures included in accounts payable and accrued expenses to related parties and affiliates.", "label": "Capital Expenditures included in Accounts Payable and Accrued Expenses to Related Parties and Affiliates", "terseLabel": "Capital expenditures included in accounts payable and accrued expenses to related parties and affiliates" } } }, "localname": "CapitalExpendituresIncludedInAccountsPayableAndAccruedExpensesToRelatedPartiesAndAffiliates", "nsuri": "http://www.nwbio.com/20201231", "presentation": [ "http://www.nwbio.com/role/DisclosureRevisionToPriorPeriodFinancialStatementsConsolidatedStatementOfCashFlowsDetaills" ], "xbrltype": "monetaryItemType" }, "nwbo_CashAndCashEquivalentsHeldByForeignSubsidiaries": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The amount of cash and cash equivalents held by foreign subsidiaries.", "label": "Cash and Cash Equivalents Held by Foreign Subsidiaries", "terseLabel": "Cash and cash equivalents held by foreign subsidiaries" } } }, "localname": "CashAndCashEquivalentsHeldByForeignSubsidiaries", "nsuri": "http://www.nwbio.com/20201231", "presentation": [ "http://www.nwbio.com/role/DisclosureSummaryOfSignificantAccountingPoliciesDetails" ], "xbrltype": "monetaryItemType" }, "nwbo_CashlessOptionsExerciseMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Represents the information pertaining to cashless options exercise.", "label": "Cashless Options Exercise [Member]", "terseLabel": "Cashless options exercise" } } }, "localname": "CashlessOptionsExerciseMember", "nsuri": "http://www.nwbio.com/20201231", "presentation": [ "http://www.nwbio.com/role/DisclosureSubsequentEventsDetails" ], "xbrltype": "domainItemType" }, "nwbo_CashlessWarrantsExerciseMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Represents the information about cashless warrants exercise.", "label": "Cashless Warrants Exercise [Member]", "terseLabel": "Cashless Warrants Exercise" } } }, "localname": "CashlessWarrantsExerciseMember", "nsuri": "http://www.nwbio.com/20201231", "presentation": [ "http://www.nwbio.com/role/DisclosureSubsequentEventsDetails" ], "xbrltype": "domainItemType" }, "nwbo_ChangeInFairValueOfContingentLiability": { "auth_ref": [], "calculation": { "http://www.nwbio.com/role/StatementConsolidatedStatementsOfCashFlows": { "order": 3.0, "parentTag": "us-gaap_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The amount of change in fair value of contingent liability.", "label": "Change in Fair Value of Contingent Liability", "negatedLabel": "Change in fair value of contingent liability" } } }, "localname": "ChangeInFairValueOfContingentLiability", "nsuri": "http://www.nwbio.com/20201231", "presentation": [ "http://www.nwbio.com/role/StatementConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "nwbo_ClassOfWarrantContingentlyIssuableWarrants": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Number of Class Of Warrant Contingently Issuable Warrants .", "label": "Class Of Warrant Contingently Issuable Warrants", "terseLabel": "Number of Warrants, Contingently issuable warrants" } } }, "localname": "ClassOfWarrantContingentlyIssuableWarrants", "nsuri": "http://www.nwbio.com/20201231", "presentation": [ "http://www.nwbio.com/role/DisclosureStockholdersDeficitDetails" ], "xbrltype": "sharesItemType" }, "nwbo_ClassOfWarrantOrRightAgreedToBeSuspended": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Represents the number of warrants agreed to be suspended.", "label": "Class of Warrant or Right, Agreed to be Suspended", "terseLabel": "Class of warrant or right, agreed to be suspended" } } }, "localname": "ClassOfWarrantOrRightAgreedToBeSuspended", "nsuri": "http://www.nwbio.com/20201231", "presentation": [ "http://www.nwbio.com/role/DisclosureStockholdersDeficitAdditionalInformationDetails", "http://www.nwbio.com/role/DisclosureSubsequentEventsDetails" ], "xbrltype": "sharesItemType" }, "nwbo_ClassOfWarrantOrRightAgreedToBeSuspendedAndUnexercisable": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Represents the number of warrants agreed to be suspended and unexercisable .", "label": "Class of Warrant or Right, Agreed to be Suspended And Unexercisable" } } }, "localname": "ClassOfWarrantOrRightAgreedToBeSuspendedAndUnexercisable", "nsuri": "http://www.nwbio.com/20201231", "presentation": [ "http://www.nwbio.com/role/DisclosureStockholdersDeficitAdditionalInformationDetails" ], "xbrltype": "sharesItemType" }, "nwbo_ClassOfWarrantOrRightExercisePeriodOfWarrantsOrRights": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Exercise period of warrants or rights outstanding.", "label": "Class of Warrant or Right, Exercise Period of Warrants or Rights", "terseLabel": "Exercise period", "verboseLabel": "Warrants exercise period" } } }, "localname": "ClassOfWarrantOrRightExercisePeriodOfWarrantsOrRights", "nsuri": "http://www.nwbio.com/20201231", "presentation": [ "http://www.nwbio.com/role/DisclosureStockholdersDeficitAdditionalInformationDetails", "http://www.nwbio.com/role/DisclosureSubsequentEventsDetails" ], "xbrltype": "durationItemType" }, "nwbo_ClassOfWarrantOrRightExpired": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Information related to class of warrant or right expired.", "label": "Class Of Warrant Or Right Expired", "negatedLabel": "Number of Warrants, Warrants expired and cancellation" } } }, "localname": "ClassOfWarrantOrRightExpired", "nsuri": "http://www.nwbio.com/20201231", "presentation": [ "http://www.nwbio.com/role/DisclosureStockholdersDeficitDetails" ], "xbrltype": "sharesItemType" }, "nwbo_ClassOfWarrantOrRightExpiredWeightedAverageExercisePrice": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Information related to class of warrant or right expired weighted average exercise price.", "label": "Class Of Warrant Or Right Expired Weighted Average Exercise Price", "terseLabel": "Weighted Average Exercise Price, Warrants expired and cancellation" } } }, "localname": "ClassOfWarrantOrRightExpiredWeightedAverageExercisePrice", "nsuri": "http://www.nwbio.com/20201231", "presentation": [ "http://www.nwbio.com/role/DisclosureStockholdersDeficitDetails" ], "xbrltype": "percentItemType" }, "nwbo_ClassOfWarrantOrRightExtendedInSuspension": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Represents the number of warrants whose suspension are extended.", "label": "Class of Warrant or Right, Extended in Suspension", "terseLabel": "Class of warrant or right,extended in suspension" } } }, "localname": "ClassOfWarrantOrRightExtendedInSuspension", "nsuri": "http://www.nwbio.com/20201231", "presentation": [ "http://www.nwbio.com/role/DisclosureStockholdersDeficitAdditionalInformationDetails", "http://www.nwbio.com/role/DisclosureSubsequentEventsDetails" ], "xbrltype": "sharesItemType" }, "nwbo_ClassOfWarrantOrRightGranted": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Aggregate number of class of warrants or rights granted during the reported period.", "label": "Class Of Warrant Or Right Granted", "verboseLabel": "Number of Warrants, Warrants granted" } } }, "localname": "ClassOfWarrantOrRightGranted", "nsuri": "http://www.nwbio.com/20201231", "presentation": [ "http://www.nwbio.com/role/DisclosureStockholdersDeficitDetails" ], "xbrltype": "sharesItemType" }, "nwbo_ClassOfWarrantOrRightGrantedWeightedAverageContingentlyIssuableWarrants": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Class Of Warrant Or Right Granted Weighted Average Contingently Issuable Warrants", "label": "Class Of Warrant Or Right Granted Weighted Average Contingently Issuable Warrants", "terseLabel": "Weighted Average Exercise Price - Contingently issuable warrants" } } }, "localname": "ClassOfWarrantOrRightGrantedWeightedAverageContingentlyIssuableWarrants", "nsuri": "http://www.nwbio.com/20201231", "presentation": [ "http://www.nwbio.com/role/DisclosureStockholdersDeficitDetails" ], "xbrltype": "perShareItemType" }, "nwbo_ClassOfWarrantOrRightGrantedWeightedAverageExercisePrice": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Weighted average exercise price of class of warrants or rights granted during the reporting period.", "label": "Class Of Warrant Or Right Granted Weighted Average Exercise Price", "verboseLabel": "Weighted Average Exercise Price - Warrants granted" } } }, "localname": "ClassOfWarrantOrRightGrantedWeightedAverageExercisePrice", "nsuri": "http://www.nwbio.com/20201231", "presentation": [ "http://www.nwbio.com/role/DisclosureStockholdersDeficitDetails" ], "xbrltype": "perShareItemType" }, "nwbo_ClassOfWarrantOrRightNumberOfWarrantsOrRightsExercisable": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Number of securities into which the class of warrant or right may be exercisable.", "label": "Class of Warrant or Right, Number of Warrants or Rights Exercisable", "terseLabel": "Number of warrants exercisable" } } }, "localname": "ClassOfWarrantOrRightNumberOfWarrantsOrRightsExercisable", "nsuri": "http://www.nwbio.com/20201231", "presentation": [ "http://www.nwbio.com/role/DisclosureStockholdersDeficitAdditionalInformationDetails" ], "xbrltype": "sharesItemType" }, "nwbo_ClassOfWarrantOrRightOutstandingRemainingContractualTerm": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Weighted average remaining contractual term for outstanding class of warrants.", "label": "Class Of Warrant Or Right Outstanding Remaining Contractual Term", "terseLabel": "Remaining Contractual Term" } } }, "localname": "ClassOfWarrantOrRightOutstandingRemainingContractualTerm", "nsuri": "http://www.nwbio.com/20201231", "presentation": [ "http://www.nwbio.com/role/DisclosureStockholdersDeficitDetails" ], "xbrltype": "durationItemType" }, "nwbo_ClassOfWarrantOrRightOutstandingWeightedAverageExercisePrice": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Weighted average exercise price of class of warrants or rights outstanding as on the date specified.", "label": "Class Of Warrant Or Right Outstanding Weighted Average Exercise Price", "periodEndLabel": "Weighted Average Exercise Price - Outstanding", "periodStartLabel": "Weighted Average Exercise Price - Outstanding" } } }, "localname": "ClassOfWarrantOrRightOutstandingWeightedAverageExercisePrice", "nsuri": "http://www.nwbio.com/20201231", "presentation": [ "http://www.nwbio.com/role/DisclosureStockholdersDeficitDetails" ], "xbrltype": "perShareItemType" }, "nwbo_ClassOfWarrantOrRightPercentageOfWarrantsIssuedOnConversion": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Represents the percentage of warrants issued on conversion.", "label": "Class of Warrant or Right, Percentage Of Warrants Issued On Conversion", "terseLabel": "Class of Warrant or Right, Percentage Of Warrants Issued On Conversion" } } }, "localname": "ClassOfWarrantOrRightPercentageOfWarrantsIssuedOnConversion", "nsuri": "http://www.nwbio.com/20201231", "presentation": [ "http://www.nwbio.com/role/DisclosureStockholdersDeficitAdditionalInformationDetails" ], "xbrltype": "percentItemType" }, "nwbo_ClassOfWarrantOrRightSuspended": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Represents the number of warrants suspended.", "label": "Class of Warrant or Right, Suspended", "terseLabel": "Number of warrants suspended" } } }, "localname": "ClassOfWarrantOrRightSuspended", "nsuri": "http://www.nwbio.com/20201231", "presentation": [ "http://www.nwbio.com/role/DisclosureStockholdersDeficitAdditionalInformationDetails", "http://www.nwbio.com/role/DisclosureSubsequentEventsDetails" ], "xbrltype": "sharesItemType" }, "nwbo_ClassOfWarrantOrRightSuspendedAndUnexercisable": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Represents the number of options and warrants previously suspended and unexercisable.", "label": "Class of Warrant or Right, Suspended And Unexercisable", "terseLabel": "Warrants and options were previously suspended and not exercisable" } } }, "localname": "ClassOfWarrantOrRightSuspendedAndUnexercisable", "nsuri": "http://www.nwbio.com/20201231", "presentation": [ "http://www.nwbio.com/role/DisclosureStockholdersDeficitAdditionalInformationDetails", "http://www.nwbio.com/role/DisclosureSubsequentEventsDetails" ], "xbrltype": "sharesItemType" }, "nwbo_ClassOfWarrantOrRightWarrantTerm": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "This Element represents the warrant term.", "label": "Class Of Warrant Or Right warrant Term", "verboseLabel": "Class of Warrant or Right, Warrant Term" } } }, "localname": "ClassOfWarrantOrRightWarrantTerm", "nsuri": "http://www.nwbio.com/20201231", "presentation": [ "http://www.nwbio.com/role/DisclosureStockholdersDeficitAdditionalInformationDetails" ], "xbrltype": "durationItemType" }, "nwbo_ClassOfWarrantOrRightWarrantsIssued": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "This Element represents the number of warrants issued during the period.", "label": "Class of Warrant or Right, Warrants Issued" } } }, "localname": "ClassOfWarrantOrRightWarrantsIssued", "nsuri": "http://www.nwbio.com/20201231", "presentation": [ "http://www.nwbio.com/role/DisclosureRelatedPartyTransactionsAdditionalInformationDetails" ], "xbrltype": "sharesItemType" }, "nwbo_CognateBioServicesNotesMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "n/a", "label": "Cognate Bio Services Notes [Member]", "terseLabel": "Cognate Bio Services Notes [Member]" } } }, "localname": "CognateBioServicesNotesMember", "nsuri": "http://www.nwbio.com/20201231", "presentation": [ "http://www.nwbio.com/role/DisclosureNotesPayableAdditionalInformationDetails", "http://www.nwbio.com/role/DisclosureSummaryOfSignificantAccountingPoliciesDetails" ], "xbrltype": "domainItemType" }, "nwbo_CommonStockOptionsMember": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Common Stock Options [Member]", "terseLabel": "Common stock options [Member]" } } }, "localname": "CommonStockOptionsMember", "nsuri": "http://www.nwbio.com/20201231", "presentation": [ "http://www.nwbio.com/role/DisclosureNetEarningsLossPerShareApplicableToCommonStockholdersDetails" ], "xbrltype": "domainItemType" }, "nwbo_CommonStockSharesIssuedUponExistingLoanConversion": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Information related to Common stock shares issued upon existing loan conversion.", "label": "Common Stock Shares Issued Upon Existing Loan Conversion" } } }, "localname": "CommonStockSharesIssuedUponExistingLoanConversion", "nsuri": "http://www.nwbio.com/20201231", "presentation": [ "http://www.nwbio.com/role/DisclosureStockholdersDeficitAdditionalInformationDetails" ], "xbrltype": "sharesItemType" }, "nwbo_CommonStockWarrantsLiabilityTreatmentMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Common stock warrants liability treatment", "label": "Common Stock Warrants Liability Treatment [Member]", "terseLabel": "Common stock warrants - liability treatment [Member]" } } }, "localname": "CommonStockWarrantsLiabilityTreatmentMember", "nsuri": "http://www.nwbio.com/20201231", "presentation": [ "http://www.nwbio.com/role/DisclosureNetEarningsLossPerShareApplicableToCommonStockholdersDetails" ], "xbrltype": "domainItemType" }, "nwbo_ComprehensiveLossPolicyPolicyTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for comprehensive loss.", "label": "Comprehensive Loss Policy [Policy Text Block]", "terseLabel": "Comprehensive Loss" } } }, "localname": "ComprehensiveLossPolicyPolicyTextBlock", "nsuri": "http://www.nwbio.com/20201231", "presentation": [ "http://www.nwbio.com/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "nwbo_ConstructionsInProgressNet": { "auth_ref": [], "calculation": { "http://www.nwbio.com/role/StatementConsolidatedBalanceSheets": { "order": 2.0, "parentTag": "us-gaap_AssetsNoncurrent", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of structure or a modification to a structure under construction. Includes recently completed structures or modifications to structures that have not been placed into service.", "label": "Constructions In Progress Net", "terseLabel": "Construction in progress", "verboseLabel": "Construction in progress" } } }, "localname": "ConstructionsInProgressNet", "nsuri": "http://www.nwbio.com/20201231", "presentation": [ "http://www.nwbio.com/role/DisclosurePropertyPlantAndEquipmentDetails", "http://www.nwbio.com/role/DisclosureRevisionToPriorPeriodFinancialStatementsConsolidatedBalanceSheetDetails", "http://www.nwbio.com/role/StatementConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "nwbo_ContingentNotePayableMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "n/a", "label": "Contingent Note Payable [Member]", "terseLabel": "Short term contingent note" } } }, "localname": "ContingentNotePayableMember", "nsuri": "http://www.nwbio.com/20201231", "presentation": [ "http://www.nwbio.com/role/DisclosureNotesPayableAdditionalInformationDetails", "http://www.nwbio.com/role/DisclosureSummaryOfSignificantAccountingPoliciesDetails" ], "xbrltype": "domainItemType" }, "nwbo_ContingentPayableDerivativeLiability": { "auth_ref": [], "calculation": { "http://www.nwbio.com/role/DisclosureFairValueMeasurementsDetails": { "order": 2.0, "parentTag": "us-gaap_LiabilitiesFairValueDisclosure", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Fair value as of the balance sheet date of the contingent payable derivative or group of contingent payable derivatives classified as a liability.", "label": "Contingent Payable Derivative Liability", "terseLabel": "Contingent payable derivative liability" } } }, "localname": "ContingentPayableDerivativeLiability", "nsuri": "http://www.nwbio.com/20201231", "presentation": [ "http://www.nwbio.com/role/DisclosureFairValueMeasurementsDetails" ], "xbrltype": "monetaryItemType" }, "nwbo_ContingentPayableDerivativeLiabilityMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "represents the information of contingent payable derivative liability.", "label": "Contingent Payable Derivative Liability [Member]", "terseLabel": "Contingent Payable Derivative Liability [Member]" } } }, "localname": "ContingentPayableDerivativeLiabilityMember", "nsuri": "http://www.nwbio.com/20201231", "presentation": [ "http://www.nwbio.com/role/DisclosureFairValueMeasurementsChangesInLevel3LiabilitiesDetails", "http://www.nwbio.com/role/DisclosureFairValueMeasurementsWeightedAverageInAggregateSignificantUnobservableInputsDetails" ], "xbrltype": "domainItemType" }, "nwbo_ConversionOfOutstandingAccountsPayablesToNotePayableAndContingentPayable": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The amount related to conversion of outstanding accounts payables to note payable and contingent payable.", "label": "Conversion Of Outstanding Accounts Payables To Note Payable And Contingent Payable", "terseLabel": "Conversion of outstanding accounts payables to note payable and contingent payable" } } }, "localname": "ConversionOfOutstandingAccountsPayablesToNotePayableAndContingentPayable", "nsuri": "http://www.nwbio.com/20201231", "presentation": [ "http://www.nwbio.com/role/StatementConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "nwbo_ConvertibleNotesMember": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Convertible Notes [Member]", "terseLabel": "Convertible notes and accrued interest [Member]" } } }, "localname": "ConvertibleNotesMember", "nsuri": "http://www.nwbio.com/20201231", "presentation": [ "http://www.nwbio.com/role/DisclosureNetEarningsLossPerShareApplicableToCommonStockholdersDetails" ], "xbrltype": "domainItemType" }, "nwbo_ConvertibleNotesPayableNetCurrent": { "auth_ref": [], "calculation": { "http://www.nwbio.com/role/StatementConsolidatedBalanceSheets": { "order": 3.0, "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Carrying value as of the balance sheet date of the portion of long-term debt due within one year or the operating cycle if longer identified as Convertible Notes Payable. Convertible Notes Payable is a written promise to pay a note which can be exchanged for a specified amount of another, related security, at the option of the issuer and the holder.", "label": "Convertible Notes Payable, Net, Current", "terseLabel": "Convertible notes, net" } } }, "localname": "ConvertibleNotesPayableNetCurrent", "nsuri": "http://www.nwbio.com/20201231", "presentation": [ "http://www.nwbio.com/role/StatementConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "nwbo_DebtConversionAccruedInterestAmount": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The amount of the accrued interest on debt being converted in a noncash (or part noncash) transaction. \"Part noncash\" refers to that portion of the transaction not resulting in cash receipts or cash payments in the period.", "label": "Debt Conversion, Accrued Interest Amount", "terseLabel": "Accrued interest amount converted" } } }, "localname": "DebtConversionAccruedInterestAmount", "nsuri": "http://www.nwbio.com/20201231", "presentation": [ "http://www.nwbio.com/role/DisclosureNotesPayableAdditionalInformationDetails" ], "xbrltype": "monetaryItemType" }, "nwbo_DebtInstrumentLegalCosts": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The amount represents the legal cost of debt instrument.", "label": "Debt Instrument, Legal Costs", "terseLabel": "Legal fees" } } }, "localname": "DebtInstrumentLegalCosts", "nsuri": "http://www.nwbio.com/20201231", "presentation": [ "http://www.nwbio.com/role/DisclosureNotesPayableAdditionalInformationDetails", "http://www.nwbio.com/role/DisclosureSubsequentEventsDetails" ], "xbrltype": "monetaryItemType" }, "nwbo_DebtInstrumentOriginalIssueDiscountAmount": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of original issue discount (OID) on the debt instrument.", "label": "Debt Instrument, Original Issue Discount Amount", "terseLabel": "Original issue discount" } } }, "localname": "DebtInstrumentOriginalIssueDiscountAmount", "nsuri": "http://www.nwbio.com/20201231", "presentation": [ "http://www.nwbio.com/role/DisclosureNotesPayableAdditionalInformationDetails", "http://www.nwbio.com/role/DisclosureSubsequentEventsDetails" ], "xbrltype": "monetaryItemType" }, "nwbo_DebtInstrumentPlacementAgentCost": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of placement agent cost incurred by the company for the debt instrument.", "label": "Debt Instrument, Placement Agent Cost", "terseLabel": "Placement agent cost" } } }, "localname": "DebtInstrumentPlacementAgentCost", "nsuri": "http://www.nwbio.com/20201231", "presentation": [ "http://www.nwbio.com/role/DisclosureNotesPayableAdditionalInformationDetails" ], "xbrltype": "monetaryItemType" }, "nwbo_DebtInstrumentRedemptionLessThanOneYearMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Represent the information pertaining to debt instrument redemption less than one year member.", "label": "Debt Instrument Redemption Less Than One Year [Member]", "terseLabel": "Less than 1 Year [Member]" } } }, "localname": "DebtInstrumentRedemptionLessThanOneYearMember", "nsuri": "http://www.nwbio.com/20201231", "presentation": [ "http://www.nwbio.com/role/DisclosureNotesPayableSummaryOfCompanySContractualObligationsOnDebtPrincipalDetails" ], "xbrltype": "domainItemType" }, "nwbo_DebtInstrumentRedemptionMoreThanOneAndLessThanTwoYearMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Represent the information pertaining to debt instrument redemption more than one and less than two year member.", "label": "Debt Instrument Redemption More Than One And Less Than Two Year [Member]", "terseLabel": "1 to 2 Years [Member]" } } }, "localname": "DebtInstrumentRedemptionMoreThanOneAndLessThanTwoYearMember", "nsuri": "http://www.nwbio.com/20201231", "presentation": [ "http://www.nwbio.com/role/DisclosureNotesPayableSummaryOfCompanySContractualObligationsOnDebtPrincipalDetails" ], "xbrltype": "domainItemType" }, "nwbo_DebtInstrumentRedemptionMoreThanThreeAndLessThanFiveYearMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "NA", "label": "Debt Instrument Redemption More Than Three And Less Than Five Year [Member]", "terseLabel": "3 to 5 Years [Member]" } } }, "localname": "DebtInstrumentRedemptionMoreThanThreeAndLessThanFiveYearMember", "nsuri": "http://www.nwbio.com/20201231", "presentation": [ "http://www.nwbio.com/role/DisclosureNotesPayableSummaryOfCompanySContractualObligationsOnDebtPrincipalDetails" ], "xbrltype": "domainItemType" }, "nwbo_DebtInstrumentTermForRepaymentOfLoanPrincipalAndInterest": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Represents the term for repayment of the loan principal and interest.", "label": "Debt Instrument, Term For Repayment Of The Loan Principal And Interest" } } }, "localname": "DebtInstrumentTermForRepaymentOfLoanPrincipalAndInterest", "nsuri": "http://www.nwbio.com/20201231", "presentation": [ "http://www.nwbio.com/role/DisclosureNotesPayableAdditionalInformationDetails" ], "xbrltype": "durationItemType" }, "nwbo_DeferredAccountsPayable": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of deferred accounts payable.", "label": "Deferred Accounts Payable" } } }, "localname": "DeferredAccountsPayable", "nsuri": "http://www.nwbio.com/20201231", "presentation": [ "http://www.nwbio.com/role/DisclosureNotesPayableAdditionalInformationDetails", "http://www.nwbio.com/role/DisclosureSummaryOfSignificantAccountingPoliciesDetails" ], "xbrltype": "monetaryItemType" }, "nwbo_DeferredOfferingCost": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of Deferred offering cost.", "label": "Deferred Offering Cost", "terseLabel": "Deferred offering cost" } } }, "localname": "DeferredOfferingCost", "nsuri": "http://www.nwbio.com/20201231", "presentation": [ "http://www.nwbio.com/role/StatementConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "nwbo_DeferredTaxAssetsTaxCreditCarryForwardUnusedResearchAndDevelopment": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible unused research and development tax credit carryforwards.", "label": "Deferred Tax Assets Tax Credit Carry Forward Unused Research And Development" } } }, "localname": "DeferredTaxAssetsTaxCreditCarryForwardUnusedResearchAndDevelopment", "nsuri": "http://www.nwbio.com/20201231", "presentation": [ "http://www.nwbio.com/role/DisclosureIncomeTaxesAdditionalInformationDetails" ], "xbrltype": "monetaryItemType" }, "nwbo_DepositsAndOtherAssetsNoncurrent": { "auth_ref": [], "calculation": { "http://www.nwbio.com/role/StatementConsolidatedStatementsOfCashFlows": { "order": 4.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Aggregate carrying amount, as of the balance sheet date, of investments and other noncurrent assets not separately disclosed in the balance sheet due to materiality considerations. Noncurrent assets are expected to be realized or consumed after one year (or the normal operating cycle, if longer).", "label": "Deposits and Other Assets Noncurrent", "negatedLabel": "Other non-current assets" } } }, "localname": "DepositsAndOtherAssetsNoncurrent", "nsuri": "http://www.nwbio.com/20201231", "presentation": [ "http://www.nwbio.com/role/StatementConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "nwbo_DirectOfferingMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "No definition available.", "label": "Direct Offering [Member]", "terseLabel": "Direct Offering [Member]" } } }, "localname": "DirectOfferingMember", "nsuri": "http://www.nwbio.com/20201231", "presentation": [ "http://www.nwbio.com/role/StatementConsolidatedStatementsOfChangesInStockholdersDeficitParenthetical" ], "xbrltype": "domainItemType" }, "nwbo_EffectiveIncomeTaxRateReconciliationExpirationOfNetOperatingLosses": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Effective Income Tax Rate Reconciliation on expiration of net operating losses", "label": "Effective Income Tax Rate Reconciliation Expiration Of Net Operating Losses", "negatedLabel": "Expiration of net operating losses" } } }, "localname": "EffectiveIncomeTaxRateReconciliationExpirationOfNetOperatingLosses", "nsuri": "http://www.nwbio.com/20201231", "presentation": [ "http://www.nwbio.com/role/DisclosureIncomeTaxesReconcilationOfUsFederalStatutoryTaxExpenseBenefitDetails" ], "xbrltype": "percentItemType" }, "nwbo_EightPercentUnsecuredMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "n/a", "label": "Eight Percent Unsecured [Member]", "terseLabel": "8% unsecured [Member]" } } }, "localname": "EightPercentUnsecuredMember", "nsuri": "http://www.nwbio.com/20201231", "presentation": [ "http://www.nwbio.com/role/DisclosureNotesPayableAdditionalInformationDetails", "http://www.nwbio.com/role/DisclosureNotesPayableDetails", "http://www.nwbio.com/role/DisclosureNotesPayableSummaryOfCompanySContractualObligationsOnDebtPrincipalDetails" ], "xbrltype": "domainItemType" }, "nwbo_EquityAndDebtFinancingCost": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of equity and debt financing cost.", "label": "Equity And Debt Financing Cost", "terseLabel": "Amount of financing" } } }, "localname": "EquityAndDebtFinancingCost", "nsuri": "http://www.nwbio.com/20201231", "presentation": [ "http://www.nwbio.com/role/DisclosureStockholdersDeficitAdditionalInformationDetails", "http://www.nwbio.com/role/DisclosureSubsequentEventsDetails" ], "xbrltype": "monetaryItemType" }, "nwbo_ErrorCorrectionAccrualAndCapitalizationErrorsMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "This member stands for corrections to accrual and capitalization errors.", "label": "Error Correction Accrual And Capitalization Errors [Member]", "terseLabel": "Accrual and capitalization error correction" } } }, "localname": "ErrorCorrectionAccrualAndCapitalizationErrorsMember", "nsuri": "http://www.nwbio.com/20201231", "presentation": [ "http://www.nwbio.com/role/DisclosureRevisionToPriorPeriodFinancialStatementsConsolidatedBalanceSheetDetails", "http://www.nwbio.com/role/DisclosureRevisionToPriorPeriodFinancialStatementsConsolidatedStatementOfCashFlowsDetaills", "http://www.nwbio.com/role/DisclosureRevisionToPriorPeriodFinancialStatementsConsolidatedStatementOfOperationsDetaills" ], "xbrltype": "domainItemType" }, "nwbo_ExtendedTermOfAgreement": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Extended term of the agreement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.", "label": "Extended Term Of Agreement", "verboseLabel": "Extended term of the Ancillary Services agreement" } } }, "localname": "ExtendedTermOfAgreement", "nsuri": "http://www.nwbio.com/20201231", "presentation": [ "http://www.nwbio.com/role/DisclosureCommitmentsAndContingenciesAdditionalInformationDetails", "http://www.nwbio.com/role/DisclosureRelatedPartyTransactionsAdditionalInformationDetails" ], "xbrltype": "durationItemType" }, "nwbo_ExtensionOfLoansFromRelatedParty": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Its represent the amount of extension of loans from related party.", "label": "Extension of Loans From Related Party", "terseLabel": "Extension of Loans" } } }, "localname": "ExtensionOfLoansFromRelatedParty", "nsuri": "http://www.nwbio.com/20201231", "presentation": [ "http://www.nwbio.com/role/DisclosureRelatedPartyTransactionsAdditionalInformationDetails" ], "xbrltype": "monetaryItemType" }, "nwbo_ExtinguishmentOfDebtPolicyPolicyTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "These lines are represents policy disclosure of extinguishment of debt.", "label": "Extinguishment Of Debt Policy [Policy Text Block]", "terseLabel": "Debt Extinguishment" } } }, "localname": "ExtinguishmentOfDebtPolicyPolicyTextBlock", "nsuri": "http://www.nwbio.com/20201231", "presentation": [ "http://www.nwbio.com/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "nwbo_ExtinguishmentOfEmbeddedDerivativeLiability": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The amount of extinguishment of embedded derivative liability upon conversion.", "label": "Extinguishment of Embedded Derivative Liability", "verboseLabel": "Embedded derivative liability extinguished" } } }, "localname": "ExtinguishmentOfEmbeddedDerivativeLiability", "nsuri": "http://www.nwbio.com/20201231", "presentation": [ "http://www.nwbio.com/role/DisclosureNotesPayableAdditionalInformationDetails" ], "xbrltype": "monetaryItemType" }, "nwbo_FairValueAssumptionsExpectedDividendRates": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Expected dividends to be paid to holders of the underlying shares or financial instruments (expressed as a percentage of the share or instrument's price).", "label": "Fair Value Assumptions Expected Dividend Rates", "verboseLabel": "Dividend yield (per share)" } } }, "localname": "FairValueAssumptionsExpectedDividendRates", "nsuri": "http://www.nwbio.com/20201231", "presentation": [ "http://www.nwbio.com/role/DisclosureFairValueMeasurementsWeightedAverageInAggregateSignificantUnobservableInputsDetails" ], "xbrltype": "percentItemType" }, "nwbo_FairValueAssumptionsExpectedTerms": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Period the instrument, asset or liability is expected to be outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.", "label": "Fair Value Assumptions Expected Terms", "verboseLabel": "Contractual term (years)" } } }, "localname": "FairValueAssumptionsExpectedTerms", "nsuri": "http://www.nwbio.com/20201231", "presentation": [ "http://www.nwbio.com/role/DisclosureFairValueMeasurementsWeightedAverageInAggregateSignificantUnobservableInputsDetails" ], "xbrltype": "durationItemType" }, "nwbo_FairValueAssumptionsExpectedVolatilityRates": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Measure of dispersion, in percentage terms (for instance, the standard deviation or variance), for a given stock price.", "label": "Fair Value Assumptions Expected Volatility Rates", "terseLabel": "Volatility (annual)" } } }, "localname": "FairValueAssumptionsExpectedVolatilityRates", "nsuri": "http://www.nwbio.com/20201231", "presentation": [ "http://www.nwbio.com/role/DisclosureFairValueMeasurementsWeightedAverageInAggregateSignificantUnobservableInputsDetails" ], "xbrltype": "percentItemType" }, "nwbo_FairValueAssumptionsRiskFreeInterestsRate": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Risk-free interest rate assumption used in valuing an instrument.", "label": "Fair Value Assumptions Risk Free Interests Rate", "terseLabel": "Risk-free rate" } } }, "localname": "FairValueAssumptionsRiskFreeInterestsRate", "nsuri": "http://www.nwbio.com/20201231", "presentation": [ "http://www.nwbio.com/role/DisclosureFairValueMeasurementsWeightedAverageInAggregateSignificantUnobservableInputsDetails" ], "xbrltype": "percentItemType" }, "nwbo_FairValueIssuanceOfNewWarrants": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The amount related to fair value issuance of warrants.", "label": "Fair Value Issuance of New Warrants", "terseLabel": "Warrants issued at fair value" } } }, "localname": "FairValueIssuanceOfNewWarrants", "nsuri": "http://www.nwbio.com/20201231", "presentation": [ "http://www.nwbio.com/role/DisclosureNotesPayableAdditionalInformationDetails" ], "xbrltype": "monetaryItemType" }, "nwbo_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityReclassificationForWarrantsExercisedForCash": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of reclassifications for warrant exercised for cash, in connection with financial instrument classified as a liability measured using unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing.", "label": "Fair Value, Measurement With Unobservable Inputs Reconciliation, Recurring Basis, Liability, Reclassification For Warrants Exercised For Cash", "negatedLabel": "Reclassification of warrant liabilities" } } }, "localname": "FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityReclassificationForWarrantsExercisedForCash", "nsuri": "http://www.nwbio.com/20201231", "presentation": [ "http://www.nwbio.com/role/DisclosureFairValueMeasurementsChangesInLevel3LiabilitiesDetails" ], "xbrltype": "monetaryItemType" }, "nwbo_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlementsRelatedToRepaymentOfDebt": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of settlements related to repayment of debt of financial instrument classified as a liability measured using unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing.", "label": "Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Liability Settlements Related To Repayment of Debt", "verboseLabel": "Extinguishement of embedded conversion option due to debt conversion and debt repayment" } } }, "localname": "FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlementsRelatedToRepaymentOfDebt", "nsuri": "http://www.nwbio.com/20201231", "presentation": [ "http://www.nwbio.com/role/DisclosureFairValueMeasurementsChangesInLevel3LiabilitiesDetails" ], "xbrltype": "monetaryItemType" }, "nwbo_FairValueOfEmbeddedConversionOption": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The fair value of embedded conversion option", "label": "Fair Value of Embedded Conversion Option", "terseLabel": "Embedded Conversion Option", "verboseLabel": "Debt Instrument, Embedded Conversion Option" } } }, "localname": "FairValueOfEmbeddedConversionOption", "nsuri": "http://www.nwbio.com/20201231", "presentation": [ "http://www.nwbio.com/role/DisclosureNotesPayableAdditionalInformationDetails", "http://www.nwbio.com/role/DisclosureNotesPayableDetails" ], "xbrltype": "monetaryItemType" }, "nwbo_FairvalueMeasurementWithUnobservableInputsReconciliationRecurringBasisExtinguishmentOfDerivativeLiabilities": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Represents of information pertaining to extinguishment of derivative liabilities.", "label": "Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Extinguishment Of Derivative Liabilities", "verboseLabel": "Extinguishment of derivative liabilities" } } }, "localname": "FairvalueMeasurementWithUnobservableInputsReconciliationRecurringBasisExtinguishmentOfDerivativeLiabilities", "nsuri": "http://www.nwbio.com/20201231", "presentation": [ "http://www.nwbio.com/role/DisclosureFairValueMeasurementsChangesInLevel3LiabilitiesDetails" ], "xbrltype": "monetaryItemType" }, "nwbo_FebruaryNotesMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "This member stands for February Notes.", "label": "February Notes [Member]", "terseLabel": "February Notes" } } }, "localname": "FebruaryNotesMember", "nsuri": "http://www.nwbio.com/20201231", "presentation": [ "http://www.nwbio.com/role/DisclosureNotesPayableAdditionalInformationDetails" ], "xbrltype": "domainItemType" }, "nwbo_FinancialConditionGoingConcernAndManagementPlansTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Financial Condition Going Concern and Management Plans Text block", "label": "Financial Condition Going Concern and Management Plans [Text Block]", "terseLabel": "Financial Condition, Going Concern and Management Plans" } } }, "localname": "FinancialConditionGoingConcernAndManagementPlansTextBlock", "nsuri": "http://www.nwbio.com/20201231", "presentation": [ "http://www.nwbio.com/role/DisclosureFinancialConditionGoingConcernAndManagementPlans" ], "xbrltype": "textBlockItemType" }, "nwbo_FlaskworksMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "This member stands for Flaskworks.", "label": "Flaskworks [Member]", "terseLabel": "Acquisition" } } }, "localname": "FlaskworksMember", "nsuri": "http://www.nwbio.com/20201231", "presentation": [ "http://www.nwbio.com/role/DisclosureFlaskworksAcquisitionDetails", "http://www.nwbio.com/role/DisclosureStockBasedCompensationAdditionalInformationDetails", "http://www.nwbio.com/role/DisclosureStockholdersDeficitAdditionalInformationDetails" ], "xbrltype": "domainItemType" }, "nwbo_ForbearanceOfDebtToRelatedPartiesMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Represent the information pertaining to forbearance of debt to related parties.", "label": "Forbearance Of Debt To Related Parties [Member]", "terseLabel": "Forbearance of debt to related parties" } } }, "localname": "ForbearanceOfDebtToRelatedPartiesMember", "nsuri": "http://www.nwbio.com/20201231", "presentation": [ "http://www.nwbio.com/role/DisclosureNotesPayableMortgageLoanDetails" ], "xbrltype": "domainItemType" }, "nwbo_ForbearanceWarrantsMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "This member stands Forbearance Warrants.", "label": "Forbearance Warrants [Member]", "terseLabel": "Forbearance Warrants [Member]" } } }, "localname": "ForbearanceWarrantsMember", "nsuri": "http://www.nwbio.com/20201231", "presentation": [ "http://www.nwbio.com/role/DisclosureRelatedPartyTransactionsAdditionalInformationDetails" ], "xbrltype": "domainItemType" }, "nwbo_GoldmanNoteMember": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Goldman Note [Member]", "terseLabel": "Goldman Note [Member]" } } }, "localname": "GoldmanNoteMember", "nsuri": "http://www.nwbio.com/20201231", "presentation": [ "http://www.nwbio.com/role/DisclosureNotesPayableAdditionalInformationDetails" ], "xbrltype": "domainItemType" }, "nwbo_IncomeTaxesLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "No definition available.", "label": "Income Taxes [Line Items]" } } }, "localname": "IncomeTaxesLineItems", "nsuri": "http://www.nwbio.com/20201231", "presentation": [ "http://www.nwbio.com/role/DisclosureIncomeTaxesAdditionalInformationDetails" ], "xbrltype": "stringItemType" }, "nwbo_IncreaseDecreaseInOperatingLeaseLiabilities": { "auth_ref": [], "calculation": { "http://www.nwbio.com/role/StatementConsolidatedStatementsOfCashFlows": { "order": 7.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The amount of increase decrease in operating lease liabilities.", "label": "Increase Decrease In Operating Lease Liabilities", "terseLabel": "Lease liabilities" } } }, "localname": "IncreaseDecreaseInOperatingLeaseLiabilities", "nsuri": "http://www.nwbio.com/20201231", "presentation": [ "http://www.nwbio.com/role/StatementConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "nwbo_IncreaseDecreaseInPrepaidExpenseAndOtherCurrentAssets": { "auth_ref": [], "calculation": { "http://www.nwbio.com/role/StatementConsolidatedStatementsOfCashFlows": { "order": 3.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The increase (decrease) during the reporting period in the amount of outstanding money paid in advance for goods or services that bring economic benefits for future periods and also includes, the increase (decrease) during the reporting period in other current operating assets not separately disclosed in the statement of cash flows.", "label": "Increase (Decrease) In Prepaid Expense and Other Current Assets", "negatedLabel": "Prepaid expenses and other current assets" } } }, "localname": "IncreaseDecreaseInPrepaidExpenseAndOtherCurrentAssets", "nsuri": "http://www.nwbio.com/20201231", "presentation": [ "http://www.nwbio.com/role/StatementConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "nwbo_IncreaseOrDecreaseInEquityDueToReclassificationOfWarrantLiabilitiesRelatedToSequencingPolicy": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The amount of increase or decrease in equity due to reclassification of warrant liabilities related to sequencing policy.", "label": "Increase or Decrease in Equity Due to Reclassification of Warrant Liabilities Related to Sequencing Policy", "terseLabel": "Reclassification of warrant liabilities related to sequencing policy" } } }, "localname": "IncreaseOrDecreaseInEquityDueToReclassificationOfWarrantLiabilitiesRelatedToSequencingPolicy", "nsuri": "http://www.nwbio.com/20201231", "presentation": [ "http://www.nwbio.com/role/StatementConsolidatedStatementsOfChangesInStockholdersDeficit" ], "xbrltype": "monetaryItemType" }, "nwbo_IncrementalChangeInFairValueOfSharesResultingFromMarketPrice": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The amount of incremental change in fair value of the shares.", "label": "Incremental Change in Fair Value of the Shares Resulting from Market Price", "terseLabel": "Incremental change in fair value of the shares" } } }, "localname": "IncrementalChangeInFairValueOfSharesResultingFromMarketPrice", "nsuri": "http://www.nwbio.com/20201231", "presentation": [ "http://www.nwbio.com/role/DisclosureFlaskworksAcquisitionDetails" ], "xbrltype": "monetaryItemType" }, "nwbo_InterestExpenseRelatedToForbearanceOfDebt": { "auth_ref": [], "calculation": { "http://www.nwbio.com/role/DisclosureRelatedPartyTransactionsTotalInterestExpensesDetails": { "order": 2.0, "parentTag": "us-gaap_InterestAndDebtExpense", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The amount of interest expense related to forbearance of debt.", "label": "Interest Expense related to Forbearance of Debt", "terseLabel": "Interest expenses related to forbearance of debt to related parties", "verboseLabel": "Interest expenses related to forbearance of debt to related parties" } } }, "localname": "InterestExpenseRelatedToForbearanceOfDebt", "nsuri": "http://www.nwbio.com/20201231", "presentation": [ "http://www.nwbio.com/role/DisclosureRelatedPartyTransactionsAdditionalInformationDetails", "http://www.nwbio.com/role/DisclosureRelatedPartyTransactionsTotalInterestExpensesDetails" ], "xbrltype": "monetaryItemType" }, "nwbo_IssuanceOfCommonSharesInSettlementAgreement": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Value of common shares issued in connection with settlement agreement.", "label": "Issuance Of Common Shares In Settlement Agreement", "verboseLabel": "Issuance of common shares in connection with a settlement agreement" } } }, "localname": "IssuanceOfCommonSharesInSettlementAgreement", "nsuri": "http://www.nwbio.com/20201231", "presentation": [ "http://www.nwbio.com/role/DisclosureStockholdersDeficitAdditionalInformationDetails", "http://www.nwbio.com/role/StatementConsolidatedStatementsOfChangesInStockholdersDeficit" ], "xbrltype": "monetaryItemType" }, "nwbo_IssuanceOfCommonSharesInSettlementAgreementInShares": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Number of common shares issued in connection with settlement agreement.", "label": "Issuance Of Common Shares In Settlement Agreement (in shares)", "verboseLabel": "Issuance of common shares in connection with a settlement agreement (in shares)" } } }, "localname": "IssuanceOfCommonSharesInSettlementAgreementInShares", "nsuri": "http://www.nwbio.com/20201231", "presentation": [ "http://www.nwbio.com/role/DisclosureStockholdersDeficitAdditionalInformationDetails", "http://www.nwbio.com/role/StatementConsolidatedStatementsOfChangesInStockholdersDeficit" ], "xbrltype": "sharesItemType" }, "nwbo_IssuanceOfCommonSharesInWithConnectionSettlementAgreement": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of common shares issued in connection with settlement agreement.", "label": "Issuance Of Common Shares In With Connection Settlement Agreement", "terseLabel": "Issuance of common shares in connection with a settlement agreement" } } }, "localname": "IssuanceOfCommonSharesInWithConnectionSettlementAgreement", "nsuri": "http://www.nwbio.com/20201231", "presentation": [ "http://www.nwbio.com/role/StatementConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "nwbo_IssuanceOfCommonStockAndWarrantsForConversionOfDebtAndAccruedInterestReceived": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Value of shares and warrants issued during the period for conversion of debt and accrued interest received.", "label": "Issuance of Common Stock and Warrants for Conversion of Debt and Accrued Interest Received", "terseLabel": "Issuance of common stock and warrants for conversion of debt and accrued interest" } } }, "localname": "IssuanceOfCommonStockAndWarrantsForConversionOfDebtAndAccruedInterestReceived", "nsuri": "http://www.nwbio.com/20201231", "presentation": [ "http://www.nwbio.com/role/StatementConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "nwbo_LeaseholdImprovementsUsefulLife": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Useful life of leasehold improvements.", "label": "Leasehold Improvements Useful Life" } } }, "localname": "LeaseholdImprovementsUsefulLife", "nsuri": "http://www.nwbio.com/20201231", "presentation": [ "http://www.nwbio.com/role/DisclosurePropertyPlantAndEquipmentDetails" ], "xbrltype": "stringItemType" }, "nwbo_LesseeOperatingLeaseLiabilityToBePaidAfterYearFour": { "auth_ref": [], "calculation": { "http://www.nwbio.com/role/DisclosureCommitmentsAndContingenciesMaturitiesOfOurOperatingLeasesDetails": { "order": 4.0, "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease due after fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).", "label": "Lessee, Operating Lease, Liability, to be Paid, after Year Four", "terseLabel": "Therafter" } } }, "localname": "LesseeOperatingLeaseLiabilityToBePaidAfterYearFour", "nsuri": "http://www.nwbio.com/20201231", "presentation": [ "http://www.nwbio.com/role/DisclosureCommitmentsAndContingenciesMaturitiesOfOurOperatingLeasesDetails" ], "xbrltype": "monetaryItemType" }, "nwbo_LiquidityAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Financial Condition, Going Concern and Management Plans" } } }, "localname": "LiquidityAbstract", "nsuri": "http://www.nwbio.com/20201231", "xbrltype": "stringItemType" }, "nwbo_LongTermNotesPayableMember": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Long Term Notes Payable [Member]", "terseLabel": "Long Term Notes Payable [Member]" } } }, "localname": "LongTermNotesPayableMember", "nsuri": "http://www.nwbio.com/20201231", "presentation": [ "http://www.nwbio.com/role/DisclosureNotesPayableDetails", "http://www.nwbio.com/role/DisclosureNotesPayableSummaryOfCompanySContractualObligationsOnDebtPrincipalDetails" ], "xbrltype": "domainItemType" }, "nwbo_MayFinancingMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Represents the information pertaining to May Financing.", "label": "May Financing [Member]", "terseLabel": "May Financing" } } }, "localname": "MayFinancingMember", "nsuri": "http://www.nwbio.com/20201231", "presentation": [ "http://www.nwbio.com/role/DisclosureStockholdersDeficitAdditionalInformationDetails" ], "xbrltype": "domainItemType" }, "nwbo_MayNoteMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Represents the information pertaining to May note.", "label": "May Note [Member]", "terseLabel": "May Note" } } }, "localname": "MayNoteMember", "nsuri": "http://www.nwbio.com/20201231", "presentation": [ "http://www.nwbio.com/role/DisclosureNotesPayableAdditionalInformationDetails" ], "xbrltype": "domainItemType" }, "nwbo_Mr.GoldmanMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "This member stands for Mr. Goldman.", "label": "Mr. Goldman [Member]", "terseLabel": "Mr. Goldman [Member]" } } }, "localname": "Mr.GoldmanMember", "nsuri": "http://www.nwbio.com/20201231", "presentation": [ "http://www.nwbio.com/role/DisclosureRelatedPartyTransactionsAdditionalInformationDetails" ], "xbrltype": "domainItemType" }, "nwbo_NetCashLoss": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Its represent amount of net cash loss.", "label": "Net Cash Loss", "terseLabel": "Net Cash Loss" } } }, "localname": "NetCashLoss", "nsuri": "http://www.nwbio.com/20201231", "presentation": [ "http://www.nwbio.com/role/DisclosureFinancialConditionGoingConcernAndManagementPlansDetailsTextual" ], "xbrltype": "monetaryItemType" }, "nwbo_NetNonCashLoss": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "It represents the amount of net non-cash loss.", "label": "Net Non-cash Loss" } } }, "localname": "NetNonCashLoss", "nsuri": "http://www.nwbio.com/20201231", "presentation": [ "http://www.nwbio.com/role/DisclosureFinancialConditionGoingConcernAndManagementPlansDetailsTextual" ], "xbrltype": "monetaryItemType" }, "nwbo_NoncashInterestExpense": { "auth_ref": [], "calculation": { "http://www.nwbio.com/role/StatementConsolidatedStatementsOfCashFlows": { "order": 4.0, "parentTag": "us-gaap_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Noncash interest expenses incurred during the period by the entity.", "label": "Noncash Interest Expense", "terseLabel": "Non-cash interest expense" } } }, "localname": "NoncashInterestExpense", "nsuri": "http://www.nwbio.com/20201231", "presentation": [ "http://www.nwbio.com/role/StatementConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "nwbo_NoteDueIn2011Member": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Note Due In2011 [Member]", "terseLabel": "Note Due In 2011 [Member]" } } }, "localname": "NoteDueIn2011Member", "nsuri": "http://www.nwbio.com/20201231", "presentation": [ "http://www.nwbio.com/role/DisclosureNotesPayableAdditionalInformationDetails" ], "xbrltype": "domainItemType" }, "nwbo_NotesMember": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Notes [Member]", "terseLabel": "Notes [Member]" } } }, "localname": "NotesMember", "nsuri": "http://www.nwbio.com/20201231", "presentation": [ "http://www.nwbio.com/role/DisclosureNotesPayableAdditionalInformationDetails" ], "xbrltype": "domainItemType" }, "nwbo_NumberOfAmortizedInInstallments": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The value represents the number of installments.", "label": "Number of Amortized in Installments", "terseLabel": "Number of installments for amortization" } } }, "localname": "NumberOfAmortizedInInstallments", "nsuri": "http://www.nwbio.com/20201231", "presentation": [ "http://www.nwbio.com/role/DisclosureNotesPayableAdditionalInformationDetails", "http://www.nwbio.com/role/DisclosureSubsequentEventsDetails" ], "xbrltype": "integerItemType" }, "nwbo_NumberOfCommonStockIssuedCashlessExercise": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "It represents the number of common stock issued cashless exercise.", "label": "Number Of Common Stock Issued Cashless Exercise", "terseLabel": "Number of common stock issued" } } }, "localname": "NumberOfCommonStockIssuedCashlessExercise", "nsuri": "http://www.nwbio.com/20201231", "presentation": [ "http://www.nwbio.com/role/DisclosureStockholdersDeficitAdditionalInformationDetails" ], "xbrltype": "sharesItemType" }, "nwbo_NumberOfExistingWarrants": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Number of existing warrants held by the company.", "label": "Number Of Existing Warrants", "terseLabel": "Number of existing warrants" } } }, "localname": "NumberOfExistingWarrants", "nsuri": "http://www.nwbio.com/20201231", "presentation": [ "http://www.nwbio.com/role/DisclosureNotesPayableAdditionalInformationDetails" ], "xbrltype": "sharesItemType" }, "nwbo_NumberOfSharesIssuedForExerciseOfStockOptionsCashlessExercise": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The number of shares issued on exercise of stock options, cashless exercise.", "label": "Number of Shares Issued for Exercise of Stock Options, Cashless Exercise", "terseLabel": "Number of shares issued for exercise of stock options, cashless" } } }, "localname": "NumberOfSharesIssuedForExerciseOfStockOptionsCashlessExercise", "nsuri": "http://www.nwbio.com/20201231", "presentation": [ "http://www.nwbio.com/role/DisclosureSubsequentEventsDetails" ], "xbrltype": "sharesItemType" }, "nwbo_NumberOfWarrantsExercisedForCash": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Number of warrants exercised for cash during the period.", "label": "Number Of Warrants Exercised For Cash", "verboseLabel": "Warrants exercised for cash (in shares)" } } }, "localname": "NumberOfWarrantsExercisedForCash", "nsuri": "http://www.nwbio.com/20201231", "presentation": [ "http://www.nwbio.com/role/StatementConsolidatedStatementsOfChangesInStockholdersDeficit" ], "xbrltype": "sharesItemType" }, "nwbo_NumberOfWarrantsWarrantsCashlessExercise": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Aggregate number of class of warrants or rights exercised cashless during the reported period.", "label": "Number Of Warrants, Warrants Cashless Exercise", "negatedLabel": "Number of Warrants, Cashless warrants exercise", "terseLabel": "Number of Warrants, cashless warrants exercise" } } }, "localname": "NumberOfWarrantsWarrantsCashlessExercise", "nsuri": "http://www.nwbio.com/20201231", "presentation": [ "http://www.nwbio.com/role/DisclosureStockholdersDeficitAdditionalInformationDetails", "http://www.nwbio.com/role/DisclosureStockholdersDeficitDetails", "http://www.nwbio.com/role/DisclosureSubsequentEventsDetails" ], "xbrltype": "sharesItemType" }, "nwbo_NumberOfWarrantsWarrantsExercisedForCash": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Aggregate number of class of warrants or rights exercised for cash during the reported period.", "label": "Number Of Warrants Warrants Exercised For Cash", "negatedLabel": "Number of Warrants, Warrants exercised for cash" } } }, "localname": "NumberOfWarrantsWarrantsExercisedForCash", "nsuri": "http://www.nwbio.com/20201231", "presentation": [ "http://www.nwbio.com/role/DisclosureStockholdersDeficitDetails" ], "xbrltype": "sharesItemType" }, "nwbo_OctoberFinancingMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "This member stands for october financing.", "label": "October Financing [Member]", "terseLabel": "October Financing [Member]" } } }, "localname": "OctoberFinancingMember", "nsuri": "http://www.nwbio.com/20201231", "presentation": [ "http://www.nwbio.com/role/DisclosureStockholdersDeficitAdditionalInformationDetails" ], "xbrltype": "domainItemType" }, "nwbo_OctoberNoteMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Represents the information pertaining to October note.", "label": "October Note [Member]", "terseLabel": "October Note" } } }, "localname": "OctoberNoteMember", "nsuri": "http://www.nwbio.com/20201231", "presentation": [ "http://www.nwbio.com/role/DisclosureNotesPayableAdditionalInformationDetails" ], "xbrltype": "domainItemType" }, "nwbo_OfferingCostRelatedToWarrantLiability": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The amount of Offering cost related to warrant liability.", "label": "Offering Cost Related To Warrant Liability", "terseLabel": "Offering cost related to warrant liability" } } }, "localname": "OfferingCostRelatedToWarrantLiability", "nsuri": "http://www.nwbio.com/20201231", "presentation": [ "http://www.nwbio.com/role/StatementConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "nwbo_OperatingLeaseOtherInformationAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "No definition available.", "label": "Operating Lease Other Information [Abstract]", "verboseLabel": "Other information" } } }, "localname": "OperatingLeaseOtherInformationAbstract", "nsuri": "http://www.nwbio.com/20201231", "presentation": [ "http://www.nwbio.com/role/DisclosureCommitmentsAndContingenciesDetails" ], "xbrltype": "stringItemType" }, "nwbo_OperatingLeaseRightOfUseAssetAmortization": { "auth_ref": [], "calculation": { "http://www.nwbio.com/role/StatementConsolidatedStatementsOfCashFlows": { "order": 6.0, "parentTag": "us-gaap_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of amortization expense attributable to right-of-use asset from operating lease.", "label": "Operating Lease Right Of Use Asset Amortization", "terseLabel": "Amortization of operating lease right-of-use asset" } } }, "localname": "OperatingLeaseRightOfUseAssetAmortization", "nsuri": "http://www.nwbio.com/20201231", "presentation": [ "http://www.nwbio.com/role/StatementConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "nwbo_OriginalTermOfAgreement": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The original term of the agreement.", "label": "Original Term of the Agreement", "terseLabel": "Original term of the agreement" } } }, "localname": "OriginalTermOfAgreement", "nsuri": "http://www.nwbio.com/20201231", "presentation": [ "http://www.nwbio.com/role/DisclosureCommitmentsAndContingenciesAdditionalInformationDetails" ], "xbrltype": "durationItemType" }, "nwbo_PaycheckProtectionProgramLoanCaresActMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "This member stands for loans under Paycheck Protection Program pursuant to CARES Act.", "label": "Paycheck Protection Program Loan Cares Act [Member]", "terseLabel": "Paycheck Protection Program loan" } } }, "localname": "PaycheckProtectionProgramLoanCaresActMember", "nsuri": "http://www.nwbio.com/20201231", "presentation": [ "http://www.nwbio.com/role/DisclosureNotesPayableAdditionalInformationDetails" ], "xbrltype": "domainItemType" }, "nwbo_PercentOfWarrantsExercisableDuringOffering": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Percentage of warrants exercisable during Offering.", "label": "Percent of Warrants exercisable During Offering", "terseLabel": "Percentage of warrants exercisable" } } }, "localname": "PercentOfWarrantsExercisableDuringOffering", "nsuri": "http://www.nwbio.com/20201231", "presentation": [ "http://www.nwbio.com/role/DisclosureStockholdersDeficitAdditionalInformationDetails", "http://www.nwbio.com/role/DisclosureSubsequentEventsDetails" ], "xbrltype": "percentItemType" }, "nwbo_PercentageOfWarrantCoverage": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The rate of percent of warrant coverage.", "label": "Percentage of Warrant Coverage" } } }, "localname": "PercentageOfWarrantCoverage", "nsuri": "http://www.nwbio.com/20201231", "presentation": [ "http://www.nwbio.com/role/DisclosureRelatedPartyTransactionsAdditionalInformationDetails" ], "xbrltype": "percentItemType" }, "nwbo_PlacementAgentMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "n/a.", "label": "Placement Agent [Member]", "terseLabel": "Placement Agent" } } }, "localname": "PlacementAgentMember", "nsuri": "http://www.nwbio.com/20201231", "presentation": [ "http://www.nwbio.com/role/DisclosureStockholdersDeficitAdditionalInformationDetails" ], "xbrltype": "domainItemType" }, "nwbo_PostModificationMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "This member stands for the scenario, post modification.", "label": "Post Modification [Member]", "terseLabel": "Post Modification" } } }, "localname": "PostModificationMember", "nsuri": "http://www.nwbio.com/20201231", "presentation": [ "http://www.nwbio.com/role/DisclosureStockBasedCompensationAssumptionsDetails" ], "xbrltype": "domainItemType" }, "nwbo_PreModificationMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "This member stands for the scenario, pre modification.", "label": "Pre Modification [Member]", "terseLabel": "Pre Modification" } } }, "localname": "PreModificationMember", "nsuri": "http://www.nwbio.com/20201231", "presentation": [ "http://www.nwbio.com/role/DisclosureStockBasedCompensationAssumptionsDetails" ], "xbrltype": "domainItemType" }, "nwbo_ProceedsFromIssuanceOfCapitalStockAndWarrants": { "auth_ref": [], "calculation": { "http://www.nwbio.com/role/StatementConsolidatedStatementsOfCashFlows": { "order": 1.0, "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The cash inflow from issuance of capital stock and warrants to common stockholders.", "label": "Proceeds From Issuance Of Capital Stock And Warrants", "verboseLabel": "Proceeds from issuance of common stock and warrants in a registered direct offering, net" } } }, "localname": "ProceedsFromIssuanceOfCapitalStockAndWarrants", "nsuri": "http://www.nwbio.com/20201231", "presentation": [ "http://www.nwbio.com/role/DisclosureStockholdersDeficitAdditionalInformationDetails", "http://www.nwbio.com/role/StatementConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "nwbo_ProceedsFromWarrantModification": { "auth_ref": [], "calculation": { "http://www.nwbio.com/role/StatementConsolidatedStatementsOfCashFlows": { "order": 8.0, "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The cash inflow associated with the amount received from holders modification their stock warrants.", "label": "Proceeds From Warrant Modification", "terseLabel": "Proceeds from warrants modification" } } }, "localname": "ProceedsFromWarrantModification", "nsuri": "http://www.nwbio.com/20201231", "presentation": [ "http://www.nwbio.com/role/StatementConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "nwbo_ProgramInitiationPayment": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of Program Initiation Payment.", "label": "Program Initiation Payment" } } }, "localname": "ProgramInitiationPayment", "nsuri": "http://www.nwbio.com/20201231", "presentation": [ "http://www.nwbio.com/role/DisclosureCommitmentsAndContingenciesAdditionalInformationDetails" ], "xbrltype": "monetaryItemType" }, "nwbo_PromissoryNoteMember": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Promissory Note [Member]", "terseLabel": "Promissory Note [Member]" } } }, "localname": "PromissoryNoteMember", "nsuri": "http://www.nwbio.com/20201231", "presentation": [ "http://www.nwbio.com/role/DisclosureNotesPayableAdditionalInformationDetails" ], "xbrltype": "domainItemType" }, "nwbo_ReclassBetweenSharesPayableAndAdditionalPaidInCapital": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount Reclass Between Shares Payable And Additional Paid In Capital.", "label": "Reclass Between Shares Payable And Additional Paid In Capital", "terseLabel": "Reclass between shares payable and additional paid-in capital" } } }, "localname": "ReclassBetweenSharesPayableAndAdditionalPaidInCapital", "nsuri": "http://www.nwbio.com/20201231", "presentation": [ "http://www.nwbio.com/role/StatementConsolidatedStatementsOfCashFlows", "http://www.nwbio.com/role/StatementConsolidatedStatementsOfChangesInStockholdersDeficit" ], "xbrltype": "monetaryItemType" }, "nwbo_ReclassificationOfWarrantLiabilitiesRelatedToSequencingPolicy": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The amount of reclassification of warrant liabilities related to sequencing policy.", "label": "Reclassification of Warrant Liabilities Related to Sequencing Policy", "terseLabel": "Reclassification of warrant liabilities related to sequencing policy" } } }, "localname": "ReclassificationOfWarrantLiabilitiesRelatedToSequencingPolicy", "nsuri": "http://www.nwbio.com/20201231", "presentation": [ "http://www.nwbio.com/role/StatementConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "nwbo_RegisteredDirectOfferingMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Registered Direct Offering", "label": "Registered Direct Offering [Member]", "terseLabel": "Registered Direct Offering [Member]" } } }, "localname": "RegisteredDirectOfferingMember", "nsuri": "http://www.nwbio.com/20201231", "presentation": [ "http://www.nwbio.com/role/DisclosureStockholdersDeficitAdditionalInformationDetails" ], "xbrltype": "domainItemType" }, "nwbo_RelatedPartyMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "No definition available.", "label": "Related Party [Member]", "terseLabel": "Related Party" } } }, "localname": "RelatedPartyMember", "nsuri": "http://www.nwbio.com/20201231", "presentation": [ "http://www.nwbio.com/role/StatementConsolidatedStatementsOfCashFlows" ], "xbrltype": "domainItemType" }, "nwbo_RepaymentOfConvertibleNotesPayableToRelatedParty": { "auth_ref": [], "calculation": { "http://www.nwbio.com/role/StatementConsolidatedStatementsOfCashFlows": { "order": 6.0, "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The Amount of Repayment of convertible notes payable to Related Party.", "label": "Repayment of convertible notes payable to Related Party", "negatedLabel": "Repayment of convertible notes payable to related parties" } } }, "localname": "RepaymentOfConvertibleNotesPayableToRelatedParty", "nsuri": "http://www.nwbio.com/20201231", "presentation": [ "http://www.nwbio.com/role/StatementConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "nwbo_SawstonBuildoutMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "This member stands for sawston buildout.", "label": "Sawston Buildout [Member]", "terseLabel": "Sawston buildout [Member]" } } }, "localname": "SawstonBuildoutMember", "nsuri": "http://www.nwbio.com/20201231", "presentation": [ "http://www.nwbio.com/role/DisclosureRelatedPartyTransactionsAdditionalInformationDetails" ], "xbrltype": "domainItemType" }, "nwbo_ScheduleOfContractualObligationsOnDebtPrincipalTableTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The tabular information pertaining to contractual obligations on debt principal.", "label": "Schedule of Contractual Obligations on Debt Principal [Table Text Block]", "verboseLabel": "Schedule of the company's contractual obligations on debt principal" } } }, "localname": "ScheduleOfContractualObligationsOnDebtPrincipalTableTextBlock", "nsuri": "http://www.nwbio.com/20201231", "presentation": [ "http://www.nwbio.com/role/DisclosureNotesPayableTables" ], "xbrltype": "textBlockItemType" }, "nwbo_ScheduleOfSettlementObligationsTableTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The tabular disclosure of settlement obligations.", "label": "Schedule Of Settlement Obligations [Table Text Block]", "verboseLabel": "Schedule of expenses incurred to related parties and amounts invoiced some of which remain unpaid" } } }, "localname": "ScheduleOfSettlementObligationsTableTextBlock", "nsuri": "http://www.nwbio.com/20201231", "presentation": [ "http://www.nwbio.com/role/DisclosureRelatedPartyTransactionsTables" ], "xbrltype": "textBlockItemType" }, "nwbo_SequencingPolicyTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "These lines are represents policy disclosure of sequence.", "label": "Sequencing [Policy Text Block]", "terseLabel": "Sequencing" } } }, "localname": "SequencingPolicyTextBlock", "nsuri": "http://www.nwbio.com/20201231", "presentation": [ "http://www.nwbio.com/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "nwbo_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfStockOptionsAgreedNotToBeExercisedByHolder": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Number of stock options that the holder has agreed to not exercise until the specified period, under the share-based payment arrangement.", "label": "Share-Based Compensation Arrangement By Share-Based Payment Award, Number Of Stock Options Agreed Not To Be Exercised By Holder", "terseLabel": "Existing options that the Company's CEO has agreed to not exercise until the specified period (in shares)" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfStockOptionsAgreedNotToBeExercisedByHolder", "nsuri": "http://www.nwbio.com/20201231", "presentation": [ "http://www.nwbio.com/role/DisclosureStockBasedCompensationAdditionalInformationDetails" ], "xbrltype": "sharesItemType" }, "nwbo_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageRemainingContractualTerm": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Weighted average remaining contractual term for option awards granted.", "label": "Share based Compensation Arrangement By Share based Payment Award Options Grants In Period Weighted Average Remaining Contractual Term", "verboseLabel": "Weighted Average Remaining Contractual Life (in years), Granted" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageRemainingContractualTerm", "nsuri": "http://www.nwbio.com/20201231", "presentation": [ "http://www.nwbio.com/role/DisclosureStockBasedCompensationStockOptionActivityDetails" ], "xbrltype": "durationItemType" }, "nwbo_ShareBasedCompensationArrangementByShareBasedPaymentAwardPeriodDuringWhichStockOptionsAgreedNotToBeExercisedByHolder": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The period over which the stock options granted under the share-based payment arrangement, are agreed not be exercised by the holder, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.", "label": "Share-Based Compensation Arrangement By Share-Based Payment Award, Period During Which Stock Options Agreed Not To Be Exercised By Holder", "terseLabel": "Period during which the Company's CEO has agreed to not exercise the options" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardPeriodDuringWhichStockOptionsAgreedNotToBeExercisedByHolder", "nsuri": "http://www.nwbio.com/20201231", "presentation": [ "http://www.nwbio.com/role/DisclosureStockBasedCompensationAdditionalInformationDetails" ], "xbrltype": "durationItemType" }, "nwbo_ShareBasedCompensationArrangementByShareBasedPaymentAwardStockOptionExtendedContractualTerm": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The extended contractual term of the stock options granted under the share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.", "label": "Share-Based Compensation Arrangement By Share-Based Payment Award, Stock Option Extended Contractual Term", "terseLabel": "Extended contractual term of the options held by the Company's CEO" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardStockOptionExtendedContractualTerm", "nsuri": "http://www.nwbio.com/20201231", "presentation": [ "http://www.nwbio.com/role/DisclosureStockBasedCompensationAdditionalInformationDetails" ], "xbrltype": "durationItemType" }, "nwbo_ShareBasedCompensationArrangementByShareBasedPaymentAwardValueOfSharesIssuedUnderAcquisition": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Value of shares issued under acquisition in relation to share-based payment arrangement.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Value of Shares Issued Under Acquisition", "verboseLabel": "Share-based Compensation" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardValueOfSharesIssuedUnderAcquisition", "nsuri": "http://www.nwbio.com/20201231", "presentation": [ "http://www.nwbio.com/role/DisclosureStockBasedCompensationAdditionalInformationDetails" ], "xbrltype": "monetaryItemType" }, "nwbo_ShareBasedCompensationTable": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Share Based Compensation [Table]" } } }, "localname": "ShareBasedCompensationTable", "nsuri": "http://www.nwbio.com/20201231", "presentation": [ "http://www.nwbio.com/role/DisclosureStockBasedCompensationAdditionalInformationDetails" ], "xbrltype": "stringItemType" }, "nwbo_ShareSettlementAgreementMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Information related to share settlement agreement", "label": "Share Settlement Agreement [Member]", "terseLabel": "Share Settlement Agreement [Member]" } } }, "localname": "ShareSettlementAgreementMember", "nsuri": "http://www.nwbio.com/20201231", "presentation": [ "http://www.nwbio.com/role/DisclosureStockholdersDeficitAdditionalInformationDetails" ], "xbrltype": "domainItemType" }, "nwbo_ShareholdersDeficitLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Shareholders Deficit [Line Items]" } } }, "localname": "ShareholdersDeficitLineItems", "nsuri": "http://www.nwbio.com/20201231", "presentation": [ "http://www.nwbio.com/role/DisclosureStockholdersDeficitAdditionalInformationDetails" ], "xbrltype": "stringItemType" }, "nwbo_ShareholdersDeficitTable": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Shareholders Deficit [Table]" } } }, "localname": "ShareholdersDeficitTable", "nsuri": "http://www.nwbio.com/20201231", "presentation": [ "http://www.nwbio.com/role/DisclosureStockholdersDeficitAdditionalInformationDetails" ], "xbrltype": "stringItemType" }, "nwbo_SharesIssuedDuringPeriodSharesUponExerciseOfWarrants": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Represents the shares issued during period shares upon exercise of warrants.", "label": "Shares Issued During Period Shares Upon Exercise Of Warrants", "verboseLabel": "Shares Issued During Period Shares, Upon Exercise Of warrants" } } }, "localname": "SharesIssuedDuringPeriodSharesUponExerciseOfWarrants", "nsuri": "http://www.nwbio.com/20201231", "presentation": [ "http://www.nwbio.com/role/DisclosureStockholdersDeficitAdditionalInformationDetails" ], "xbrltype": "sharesItemType" }, "nwbo_ShortTermConvertibleNoteMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Represent the information pertaining to short term convertible note.", "label": "Short Term Convertible Note [Member]", "terseLabel": "Short term convertible note" } } }, "localname": "ShortTermConvertibleNoteMember", "nsuri": "http://www.nwbio.com/20201231", "presentation": [ "http://www.nwbio.com/role/DisclosureNotesPayableSummaryOfCompanySContractualObligationsOnDebtPrincipalDetails" ], "xbrltype": "domainItemType" }, "nwbo_ShortTermNotesPayableMember": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Short Term Notes Payable [Member]", "terseLabel": "Short Term Notes Payable [Member]" } } }, "localname": "ShortTermNotesPayableMember", "nsuri": "http://www.nwbio.com/20201231", "presentation": [ "http://www.nwbio.com/role/DisclosureNotesPayableAdditionalInformationDetails", "http://www.nwbio.com/role/DisclosureNotesPayableDetails", "http://www.nwbio.com/role/DisclosureNotesPayableSummaryOfCompanySContractualObligationsOnDebtPrincipalDetails" ], "xbrltype": "domainItemType" }, "nwbo_ShortTermNotesPayableRelatedPartiesMember": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Short Term Notes Payable Related Parties [Member]", "terseLabel": "Short term convertible notes payable - related parties [Member]" } } }, "localname": "ShortTermNotesPayableRelatedPartiesMember", "nsuri": "http://www.nwbio.com/20201231", "presentation": [ "http://www.nwbio.com/role/DisclosureNotesPayableDetails", "http://www.nwbio.com/role/DisclosureNotesPayableMortgageLoanDetails", "http://www.nwbio.com/role/DisclosureNotesPayableSummaryOfCompanySContractualObligationsOnDebtPrincipalDetails" ], "xbrltype": "domainItemType" }, "nwbo_SixPercentSecuredMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "N/a", "label": "Six Percent Secured [Member]", "terseLabel": "6% secured [Member]" } } }, "localname": "SixPercentSecuredMember", "nsuri": "http://www.nwbio.com/20201231", "presentation": [ "http://www.nwbio.com/role/DisclosureNotesPayableAdditionalInformationDetails", "http://www.nwbio.com/role/DisclosureNotesPayableDetails", "http://www.nwbio.com/role/DisclosureNotesPayableSummaryOfCompanySContractualObligationsOnDebtPrincipalDetails" ], "xbrltype": "domainItemType" }, "nwbo_SixPercentUnsecurbleMember": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Six Percent Unsecurble [Member]", "terseLabel": "6% Unsecurble [Member]" } } }, "localname": "SixPercentUnsecurbleMember", "nsuri": "http://www.nwbio.com/20201231", "presentation": [ "http://www.nwbio.com/role/DisclosureNotesPayableDetails" ], "xbrltype": "domainItemType" }, "nwbo_SixPercentUnsecuredMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Represent the information pertaining to six percent unsecured member.", "label": "Six Percent Unsecured [Member]", "terseLabel": "6% unsecured [Member]" } } }, "localname": "SixPercentUnsecuredMember", "nsuri": "http://www.nwbio.com/20201231", "presentation": [ "http://www.nwbio.com/role/DisclosureNotesPayableSummaryOfCompanySContractualObligationsOnDebtPrincipalDetails" ], "xbrltype": "domainItemType" }, "nwbo_SixPercentageNotePayableOneMember": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Six Percentage Note Payable One [Member]", "terseLabel": "Six Percentage Note Payable One [Member]" } } }, "localname": "SixPercentageNotePayableOneMember", "nsuri": "http://www.nwbio.com/20201231", "presentation": [ "http://www.nwbio.com/role/DisclosureNotesPayableAdditionalInformationDetails" ], "xbrltype": "domainItemType" }, "nwbo_SpecialConsiderationPayment": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "It represents the amount of special consideration payment.", "label": "Special Consideration Payment", "terseLabel": "Special consideration payment" } } }, "localname": "SpecialConsiderationPayment", "nsuri": "http://www.nwbio.com/20201231", "presentation": [ "http://www.nwbio.com/role/DisclosureStockholdersDeficitAdditionalInformationDetails" ], "xbrltype": "monetaryItemType" }, "nwbo_StockAndWarrantsIssuedDuringPeriodSharesConversionOfDebtAndAccruedInterest": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Number of shares issued and warrants during the period for conversion of debt and accrued interest.", "label": "Stock And Warrants Issued During Period, Shares ,Conversion Of Debt And Accrued Interest", "verboseLabel": "Issuance of common stock and warrants for conversion of debt and accrued interest (in shares)" } } }, "localname": "StockAndWarrantsIssuedDuringPeriodSharesConversionOfDebtAndAccruedInterest", "nsuri": "http://www.nwbio.com/20201231", "presentation": [ "http://www.nwbio.com/role/StatementConsolidatedStatementsOfChangesInStockholdersDeficit" ], "xbrltype": "sharesItemType" }, "nwbo_StockAndWarrantsIssuedDuringPeriodValueConversionOfDebtAndAccruedInterest": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Value of shares and warrants issued during the period for conversion of debt and accrued interest.", "label": "Stock And Warrants Issued During Period, Value ,Conversion Of Debt And Accrued Interest", "verboseLabel": "Issuance of common stock and warrants for conversion of debt and accrued interest" } } }, "localname": "StockAndWarrantsIssuedDuringPeriodValueConversionOfDebtAndAccruedInterest", "nsuri": "http://www.nwbio.com/20201231", "presentation": [ "http://www.nwbio.com/role/StatementConsolidatedStatementsOfChangesInStockholdersDeficit" ], "xbrltype": "monetaryItemType" }, "nwbo_StockBasedCompensationRelatedToWarrantsModification": { "auth_ref": [], "calculation": { "http://www.nwbio.com/role/StatementConsolidatedStatementsOfCashFlows": { "order": 8.0, "parentTag": "us-gaap_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "It represents stock based compensation related to warrants modification.", "label": "Stock based compensation related to warrants modification", "terseLabel": "Stock-based compensation related to warrants modification" } } }, "localname": "StockBasedCompensationRelatedToWarrantsModification", "nsuri": "http://www.nwbio.com/20201231", "presentation": [ "http://www.nwbio.com/role/StatementConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "nwbo_StockIssuedDuringPeriodSharesIssuedForNonCashConsideration1": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Number of shares issued for noncash consideration for development stage entities.", "label": "Stock Issued During Period Shares Issued For Non Cash Consideration 1", "verboseLabel": "Cashless warrants exercise (in shares)" } } }, "localname": "StockIssuedDuringPeriodSharesIssuedForNonCashConsideration1", "nsuri": "http://www.nwbio.com/20201231", "presentation": [ "http://www.nwbio.com/role/DisclosureStockholdersDeficitAdditionalInformationDetails", "http://www.nwbio.com/role/StatementConsolidatedStatementsOfChangesInStockholdersDeficit" ], "xbrltype": "sharesItemType" }, "nwbo_StockIssuedDuringPeriodSharesWarrantExercises": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Represents the information pertaining to shares issued during the period from warrant exercises.", "label": "Stock Issued During Period, Shares, Warrant Exercises", "terseLabel": "Stock issued on exercise of warrants" } } }, "localname": "StockIssuedDuringPeriodSharesWarrantExercises", "nsuri": "http://www.nwbio.com/20201231", "presentation": [ "http://www.nwbio.com/role/DisclosureSubsequentEventsDetails" ], "xbrltype": "sharesItemType" }, "nwbo_StockIssuedDuringPeriodValueForWarrantCashlessExercise": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Value of shares issued for noncash consideration for development stage entities.", "label": "Stock Issued During Period Value For Warrant Cashless Exercise", "verboseLabel": "Cashless warrants exercise" } } }, "localname": "StockIssuedDuringPeriodValueForWarrantCashlessExercise", "nsuri": "http://www.nwbio.com/20201231", "presentation": [ "http://www.nwbio.com/role/StatementConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "nwbo_StockIssuedDuringPeriodValueIssuedForNonCashConsideration": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Value of shares issued for noncash consideration for development stage entities.", "label": "Stock Issued During Period Value Issued For Non Cash Consideration", "verboseLabel": "Cashless warrants exercise" } } }, "localname": "StockIssuedDuringPeriodValueIssuedForNonCashConsideration", "nsuri": "http://www.nwbio.com/20201231", "presentation": [ "http://www.nwbio.com/role/StatementConsolidatedStatementsOfChangesInStockholdersDeficit" ], "xbrltype": "monetaryItemType" }, "nwbo_SubscriptionReceivableMember": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Subscription Receivable [Member]", "terseLabel": "Subscription Receivable" } } }, "localname": "SubscriptionReceivableMember", "nsuri": "http://www.nwbio.com/20201231", "presentation": [ "http://www.nwbio.com/role/StatementConsolidatedStatementsOfChangesInStockholdersDeficit" ], "xbrltype": "domainItemType" }, "nwbo_TaxSettlementOfferForMoreRecentYears": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The amount of tax settlement offer for more recent years.", "label": "Tax Settlement Offer for More Recent Years", "terseLabel": "Tax settlement offer for more recent years" } } }, "localname": "TaxSettlementOfferForMoreRecentYears", "nsuri": "http://www.nwbio.com/20201231", "presentation": [ "http://www.nwbio.com/role/DisclosureCommitmentsAndContingenciesAdditionalInformationDetails" ], "xbrltype": "monetaryItemType" }, "nwbo_TenPercentUnsecuredMember": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Ten Percent Unsecured [Member]", "terseLabel": "10% unsecured [Member]" } } }, "localname": "TenPercentUnsecuredMember", "nsuri": "http://www.nwbio.com/20201231", "presentation": [ "http://www.nwbio.com/role/DisclosureNotesPayableAdditionalInformationDetails", "http://www.nwbio.com/role/DisclosureNotesPayableDetails", "http://www.nwbio.com/role/DisclosureNotesPayableSummaryOfCompanySContractualObligationsOnDebtPrincipalDetails" ], "xbrltype": "domainItemType" }, "nwbo_TwelvePercentUnsecuredMember": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Twelve Percent Unsecured [Member]", "terseLabel": "12% unsecured [Member]" } } }, "localname": "TwelvePercentUnsecuredMember", "nsuri": "http://www.nwbio.com/20201231", "presentation": [ "http://www.nwbio.com/role/DisclosureNotesPayableAdditionalInformationDetails", "http://www.nwbio.com/role/DisclosureNotesPayableDetails", "http://www.nwbio.com/role/DisclosureNotesPayableSummaryOfCompanySContractualObligationsOnDebtPrincipalDetails" ], "xbrltype": "domainItemType" }, "nwbo_ValueOfWarrantsExercisedForCash": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Value of warrants exercised for cash during the period.", "label": "Value of Warrants Exercised For Cash", "verboseLabel": "Warrants exercised for cash" } } }, "localname": "ValueOfWarrantsExercisedForCash", "nsuri": "http://www.nwbio.com/20201231", "presentation": [ "http://www.nwbio.com/role/DisclosureStockholdersDeficitAdditionalInformationDetails", "http://www.nwbio.com/role/StatementConsolidatedStatementsOfChangesInStockholdersDeficit" ], "xbrltype": "monetaryItemType" }, "nwbo_WarrantLiabilityMember": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Warrant Liability [Member]", "terseLabel": "Warrant Liability [Member]" } } }, "localname": "WarrantLiabilityMember", "nsuri": "http://www.nwbio.com/20201231", "presentation": [ "http://www.nwbio.com/role/DisclosureFairValueMeasurementsChangesInLevel3LiabilitiesDetails", "http://www.nwbio.com/role/DisclosureFairValueMeasurementsWeightedAverageInAggregateSignificantUnobservableInputsDetails" ], "xbrltype": "domainItemType" }, "nwbo_WarrantModificationInConnectionWithDebtAmendment": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of warrant modification in connection with debt amendment.", "label": "Warrant Modification In Connection With Debt Amendment", "terseLabel": "Warrant modification in connection with debt amendment" } } }, "localname": "WarrantModificationInConnectionWithDebtAmendment", "nsuri": "http://www.nwbio.com/20201231", "presentation": [ "http://www.nwbio.com/role/StatementConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "nwbo_WarrantsExerciseNumber": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The number of warrants exercise during period.", "label": "Warrants exercise, Number" } } }, "localname": "WarrantsExerciseNumber", "nsuri": "http://www.nwbio.com/20201231", "presentation": [ "http://www.nwbio.com/role/DisclosureNotesPayableAdditionalInformationDetails" ], "xbrltype": "sharesItemType" }, "nwbo_WarrantsIssuedAsConsiderationForWarrantsSuspensionMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Represents the warrants issued as consideration for warrants suspension.", "label": "Warrants Issued As Consideration For Warrants Suspension [Member]", "terseLabel": "Warrants issued as consideration for warrants suspension" } } }, "localname": "WarrantsIssuedAsConsiderationForWarrantsSuspensionMember", "nsuri": "http://www.nwbio.com/20201231", "presentation": [ "http://www.nwbio.com/role/DisclosureStockholdersDeficitAdditionalInformationDetails" ], "xbrltype": "domainItemType" }, "nwbo_WarrantsIssuedAsPercentageOfCommonSharesIssuedUponConversion": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Percentage of the number of common shares issued upon conversion, issued by the company as warrants pursuant to a debt instrument.", "label": "Warrants Issued As A Percentage Of Common Shares Issued Upon Conversion", "terseLabel": "Warrants issued as a percentage of common shares issued upon conversion" } } }, "localname": "WarrantsIssuedAsPercentageOfCommonSharesIssuedUponConversion", "nsuri": "http://www.nwbio.com/20201231", "presentation": [ "http://www.nwbio.com/role/DisclosureNotesPayableAdditionalInformationDetails" ], "xbrltype": "percentItemType" }, "nwbo_WarrantsIssuedAssociatedWithConvertibleNotesPayable": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The amount of warrants issued with convertible notes payable.", "label": "Warrants Issued Associated With Convertible Notes Payable", "verboseLabel": "Issuance of warrants in conjunction with convertible note payable" } } }, "localname": "WarrantsIssuedAssociatedWithConvertibleNotesPayable", "nsuri": "http://www.nwbio.com/20201231", "presentation": [ "http://www.nwbio.com/role/StatementConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "nwbo_WarrantsIssuedInConnectionWithDebtModification": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The amount of Issuance of warrants in connection with debt modification.", "label": "Warrants Issued In Connection With Debt Modification", "verboseLabel": "Issuance of warrants in connection with debt modification" } } }, "localname": "WarrantsIssuedInConnectionWithDebtModification", "nsuri": "http://www.nwbio.com/20201231", "presentation": [ "http://www.nwbio.com/role/StatementConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "nwbo_WarrantsOherNewSharePurchasesMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Represents the information about other new share purchases of warrants suspended.", "label": "Warrants Oher New Share Purchases [Member]", "terseLabel": "Warrants Oher New Share Purchases" } } }, "localname": "WarrantsOherNewSharePurchasesMember", "nsuri": "http://www.nwbio.com/20201231", "presentation": [ "http://www.nwbio.com/role/DisclosureStockholdersDeficitAdditionalInformationDetails", "http://www.nwbio.com/role/DisclosureSubsequentEventsDetails" ], "xbrltype": "domainItemType" }, "nwbo_WarrantsThroughDecemberFifteenTwoThousandAndTwentyMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Represents the information about through December 15, 2020.", "label": "Warrants Through December Fifteen Two Thousand And Twenty [Member]", "terseLabel": "Warrants through December 15, 2020" } } }, "localname": "WarrantsThroughDecemberFifteenTwoThousandAndTwentyMember", "nsuri": "http://www.nwbio.com/20201231", "presentation": [ "http://www.nwbio.com/role/DisclosureStockholdersDeficitAdditionalInformationDetails", "http://www.nwbio.com/role/DisclosureSubsequentEventsDetails" ], "xbrltype": "domainItemType" }, "nwbo_WeightedAverageExercisePriceExercisedForCash": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Weighted average exercise price for cash during the reporting period.", "label": "Weighted Average Exercise Price - exercised for cash", "terseLabel": "Weighted Average Exercise Price - Warrants exercised for cash" } } }, "localname": "WeightedAverageExercisePriceExercisedForCash", "nsuri": "http://www.nwbio.com/20201231", "presentation": [ "http://www.nwbio.com/role/DisclosureStockholdersDeficitDetails" ], "xbrltype": "perShareItemType" }, "nwbo_WeightedAverageExercisePriceWarrantsCashlessExercise": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Weighted average exercise price for cashless exercise during the reporting period.", "label": "Weighted Average Exercise Price, Warrants Cashless Exercise", "terseLabel": "Weighted Average Exercise Price, Cashless warrants exercise" } } }, "localname": "WeightedAverageExercisePriceWarrantsCashlessExercise", "nsuri": "http://www.nwbio.com/20201231", "presentation": [ "http://www.nwbio.com/role/DisclosureStockholdersDeficitAdditionalInformationDetails", "http://www.nwbio.com/role/DisclosureStockholdersDeficitDetails" ], "xbrltype": "perShareItemType" }, "nwbo_ZeroPercentUnsecuredMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "n/a", "label": "Zero Percent Unsecured [Member]", "terseLabel": "0% unsecured [Member]" } } }, "localname": "ZeroPercentUnsecuredMember", "nsuri": "http://www.nwbio.com/20201231", "presentation": [ "http://www.nwbio.com/role/DisclosureNotesPayableDetails", "http://www.nwbio.com/role/DisclosureNotesPayableSummaryOfCompanySContractualObligationsOnDebtPrincipalDetails" ], "xbrltype": "domainItemType" }, "srt_CumulativeEffectPeriodOfAdoptionAdjustmentMember": { "auth_ref": [ "r109", "r114", "r169", "r263", "r264", "r265", "r293", "r294" ], "lang": { "en-us": { "role": { "label": "Cumulative Effect Period Of Adoption Adjustment [Member]", "terseLabel": "Cumulative Effect, Period of Adoption, Adjustment" } } }, "localname": "CumulativeEffectPeriodOfAdoptionAdjustmentMember", "nsuri": "http://fasb.org/srt/2020-01-31", "presentation": [ "http://www.nwbio.com/role/DisclosureSummaryOfSignificantAccountingPoliciesDetails", "http://www.nwbio.com/role/StatementConsolidatedStatementsOfChangesInStockholdersDeficit" ], "xbrltype": "domainItemType" }, "srt_CumulativeEffectPeriodOfAdoptionAxis": { "auth_ref": [ "r109", "r114", "r169", "r263", "r264", "r265", "r293", "r294" ], "lang": { "en-us": { "role": { "label": "Cumulative Effect, Period of Adoption [Axis]" } } }, "localname": "CumulativeEffectPeriodOfAdoptionAxis", "nsuri": "http://fasb.org/srt/2020-01-31", "presentation": [ "http://www.nwbio.com/role/DisclosureSummaryOfSignificantAccountingPoliciesDetails", "http://www.nwbio.com/role/StatementConsolidatedStatementsOfChangesInStockholdersDeficit" ], "xbrltype": "stringItemType" }, "srt_CumulativeEffectPeriodOfAdoptionDomain": { "auth_ref": [ "r109", "r114", "r169", "r263", "r264", "r265", "r293", "r294" ], "lang": { "en-us": { "role": { "label": "Cumulative Effect Period Of Adoption [Domain]", "terseLabel": "Cumulative Effect, Period of Adoption [Domain]" } } }, "localname": "CumulativeEffectPeriodOfAdoptionDomain", "nsuri": "http://fasb.org/srt/2020-01-31", "presentation": [ "http://www.nwbio.com/role/DisclosureSummaryOfSignificantAccountingPoliciesDetails", "http://www.nwbio.com/role/StatementConsolidatedStatementsOfChangesInStockholdersDeficit" ], "xbrltype": "domainItemType" }, "srt_ExecutiveOfficerMember": { "auth_ref": [ "r166" ], "lang": { "en-us": { "role": { "label": "Executive Officer [Member]", "terseLabel": "Senior Vice President" } } }, "localname": "ExecutiveOfficerMember", "nsuri": "http://fasb.org/srt/2020-01-31", "presentation": [ "http://www.nwbio.com/role/DisclosureRelatedPartyTransactionsAdditionalInformationDetails" ], "xbrltype": "domainItemType" }, "srt_MaximumMember": { "auth_ref": [ "r231", "r234", "r404", "r405", "r406", "r407", "r408", "r409", "r410", "r453", "r456" ], "lang": { "en-us": { "role": { "label": "Maximum [Member]", "terseLabel": "Maximum" } } }, "localname": "MaximumMember", "nsuri": "http://fasb.org/srt/2020-01-31", "presentation": [ "http://www.nwbio.com/role/DisclosureNotesPayableAdditionalInformationDetails", "http://www.nwbio.com/role/DisclosurePropertyPlantAndEquipmentDetails", "http://www.nwbio.com/role/DisclosureRelatedPartyTransactionsAdditionalInformationDetails", "http://www.nwbio.com/role/DisclosureStockholdersDeficitAdditionalInformationDetails", "http://www.nwbio.com/role/DisclosureSubsequentEventsDetails" ], "xbrltype": "domainItemType" }, "srt_MinimumMember": { "auth_ref": [ "r231", "r234", "r404", "r405", "r406", "r407", "r408", "r409", "r410", "r453", "r456" ], "lang": { "en-us": { "role": { "label": "Minimum [Member]", "terseLabel": "Minimum" } } }, "localname": "MinimumMember", "nsuri": "http://fasb.org/srt/2020-01-31", "presentation": [ "http://www.nwbio.com/role/DisclosureNotesPayableAdditionalInformationDetails", "http://www.nwbio.com/role/DisclosurePropertyPlantAndEquipmentDetails", "http://www.nwbio.com/role/DisclosureRelatedPartyTransactionsAdditionalInformationDetails", "http://www.nwbio.com/role/DisclosureStockholdersDeficitAdditionalInformationDetails", "http://www.nwbio.com/role/DisclosureSubsequentEventsDetails" ], "xbrltype": "domainItemType" }, "srt_ProductOrServiceAxis": { "auth_ref": [ "r162", "r216", "r217", "r411", "r452", "r454" ], "lang": { "en-us": { "role": { "label": "Product and Service [Axis]" } } }, "localname": "ProductOrServiceAxis", "nsuri": "http://fasb.org/srt/2020-01-31", "presentation": [ "http://www.nwbio.com/role/DisclosureCommitmentsAndContingenciesAdditionalInformationDetails" ], "xbrltype": "stringItemType" }, "srt_ProductsAndServicesDomain": { "auth_ref": [ "r162", "r216", "r217", "r411", "r452", "r454" ], "lang": { "en-us": { "role": { "label": "Products And Services [Domain]", "terseLabel": "Product and Service [Domain]" } } }, "localname": "ProductsAndServicesDomain", "nsuri": "http://fasb.org/srt/2020-01-31", "presentation": [ "http://www.nwbio.com/role/DisclosureCommitmentsAndContingenciesAdditionalInformationDetails" ], "xbrltype": "domainItemType" }, "srt_RangeAxis": { "auth_ref": [ "r220", "r231", "r234", "r404", "r405", "r406", "r407", "r408", "r409", "r410", "r453", "r456" ], "lang": { "en-us": { "role": { "label": "Range [Axis]" } } }, "localname": "RangeAxis", "nsuri": "http://fasb.org/srt/2020-01-31", "presentation": [ "http://www.nwbio.com/role/DisclosureNotesPayableAdditionalInformationDetails", "http://www.nwbio.com/role/DisclosurePropertyPlantAndEquipmentDetails", "http://www.nwbio.com/role/DisclosureRelatedPartyTransactionsAdditionalInformationDetails", "http://www.nwbio.com/role/DisclosureStockholdersDeficitAdditionalInformationDetails", "http://www.nwbio.com/role/DisclosureSubsequentEventsDetails" ], "xbrltype": "stringItemType" }, "srt_RangeMember": { "auth_ref": [ "r220", "r231", "r234", "r404", "r405", "r406", "r407", "r408", "r409", "r410", "r453", "r456" ], "lang": { "en-us": { "role": { "label": "Range [Member]", "terseLabel": "Range [Domain]" } } }, "localname": "RangeMember", "nsuri": "http://fasb.org/srt/2020-01-31", "presentation": [ "http://www.nwbio.com/role/DisclosureNotesPayableAdditionalInformationDetails", "http://www.nwbio.com/role/DisclosurePropertyPlantAndEquipmentDetails", "http://www.nwbio.com/role/DisclosureRelatedPartyTransactionsAdditionalInformationDetails", "http://www.nwbio.com/role/DisclosureStockholdersDeficitAdditionalInformationDetails", "http://www.nwbio.com/role/DisclosureSubsequentEventsDetails" ], "xbrltype": "domainItemType" }, "srt_RestatementAxis": { "auth_ref": [ "r105", "r106", "r107", "r108", "r110", "r111", "r112", "r113", "r114", "r116", "r117", "r118", "r119", "r120", "r132", "r170", "r171", "r266", "r294", "r457", "r458", "r459", "r460", "r461", "r462", "r463", "r464", "r465", "r466" ], "lang": { "en-us": { "role": { "label": "Restatement [Axis]" } } }, "localname": "RestatementAxis", "nsuri": "http://fasb.org/srt/2020-01-31", "presentation": [ "http://www.nwbio.com/role/DisclosureRevisionToPriorPeriodFinancialStatementsConsolidatedBalanceSheetDetails", "http://www.nwbio.com/role/DisclosureRevisionToPriorPeriodFinancialStatementsConsolidatedStatementOfCashFlowsDetaills", "http://www.nwbio.com/role/DisclosureRevisionToPriorPeriodFinancialStatementsConsolidatedStatementOfOperationsDetaills" ], "xbrltype": "stringItemType" }, "srt_RestatementDomain": { "auth_ref": [ "r105", "r106", "r107", "r108", "r110", "r111", "r112", "r113", "r114", "r116", "r117", "r118", "r119", "r120", "r132", "r170", "r171", "r266", "r294", "r457", "r458", "r459", "r460", "r461", "r462", "r463", "r464", "r465", "r466" ], "lang": { "en-us": { "role": { "label": "Restatement [Domain]", "terseLabel": "Restatement [Domain]" } } }, "localname": "RestatementDomain", "nsuri": "http://fasb.org/srt/2020-01-31", "presentation": [ "http://www.nwbio.com/role/DisclosureRevisionToPriorPeriodFinancialStatementsConsolidatedBalanceSheetDetails", "http://www.nwbio.com/role/DisclosureRevisionToPriorPeriodFinancialStatementsConsolidatedStatementOfCashFlowsDetaills", "http://www.nwbio.com/role/DisclosureRevisionToPriorPeriodFinancialStatementsConsolidatedStatementOfOperationsDetaills" ], "xbrltype": "domainItemType" }, "srt_RevisionOfPriorPeriodErrorCorrectionAdjustmentMember": { "auth_ref": [ "r112", "r113", "r116", "r117", "r119", "r120" ], "lang": { "en-us": { "role": { "label": "Revision Of Prior Period Error Correction Adjustment [Member]", "terseLabel": "Adjustments" } } }, "localname": "RevisionOfPriorPeriodErrorCorrectionAdjustmentMember", "nsuri": "http://fasb.org/srt/2020-01-31", "presentation": [ "http://www.nwbio.com/role/DisclosureRevisionToPriorPeriodFinancialStatementsConsolidatedBalanceSheetDetails", "http://www.nwbio.com/role/DisclosureRevisionToPriorPeriodFinancialStatementsConsolidatedStatementOfCashFlowsDetaills", "http://www.nwbio.com/role/DisclosureRevisionToPriorPeriodFinancialStatementsConsolidatedStatementOfOperationsDetaills" ], "xbrltype": "domainItemType" }, "srt_ScenarioPreviouslyReportedMember": { "auth_ref": [ "r105", "r107", "r108", "r110", "r111", "r112", "r113", "r114", "r116", "r117", "r119", "r120", "r132", "r170", "r171", "r266", "r294", "r457", "r458", "r459", "r460", "r461", "r462", "r463", "r464", "r465", "r466" ], "lang": { "en-us": { "role": { "label": "Scenario Previously Reported [Member]", "terseLabel": "As Previously Reported" } } }, "localname": "ScenarioPreviouslyReportedMember", "nsuri": "http://fasb.org/srt/2020-01-31", "presentation": [ "http://www.nwbio.com/role/DisclosureRevisionToPriorPeriodFinancialStatementsConsolidatedBalanceSheetDetails", "http://www.nwbio.com/role/DisclosureRevisionToPriorPeriodFinancialStatementsConsolidatedStatementOfCashFlowsDetaills", "http://www.nwbio.com/role/DisclosureRevisionToPriorPeriodFinancialStatementsConsolidatedStatementOfOperationsDetaills" ], "xbrltype": "domainItemType" }, "srt_ScenarioUnspecifiedDomain": { "auth_ref": [ "r232" ], "lang": { "en-us": { "role": { "label": "Scenario Unspecified [Domain]", "terseLabel": "Scenario, Unspecified [Domain]" } } }, "localname": "ScenarioUnspecifiedDomain", "nsuri": "http://fasb.org/srt/2020-01-31", "presentation": [ "http://www.nwbio.com/role/DisclosureNotesPayableAdditionalInformationDetails", "http://www.nwbio.com/role/DisclosureStockBasedCompensationAssumptionsDetails" ], "xbrltype": "domainItemType" }, "srt_SegmentGeographicalDomain": { "auth_ref": [ "r163", "r164", "r216", "r218", "r455", "r473", "r474", "r475", "r476", "r477", "r478", "r479", "r480" ], "lang": { "en-us": { "role": { "label": "Segment Geographical [Domain]", "terseLabel": "Geographical [Domain]" } } }, "localname": "SegmentGeographicalDomain", "nsuri": "http://fasb.org/srt/2020-01-31", "presentation": [ "http://www.nwbio.com/role/DisclosureCommitmentsAndContingenciesAdditionalInformationDetails", "http://www.nwbio.com/role/DisclosureCommitmentsAndContingenciesDetails", "http://www.nwbio.com/role/DisclosureCommitmentsAndContingenciesMaturitiesOfOurOperatingLeasesDetails", "http://www.nwbio.com/role/DisclosureIncomeTaxesAdditionalInformationDetails", "http://www.nwbio.com/role/DisclosurePropertyPlantAndEquipmentDetails", "http://www.nwbio.com/role/DisclosureSummaryOfSignificantAccountingPoliciesDetails" ], "xbrltype": "domainItemType" }, "srt_StatementGeographicalAxis": { "auth_ref": [ "r163", "r164", "r216", "r218", "r455", "r468", "r473", "r474", "r475", "r476", "r477", "r478", "r479", "r480", "r481" ], "lang": { "en-us": { "role": { "label": "Geographical [Axis]" } } }, "localname": "StatementGeographicalAxis", "nsuri": "http://fasb.org/srt/2020-01-31", "presentation": [ "http://www.nwbio.com/role/DisclosureCommitmentsAndContingenciesAdditionalInformationDetails", "http://www.nwbio.com/role/DisclosureCommitmentsAndContingenciesDetails", "http://www.nwbio.com/role/DisclosureCommitmentsAndContingenciesMaturitiesOfOurOperatingLeasesDetails", "http://www.nwbio.com/role/DisclosureIncomeTaxesAdditionalInformationDetails", "http://www.nwbio.com/role/DisclosurePropertyPlantAndEquipmentDetails", "http://www.nwbio.com/role/DisclosureSummaryOfSignificantAccountingPoliciesDetails" ], "xbrltype": "stringItemType" }, "srt_StatementScenarioAxis": { "auth_ref": [ "r189", "r232", "r399" ], "lang": { "en-us": { "role": { "label": "Scenario [Axis]" } } }, "localname": "StatementScenarioAxis", "nsuri": "http://fasb.org/srt/2020-01-31", "presentation": [ "http://www.nwbio.com/role/DisclosureNotesPayableAdditionalInformationDetails", "http://www.nwbio.com/role/DisclosureStockBasedCompensationAssumptionsDetails" ], "xbrltype": "stringItemType" }, "srt_TitleOfIndividualAxis": { "auth_ref": [ "r166", "r391" ], "lang": { "en-us": { "role": { "label": "Title of Individual [Axis]" } } }, "localname": "TitleOfIndividualAxis", "nsuri": "http://fasb.org/srt/2020-01-31", "presentation": [ "http://www.nwbio.com/role/DisclosureRelatedPartyTransactionsAdditionalInformationDetails" ], "xbrltype": "stringItemType" }, "srt_TitleOfIndividualWithRelationshipToEntityDomain": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Title Of Individual With Relationship To Entity [Domain]", "terseLabel": "Relationship to Entity [Domain]" } } }, "localname": "TitleOfIndividualWithRelationshipToEntityDomain", "nsuri": "http://fasb.org/srt/2020-01-31", "presentation": [ "http://www.nwbio.com/role/DisclosureRelatedPartyTransactionsAdditionalInformationDetails" ], "xbrltype": "domainItemType" }, "us-gaap_AccountingChangesAndErrorCorrectionsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Revision to Prior Period Financial Statements" } } }, "localname": "AccountingChangesAndErrorCorrectionsAbstract", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "xbrltype": "stringItemType" }, "us-gaap_AccountingChangesAndErrorCorrectionsTextBlock": { "auth_ref": [ "r118", "r121" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for reporting accounting changes and error corrections. It includes the conveyance of information necessary for a user of the Company's financial information to understand all aspects and required disclosure information concerning all changes and error corrections reported in the Company's financial statements for the period.", "label": "Accounting Changes and Error Corrections [Text Block]", "verboseLabel": "Revision to Prior Period Financial Statements" } } }, "localname": "AccountingChangesAndErrorCorrectionsTextBlock", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.nwbio.com/role/DisclosureRevisionToPriorPeriodFinancialStatements" ], "xbrltype": "textBlockItemType" }, "us-gaap_AccountingPoliciesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Summary of Significant Accounting Policies" } } }, "localname": "AccountingPoliciesAbstract", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "xbrltype": "stringItemType" }, "us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent": { "auth_ref": [ "r41" ], "calculation": { "http://www.nwbio.com/role/StatementConsolidatedBalanceSheets": { "order": 1.0, "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Sum of the carrying values as of the balance sheet date of obligations incurred through that date and due within one year (or the operating cycle, if longer), including liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received, taxes, interest, rent and utilities, accrued salaries and bonuses, payroll taxes and fringe benefits.", "label": "Accounts Payable and Accrued Liabilities, Current", "terseLabel": "Accounts payable and accrued expenses" } } }, "localname": "AccountsPayableAndAccruedLiabilitiesCurrent", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.nwbio.com/role/StatementConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_AccountsPayableRelatedPartiesCurrentAndNoncurrent": { "auth_ref": [ "r103", "r389", "r429", "r448" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount for accounts payable to related parties.", "label": "Accounts Payable, Related Parties" } } }, "localname": "AccountsPayableRelatedPartiesCurrentAndNoncurrent", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.nwbio.com/role/DisclosureNotesPayableAdditionalInformationDetails", "http://www.nwbio.com/role/DisclosureRelatedPartyTransactionsAdditionalInformationDetails", "http://www.nwbio.com/role/DisclosureRelatedPartyTransactionsSummaryOfOutstandingUnpaidAccountsPayableHeldByRelatedPartiesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment": { "auth_ref": [ "r35", "r181" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of accumulated depreciation, depletion and amortization for physical assets used in the normal conduct of business to produce goods and services.", "label": "Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment", "negatedLabel": "Less: accumulated depreciation" } } }, "localname": "AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.nwbio.com/role/DisclosurePropertyPlantAndEquipmentDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax": { "auth_ref": [ "r26", "r53", "r55", "r56", "r442", "r462", "r466" ], "calculation": { "http://www.nwbio.com/role/StatementConsolidatedBalanceSheets": { "order": 6.0, "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Accumulated change in equity from transactions and other events and circumstances from non-owner sources, net of tax effect, at period end. Excludes Net Income (Loss), and accumulated changes in equity from transactions resulting from investments by owners and distributions to owners. Includes foreign currency translation items, certain pension adjustments, unrealized gains and losses on certain investments in debt and equity securities, other than temporary impairment (OTTI) losses related to factors other than credit losses on available-for-sale and held-to-maturity debt securities that an entity does not intend to sell and it is not more likely than not that the entity will be required to sell before recovery of the amortized cost basis, as well as changes in the fair value of derivatives related to the effective portion of a designated cash flow hedge.", "label": "Accumulated Other Comprehensive Income (Loss), Net of Tax", "verboseLabel": "Accumulated other comprehensive income" } } }, "localname": "AccumulatedOtherComprehensiveIncomeLossNetOfTax", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.nwbio.com/role/StatementConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_AccumulatedTranslationAdjustmentMember": { "auth_ref": [ "r52", "r56", "r57", "r323", "r357", "r358", "r359", "r360", "r362" ], "lang": { "en-us": { "role": { "documentation": "Accumulated other comprehensive income (loss) resulting from foreign currency translation adjustments, foreign currency transactions designated and effective as economic hedges of a net investment in a foreign entity and intra-entity foreign currency transactions that are of a long-term-investment nature, attributable to the parent.", "label": "Accumulated Translation Adjustment [Member]", "terseLabel": "Accumulated Other Comprehensive Income (Loss)" } } }, "localname": "AccumulatedTranslationAdjustmentMember", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.nwbio.com/role/StatementConsolidatedStatementsOfChangesInStockholdersDeficit" ], "xbrltype": "domainItemType" }, "us-gaap_AdditionalPaidInCapitalCommonStock": { "auth_ref": [ "r24" ], "calculation": { "http://www.nwbio.com/role/StatementConsolidatedBalanceSheets": { "order": 3.0, "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Value received from shareholders in common stock-related transactions that are in excess of par value or stated value and amounts received from other stock-related transactions. Includes only common stock transactions (excludes preferred stock transactions). May be called contributed capital, capital in excess of par, capital surplus, or paid-in capital.", "label": "Additional Paid in Capital, Common Stock", "verboseLabel": "Additional paid-in capital" } } }, "localname": "AdditionalPaidInCapitalCommonStock", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.nwbio.com/role/StatementConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_AdditionalPaidInCapitalMember": { "auth_ref": [ "r105", "r106", "r108", "r263", "r264", "r265" ], "lang": { "en-us": { "role": { "documentation": "Excess of issue price over par or stated value of the entity's capital stock and amounts received from other transactions involving the entity's stock or stockholders.", "label": "Additional Paid In Capital [Member]", "terseLabel": "Additional Paid-in Capital" } } }, "localname": "AdditionalPaidInCapitalMember", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.nwbio.com/role/DisclosureStockholdersDeficitAdditionalInformationDetails", "http://www.nwbio.com/role/StatementConsolidatedStatementsOfChangesInStockholdersDeficit" ], "xbrltype": "domainItemType" }, "us-gaap_AdjustmentsForErrorCorrectionDomain": { "auth_ref": [ "r107", "r112", "r113", "r116", "r117", "r119", "r120" ], "lang": { "en-us": { "role": { "documentation": "Type of error correction.", "label": "Adjustments For Error Correction [Domain]", "terseLabel": "Error Correction, Type [Domain]" } } }, "localname": "AdjustmentsForErrorCorrectionDomain", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.nwbio.com/role/DisclosureRevisionToPriorPeriodFinancialStatementsConsolidatedBalanceSheetDetails", "http://www.nwbio.com/role/DisclosureRevisionToPriorPeriodFinancialStatementsConsolidatedStatementOfCashFlowsDetaills", "http://www.nwbio.com/role/DisclosureRevisionToPriorPeriodFinancialStatementsConsolidatedStatementOfOperationsDetaills" ], "xbrltype": "domainItemType" }, "us-gaap_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivities": { "auth_ref": [ "r86" ], "calculation": { "http://www.nwbio.com/role/StatementConsolidatedStatementsOfCashFlows": { "order": 2.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The aggregate amount of adjustments to net income or loss necessary to remove the effects of all items whose cash effects are investing or financing cash flows. The aggregate amount also includes all noncash expenses and income items which reduce or increase net income and are thus added back or deducted when calculating cash provided by or used in operating activities.", "label": "Adjustments, Noncash Items, to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities", "totalLabel": "Subtotal of non-cash charges" } } }, "localname": "AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivities", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.nwbio.com/role/StatementConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue": { "auth_ref": [ "r235", "r237", "r269", "r270" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of increase to additional paid-in capital (APIC) for recognition of cost for award under share-based payment arrangement.", "label": "Adjustments to Additional Paid in Capital, Share-based Compensation, Requisite Service Period Recognition", "terseLabel": "Stock-based compensation" } } }, "localname": "AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.nwbio.com/role/StatementConsolidatedStatementsOfChangesInStockholdersDeficit" ], "xbrltype": "monetaryItemType" }, "us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Adjustments to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract]", "terseLabel": "Reconciliation of net loss to net cash used in operating activities:" } } }, "localname": "AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.nwbio.com/role/StatementConsolidatedStatementsOfCashFlows" ], "xbrltype": "stringItemType" }, "us-gaap_AllocatedShareBasedCompensationExpense": { "auth_ref": [ "r237", "r258", "r268" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.", "label": "Allocated Share-based Compensation Expense", "terseLabel": "Total stock-based compensation expense" } } }, "localname": "AllocatedShareBasedCompensationExpense", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.nwbio.com/role/DisclosureStockBasedCompensationAdditionalInformationDetails", "http://www.nwbio.com/role/DisclosureStockBasedCompensationSummaryOfStockBasedCompensationExpenseDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_AmortizationOfDebtDiscountPremium": { "auth_ref": [ "r72", "r86", "r367" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of noncash expense included in interest expense to amortize debt discount and premium associated with the related debt instruments. Excludes amortization of financing costs. Alternate captions include noncash interest expense.", "label": "Amortization of Debt Discount (Premium)", "verboseLabel": "Amortization of Debt Discount (Premium)" } } }, "localname": "AmortizationOfDebtDiscountPremium", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.nwbio.com/role/DisclosureNotesPayableAdditionalInformationDetails", "http://www.nwbio.com/role/DisclosureNotesPayableMortgageLoanDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_AmortizationOfFinancingCostsAndDiscounts": { "auth_ref": [ "r86", "r369" ], "calculation": { "http://www.nwbio.com/role/DisclosureRelatedPartyTransactionsTotalInterestExpensesDetails": { "order": 3.0, "parentTag": "us-gaap_InterestAndDebtExpense", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of amortization expense attributable to debt discount (premium) and debt issuance costs.", "label": "Amortization of Debt Issuance Costs and Discounts", "verboseLabel": "Amortization of debt discount" } } }, "localname": "AmortizationOfFinancingCostsAndDiscounts", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.nwbio.com/role/DisclosureNotesPayableMortgageLoanDetails", "http://www.nwbio.com/role/DisclosureRelatedPartyTransactionsTotalInterestExpensesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount": { "auth_ref": [ "r129" ], "lang": { "en-us": { "role": { "documentation": "Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented.", "label": "Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount", "verboseLabel": "Potentially dilutive securities" } } }, "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.nwbio.com/role/DisclosureNetEarningsLossPerShareApplicableToCommonStockholdersDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis": { "auth_ref": [ "r129" ], "lang": { "en-us": { "role": { "documentation": "Information by type of antidilutive security.", "label": "Antidilutive Securities [Axis]" } } }, "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.nwbio.com/role/DisclosureNetEarningsLossPerShareApplicableToCommonStockholdersDetails" ], "xbrltype": "stringItemType" }, "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]" } } }, "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.nwbio.com/role/DisclosureNetEarningsLossPerShareApplicableToCommonStockholdersDetails" ], "xbrltype": "stringItemType" }, "us-gaap_AntidilutiveSecuritiesNameDomain": { "auth_ref": [ "r129" ], "lang": { "en-us": { "role": { "documentation": "Incremental common shares attributable to securities that were not included in diluted earnings per share (EPS) because to do so would increase EPS amounts or decrease loss per share amounts for the period presented.", "label": "Antidilutive Securities Name [Domain]", "terseLabel": "Antidilutive Securities, Name [Domain]" } } }, "localname": "AntidilutiveSecuritiesNameDomain", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.nwbio.com/role/DisclosureNetEarningsLossPerShareApplicableToCommonStockholdersDetails" ], "xbrltype": "domainItemType" }, "us-gaap_Assets": { "auth_ref": [ "r97", "r151", "r154", "r160", "r168", "r319", "r324", "r351", "r425", "r439" ], "calculation": { "http://www.nwbio.com/role/StatementConsolidatedBalanceSheets": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.", "label": "Assets", "totalLabel": "TOTAL ASSETS" } } }, "localname": "Assets", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.nwbio.com/role/DisclosureRevisionToPriorPeriodFinancialStatementsConsolidatedBalanceSheetDetails", "http://www.nwbio.com/role/StatementConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_AssetsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Assets [Abstract]", "verboseLabel": "ASSETS" } } }, "localname": "AssetsAbstract", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.nwbio.com/role/StatementConsolidatedBalanceSheets" ], "xbrltype": "stringItemType" }, "us-gaap_AssetsCurrent": { "auth_ref": [ "r3", "r4", "r49", "r97", "r168", "r319", "r324", "r351" ], "calculation": { "http://www.nwbio.com/role/StatementConsolidatedBalanceSheets": { "order": 1.0, "parentTag": "us-gaap_Assets", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.", "label": "Assets, Current", "totalLabel": "Total current assets" } } }, "localname": "AssetsCurrent", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.nwbio.com/role/StatementConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_AssetsCurrentAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Assets, Current [Abstract]", "verboseLabel": "Current assets:" } } }, "localname": "AssetsCurrentAbstract", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.nwbio.com/role/StatementConsolidatedBalanceSheets" ], "xbrltype": "stringItemType" }, "us-gaap_AssetsNoncurrent": { "auth_ref": [ "r8", "r9", "r10", "r11", "r12", "r13", "r14", "r15", "r97", "r168", "r319", "r324", "r351" ], "calculation": { "http://www.nwbio.com/role/StatementConsolidatedBalanceSheets": { "order": 2.0, "parentTag": "us-gaap_Assets", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold or consumed after one year or beyond the normal operating cycle, if longer.", "label": "Assets, Noncurrent", "totalLabel": "Total non-current assets", "verboseLabel": "Total non-current assets" } } }, "localname": "AssetsNoncurrent", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.nwbio.com/role/DisclosureRevisionToPriorPeriodFinancialStatementsConsolidatedBalanceSheetDetails", "http://www.nwbio.com/role/StatementConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_AssetsNoncurrentAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Assets, Noncurrent [Abstract]", "verboseLabel": "Non-current assets:" } } }, "localname": "AssetsNoncurrentAbstract", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.nwbio.com/role/StatementConsolidatedBalanceSheets" ], "xbrltype": "stringItemType" }, "us-gaap_AwardTypeAxis": { "auth_ref": [ "r239", "r261" ], "lang": { "en-us": { "role": { "documentation": "Information by type of award under share-based payment arrangement.", "label": "Award Type [Axis]" } } }, "localname": "AwardTypeAxis", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.nwbio.com/role/DisclosureRelatedPartyTransactionsAdditionalInformationDetails", "http://www.nwbio.com/role/DisclosureStockBasedCompensationAdditionalInformationDetails", "http://www.nwbio.com/role/DisclosureSubsequentEventsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_BasisOfAccountingPolicyPolicyTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for basis of accounting, or basis of presentation, used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS).", "label": "Basis of Accounting, Policy [Policy Text Block]", "verboseLabel": "Basis of Presentation" } } }, "localname": "BasisOfAccountingPolicyPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.nwbio.com/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_BusinessAcquisitionAcquireeDomain": { "auth_ref": [ "r230", "r233" ], "lang": { "en-us": { "role": { "documentation": "Identification of the acquiree in a material business combination (or series of individually immaterial business combinations), which may include the name or other type of identification of the acquiree.", "label": "Business Acquisition Acquiree [Domain]", "terseLabel": "Business Acquisition, Acquiree [Domain]" } } }, "localname": "BusinessAcquisitionAcquireeDomain", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.nwbio.com/role/DisclosureFlaskworksAcquisitionDetails", "http://www.nwbio.com/role/DisclosureStockBasedCompensationAdditionalInformationDetails", "http://www.nwbio.com/role/DisclosureStockholdersDeficitAdditionalInformationDetails" ], "xbrltype": "domainItemType" }, "us-gaap_BusinessAcquisitionAxis": { "auth_ref": [ "r230", "r233", "r305", "r306" ], "lang": { "en-us": { "role": { "documentation": "Information by business combination or series of individually immaterial business combinations.", "label": "Business Acquisition [Axis]" } } }, "localname": "BusinessAcquisitionAxis", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.nwbio.com/role/DisclosureFlaskworksAcquisitionDetails", "http://www.nwbio.com/role/DisclosureStockBasedCompensationAdditionalInformationDetails", "http://www.nwbio.com/role/DisclosureStockholdersDeficitAdditionalInformationDetails" ], "xbrltype": "stringItemType" }, "us-gaap_BusinessAcquisitionLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Business Acquisition [Line Items]" } } }, "localname": "BusinessAcquisitionLineItems", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.nwbio.com/role/DisclosureFlaskworksAcquisitionDetails" ], "xbrltype": "stringItemType" }, "us-gaap_BusinessAcquisitionPercentageOfVotingInterestsAcquired": { "auth_ref": [ "r304" ], "lang": { "en-us": { "role": { "documentation": "Percentage of voting equity interests acquired at the acquisition date in the business combination.", "label": "Business Acquisition, Percentage of Voting Interests Acquired", "terseLabel": "Acquired ownership units percentage" } } }, "localname": "BusinessAcquisitionPercentageOfVotingInterestsAcquired", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.nwbio.com/role/DisclosureFlaskworksAcquisitionDetails" ], "xbrltype": "percentItemType" }, "us-gaap_BusinessAcquisitionSharePrice": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Price of a single share of a number of saleable stocks paid or offered to be paid in a business combination.", "label": "Business Acquisition, Share Price" } } }, "localname": "BusinessAcquisitionSharePrice", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.nwbio.com/role/DisclosureFlaskworksAcquisitionDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_BusinessCombinationConsiderationTransferred1": { "auth_ref": [ "r310", "r311", "r313" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of consideration transferred, consisting of acquisition-date fair value of assets transferred by the acquirer, liabilities incurred by the acquirer, and equity interest issued by the acquirer.", "label": "Business Combination, Consideration Transferred", "terseLabel": "Total purchase price" } } }, "localname": "BusinessCombinationConsiderationTransferred1", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.nwbio.com/role/DisclosureFlaskworksAcquisitionDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_BusinessCombinationConsiderationTransferredEquityInterestsIssuedAndIssuable": { "auth_ref": [ "r310", "r311" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of equity interests of the acquirer, including instruments or interests issued or issuable in consideration for the business combination.", "label": "Business Combination, Consideration Transferred, Equity Interests Issued and Issuable", "netLabel": "Special consideration", "terseLabel": "Purchase price paid in stock" } } }, "localname": "BusinessCombinationConsiderationTransferredEquityInterestsIssuedAndIssuable", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.nwbio.com/role/DisclosureFlaskworksAcquisitionDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_BusinessCombinationConsiderationTransferredOther1": { "auth_ref": [ "r315" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of tangible or intangible assets, including a business or subsidiary of the acquirer transferred by the entity to the former owners of the acquiree. Excludes cash.", "label": "Business Combination, Consideration Transferred, Other" } } }, "localname": "BusinessCombinationConsiderationTransferredOther1", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.nwbio.com/role/DisclosureFlaskworksAcquisitionDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_BusinessCombinationContingentConsiderationLiabilityCurrent": { "auth_ref": [ "r309", "r312" ], "calculation": { "http://www.nwbio.com/role/StatementConsolidatedBalanceSheets": { "order": 6.0, "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of liability recognized arising from contingent consideration in a business combination, expected to be settled within one year or the normal operating cycle, if longer.", "label": "Business Combination, Contingent Consideration, Liability, Current", "terseLabel": "Contingent payable derivative liability" } } }, "localname": "BusinessCombinationContingentConsiderationLiabilityCurrent", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.nwbio.com/role/StatementConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_BusinessCombinationDisclosureTextBlock": { "auth_ref": [ "r316" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for a business combination (or series of individually immaterial business combinations) completed during the period, including background, timing, and recognized assets and liabilities. The disclosure may include leverage buyout transactions (as applicable).", "label": "Business Combination Disclosure [Text Block]", "terseLabel": "Flaskworks Acquisition" } } }, "localname": "BusinessCombinationDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.nwbio.com/role/DisclosureFlaskworksAcquisition" ], "xbrltype": "textBlockItemType" }, "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets": { "auth_ref": [ "r308" ], "calculation": { "http://www.nwbio.com/role/DisclosureFlaskworksAcquisitionDetails": { "order": 1.0, "parentTag": "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of assets acquired at the acquisition date.", "label": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Assets", "totalLabel": "Total assets acquired" } } }, "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.nwbio.com/role/DisclosureFlaskworksAcquisitionDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents": { "auth_ref": [ "r308" ], "calculation": { "http://www.nwbio.com/role/DisclosureFlaskworksAcquisitionDetails": { "order": 1.0, "parentTag": "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of currency on hand as well as demand deposits with banks or financial institutions, acquired at the acquisition date. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.", "label": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Cash and Equivalents", "terseLabel": "Cash" } } }, "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.nwbio.com/role/DisclosureFlaskworksAcquisitionDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsOther": { "auth_ref": [ "r308" ], "calculation": { "http://www.nwbio.com/role/DisclosureFlaskworksAcquisitionDetails": { "order": 2.0, "parentTag": "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of other assets expected to be realized or consumed before one year or the normal operating cycle, if longer, acquired at the acquisition date.", "label": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Current Assets, Other", "terseLabel": "Current assets" } } }, "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsOther", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.nwbio.com/role/DisclosureFlaskworksAcquisitionDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccountsPayable": { "auth_ref": [ "r308" ], "calculation": { "http://www.nwbio.com/role/DisclosureFlaskworksAcquisitionDetails": { "order": 1.0, "parentTag": "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of liabilities incurred for goods and services received that are used in an entity's business and related party payables, assumed at the acquisition date.", "label": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Current Liabilities, Accounts Payable", "negatedLabel": "Accounts payable" } } }, "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccountsPayable", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.nwbio.com/role/DisclosureFlaskworksAcquisitionDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIndefiniteLivedIntangibleAssets": { "auth_ref": [ "r308" ], "calculation": { "http://www.nwbio.com/role/DisclosureFlaskworksAcquisitionDetails": { "order": 3.0, "parentTag": "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of assets, excluding financial assets and goodwill, that lack physical substance, having a projected indefinite period of benefit, acquired at the acquisition date.", "label": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Indefinite-Lived Intangible Assets", "terseLabel": "Indefinite-lived intangible asset" } } }, "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIndefiniteLivedIntangibleAssets", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.nwbio.com/role/DisclosureFlaskworksAcquisitionDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities": { "auth_ref": [ "r308" ], "calculation": { "http://www.nwbio.com/role/DisclosureFlaskworksAcquisitionDetails": { "order": 2.0, "parentTag": "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of liabilities assumed at the acquisition date.", "label": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Liabilities", "negatedTotalLabel": "Total liabilities assumed" } } }, "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.nwbio.com/role/DisclosureFlaskworksAcquisitionDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet": { "auth_ref": [ "r307", "r308" ], "calculation": { "http://www.nwbio.com/role/DisclosureFlaskworksAcquisitionDetails": { "order": 2.0, "parentTag": "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount recognized as of the acquisition date for the identifiable assets acquired in excess of (less than) the aggregate liabilities assumed.", "label": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Net", "totalLabel": "Net identifiable assets acquired" } } }, "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.nwbio.com/role/DisclosureFlaskworksAcquisitionDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPropertyPlantAndEquipment": { "auth_ref": [ "r307", "r308" ], "calculation": { "http://www.nwbio.com/role/DisclosureFlaskworksAcquisitionDetails": { "order": 4.0, "parentTag": "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The amount of property, plant, and equipment recognized as of the acquisition date.", "label": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Property, Plant, and Equipment", "terseLabel": "Fixed assets, net" } } }, "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPropertyPlantAndEquipment", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.nwbio.com/role/DisclosureFlaskworksAcquisitionDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedLessNoncontrollingInterestAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Business Combination, Recognized Identifiable Assets Acquired, Goodwill, and Liabilities Assumed, Less Noncontrolling Interest [Abstract]", "terseLabel": "Assets acquired and liabilities assumed" } } }, "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedLessNoncontrollingInterestAbstract", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.nwbio.com/role/DisclosureFlaskworksAcquisitionDetails" ], "xbrltype": "stringItemType" }, "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet": { "auth_ref": [ "r308" ], "calculation": { "http://www.nwbio.com/role/DisclosureFlaskworksAcquisitionDetails": { "order": 3.0, "parentTag": "nwbo_BusinessCombinationConsiderationTransferredNetOfCashAcquired", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount recognized for assets, including goodwill, in excess of (less than) the aggregate liabilities assumed.", "label": "Business Combination, Recognized Identifiable Assets Acquired, Goodwill, and Liabilities Assumed, Net", "totalLabel": "Total estimated consideration" } } }, "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.nwbio.com/role/DisclosureFlaskworksAcquisitionDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_BusinessCombinationsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Flaskworks Acquisition" } } }, "localname": "BusinessCombinationsAbstract", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "xbrltype": "stringItemType" }, "us-gaap_CashAndCashEquivalentsAtCarryingValue": { "auth_ref": [ "r2", "r32", "r88" ], "calculation": { "http://www.nwbio.com/role/StatementConsolidatedBalanceSheets": { "order": 1.0, "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.", "label": "Cash and Cash Equivalents, at Carrying Value", "periodEndLabel": "Cash and cash equivalents, end of the year", "periodStartLabel": "Cash and cash equivalents, beginning of the year", "verboseLabel": "Cash and cash equivalents" } } }, "localname": "CashAndCashEquivalentsAtCarryingValue", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.nwbio.com/role/StatementConsolidatedBalanceSheets", "http://www.nwbio.com/role/StatementConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect": { "auth_ref": [ "r82", "r355" ], "calculation": { "http://www.nwbio.com/role/StatementConsolidatedStatementsOfCashFlows": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of increase (decrease) in cash, cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.", "label": "Cash and Cash Equivalents, Period Increase (Decrease)", "totalLabel": "Net increase (decrease) in cash and cash equivalents" } } }, "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.nwbio.com/role/StatementConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_CashFDICInsuredAmount": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The amount of cash deposited in financial institutions as of the balance sheet date that is insured by the Federal Deposit Insurance Corporation.", "label": "Cash, FDIC Insured Amount", "verboseLabel": "Federal depository insurance coverage" } } }, "localname": "CashFDICInsuredAmount", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.nwbio.com/role/DisclosureSummaryOfSignificantAccountingPoliciesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Cash Flow, Noncash Investing and Financing Activities Disclosure [Abstract]", "terseLabel": "Supplemental schedule of non-cash investing and financing activities:", "verboseLabel": "Supplemental schedule of non-cash investing and financing activities:" } } }, "localname": "CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.nwbio.com/role/DisclosureRevisionToPriorPeriodFinancialStatementsConsolidatedStatementOfCashFlowsDetaills", "http://www.nwbio.com/role/StatementConsolidatedStatementsOfCashFlows" ], "xbrltype": "stringItemType" }, "us-gaap_CashUninsuredAmount": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The amount of cash as of the balance sheet date that is not insured by the Federal Deposit Insurance Corporation.", "label": "Cash, Uninsured Amount", "verboseLabel": "Cash and cash equivalents uninsured amount" } } }, "localname": "CashUninsuredAmount", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.nwbio.com/role/DisclosureSummaryOfSignificantAccountingPoliciesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_ClassOfStockDomain": { "auth_ref": [ "r95", "r97", "r122", "r123", "r124", "r126", "r128", "r135", "r136", "r137", "r168", "r351" ], "lang": { "en-us": { "role": { "documentation": "Share of stock differentiated by the voting rights the holder receives. Examples include, but are not limited to, common stock, redeemable preferred stock, nonredeemable preferred stock, and convertible stock.", "label": "Class Of Stock [Domain]", "terseLabel": "Class of Stock [Domain]" } } }, "localname": "ClassOfStockDomain", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.nwbio.com/role/DisclosureStockholdersDeficitAdditionalInformationDetails" ], "xbrltype": "domainItemType" }, "us-gaap_ClassOfWarrantOrRightAxis": { "auth_ref": [ "r205", "r236" ], "lang": { "en-us": { "role": { "documentation": "Information by type of warrant or right issued.", "label": "Class of Warrant or Right [Axis]" } } }, "localname": "ClassOfWarrantOrRightAxis", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.nwbio.com/role/DisclosureStockholdersDeficitAdditionalInformationDetails", "http://www.nwbio.com/role/DisclosureSubsequentEventsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ClassOfWarrantOrRightDomain": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Name of the class or type of warrant or right outstanding. Warrants and rights represent derivative securities that give the holder the right to purchase securities (usually equity) from the issuer at a specific price within a certain time frame. Warrants are often included in a new debt issue to entice investors by a higher return potential. The main difference between warrants and call options is that warrants are issued and guaranteed by the company, whereas options are exchange instruments and are not issued by the company. Also, the lifetime of a warrant is often measured in years, while the lifetime of a typical option is measured in months.", "label": "Class Of Warrant Or Right [Domain]", "terseLabel": "Class of Warrant or Right [Domain]" } } }, "localname": "ClassOfWarrantOrRightDomain", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.nwbio.com/role/DisclosureStockholdersDeficitAdditionalInformationDetails", "http://www.nwbio.com/role/DisclosureSubsequentEventsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1": { "auth_ref": [ "r203" ], "lang": { "en-us": { "role": { "documentation": "Exercise price per share or per unit of warrants or rights outstanding.", "label": "Class of Warrant or Right, Exercise Price of Warrants or Rights", "terseLabel": "Warrants exercise price" } } }, "localname": "ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.nwbio.com/role/DisclosureNotesPayableAdditionalInformationDetails", "http://www.nwbio.com/role/DisclosureRelatedPartyTransactionsAdditionalInformationDetails", "http://www.nwbio.com/role/DisclosureStockholdersDeficitAdditionalInformationDetails", "http://www.nwbio.com/role/DisclosureSubsequentEventsDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights": { "auth_ref": [ "r203" ], "lang": { "en-us": { "role": { "documentation": "Number of securities into which the class of warrant or right may be converted. For example, but not limited to, 500,000 warrants may be converted into 1,000,000 shares.", "label": "Class of Warrant or Right, Number of Securities Called by Warrants or Rights", "terseLabel": "Warrants to be issued to holder" } } }, "localname": "ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.nwbio.com/role/DisclosureNotesPayableAdditionalInformationDetails", "http://www.nwbio.com/role/DisclosureStockholdersDeficitAdditionalInformationDetails", "http://www.nwbio.com/role/DisclosureSubsequentEventsDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_ClassOfWarrantOrRightOutstanding": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Number of warrants or rights outstanding.", "label": "Class of Warrant or Right, Outstanding", "periodEndLabel": "Number of Warrants, Outstanding", "periodStartLabel": "Number of Warrants, Outstanding" } } }, "localname": "ClassOfWarrantOrRightOutstanding", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.nwbio.com/role/DisclosureStockholdersDeficitAdditionalInformationDetails", "http://www.nwbio.com/role/DisclosureStockholdersDeficitDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_CommitmentsAndContingencies": { "auth_ref": [ "r47", "r188", "r430", "r446" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Represents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur.", "label": "Commitments and Contingencies", "terseLabel": "COMMITMENTS AND CONTINGENCIES (Note 12)" } } }, "localname": "CommitmentsAndContingencies", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.nwbio.com/role/StatementConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_CommitmentsAndContingenciesDisclosureAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Commitments and Contingencies." } } }, "localname": "CommitmentsAndContingenciesDisclosureAbstract", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "xbrltype": "stringItemType" }, "us-gaap_CommitmentsAndContingenciesDisclosureTextBlock": { "auth_ref": [ "r185", "r186", "r187", "r190" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for commitments and contingencies.", "label": "Commitments and Contingencies Disclosure [Text Block]", "verboseLabel": "Commitments and Contingencies" } } }, "localname": "CommitmentsAndContingenciesDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.nwbio.com/role/DisclosureCommitmentsAndContingencies" ], "xbrltype": "textBlockItemType" }, "us-gaap_CommonStockMember": { "auth_ref": [ "r105", "r106" ], "lang": { "en-us": { "role": { "documentation": "Stock that is subordinate to all other stock of the issuer.", "label": "Common Stock [Member]", "terseLabel": "Common Stock" } } }, "localname": "CommonStockMember", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.nwbio.com/role/DisclosureStockholdersDeficitAdditionalInformationDetails", "http://www.nwbio.com/role/StatementConsolidatedStatementsOfChangesInStockholdersDeficit" ], "xbrltype": "domainItemType" }, "us-gaap_CommonStockParOrStatedValuePerShare": { "auth_ref": [ "r23" ], "lang": { "en-us": { "role": { "documentation": "Face amount or stated value per share of common stock.", "label": "Common Stock, Par or Stated Value Per Share", "verboseLabel": "Common stock, par value (in dollars per share)" } } }, "localname": "CommonStockParOrStatedValuePerShare", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.nwbio.com/role/DisclosureStockholdersDeficitAdditionalInformationDetails", "http://www.nwbio.com/role/StatementConsolidatedBalanceSheetsParenthetical" ], "xbrltype": "perShareItemType" }, "us-gaap_CommonStockShareSubscribedButUnissuedSubscriptionsReceivable": { "auth_ref": [ "r23" ], "calculation": { "http://www.nwbio.com/role/StatementConsolidatedBalanceSheets": { "order": 4.0, "parentTag": "us-gaap_StockholdersEquity", "weight": -1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of subscription receivable from investors who have been allocated common stock.", "label": "Common Stock, Share Subscribed but Unissued, Subscriptions Receivable", "negatedLabel": "Stock subscription receivable" } } }, "localname": "CommonStockShareSubscribedButUnissuedSubscriptionsReceivable", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.nwbio.com/role/StatementConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_CommonStockSharesAuthorized": { "auth_ref": [ "r23" ], "lang": { "en-us": { "role": { "documentation": "The maximum number of common shares permitted to be issued by an entity's charter and bylaws.", "label": "Common Stock, Shares Authorized", "verboseLabel": "Common stock, shares authorized" } } }, "localname": "CommonStockSharesAuthorized", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.nwbio.com/role/DisclosureStockholdersDeficitAdditionalInformationDetails", "http://www.nwbio.com/role/StatementConsolidatedBalanceSheetsParenthetical" ], "xbrltype": "sharesItemType" }, "us-gaap_CommonStockSharesIssued": { "auth_ref": [ "r23" ], "lang": { "en-us": { "role": { "documentation": "Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.", "label": "Common Stock, Shares, Issued", "verboseLabel": "Common stock, shares issued" } } }, "localname": "CommonStockSharesIssued", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.nwbio.com/role/DisclosureStockholdersDeficitAdditionalInformationDetails", "http://www.nwbio.com/role/StatementConsolidatedBalanceSheetsParenthetical" ], "xbrltype": "sharesItemType" }, "us-gaap_CommonStockSharesOutstanding": { "auth_ref": [ "r23", "r202" ], "lang": { "en-us": { "role": { "documentation": "Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.", "label": "Common Stock, Shares, Outstanding", "verboseLabel": "Common stock, shares outstanding" } } }, "localname": "CommonStockSharesOutstanding", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.nwbio.com/role/StatementConsolidatedBalanceSheetsParenthetical" ], "xbrltype": "sharesItemType" }, "us-gaap_CommonStockValue": { "auth_ref": [ "r23" ], "calculation": { "http://www.nwbio.com/role/StatementConsolidatedBalanceSheets": { "order": 2.0, "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity.", "label": "Common Stock, Value, Issued", "verboseLabel": "Common stock ($0.001 par value); 1,200,000,000 shares authorized; 829.6 million and 614.3 million shares issued and outstanding as of December 31, 2020 and 2019, respectively" } } }, "localname": "CommonStockValue", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.nwbio.com/role/StatementConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_ComprehensiveIncomeNetOfTax": { "auth_ref": [ "r60", "r62", "r63", "r68", "r432", "r450" ], "calculation": { "http://www.nwbio.com/role/StatementCondensedConsolidatedStatementsOfOperationsCalc2": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income, attributable to parent entity. Excludes changes in equity resulting from investments by owners and distributions to owners.", "label": "Comprehensive Income (Loss), Net of Tax, Attributable to Parent", "totalLabel": "Total comprehensive loss" } } }, "localname": "ComprehensiveIncomeNetOfTax", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.nwbio.com/role/DisclosureRevisionToPriorPeriodFinancialStatementsConsolidatedStatementOfOperationsDetaills", "http://www.nwbio.com/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss" ], "xbrltype": "monetaryItemType" }, "us-gaap_ConcentrationRiskCreditRisk": { "auth_ref": [ "r140", "r437" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for credit risk.", "label": "Concentration Risk, Credit Risk, Policy [Policy Text Block]", "verboseLabel": "Concentration of Credit Risk" } } }, "localname": "ConcentrationRiskCreditRisk", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.nwbio.com/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_ConsolidationPolicyTextBlock": { "auth_ref": [ "r93", "r321" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy regarding (1) the principles it follows in consolidating or combining the separate financial statements, including the principles followed in determining the inclusion or exclusion of subsidiaries or other entities in the consolidated or combined financial statements and (2) its treatment of interests (for example, common stock, a partnership interest or other means of exerting influence) in other entities, for example consolidation or use of the equity or cost methods of accounting. The accounting policy may also address the accounting treatment for intercompany accounts and transactions, noncontrolling interest, and the income statement treatment in consolidation for issuances of stock by a subsidiary.", "label": "Consolidation, Policy [Policy Text Block]", "terseLabel": "Consolidation" } } }, "localname": "ConsolidationPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.nwbio.com/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_ContractualInterestExpenseOnPrepetitionLiabilitiesNotRecognizedInStatementOfOperations": { "auth_ref": [ "r395", "r396" ], "calculation": { "http://www.nwbio.com/role/DisclosureRelatedPartyTransactionsTotalInterestExpensesDetails": { "order": 1.0, "parentTag": "us-gaap_InterestAndDebtExpense", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The amount of contractual interest expense on prepetition liabilities not included in the statement of operations.", "label": "Contractual Interest Expense on Prepetition Liabilities Not Recognized in Statement of Operations", "terseLabel": "Contractual interest" } } }, "localname": "ContractualInterestExpenseOnPrepetitionLiabilitiesNotRecognizedInStatementOfOperations", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.nwbio.com/role/DisclosureNotesPayableMortgageLoanDetails", "http://www.nwbio.com/role/DisclosureRelatedPartyTransactionsTotalInterestExpensesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_ConvertibleDebtFairValueDisclosures": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Fair value portion of borrowing which can be exchanged for a specified number of another security at the option of the issuer or the holder, for example, but not limited to, the entity's common stock.", "label": "Convertible Debt, Fair Value Disclosures", "verboseLabel": "Fair value of debt converted" } } }, "localname": "ConvertibleDebtFairValueDisclosures", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.nwbio.com/role/DisclosureNotesPayableAdditionalInformationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_ConvertibleDebtMember": { "auth_ref": [ "r193" ], "lang": { "en-us": { "role": { "documentation": "Borrowing which can be exchanged for a specified number of another security at the option of the issuer or the holder, for example, but not limited to, the entity's common stock.", "label": "Convertible Debt [Member]", "terseLabel": "Note [Member]" } } }, "localname": "ConvertibleDebtMember", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.nwbio.com/role/DisclosureSubsequentEventsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_ConvertibleDebtSecuritiesMember": { "auth_ref": [ "r221" ], "lang": { "en-us": { "role": { "documentation": "Debt securities that can be exchanged for equity of the debt issuer at the option of the issuer or the holder.", "label": "Convertible Debt Securities [Member]", "terseLabel": "Convertible Debt Securities [Member]" } } }, "localname": "ConvertibleDebtSecuritiesMember", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.nwbio.com/role/DisclosureStockholdersDeficitAdditionalInformationDetails", "http://www.nwbio.com/role/DisclosureSubsequentEventsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_ConvertibleLongTermNotesPayable": { "auth_ref": [ "r46" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Carrying value as of the balance sheet date of long-term debt (with maturities initially due after one year or beyond the operating cycle if longer) identified as Convertible Notes Payable, excluding current portion. Convertible Notes Payable is a written promise to pay a note which can be exchanged for a specified amount of another, related security, at the option of the issuer and the holder.", "label": "Convertible Notes Payable, Noncurrent", "verboseLabel": "Convertible notes payable" } } }, "localname": "ConvertibleLongTermNotesPayable", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.nwbio.com/role/DisclosureRelatedPartyTransactionsAdditionalInformationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_ConvertibleNotesPayableMember": { "auth_ref": [ "r17", "r426", "r438", "r467" ], "lang": { "en-us": { "role": { "documentation": "Written promise to pay a note which can be exchanged for a specified quantity of securities (typically common stock), at the option of the issuer or the holder.", "label": "Convertible Notes Payable [Member]", "terseLabel": "Convertible notes payable" } } }, "localname": "ConvertibleNotesPayableMember", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.nwbio.com/role/DisclosureStockholdersDeficitAdditionalInformationDetails", "http://www.nwbio.com/role/StatementConsolidatedStatementsOfCashFlows" ], "xbrltype": "domainItemType" }, "us-gaap_ConvertiblePreferredStockMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Preferred stock that may be exchanged into common shares or other types of securities at the owner's option.", "label": "Convertible Preferred Stock [Member]", "terseLabel": "Convertible Preferred Stock [Member]" } } }, "localname": "ConvertiblePreferredStockMember", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.nwbio.com/role/DisclosureStockholdersDeficitAdditionalInformationDetails" ], "xbrltype": "domainItemType" }, "us-gaap_CostsAndExpensesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Costs and Expenses [Abstract]", "verboseLabel": "Operating costs and expenses:" } } }, "localname": "CostsAndExpensesAbstract", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.nwbio.com/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss" ], "xbrltype": "stringItemType" }, "us-gaap_CurrentFederalTaxExpenseBenefit": { "auth_ref": [ "r98", "r290", "r297" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of current federal tax expense (benefit) pertaining to income (loss) from continuing operations.", "label": "Current Federal Tax Expense (Benefit)", "verboseLabel": "Current" } } }, "localname": "CurrentFederalTaxExpenseBenefit", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.nwbio.com/role/DisclosureIncomeTaxesSummaryOfTaxProvisionBenefitDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_CurrentForeignTaxExpenseBenefit": { "auth_ref": [ "r102", "r290" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of current foreign income tax expense (benefit) pertaining to income (loss) from continuing operations.", "label": "Current Foreign Tax Expense (Benefit)", "verboseLabel": "Current" } } }, "localname": "CurrentForeignTaxExpenseBenefit", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.nwbio.com/role/DisclosureIncomeTaxesSummaryOfTaxProvisionBenefitDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_CurrentStateAndLocalTaxExpenseBenefit": { "auth_ref": [ "r98", "r290", "r297" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of current state and local tax expense (benefit) pertaining to income (loss) from continuing operations.", "label": "Current State and Local Tax Expense (Benefit)", "verboseLabel": "Current" } } }, "localname": "CurrentStateAndLocalTaxExpenseBenefit", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.nwbio.com/role/DisclosureIncomeTaxesSummaryOfTaxProvisionBenefitDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DebtConversionConvertedInstrumentAmount1": { "auth_ref": [ "r90", "r92" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The value of the financial instrument(s) that the original debt is being converted into in a noncash (or part noncash) transaction. \"Part noncash\" refers to that portion of the transaction not resulting in cash receipts or cash payments in the period.", "label": "Debt Conversion, Converted Instrument, Amount" } } }, "localname": "DebtConversionConvertedInstrumentAmount1", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.nwbio.com/role/DisclosureNotesPayableAdditionalInformationDetails", "http://www.nwbio.com/role/DisclosureStockholdersDeficitAdditionalInformationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DebtConversionConvertedInstrumentSharesIssued1": { "auth_ref": [ "r90", "r92" ], "lang": { "en-us": { "role": { "documentation": "The number of shares issued in exchange for the original debt being converted in a noncash (or part noncash) transaction. \"Part noncash\" refers to that portion of the transaction not resulting in cash receipts or payments in the period.", "label": "Debt Conversion, Converted Instrument, Shares Issued", "terseLabel": "Shares issued upon conversion" } } }, "localname": "DebtConversionConvertedInstrumentSharesIssued1", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.nwbio.com/role/DisclosureNotesPayableAdditionalInformationDetails", "http://www.nwbio.com/role/DisclosureStockholdersDeficitAdditionalInformationDetails", "http://www.nwbio.com/role/DisclosureSubsequentEventsDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_DebtConversionConvertedInstrumentWarrantsOrOptionsIssued1": { "auth_ref": [ "r90", "r92" ], "lang": { "en-us": { "role": { "documentation": "The number of warrants issued in exchange for the original debt being converted in a noncash (or part noncash) transaction. \"Part noncash\" refers to that portion of the transaction not resulting in cash receipts or cash payments in the period.", "label": "Debt Conversion, Converted Instrument, Warrants or Options Issued", "terseLabel": "Number of warrants issued", "verboseLabel": "Det converted to warrants (in shares)" } } }, "localname": "DebtConversionConvertedInstrumentWarrantsOrOptionsIssued1", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.nwbio.com/role/DisclosureNotesPayableAdditionalInformationDetails", "http://www.nwbio.com/role/DisclosureStockholdersDeficitAdditionalInformationDetails", "http://www.nwbio.com/role/DisclosureSubsequentEventsDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_DebtConversionOriginalDebtAmount1": { "auth_ref": [ "r90", "r92" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The amount of the original debt being converted in a noncash (or part noncash) transaction. \"Part noncash\" refers to that portion of the transaction not resulting in cash receipts or cash payments in the period.", "label": "Debt Conversion, Original Debt, Amount", "terseLabel": "Debt amount converted", "verboseLabel": "Amount of debt converted" } } }, "localname": "DebtConversionOriginalDebtAmount1", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.nwbio.com/role/DisclosureNotesPayableAdditionalInformationDetails", "http://www.nwbio.com/role/DisclosureStockholdersDeficitAdditionalInformationDetails", "http://www.nwbio.com/role/DisclosureSubsequentEventsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DebtDisclosureAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Notes Payable" } } }, "localname": "DebtDisclosureAbstract", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "xbrltype": "stringItemType" }, "us-gaap_DebtDisclosureTextBlock": { "auth_ref": [ "r200" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for information about short-term and long-term debt arrangements, which includes amounts of borrowings under each line of credit, note payable, commercial paper issue, bonds indenture, debenture issue, own-share lending arrangements and any other contractual agreement to repay funds, and about the underlying arrangements, rationale for a classification as long-term, including repayment terms, interest rates, collateral provided, restrictions on use of assets and activities, whether or not in compliance with debt covenants, and other matters important to users of the financial statements, such as the effects of refinancing and noncompliance with debt covenants.", "label": "Debt Disclosure [Text Block]", "verboseLabel": "Notes Payable" } } }, "localname": "DebtDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.nwbio.com/role/DisclosureNotesPayable" ], "xbrltype": "textBlockItemType" }, "us-gaap_DebtInstrumentAxis": { "auth_ref": [ "r17", "r18", "r19", "r426", "r427", "r438" ], "lang": { "en-us": { "role": { "documentation": "Information by type of debt instrument, including, but not limited to, draws against credit facilities.", "label": "Debt Instrument [Axis]" } } }, "localname": "DebtInstrumentAxis", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.nwbio.com/role/DisclosureNotesPayableAdditionalInformationDetails", "http://www.nwbio.com/role/DisclosureStockholdersDeficitAdditionalInformationDetails", "http://www.nwbio.com/role/DisclosureSubsequentEventsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_DebtInstrumentConvertibleConversionPrice1": { "auth_ref": [ "r195" ], "lang": { "en-us": { "role": { "documentation": "The price per share of the conversion feature embedded in the debt instrument.", "label": "Debt Instrument, Convertible, Conversion Price", "terseLabel": "Conversion price", "verboseLabel": "Debt Instrument, Conversion Price" } } }, "localname": "DebtInstrumentConvertibleConversionPrice1", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.nwbio.com/role/DisclosureNotesPayableAdditionalInformationDetails", "http://www.nwbio.com/role/DisclosureNotesPayableDetails", "http://www.nwbio.com/role/DisclosureStockholdersDeficitAdditionalInformationDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_DebtInstrumentFaceAmount": { "auth_ref": [ "r368", "r370" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Face (par) amount of debt instrument at time of issuance.", "label": "Debt Instrument, Face Amount", "terseLabel": "Principal amount", "verboseLabel": "Debt Instrument, Face Value" } } }, "localname": "DebtInstrumentFaceAmount", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.nwbio.com/role/DisclosureNotesPayableAdditionalInformationDetails", "http://www.nwbio.com/role/DisclosureNotesPayableDetails", "http://www.nwbio.com/role/DisclosureNotesPayableSummaryOfCompanySContractualObligationsOnDebtPrincipalDetails", "http://www.nwbio.com/role/DisclosureStockholdersDeficitAdditionalInformationDetails", "http://www.nwbio.com/role/DisclosureSubsequentEventsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DebtInstrumentFairValue": { "auth_ref": [ "r350" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Fair value portion of debt instrument payable, including, but not limited to, notes payable and loans payable.", "label": "Debt Instrument, Fair Value Disclosure" } } }, "localname": "DebtInstrumentFairValue", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.nwbio.com/role/DisclosureStockholdersDeficitAdditionalInformationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DebtInstrumentIncreaseAccruedInterest": { "auth_ref": [ "r101" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Increase for accrued, but unpaid interest on the debt instrument for the period.", "label": "Debt Instrument, Increase, Accrued Interest" } } }, "localname": "DebtInstrumentIncreaseAccruedInterest", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.nwbio.com/role/DisclosureNotesPayableAdditionalInformationDetails", "http://www.nwbio.com/role/DisclosureStockholdersDeficitAdditionalInformationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DebtInstrumentInterestRateStatedPercentage": { "auth_ref": [ "r44" ], "lang": { "en-us": { "role": { "documentation": "Contractual interest rate for funds borrowed, under the debt agreement.", "label": "Debt Instrument, Interest Rate, Stated Percentage", "terseLabel": "Interest rate", "verboseLabel": "Debt Instrument, Stated Interest Rate" } } }, "localname": "DebtInstrumentInterestRateStatedPercentage", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.nwbio.com/role/DisclosureNotesPayableAdditionalInformationDetails", "http://www.nwbio.com/role/DisclosureNotesPayableDetails", "http://www.nwbio.com/role/DisclosureRelatedPartyTransactionsAdditionalInformationDetails", "http://www.nwbio.com/role/DisclosureSubsequentEventsDetails" ], "xbrltype": "percentItemType" }, "us-gaap_DebtInstrumentMaturityDateDescription": { "auth_ref": [ "r45" ], "lang": { "en-us": { "role": { "documentation": "Description of the maturity date of the debt instrument including whether the debt matures serially and, if so, a brief description of the serial maturities.", "label": "Debt Instrument, Maturity Date, Description" } } }, "localname": "DebtInstrumentMaturityDateDescription", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.nwbio.com/role/DisclosureNotesPayableDetails" ], "xbrltype": "stringItemType" }, "us-gaap_DebtInstrumentNameDomain": { "auth_ref": [ "r46" ], "lang": { "en-us": { "role": { "documentation": "The name for the particular debt instrument or borrowing that distinguishes it from other debt instruments or borrowings, including draws against credit facilities.", "label": "Debt Instrument Name [Domain]", "terseLabel": "Debt Instrument, Name [Domain]" } } }, "localname": "DebtInstrumentNameDomain", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.nwbio.com/role/DisclosureNotesPayableAdditionalInformationDetails", "http://www.nwbio.com/role/DisclosureStockholdersDeficitAdditionalInformationDetails", "http://www.nwbio.com/role/DisclosureSubsequentEventsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_DebtInstrumentRedemptionPeriodAxis": { "auth_ref": [ "r436" ], "lang": { "en-us": { "role": { "documentation": "Information about timing of debt redemption features under terms of the debt agreement.", "label": "Debt Instrument, Redemption, Period [Axis]" } } }, "localname": "DebtInstrumentRedemptionPeriodAxis", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.nwbio.com/role/DisclosureNotesPayableSummaryOfCompanySContractualObligationsOnDebtPrincipalDetails" ], "xbrltype": "stringItemType" }, "us-gaap_DebtInstrumentRedemptionPeriodDomain": { "auth_ref": [ "r436" ], "lang": { "en-us": { "role": { "documentation": "Period as defined under terms of the debt agreement for debt redemption features.", "label": "Debt Instrument Redemption Period [Domain]", "terseLabel": "Debt Instrument, Redemption, Period [Domain]" } } }, "localname": "DebtInstrumentRedemptionPeriodDomain", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.nwbio.com/role/DisclosureNotesPayableSummaryOfCompanySContractualObligationsOnDebtPrincipalDetails" ], "xbrltype": "domainItemType" }, "us-gaap_DebtInstrumentTerm": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Period of time between issuance and maturity of debt instrument, in PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.", "label": "Debt Instrument, Term.", "terseLabel": "Debt instrument term" } } }, "localname": "DebtInstrumentTerm", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.nwbio.com/role/DisclosureNotesPayableAdditionalInformationDetails", "http://www.nwbio.com/role/DisclosureRelatedPartyTransactionsAdditionalInformationDetails", "http://www.nwbio.com/role/DisclosureSubsequentEventsDetails" ], "xbrltype": "durationItemType" }, "us-gaap_DebtInstrumentUnamortizedDiscount": { "auth_ref": [ "r367", "r370" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount, after accumulated amortization, of debt discount.", "label": "Debt Instrument, Unamortized Discount", "negatedLabel": "Debt Instrument, Remaining Debt Discount" } } }, "localname": "DebtInstrumentUnamortizedDiscount", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.nwbio.com/role/DisclosureNotesPayableAdditionalInformationDetails", "http://www.nwbio.com/role/DisclosureNotesPayableDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DebtPolicyTextBlock": { "auth_ref": [ "r93", "r191" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy related to debt. Includes, but is not limited to, debt issuance costs, the effects of refinancings, method of amortizing debt issuance costs and original issue discount, and classifications of debt.", "label": "Debt, Policy [Policy Text Block]", "terseLabel": "Debt" } } }, "localname": "DebtPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.nwbio.com/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_DeferredFederalIncomeTaxExpenseBenefit": { "auth_ref": [ "r98", "r291", "r297" ], "calculation": { "http://www.nwbio.com/role/DisclosureIncomeTaxesSummaryOfTaxProvisionBenefitDetails": { "order": 1.0, "parentTag": "us-gaap_IncomeTaxExpenseBenefit", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of deferred federal income tax expense (benefit) pertaining to income (loss) from continuing operations.", "label": "Deferred Federal Income Tax Expense (Benefit)", "verboseLabel": "Deferred" } } }, "localname": "DeferredFederalIncomeTaxExpenseBenefit", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.nwbio.com/role/DisclosureIncomeTaxesSummaryOfTaxProvisionBenefitDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DeferredForeignIncomeTaxExpenseBenefit": { "auth_ref": [ "r98", "r291", "r297" ], "calculation": { "http://www.nwbio.com/role/DisclosureIncomeTaxesSummaryOfTaxProvisionBenefitDetails": { "order": 3.0, "parentTag": "us-gaap_IncomeTaxExpenseBenefit", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of deferred foreign income tax expense (benefit) pertaining to income (loss) from continuing operations.", "label": "Deferred Foreign Income Tax Expense (Benefit)", "verboseLabel": "Deferred" } } }, "localname": "DeferredForeignIncomeTaxExpenseBenefit", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.nwbio.com/role/DisclosureIncomeTaxesSummaryOfTaxProvisionBenefitDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit": { "auth_ref": [ "r98", "r291", "r297" ], "calculation": { "http://www.nwbio.com/role/DisclosureIncomeTaxesSummaryOfTaxProvisionBenefitDetails": { "order": 2.0, "parentTag": "us-gaap_IncomeTaxExpenseBenefit", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of deferred state and local tax expense (benefit) pertaining to income (loss) from continuing operations.", "label": "Deferred State and Local Income Tax Expense (Benefit)", "terseLabel": "Deferred" } } }, "localname": "DeferredStateAndLocalIncomeTaxExpenseBenefit", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.nwbio.com/role/DisclosureIncomeTaxesSummaryOfTaxProvisionBenefitDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DeferredTaxAssetsGross": { "auth_ref": [ "r282" ], "calculation": { "http://www.nwbio.com/role/DisclosureIncomeTaxesSummaryOfDeferredTaxAssetsAndLiabilitiesDetails": { "order": 1.0, "parentTag": "us-gaap_DeferredTaxAssetsNet", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences and carryforwards.", "label": "Deferred Tax Assets, Gross", "totalLabel": "Total deferred tax assets" } } }, "localname": "DeferredTaxAssetsGross", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.nwbio.com/role/DisclosureIncomeTaxesSummaryOfDeferredTaxAssetsAndLiabilitiesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment": { "auth_ref": [ "r288", "r289" ], "calculation": { "http://www.nwbio.com/role/DisclosureIncomeTaxesSummaryOfDeferredTaxAssetsAndLiabilitiesDetails": { "order": 2.0, "parentTag": "us-gaap_DeferredTaxAssetsGross", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from in-process research and development costs expensed in connection with a business combination.", "label": "Deferred Tax Assets, in Process Research and Development", "verboseLabel": "Research and development credit carry forwards" } } }, "localname": "DeferredTaxAssetsInProcessResearchAndDevelopment", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.nwbio.com/role/DisclosureIncomeTaxesSummaryOfDeferredTaxAssetsAndLiabilitiesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DeferredTaxAssetsNet": { "auth_ref": [ "r284" ], "calculation": { "http://www.nwbio.com/role/DisclosureIncomeTaxesSummaryOfDeferredTaxAssetsAndLiabilitiesDetails": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount after allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences and carryforwards.", "label": "Deferred Tax Assets, Net of Valuation Allowance", "totalLabel": "Deferred tax asset, net of allowance" } } }, "localname": "DeferredTaxAssetsNet", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.nwbio.com/role/DisclosureIncomeTaxesSummaryOfDeferredTaxAssetsAndLiabilitiesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DeferredTaxAssetsNetOfValuationAllowanceAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Deferred Tax Assets, Net of Valuation Allowance [Abstract]", "verboseLabel": "Deferred tax asset" } } }, "localname": "DeferredTaxAssetsNetOfValuationAllowanceAbstract", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.nwbio.com/role/DisclosureIncomeTaxesSummaryOfDeferredTaxAssetsAndLiabilitiesDetails" ], "xbrltype": "stringItemType" }, "us-gaap_DeferredTaxAssetsOperatingLossCarryforwards": { "auth_ref": [ "r288", "r289" ], "calculation": { "http://www.nwbio.com/role/DisclosureIncomeTaxesSummaryOfDeferredTaxAssetsAndLiabilitiesDetails": { "order": 1.0, "parentTag": "us-gaap_DeferredTaxAssetsGross", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible operating loss carryforwards.", "label": "Deferred Tax Assets, Operating Loss Carryforwards", "verboseLabel": "Net operating loss carryforward" } } }, "localname": "DeferredTaxAssetsOperatingLossCarryforwards", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.nwbio.com/role/DisclosureIncomeTaxesSummaryOfDeferredTaxAssetsAndLiabilitiesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DeferredTaxAssetsOther": { "auth_ref": [ "r288", "r289" ], "calculation": { "http://www.nwbio.com/role/DisclosureIncomeTaxesSummaryOfDeferredTaxAssetsAndLiabilitiesDetails": { "order": 3.0, "parentTag": "us-gaap_DeferredTaxAssetsGross", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount, before allocation of valuation allowance, of deferred tax asset attributable to deductible temporary differences, classified as other.", "label": "Deferred Tax Assets, Other", "verboseLabel": "Stock based compensation and other" } } }, "localname": "DeferredTaxAssetsOther", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.nwbio.com/role/DisclosureIncomeTaxesSummaryOfDeferredTaxAssetsAndLiabilitiesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsForeign": { "auth_ref": [ "r287", "r288", "r289" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible foreign tax credit carryforwards.", "label": "Deferred Tax Assets, Tax Credit Carryforwards, Foreign" } } }, "localname": "DeferredTaxAssetsTaxCreditCarryforwardsForeign", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.nwbio.com/role/DisclosureIncomeTaxesAdditionalInformationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch": { "auth_ref": [ "r287", "r288", "r289" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible research tax credit carryforwards.", "label": "Deferred Tax Assets, Tax Credit Carryforwards, Research" } } }, "localname": "DeferredTaxAssetsTaxCreditCarryforwardsResearch", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.nwbio.com/role/DisclosureIncomeTaxesAdditionalInformationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DeferredTaxAssetsValuationAllowance": { "auth_ref": [ "r283" ], "calculation": { "http://www.nwbio.com/role/DisclosureIncomeTaxesSummaryOfDeferredTaxAssetsAndLiabilitiesDetails": { "order": 2.0, "parentTag": "us-gaap_DeferredTaxAssetsNet", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of deferred tax assets for which it is more likely than not that a tax benefit will not be realized.", "label": "Deferred Tax Assets, Valuation Allowance", "negatedLabel": "Valuation Allowance" } } }, "localname": "DeferredTaxAssetsValuationAllowance", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.nwbio.com/role/DisclosureIncomeTaxesSummaryOfDeferredTaxAssetsAndLiabilitiesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_Depreciation": { "auth_ref": [ "r86", "r179" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The amount of expense recognized in the current period that reflects the allocation of the cost of tangible assets over the assets' useful lives. Includes production and non-production related depreciation.", "label": "Depreciation" } } }, "localname": "Depreciation", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.nwbio.com/role/DisclosurePropertyPlantAndEquipmentAdditionalInformationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DepreciationAndAmortization": { "auth_ref": [ "r86", "r179" ], "calculation": { "http://www.nwbio.com/role/StatementConsolidatedStatementsOfCashFlows": { "order": 1.0, "parentTag": "us-gaap_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The current period expense charged against earnings on long-lived, physical assets not used in production, and which are not intended for resale, to allocate or recognize the cost of such assets over their useful lives; or to record the reduction in book value of an intangible asset over the benefit period of such asset; or to reflect consumption during the period of an asset that is not used in production.", "label": "Depreciation, Depletion and Amortization, Nonproduction", "verboseLabel": "Depreciation and amortization" } } }, "localname": "DepreciationAndAmortization", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.nwbio.com/role/StatementConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_DerivativeContractTypeDomain": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Financial instrument or contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset.", "label": "Derivative Contract Type [Domain]", "terseLabel": "Derivative Contract [Domain]" } } }, "localname": "DerivativeContractTypeDomain", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.nwbio.com/role/DisclosureFairValueMeasurementsChangesInLevel3LiabilitiesDetails", "http://www.nwbio.com/role/DisclosureFairValueMeasurementsWeightedAverageInAggregateSignificantUnobservableInputsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_DerivativeGainLossOnDerivativeNet": { "auth_ref": [ "r331" ], "calculation": { "http://www.nwbio.com/role/StatementConsolidatedStatementsOfCashFlows": { "order": 5.0, "parentTag": "us-gaap_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivities", "weight": -1.0 }, "http://www.nwbio.com/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss": { "order": 1.0, "parentTag": "us-gaap_OtherNonoperatingIncomeExpense", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of increase (decrease) in the fair value of derivatives recognized in the income statement.", "label": "Derivative, Gain (Loss) on Derivative, Net", "negatedLabel": "Change in fair value of derivatives", "verboseLabel": "Change in fair value of derivative liabilities" } } }, "localname": "DerivativeGainLossOnDerivativeNet", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.nwbio.com/role/StatementConsolidatedStatementsOfCashFlows", "http://www.nwbio.com/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss" ], "xbrltype": "monetaryItemType" }, "us-gaap_DerivativeInstrumentRiskAxis": { "auth_ref": [ "r330", "r333", "r334", "r335" ], "lang": { "en-us": { "role": { "documentation": "Information by type of derivative contract.", "label": "Derivative Instrument [Axis]" } } }, "localname": "DerivativeInstrumentRiskAxis", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.nwbio.com/role/DisclosureFairValueMeasurementsChangesInLevel3LiabilitiesDetails", "http://www.nwbio.com/role/DisclosureFairValueMeasurementsWeightedAverageInAggregateSignificantUnobservableInputsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_DerivativeLiabilitiesCurrent": { "auth_ref": [ "r50" ], "calculation": { "http://www.nwbio.com/role/DisclosureFairValueMeasurementsDetails": { "order": 1.0, "parentTag": "us-gaap_LiabilitiesFairValueDisclosure", "weight": 1.0 }, "http://www.nwbio.com/role/StatementConsolidatedBalanceSheets": { "order": 7.0, "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Fair value, after the effects of master netting arrangements, of a financial liability or contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset, expected to be settled within one year or normal operating cycle, if longer. Includes assets not subject to a master netting arrangement and not elected to be offset.", "label": "Derivative Liability, Current", "terseLabel": "Warrant liability" } } }, "localname": "DerivativeLiabilitiesCurrent", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.nwbio.com/role/DisclosureFairValueMeasurementsDetails", "http://www.nwbio.com/role/StatementConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_DerivativesEmbeddedDerivatives": { "auth_ref": [ "r93", "r327", "r328", "r336", "r337" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for embedded derivatives, including how such derivatives are identified and analyzed for possible separation from their host contracts.", "label": "Derivatives, Embedded Derivatives [Policy Text Block]", "terseLabel": "Embedded Conversion Features" } } }, "localname": "DerivativesEmbeddedDerivatives", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.nwbio.com/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_DerivativesReportingOfDerivativeActivity": { "auth_ref": [ "r93", "r329" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for derivatives entered into for trading purposes and those entered into for purposes other than trading including where and when derivative financial instruments and derivative commodity instruments and their related gains or losses are reported in the entity's statements of financial position, cash flows, and results of operations.", "label": "Derivatives, Reporting of Derivative Activity [Policy Text Block]", "terseLabel": "Derivative Financial Instruments" } } }, "localname": "DerivativesReportingOfDerivativeActivity", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.nwbio.com/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock": { "auth_ref": [ "r271" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for share-based payment arrangement.", "label": "Disclosure of Compensation Related Costs, Share-based Payments [Text Block]", "terseLabel": "Stock-based Compensation" } } }, "localname": "DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.nwbio.com/role/DisclosureStockBasedCompensation" ], "xbrltype": "textBlockItemType" }, "us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Stock-based Compensation" } } }, "localname": "DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "xbrltype": "stringItemType" }, "us-gaap_EarningsPerShareAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Net Loss per Share Applicable to Common Stockholders" } } }, "localname": "EarningsPerShareAbstract", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "xbrltype": "stringItemType" }, "us-gaap_EarningsPerShareBasicAndDiluted": { "auth_ref": [ "r127" ], "lang": { "en-us": { "role": { "documentation": "The amount of net income or loss for the period per each share in instances when basic and diluted earnings per share are the same amount and reported as a single line item on the face of the financial statements. Basic earnings per share is the amount of net income or loss for the period per each share of common stock or unit outstanding during the reporting period. Diluted earnings per share includes the amount of net income or loss for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.", "label": "Earnings Per Share, Basic and Diluted", "verboseLabel": "Net loss per share applicable to common stockholders - basic and diluted" } } }, "localname": "EarningsPerShareBasicAndDiluted", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.nwbio.com/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss" ], "xbrltype": "perShareItemType" }, "us-gaap_EarningsPerSharePolicyTextBlock": { "auth_ref": [ "r93", "r129", "r130" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for computing basic and diluted earnings or loss per share for each class of common stock and participating security. Addresses all significant policy factors, including any antidilutive items that have been excluded from the computation and takes into account stock dividends, splits and reverse splits that occur after the balance sheet date of the latest reporting period but before the issuance of the financial statements.", "label": "Earnings Per Share, Policy [Policy Text Block]", "terseLabel": "Loss per Share" } } }, "localname": "EarningsPerSharePolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.nwbio.com/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_EarningsPerShareTextBlock": { "auth_ref": [ "r129", "r130", "r131", "r133" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for earnings per share.", "label": "Earnings Per Share [Text Block]", "verboseLabel": "Net Loss per Share Applicable to Common Stockholders" } } }, "localname": "EarningsPerShareTextBlock", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.nwbio.com/role/DisclosureNetLossPerShareApplicableToCommonStockholders" ], "xbrltype": "textBlockItemType" }, "us-gaap_EffectOfExchangeRateOnCashAndCashEquivalents": { "auth_ref": [ "r355" ], "calculation": { "http://www.nwbio.com/role/StatementConsolidatedStatementsOfCashFlows": { "order": 2.0, "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of increase (decrease) from the effect of exchange rate changes on cash and cash equivalent balances held in foreign currencies.", "label": "Effect of Exchange Rate on Cash and Cash Equivalents", "verboseLabel": "Effect of exchange rate changes on cash and cash equivalents" } } }, "localname": "EffectOfExchangeRateOnCashAndCashEquivalents", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.nwbio.com/role/StatementConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_EffectiveIncomeTaxRateContinuingOperations": { "auth_ref": [ "r276" ], "lang": { "en-us": { "role": { "documentation": "Percentage of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.", "label": "Effective Income Tax Rate Reconciliation, Percent", "verboseLabel": "Income tax provision (benefit)" } } }, "localname": "EffectiveIncomeTaxRateContinuingOperations", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.nwbio.com/role/DisclosureIncomeTaxesReconcilationOfUsFederalStatutoryTaxExpenseBenefitDetails" ], "xbrltype": "percentItemType" }, "us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate": { "auth_ref": [ "r276", "r298" ], "lang": { "en-us": { "role": { "documentation": "Percentage of domestic federal statutory tax rate applicable to pretax income (loss).", "label": "Effective Income Tax Rate Reconciliation, at Federal Statutory Income Tax Rate, Percent", "verboseLabel": "Statutory federal income tax rate" } } }, "localname": "EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.nwbio.com/role/DisclosureIncomeTaxesReconcilationOfUsFederalStatutoryTaxExpenseBenefitDetails" ], "xbrltype": "percentItemType" }, "us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance": { "auth_ref": [ "r276", "r298" ], "lang": { "en-us": { "role": { "documentation": "Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to changes in the valuation allowance for deferred tax assets.", "label": "Effective Income Tax Rate Reconciliation, Change in Deferred Tax Assets Valuation Allowance, Percent", "verboseLabel": "Change in valuation allowance" } } }, "localname": "EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.nwbio.com/role/DisclosureIncomeTaxesReconcilationOfUsFederalStatutoryTaxExpenseBenefitDetails" ], "xbrltype": "percentItemType" }, "us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential": { "auth_ref": [ "r276", "r298" ], "lang": { "en-us": { "role": { "documentation": "Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations applicable to statutory income tax expense (benefit) outside of the country of domicile.", "label": "Effective Income Tax Rate Reconciliation, Foreign Income Tax Rate Differential, Percent", "negatedLabel": "Tax rate differential on foreign income" } } }, "localname": "EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.nwbio.com/role/DisclosureIncomeTaxesReconcilationOfUsFederalStatutoryTaxExpenseBenefitDetails" ], "xbrltype": "percentItemType" }, "us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseOther": { "auth_ref": [ "r276", "r298" ], "lang": { "en-us": { "role": { "documentation": "Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to other nondeductible expenses.", "label": "Effective Income Tax Rate Reconciliation, Nondeductible Expense, Other, Percent", "verboseLabel": "Derivative gain or loss" } } }, "localname": "EffectiveIncomeTaxRateReconciliationNondeductibleExpenseOther", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.nwbio.com/role/DisclosureIncomeTaxesReconcilationOfUsFederalStatutoryTaxExpenseBenefitDetails" ], "xbrltype": "percentItemType" }, "us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments": { "auth_ref": [ "r276", "r298" ], "lang": { "en-us": { "role": { "documentation": "Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to other adjustments.", "label": "Effective Income Tax Rate Reconciliation, Other Adjustments, Percent", "verboseLabel": "Other permanent items and true ups" } } }, "localname": "EffectiveIncomeTaxRateReconciliationOtherAdjustments", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.nwbio.com/role/DisclosureIncomeTaxesReconcilationOfUsFederalStatutoryTaxExpenseBenefitDetails" ], "xbrltype": "percentItemType" }, "us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes": { "auth_ref": [ "r276", "r298" ], "lang": { "en-us": { "role": { "documentation": "Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations applicable to state and local income tax expense (benefit), net of federal tax expense (benefit).", "label": "Effective Income Tax Rate Reconciliation, State and Local Income Taxes, Percent", "verboseLabel": "State taxes, net of federal tax benefit" } } }, "localname": "EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.nwbio.com/role/DisclosureIncomeTaxesReconcilationOfUsFederalStatutoryTaxExpenseBenefitDetails" ], "xbrltype": "percentItemType" }, "us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsResearch": { "auth_ref": [ "r276", "r298" ], "lang": { "en-us": { "role": { "documentation": "Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to research tax credit.", "label": "Effective Income Tax Rate Reconciliation, Tax Credit, Research, Percent", "verboseLabel": "R&D Credit" } } }, "localname": "EffectiveIncomeTaxRateReconciliationTaxCreditsResearch", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.nwbio.com/role/DisclosureIncomeTaxesReconcilationOfUsFederalStatutoryTaxExpenseBenefitDetails" ], "xbrltype": "percentItemType" }, "us-gaap_EmbeddedDerivativeFairValueOfEmbeddedDerivativeLiability": { "auth_ref": [ "r332" ], "calculation": { "http://www.nwbio.com/role/DisclosureFairValueMeasurementsDetails": { "order": 3.0, "parentTag": "us-gaap_LiabilitiesFairValueDisclosure", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Fair value as of the balance sheet date of the embedded derivative or group of embedded derivatives classified as a liability.", "label": "Embedded Derivative, Fair Value of Embedded Derivative Liability", "terseLabel": "Embedded conversion option" } } }, "localname": "EmbeddedDerivativeFairValueOfEmbeddedDerivativeLiability", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.nwbio.com/role/DisclosureFairValueMeasurementsDetails", "http://www.nwbio.com/role/DisclosureNotesPayableAdditionalInformationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_EmbeddedDerivativeFinancialInstrumentsMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Derivative instrument embedded in host contract.", "label": "Embedded Derivative Financial Instruments [Member]", "terseLabel": "Embedded Conversion Option [Member]" } } }, "localname": "EmbeddedDerivativeFinancialInstrumentsMember", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.nwbio.com/role/DisclosureFairValueMeasurementsChangesInLevel3LiabilitiesDetails", "http://www.nwbio.com/role/DisclosureFairValueMeasurementsWeightedAverageInAggregateSignificantUnobservableInputsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized": { "auth_ref": [ "r260" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of cost not yet recognized for nonvested award under share-based payment arrangement.", "label": "Employee Service Share-based Compensation, Nonvested Awards, Compensation Cost Not yet Recognized" } } }, "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.nwbio.com/role/DisclosureStockBasedCompensationAdditionalInformationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1": { "auth_ref": [ "r260" ], "lang": { "en-us": { "role": { "documentation": "Weighted-average period over which cost not yet recognized is expected to be recognized for award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.", "label": "Employee Service Share-based Compensation, Nonvested Awards, Compensation Cost Not yet Recognized, Period for Recognition" } } }, "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.nwbio.com/role/DisclosureStockBasedCompensationAdditionalInformationDetails" ], "xbrltype": "durationItemType" }, "us-gaap_EmployeeStockOptionMember": { "auth_ref": [ "r256" ], "lang": { "en-us": { "role": { "documentation": "Share-based payment arrangement granting right, subject to vesting and other restrictions, to purchase or sell certain number of shares at predetermined price for specified period of time.", "label": "Employee Stock Option [Member]", "terseLabel": "Stock options" } } }, "localname": "EmployeeStockOptionMember", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.nwbio.com/role/DisclosureStockBasedCompensationAdditionalInformationDetails" ], "xbrltype": "domainItemType" }, "us-gaap_EquityComponentDomain": { "auth_ref": [ "r105", "r106", "r108", "r111", "r117", "r120", "r134", "r169", "r202", "r204", "r263", "r264", "r265", "r293", "r294", "r356", "r357", "r358", "r359", "r360", "r362", "r457", "r458", "r459" ], "lang": { "en-us": { "role": { "documentation": "Components of equity are the parts of the total Equity balance including that which is allocated to common, preferred, treasury stock, retained earnings, etc.", "label": "Equity Component [Domain]", "terseLabel": "Equity Component [Domain]" } } }, "localname": "EquityComponentDomain", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.nwbio.com/role/DisclosureNotesPayableAdditionalInformationDetails", "http://www.nwbio.com/role/DisclosureStockholdersDeficitAdditionalInformationDetails", "http://www.nwbio.com/role/StatementConsolidatedStatementsOfChangesInStockholdersDeficit" ], "xbrltype": "domainItemType" }, "us-gaap_ErrorCorrectionsAndPriorPeriodAdjustmentsRestatementByRestatementPeriodAndAmountAxis": { "auth_ref": [ "r107", "r112", "r113", "r116", "r117", "r119", "r120" ], "lang": { "en-us": { "role": { "documentation": "Information by type of error correction.", "label": "Error Correction, Type [Axis]" } } }, "localname": "ErrorCorrectionsAndPriorPeriodAdjustmentsRestatementByRestatementPeriodAndAmountAxis", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.nwbio.com/role/DisclosureRevisionToPriorPeriodFinancialStatementsConsolidatedBalanceSheetDetails", "http://www.nwbio.com/role/DisclosureRevisionToPriorPeriodFinancialStatementsConsolidatedStatementOfCashFlowsDetaills", "http://www.nwbio.com/role/DisclosureRevisionToPriorPeriodFinancialStatementsConsolidatedStatementOfOperationsDetaills" ], "xbrltype": "stringItemType" }, "us-gaap_ErrorCorrectionsAndPriorPeriodAdjustmentsRestatementLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Error Corrections and Prior Period Adjustments Restatement [Line Items]" } } }, "localname": "ErrorCorrectionsAndPriorPeriodAdjustmentsRestatementLineItems", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.nwbio.com/role/DisclosureRevisionToPriorPeriodFinancialStatementsConsolidatedBalanceSheetDetails", "http://www.nwbio.com/role/DisclosureRevisionToPriorPeriodFinancialStatementsConsolidatedStatementOfCashFlowsDetaills", "http://www.nwbio.com/role/DisclosureRevisionToPriorPeriodFinancialStatementsConsolidatedStatementOfOperationsDetaills" ], "xbrltype": "stringItemType" }, "us-gaap_ExtinguishmentOfDebtAmount": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Gross amount of debt extinguished.", "label": "Extinguishment of Debt, Amount" } } }, "localname": "ExtinguishmentOfDebtAmount", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.nwbio.com/role/DisclosureNotesPayableAdditionalInformationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_ExtinguishmentOfDebtAxis": { "auth_ref": [ "r199" ], "lang": { "en-us": { "role": { "documentation": "Information pertaining to the debt extinguished including the amount of gain (loss), the income tax effect on the gain (loss), and the amount of gain (loss), net or the related income tax, by debt instrument.", "label": "Extinguishment of Debt [Axis]" } } }, "localname": "ExtinguishmentOfDebtAxis", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.nwbio.com/role/DisclosureNotesPayableAdditionalInformationDetails", "http://www.nwbio.com/role/DisclosureNotesPayableDetails", "http://www.nwbio.com/role/DisclosureNotesPayableMortgageLoanDetails", "http://www.nwbio.com/role/DisclosureNotesPayableSummaryOfCompanySContractualObligationsOnDebtPrincipalDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ExtinguishmentOfDebtTypeDomain": { "auth_ref": [ "r199" ], "lang": { "en-us": { "role": { "documentation": "Type of debt extinguished.", "label": "Extinguishment Of Debt Type [Domain]", "terseLabel": "Extinguishment of Debt, Type [Domain]" } } }, "localname": "ExtinguishmentOfDebtTypeDomain", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.nwbio.com/role/DisclosureNotesPayableAdditionalInformationDetails", "http://www.nwbio.com/role/DisclosureNotesPayableDetails", "http://www.nwbio.com/role/DisclosureNotesPayableMortgageLoanDetails", "http://www.nwbio.com/role/DisclosureNotesPayableSummaryOfCompanySContractualObligationsOnDebtPrincipalDetails" ], "xbrltype": "domainItemType" }, "us-gaap_FairValueAdjustmentOfWarrants": { "auth_ref": [ "r86", "r201" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of expense (income) related to adjustment to fair value of warrant liability.", "label": "Fair Value Adjustment of Warrants", "terseLabel": "Incremental change in fair value of warrants", "verboseLabel": "Warrant liability" } } }, "localname": "FairValueAdjustmentOfWarrants", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.nwbio.com/role/DisclosureNotesPayableAdditionalInformationDetails", "http://www.nwbio.com/role/DisclosureRelatedPartyTransactionsAdditionalInformationDetails", "http://www.nwbio.com/role/DisclosureStockholdersDeficitAdditionalInformationDetails", "http://www.nwbio.com/role/StatementConsolidatedStatementsOfChangesInStockholdersDeficitParenthetical" ], "xbrltype": "monetaryItemType" }, "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]" } } }, "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.nwbio.com/role/DisclosureFairValueMeasurementsChangesInLevel3LiabilitiesDetails", "http://www.nwbio.com/role/DisclosureFairValueMeasurementsDetails", "http://www.nwbio.com/role/DisclosureFairValueMeasurementsWeightedAverageInAggregateSignificantUnobservableInputsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable": { "auth_ref": [ "r338", "r339", "r340", "r347" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of information about asset and liability measured at fair value on recurring and nonrecurring basis.", "label": "Fair Value Measurements, Recurring and Nonrecurring [Table]" } } }, "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.nwbio.com/role/DisclosureFairValueMeasurementsChangesInLevel3LiabilitiesDetails", "http://www.nwbio.com/role/DisclosureFairValueMeasurementsDetails", "http://www.nwbio.com/role/DisclosureFairValueMeasurementsWeightedAverageInAggregateSignificantUnobservableInputsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock": { "auth_ref": [ "r341" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of input and valuation technique used to measure fair value and change in valuation approach and technique for each separate class of asset and liability measured on recurring and nonrecurring basis.", "label": "Fair Value Measurement Inputs and Valuation Techniques [Table Text Block]", "verboseLabel": "Schedule of Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis Valuation Techniques" } } }, "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.nwbio.com/role/DisclosureFairValueMeasurementsTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_FairValueByFairValueHierarchyLevelAxis": { "auth_ref": [ "r221", "r222", "r223", "r224", "r225", "r226", "r227", "r229", "r339", "r401", "r402", "r403" ], "lang": { "en-us": { "role": { "documentation": "Information by level within fair value hierarchy and fair value measured at net asset value per share as practical expedient.", "label": "Fair Value, Hierarchy [Axis]" } } }, "localname": "FairValueByFairValueHierarchyLevelAxis", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.nwbio.com/role/DisclosureFairValueMeasurementsDetails", "http://www.nwbio.com/role/DisclosureFairValueMeasurementsWeightedAverageInAggregateSignificantUnobservableInputsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_FairValueDisclosuresAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Fair Value Measurements" } } }, "localname": "FairValueDisclosuresAbstract", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "xbrltype": "stringItemType" }, "us-gaap_FairValueDisclosuresTextBlock": { "auth_ref": [ "r346" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for the fair value of financial instruments (as defined), including financial assets and financial liabilities (collectively, as defined), and the measurements of those instruments as well as disclosures related to the fair value of non-financial assets and liabilities. Such disclosures about the financial instruments, assets, and liabilities would include: (1) the fair value of the required items together with their carrying amounts (as appropriate); (2) for items for which it is not practicable to estimate fair value, disclosure would include: (a) information pertinent to estimating fair value (including, carrying amount, effective interest rate, and maturity, and (b) the reasons why it is not practicable to estimate fair value; (3) significant concentrations of credit risk including: (a) information about the activity, region, or economic characteristics identifying a concentration, (b) the maximum amount of loss the entity is exposed to based on the gross fair value of the related item, (c) policy for requiring collateral or other security and information as to accessing such collateral or security, and (d) the nature and brief description of such collateral or security; (4) quantitative information about market risks and how such risks are managed; (5) for items measured on both a recurring and nonrecurring basis information regarding the inputs used to develop the fair value measurement; and (6) for items presented in the financial statement for which fair value measurement is elected: (a) information necessary to understand the reasons for the election, (b) discussion of the effect of fair value changes on earnings, (c) a description of [similar groups] items for which the election is made and the relation thereof to the balance sheet, the aggregate carrying value of items included in the balance sheet that are not eligible for the election; (7) all other required (as defined) and desired information.", "label": "Fair Value Disclosures [Text Block]", "verboseLabel": "Fair Value Measurements" } } }, "localname": "FairValueDisclosuresTextBlock", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.nwbio.com/role/DisclosureFairValueMeasurements" ], "xbrltype": "textBlockItemType" }, "us-gaap_FairValueInputsLevel1Member": { "auth_ref": [ "r221", "r222", "r227", "r229", "r339", "r401" ], "lang": { "en-us": { "role": { "documentation": "Quoted prices in active markets for identical assets or liabilities that the reporting entity can access at the measurement date.", "label": "Fair Value Inputs Level1 [Member]", "terseLabel": "Fair Value, Inputs, Level 1 [Member]" } } }, "localname": "FairValueInputsLevel1Member", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.nwbio.com/role/DisclosureFairValueMeasurementsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_FairValueInputsLevel2Member": { "auth_ref": [ "r221", "r222", "r227", "r229", "r339", "r402" ], "lang": { "en-us": { "role": { "documentation": "Inputs other than quoted prices included within level 1 that are observable for an asset or liability, either directly or indirectly, including, but not limited to, quoted prices for similar assets or liabilities in active markets, or quoted prices for identical or similar assets or liabilities in inactive markets.", "label": "Fair Value Inputs Level2 [Member]", "terseLabel": "Fair Value, Inputs, Level 2 [Member]" } } }, "localname": "FairValueInputsLevel2Member", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.nwbio.com/role/DisclosureFairValueMeasurementsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_FairValueInputsLevel3Member": { "auth_ref": [ "r221", "r222", "r223", "r224", "r225", "r226", "r227", "r229", "r339", "r403" ], "lang": { "en-us": { "role": { "documentation": "Unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing.", "label": "Fair Value Inputs Level3 [Member]", "terseLabel": "Fair Value, Inputs, Level 3 [Member]" } } }, "localname": "FairValueInputsLevel3Member", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.nwbio.com/role/DisclosureFairValueMeasurementsDetails", "http://www.nwbio.com/role/DisclosureFairValueMeasurementsWeightedAverageInAggregateSignificantUnobservableInputsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisChangeInUnrealizedGainLoss": { "auth_ref": [ "r345" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of unrealized gain (loss) recognized in income from liability measured at fair value on recurring basis using unobservable input (level 3) and still held.", "label": "Fair Value, Liabilities Measured on Recurring Basis, Change in Unrealized Gain (Loss)", "verboseLabel": "Change in fair value" } } }, "localname": "FairValueLiabilitiesMeasuredOnRecurringBasisChangeInUnrealizedGainLoss", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.nwbio.com/role/DisclosureFairValueMeasurementsChangesInLevel3LiabilitiesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock": { "auth_ref": [ "r343", "r347" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of the fair value measurement of liabilities using significant unobservable inputs (Level 3), a reconciliation of the beginning and ending balances, separately presenting changes attributable to the following: (1) total gains or losses for the period (realized and unrealized), segregating those gains or losses included in earnings (or changes in net assets), and gains or losses recognized in other comprehensive income (loss) and a description of where those gains or losses included in earnings (or changes in net assets) are reported in the statement of income (or activities); (2) purchases, sales, issues, and settlements (each type disclosed separately); and (3) transfers in and transfers out of Level 3 (for example, transfers due to changes in the observability of significant inputs) by class of liability.", "label": "Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Table Text Block]", "verboseLabel": "Schedule of Fair Value Liabilities Measured On Recurring Basis Unobservable Input Reconciliation" } } }, "localname": "FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.nwbio.com/role/DisclosureFairValueMeasurementsTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityIssues": { "auth_ref": [ "r344" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of issuances of financial instrument classified as a liability measured using unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing.", "label": "Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Issuances", "terseLabel": "Additional warrant liability" } } }, "localname": "FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityIssues", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.nwbio.com/role/DisclosureFairValueMeasurementsChangesInLevel3LiabilitiesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySales": { "auth_ref": [ "r344" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of sales of financial instrument classified as a liability measured using unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing.", "label": "Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Sales", "negatedLabel": "Extinguishment of warrant liabilities related to warrants exercised for cash" } } }, "localname": "FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySales", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.nwbio.com/role/DisclosureFairValueMeasurementsChangesInLevel3LiabilitiesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements": { "auth_ref": [ "r344" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of settlements of financial instrument classified as a liability measured using unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing.", "label": "Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Settlements", "verboseLabel": "Additional contingent liability in connection with a settlement agreement" } } }, "localname": "FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.nwbio.com/role/DisclosureFairValueMeasurementsChangesInLevel3LiabilitiesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue": { "auth_ref": [ "r343" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Fair value of financial instrument classified as a liability measured using unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing.", "label": "Fair Value, Measurement with Unobservable Inputs Reconciliations, Recurring Basis, Liability Value", "periodEndLabel": "Balance", "periodStartLabel": "Balance" } } }, "localname": "FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.nwbio.com/role/DisclosureFairValueMeasurementsChangesInLevel3LiabilitiesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_FairValueMeasurementsFairValueHierarchyDomain": { "auth_ref": [ "r221", "r222", "r223", "r224", "r225", "r226", "r227", "r229", "r401", "r402", "r403" ], "lang": { "en-us": { "role": { "documentation": "Categories used to prioritize the inputs to valuation techniques to measure fair value.", "label": "Fair Value Measurements Fair Value Hierarchy [Domain]", "terseLabel": "Fair Value Hierarchy [Domain]" } } }, "localname": "FairValueMeasurementsFairValueHierarchyDomain", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.nwbio.com/role/DisclosureFairValueMeasurementsDetails", "http://www.nwbio.com/role/DisclosureFairValueMeasurementsWeightedAverageInAggregateSignificantUnobservableInputsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_FairValueOfFinancialInstrumentsPolicy": { "auth_ref": [ "r93", "r348", "r349" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for determining the fair value of financial instruments.", "label": "Fair Value of Financial Instruments, Policy [Policy Text Block]", "terseLabel": "Fair Value of Financial Instruments" } } }, "localname": "FairValueOfFinancialInstrumentsPolicy", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.nwbio.com/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_FederalIncomeTaxExpenseBenefitContinuingOperationsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Federal Income Tax Expense (Benefit), Continuing Operations [Abstract]", "verboseLabel": "Federal" } } }, "localname": "FederalIncomeTaxExpenseBenefitContinuingOperationsAbstract", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.nwbio.com/role/DisclosureIncomeTaxesSummaryOfTaxProvisionBenefitDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ForeignCountryMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Designated tax departments of governments entitled to levy and collect income taxes from the entity outside the entity's country of domicile.", "label": "Foreign Country [Member]", "terseLabel": "Foreign Tax Authorities" } } }, "localname": "ForeignCountryMember", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.nwbio.com/role/DisclosureCommitmentsAndContingenciesAdditionalInformationDetails", "http://www.nwbio.com/role/DisclosureIncomeTaxesAdditionalInformationDetails" ], "xbrltype": "domainItemType" }, "us-gaap_ForeignCurrencyTransactionGainLossRealized": { "auth_ref": [ "r352", "r354" ], "calculation": { "http://www.nwbio.com/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss": { "order": 4.0, "parentTag": "us-gaap_OtherNonoperatingIncomeExpense", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount before tax of foreign currency transaction realized gain (loss) recognized in the income statement.", "label": "Foreign Currency Transaction Gain (Loss), Realized", "terseLabel": "Foreign currency transaction gain" } } }, "localname": "ForeignCurrencyTransactionGainLossRealized", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.nwbio.com/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss" ], "xbrltype": "monetaryItemType" }, "us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock": { "auth_ref": [ "r93", "r364" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for (1) transactions denominated in a currency other than the reporting enterprise's functional currency, (2) translating foreign currency financial statements that are incorporated into the financial statements of the reporting enterprise by consolidation, combination, or the equity method of accounting, and (3) remeasurement of the financial statements of a foreign reporting enterprise in a hyperinflationary economy.", "label": "Foreign Currency Transactions and Translations Policy [Policy Text Block]", "terseLabel": "Foreign Currency Translation and Transactions" } } }, "localname": "ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.nwbio.com/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_ForeignIncomeTaxExpenseBenefitContinuingOperationsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Foreign Income Tax Expense (Benefit), Continuing Operations [Abstract]", "verboseLabel": "Foreign" } } }, "localname": "ForeignIncomeTaxExpenseBenefitContinuingOperationsAbstract", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.nwbio.com/role/DisclosureIncomeTaxesSummaryOfTaxProvisionBenefitDetails" ], "xbrltype": "stringItemType" }, "us-gaap_FurnitureAndFixturesMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Equipment commonly used in offices and stores that have no permanent connection to the structure of a building or utilities. Examples include, but are not limited to, desks, chairs, tables, and bookcases.", "label": "Furniture And Fixtures [Member]", "terseLabel": "Office furniture and equipment [Member]" } } }, "localname": "FurnitureAndFixturesMember", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.nwbio.com/role/DisclosurePropertyPlantAndEquipmentDetails" ], "xbrltype": "domainItemType" }, "us-gaap_GainsLossesOnExtinguishmentOfDebt": { "auth_ref": [ "r86", "r197", "r198" ], "calculation": { "http://www.nwbio.com/role/StatementConsolidatedStatementsOfCashFlows": { "order": 7.0, "parentTag": "us-gaap_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivities", "weight": -1.0 }, "http://www.nwbio.com/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss": { "order": 2.0, "parentTag": "us-gaap_OtherNonoperatingIncomeExpense", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "definitionGuidance": "Gain (Loss) on Extinguishment of Debt", "documentation": "Difference between the fair value of payments made and the carrying amount of debt which is extinguished prior to maturity.", "label": "Gain (Loss) on Extinguishment of Debt", "negatedLabel": "Loss (gain) from extinguishment of debt", "verboseLabel": "Loss from extinguishment of debt" } } }, "localname": "GainsLossesOnExtinguishmentOfDebt", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.nwbio.com/role/DisclosureNotesPayableAdditionalInformationDetails", "http://www.nwbio.com/role/DisclosureStockholdersDeficitAdditionalInformationDetails", "http://www.nwbio.com/role/StatementConsolidatedStatementsOfCashFlows", "http://www.nwbio.com/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss" ], "xbrltype": "monetaryItemType" }, "us-gaap_GeneralAndAdministrativeExpense": { "auth_ref": [ "r71" ], "calculation": { "http://www.nwbio.com/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss": { "order": 2.0, "parentTag": "us-gaap_OperatingCostsAndExpenses", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The aggregate total of expenses of managing and administering the affairs of an entity, including affiliates of the reporting entity, which are not directly or indirectly associated with the manufacture, sale or creation of a product or product line.", "label": "General and Administrative Expense", "terseLabel": "General and administrative expenses", "verboseLabel": "General and administrative" } } }, "localname": "GeneralAndAdministrativeExpense", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.nwbio.com/role/DisclosureStockholdersDeficitAdditionalInformationDetails", "http://www.nwbio.com/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss" ], "xbrltype": "monetaryItemType" }, "us-gaap_GeneralAndAdministrativeExpenseMember": { "auth_ref": [ "r69" ], "lang": { "en-us": { "role": { "documentation": "Primary financial statement caption encompassing general and administrative expense.", "label": "General And Administrative Expense [Member]", "terseLabel": "General and administrative" } } }, "localname": "GeneralAndAdministrativeExpenseMember", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.nwbio.com/role/DisclosureStockBasedCompensationAdditionalInformationDetails", "http://www.nwbio.com/role/DisclosureStockBasedCompensationSummaryOfStockBasedCompensationExpenseDetails" ], "xbrltype": "domainItemType" }, "us-gaap_GeographicDistributionAxis": { "auth_ref": [ "r172", "r434", "r435" ], "lang": { "en-us": { "role": { "documentation": "Information by geographic distribution of business activity identified as either domestic or foreign. Excludes names of countries, states and provinces, and cities.", "label": "Geographic Distribution [Axis]" } } }, "localname": "GeographicDistributionAxis", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.nwbio.com/role/DisclosurePropertyPlantAndEquipmentDetails" ], "xbrltype": "stringItemType" }, "us-gaap_GeographicDistributionDomain": { "auth_ref": [ "r434", "r435" ], "lang": { "en-us": { "role": { "documentation": "Allocation of business activity identified as domestic or foreign. Excludes names of countries, states and provinces, and cities.", "label": "Geographic Distribution [Domain]", "terseLabel": "Geographic Distribution [Domain]" } } }, "localname": "GeographicDistributionDomain", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.nwbio.com/role/DisclosurePropertyPlantAndEquipmentDetails" ], "xbrltype": "domainItemType" }, "us-gaap_GeographicDistributionDomesticMember": { "auth_ref": [ "r173" ], "lang": { "en-us": { "role": { "documentation": "Allocation of business activity identified as domestic.", "label": "Geographic Distribution Domestic [Member]", "terseLabel": "Domestic [Member]" } } }, "localname": "GeographicDistributionDomesticMember", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.nwbio.com/role/DisclosurePropertyPlantAndEquipmentDetails" ], "xbrltype": "domainItemType" }, "us-gaap_Goodwill": { "auth_ref": [ "r174", "r175", "r424" ], "calculation": { "http://www.nwbio.com/role/DisclosureFlaskworksAcquisitionDetails": { "order": 1.0, "parentTag": "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet", "weight": 1.0 }, "http://www.nwbio.com/role/StatementConsolidatedBalanceSheets": { "order": 4.0, "parentTag": "us-gaap_AssetsNoncurrent", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount after accumulated impairment loss of an asset representing future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized.", "label": "Goodwill", "verboseLabel": "Goodwill" } } }, "localname": "Goodwill", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.nwbio.com/role/DisclosureFlaskworksAcquisitionDetails", "http://www.nwbio.com/role/StatementConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_GoodwillAndIntangibleAssetImpairment": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Total loss recognized during the period from the impairment of goodwill plus the loss recognized in the period resulting from the impairment of the carrying amount of intangible assets, other than goodwill.", "label": "Goodwill and Intangible Asset Impairment", "verboseLabel": "Impairment charge" } } }, "localname": "GoodwillAndIntangibleAssetImpairment", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.nwbio.com/role/DisclosureSummaryOfSignificantAccountingPoliciesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_GoodwillAndIntangibleAssetsPolicyTextBlock": { "auth_ref": [ "r93", "r176", "r177" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for goodwill and intangible assets. This accounting policy also may address how an entity assesses and measures impairment of goodwill and intangible assets.", "label": "Goodwill and Intangible Assets, Policy [Policy Text Block]", "terseLabel": "Goodwill and Intangible Assets" } } }, "localname": "GoodwillAndIntangibleAssetsPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.nwbio.com/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_IncomeStatementAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS" } } }, "localname": "IncomeStatementAbstract", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "xbrltype": "stringItemType" }, "us-gaap_IncomeStatementLocationAxis": { "auth_ref": [ "r183" ], "lang": { "en-us": { "role": { "documentation": "Information by location in the income statement.", "label": "Income Statement Location [Axis]" } } }, "localname": "IncomeStatementLocationAxis", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.nwbio.com/role/DisclosureStockBasedCompensationAdditionalInformationDetails", "http://www.nwbio.com/role/DisclosureStockBasedCompensationSummaryOfStockBasedCompensationExpenseDetails" ], "xbrltype": "stringItemType" }, "us-gaap_IncomeStatementLocationDomain": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Location in the income statement.", "label": "Income Statement Location [Domain]", "terseLabel": "Income Statement Location [Domain]" } } }, "localname": "IncomeStatementLocationDomain", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.nwbio.com/role/DisclosureStockBasedCompensationAdditionalInformationDetails", "http://www.nwbio.com/role/DisclosureStockBasedCompensationSummaryOfStockBasedCompensationExpenseDetails" ], "xbrltype": "domainItemType" }, "us-gaap_IncomeTaxAuthorityAxis": { "auth_ref": [ "r279" ], "lang": { "en-us": { "role": { "documentation": "Information by tax jurisdiction.", "label": "Income Tax Authority [Axis]" } } }, "localname": "IncomeTaxAuthorityAxis", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.nwbio.com/role/DisclosureCommitmentsAndContingenciesAdditionalInformationDetails", "http://www.nwbio.com/role/DisclosureIncomeTaxesAdditionalInformationDetails" ], "xbrltype": "stringItemType" }, "us-gaap_IncomeTaxAuthorityDomain": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Agency, division or body classification that levies income taxes, examines tax returns for compliance, or grants exemptions from or makes other decisions pertaining to income taxes.", "label": "Income Tax Authority [Domain]", "terseLabel": "Income Tax Authority [Domain]" } } }, "localname": "IncomeTaxAuthorityDomain", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.nwbio.com/role/DisclosureCommitmentsAndContingenciesAdditionalInformationDetails", "http://www.nwbio.com/role/DisclosureIncomeTaxesAdditionalInformationDetails" ], "xbrltype": "domainItemType" }, "us-gaap_IncomeTaxDisclosureAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Income Taxes" } } }, "localname": "IncomeTaxDisclosureAbstract", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "xbrltype": "stringItemType" }, "us-gaap_IncomeTaxDisclosureTextBlock": { "auth_ref": [ "r277", "r280", "r286", "r295", "r299", "r301", "r302", "r303" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for income taxes. Disclosures may include net deferred tax liability or asset recognized in an enterprise's statement of financial position, net change during the year in the total valuation allowance, approximate tax effect of each type of temporary difference and carryforward that gives rise to a significant portion of deferred tax liabilities and deferred tax assets, utilization of a tax carryback, and tax uncertainties information.", "label": "Income Tax Disclosure [Text Block]", "terseLabel": "Income Taxes" } } }, "localname": "IncomeTaxDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.nwbio.com/role/DisclosureIncomeTaxes" ], "xbrltype": "textBlockItemType" }, "us-gaap_IncomeTaxExaminationPenaltiesAndInterestAccrued": { "auth_ref": [ "r278" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The amount of estimated penalties and interest accrued as of the balance sheet date arising from income tax examinations.", "label": "Income Tax Examination, Penalties and Interest Accrued", "terseLabel": "Amounts accrued for penalties or interest" } } }, "localname": "IncomeTaxExaminationPenaltiesAndInterestAccrued", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.nwbio.com/role/DisclosureIncomeTaxesAdditionalInformationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncomeTaxExpenseBenefit": { "auth_ref": [ "r98", "r119", "r120", "r150", "r275", "r296", "r300", "r451" ], "calculation": { "http://www.nwbio.com/role/DisclosureIncomeTaxesSummaryOfTaxProvisionBenefitDetails": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.", "label": "Income Tax Expense (Benefit)", "totalLabel": "Income tax provision (benefit)" } } }, "localname": "IncomeTaxExpenseBenefit", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.nwbio.com/role/DisclosureIncomeTaxesSummaryOfTaxProvisionBenefitDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncomeTaxPolicyTextBlock": { "auth_ref": [ "r64", "r93", "r273", "r274", "r280", "r281", "r285", "r292", "r469" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for income taxes, which may include its accounting policies for recognizing and measuring deferred tax assets and liabilities and related valuation allowances, recognizing investment tax credits, operating loss carryforwards, tax credit carryforwards, and other carryforwards, methodologies for determining its effective income tax rate and the characterization of interest and penalties in the financial statements.", "label": "Income Tax, Policy [Policy Text Block]", "terseLabel": "Income Taxes" } } }, "localname": "IncomeTaxPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.nwbio.com/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_IncreaseDecreaseInDueToRelatedPartiesCurrent": { "auth_ref": [ "r85" ], "calculation": { "http://www.nwbio.com/role/StatementConsolidatedStatementsOfCashFlows": { "order": 6.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The increase (decrease) during the reporting period in the aggregate amount of obligations to be paid to the following types of related parties: a parent company and its subsidiaries; subsidiaries of a common parent; an entity and trust for the benefit of employees, such as pension and profit-sharing trusts that are managed by or under the trusteeship of the entities' management; an entity and its principal owners, management, or member of their immediate families, affiliates, or other parties with the ability to exert significant influence.", "label": "Increase (Decrease) in Due to Related Parties, Current", "verboseLabel": "Related party accounts payable and accrued expenses" } } }, "localname": "IncreaseDecreaseInDueToRelatedPartiesCurrent", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.nwbio.com/role/DisclosureRevisionToPriorPeriodFinancialStatementsConsolidatedStatementOfCashFlowsDetaills", "http://www.nwbio.com/role/StatementConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncreaseDecreaseInOperatingCapitalAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Increase (Decrease) in Operating Capital [Abstract]", "terseLabel": "Changes in operating assets and liabilities:" } } }, "localname": "IncreaseDecreaseInOperatingCapitalAbstract", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.nwbio.com/role/StatementConsolidatedStatementsOfCashFlows" ], "xbrltype": "stringItemType" }, "us-gaap_IncreaseDecreaseInOtherAccountsPayableAndAccruedLiabilities": { "auth_ref": [ "r85" ], "calculation": { "http://www.nwbio.com/role/StatementConsolidatedStatementsOfCashFlows": { "order": 5.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The increase (decrease) during the reporting period in other obligations or expenses incurred but not yet paid.", "label": "Increase (Decrease) in Other Accounts Payable and Accrued Liabilities", "terseLabel": "Accounts payable and accrued expenses" } } }, "localname": "IncreaseDecreaseInOtherAccountsPayableAndAccruedLiabilities", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.nwbio.com/role/StatementConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill": { "auth_ref": [ "r178" ], "calculation": { "http://www.nwbio.com/role/StatementConsolidatedBalanceSheets": { "order": 5.0, "parentTag": "us-gaap_AssetsNoncurrent", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of assets, excluding financial assets and goodwill, lacking physical substance and having a projected indefinite period of benefit.", "label": "Indefinite-lived Intangible Assets (Excluding Goodwill)", "terseLabel": "Indefinite-lived intangible asset" } } }, "localname": "IndefiniteLivedIntangibleAssetsExcludingGoodwill", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.nwbio.com/role/StatementConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_InterestAndDebtExpense": { "auth_ref": [ "r366" ], "calculation": { "http://www.nwbio.com/role/DisclosureRelatedPartyTransactionsTotalInterestExpensesDetails": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Interest and debt related expenses associated with nonoperating financing activities of the entity.", "label": "Interest and Debt Expense", "verboseLabel": "Total interest expense" } } }, "localname": "InterestAndDebtExpense", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.nwbio.com/role/DisclosureNotesPayableMortgageLoanDetails", "http://www.nwbio.com/role/DisclosureRelatedPartyTransactionsTotalInterestExpensesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_InterestExpense": { "auth_ref": [ "r65", "r149", "r365", "r369", "r433" ], "calculation": { "http://www.nwbio.com/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss": { "order": 3.0, "parentTag": "us-gaap_OtherNonoperatingIncomeExpense", "weight": -1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of the cost of borrowed funds accounted for as interest expense.", "label": "Interest Expense", "negatedLabel": "Interest expense", "terseLabel": "Total interest expense" } } }, "localname": "InterestExpense", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.nwbio.com/role/DisclosureNotesPayableMortgageLoanDetails", "http://www.nwbio.com/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss" ], "xbrltype": "monetaryItemType" }, "us-gaap_InterestExpenseDebt": { "auth_ref": [ "r72", "r196" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of the cost of borrowed funds accounted for as interest expense for debt.", "label": "Interest Expense, Debt" } } }, "localname": "InterestExpenseDebt", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.nwbio.com/role/DisclosureNotesPayableAdditionalInformationDetails", "http://www.nwbio.com/role/DisclosureNotesPayableMortgageLoanDetails", "http://www.nwbio.com/role/DisclosureRelatedPartyTransactionsAdditionalInformationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_InterestExpenseOther": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of interest expense classified as other.", "label": "Interest Expense, Other", "verboseLabel": "Other interest expenses" } } }, "localname": "InterestExpenseOther", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.nwbio.com/role/DisclosureNotesPayableMortgageLoanDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_InterestIncomeAndInterestExpenseDisclosureTableTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of interest income and expense, including, but not limited to, interest income and expense from investments, loans, and securities.", "label": "Interest Income and Interest Expense Disclosure [Table Text Block]", "terseLabel": "Schedule of total interest expenses related to outstanding notes and mortgage loan" } } }, "localname": "InterestIncomeAndInterestExpenseDisclosureTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.nwbio.com/role/DisclosureNotesPayableTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_InterestPaidNet": { "auth_ref": [ "r81", "r83", "r89" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of cash paid for interest, excluding capitalized interest, classified as operating activity. Includes, but is not limited to, payment to settle zero-coupon bond for accreted interest of debt discount and debt instrument with insignificant coupon interest rate in relation to effective interest rate of borrowing attributable to accreted interest of debt discount.", "label": "Interest Paid, Net", "negatedLabel": "Interest payments" } } }, "localname": "InterestPaidNet", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.nwbio.com/role/StatementConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_InterestPayableCurrentAndNoncurrent": { "auth_ref": [ "r429", "r447" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of interest payable on debt, including, but not limited to, trade payables.", "label": "Interest Payable" } } }, "localname": "InterestPayableCurrentAndNoncurrent", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.nwbio.com/role/DisclosureNotesPayableAdditionalInformationDetails", "http://www.nwbio.com/role/DisclosureRelatedPartyTransactionsAdditionalInformationDetails", "http://www.nwbio.com/role/DisclosureStockholdersDeficitAdditionalInformationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_InvestorMember": { "auth_ref": [ "r388", "r389" ], "lang": { "en-us": { "role": { "documentation": "Business entity or individual that puts money, by purchase or expenditure, in something offering potential profitable returns, such as interest income or appreciation in value.", "label": "Investor [Member]", "terseLabel": "Investor [Member]" } } }, "localname": "InvestorMember", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.nwbio.com/role/DisclosureSubsequentEventsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_IssuanceOfStockAndWarrantsForServicesOrClaims": { "auth_ref": [ "r86" ], "calculation": { "http://www.nwbio.com/role/StatementConsolidatedStatementsOfCashFlows": { "order": 9.0, "parentTag": "us-gaap_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Fair value of share-based compensation granted to nonemployees as payment for services rendered or acknowledged claims.", "label": "Issuance of Stock and Warrants for Services or Claims", "terseLabel": "Stock-based compensation for services" } } }, "localname": "IssuanceOfStockAndWarrantsForServicesOrClaims", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.nwbio.com/role/StatementConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_LandMember": { "auth_ref": [ "r217" ], "lang": { "en-us": { "role": { "documentation": "Part of earth's surface not covered by water.", "label": "Land [Member]", "terseLabel": "Land [Member]" } } }, "localname": "LandMember", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.nwbio.com/role/DisclosurePropertyPlantAndEquipmentDetails" ], "xbrltype": "domainItemType" }, "us-gaap_LeaseCost": { "auth_ref": [ "r382", "r384" ], "calculation": { "http://www.nwbio.com/role/DisclosureCommitmentsAndContingenciesDetails": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of lease cost recognized by lessee for lease contract.", "label": "Lease, Cost", "totalLabel": "Total" } } }, "localname": "LeaseCost", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.nwbio.com/role/DisclosureCommitmentsAndContingenciesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LeaseCostAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Lease, Cost [Abstract]", "verboseLabel": "Lease cost" } } }, "localname": "LeaseCostAbstract", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.nwbio.com/role/DisclosureCommitmentsAndContingenciesDetails" ], "xbrltype": "stringItemType" }, "us-gaap_LeaseCostTableTextBlock": { "auth_ref": [ "r382" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of lessee's lease cost. Includes, but is not limited to, interest expense for finance lease, amortization of right-of-use asset for finance lease, operating lease cost, short-term lease cost, variable lease cost and sublease income.", "label": "Lessee, Operating Lease, Disclosure [Table Text Block]", "verboseLabel": "Schedule of quantitative information about the company's operating leases" } } }, "localname": "LeaseCostTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.nwbio.com/role/DisclosureCommitmentsAndContingenciesTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_LeasePracticalExpedientLessorSingleLeaseComponent": { "auth_ref": [ "r385" ], "lang": { "en-us": { "role": { "documentation": "Indicates (true false) whether practical expedient is elected to account for lease component and nonlease component as single lease component.", "label": "Lease, Practical Expedient, Lessor Single Lease Component [true false]" } } }, "localname": "LeasePracticalExpedientLessorSingleLeaseComponent", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.nwbio.com/role/DisclosureCommitmentsAndContingenciesAdditionalInformationDetails" ], "xbrltype": "booleanItemType" }, "us-gaap_LeaseholdImprovementsMember": { "auth_ref": [ "r180" ], "lang": { "en-us": { "role": { "documentation": "Additions or improvements to assets held under a lease arrangement.", "label": "Leasehold Improvements [Member]", "terseLabel": "Leasehold improvements [Member]" } } }, "localname": "LeaseholdImprovementsMember", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.nwbio.com/role/DisclosurePropertyPlantAndEquipmentDetails" ], "xbrltype": "domainItemType" }, "us-gaap_LegalFees": { "auth_ref": [ "r70" ], "calculation": { "http://www.nwbio.com/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss": { "order": 3.0, "parentTag": "us-gaap_OperatingCostsAndExpenses", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The amount of expense provided in the period for legal costs incurred on or before the balance sheet date pertaining to resolved, pending or threatened litigation, including arbitration and mediation proceedings.", "label": "Legal Fees", "terseLabel": "Legal expenses" } } }, "localname": "LegalFees", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.nwbio.com/role/DisclosureNotesPayableAdditionalInformationDetails", "http://www.nwbio.com/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss" ], "xbrltype": "monetaryItemType" }, "us-gaap_LesseeLeasesPolicyTextBlock": { "auth_ref": [ "r374" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for leasing arrangement entered into by lessee.", "label": "Lessee, Leases [Policy Text Block]", "terseLabel": "Leases" } } }, "localname": "LesseeLeasesPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.nwbio.com/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock": { "auth_ref": [ "r383" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of undiscounted cash flows of lessee's operating lease liability. Includes, but is not limited to, reconciliation of undiscounted cash flows to operating lease liability recognized in statement of financial position.", "label": "Lessee, Operating Lease, Liability, Maturity [Table Text Block]", "verboseLabel": "Schedule of maturities of our operating leases, excluding short-term leases" } } }, "localname": "LesseeOperatingLeaseLiabilityMaturityTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.nwbio.com/role/DisclosureCommitmentsAndContingenciesTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue": { "auth_ref": [ "r383" ], "calculation": { "http://www.nwbio.com/role/DisclosureCommitmentsAndContingenciesMaturitiesOfOurOperatingLeasesDetails": { "order": null, "parentTag": null, "root": true, "weight": null }, "http://www.nwbio.com/role/DisclosureCommitmentsAndContingenciesMaturitiesOfOurOperatingLeasesDetailsCalc2": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease.", "label": "Lessee, Operating Lease, Liability, Payments, Due", "totalLabel": "Total" } } }, "localname": "LesseeOperatingLeaseLiabilityPaymentsDue", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.nwbio.com/role/DisclosureCommitmentsAndContingenciesMaturitiesOfOurOperatingLeasesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths": { "auth_ref": [ "r383" ], "calculation": { "http://www.nwbio.com/role/DisclosureCommitmentsAndContingenciesMaturitiesOfOurOperatingLeasesDetails": { "order": 5.0, "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).", "label": "Operating Leases, Future Minimum Payments Due, Next Twelve Months", "verboseLabel": "Year ended December 31, 2021" } } }, "localname": "LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.nwbio.com/role/DisclosureCommitmentsAndContingenciesMaturitiesOfOurOperatingLeasesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour": { "auth_ref": [ "r383" ], "calculation": { "http://www.nwbio.com/role/DisclosureCommitmentsAndContingenciesMaturitiesOfOurOperatingLeasesDetails": { "order": 1.0, "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).", "label": "Lessee, Operating Lease, Liability, Payments, Due Year Four", "terseLabel": "Year ended December 31, 2024" } } }, "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearFour", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.nwbio.com/role/DisclosureCommitmentsAndContingenciesMaturitiesOfOurOperatingLeasesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree": { "auth_ref": [ "r383" ], "calculation": { "http://www.nwbio.com/role/DisclosureCommitmentsAndContingenciesMaturitiesOfOurOperatingLeasesDetails": { "order": 2.0, "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).", "label": "Lessee, Operating Lease, Liability, Payments, Due Year Three", "terseLabel": "Year ended December 31, 2023" } } }, "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearThree", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.nwbio.com/role/DisclosureCommitmentsAndContingenciesMaturitiesOfOurOperatingLeasesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo": { "auth_ref": [ "r383" ], "calculation": { "http://www.nwbio.com/role/DisclosureCommitmentsAndContingenciesMaturitiesOfOurOperatingLeasesDetails": { "order": 3.0, "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).", "label": "Lessee, Operating Lease, Liability, Payments, Due Year Two", "terseLabel": "Year ended December 31, 2022" } } }, "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearTwo", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.nwbio.com/role/DisclosureCommitmentsAndContingenciesMaturitiesOfOurOperatingLeasesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount": { "auth_ref": [ "r383" ], "calculation": { "http://www.nwbio.com/role/DisclosureCommitmentsAndContingenciesMaturitiesOfOurOperatingLeasesDetailsCalc2": { "order": 1.0, "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of lessee's undiscounted obligation for lease payments in excess of discounted obligation for lease payments for operating lease.", "label": "Lessee, Operating Lease, Liability, Undiscounted Excess Amount", "negatedLabel": "Less present value discount" } } }, "localname": "LesseeOperatingLeaseLiabilityUndiscountedExcessAmount", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.nwbio.com/role/DisclosureCommitmentsAndContingenciesMaturitiesOfOurOperatingLeasesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LesseeOperatingLeaseTermOfContract": { "auth_ref": [ "r375" ], "lang": { "en-us": { "role": { "documentation": "Term of lessee's operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.", "label": "Lessee, Operating Lease, Term of Contract" } } }, "localname": "LesseeOperatingLeaseTermOfContract", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.nwbio.com/role/DisclosureCommitmentsAndContingenciesAdditionalInformationDetails" ], "xbrltype": "durationItemType" }, "us-gaap_Liabilities": { "auth_ref": [ "r42", "r97", "r155", "r168", "r320", "r324", "r325", "r351" ], "calculation": { "http://www.nwbio.com/role/StatementConsolidatedBalanceSheets": { "order": 1.0, "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Sum of the carrying amounts as of the balance sheet date of all liabilities that are recognized. Liabilities are probable future sacrifices of economic benefits arising from present obligations of an entity to transfer assets or provide services to other entities in the future.", "label": "Liabilities", "totalLabel": "Total liabilities" } } }, "localname": "Liabilities", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.nwbio.com/role/DisclosureRevisionToPriorPeriodFinancialStatementsConsolidatedBalanceSheetDetails", "http://www.nwbio.com/role/StatementConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_LiabilitiesAndStockholdersEquity": { "auth_ref": [ "r29", "r97", "r168", "r351", "r428", "r444" ], "calculation": { "http://www.nwbio.com/role/StatementConsolidatedBalanceSheets": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.", "label": "Liabilities and Equity", "totalLabel": "TOTAL LIABILITIES AND STOCKHOLDERS' DEFICIT" } } }, "localname": "LiabilitiesAndStockholdersEquity", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.nwbio.com/role/DisclosureRevisionToPriorPeriodFinancialStatementsConsolidatedBalanceSheetDetails", "http://www.nwbio.com/role/StatementConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_LiabilitiesAndStockholdersEquityAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Liabilities and Equity [Abstract]", "verboseLabel": "LIABILITIES AND STOCKHOLDERS' DEFICIT" } } }, "localname": "LiabilitiesAndStockholdersEquityAbstract", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.nwbio.com/role/StatementConsolidatedBalanceSheets" ], "xbrltype": "stringItemType" }, "us-gaap_LiabilitiesCurrent": { "auth_ref": [ "r43", "r97", "r168", "r320", "r324", "r325", "r351" ], "calculation": { "http://www.nwbio.com/role/StatementConsolidatedBalanceSheets": { "order": 1.0, "parentTag": "us-gaap_Liabilities", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.", "label": "Liabilities, Current", "totalLabel": "Total current liabilities", "verboseLabel": "Total current liabilities" } } }, "localname": "LiabilitiesCurrent", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.nwbio.com/role/DisclosureRevisionToPriorPeriodFinancialStatementsConsolidatedBalanceSheetDetails", "http://www.nwbio.com/role/StatementConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_LiabilitiesCurrentAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Liabilities, Current [Abstract]", "verboseLabel": "Current liabilities:" } } }, "localname": "LiabilitiesCurrentAbstract", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.nwbio.com/role/StatementConsolidatedBalanceSheets" ], "xbrltype": "stringItemType" }, "us-gaap_LiabilitiesFairValueDisclosure": { "auth_ref": [ "r338" ], "calculation": { "http://www.nwbio.com/role/DisclosureFairValueMeasurementsDetails": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Fair value of financial and nonfinancial obligations.", "label": "Financial and Nonfinancial Liabilities, Fair Value Disclosure", "totalLabel": "Total fair value" } } }, "localname": "LiabilitiesFairValueDisclosure", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.nwbio.com/role/DisclosureFairValueMeasurementsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LiabilitiesNoncurrent": { "auth_ref": [ "r5", "r6", "r7", "r19", "r20", "r97", "r168", "r320", "r324", "r325", "r351" ], "calculation": { "http://www.nwbio.com/role/StatementConsolidatedBalanceSheets": { "order": 2.0, "parentTag": "us-gaap_Liabilities", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of obligation due after one year or beyond the normal operating cycle, if longer.", "label": "Liabilities, Noncurrent", "totalLabel": "Total non-current liabilities" } } }, "localname": "LiabilitiesNoncurrent", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.nwbio.com/role/StatementConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_LiabilitiesNoncurrentAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Liabilities, Noncurrent [Abstract]", "verboseLabel": "Non-current liabilities:" } } }, "localname": "LiabilitiesNoncurrentAbstract", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.nwbio.com/role/StatementConsolidatedBalanceSheets" ], "xbrltype": "stringItemType" }, "us-gaap_LineOfCreditFacilityAxis": { "auth_ref": [ "r39", "r100" ], "lang": { "en-us": { "role": { "documentation": "Information by name of lender, which may be a single entity (for example, but not limited to, a bank, pension fund, venture capital firm) or a group of entities that participate in the line of credit.", "label": "Lender Name [Axis]" } } }, "localname": "LineOfCreditFacilityAxis", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.nwbio.com/role/DisclosureNotesPayableAdditionalInformationDetails" ], "xbrltype": "stringItemType" }, "us-gaap_LineOfCreditFacilityLenderDomain": { "auth_ref": [ "r39" ], "lang": { "en-us": { "role": { "documentation": "Identification of the lender, which may be a single entity (for example, a bank, pension fund, venture capital firm) or a group of entities that participate in the line of credit, including a letter of credit facility.", "label": "Line Of Credit Facility Lender [Domain]", "terseLabel": "Line of Credit Facility, Lender [Domain]" } } }, "localname": "LineOfCreditFacilityLenderDomain", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.nwbio.com/role/DisclosureNotesPayableAdditionalInformationDetails" ], "xbrltype": "domainItemType" }, "us-gaap_LitigationSettlementAmountAwardedToOtherParty": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount awarded to other party in judgment or settlement of litigation.", "label": "Litigation Settlement, Amount Awarded to Other Party", "terseLabel": "Approved tax settlement offer" } } }, "localname": "LitigationSettlementAmountAwardedToOtherParty", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.nwbio.com/role/DisclosureCommitmentsAndContingenciesAdditionalInformationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LongTermDebt": { "auth_ref": [ "r19", "r194", "r427", "r441" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount, after unamortized (discount) premium and debt issuance costs, of long-term debt. Includes, but not limited to, notes payable, bonds payable, debentures, mortgage loans and commercial paper. Excludes capital lease obligations.", "label": "Long-term Debt", "netLabel": "Carrying Value", "verboseLabel": "Debt Instrument, Carrying Value" } } }, "localname": "LongTermDebt", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.nwbio.com/role/DisclosureNotesPayableAdditionalInformationDetails", "http://www.nwbio.com/role/DisclosureNotesPayableDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LongTermNotesPayable": { "auth_ref": [ "r46" ], "calculation": { "http://www.nwbio.com/role/StatementConsolidatedBalanceSheets": { "order": 1.0, "parentTag": "us-gaap_LiabilitiesNoncurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Carrying value as of the balance sheet date of notes payable (with maturities initially due after one year or beyond the operating cycle if longer), excluding current portion.", "label": "Notes Payable, Noncurrent", "verboseLabel": "Note payable, net of current portion, net" } } }, "localname": "LongTermNotesPayable", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.nwbio.com/role/StatementConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_LongtermDebtTypeAxis": { "auth_ref": [ "r46" ], "lang": { "en-us": { "role": { "documentation": "Information by type of long-term debt.", "label": "Long-term Debt, Type [Axis]" } } }, "localname": "LongtermDebtTypeAxis", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.nwbio.com/role/DisclosureNotesPayableAdditionalInformationDetails" ], "xbrltype": "stringItemType" }, "us-gaap_LongtermDebtTypeDomain": { "auth_ref": [ "r46", "r192" ], "lang": { "en-us": { "role": { "documentation": "Type of long-term debt arrangement, such as notes, line of credit, commercial paper, asset-based financing, project financing, letter of credit financing. These are debt arrangements that originally required repayment more than twelve months after issuance or greater than the normal operating cycle of the company, if longer.", "label": "Longterm Debt Type [Domain]", "terseLabel": "Long-term Debt, Type [Domain]" } } }, "localname": "LongtermDebtTypeDomain", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.nwbio.com/role/DisclosureNotesPayableAdditionalInformationDetails" ], "xbrltype": "domainItemType" }, "us-gaap_NetCashProvidedByUsedInFinancingActivities": { "auth_ref": [ "r82" ], "calculation": { "http://www.nwbio.com/role/StatementConsolidatedStatementsOfCashFlows": { "order": 4.0, "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.", "label": "Net Cash Provided by (Used in) Financing Activities", "totalLabel": "Net cash provided by financing activities" } } }, "localname": "NetCashProvidedByUsedInFinancingActivities", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.nwbio.com/role/StatementConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Net Cash Provided by (Used in) Financing Activities [Abstract]", "terseLabel": "Cash Flows from Financing Activities:" } } }, "localname": "NetCashProvidedByUsedInFinancingActivitiesAbstract", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.nwbio.com/role/StatementConsolidatedStatementsOfCashFlows" ], "xbrltype": "stringItemType" }, "us-gaap_NetCashProvidedByUsedInInvestingActivities": { "auth_ref": [ "r82" ], "calculation": { "http://www.nwbio.com/role/StatementConsolidatedStatementsOfCashFlows": { "order": 3.0, "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets.", "label": "Net Cash Provided by (Used in) Investing Activities", "totalLabel": "Net cash used in investing activities" } } }, "localname": "NetCashProvidedByUsedInInvestingActivities", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.nwbio.com/role/StatementConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Net Cash Provided by (Used in) Investing Activities [Abstract]", "terseLabel": "Cash Flows from Investing Activities:" } } }, "localname": "NetCashProvidedByUsedInInvestingActivitiesAbstract", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.nwbio.com/role/StatementConsolidatedStatementsOfCashFlows" ], "xbrltype": "stringItemType" }, "us-gaap_NetCashProvidedByUsedInOperatingActivities": { "auth_ref": [ "r82", "r84", "r87" ], "calculation": { "http://www.nwbio.com/role/StatementConsolidatedStatementsOfCashFlows": { "order": 1.0, "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect", "weight": 1.0 } }, "lang": { "en-us": { "role": { "documentation": "Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.", "label": "Net Cash Provided by (Used in) Operating Activities", "totalLabel": "Net cash used in operating activities" } } }, "localname": "NetCashProvidedByUsedInOperatingActivities", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.nwbio.com/role/DisclosureFinancialConditionGoingConcernAndManagementPlansDetailsTextual", "http://www.nwbio.com/role/DisclosureRevisionToPriorPeriodFinancialStatementsConsolidatedStatementOfCashFlowsDetaills", "http://www.nwbio.com/role/StatementConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Net Cash Provided by (Used in) Operating Activities [Abstract]", "verboseLabel": "Cash Flows from Operating Activities:" } } }, "localname": "NetCashProvidedByUsedInOperatingActivitiesAbstract", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.nwbio.com/role/DisclosureRevisionToPriorPeriodFinancialStatementsConsolidatedStatementOfCashFlowsDetaills", "http://www.nwbio.com/role/StatementConsolidatedStatementsOfCashFlows" ], "xbrltype": "stringItemType" }, "us-gaap_NetIncomeLoss": { "auth_ref": [ "r0", "r58", "r61", "r67", "r87", "r97", "r110", "r112", "r113", "r114", "r115", "r119", "r120", "r125", "r151", "r153", "r156", "r159", "r161", "r168", "r351", "r431", "r449" ], "calculation": { "http://www.nwbio.com/role/StatementCondensedConsolidatedStatementsOfOperationsCalc2": { "order": 1.0, "parentTag": "us-gaap_ComprehensiveIncomeNetOfTax", "weight": 1.0 }, "http://www.nwbio.com/role/StatementConsolidatedStatementsOfCashFlows": { "order": 1.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 }, "http://www.nwbio.com/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.", "label": "Net Income (Loss) Attributable to Parent", "terseLabel": "Net loss", "totalLabel": "Net loss" } } }, "localname": "NetIncomeLoss", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.nwbio.com/role/DisclosureFinancialConditionGoingConcernAndManagementPlansDetailsTextual", "http://www.nwbio.com/role/DisclosureRevisionToPriorPeriodFinancialStatementsConsolidatedStatementOfCashFlowsDetaills", "http://www.nwbio.com/role/DisclosureRevisionToPriorPeriodFinancialStatementsConsolidatedStatementOfOperationsDetaills", "http://www.nwbio.com/role/StatementConsolidatedStatementsOfCashFlows", "http://www.nwbio.com/role/StatementConsolidatedStatementsOfChangesInStockholdersDeficit", "http://www.nwbio.com/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss" ], "xbrltype": "monetaryItemType" }, "us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact.", "label": "New Accounting Pronouncements, Policy [Policy Text Block]", "verboseLabel": "Recent Accounting Standards" } } }, "localname": "NewAccountingPronouncementsPolicyPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.nwbio.com/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_NoncashOrPartNoncashAcquisitionNoncashFinancialOrEquityInstrumentConsiderationSharesIssued1": { "auth_ref": [ "r90", "r91", "r92" ], "lang": { "en-us": { "role": { "documentation": "The number of shares issued as [noncash or part noncash] consideration for a business or asset acquired. Noncash is defined as transactions during a period that affect recognized assets or liabilities but that do not result in cash receipts or cash payments in the period. \"Part noncash\" refers to that portion of the transaction not resulting in cash receipts or cash payments in the period.", "label": "Noncash or Part Noncash Acquisition, Noncash Financial or Equity Instrument Consideration, Shares Issued", "verboseLabel": "Issuance of common stock as consideration related to Flaskworks acquisition" } } }, "localname": "NoncashOrPartNoncashAcquisitionNoncashFinancialOrEquityInstrumentConsiderationSharesIssued1", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.nwbio.com/role/StatementConsolidatedStatementsOfCashFlows" ], "xbrltype": "sharesItemType" }, "us-gaap_NonoperatingIncomeExpenseAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Nonoperating Income (Expense) [Abstract]", "verboseLabel": "Other income (expense):" } } }, "localname": "NonoperatingIncomeExpenseAbstract", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.nwbio.com/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss" ], "xbrltype": "stringItemType" }, "us-gaap_NotesPayable": { "auth_ref": [ "r19", "r427", "r441" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Including the current and noncurrent portions, aggregate carrying amount of all types of notes payable, as of the balance sheet date, with initial maturities beyond one year or beyond the normal operating cycle, if longer.", "label": "Notes Payable.", "verboseLabel": "Notes Payable" } } }, "localname": "NotesPayable", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.nwbio.com/role/DisclosureNotesPayableAdditionalInformationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_NotesPayableCurrent": { "auth_ref": [ "r41" ], "calculation": { "http://www.nwbio.com/role/StatementConsolidatedBalanceSheets": { "order": 4.0, "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Sum of the carrying values as of the balance sheet date of the portions of long-term notes payable due within one year or the operating cycle if longer.", "label": "Notes Payable, Current", "terseLabel": "Notes payable, net" } } }, "localname": "NotesPayableCurrent", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.nwbio.com/role/StatementConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_NotesPayableOtherPayablesMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "A written promise to pay a note to a third party.", "label": "Notes Payable Other Payables [Member]", "terseLabel": "Notes payable" } } }, "localname": "NotesPayableOtherPayablesMember", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.nwbio.com/role/DisclosureNotesPayableMortgageLoanDetails", "http://www.nwbio.com/role/StatementConsolidatedStatementsOfCashFlows" ], "xbrltype": "domainItemType" }, "us-gaap_NotesPayableRelatedPartiesClassifiedCurrent": { "auth_ref": [ "r37", "r103", "r390" ], "calculation": { "http://www.nwbio.com/role/StatementConsolidatedBalanceSheets": { "order": 5.0, "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The amount for notes payable (written promise to pay), due to related parties. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).", "label": "Notes Payable, Related Parties, Current", "terseLabel": "Notes payable to related party" } } }, "localname": "NotesPayableRelatedPartiesClassifiedCurrent", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.nwbio.com/role/StatementConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_NumberOfOperatingSegments": { "auth_ref": [ "r146" ], "lang": { "en-us": { "role": { "documentation": "Number of operating segments. An operating segment is a component of an enterprise: (a) that engages in business activities from which it may earn revenues and incur expenses (including revenues and expenses relating to transactions with other components of the same enterprise), (b) whose operating results are regularly reviewed by the enterprise's chief operating decision maker to make decisions about resources to be allocated to the segment and assess its performance, and (c) for which discrete financial information is available. An operating segment may engage in business activities for which it has yet to earn revenues, for example, start-up operations may be operating segments before earning revenues.", "label": "Number of Operating Segments" } } }, "localname": "NumberOfOperatingSegments", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.nwbio.com/role/DisclosureSummaryOfSignificantAccountingPoliciesDetails" ], "xbrltype": "integerItemType" }, "us-gaap_NumberOfReportableSegments": { "auth_ref": [ "r146" ], "lang": { "en-us": { "role": { "documentation": "Number of segments reported by the entity. A reportable segment is a component of an entity for which there is an accounting requirement to report separate financial information on that component in the entity's financial statements.", "label": "Number of Reportable Segments", "verboseLabel": "Number of reporting segments" } } }, "localname": "NumberOfReportableSegments", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.nwbio.com/role/DisclosureSummaryOfSignificantAccountingPoliciesDetails" ], "xbrltype": "integerItemType" }, "us-gaap_OperatingCostsAndExpenses": { "auth_ref": [], "calculation": { "http://www.nwbio.com/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss": { "order": 2.0, "parentTag": "us-gaap_OperatingIncomeLoss", "weight": -1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Generally recurring costs associated with normal operations except for the portion of these expenses which can be clearly related to production and included in cost of sales or services. Excludes Selling, General and Administrative Expense.", "label": "Operating Costs and Expenses", "totalLabel": "Total operating costs and expenses", "verboseLabel": "Total operating costs and expenses" } } }, "localname": "OperatingCostsAndExpenses", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.nwbio.com/role/DisclosureRevisionToPriorPeriodFinancialStatementsConsolidatedStatementOfOperationsDetaills", "http://www.nwbio.com/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingIncomeLoss": { "auth_ref": [ "r151", "r153", "r156", "r159", "r161" ], "calculation": { "http://www.nwbio.com/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss": { "order": 1.0, "parentTag": "us-gaap_NetIncomeLoss", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The net result for the period of deducting operating expenses from operating revenues.", "label": "Operating Income (Loss)", "totalLabel": "Loss from operations" } } }, "localname": "OperatingIncomeLoss", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.nwbio.com/role/DisclosureRevisionToPriorPeriodFinancialStatementsConsolidatedStatementOfOperationsDetaills", "http://www.nwbio.com/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingLeaseCost": { "auth_ref": [ "r376", "r384" ], "calculation": { "http://www.nwbio.com/role/DisclosureCommitmentsAndContingenciesDetails": { "order": 1.0, "parentTag": "us-gaap_LeaseCost", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of single lease cost, calculated by allocation of remaining cost of lease over remaining lease term. Includes, but is not limited to, single lease cost, after impairment of right-of-use asset, calculated by amortization of remaining right-of-use asset and accretion of lease liability.", "label": "Operating Lease, Cost", "verboseLabel": "Operating lease cost" } } }, "localname": "OperatingLeaseCost", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.nwbio.com/role/DisclosureCommitmentsAndContingenciesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingLeaseLiability": { "auth_ref": [ "r372" ], "calculation": { "http://www.nwbio.com/role/DisclosureCommitmentsAndContingenciesMaturitiesOfOurOperatingLeasesDetailsCalc2": { "order": 2.0, "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease.", "label": "Operating Lease, Liability", "terseLabel": "Operating lease liabilities included in the Consolidated Balance Sheet at December 31, 2020" } } }, "localname": "OperatingLeaseLiability", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.nwbio.com/role/DisclosureCommitmentsAndContingenciesAdditionalInformationDetails", "http://www.nwbio.com/role/DisclosureCommitmentsAndContingenciesMaturitiesOfOurOperatingLeasesDetails", "http://www.nwbio.com/role/DisclosureSummaryOfSignificantAccountingPoliciesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingLeaseLiabilityCurrent": { "auth_ref": [ "r372" ], "calculation": { "http://www.nwbio.com/role/StatementConsolidatedBalanceSheets": { "order": 8.0, "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as current.", "label": "Operating Lease, Liability, Current", "verboseLabel": "Lease liabilities" } } }, "localname": "OperatingLeaseLiabilityCurrent", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.nwbio.com/role/StatementConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingLeaseLiabilityNoncurrent": { "auth_ref": [ "r372" ], "calculation": { "http://www.nwbio.com/role/StatementConsolidatedBalanceSheets": { "order": 2.0, "parentTag": "us-gaap_LiabilitiesNoncurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent.", "label": "Operating Lease, Liability, Noncurrent", "verboseLabel": "Lease liabilities, net of current portion" } } }, "localname": "OperatingLeaseLiabilityNoncurrent", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.nwbio.com/role/StatementConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingLeasePayments": { "auth_ref": [ "r373", "r379" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of cash outflow from operating lease, excluding payments to bring another asset to condition and location necessary for its intended use.", "label": "Operating Lease, Payments", "negatedLabel": "Operating cash flows from operating leases" } } }, "localname": "OperatingLeasePayments", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.nwbio.com/role/DisclosureCommitmentsAndContingenciesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingLeaseRightOfUseAsset": { "auth_ref": [ "r371" ], "calculation": { "http://www.nwbio.com/role/StatementConsolidatedBalanceSheets": { "order": 3.0, "parentTag": "us-gaap_AssetsNoncurrent", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of lessee's right to use underlying asset under operating lease.", "label": "Operating Lease, Right-of-Use Asset", "verboseLabel": "Right-of-use asset, net" } } }, "localname": "OperatingLeaseRightOfUseAsset", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.nwbio.com/role/DisclosureCommitmentsAndContingenciesAdditionalInformationDetails", "http://www.nwbio.com/role/DisclosureSummaryOfSignificantAccountingPoliciesDetails", "http://www.nwbio.com/role/StatementConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent": { "auth_ref": [ "r381", "r384" ], "lang": { "en-us": { "role": { "documentation": "Weighted average discount rate for operating lease calculated at point in time.", "label": "Operating Lease, Weighted Average Discount Rate, Percent", "verboseLabel": "Weighted-average discount rate - operating leases" } } }, "localname": "OperatingLeaseWeightedAverageDiscountRatePercent", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.nwbio.com/role/DisclosureCommitmentsAndContingenciesDetails" ], "xbrltype": "percentItemType" }, "us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1": { "auth_ref": [ "r380", "r384" ], "lang": { "en-us": { "role": { "documentation": "Weighted average remaining lease term for operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.", "label": "Operating Lease, Weighted Average Remaining Lease Term", "verboseLabel": "Weighted-average remaining lease term - operating leases" } } }, "localname": "OperatingLeaseWeightedAverageRemainingLeaseTerm1", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.nwbio.com/role/DisclosureCommitmentsAndContingenciesDetails" ], "xbrltype": "durationItemType" }, "us-gaap_OperatingLossCarryforwards": { "auth_ref": [ "r287" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of operating loss carryforward, before tax effects, available to reduce future taxable income under enacted tax laws.", "label": "Operating Loss Carryforwards" } } }, "localname": "OperatingLossCarryforwards", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.nwbio.com/role/DisclosureIncomeTaxesAdditionalInformationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Organization and Description of Business" } } }, "localname": "OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "xbrltype": "stringItemType" }, "us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock": { "auth_ref": [ "r1", "r326" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for organization, consolidation and basis of presentation of financial statements disclosure.", "label": "Organization, Consolidation and Presentation of Financial Statements Disclosure [Text Block]", "verboseLabel": "Organization and Description of Business" } } }, "localname": "OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.nwbio.com/role/DisclosureOrganizationAndDescriptionOfBusiness" ], "xbrltype": "textBlockItemType" }, "us-gaap_OtherAssetsNoncurrent": { "auth_ref": [ "r36" ], "calculation": { "http://www.nwbio.com/role/StatementConsolidatedBalanceSheets": { "order": 6.0, "parentTag": "us-gaap_AssetsNoncurrent", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of noncurrent assets classified as other.", "label": "Other Assets, Noncurrent", "verboseLabel": "Other assets" } } }, "localname": "OtherAssetsNoncurrent", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.nwbio.com/role/StatementConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentTax": { "auth_ref": [ "r51", "r54", "r353", "r361" ], "calculation": { "http://www.nwbio.com/role/StatementCondensedConsolidatedStatementsOfOperationsCalc2": { "order": 2.0, "parentTag": "us-gaap_ComprehensiveIncomeNetOfTax", "weight": -1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of tax expense (benefit), after reclassification adjustments of gain (loss) on foreign currency translation adjustments, foreign currency transactions designated and effective as economic hedges of a net investment in a foreign entity and intra-entity foreign currency transactions that are of a long-term-investment nature.", "label": "Other Comprehensive Income (Loss), Foreign Currency Translation Adjustment, Tax", "negatedTerseLabel": "Foreign currency translation adjustment" } } }, "localname": "OtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentTax", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.nwbio.com/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent": { "auth_ref": [ "r59", "r62", "r317", "r318", "r322" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount after tax of other comprehensive income (loss) attributable to parent entity.", "label": "Other Comprehensive Income (Loss), Net of Tax, Portion Attributable to Parent", "verboseLabel": "Cumulative translation adjustment" } } }, "localname": "OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.nwbio.com/role/StatementConsolidatedStatementsOfChangesInStockholdersDeficit" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherComprehensiveIncomeLossTaxAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Other Comprehensive Income (Loss), Tax [Abstract]", "verboseLabel": "Other comprehensive loss" } } }, "localname": "OtherComprehensiveIncomeLossTaxAbstract", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.nwbio.com/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss" ], "xbrltype": "stringItemType" }, "us-gaap_OtherNonoperatingIncomeExpense": { "auth_ref": [ "r73" ], "calculation": { "http://www.nwbio.com/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss": { "order": 2.0, "parentTag": "us-gaap_NetIncomeLoss", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of income (expense) related to nonoperating activities, classified as other.", "label": "Other Nonoperating Income (Expense)", "totalLabel": "Total other income(expense)" } } }, "localname": "OtherNonoperatingIncomeExpense", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.nwbio.com/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss" ], "xbrltype": "monetaryItemType" }, "us-gaap_PaymentsForRepurchaseOfInitialPublicOffering": { "auth_ref": [ "r78" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The cash outflow associated with the repurchase of amount received from entity's first offering of stock to the public.", "label": "Payments for Repurchase of Initial Public Offering" } } }, "localname": "PaymentsForRepurchaseOfInitialPublicOffering", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.nwbio.com/role/DisclosureStockholdersDeficitAdditionalInformationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_PaymentsOfStockIssuanceCosts": { "auth_ref": [ "r80" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The cash outflow for cost incurred directly with the issuance of an equity security.", "label": "Payments of Stock Issuance Costs", "verboseLabel": "Payments of stock issuance costs" } } }, "localname": "PaymentsOfStockIssuanceCosts", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.nwbio.com/role/DisclosureStockholdersDeficitAdditionalInformationDetails", "http://www.nwbio.com/role/StatementConsolidatedStatementsOfChangesInStockholdersDeficitParenthetical" ], "xbrltype": "monetaryItemType" }, "us-gaap_PaymentsToAcquireBusinessesGross": { "auth_ref": [ "r74", "r314" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The cash outflow associated with the acquisition of business during the period. The cash portion only of the acquisition price.", "label": "Payments to Acquire Businesses, Gross", "terseLabel": "Purchase price paid in cash", "verboseLabel": "Purchase price paid in cash" } } }, "localname": "PaymentsToAcquireBusinessesGross", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.nwbio.com/role/DisclosureFlaskworksAcquisitionDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired": { "auth_ref": [ "r74" ], "calculation": { "http://www.nwbio.com/role/StatementConsolidatedStatementsOfCashFlows": { "order": 2.0, "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The cash outflow associated with the acquisition of a business, net of the cash acquired from the purchase.", "label": "Payments to Acquire Businesses, Net of Cash Acquired", "negatedLabel": "Acquisition of Flaskworks, net of cash" } } }, "localname": "PaymentsToAcquireBusinessesNetOfCashAcquired", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.nwbio.com/role/StatementConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_PaymentsToAcquireOtherProductiveAssets": { "auth_ref": [ "r75" ], "calculation": { "http://www.nwbio.com/role/StatementConsolidatedStatementsOfCashFlows": { "order": 1.0, "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of cash outflow for the purchase of or improvements to tangible or intangible assets, used to produce goods or deliver services, classified as other.", "label": "Payments to Acquire Other Productive Assets", "negatedLabel": "Purchase of equipment and construction in progress" } } }, "localname": "PaymentsToAcquireOtherProductiveAssets", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.nwbio.com/role/StatementConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_PreferredStockParOrStatedValuePerShare": { "auth_ref": [ "r22" ], "lang": { "en-us": { "role": { "documentation": "Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer.", "label": "Preferred Stock, Par or Stated Value Per Share", "terseLabel": "Preferred stock, par value (in dollars per share)" } } }, "localname": "PreferredStockParOrStatedValuePerShare", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.nwbio.com/role/DisclosureStockholdersDeficitAdditionalInformationDetails", "http://www.nwbio.com/role/StatementConsolidatedBalanceSheetsParenthetical" ], "xbrltype": "perShareItemType" }, "us-gaap_PreferredStockSharesAuthorized": { "auth_ref": [ "r22" ], "lang": { "en-us": { "role": { "documentation": "The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws.", "label": "Preferred Stock, Shares Authorized", "terseLabel": "Preferred Stock, shares authorized" } } }, "localname": "PreferredStockSharesAuthorized", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.nwbio.com/role/DisclosureStockholdersDeficitAdditionalInformationDetails", "http://www.nwbio.com/role/StatementConsolidatedBalanceSheetsParenthetical" ], "xbrltype": "sharesItemType" }, "us-gaap_PreferredStockValue": { "auth_ref": [ "r22" ], "calculation": { "http://www.nwbio.com/role/StatementConsolidatedBalanceSheets": { "order": 1.0, "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Aggregate par or stated value of issued nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable preferred shares, par value and other disclosure concepts are in another section within stockholders' equity.", "label": "Preferred Stock, Value, Issued", "verboseLabel": "Preferred stock ($0.001 par value); 100,000,000 shares authorized as of December 31, 2020 and 2019, respectively" } } }, "localname": "PreferredStockValue", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.nwbio.com/role/StatementConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_PrepaidExpenseAndOtherAssetsCurrent": { "auth_ref": [ "r3", "r30", "r31" ], "calculation": { "http://www.nwbio.com/role/StatementConsolidatedBalanceSheets": { "order": 2.0, "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer.", "label": "Prepaid Expense and Other Assets, Current", "verboseLabel": "Prepaid expenses and other current assets" } } }, "localname": "PrepaidExpenseAndOtherAssetsCurrent", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.nwbio.com/role/StatementConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_ProceedsFromConvertibleDebt": { "auth_ref": [ "r77" ], "calculation": { "http://www.nwbio.com/role/StatementConsolidatedStatementsOfCashFlows": { "order": 4.0, "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The cash inflow from the issuance of a long-term debt instrument which can be exchanged for a specified amount of another security, typically the entity's common stock, at the option of the issuer or the holder.", "label": "Proceeds from Convertible Debt", "terseLabel": "Proceeds from issuance of convertible notes payable, net" } } }, "localname": "ProceedsFromConvertibleDebt", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.nwbio.com/role/DisclosureStockholdersDeficitAdditionalInformationDetails", "http://www.nwbio.com/role/StatementConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_ProceedsFromIssuanceInitialPublicOffering": { "auth_ref": [ "r76" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The cash inflow associated with the amount received from entity's first offering of stock to the public.", "label": "Proceeds from Issuance Initial Public Offering" } } }, "localname": "ProceedsFromIssuanceInitialPublicOffering", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.nwbio.com/role/DisclosureStockholdersDeficitAdditionalInformationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_ProceedsFromIssuanceOfDebt": { "auth_ref": [ "r77" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The cash inflow during the period from additional borrowings in aggregate debt. Includes proceeds from short-term and long-term debt.", "label": "Proceeds from Issuance of Debt", "verboseLabel": "Proceeds from issuance of debt" } } }, "localname": "ProceedsFromIssuanceOfDebt", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.nwbio.com/role/DisclosureNotesPayableAdditionalInformationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_ProceedsFromIssuanceOfWarrants": { "auth_ref": [ "r76" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The cash inflow from issuance of rights to purchase common shares at predetermined price (usually issued together with corporate debt).", "label": "Proceeds from Issuance of Warrants", "verboseLabel": "Proceeds from issuance of warrants" } } }, "localname": "ProceedsFromIssuanceOfWarrants", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.nwbio.com/role/DisclosureStockholdersDeficitAdditionalInformationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_ProceedsFromNotesPayable": { "auth_ref": [ "r77" ], "calculation": { "http://www.nwbio.com/role/StatementConsolidatedStatementsOfCashFlows": { "order": 2.0, "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The cash inflow from a borrowing supported by a written promise to pay an obligation.", "label": "Proceeds from Notes Payable", "verboseLabel": "Proceeds from issuance of notes payable, net" } } }, "localname": "ProceedsFromNotesPayable", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.nwbio.com/role/StatementConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_ProceedsFromRelatedPartyDebt": { "auth_ref": [ "r77" ], "calculation": { "http://www.nwbio.com/role/StatementConsolidatedStatementsOfCashFlows": { "order": 3.0, "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The cash inflow from a long-term borrowing made from related parties where one party can exercise control or significant influence over another party; including affiliates, owners or officers and their immediate families, pension trusts, and so forth. Alternate caption: Proceeds from Advances from Affiliates.", "label": "Proceeds from Related Party Debt", "terseLabel": "Proceeds from issuance of convertible notes payable to related party" } } }, "localname": "ProceedsFromRelatedPartyDebt", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.nwbio.com/role/StatementConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_ProceedsFromStockOptionsExercised": { "auth_ref": [ "r76", "r262" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of cash inflow from exercise of option under share-based payment arrangement.", "label": "Proceeds from Stock Options Exercised", "terseLabel": "Proceeds from exercise of stock options" } } }, "localname": "ProceedsFromStockOptionsExercised", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.nwbio.com/role/DisclosureSubsequentEventsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_ProceedsFromWarrantExercises": { "auth_ref": [ "r76" ], "calculation": { "http://www.nwbio.com/role/StatementConsolidatedStatementsOfCashFlows": { "order": 7.0, "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The cash inflow associated with the amount received from holders exercising their stock warrants.", "label": "Proceeds from Warrant Exercises", "terseLabel": "Proceeds from exercise of warrants", "verboseLabel": "Aggregate proceeds from exercise of warrants" } } }, "localname": "ProceedsFromWarrantExercises", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.nwbio.com/role/DisclosureStockholdersDeficitAdditionalInformationDetails", "http://www.nwbio.com/role/DisclosureSubsequentEventsDetails", "http://www.nwbio.com/role/StatementConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_PropertyPlantAndEquipmentAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Property, Plant and Equipment" } } }, "localname": "PropertyPlantAndEquipmentAbstract", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "xbrltype": "stringItemType" }, "us-gaap_PropertyPlantAndEquipmentByTypeAxis": { "auth_ref": [ "r35", "r182" ], "lang": { "en-us": { "role": { "documentation": "Information by type of long-lived, physical assets used to produce goods and services and not intended for resale.", "label": "Property, Plant and Equipment, Type [Axis]" } } }, "localname": "PropertyPlantAndEquipmentByTypeAxis", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.nwbio.com/role/DisclosurePropertyPlantAndEquipmentDetails" ], "xbrltype": "stringItemType" }, "us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock": { "auth_ref": [ "r184", "r470", "r471", "r472" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for long-lived, physical asset used in normal conduct of business and not intended for resale. Includes, but is not limited to, work of art, historical treasure, and similar asset classified as collections.", "label": "Property, Plant and Equipment Disclosure [Text Block]", "verboseLabel": "Property, Plant and Equipment" } } }, "localname": "PropertyPlantAndEquipmentDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.nwbio.com/role/DisclosurePropertyPlantAndEquipment" ], "xbrltype": "textBlockItemType" }, "us-gaap_PropertyPlantAndEquipmentGross": { "auth_ref": [ "r34", "r180" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount before accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.", "label": "Property, Plant and Equipment, Gross", "verboseLabel": "Property, Plant and Equipment, Gross" } } }, "localname": "PropertyPlantAndEquipmentGross", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.nwbio.com/role/DisclosurePropertyPlantAndEquipmentDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_PropertyPlantAndEquipmentNet": { "auth_ref": [ "r11", "r12", "r182", "r445" ], "calculation": { "http://www.nwbio.com/role/StatementConsolidatedBalanceSheets": { "order": 1.0, "parentTag": "us-gaap_AssetsNoncurrent", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.", "label": "Property, Plant and Equipment, Net", "terseLabel": "Property, plant and equipment, net", "verboseLabel": "Total property, plant and equipment, net" } } }, "localname": "PropertyPlantAndEquipmentNet", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.nwbio.com/role/DisclosurePropertyPlantAndEquipmentDetails", "http://www.nwbio.com/role/StatementConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_PropertyPlantAndEquipmentOtherTypesMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Long-lived, physical assets used to produce goods and services and not intended for resale, classified as other.", "label": "Property Plant And Equipment Other Types [Member]", "terseLabel": "Computer equipment and software [Member]" } } }, "localname": "PropertyPlantAndEquipmentOtherTypesMember", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.nwbio.com/role/DisclosurePropertyPlantAndEquipmentDetails" ], "xbrltype": "domainItemType" }, "us-gaap_PropertyPlantAndEquipmentPolicyTextBlock": { "auth_ref": [ "r33", "r93", "r182", "r470", "r471" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for long-lived, physical asset used in normal conduct of business and not intended for resale. Includes, but is not limited to, work of art, historical treasure, and similar asset classified as collections.", "label": "Property, Plant and Equipment, Policy [Policy Text Block]", "terseLabel": "Property, Plant and Equipment" } } }, "localname": "PropertyPlantAndEquipmentPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.nwbio.com/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_PropertyPlantAndEquipmentTextBlock": { "auth_ref": [ "r11", "r182" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation.", "label": "Property, Plant and Equipment [Table Text Block]", "verboseLabel": "Schedule of property and equipment" } } }, "localname": "PropertyPlantAndEquipmentTextBlock", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.nwbio.com/role/DisclosurePropertyPlantAndEquipmentTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_PropertyPlantAndEquipmentTypeDomain": { "auth_ref": [ "r11", "r180" ], "lang": { "en-us": { "role": { "documentation": "Listing of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale. Examples include land, buildings, machinery and equipment, and other types of furniture and equipment including, but not limited to, office equipment, furniture and fixtures, and computer equipment and software.", "label": "Property Plant And Equipment Type [Domain]", "terseLabel": "Property, Plant and Equipment, Type [Domain]" } } }, "localname": "PropertyPlantAndEquipmentTypeDomain", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.nwbio.com/role/DisclosurePropertyPlantAndEquipmentDetails" ], "xbrltype": "domainItemType" }, "us-gaap_PropertyPlantAndEquipmentUsefulLife": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Useful life of long lived, physical assets used in the normal conduct of business and not intended for resale, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days. Examples include, but not limited to, land, buildings, machinery and equipment, office equipment, furniture and fixtures, and computer equipment.", "label": "Property, Plant and Equipment, Useful Life" } } }, "localname": "PropertyPlantAndEquipmentUsefulLife", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.nwbio.com/role/DisclosurePropertyPlantAndEquipmentDetails" ], "xbrltype": "durationItemType" }, "us-gaap_RelatedPartyDomain": { "auth_ref": [ "r228", "r388", "r389" ], "lang": { "en-us": { "role": { "documentation": "Related parties include affiliates; other entities for which investments are accounted for by the equity method by the entity; trusts for benefit of employees; and principal owners, management, and members of immediate families. It also may include other parties with which the entity may control or can significantly influence the management or operating policies of the other to an extent that one of the transacting parties might be prevented from fully pursuing its own separate interests.", "label": "Related Party [Domain]", "terseLabel": "Related Party [Domain]" } } }, "localname": "RelatedPartyDomain", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.nwbio.com/role/DisclosureRelatedPartyTransactionsAdditionalInformationDetails", "http://www.nwbio.com/role/DisclosureRelatedPartyTransactionsSummaryOfOutstandingUnpaidAccountsPayableHeldByRelatedPartiesDetails", "http://www.nwbio.com/role/DisclosureStockholdersDeficitAdditionalInformationDetails", "http://www.nwbio.com/role/DisclosureSubsequentEventsDetails", "http://www.nwbio.com/role/StatementConsolidatedStatementsOfCashFlows" ], "xbrltype": "domainItemType" }, "us-gaap_RelatedPartyTransactionAxis": { "auth_ref": [ "r228", "r388", "r389", "r392" ], "lang": { "en-us": { "role": { "documentation": "Information by type of related party transaction.", "label": "Related Party Transaction [Axis]" } } }, "localname": "RelatedPartyTransactionAxis", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.nwbio.com/role/DisclosureNotesPayableAdditionalInformationDetails", "http://www.nwbio.com/role/DisclosureSummaryOfSignificantAccountingPoliciesDetails" ], "xbrltype": "stringItemType" }, "us-gaap_RelatedPartyTransactionDomain": { "auth_ref": [ "r228" ], "lang": { "en-us": { "role": { "documentation": "Transaction between related party.", "label": "Related Party Transaction [Domain]", "terseLabel": "Related Party Transaction [Domain]" } } }, "localname": "RelatedPartyTransactionDomain", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.nwbio.com/role/DisclosureNotesPayableAdditionalInformationDetails", "http://www.nwbio.com/role/DisclosureSummaryOfSignificantAccountingPoliciesDetails" ], "xbrltype": "domainItemType" }, "us-gaap_RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty": { "auth_ref": [ "r388" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Expenses recognized resulting from transactions (excluding transactions that are eliminated in consolidated or combined financial statements) with related party.", "label": "Related Party Transaction, Expenses from Transactions with Related Party", "terseLabel": "Capitalized costs to related party" } } }, "localname": "RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.nwbio.com/role/DisclosureRelatedPartyTransactionsAdditionalInformationDetails", "http://www.nwbio.com/role/DisclosureRelatedPartyTransactionsSummaryOfOutstandingUnpaidAccountsPayableHeldByRelatedPartiesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_RelatedPartyTransactionLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Related Party Transaction [Line Items]" } } }, "localname": "RelatedPartyTransactionLineItems", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.nwbio.com/role/DisclosureRelatedPartyTransactionsAdditionalInformationDetails" ], "xbrltype": "stringItemType" }, "us-gaap_RelatedPartyTransactionsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Related Party Transactions" } } }, "localname": "RelatedPartyTransactionsAbstract", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "xbrltype": "stringItemType" }, "us-gaap_RelatedPartyTransactionsByRelatedPartyAxis": { "auth_ref": [ "r228", "r388", "r392", "r412", "r413", "r414", "r415", "r416", "r417", "r418", "r419", "r420", "r421", "r422", "r423" ], "lang": { "en-us": { "role": { "documentation": "Information by type of related party. Related parties include, but not limited to, affiliates; other entities for which investments are accounted for by the equity method by the entity; trusts for benefit of employees; and principal owners, management, and members of immediate families. It also may include other parties with which the entity may control or can significantly influence the management or operating policies of the other to an extent that one of the transacting parties might be prevented from fully pursuing its own separate interests.", "label": "Related Party [Axis]" } } }, "localname": "RelatedPartyTransactionsByRelatedPartyAxis", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.nwbio.com/role/DisclosureRelatedPartyTransactionsAdditionalInformationDetails", "http://www.nwbio.com/role/DisclosureRelatedPartyTransactionsSummaryOfOutstandingUnpaidAccountsPayableHeldByRelatedPartiesDetails", "http://www.nwbio.com/role/DisclosureStockholdersDeficitAdditionalInformationDetails", "http://www.nwbio.com/role/DisclosureSubsequentEventsDetails", "http://www.nwbio.com/role/StatementConsolidatedStatementsOfCashFlows" ], "xbrltype": "stringItemType" }, "us-gaap_RelatedPartyTransactionsDisclosureTextBlock": { "auth_ref": [ "r386", "r387", "r389", "r393", "r394" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for related party transactions. Examples of related party transactions include transactions between (a) a parent company and its subsidiary; (b) subsidiaries of a common parent; (c) and entity and its principal owners; and (d) affiliates.", "label": "Related Party Transactions Disclosure [Text Block]", "verboseLabel": "Related Party Transactions" } } }, "localname": "RelatedPartyTransactionsDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.nwbio.com/role/DisclosureRelatedPartyTransactions" ], "xbrltype": "textBlockItemType" }, "us-gaap_RepaymentsOfConvertibleDebt": { "auth_ref": [ "r79" ], "calculation": { "http://www.nwbio.com/role/StatementConsolidatedStatementsOfCashFlows": { "order": 5.0, "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The cash outflow from the repayment of a long-term debt instrument which can be exchanged for a specified amount of another security, typically the entity's common stock, at the option of the issuer or the holder.", "label": "Repayments of Convertible Debt", "negatedLabel": "Repayment of convertible notes payable" } } }, "localname": "RepaymentsOfConvertibleDebt", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.nwbio.com/role/StatementConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_RepaymentsOfDebt": { "auth_ref": [ "r79" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The cash outflow during the period from the repayment of aggregate short-term and long-term debt. Excludes payment of capital lease obligations.", "label": "Repayments of Debt" } } }, "localname": "RepaymentsOfDebt", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.nwbio.com/role/DisclosureNotesPayableAdditionalInformationDetails", "http://www.nwbio.com/role/DisclosureSubsequentEventsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_RepaymentsOfNotesPayable": { "auth_ref": [ "r79" ], "calculation": { "http://www.nwbio.com/role/StatementConsolidatedStatementsOfCashFlows": { "order": 9.0, "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The cash outflow for a borrowing supported by a written promise to pay an obligation.", "label": "Repayments of Notes Payable", "negatedLabel": "Repayment of notes payable" } } }, "localname": "RepaymentsOfNotesPayable", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.nwbio.com/role/StatementConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_RepaymentsOfRelatedPartyDebt": { "auth_ref": [ "r79" ], "calculation": { "http://www.nwbio.com/role/StatementConsolidatedStatementsOfCashFlows": { "order": 10.0, "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The cash outflow for the payment of a long-term borrowing made from a related party where one party can exercise control or significant influence over another party; including affiliates, owners or officers and their immediate families, pension trusts, and so forth. Alternate caption: Payments for Advances from Affiliates.", "label": "Repayments of Related Party Debt", "negatedTerseLabel": "Repayment of notes payable to related parties", "verboseLabel": "Repayments of notes" } } }, "localname": "RepaymentsOfRelatedPartyDebt", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.nwbio.com/role/DisclosureNotesPayableAdditionalInformationDetails", "http://www.nwbio.com/role/DisclosureRelatedPartyTransactionsAdditionalInformationDetails", "http://www.nwbio.com/role/StatementConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_ResearchAndDevelopmentExpense": { "auth_ref": [ "r272", "r482" ], "calculation": { "http://www.nwbio.com/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss": { "order": 1.0, "parentTag": "us-gaap_OperatingCostsAndExpenses", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use.", "label": "Research and Development Expense", "terseLabel": "Research and development", "verboseLabel": "Research and development expenses" } } }, "localname": "ResearchAndDevelopmentExpense", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.nwbio.com/role/DisclosureRevisionToPriorPeriodFinancialStatementsConsolidatedStatementOfOperationsDetaills", "http://www.nwbio.com/role/DisclosureStockholdersDeficitAdditionalInformationDetails", "http://www.nwbio.com/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss" ], "xbrltype": "monetaryItemType" }, "us-gaap_ResearchAndDevelopmentExpenseMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Primary financial statement caption in which the reported facts about research and development expense have been included.", "label": "Research And Development Expense [Member]", "terseLabel": "Research and development" } } }, "localname": "ResearchAndDevelopmentExpenseMember", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.nwbio.com/role/DisclosureStockBasedCompensationAdditionalInformationDetails", "http://www.nwbio.com/role/DisclosureStockBasedCompensationSummaryOfStockBasedCompensationExpenseDetails" ], "xbrltype": "domainItemType" }, "us-gaap_ResearchAndDevelopmentExpensePolicy": { "auth_ref": [ "r93", "r272" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for costs it has incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process.", "label": "Research and Development Expense, Policy [Policy Text Block]", "terseLabel": "Research and Development Costs" } } }, "localname": "ResearchAndDevelopmentExpensePolicy", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.nwbio.com/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_RetainedEarningsAccumulatedDeficit": { "auth_ref": [ "r25", "r204", "r266", "r443", "r461", "r466" ], "calculation": { "http://www.nwbio.com/role/StatementConsolidatedBalanceSheets": { "order": 5.0, "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The cumulative amount of the reporting entity's undistributed earnings or deficit.", "label": "Retained Earnings (Accumulated Deficit)", "terseLabel": "Cumulative effect of adopting new accounting standard", "verboseLabel": "Accumulated deficit" } } }, "localname": "RetainedEarningsAccumulatedDeficit", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.nwbio.com/role/DisclosureRevisionToPriorPeriodFinancialStatementsConsolidatedBalanceSheetDetails", "http://www.nwbio.com/role/DisclosureSummaryOfSignificantAccountingPoliciesDetails", "http://www.nwbio.com/role/StatementConsolidatedBalanceSheets", "http://www.nwbio.com/role/StatementConsolidatedStatementsOfChangesInStockholdersDeficit" ], "xbrltype": "monetaryItemType" }, "us-gaap_RetainedEarningsMember": { "auth_ref": [ "r105", "r106", "r108", "r111", "r117", "r120", "r169", "r263", "r264", "r265", "r293", "r294", "r457", "r459" ], "lang": { "en-us": { "role": { "documentation": "The cumulative amount of the reporting entity's undistributed earnings or deficit.", "label": "Retained Earnings [Member]", "terseLabel": "Accumulated Deficit" } } }, "localname": "RetainedEarningsMember", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.nwbio.com/role/StatementConsolidatedStatementsOfChangesInStockholdersDeficit" ], "xbrltype": "domainItemType" }, "us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax": { "auth_ref": [ "r147", "r148", "r152", "r157", "r158", "r162", "r163", "r165", "r215", "r216", "r411" ], "calculation": { "http://www.nwbio.com/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss": { "order": 1.0, "parentTag": "us-gaap_Revenues", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount, including tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value-added and excise.", "label": "Revenue from Contract with Customer, Including Assessed Tax", "verboseLabel": "Research and other" } } }, "localname": "RevenueFromContractWithCustomerIncludingAssessedTax", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.nwbio.com/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss" ], "xbrltype": "monetaryItemType" }, "us-gaap_RevenueFromContractWithCustomerPolicyTextBlock": { "auth_ref": [ "r94", "r207", "r208", "r209", "r210", "r211", "r212", "r213", "r214", "r219" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for revenue from contract with customer.", "label": "Revenue from Contract with Customer [Policy Text Block]", "terseLabel": "Revenue Recognition" } } }, "localname": "RevenueFromContractWithCustomerPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.nwbio.com/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_Revenues": { "auth_ref": [ "r66", "r97", "r147", "r148", "r152", "r157", "r158", "r162", "r163", "r165", "r168", "r351", "r435" ], "calculation": { "http://www.nwbio.com/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss": { "order": 1.0, "parentTag": "us-gaap_OperatingIncomeLoss", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of revenue recognized from goods sold, services rendered, insurance premiums, or other activities that constitute an earning process. Includes, but is not limited to, investment and interest income before deduction of interest expense when recognized as a component of revenue, and sales and trading gain (loss).", "label": "Revenues", "totalLabel": "Total revenues" } } }, "localname": "Revenues", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.nwbio.com/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss" ], "xbrltype": "monetaryItemType" }, "us-gaap_RevenuesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Revenues [Abstract]", "verboseLabel": "Revenues:" } } }, "localname": "RevenuesAbstract", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.nwbio.com/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss" ], "xbrltype": "stringItemType" }, "us-gaap_SaleOfStockNameOfTransactionDomain": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Sale of the entity's stock, including, but not limited to, initial public offering (IPO) and private placement.", "label": "Sale Of Stock Name Of Transaction [Domain]", "terseLabel": "Sale of Stock [Domain]" } } }, "localname": "SaleOfStockNameOfTransactionDomain", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.nwbio.com/role/DisclosureStockholdersDeficitAdditionalInformationDetails", "http://www.nwbio.com/role/StatementConsolidatedStatementsOfChangesInStockholdersDeficitParenthetical" ], "xbrltype": "domainItemType" }, "us-gaap_SaleOfStockPricePerShare": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Per share amount received by subsidiary or equity investee for each share of common stock issued or sold in the stock transaction.", "label": "Sale of Stock, Price Per Share" } } }, "localname": "SaleOfStockPricePerShare", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.nwbio.com/role/DisclosureStockholdersDeficitAdditionalInformationDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable": { "auth_ref": [ "r129" ], "lang": { "en-us": { "role": { "documentation": "Schedule for securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) in the future that were not included in the computation of diluted EPS because to do so would increase EPS amounts or decrease loss per share amounts for the period presented, by Antidilutive Securities.", "label": "Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table]" } } }, "localname": "ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.nwbio.com/role/DisclosureNetEarningsLossPerShareApplicableToCommonStockholdersDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock": { "auth_ref": [ "r129" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) in the future that were not included in the computation of diluted EPS because to do so would increase EPS amounts or decrease loss per share amounts for the period presented, by antidilutive securities.", "label": "Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table Text Block]", "terseLabel": "Schedule of antidilutive securities excluded from computation of earnings per share" } } }, "localname": "ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.nwbio.com/role/DisclosureNetLossPerShareApplicableToCommonStockholdersTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable": { "auth_ref": [ "r305", "r306" ], "lang": { "en-us": { "role": { "documentation": "Schedule reflecting each material business combination (or series of individually immaterial business combinations) completed during the period, including background, timing, and recognized assets and liabilities.", "label": "Schedule of Business Acquisitions, by Acquisition [Table]" } } }, "localname": "ScheduleOfBusinessAcquisitionsByAcquisitionTable", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.nwbio.com/role/DisclosureFlaskworksAcquisitionDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTextBlock": { "auth_ref": [ "r305", "r306" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of a material business combination completed during the period, including background, timing, and recognized assets and liabilities. This table does not include leveraged buyouts.", "label": "Schedule of Business Acquisitions, by Acquisition [Table Text Block]", "terseLabel": "Schedule of assets acquired and liabilities assumed" } } }, "localname": "ScheduleOfBusinessAcquisitionsByAcquisitionTextBlock", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.nwbio.com/role/DisclosureFlaskworksAcquisitionTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock": { "auth_ref": [ "r292" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of the components of income tax expense attributable to continuing operations for each year presented including, but not limited to: current tax expense (benefit), deferred tax expense (benefit), investment tax credits, government grants, the benefits of operating loss carryforwards, tax expense that results from allocating certain tax benefits either directly to contributed capital or to reduce goodwill or other noncurrent intangible assets of an acquired entity, adjustments of a deferred tax liability or asset for enacted changes in tax laws or rates or a change in the tax status of the entity, and adjustments of the beginning-of-the-year balances of a valuation allowance because of a change in circumstances that causes a change in judgment about the realizability of the related deferred tax asset in future years.", "label": "Schedule of Components of Income Tax Expense (Benefit) [Table Text Block]", "terseLabel": "Schedule of Components of Income Tax Expense (Benefit)" } } }, "localname": "ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.nwbio.com/role/DisclosureIncomeTaxesTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfDebtTableTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of information pertaining to short-term and long-debt instruments or arrangements, including but not limited to identification of terms, features, collateral requirements and other information necessary to a fair presentation.", "label": "Schedule of Debt [Table Text Block]", "terseLabel": "Schedule of outstanding debt" } } }, "localname": "ScheduleOfDebtTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.nwbio.com/role/DisclosureNotesPayableTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock": { "auth_ref": [ "r284" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of the components of net deferred tax asset or liability recognized in an entity's statement of financial position, including the following: the total of all deferred tax liabilities, the total of all deferred tax assets, the total valuation allowance recognized for deferred tax assets.", "label": "Schedule of Deferred Tax Assets and Liabilities [Table Text Block]", "terseLabel": "Schedule of Deferred Tax Assets and Liabilities" } } }, "localname": "ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.nwbio.com/role/DisclosureIncomeTaxesTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock": { "auth_ref": [ "r276" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of the reconciliation using percentage or dollar amounts of the reported amount of income tax expense attributable to continuing operations for the year to the amount of income tax expense that would result from applying domestic federal statutory tax rates to pretax income from continuing operations.", "label": "Schedule of Effective Income Tax Rate Reconciliation [Table Text Block]", "terseLabel": "Schedule of Effective Income Tax Rate Reconciliation" } } }, "localname": "ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.nwbio.com/role/DisclosureIncomeTaxesTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock": { "auth_ref": [ "r237", "r257", "r268" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of allocation of amount expensed and capitalized for award under share-based payment arrangement to statement of income or comprehensive income and statement of financial position. Includes, but is not limited to, corresponding line item in financial statement.", "label": "Schedule of Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Table Text Block]", "terseLabel": "Schedule of stock based compensation" } } }, "localname": "ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.nwbio.com/role/DisclosureStockBasedCompensationTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfErrorCorrectionsAndPriorPeriodAdjustmentRestatementTable": { "auth_ref": [ "r107", "r112", "r113", "r116", "r117", "r119", "r120", "r132" ], "lang": { "en-us": { "role": { "documentation": "Schedule of prior period adjustments to correct an error in previously issued financial statements. The disclosure may include, but is not limited to: (1) the effect of the correction on each financial statement line item and any per-share amounts affected for each prior period presented (2) the cumulative effect of the change on retained earnings or other appropriate components of equity or net assets in the statement of financial position, as of the beginning of the earliest period presented, and (3) the effect of the prior period adjustment (both gross and net of applicable income tax) on the net income of each prior period presented in the entity's annual report for the year in which the adjustments are made. This table can be used to disclose the amounts as previously reported and the effect of the correction or other adjustment on per line item or per share amount basis. This table uses as its line items financial statement line items that are affected by prior period adjustments.", "label": "Schedule of Error Corrections and Prior Period Adjustment Restatement [Table]" } } }, "localname": "ScheduleOfErrorCorrectionsAndPriorPeriodAdjustmentRestatementTable", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.nwbio.com/role/DisclosureRevisionToPriorPeriodFinancialStatementsConsolidatedBalanceSheetDetails", "http://www.nwbio.com/role/DisclosureRevisionToPriorPeriodFinancialStatementsConsolidatedStatementOfCashFlowsDetaills", "http://www.nwbio.com/role/DisclosureRevisionToPriorPeriodFinancialStatementsConsolidatedStatementOfOperationsDetaills" ], "xbrltype": "stringItemType" }, "us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock": { "auth_ref": [ "r338", "r339" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of assets and liabilities, including [financial] instruments measured at fair value that are classified in stockholders' equity, if any, that are measured at fair value on a recurring basis. The disclosures contemplated herein include the fair value measurements at the reporting date by the level within the fair value hierarchy in which the fair value measurements in their entirety fall, segregating fair value measurements using quoted prices in active markets for identical assets (Level 1), significant other observable inputs (Level 2), and significant unobservable inputs (Level 3).", "label": "Schedule of Fair Value, Assets and Liabilities Measured on Recurring Basis [Table Text Block]", "verboseLabel": "Schedule of fair value assets and liabilities measured on recurring basis" } } }, "localname": "ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.nwbio.com/role/DisclosureFairValueMeasurementsTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable": { "auth_ref": [ "r99", "r390", "r392" ], "lang": { "en-us": { "role": { "documentation": "Schedule of quantitative and qualitative information pertaining to related party transactions. Examples of related party transactions include transactions between (a) a parent company and its subsidiary; (b) subsidiaries of a common parent; (c) and entity and its principal owners; and (d) affiliates.", "label": "Schedule of Related Party Transactions, by Related Party [Table]" } } }, "localname": "ScheduleOfRelatedPartyTransactionsByRelatedPartyTable", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.nwbio.com/role/DisclosureRelatedPartyTransactionsAdditionalInformationDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ScheduleOfRelatedPartyTransactionsTableTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of related party transactions. Examples of related party transactions include, but are not limited to, transactions between (a) a parent company and its subsidiary; (b) subsidiaries of a common parent; (c) and entity and its principal owners and (d) affiliates.", "label": "Schedule of Related Party Transactions [Table Text Block]", "verboseLabel": "Schedule of outstanding unpaid accounts payable held by related parties" } } }, "localname": "ScheduleOfRelatedPartyTransactionsTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.nwbio.com/role/DisclosureRelatedPartyTransactionsTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock": { "auth_ref": [ "r242", "r248", "r250" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure for stock option plans. Includes, but is not limited to, outstanding awards at beginning and end of year, grants, exercises, forfeitures, and weighted-average grant date fair value.", "label": "Share-based Compensation, Stock Options, Activity [Table Text Block]", "terseLabel": "Schedule of stock-based compensation expense" } } }, "localname": "ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.nwbio.com/role/DisclosureStockBasedCompensationTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock": { "auth_ref": [ "r252" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of the significant assumptions used during the year to estimate the fair value of stock options, including, but not limited to: (a) expected term of share options and similar instruments, (b) expected volatility of the entity's shares, (c) expected dividends, (d) risk-free rate(s), and (e) discount for post-vesting restrictions.", "label": "Schedule of Share-based Payment Award, Stock Options, Valuation Assumptions [Table Text Block]", "verboseLabel": "Schedule of weighted average assumptions for stock options modification" } } }, "localname": "ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.nwbio.com/role/DisclosureStockBasedCompensationTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock": { "auth_ref": [ "r205", "r236" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of warrants or rights issued. Warrants and rights outstanding are derivative securities that give the holder the right to purchase securities (usually equity) from the issuer at a specific price within a certain time frame. Warrants are often included in a new debt issue to entice investors by a higher return potential. The main difference between warrants and call options is that warrants are issued and guaranteed by the company, whereas options are exchange instruments and are not issued by the company. Also, the lifetime of a warrant is often measured in years, while the lifetime of a typical option is measured in months. Disclose the title of issue of securities called for by warrants and rights outstanding, the aggregate amount of securities called for by warrants and rights outstanding, the date from which the warrants or rights are exercisable, and the price at which the warrant or right is exercisable.", "label": "Schedule of Stockholders' Equity Note, Warrants or Rights [Table Text Block]", "terseLabel": "Schedule of warrant activity" } } }, "localname": "ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.nwbio.com/role/DisclosureStockholdersDeficitTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Agreed-upon price for the exchange of the underlying asset relating to the share-based payment award.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Exercise Price", "verboseLabel": "Exercise price" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.nwbio.com/role/DisclosureStockBasedCompensationAssumptionsDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate": { "auth_ref": [ "r254" ], "lang": { "en-us": { "role": { "documentation": "The estimated measure of the percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Volatility Rate", "verboseLabel": "Expected stock price volatility" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.nwbio.com/role/DisclosureStockBasedCompensationAssumptionsDetails" ], "xbrltype": "percentItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate": { "auth_ref": [ "r255" ], "lang": { "en-us": { "role": { "documentation": "The risk-free interest rate assumption that is used in valuing an option on its own shares.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate", "verboseLabel": "Risk-free rate of interest" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.nwbio.com/role/DisclosureStockBasedCompensationAssumptionsDetails" ], "xbrltype": "percentItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Share-based Compensation Arrangement by Share-based Payment Award [Line Items]" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.nwbio.com/role/DisclosureStockBasedCompensationAdditionalInformationDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod": { "auth_ref": [ "r247" ], "lang": { "en-us": { "role": { "documentation": "Number of options or other stock instruments for which the right to exercise has lapsed under the terms of the plan agreements.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Expirations in Period", "terseLabel": "Share-based compensation arrangement by share-based payment award, options, cancelled in period" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.nwbio.com/role/DisclosureStockBasedCompensationAdditionalInformationDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod": { "auth_ref": [ "r246" ], "lang": { "en-us": { "role": { "documentation": "For presentations that combine terminations, the number of shares under options that were cancelled during the reporting period as a result of occurrence of a terminating event specified in contractual agreements pertaining to the stock option plan or that expired.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures and Expirations in Period", "negatedLabel": "Number of Shares, Forfeited/expired" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.nwbio.com/role/DisclosureStockBasedCompensationStockOptionActivityDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice": { "auth_ref": [ "r246" ], "lang": { "en-us": { "role": { "documentation": "Weighted average price of options that were either forfeited or expired.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures and Expirations in Period, Weighted Average Exercise Price", "verboseLabel": "Weighted Average Exercise Price, Forfeited/expired" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.nwbio.com/role/DisclosureStockBasedCompensationStockOptionActivityDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Gross number of share options (or share units) granted during the period.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross", "verboseLabel": "Number of Shares, Granted" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.nwbio.com/role/DisclosureStockBasedCompensationStockOptionActivityDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue": { "auth_ref": [ "r261" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount by which the current fair value of the underlying stock exceeds the exercise price of options outstanding.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Intrinsic Value", "periodEndLabel": "Total Intrinsic Value, Outstanding", "periodStartLabel": "Total Intrinsic Value, Outstanding" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.nwbio.com/role/DisclosureStockBasedCompensationStockOptionActivityDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber": { "auth_ref": [ "r244", "r261" ], "lang": { "en-us": { "role": { "documentation": "Number of options outstanding, including both vested and non-vested options.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Number", "periodEndLabel": "Number of Shares, Outstanding", "periodStartLabel": "Number of Shares, Outstanding", "terseLabel": "Number of Shares, Outstanding" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.nwbio.com/role/DisclosureStockBasedCompensationAdditionalInformationDetails", "http://www.nwbio.com/role/DisclosureStockBasedCompensationStockOptionActivityDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice": { "auth_ref": [ "r243" ], "lang": { "en-us": { "role": { "documentation": "Weighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price", "periodEndLabel": "Weighted Average Exercise Price, Outstanding", "periodStartLabel": "Weighted Average Exercise Price, Outstanding" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.nwbio.com/role/DisclosureStockBasedCompensationStockOptionActivityDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue": { "auth_ref": [ "r250" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount by which current fair value of underlying stock exceeds exercise price of fully vested and expected to vest options outstanding. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Outstanding, Aggregate Intrinsic Value", "verboseLabel": "Total Intrinsic Value, Options vested" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.nwbio.com/role/DisclosureStockBasedCompensationStockOptionActivityDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber": { "auth_ref": [ "r251" ], "lang": { "en-us": { "role": { "documentation": "Number of fully vested and expected to vest options outstanding that can be converted into shares under option plan. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Outstanding, Number", "verboseLabel": "Number of Shares, Options vested" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.nwbio.com/role/DisclosureStockBasedCompensationStockOptionActivityDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice": { "auth_ref": [ "r251" ], "lang": { "en-us": { "role": { "documentation": "Weighted-average exercise price, at which grantee can acquire shares reserved for issuance, for fully vested and expected to vest options outstanding. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Outstanding, Weighted Average Exercise Price", "terseLabel": "Weighted Average Exercise Price, Options vested" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.nwbio.com/role/DisclosureStockBasedCompensationStockOptionActivityDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPlanModificationIncrementalCompensationCost": { "auth_ref": [ "r259" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "An excess of the fair value of the modified award over the fair value of the award immediately before the modification.", "label": "Share-based Payment Arrangement, Plan Modification, Incremental Cost", "terseLabel": "Incremental stock-based compensation for stock options modification" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardPlanModificationIncrementalCompensationCost", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.nwbio.com/role/DisclosureStockBasedCompensationAdditionalInformationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain": { "auth_ref": [ "r236", "r240" ], "lang": { "en-us": { "role": { "documentation": "Award under share-based payment arrangement.", "label": "Share Based Compensation Arrangements By Share Based Payment Award Award Type And Plan Name [Domain]", "terseLabel": "Equity Award [Domain]" } } }, "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.nwbio.com/role/DisclosureRelatedPartyTransactionsAdditionalInformationDetails", "http://www.nwbio.com/role/DisclosureStockBasedCompensationAdditionalInformationDetails", "http://www.nwbio.com/role/DisclosureSubsequentEventsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Weighted average price at which option holders acquired shares when converting their stock options into shares.", "label": "Share-based Compensation Arrangements by Share-based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price", "terseLabel": "Exercise price of stock options", "verboseLabel": "Weighted Average Exercise Price, Cashless exercise" } } }, "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.nwbio.com/role/DisclosureStockBasedCompensationStockOptionActivityDetails", "http://www.nwbio.com/role/DisclosureSubsequentEventsDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Weighted average per share amount at which grantees can acquire shares of common stock by exercise of options.", "label": "Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price", "verboseLabel": "Weighted Average Exercise Price, Granted" } } }, "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.nwbio.com/role/DisclosureStockBasedCompensationAdditionalInformationDetails", "http://www.nwbio.com/role/DisclosureStockBasedCompensationStockOptionActivityDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy": { "auth_ref": [ "r93", "r239", "r241" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for award under share-based payment arrangement. Includes, but is not limited to, methodology and assumption used in measuring cost.", "label": "Share-based Compensation, Option and Incentive Plans Policy [Policy Text Block]", "terseLabel": "Stock Based Compensation" } } }, "localname": "ShareBasedCompensationOptionAndIncentivePlansPolicy", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.nwbio.com/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_SharePrice": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Price of a single share of a number of saleable stocks of a company.", "label": "Share Price", "terseLabel": "Strike price" } } }, "localname": "SharePrice", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.nwbio.com/role/DisclosureFairValueMeasurementsWeightedAverageInAggregateSignificantUnobservableInputsDetails", "http://www.nwbio.com/role/DisclosureStockholdersDeficitAdditionalInformationDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1": { "auth_ref": [ "r253", "r267" ], "lang": { "en-us": { "role": { "documentation": "Expected term of award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Term", "terseLabel": "Expected term (years)" } } }, "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.nwbio.com/role/DisclosureStockBasedCompensationAssumptionsDetails" ], "xbrltype": "durationItemType" }, "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2": { "auth_ref": [ "r251" ], "lang": { "en-us": { "role": { "documentation": "Weighted average remaining contractual term for option awards outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Remaining Contractual Term", "verboseLabel": "Weighted Average Remaining Contractual Life (in years), Outstanding" } } }, "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.nwbio.com/role/DisclosureStockBasedCompensationStockOptionActivityDetails" ], "xbrltype": "durationItemType" }, "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1": { "auth_ref": [ "r251" ], "lang": { "en-us": { "role": { "documentation": "Weighted average remaining contractual term for fully vested and expected to vest options outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Outstanding, Weighted Average Remaining Contractual Term", "terseLabel": "Weighted Average Remaining Contractual Life (in years), Options vested" } } }, "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.nwbio.com/role/DisclosureStockBasedCompensationStockOptionActivityDetails" ], "xbrltype": "durationItemType" }, "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Number of options vested.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested, Number of Shares", "terseLabel": "Number of shares, Vested" } } }, "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.nwbio.com/role/DisclosureStockBasedCompensationAdditionalInformationDetails", "http://www.nwbio.com/role/DisclosureStockBasedCompensationStockOptionActivityDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_SharesOutstanding": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Number of shares issued which are neither cancelled nor held in the treasury.", "label": "Shares, Outstanding", "periodEndLabel": "Balance (in shares)", "periodStartLabel": "Balance (in shares)" } } }, "localname": "SharesOutstanding", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.nwbio.com/role/StatementConsolidatedStatementsOfChangesInStockholdersDeficit" ], "xbrltype": "sharesItemType" }, "us-gaap_ShortTermBorrowings": { "auth_ref": [ "r16", "r426", "r440" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Reflects the total carrying amount as of the balance sheet date of debt having initial terms less than one year or the normal operating cycle, if longer.", "label": "Short-term Debt" } } }, "localname": "ShortTermBorrowings", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.nwbio.com/role/DisclosureNotesPayableAdditionalInformationDetails", "http://www.nwbio.com/role/DisclosureRelatedPartyTransactionsAdditionalInformationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_ShortTermDebtMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Debt arrangement having an initial term within one year or the normal operating cycle, if longer.", "label": "Short Term Debt [Member]", "terseLabel": "Short term convertible notes payable [Member]" } } }, "localname": "ShortTermDebtMember", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.nwbio.com/role/DisclosureNotesPayableAdditionalInformationDetails", "http://www.nwbio.com/role/DisclosureNotesPayableDetails" ], "xbrltype": "domainItemType" }, "us-gaap_ShortTermDebtTypeAxis": { "auth_ref": [ "r40" ], "lang": { "en-us": { "role": { "documentation": "Information by type of short-term debt arrangement.", "label": "Short-term Debt, Type [Axis]" } } }, "localname": "ShortTermDebtTypeAxis", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.nwbio.com/role/DisclosureNotesPayableAdditionalInformationDetails", "http://www.nwbio.com/role/DisclosureNotesPayableDetails", "http://www.nwbio.com/role/DisclosureNotesPayableMortgageLoanDetails", "http://www.nwbio.com/role/DisclosureNotesPayableSummaryOfCompanySContractualObligationsOnDebtPrincipalDetails", "http://www.nwbio.com/role/DisclosureSubsequentEventsDetails", "http://www.nwbio.com/role/DisclosureSummaryOfSignificantAccountingPoliciesDetails", "http://www.nwbio.com/role/StatementConsolidatedStatementsOfCashFlows" ], "xbrltype": "stringItemType" }, "us-gaap_ShortTermDebtTypeDomain": { "auth_ref": [ "r38" ], "lang": { "en-us": { "role": { "documentation": "Type of short-term debt arrangement, such as notes, line of credit, commercial paper, asset-based financing, project financing, letter of credit financing.", "label": "Short Term Debt Type [Domain]", "terseLabel": "Short-term Debt, Type [Domain]" } } }, "localname": "ShortTermDebtTypeDomain", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.nwbio.com/role/DisclosureNotesPayableAdditionalInformationDetails", "http://www.nwbio.com/role/DisclosureNotesPayableDetails", "http://www.nwbio.com/role/DisclosureNotesPayableMortgageLoanDetails", "http://www.nwbio.com/role/DisclosureNotesPayableSummaryOfCompanySContractualObligationsOnDebtPrincipalDetails", "http://www.nwbio.com/role/DisclosureSubsequentEventsDetails", "http://www.nwbio.com/role/DisclosureSummaryOfSignificantAccountingPoliciesDetails", "http://www.nwbio.com/role/StatementConsolidatedStatementsOfCashFlows" ], "xbrltype": "domainItemType" }, "us-gaap_ShortTermLeaseCost": { "auth_ref": [ "r377", "r384" ], "calculation": { "http://www.nwbio.com/role/DisclosureCommitmentsAndContingenciesDetails": { "order": 2.0, "parentTag": "us-gaap_LeaseCost", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of short-term lease cost, excluding expense for lease with term of one month or less.", "label": "Short-term Lease, Cost", "verboseLabel": "Short-term lease cost" } } }, "localname": "ShortTermLeaseCost", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.nwbio.com/role/DisclosureCommitmentsAndContingenciesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_SignificantAccountingPoliciesTextBlock": { "auth_ref": [ "r104" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for all significant accounting policies of the reporting entity.", "label": "Significant Accounting Policies [Text Block]", "verboseLabel": "Summary of Significant Accounting Policies" } } }, "localname": "SignificantAccountingPoliciesTextBlock", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.nwbio.com/role/DisclosureSummaryOfSignificantAccountingPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_StateAndLocalIncomeTaxExpenseBenefitContinuingOperationsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "State and Local Income Tax Expense (Benefit), Continuing Operations [Abstract]", "verboseLabel": "State" } } }, "localname": "StateAndLocalIncomeTaxExpenseBenefitContinuingOperationsAbstract", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.nwbio.com/role/DisclosureIncomeTaxesSummaryOfTaxProvisionBenefitDetails" ], "xbrltype": "stringItemType" }, "us-gaap_StatementClassOfStockAxis": { "auth_ref": [ "r21", "r22", "r23", "r95", "r97", "r122", "r123", "r124", "r126", "r128", "r135", "r136", "r137", "r168", "r202", "r351" ], "lang": { "en-us": { "role": { "documentation": "Information by the different classes of stock of the entity.", "label": "Class of Stock [Axis]" } } }, "localname": "StatementClassOfStockAxis", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.nwbio.com/role/DisclosureStockholdersDeficitAdditionalInformationDetails" ], "xbrltype": "stringItemType" }, "us-gaap_StatementEquityComponentsAxis": { "auth_ref": [ "r48", "r105", "r106", "r108", "r111", "r117", "r120", "r134", "r169", "r202", "r204", "r263", "r264", "r265", "r293", "r294", "r356", "r357", "r358", "r359", "r360", "r362", "r457", "r458", "r459" ], "lang": { "en-us": { "role": { "documentation": "Information by component of equity.", "label": "Equity Components [Axis]" } } }, "localname": "StatementEquityComponentsAxis", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.nwbio.com/role/DisclosureNotesPayableAdditionalInformationDetails", "http://www.nwbio.com/role/DisclosureStockholdersDeficitAdditionalInformationDetails", "http://www.nwbio.com/role/StatementConsolidatedStatementsOfChangesInStockholdersDeficit" ], "xbrltype": "stringItemType" }, "us-gaap_StatementLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Statement [Line Items]" } } }, "localname": "StatementLineItems", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.nwbio.com/role/DisclosureCommitmentsAndContingenciesAdditionalInformationDetails", "http://www.nwbio.com/role/DisclosureCommitmentsAndContingenciesDetails", "http://www.nwbio.com/role/DisclosureCommitmentsAndContingenciesMaturitiesOfOurOperatingLeasesDetails", "http://www.nwbio.com/role/DisclosureNotesPayableAdditionalInformationDetails", "http://www.nwbio.com/role/DisclosureNotesPayableDetails", "http://www.nwbio.com/role/DisclosureNotesPayableMortgageLoanDetails", "http://www.nwbio.com/role/DisclosureNotesPayableSummaryOfCompanySContractualObligationsOnDebtPrincipalDetails", "http://www.nwbio.com/role/DisclosurePropertyPlantAndEquipmentDetails", "http://www.nwbio.com/role/DisclosureRelatedPartyTransactionsSummaryOfOutstandingUnpaidAccountsPayableHeldByRelatedPartiesDetails", "http://www.nwbio.com/role/DisclosureStockBasedCompensationAssumptionsDetails", "http://www.nwbio.com/role/DisclosureStockBasedCompensationSummaryOfStockBasedCompensationExpenseDetails", "http://www.nwbio.com/role/DisclosureSummaryOfSignificantAccountingPoliciesDetails", "http://www.nwbio.com/role/StatementConsolidatedStatementsOfCashFlows", "http://www.nwbio.com/role/StatementConsolidatedStatementsOfChangesInStockholdersDeficit", "http://www.nwbio.com/role/StatementConsolidatedStatementsOfChangesInStockholdersDeficitParenthetical" ], "xbrltype": "stringItemType" }, "us-gaap_StatementOfCashFlowsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "CONSOLIDATED STATEMENTS OF CASH FLOWS" } } }, "localname": "StatementOfCashFlowsAbstract", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "xbrltype": "stringItemType" }, "us-gaap_StatementOfFinancialPositionAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "CONSOLIDATED BALANCE SHEETS" } } }, "localname": "StatementOfFinancialPositionAbstract", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "xbrltype": "stringItemType" }, "us-gaap_StatementOfStockholdersEquityAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "CONSOLIDATED STATEMENTS OF CHANGES IN STOCKHOLDERS' DEFICIT" } } }, "localname": "StatementOfStockholdersEquityAbstract", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "xbrltype": "stringItemType" }, "us-gaap_StatementTable": { "auth_ref": [ "r105", "r106", "r108", "r134", "r411" ], "lang": { "en-us": { "role": { "documentation": "Schedule reflecting a Statement of Income, Statement of Cash Flows, Statement of Financial Position, Statement of Shareholders' Equity and Other Comprehensive Income, or other statement as needed.", "label": "Statement [Table]" } } }, "localname": "StatementTable", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.nwbio.com/role/DisclosureCommitmentsAndContingenciesAdditionalInformationDetails", "http://www.nwbio.com/role/DisclosureCommitmentsAndContingenciesDetails", "http://www.nwbio.com/role/DisclosureCommitmentsAndContingenciesMaturitiesOfOurOperatingLeasesDetails", "http://www.nwbio.com/role/DisclosureIncomeTaxesAdditionalInformationDetails", "http://www.nwbio.com/role/DisclosureNotesPayableAdditionalInformationDetails", "http://www.nwbio.com/role/DisclosureNotesPayableDetails", "http://www.nwbio.com/role/DisclosureNotesPayableMortgageLoanDetails", "http://www.nwbio.com/role/DisclosureNotesPayableSummaryOfCompanySContractualObligationsOnDebtPrincipalDetails", "http://www.nwbio.com/role/DisclosurePropertyPlantAndEquipmentDetails", "http://www.nwbio.com/role/DisclosureRelatedPartyTransactionsSummaryOfOutstandingUnpaidAccountsPayableHeldByRelatedPartiesDetails", "http://www.nwbio.com/role/DisclosureStockBasedCompensationAssumptionsDetails", "http://www.nwbio.com/role/DisclosureStockBasedCompensationSummaryOfStockBasedCompensationExpenseDetails", "http://www.nwbio.com/role/DisclosureSummaryOfSignificantAccountingPoliciesDetails", "http://www.nwbio.com/role/StatementConsolidatedStatementsOfCashFlows", "http://www.nwbio.com/role/StatementConsolidatedStatementsOfChangesInStockholdersDeficit", "http://www.nwbio.com/role/StatementConsolidatedStatementsOfChangesInStockholdersDeficitParenthetical" ], "xbrltype": "stringItemType" }, "us-gaap_StockIssuedDuringPeriodSharesAcquisitions": { "auth_ref": [ "r22", "r23", "r204" ], "lang": { "en-us": { "role": { "documentation": "Number of shares of stock issued during the period pursuant to acquisitions.", "label": "Stock Issued During Period, Shares, Acquisitions", "netLabel": "Issuance of common stock in acquisition (in shares)", "verboseLabel": "Issuance of common stock in connection with Flaskworks acquisition (in shares)" } } }, "localname": "StockIssuedDuringPeriodSharesAcquisitions", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.nwbio.com/role/DisclosureFlaskworksAcquisitionDetails", "http://www.nwbio.com/role/DisclosureStockholdersDeficitAdditionalInformationDetails", "http://www.nwbio.com/role/StatementConsolidatedStatementsOfChangesInStockholdersDeficit" ], "xbrltype": "sharesItemType" }, "us-gaap_StockIssuedDuringPeriodSharesNewIssues": { "auth_ref": [ "r22", "r23", "r202", "r204" ], "lang": { "en-us": { "role": { "documentation": "Number of new stock issued during the period.", "label": "Stock Issued During Period, Shares, New Issues", "terseLabel": "Shares issued" } } }, "localname": "StockIssuedDuringPeriodSharesNewIssues", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.nwbio.com/role/DisclosureStockholdersDeficitAdditionalInformationDetails", "http://www.nwbio.com/role/DisclosureSubsequentEventsDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_StockIssuedDuringPeriodSharesOther": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Number of shares of stock issued attributable to transactions classified as other.", "label": "Stock Issued During Period, Shares, Other", "verboseLabel": "Issuance of common stock and warrants for cash in a registered direct offering (in shares)" } } }, "localname": "StockIssuedDuringPeriodSharesOther", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.nwbio.com/role/DisclosureStockholdersDeficitAdditionalInformationDetails", "http://www.nwbio.com/role/StatementConsolidatedStatementsOfChangesInStockholdersDeficit" ], "xbrltype": "sharesItemType" }, "us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation": { "auth_ref": [ "r22", "r23", "r202", "r204" ], "lang": { "en-us": { "role": { "documentation": "Number, after forfeiture, of shares or units issued under share-based payment arrangement. Excludes shares or units issued under employee stock ownership plan (ESOP).", "label": "Stock Issued During Period, Shares, Share-based Compensation, Net of Forfeitures", "verboseLabel": "Stock-based compensation (in shares)" } } }, "localname": "StockIssuedDuringPeriodSharesShareBasedCompensation", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.nwbio.com/role/StatementConsolidatedStatementsOfChangesInStockholdersDeficit" ], "xbrltype": "sharesItemType" }, "us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised": { "auth_ref": [ "r22", "r23", "r202", "r204", "r245" ], "lang": { "en-us": { "role": { "documentation": "Number of share options (or share units) exercised during the current period.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period", "negatedLabel": "Number of Shares, Cashless exercise", "terseLabel": "Number of Shares, Cashless exercise", "verboseLabel": "Cashless option exercise (in shares)" } } }, "localname": "StockIssuedDuringPeriodSharesStockOptionsExercised", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.nwbio.com/role/DisclosureStockBasedCompensationStockOptionActivityDetails", "http://www.nwbio.com/role/DisclosureSubsequentEventsDetails", "http://www.nwbio.com/role/StatementConsolidatedStatementsOfChangesInStockholdersDeficit" ], "xbrltype": "sharesItemType" }, "us-gaap_StockIssuedDuringPeriodValueAcquisitions": { "auth_ref": [ "r48", "r202", "r204" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Value of stock issued pursuant to acquisitions during the period.", "label": "Stock Issued During Period, Value, Acquisitions", "verboseLabel": "Issuance of common stock in connection with Flaskworks acquisition" } } }, "localname": "StockIssuedDuringPeriodValueAcquisitions", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.nwbio.com/role/StatementConsolidatedStatementsOfChangesInStockholdersDeficit" ], "xbrltype": "monetaryItemType" }, "us-gaap_StockIssuedDuringPeriodValueNewIssues": { "auth_ref": [ "r22", "r23", "r202", "r204" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Equity impact of the value of new stock issued during the period. Includes shares issued in an initial public offering or a secondary public offering.", "label": "Stock Issued During Period, Value, New Issues", "terseLabel": "Amount from offering of newly registered common stock" } } }, "localname": "StockIssuedDuringPeriodValueNewIssues", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.nwbio.com/role/DisclosureStockholdersDeficitAdditionalInformationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_StockIssuedDuringPeriodValueOther": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Value of shares of stock issued attributable to transactions classified as other.", "label": "Stock Issued During Period, Value, Other", "verboseLabel": "Issuance of common stock and warrants for cash in a registered direct offering" } } }, "localname": "StockIssuedDuringPeriodValueOther", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.nwbio.com/role/StatementConsolidatedStatementsOfChangesInStockholdersDeficit" ], "xbrltype": "monetaryItemType" }, "us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation": { "auth_ref": [ "r22", "r23", "r204", "r238", "r249" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Value, after forfeiture, of shares issued under share-based payment arrangement. Excludes employee stock ownership plan (ESOP).", "label": "Shares Issued, Value, Share-based Payment Arrangement, after Forfeiture", "verboseLabel": "Stock-based compensation" } } }, "localname": "StockIssuedDuringPeriodValueShareBasedCompensation", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.nwbio.com/role/StatementConsolidatedStatementsOfChangesInStockholdersDeficit" ], "xbrltype": "monetaryItemType" }, "us-gaap_StockholdersEquity": { "auth_ref": [ "r23", "r27", "r28", "r97", "r167", "r168", "r351" ], "calculation": { "http://www.nwbio.com/role/StatementConsolidatedBalanceSheets": { "order": 2.0, "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.", "label": "Stockholders' Equity Attributable to Parent", "periodEndLabel": "Balance", "periodStartLabel": "Balance", "totalLabel": "Total stockholders' deficit", "verboseLabel": "Total stockholders' deficit" } } }, "localname": "StockholdersEquity", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.nwbio.com/role/DisclosureRevisionToPriorPeriodFinancialStatementsConsolidatedBalanceSheetDetails", "http://www.nwbio.com/role/StatementConsolidatedBalanceSheets", "http://www.nwbio.com/role/StatementConsolidatedStatementsOfChangesInStockholdersDeficit" ], "xbrltype": "monetaryItemType" }, "us-gaap_StockholdersEquityAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Stockholders' Equity Attributable to Parent [Abstract]", "terseLabel": "Stockholders' deficit:" } } }, "localname": "StockholdersEquityAbstract", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.nwbio.com/role/StatementConsolidatedBalanceSheets" ], "xbrltype": "stringItemType" }, "us-gaap_StockholdersEquityNoteAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Stockholders' Deficit" } } }, "localname": "StockholdersEquityNoteAbstract", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "xbrltype": "stringItemType" }, "us-gaap_StockholdersEquityNoteDisclosureTextBlock": { "auth_ref": [ "r96", "r204", "r206" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for shareholders' equity comprised of portions attributable to the parent entity and noncontrolling interest, including other comprehensive income. Includes, but is not limited to, balances of common stock, preferred stock, additional paid-in capital, other capital and retained earnings, accumulated balance for each classification of other comprehensive income and amount of comprehensive income.", "label": "Stockholders' Equity Note Disclosure [Text Block]", "terseLabel": "Stockholders' Deficit" } } }, "localname": "StockholdersEquityNoteDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.nwbio.com/role/DisclosureStockholdersDeficit" ], "xbrltype": "textBlockItemType" }, "us-gaap_SubsequentEventLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Detail information of subsequent event by type. User is expected to use existing line items from elsewhere in the taxonomy as the primary line items for this disclosure, which is further associated with dimension and member elements pertaining to a subsequent event.", "label": "Subsequent Event [Line Items]" } } }, "localname": "SubsequentEventLineItems", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.nwbio.com/role/DisclosureSubsequentEventsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_SubsequentEventMember": { "auth_ref": [ "r363", "r398" ], "lang": { "en-us": { "role": { "documentation": "Identifies event that occurred after the balance sheet date but before financial statements are issued or available to be issued.", "label": "Subsequent Event [Member]", "terseLabel": "Subsequent Event" } } }, "localname": "SubsequentEventMember", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.nwbio.com/role/DisclosureNotesPayableAdditionalInformationDetails", "http://www.nwbio.com/role/DisclosureRelatedPartyTransactionsAdditionalInformationDetails", "http://www.nwbio.com/role/DisclosureStockholdersDeficitAdditionalInformationDetails", "http://www.nwbio.com/role/DisclosureSubsequentEventsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_SubsequentEventTable": { "auth_ref": [ "r363", "r398" ], "lang": { "en-us": { "role": { "documentation": "Discloses pertinent information about one or more significant events or transactions that occurred after the balance sheet date through the date the financial statements were issued or the date the financial statements were available to be issued.", "label": "Subsequent Event [Table]" } } }, "localname": "SubsequentEventTable", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.nwbio.com/role/DisclosureSubsequentEventsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_SubsequentEventTypeAxis": { "auth_ref": [ "r363", "r398" ], "lang": { "en-us": { "role": { "documentation": "Information by event that occurred after the balance sheet date but before financial statements are issued or available to be issued.", "label": "Subsequent Event Type [Axis]" } } }, "localname": "SubsequentEventTypeAxis", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.nwbio.com/role/DisclosureNotesPayableAdditionalInformationDetails", "http://www.nwbio.com/role/DisclosureRelatedPartyTransactionsAdditionalInformationDetails", "http://www.nwbio.com/role/DisclosureStockholdersDeficitAdditionalInformationDetails", "http://www.nwbio.com/role/DisclosureSubsequentEventsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_SubsequentEventTypeDomain": { "auth_ref": [ "r363", "r398" ], "lang": { "en-us": { "role": { "documentation": "Event that occurred after the balance sheet date but before financial statements are issued or available to be issued.", "label": "Subsequent Event Type [Domain]", "terseLabel": "Subsequent Event Type [Domain]" } } }, "localname": "SubsequentEventTypeDomain", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.nwbio.com/role/DisclosureNotesPayableAdditionalInformationDetails", "http://www.nwbio.com/role/DisclosureRelatedPartyTransactionsAdditionalInformationDetails", "http://www.nwbio.com/role/DisclosureStockholdersDeficitAdditionalInformationDetails", "http://www.nwbio.com/role/DisclosureSubsequentEventsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_SubsequentEventsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Subsequent Events" } } }, "localname": "SubsequentEventsAbstract", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "xbrltype": "stringItemType" }, "us-gaap_SubsequentEventsTextBlock": { "auth_ref": [ "r397", "r400" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for significant events or transactions that occurred after the balance sheet date through the date the financial statements were issued or the date the financial statements were available to be issued. Examples include: the sale of a capital stock issue, purchase of a business, settlement of litigation, catastrophic loss, significant foreign exchange rate changes, loans to insiders or affiliates, and transactions not in the ordinary course of business.", "label": "Subsequent Events [Text Block]", "verboseLabel": "Subsequent Events" } } }, "localname": "SubsequentEventsTextBlock", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.nwbio.com/role/DisclosureSubsequentEvents" ], "xbrltype": "textBlockItemType" }, "us-gaap_SubsidiarySaleOfStockAxis": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Information by type of sale of the entity's stock.", "label": "Sale of Stock [Axis]" } } }, "localname": "SubsidiarySaleOfStockAxis", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.nwbio.com/role/DisclosureStockholdersDeficitAdditionalInformationDetails", "http://www.nwbio.com/role/StatementConsolidatedStatementsOfChangesInStockholdersDeficitParenthetical" ], "xbrltype": "stringItemType" }, "us-gaap_SupplementalCashFlowInformationAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Supplemental Cash Flow Information [Abstract]", "terseLabel": "Supplemental disclosure of cash flow information" } } }, "localname": "SupplementalCashFlowInformationAbstract", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.nwbio.com/role/StatementConsolidatedStatementsOfCashFlows" ], "xbrltype": "stringItemType" }, "us-gaap_UseOfEstimates": { "auth_ref": [ "r138", "r139", "r141", "r142", "r143", "r144", "r145" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles.", "label": "Use of Estimates, Policy [Policy Text Block]", "verboseLabel": "Use of Estimates" } } }, "localname": "UseOfEstimates", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.nwbio.com/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount": { "auth_ref": [ "r284" ], "calculation": { "http://www.nwbio.com/role/DisclosureIncomeTaxesSummaryOfTaxProvisionBenefitDetails": { "order": 4.0, "parentTag": "us-gaap_IncomeTaxExpenseBenefit", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of increase (decrease) in the valuation allowance for a specified deferred tax asset.", "label": "Valuation Allowance, Deferred Tax Asset, Increase (Decrease), Amount", "negatedLabel": "Change in valuation allowance" } } }, "localname": "ValuationAllowanceDeferredTaxAssetChangeInAmount", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.nwbio.com/role/DisclosureIncomeTaxesSummaryOfTaxProvisionBenefitDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_VariableLeaseCost": { "auth_ref": [ "r378", "r384" ], "calculation": { "http://www.nwbio.com/role/DisclosureCommitmentsAndContingenciesDetails": { "order": 3.0, "parentTag": "us-gaap_LeaseCost", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of variable lease cost, excluded from lease liability, recognized when obligation for payment is incurred for finance and operating leases.", "label": "Variable Lease, Cost", "verboseLabel": "Variable lease cost" } } }, "localname": "VariableLeaseCost", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.nwbio.com/role/DisclosureCommitmentsAndContingenciesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_WarrantMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Security that gives the holder the right to purchase shares of stock in accordance with the terms of the instrument, usually upon payment of a specified amount.", "label": "Warrant [Member]", "terseLabel": "Warrants [Member]" } } }, "localname": "WarrantMember", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.nwbio.com/role/DisclosureNetEarningsLossPerShareApplicableToCommonStockholdersDetails", "http://www.nwbio.com/role/DisclosureNotesPayableAdditionalInformationDetails", "http://www.nwbio.com/role/DisclosureStockholdersDeficitAdditionalInformationDetails" ], "xbrltype": "domainItemType" }, "us-gaap_WarrantsAndRightsOutstanding": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Value of outstanding derivative securities that permit the holder the right to purchase securities (usually equity) from the issuer at a specified price.", "label": "Warrants and Rights Outstanding", "terseLabel": "Fair value of warrants" } } }, "localname": "WarrantsAndRightsOutstanding", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.nwbio.com/role/DisclosureNotesPayableAdditionalInformationDetails", "http://www.nwbio.com/role/DisclosureStockholdersDeficitAdditionalInformationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_WarrantsAndRightsOutstandingTerm": { "auth_ref": [ "r342" ], "lang": { "en-us": { "role": { "documentation": "Period between issuance and expiration of outstanding warrant and right embodying unconditional obligation requiring redemption by transferring asset at specified or determinable date or upon event certain to occur, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.", "label": "Warrants and Rights Outstanding, Term" } } }, "localname": "WarrantsAndRightsOutstandingTerm", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.nwbio.com/role/DisclosureNotesPayableAdditionalInformationDetails" ], "xbrltype": "durationItemType" }, "us-gaap_WarrantsNotSettleableInCashFairValueDisclosure": { "auth_ref": [ "r338" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Fair value portion of warrants not settleable in cash classified as equity.", "label": "Warrants Not Settleable in Cash, Fair Value Disclosure" } } }, "localname": "WarrantsNotSettleableInCashFairValueDisclosure", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.nwbio.com/role/DisclosureStockholdersDeficitAdditionalInformationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Average number of shares or units issued and outstanding that are used in calculating basic and diluted earnings per share (EPS).", "label": "Weighted Average Number of Shares Outstanding, Basic and Diluted", "verboseLabel": "Weighted average shares used in computing basic and diluted loss per share" } } }, "localname": "WeightedAverageNumberOfShareOutstandingBasicAndDiluted", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.nwbio.com/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss" ], "xbrltype": "sharesItemType" } }, "unitCount": 8 } }, "std_ref": { "r0": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "205", "URI": "http://asc.fasb.org/extlink&oid=109222650&loc=SL51721683-107760" }, "r1": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "205", "URI": "http://asc.fasb.org/topic&trid=2122149" }, "r10": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(12))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r100": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08.(e),(f))", "Topic": "235", "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690" }, "r101": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08.(f))", "Topic": "235", "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690" }, "r102": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08.(h))", "Topic": "235", "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690" }, "r103": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08.(k)(1))", "Topic": "235", "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690" }, "r104": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "235", "URI": "http://asc.fasb.org/topic&trid=2122369" }, "r105": { "Name": "Accounting Standards Codification", "Paragraph": "23", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=115929471&loc=d3e21914-107793" }, "r106": { "Name": "Accounting Standards Codification", "Paragraph": "24", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=115929471&loc=d3e21930-107793" }, "r107": { "Name": "Accounting Standards Codification", "Paragraph": "27", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=115929471&loc=d3e22044-107793" }, "r108": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=115929471&loc=d3e21711-107793" }, "r109": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=115929471&loc=d3e21728-107793" }, "r11": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(13))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r110": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)(2)", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=109234566&loc=d3e22499-107794" }, "r111": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)(3)", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=109234566&loc=d3e22499-107794" }, "r112": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=109234566&loc=d3e22694-107794" }, "r113": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=109234566&loc=d3e22694-107794" }, "r114": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=109234566&loc=d3e22583-107794" }, "r115": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=109234566&loc=d3e22595-107794" }, "r116": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=109234566&loc=d3e22644-107794" }, "r117": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=109234566&loc=d3e22644-107794" }, "r118": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=109234566&loc=d3e22644-107794" }, "r119": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=109234566&loc=d3e22658-107794" }, "r12": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(14))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r120": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=109234566&loc=d3e22663-107794" }, "r121": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "250", "URI": "http://asc.fasb.org/topic&trid=2122394" }, "r122": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=121326447&loc=d3e1252-109256" }, "r123": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=121326447&loc=d3e1278-109256" }, "r124": { "Name": "Accounting Standards Codification", "Paragraph": "55", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=121326447&loc=d3e2626-109256" }, "r125": { "Name": "Accounting Standards Codification", "Paragraph": "60B", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=121326447&loc=SL5780133-109256" }, "r126": { "Name": "Accounting Standards Codification", "Paragraph": "60B", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=121326447&loc=SL5780133-109256" }, "r127": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=121326447&loc=d3e1337-109256" }, "r128": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=6371337&loc=d3e3550-109257" }, "r129": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=6371337&loc=d3e3550-109257" }, "r13": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(15))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r130": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=6371337&loc=d3e3630-109257" }, "r131": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=109243012&loc=SL65017193-207537" }, "r132": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=120380238&loc=d3e3842-109258" }, "r133": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "260", "URI": "http://asc.fasb.org/topic&trid=2144383" }, "r134": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "272", "URI": "http://asc.fasb.org/extlink&oid=6828210&loc=d3e70191-108054" }, "r135": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "272", "URI": "http://asc.fasb.org/extlink&oid=6828210&loc=d3e70229-108054" }, "r136": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "272", "URI": "http://asc.fasb.org/extlink&oid=6373374&loc=d3e70434-108055" }, "r137": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "272", "URI": "http://asc.fasb.org/extlink&oid=6373374&loc=d3e70478-108055" }, "r138": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "275", "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e5967-108592" }, "r139": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "275", "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e5967-108592" }, "r14": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(16))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r140": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "275", "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e5967-108592" }, "r141": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "275", "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6161-108592" }, "r142": { "Name": "Accounting Standards Codification", "Paragraph": "12", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "275", "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6191-108592" }, "r143": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "275", "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6061-108592" }, "r144": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "275", "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6132-108592" }, "r145": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "275", "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6143-108592" }, "r146": { "Name": "Accounting Standards Codification", "Paragraph": "18", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8672-108599" }, "r147": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8736-108599" }, "r148": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8736-108599" }, "r149": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8736-108599" }, "r15": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(17))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r150": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(h)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8736-108599" }, "r151": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8736-108599" }, "r152": { "Name": "Accounting Standards Codification", "Paragraph": "30", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8906-108599" }, "r153": { "Name": "Accounting Standards Codification", "Paragraph": "30", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8906-108599" }, "r154": { "Name": "Accounting Standards Codification", "Paragraph": "30", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8906-108599" }, "r155": { "Name": "Accounting Standards Codification", "Paragraph": "30", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8906-108599" }, "r156": { "Name": "Accounting Standards Codification", "Paragraph": "31", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8924-108599" }, "r157": { "Name": "Accounting Standards Codification", "Paragraph": "32", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8933-108599" }, "r158": { "Name": "Accounting Standards Codification", "Paragraph": "32", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8933-108599" }, "r159": { "Name": "Accounting Standards Codification", "Paragraph": "32", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8933-108599" }, "r16": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(19)(a))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r160": { "Name": "Accounting Standards Codification", "Paragraph": "32", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8933-108599" }, "r161": { "Name": "Accounting Standards Codification", "Paragraph": "32", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8933-108599" }, "r162": { "Name": "Accounting Standards Codification", "Paragraph": "40", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e9031-108599" }, "r163": { "Name": "Accounting Standards Codification", "Paragraph": "41", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e9038-108599" }, "r164": { "Name": "Accounting Standards Codification", "Paragraph": "41", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e9038-108599" }, "r165": { "Name": "Accounting Standards Codification", "Paragraph": "42", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e9054-108599" }, "r166": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "310", "URI": "http://asc.fasb.org/extlink&oid=121593590&loc=d3e4647-111522" }, "r167": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 4.E)", "Topic": "310", "URI": "http://asc.fasb.org/extlink&oid=27010918&loc=d3e74512-122707" }, "r168": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "323", "URI": "http://asc.fasb.org/extlink&oid=114001798&loc=d3e33918-111571" }, "r169": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "326", "URI": "http://asc.fasb.org/extlink&oid=121646688&loc=SL121648383-210437" }, "r17": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(19))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r170": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(e)(3)", "Topic": "326", "URI": "http://asc.fasb.org/extlink&oid=121646688&loc=SL121648383-210437" }, "r171": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(e)(4)", "Topic": "326", "URI": "http://asc.fasb.org/extlink&oid=121646688&loc=SL121648383-210437" }, "r172": { "Name": "Accounting Standards Codification", "Paragraph": "12", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Subparagraph": "(e)", "Topic": "326", "URI": "http://asc.fasb.org/extlink&oid=121647567&loc=SL82921835-210448" }, "r173": { "Name": "Accounting Standards Codification", "Paragraph": "12", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Subparagraph": "(e)(1)", "Topic": "326", "URI": "http://asc.fasb.org/extlink&oid=121647567&loc=SL82921835-210448" }, "r174": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Topic": "350", "URI": "http://asc.fasb.org/extlink&oid=99380562&loc=d3e13770-109266" }, "r175": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Topic": "350", "URI": "http://asc.fasb.org/extlink&oid=120320667&loc=SL49117168-202975" }, "r176": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "350", "URI": "http://asc.fasb.org/extlink&oid=121556970&loc=d3e13816-109267" }, "r177": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Topic": "350", "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16265-109275" }, "r178": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(b)", "Topic": "350", "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275" }, "r179": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "360", "URI": "http://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229" }, "r18": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(20))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r180": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "360", "URI": "http://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229" }, "r181": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "360", "URI": "http://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229" }, "r182": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "360", "URI": "http://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229" }, "r183": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "360", "URI": "http://asc.fasb.org/extlink&oid=109226691&loc=d3e2941-110230" }, "r184": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "360", "URI": "http://asc.fasb.org/topic&trid=2155823" }, "r185": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "440", "URI": "http://asc.fasb.org/extlink&oid=121559207&loc=d3e25336-109308" }, "r186": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "440", "URI": "http://asc.fasb.org/extlink&oid=121559207&loc=d3e25336-109308" }, "r187": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "440", "URI": "http://asc.fasb.org/topic&trid=2144648" }, "r188": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "450", "URI": "http://asc.fasb.org/extlink&oid=121557415&loc=d3e14326-108349" }, "r189": { "Name": "Accounting Standards Codification", "Paragraph": "10", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "450", "URI": "http://asc.fasb.org/extlink&oid=121557415&loc=d3e14615-108349" }, "r19": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(22))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r190": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "450", "URI": "http://asc.fasb.org/topic&trid=2127136" }, "r191": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=6802200&loc=d3e1835-112601" }, "r192": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=6802200&loc=SL6230698-112601" }, "r193": { "Name": "Accounting Standards Codification", "Paragraph": "10", "Publisher": "FASB", "Section": "25", "SubTopic": "20", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=109126253&loc=d3e4852-112606" }, "r194": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(3)", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=120520924&loc=SL6031897-161870" }, "r195": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=120520924&loc=SL6031898-161870" }, "r196": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=120520924&loc=SL6036836-161870" }, "r197": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "40", "SubTopic": "50", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=117329964&loc=d3e12317-112629" }, "r198": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "40", "SubTopic": "50", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=117329964&loc=d3e12355-112629" }, "r199": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "50", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=7516071&loc=d3e13374-112631" }, "r2": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=121566466&loc=d3e6676-107765" }, "r20": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(23))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r200": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "470", "URI": "http://asc.fasb.org/topic&trid=2208564" }, "r201": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "25", "SubTopic": "10", "Topic": "480", "URI": "http://asc.fasb.org/extlink&oid=109262497&loc=d3e20148-110875" }, "r202": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=109259400&loc=d3e21463-112644" }, "r203": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=109259400&loc=d3e21475-112644" }, "r204": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.3-04)", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=120397183&loc=d3e187085-122770" }, "r205": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "50", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=6784392&loc=d3e188667-122775" }, "r206": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "505", "URI": "http://asc.fasb.org/topic&trid=2208762" }, "r207": { "Name": "Accounting Standards Codification", "Paragraph": "17", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=121604090&loc=SL49130561-203045" }, "r208": { "Name": "Accounting Standards Codification", "Paragraph": "18", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=121604090&loc=SL49130563-203045" }, "r209": { "Name": "Accounting Standards Codification", "Paragraph": "18", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=121604090&loc=SL49130563-203045" }, "r21": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(27))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r210": { "Name": "Accounting Standards Codification", "Paragraph": "19", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=121604090&loc=SL49130564-203045" }, "r211": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=121604090&loc=SL49130566-203045" }, "r212": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=121604090&loc=SL49130566-203045" }, "r213": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=121604090&loc=SL49130566-203045" }, "r214": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=121604090&loc=SL49130566-203045" }, "r215": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=121604090&loc=SL49130543-203045" }, "r216": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=121604090&loc=SL49130545-203045" }, "r217": { "Name": "Accounting Standards Codification", "Paragraph": "91", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=121551570&loc=SL49130690-203046-203046" }, "r218": { "Name": "Accounting Standards Codification", "Paragraph": "91", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=121551570&loc=SL49130690-203046-203046" }, "r219": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "606", "URI": "http://asc.fasb.org/topic&trid=49130388" }, "r22": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(28))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r220": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)(i)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920" }, "r221": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)(ii)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920" }, "r222": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)(iv)(01)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920" }, "r223": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)(iv)(02)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920" }, "r224": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)(iv)(02)(A)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920" }, "r225": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)(iv)(02)(B)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920" }, "r226": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)(iv)(02)(C)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920" }, "r227": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)(iv)(03)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920" }, "r228": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(n)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920" }, "r229": { "Name": "Accounting Standards Codification", "Paragraph": "17", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=118257860&loc=d3e4179-114921" }, "r23": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(29))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r230": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "50", "SubTopic": "80", "Subparagraph": "(a)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=65877416&loc=SL14450702-114947" }, "r231": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "80", "Subparagraph": "(d)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=65877416&loc=SL14450657-114947" }, "r232": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "80", "Subparagraph": "(f)(3)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=65877416&loc=SL14450657-114947" }, "r233": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "80", "Subparagraph": "(a)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=65877416&loc=SL14450673-114947" }, "r234": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "55", "SubTopic": "80", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=35742348&loc=SL14450788-114948" }, "r235": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "35", "SubTopic": "10", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=121326096&loc=d3e4534-113899" }, "r236": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5047-113901" }, "r237": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5047-113901" }, "r238": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5047-113901" }, "r239": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5047-113901" }, "r24": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(30)(a)(1))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r240": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a),(g)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r241": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b),(f)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r242": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r243": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(i)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r244": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(i)-(ii)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r245": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(iv)(2)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r246": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(iv)(3)-(4)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r247": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(iv)(4)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r248": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r249": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)(1)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r25": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(30)(a)(3))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r250": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(e)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r251": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(e)(1)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r252": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)(2)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r253": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)(2)(i)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r254": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)(2)(ii)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r255": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)(2)(iv)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r256": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(g)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r257": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(h)(1)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r258": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(h)(1)(i)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r259": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(h)(2)(iii)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r26": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(30)(a)(4))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r260": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(i)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r261": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r262": { "Name": "Accounting Standards Codification", "Paragraph": "2A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=SL79508275-113901" }, "r263": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(e)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333" }, "r264": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(f)(1)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333" }, "r265": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(f)(2)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333" }, "r266": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(g)(2)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333" }, "r267": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 14.D.2)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=115993241&loc=d3e301413-122809" }, "r268": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 14.F)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=115993241&loc=d3e301413-122809" }, "r269": { "Name": "Accounting Standards Codification", "Paragraph": "12", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120383193&loc=d3e11149-113907" }, "r27": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(30))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r270": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120383193&loc=d3e11178-113907" }, "r271": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "718", "URI": "http://asc.fasb.org/topic&trid=2228938" }, "r272": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "730", "URI": "http://asc.fasb.org/extlink&oid=6420194&loc=d3e21568-108373" }, "r273": { "Name": "Accounting Standards Codification", "Paragraph": "25", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=120406818&loc=d3e32247-109318" }, "r274": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=120406818&loc=d3e32280-109318" }, "r275": { "Name": "Accounting Standards Codification", "Paragraph": "10", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32672-109319" }, "r276": { "Name": "Accounting Standards Codification", "Paragraph": "12", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32687-109319" }, "r277": { "Name": "Accounting Standards Codification", "Paragraph": "14", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32705-109319" }, "r278": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32718-109319" }, "r279": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(e)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32718-109319" }, "r28": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(31))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r280": { "Name": "Accounting Standards Codification", "Paragraph": "17", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32809-109319" }, "r281": { "Name": "Accounting Standards Codification", "Paragraph": "19", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32840-109319" }, "r282": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32537-109319" }, "r283": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32537-109319" }, "r284": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32537-109319" }, "r285": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32847-109319" }, "r286": { "Name": "Accounting Standards Codification", "Paragraph": "21", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32857-109319" }, "r287": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32559-109319" }, "r288": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32621-109319" }, "r289": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32632-109319" }, "r29": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(32))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r290": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32639-109319" }, "r291": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32639-109319" }, "r292": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32639-109319" }, "r293": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(d)(2)", "Topic": "740" }, "r294": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(d)(3)", "Topic": "740" }, "r295": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB TOPIC 6.I.5.Q1)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=116825942&loc=d3e330036-122817" }, "r296": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB TOPIC 6.I.7)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=116825942&loc=d3e330036-122817" }, "r297": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 6.I.7)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=116825942&loc=d3e330036-122817" }, "r298": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 6.I.Fact.4)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=116825942&loc=d3e330036-122817" }, "r299": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 11.C)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=116825942&loc=d3e330215-122817" }, "r3": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=121566466&loc=d3e6676-107765" }, "r30": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(7))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r300": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=120385591&loc=d3e38679-109324" }, "r301": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "270", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=6424409&loc=d3e44925-109338" }, "r302": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(a)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=6424122&loc=d3e41874-109331" }, "r303": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "740", "URI": "http://asc.fasb.org/topic&trid=2144680" }, "r304": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "805", "URI": "http://asc.fasb.org/extlink&oid=79982066&loc=d3e1392-128463" }, "r305": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "805", "URI": "http://asc.fasb.org/extlink&oid=79982066&loc=d3e1392-128463" }, "r306": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "805", "URI": "http://asc.fasb.org/extlink&oid=79982066&loc=d3e1486-128463" }, "r307": { "Name": "Accounting Standards Codification", "Paragraph": "37", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Topic": "805", "URI": "http://asc.fasb.org/extlink&oid=121600890&loc=d3e2207-128464" }, "r308": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)", "Topic": "805", "URI": "http://asc.fasb.org/extlink&oid=121647850&loc=d3e4845-128472" }, "r309": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "25", "SubTopic": "30", "Topic": "805", "URI": "http://asc.fasb.org/extlink&oid=6911189&loc=d3e6408-128476" }, "r31": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(8))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r310": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "30", "SubTopic": "30", "Topic": "805", "URI": "http://asc.fasb.org/extlink&oid=116859721&loc=d3e6578-128477" }, "r311": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "30", "SubTopic": "30", "Topic": "805", "URI": "http://asc.fasb.org/extlink&oid=116859721&loc=d3e6613-128477" }, "r312": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "35", "SubTopic": "30", "Subparagraph": "b", "Topic": "805", "URI": "http://asc.fasb.org/extlink&oid=116859824&loc=d3e6819-128478" }, "r313": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(b)", "Topic": "805", "URI": "http://asc.fasb.org/extlink&oid=120321790&loc=d3e6927-128479" }, "r314": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(b)(1)", "Topic": "805", "URI": "http://asc.fasb.org/extlink&oid=120321790&loc=d3e6927-128479" }, "r315": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(b)(2)", "Topic": "805", "URI": "http://asc.fasb.org/extlink&oid=120321790&loc=d3e6927-128479" }, "r316": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "805", "URI": "http://asc.fasb.org/topic&trid=2303972" }, "r317": { "Name": "Accounting Standards Codification", "Paragraph": "19", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "810", "URI": "http://asc.fasb.org/extlink&oid=108774443&loc=SL4569616-111683" }, "r318": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "810", "URI": "http://asc.fasb.org/extlink&oid=108774443&loc=SL4569643-111683" }, "r319": { "Name": "Accounting Standards Codification", "Paragraph": "25", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "810", "URI": "http://asc.fasb.org/extlink&oid=116870748&loc=SL6758485-165988" }, "r32": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.1)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r320": { "Name": "Accounting Standards Codification", "Paragraph": "25", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "810", "URI": "http://asc.fasb.org/extlink&oid=116870748&loc=SL6758485-165988" }, "r321": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "810", "URI": "http://asc.fasb.org/extlink&oid=109239629&loc=d3e5614-111684" }, "r322": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(3)", "Topic": "810", "URI": "http://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684" }, "r323": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c),(3)", "Topic": "810", "URI": "http://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684" }, "r324": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(bb)", "Topic": "810", "URI": "http://asc.fasb.org/extlink&oid=121559654&loc=d3e5710-111685" }, "r325": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "810", "URI": "http://asc.fasb.org/extlink&oid=121559654&loc=d3e5710-111685" }, "r326": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "810", "URI": "http://asc.fasb.org/topic&trid=2197479" }, "r327": { "Name": "Accounting Standards Codification", "Paragraph": "5B", "Publisher": "FASB", "Section": "25", "SubTopic": "10", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=107671284&loc=SL5844817-113951" }, "r328": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "35", "SubTopic": "10", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=77984636&loc=d3e40733-113955" }, "r329": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=121590274&loc=SL5579240-113959" }, "r33": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.13(a))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r330": { "Name": "Accounting Standards Codification", "Paragraph": "4A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=121590274&loc=SL5618551-113959" }, "r331": { "Name": "Accounting Standards Codification", "Paragraph": "4A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)(1)", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=121590274&loc=SL5618551-113959" }, "r332": { "Name": "Accounting Standards Codification", "Paragraph": "4B", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=121590274&loc=SL5624163-113959" }, "r333": { "Name": "Accounting Standards Codification", "Paragraph": "4B", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=121590274&loc=SL5624163-113959" }, "r334": { "Name": "Accounting Standards Codification", "Paragraph": "4C", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=121590274&loc=SL5624171-113959" }, "r335": { "Name": "Accounting Standards Codification", "Paragraph": "4D", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=121590274&loc=SL5624177-113959" }, "r336": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "25", "SubTopic": "15", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=121596415&loc=d3e48542-113965" }, "r337": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "35", "SubTopic": "15", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=56949186&loc=d3e50579-113967" }, "r338": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "820", "URI": "http://asc.fasb.org/extlink&oid=117815213&loc=d3e19207-110258" }, "r339": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "820", "URI": "http://asc.fasb.org/extlink&oid=117815213&loc=d3e19207-110258" }, "r34": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.13)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r340": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(bb)", "Topic": "820", "URI": "http://asc.fasb.org/extlink&oid=117815213&loc=d3e19207-110258" }, "r341": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(bbb)", "Topic": "820", "URI": "http://asc.fasb.org/extlink&oid=117815213&loc=d3e19207-110258" }, "r342": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(bbb)(2)", "Topic": "820", "URI": "http://asc.fasb.org/extlink&oid=117815213&loc=d3e19207-110258" }, "r343": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "820", "URI": "http://asc.fasb.org/extlink&oid=117815213&loc=d3e19207-110258" }, "r344": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(2)", "Topic": "820", "URI": "http://asc.fasb.org/extlink&oid=117815213&loc=d3e19207-110258" }, "r345": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "820", "URI": "http://asc.fasb.org/extlink&oid=117815213&loc=d3e19207-110258" }, "r346": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "820", "URI": "http://asc.fasb.org/extlink&oid=117815213&loc=d3e19207-110258" }, "r347": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "820", "URI": "http://asc.fasb.org/extlink&oid=117815213&loc=d3e19279-110258" }, "r348": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "60", "SubTopic": "10", "Topic": "820", "URI": "http://asc.fasb.org/extlink&oid=7493716&loc=d3e21868-110260" }, "r349": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "825", "URI": "http://asc.fasb.org/extlink&oid=121572278&loc=d3e13279-108611" }, "r35": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.14)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r350": { "Name": "Accounting Standards Codification", "Paragraph": "10", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "825", "URI": "http://asc.fasb.org/extlink&oid=121572278&loc=d3e13433-108611" }, "r351": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)", "Topic": "825", "URI": "http://asc.fasb.org/extlink&oid=75031198&loc=d3e14064-108612" }, "r352": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Topic": "830", "URI": "http://asc.fasb.org/extlink&oid=109240200&loc=d3e30690-110894" }, "r353": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Topic": "830", "URI": "http://asc.fasb.org/extlink&oid=109240200&loc=d3e30755-110894" }, "r354": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "830", "URI": "http://asc.fasb.org/extlink&oid=6450222&loc=d3e30840-110895" }, "r355": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "230", "Topic": "830", "URI": "http://asc.fasb.org/extlink&oid=98513438&loc=d3e33268-110906" }, "r356": { "Name": "Accounting Standards Codification", "Paragraph": "17", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Topic": "830", "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32136-110900" }, "r357": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Subparagraph": "(a)", "Topic": "830", "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900" }, "r358": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Subparagraph": "(b)", "Topic": "830", "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900" }, "r359": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Subparagraph": "(c)", "Topic": "830", "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900" }, "r36": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.17)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r360": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Subparagraph": "(d)", "Topic": "830", "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900" }, "r361": { "Name": "Accounting Standards Codification", "Paragraph": "21", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Topic": "830", "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32262-110900" }, "r362": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Topic": "830", "URI": "http://asc.fasb.org/extlink&oid=6450520&loc=d3e32583-110901" }, "r363": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Topic": "830", "URI": "http://asc.fasb.org/extlink&oid=6450520&loc=d3e32618-110901" }, "r364": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "830", "URI": "http://asc.fasb.org/topic&trid=2175825" }, "r365": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "835", "URI": "http://asc.fasb.org/extlink&oid=6450988&loc=d3e26243-108391" }, "r366": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "835", "URI": "http://asc.fasb.org/extlink&oid=6450988&loc=d3e26243-108391" }, "r367": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Topic": "835", "URI": "http://asc.fasb.org/extlink&oid=119993939&loc=d3e28541-108399" }, "r368": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Topic": "835", "URI": "http://asc.fasb.org/extlink&oid=119993939&loc=d3e28551-108399" }, "r369": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Topic": "835", "URI": "http://asc.fasb.org/extlink&oid=119993939&loc=d3e28555-108399" }, "r37": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.19(a)(5))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r370": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "55", "SubTopic": "30", "Topic": "835", "URI": "http://asc.fasb.org/extlink&oid=114775985&loc=d3e28878-108400" }, "r371": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "842", "URI": "http://asc.fasb.org/extlink&oid=121603541&loc=SL77918627-209977" }, "r372": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "842", "URI": "http://asc.fasb.org/extlink&oid=121603541&loc=SL77918627-209977" }, "r373": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Subparagraph": "(c)", "Topic": "842", "URI": "http://asc.fasb.org/extlink&oid=121603541&loc=SL77918643-209977" }, "r374": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "842", "URI": "http://asc.fasb.org/extlink&oid=121609121&loc=SL77918666-209980" }, "r375": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)(3)", "Topic": "842", "URI": "http://asc.fasb.org/extlink&oid=121609121&loc=SL77918673-209980" }, "r376": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "842", "URI": "http://asc.fasb.org/extlink&oid=121609121&loc=SL77918686-209980" }, "r377": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)", "Topic": "842", "URI": "http://asc.fasb.org/extlink&oid=121609121&loc=SL77918686-209980" }, "r378": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)", "Topic": "842", "URI": "http://asc.fasb.org/extlink&oid=121609121&loc=SL77918686-209980" }, "r379": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(g)(1)", "Topic": "842", "URI": "http://asc.fasb.org/extlink&oid=121609121&loc=SL77918686-209980" }, "r38": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.19(a))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r380": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(g)(3)", "Topic": "842", "URI": "http://asc.fasb.org/extlink&oid=121609121&loc=SL77918686-209980" }, "r381": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(g)(4)", "Topic": "842", "URI": "http://asc.fasb.org/extlink&oid=121609121&loc=SL77918686-209980" }, "r382": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "842", "URI": "http://asc.fasb.org/extlink&oid=121609121&loc=SL77918686-209980" }, "r383": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "842", "URI": "http://asc.fasb.org/extlink&oid=121609121&loc=SL77918701-209980" }, "r384": { "Name": "Accounting Standards Codification", "Paragraph": "53", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "842", "URI": "http://asc.fasb.org/extlink&oid=121568110&loc=SL77918982-209971" }, "r385": { "Name": "Accounting Standards Codification", "Paragraph": "3A", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(a)", "Topic": "842", "URI": "http://asc.fasb.org/extlink&oid=121576215&loc=SL117410129-209981" }, "r386": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "850", "URI": "http://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864" }, "r387": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "850", "URI": "http://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864" }, "r388": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "850", "URI": "http://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864" }, "r389": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "850", "URI": "http://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864" }, "r39": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.19(b),22(b))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r390": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "850", "URI": "http://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864" }, "r391": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "850", "URI": "http://asc.fasb.org/extlink&oid=6457730&loc=d3e39599-107864" }, "r392": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "850", "URI": "http://asc.fasb.org/extlink&oid=6457730&loc=d3e39603-107864" }, "r393": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "850", "URI": "http://asc.fasb.org/extlink&oid=6457730&loc=d3e39691-107864" }, "r394": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "850", "URI": "http://asc.fasb.org/topic&trid=2122745" }, "r395": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "852", "URI": "http://asc.fasb.org/extlink&oid=120604989&loc=d3e56068-112765" }, "r396": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Topic": "852", "URI": "http://asc.fasb.org/extlink&oid=84165509&loc=d3e56145-112766" }, "r397": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "855", "URI": "http://asc.fasb.org/extlink&oid=6842918&loc=SL6314017-165662" }, "r398": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "855", "URI": "http://asc.fasb.org/extlink&oid=6842918&loc=SL6314017-165662" }, "r399": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "855", "URI": "http://asc.fasb.org/extlink&oid=6842918&loc=SL6314020-165662" }, "r4": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=121566466&loc=d3e6801-107765" }, "r40": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.19)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r400": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "855", "URI": "http://asc.fasb.org/topic&trid=2122774" }, "r401": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(bb)(1)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719" }, "r402": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(bb)(2)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719" }, "r403": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(bb)(3)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719" }, "r404": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)(1)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719" }, "r405": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)(2)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719" }, "r406": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)(3)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719" }, "r407": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(1)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719" }, "r408": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(2)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719" }, "r409": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(3)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719" }, "r41": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.19,20)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r410": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "910", "URI": "http://asc.fasb.org/extlink&oid=119991564&loc=SL119991595-234733" }, "r411": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 11.L)", "Topic": "924", "URI": "http://asc.fasb.org/extlink&oid=6472922&loc=d3e499488-122856" }, "r412": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(a)", "Topic": "932", "URI": "http://asc.fasb.org/extlink&oid=68064819&loc=d3e61929-109447" }, "r413": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(b)", "Topic": "932", "URI": "http://asc.fasb.org/extlink&oid=68064819&loc=d3e61929-109447" }, "r414": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(a)", "Topic": "932", "URI": "http://asc.fasb.org/extlink&oid=68064819&loc=d3e62059-109447" }, "r415": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(b)", "Topic": "932", "URI": "http://asc.fasb.org/extlink&oid=68064819&loc=d3e62059-109447" }, "r416": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(a)", "Topic": "932", "URI": "http://asc.fasb.org/extlink&oid=68064819&loc=d3e62395-109447" }, "r417": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(b)", "Topic": "932", "URI": "http://asc.fasb.org/extlink&oid=68064819&loc=d3e62395-109447" }, "r418": { "Name": "Accounting Standards Codification", "Paragraph": "33", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(a)", "Topic": "932", "URI": "http://asc.fasb.org/extlink&oid=68064819&loc=d3e62479-109447" }, "r419": { "Name": "Accounting Standards Codification", "Paragraph": "33", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(b)", "Topic": "932", "URI": "http://asc.fasb.org/extlink&oid=68064819&loc=d3e62479-109447" }, "r42": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.19-26)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r420": { "Name": "Accounting Standards Codification", "Paragraph": "35A", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(a)", "Topic": "932", "URI": "http://asc.fasb.org/extlink&oid=68064819&loc=SL6807758-109447" }, "r421": { "Name": "Accounting Standards Codification", "Paragraph": "35A", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(b)", "Topic": "932", "URI": "http://asc.fasb.org/extlink&oid=68064819&loc=SL6807758-109447" }, "r422": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(c)(1)", "Topic": "932", "URI": "http://asc.fasb.org/extlink&oid=68064819&loc=d3e61872-109447" }, "r423": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(c)(2)", "Topic": "932", "URI": "http://asc.fasb.org/extlink&oid=68064819&loc=d3e61872-109447" }, "r424": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03(10)(1))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878" }, "r425": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03(11))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878" }, "r426": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03(13))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878" }, "r427": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03(16))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878" }, "r428": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03(23))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878" }, "r429": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03.15(5))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878" }, "r43": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.21)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r430": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03.17)", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878" }, "r431": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.9-04(22))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260" }, "r432": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.9-04(26))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260" }, "r433": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.9-04.9)", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260" }, "r434": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "235", "Subparagraph": "(SX 210.9-05(b)(1))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=120399901&loc=d3e537907-122884" }, "r435": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "235", "Subparagraph": "(SX 210.9-05(b)(2))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=120399901&loc=d3e537907-122884" }, "r436": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "470", "Subparagraph": "e", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=75038535&loc=d3e64711-112823" }, "r437": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "825", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=108315417&loc=d3e61044-112788" }, "r438": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(16))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910" }, "r439": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(12))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910" }, "r44": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.22(a)(1))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r440": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(16)(a)(1))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910" }, "r441": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(16))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910" }, "r442": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(23)(a)(3))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910" }, "r443": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(23)(a)(4))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910" }, "r444": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(25))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910" }, "r445": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(8))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910" }, "r446": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03.(a),19)", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910" }, "r447": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03.15(a))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910" }, "r448": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03.17)", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910" }, "r449": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.7-04(18))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263" }, "r45": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.22(a)(2))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r450": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.7-04(22))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263" }, "r451": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.7-04(9))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263" }, "r452": { "Name": "Accounting Standards Codification", "Paragraph": "4H", "Publisher": "FASB", "Section": "50", "SubTopic": "40", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=116884468&loc=SL65671331-158438" }, "r453": { "Name": "Accounting Standards Codification", "Paragraph": "7A", "Publisher": "FASB", "Section": "50", "SubTopic": "40", "Subparagraph": "(d)", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=121643868&loc=SL117782755-158439" }, "r454": { "Name": "Accounting Standards Codification", "Paragraph": "13H", "Publisher": "FASB", "Section": "55", "SubTopic": "40", "Subparagraph": "(a)", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=121639165&loc=SL117783719-158441" }, "r455": { "Name": "Accounting Standards Codification", "Paragraph": "13H", "Publisher": "FASB", "Section": "55", "SubTopic": "40", "Subparagraph": "(b)", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=121639165&loc=SL117783719-158441" }, "r456": { "Name": "Accounting Standards Codification", "Paragraph": "29F", "Publisher": "FASB", "Section": "55", "SubTopic": "40", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=121639165&loc=SL117819544-158441" }, "r457": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(e)", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=121370832&loc=SL117420844-207641" }, "r458": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(f)(1)", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=121370832&loc=SL117420844-207641" }, "r459": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(f)(2)", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=121370832&loc=SL117420844-207641" }, "r46": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.22)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r460": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(g)(1)", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=121370832&loc=SL117420844-207641" }, "r461": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(g)(2)(i)", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=121370832&loc=SL117420844-207641" }, "r462": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(g)(2)(ii)", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=121370832&loc=SL117420844-207641" }, "r463": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(g)(2)(iii)", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=121370832&loc=SL117420844-207641" }, "r464": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(g)(2)(iv)", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=121370832&loc=SL117420844-207641" }, "r465": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(h)(1)", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=121370832&loc=SL117420844-207641" }, "r466": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(h)(2)", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=121370832&loc=SL117420844-207641" }, "r467": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.6-04(13))", "Topic": "946", "URI": "http://asc.fasb.org/extlink&oid=120401414&loc=d3e603758-122996" }, "r468": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "310", "Subparagraph": "(SX 210.12-29(Footnote 4))", "Topic": "948", "URI": "http://asc.fasb.org/extlink&oid=120402547&loc=d3e617274-123014" }, "r469": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "740", "Topic": "954", "URI": "http://asc.fasb.org/extlink&oid=6491622&loc=d3e9504-115650" }, "r47": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.25)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r470": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "360", "Subparagraph": "(d)", "Topic": "958", "URI": "http://asc.fasb.org/extlink&oid=120429125&loc=d3e99779-112916" }, "r471": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "360", "Topic": "958", "URI": "http://asc.fasb.org/extlink&oid=120429125&loc=d3e99893-112916" }, "r472": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "360", "Topic": "958", "URI": "http://asc.fasb.org/extlink&oid=120429125&loc=SL120174063-112916" }, "r473": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "360", "Subparagraph": "(SX 210.12-28(Column B))", "Topic": "970", "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024" }, "r474": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "360", "Subparagraph": "(SX 210.12-28(Column C))", "Topic": "970", "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024" }, "r475": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "360", "Subparagraph": "(SX 210.12-28(Column D))", "Topic": "970", "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024" }, "r476": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "360", "Subparagraph": "(SX 210.12-28(Column E))", "Topic": "970", "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024" }, "r477": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "360", "Subparagraph": "(SX 210.12-28(Column F))", "Topic": "970", "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024" }, "r478": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "360", "Subparagraph": "(SX 210.12-28(Column G))", "Topic": "970", "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024" }, "r479": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "360", "Subparagraph": "(SX 210.12-28(Column H))", "Topic": "970", "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024" }, "r48": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.29-31)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r480": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "360", "Subparagraph": "(SX 210.12-28(Column I))", "Topic": "970", "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024" }, "r481": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "360", "Subparagraph": "(SX 210.12-28(Footnote 2))", "Topic": "970", "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024" }, "r482": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "985", "URI": "http://asc.fasb.org/extlink&oid=6501960&loc=d3e128462-111756" }, "r483": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b" }, "r484": { "Name": "Form 10-K", "Number": "249", "Publisher": "SEC", "Section": "310" }, "r485": { "Name": "Form 20-F", "Number": "249", "Publisher": "SEC", "Section": "220", "Subsection": "f" }, "r486": { "Name": "Form 40-F", "Number": "249", "Publisher": "SEC", "Section": "240", "Subsection": "f" }, "r487": { "Name": "Forms 10-K, 10-Q, 20-F", "Number": "240", "Publisher": "SEC", "Section": "13", "Subsection": "a-1" }, "r488": { "Name": "Regulation 12B", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b-2" }, "r489": { "Name": "Regulation S-T", "Number": "232", "Publisher": "SEC", "Section": "405" }, "r49": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.9)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r5": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 201.5-02(24))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r50": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=51824906&loc=SL20225862-175312" }, "r51": { "Name": "Accounting Standards Codification", "Paragraph": "10A", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=121641772&loc=SL7669646-108580" }, "r52": { "Name": "Accounting Standards Codification", "Paragraph": "10A", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a),(b),(c)", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=121641772&loc=SL7669646-108580" }, "r53": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=121641772&loc=d3e637-108580" }, "r54": { "Name": "Accounting Standards Codification", "Paragraph": "12", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=121641772&loc=d3e640-108580" }, "r55": { "Name": "Accounting Standards Codification", "Paragraph": "14", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=121641772&loc=d3e681-108580" }, "r56": { "Name": "Accounting Standards Codification", "Paragraph": "14A", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=121641772&loc=SL7669686-108580" }, "r57": { "Name": "Accounting Standards Codification", "Paragraph": "17B", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=121641772&loc=SL34724394-108580" }, "r58": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=121641772&loc=SL7669619-108580" }, "r59": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=121641772&loc=SL7669619-108580" }, "r6": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 201.5-02(25))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r60": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=121641772&loc=SL7669619-108580" }, "r61": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=121641772&loc=SL7669625-108580" }, "r62": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=121641772&loc=SL7669625-108580" }, "r63": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=121641772&loc=d3e557-108580" }, "r64": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=116657188&loc=SL116659661-227067" }, "r65": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(210.5-03(11))", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=120395209&loc=SL114868664-224227" }, "r66": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03(1))", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=120395209&loc=SL114868664-224227" }, "r67": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03(20))", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=120395209&loc=SL114868664-224227" }, "r68": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03(24))", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=120395209&loc=SL114868664-224227" }, "r69": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03(4))", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=120395209&loc=SL114868664-224227" }, "r7": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 201.5-02(26))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r70": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03.3)", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=120395209&loc=SL114868664-224227" }, "r71": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03.4)", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=120395209&loc=SL114868664-224227" }, "r72": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03.8)", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=120395209&loc=SL114868664-224227" }, "r73": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03.9)", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=120395209&loc=SL114868664-224227" }, "r74": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3213-108585" }, "r75": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3213-108585" }, "r76": { "Name": "Accounting Standards Codification", "Paragraph": "14", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3255-108585" }, "r77": { "Name": "Accounting Standards Codification", "Paragraph": "14", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3255-108585" }, "r78": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3291-108585" }, "r79": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3291-108585" }, "r8": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(10))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r80": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3291-108585" }, "r81": { "Name": "Accounting Standards Codification", "Paragraph": "17", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3367-108585" }, "r82": { "Name": "Accounting Standards Codification", "Paragraph": "24", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3521-108585" }, "r83": { "Name": "Accounting Standards Codification", "Paragraph": "25", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(e)", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3536-108585" }, "r84": { "Name": "Accounting Standards Codification", "Paragraph": "25", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3536-108585" }, "r85": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3602-108585" }, "r86": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3602-108585" }, "r87": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3602-108585" }, "r88": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3044-108585" }, "r89": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=121583591&loc=d3e4297-108586" }, "r9": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(11))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r90": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=121583591&loc=d3e4304-108586" }, "r91": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=121583591&loc=d3e4313-108586" }, "r92": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=121583591&loc=d3e4332-108586" }, "r93": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "235", "URI": "http://asc.fasb.org/extlink&oid=84158767&loc=d3e18780-107790" }, "r94": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(e)", "Topic": "235", "URI": "http://asc.fasb.org/extlink&oid=84158767&loc=d3e18823-107790" }, "r95": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(d))", "Topic": "235", "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690" }, "r96": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(e)(1))", "Topic": "235", "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690" }, "r97": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(g)(1)(ii))", "Topic": "235", "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690" }, "r98": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(h))", "Topic": "235", "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690" }, "r99": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(k))", "Topic": "235", "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690" } }, "version": "2.1" } ZIP 93 0001104659-21-044832-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0001104659-21-044832-xbrl.zip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�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◉DTU"]5K[F!B&QKWAP?L//J=/M1 M8X>! 1Q6-L#:8-'IE; -XRA!A%)9R=00MH]QM//1SW&D;1R)86'C%;A*-3ZB M< 50_/'H.UB9V;RT(AOI/0PGYK<_1Y6N424'R8'X"C36YEW@@1D,8 SNX1OY M,<9'4[BNNX M]F=38/>ABNQX.#X_^QQ9^S0Q2$+3<3XQZ91Z>]BG416%$N"1^ =!1 \ML=<. M? XB+3NY9K@H\SA2E$#8O(6+G5NXXZ]]CB-=BU$=",I\GN992D#:ED]3.E>5 M:GP ^[!LXZ]\CA1=(X6E?%7ISHPZ#A7P,$A=_/F3C3)LY&I-E6>888E0NP!$ M^61;][5/FN]ATFT$@C+',#63K_BA^%NP#:"KZTO2:F+[IJMG06831\N7CH1P)/^DA@,TZ:R=_>I M*!,WAF_I3;%,T-FSW:"S:9L_OY)/#$9<\QZC7:.$?T?'X_.3DY.CX^'YV?E84[2SM(L[G)F0 MO%WS](70Y<>F2"[%Y(>#O(Q1T32)H]@)/#R&'Q).%B/EWS%NHNR $+MGD/VH M49$W?9;H_CEV4/$PM(\,_T)2V$5W0?8*G!=TH8,O?;*\2T4:D =E#_$>2AN MZ.8=(!=&S'B5\@T=*$/5Z*FM1SCU@*1MDGVM'[&OC!'[&][[XVUZNB05#Y!Y MLZSB3QTHB?>E2>VY7LS82=R&: 9@G) P,@'QZ8#9076]4G6TKZC][@'3?^]J M;>N(;=:4;\G)M2W._#)"1E#FK MBW&BK@>?8T6'@MMZ,_=G/:E39*$KK<-%JA-50(?#\5!S H-^C)CV.E;EX-R# M4=/6DJ%A;]:J3Y]CR@R5=^/\W<PZ5ZYJOR\#\-M?=Q-NH)L<67+UN$3(.F \>^OB% EB/>P-IO3PYX-!F@Z-;> M_ KV<@P'?K7^8H):HGG^:^G(80T+P_2LZLV (2>P<\2O:FSH+T;3T)>G)3 MVF/J?[J8*==G07XU;@*V&\\F\SE*G4;W,C0:]^=SU="O[F)@=>%/L.?7S^F+ M\TQ'LJ^>1Q*OGDN?^7SKS!T"X[/S4TTQF_#V)DX'TPLG6'&U4'5XC,C_LVW9!X.!5?_(.M]^9,=4AL S3H6&6-@4\.B2T$I:3K("N> M$GO](YZEOH8>[KZ;*OPKH#R#X)0T"THI2+8,V1+R&0LF H)8T@I:!*6P>!TD MV=.ZG;HO$O#6;:G6!8U!O=%2*BF7(KC5;97V9YQ8)Q4OG8\Z]=JI_:"YS..3 M2*')H)F.%"T_/;[GI.LM-[=T<6]9^T'+R+P_'=FR JN= C*M_1;ZN!D?G_&> M,)C[F:!I7[:,W!J4I2C?K"%3MBH%/L'HCUL$0!%R=%\LIWWWD^/M5*4HL) ! M]Q3/R7+IH(_IC/[G/ &4[!7&L4S@UJP'@W VB$JEW'(ID'7C\XICI]'/^PP= M]QE&7%YHSX-[%^!!"C93=YA9H"AW&P(UC&-((].,K(!,1AB$)_7*0ZB.<9C* MPB,,L,F7(6K(\83!PHI>3 +O&KP!/UP1^?/] =7X+E&SJKCCX^&IF401LLJW ME=L2PGP! 4 .2<0P\98P@&3EC.$;$*&,4%TK2=-<W.VKA MUGB[,_'3QH%'/\/GC&>@+U;97$;PP=UE10MY.UA/-D>/D2:[Q<3S8";'73 + MT3*;:27-%"CBTX?V]),$'7%C9L5.E#YEI.( MK#:,<[,TR3BAD3&-P&QAIJBC@T'(JC)3&# ?R,+3RDSQ>>H\F%,GDRZM3YU] MI\VG=4N6,BVM6WTW4Z1WR"_X*YP-1:6,,210M(6H%XZ)M)&N',RXKQM! ^_1 M=X('9PFX>XTN/F4,>\3A;^"KH4HQEBQ*-\N5'WX 4,KKQEV*F.6K2CH9CL>: M\XWOC0F[))13DB5,*E)6IVFH(UAS$&:4-H9%BE8P&3$Y+HT[EE#]T&;)QOFK M5&T]8^!N@I<8VO7R:A__#&/HK>]$?_P(T1\1^]W;=IE> %H/R99E4TA*[3!J M]D>NO4MMW; QY%*T.'2D$46.PQKMZNO]$T!OT 5T/3V$P5L6&8:H)'H)8\\8PMF/*<;; >U%I_Z^2.M-7%@;V-D3Y MKT@YUFN^_7;B8V9^2\Z'3-@%!-03#9O"<*;JH:8S' M^@RUN:>.)G,$\.DJC%_"R[6*O,N/?X:^1[\#VN/G#V\H&*'A?!RTS46@: E1 M/0JRR>$Z021+SP*Z"TW#H44_JJB1=W^?XV*?JLX'2-N< H8.D))R;O*';EWF M"ZS_W"?=]Z+1XE;MR$Y:IY&Y"@/R710EP/N&58-*KB)*>2WPO4]B[T>E!;/5 M1GQML;/OZ6OW0V"H OT4=*/=MN[OD?LC"E< Q1_$H!23=$IXC*0/:N2>M)\? M#;>?M!Y^M,H1DOU'%7O@O7_7Y\K"DL6NOP>!I';@,5 M4TQ#];+UWRF(J9W+CYIG80(UC>&#!*2[/&@JJ%&OS9E"$!&X'O8"-8W#N2ED M$N#72&^)J_8]P)N01>A[=\L5"M\RBSCW]1:G1G]H4@/N+DUDI;:$'K<)"F", M=VA8>;?PG?R+SPYVA:J:SO 6^<06.0ESIJ MR(O6950*,=3 ?+NS[*2BK++&H"8/P!9X4A(:L?N+"MPCX/XR#]]^=<,DB-%' M!GW^PS;R^:^_?[G<@GGS![,PE<)E@VF-.$8 J"+*6*&6:Q(K"[XF*2QLFP^[ M@C&HMS+U2,K'W&"9 R;7M,.K8AR@DMB(@FOZ--TA,4 40[9O-%X1RCU ;($8>$.D"W_FH,+/4:IJ!A MYWCZZKS#9;)DPE?YNWD CCZ#" ,^B.6_]QG$6CDLL4HKR\O2M[5/ M4BY%#Q]-]&SX@L)(VJDAK535U/EH=&QX'A;F!K>!G-9DL)^X;K),TI04UP!W MWH59V&BP\D&*7>!-EB&*X;_3WS-5Q7)R5-2\/63K5"-MUZ5Q1LL S$G_5 8W MO H#?'9,W/3%QQT1:XY!BQ[ -G-J2O>?"$T$[#2RRJEA2](N)T2J])\8C:7L M)'-YBTS$C"F ZA;T+0*SQ+^',VK"IYHJ_<>\L906;TF9E)"HV7]FM!5641B* M"D'V_U1"04K \Z.1W/L),_,"=ORPXE33+J"\!V8,]W(18\9U _7NCNU:R;IX M4M'9('X(8Q ].A_$_B(W1"]VGSBEC0WRUC1GY 2O\:9O=9DVJ84)N.MTCB>G M9T>CXYZ^8[H8C4Z&>I=2"15S+'YLV?K_CNGF/8;!/('1(G6/G1&-<1Q96,6- M0UX O%W$I:0SZID2K>>U+Y3XE8R#5 H=,7!KI#7S DY^)E^$*":A)(C(7+\5 M2LE>T* &1\K<+BBH=@8P(VOD_2_OI-BY8#C%[<*WD;3:KVAE0,Z3@C\Z*(:, MET!RE0^% ,*R:W_^PS**AL%NUT0=H)8UC@F-=NWB MHAF6DG:KVS599:FES4-0& P!($W>FK/6;/C^")!+C.Y!!-P$\?=ES-+F RNQ M',M):2JT-R1$<5400']@6U?<)G!EQ31UL_T" G%LF85M0E9.2%-WS2\_@/\& M)*#EE+<*75DYM6^::U?73Y'.G.6P(-Z MK821EEG1B4W_ Y:J'JY($E\40SP99_^,TC<4T 6L',S"]6VECJS(BI8ETYAS MZ[A@LB21;H2(LBEN*R]J).SDT8%^&GP+G.SU%?"(CYDP'RCU;"6&J*AM3Z+= M/4:[=2#*4UG^*6U7*EJM_YBWDE31"57_I%#,#TGKO MO=;[Z:)^=D(:-M%%7=(?O1"$<\!7&X9)LZ^*"< )P-'$5Z6'4+9V7#$"3F%D MFCFN".#:)\M\>9U,@ZKG_^;'IJ^I93XI.,#NTJ*)M);0HXMG1480HLFD+R4= MQ]JJ>=[O^HV1"?A*026&M.GK@3F/#TPE@/#$KT!V4^EP&Z)7X" G<$&NE%"4 M#()5J^HXQ1TX[SL5VDBNW4_2+ \.$PC1[,0G)A?GJDSSLE]*1UY<'><)=:?! M(P(K$,/,VN:\0A\25N.)[PFXX3P@=O^[8*V!Z6RZ BA%C,6";CYF+I/XI-AE MTQ[UT\%*I#[#?#G^83;%,J[B:DKWGR%-!#3WK,$6!+-\"9,E8_ZHK==_H-N) MVHE+1HMQW05=;F& MUQX[W851G$T"=9WSZQ51[2ZK>21E+CC()*:.+2UGG*N M$Q[GTN2 V6U<+VP2D@'\N%:5.T& 6L19\'_$6WI[:]N-\\)\NE@SZFLZMPN7*"C^?2X7?Z MZL-Y=GB=!F1B>T00[V!6CB_KJ'-2YZ@39=T8A+,!'FX#-^O,?T3X7^ON#,)- M?P9A,/!PCXC>LBY]>O?H\>XY&PV/3O6.=37>/;D@YKJ$5+U^GX 'EFGG'@'N MF<>Y^*VO:!RD D#MHMM0SKXBSKT2%JEJ'.H- 91E D=Z4V\&60+=@RAZ63C! M- #_#1S$OA^4:J!GQ.#@N66Z;:^%OA'D:XA +AD^G19ROOP(F]%%H+F#(T]3 MG6B_?&Y(I1=J7G[,3H(^#.2*W1"ZAKL-J:_AL(;#S::B.E6X:S MH+2F[@MU."O;2P!AV;5OZ?89*=T.P"6%U1[TTCHPO#8!6?J.6$-!77G=#O8N%Y+<953DA3-]P= MQ<+O.;:R8IJZ?^XL9GK/\9664_OV>3\QTWL.JXR(!Q4SO>>X2DKY&3/=// ; MG7+%Y.+,S4;Y5JF)-FL4FGQ@=A&5DE#&9VXO?LP3SX-9'^Z"68B6::NR;LJG M=6[*FZ\,2I_IO>LQ@7B=J_WL[/2D$BZS3][(%\/Q^;%^[Q!!%7.F5;9L_<\O M0&:FZ>P*]Q22>8:\H?_@V(I9Q8U#7@"\7<2EI!.8=H_-P?2>S+.(:SJNJV8< MQE)PB:%=*Z^I=L#_9]Z)>5BWAWI!^W!6?*],EC% MC0-0$(LZ$&LDU#YR&1/P(]8%C*(0??#=HVGE#(>R!I&M.5A80%.1)-V^3L!= M@/\P9 -)*685CJ+RF>IUD=I\^?!1W77'H]&I 6E.VL#&D\M4-XI'Y\-= /$!6I(0+>>Y2Z M2E9!WTQ:4WTR;L$K2IQLT\"+C[Y;S"I01>73[G_!LD.L$/1K,-PN8Q6 0L(I MBCBG'+VO3LWII5+ *MSJ)>L@6IP2T*9N'.(^\X';*605>&+2Y0".30-PDLR3 M*.;CMUW&*OB$A"O,!4<]M]F21X6QV.LZ6E'C@&_F+2$J&?-\8@)T?)<(:F'C MX!-&HAY$CH2FVOJ^A+ZW= +^W+M3J"+B^=%H-!J:!2('B:VI5TPV[? I=DN\ M^3.!\0<)E1L&^,>(]\*95\(5M9<%(4!V055 M7%)+!O?O#D(.P_6!6L8XV,4AVX6[7C(S819R5GIR@CEMGUSYFW%P2ON2\479 M6\8)<4BH8VWKKU59AL/QA298ZC5,08,C0X_'TU<8P&6R9,)7^;MY '+Z586P M7HX^@^B\\T$L_[W/(-;*H=T#0='I)'F-P)\)V?:]D56C)O(2O;0Q0+<[D4@( MQ[E+T1U]:5<*?OPE5GGS0)7 1PA=CIQF3M%MR< ]IE#+]H$$'!AK:="[55IS M8#TC*-!H-CQ]&981%#9.9Q"1FU#^']Q=(S$E8.-%LW M G)"FHIK1S'7>HZMK)C:3U;[CKG6PRHCHJD.W20?*0SF MQ#=HXZK,B2G +EX5^QC+K?OE8G-D9<74[KVM9B]="IK_\8*<('+2IPN<\Q"G MAGE\:'(JDA60Z@.3!M3>G2TIH*\U4X#[ JQ''F5K /:'EQM1^G%#E<=9#5SP1&-%JW MI:1C^[";@F.M85,BJ\[Y"7DZ;EX2((E%NX&TVJ?S#LS=_-NJW9*]H$$-CC7V M;HZ@VAFPW^Q^O<>WD;26K.6J J";0()VSN]\N8HQW>-PO61,9"E*(]SU/%DI M\$HAF](XX4,& 42KFTL+/L*[U&@E*_[P@\47NHB@!7F/65!HY(.[4 MRZUHA=',(-6Y&X3I3N"";&_& M8 "[@CT&XE+O=YI;EQC3PQ=6_+W3-$435.)VRXSK/;LX95:%2BZ M:&31[E31D;8ZH4X1G$.2.H8(1G)WD+F5NN3(5>X_213(VT'$*>T>^E6-? N< M98AB^&_@%?H0VJE0ZO6?,>U$513@JM'>A15@SH'H-\=/\&)[LWP%G@>\S729 MS8BT24*@6E4#9\/QA>X$V8VFAZ:2=A 72_O^A 34*"R]C#F@7*3_#!"6JFT0 MK7&&=@!B4[ N&WP96)>+V(-UK52J0FZQ=H&:5OU[,'?\6P"88;>*O]L#-5\D MK<9M5OCNA%R]3&>38K]Q%Y!MB./[1/YMZ$2J]!_-QE(6 *N\K6IQF%/DOI!O M4JX!@F\8MS= V<%L_G@/G=AS%V#V@RA^ MPMI-5>QMHF\+'1-Y#=A#HI8R%[1I:^\TAC:Y(0[B/=;F-/6(H MXMDRA^E4% MGI\>#DK@]1^C_*\1:Q9HU%95L1?#\7C4,]:H%[_@ ME19;9!>W987A/G5EE7#9H=2SAR_-1"VXT=9V:JI$&3V#E?*2& M(JXCSG:QJCK&P_%Q7^\SA20K@.ZQ]^;:=#/Q_I5$<<;O8L?$0)U;QQX*R(M9 M\$&++V:-@?SF'49D%F-@RRW;?TSEQ2NP5!GS9&,+'^H9[<7NY>9]!8((<&9V M2LG^LT!6N((#/;8REM>Q\E-FP45]NTI%31='6$U]W=-)2UF008OY4.WPSR_S MKQ)$U#L)O(UA@*AP!>(]-AI.W-0]LW#P*4V%$$02,X1T._:P18WH!9=H1L;& MGE!,?_B,G%L]IWN_4XM613CMX49 6KH"()IU3SU 93OUENV1_U2AIIHUP#63 MM'@MIS(]Z ;^8X7P;TS0C[[CIAJ:S--K[QU#O5"=JCK.AF/=*255O$X1%+- M766LC6X&_4:TU!>32$0UU;#*6HERC7@%NE:Y+1;&*;QQR*ZMITDLO8'#E3GF<)(GH:0AND)QO%]X%U^;/O1R'@DB;=:5?\Y MWK6->\; +A51\+#'1DC>O-U@4;.'+])2%F3HYJVUIF=V):]>L@E<7\*2=\1^ M&"6(^1Y+H*8]9&DJ;,&9MA9+98%"6(E9MEQNQ!_JR%:OJND"K_>]-(BTE;@@ M1EL?1\,><7YQ8!#=AU$$HFE \^-B3":U]?I/FW:B%GQI_\)[3JSEIBP_^7/) M%+A,^B* Q2,"2YBPSMVU]2I*'.-CQ7E?8]8U$[4(4*7%*;(NULZ^3\YXQ05*V@@ T&VRW=G+2 MI=L0K?UYIK/[T"'O ,7KAP?GZ88SQM:M=5_@-6+7W" 9EQM?$-F=HC)7B+? M4,8"7D7>D)2MWM]_+:L/B_-']NOMW^:R[&@04QJ&O[CA,OO0YBS\ .(;!P7$ MCX=L=!\!2NV_D]7*ARZY\'\)<[-P'+I_+$(?2QI=@]B!_GH;D&$(WF,0X&/5 M^K\;6N7O$LX;C;XP7WX'M=E>^G8TW#_ME= "_Q,:LG00P] MZ"?D(+RQO=Z\NWZ"T20C ".P2N)\5[LMR@LGZI/:CU2''CYLG9SHF5[$D=V= M6?:@DOX'3F^IFLL/>@.<%$L=?M$8VNZ1@I2C\9X5S!P$YO#YP5GR,T7553.. M6?L&691F-2HS-=U0:>.5!YSFI0ZDE^T)1VH0VCJ;20G; ;HM7JO50UU8D]:7 M$B\(..D;2R'TZZK;3HA&\EN2BRJ7G9MLKE+&-C*("ZDH-T@76=Z+V^O:9+&T MDK8A*BNJHFP?1KU-;KFM6AN_NCG[T&UKX_%P?*;;0[*'!QV^-ON?T:JE>K@! M=Y2T;1R+.R64[9K/\^8&:;<&Y7[A/^9=&X2S0;CIW"!)>S=P\NX-5EG_ M!@OL,8N(=Z H#?H\L[GC*)&0\Q!9.M(+B.==C 5+]YU!^H: MMQ,30&\T20O*U?]#*F/6RX.BI5Y!YK(#[31X1& %,'8ID;(K37)_$L9/P WG09:_;#UBIK/I"J"4=IS' MH!U\S+A)1)0@6T]']Z6:3KT2-/F45I\_W<+ "5P8S-/P-'C:+=Y",>^A!*N7 M]4FLH^,3S:F^FE"ME;"*=MA=OU3>&D.YFE["VQ"] @XU'12(VH$G M@_:WINMP=7@D8+ESQ3#F#7KA7M.B@6B*'!]JYX2][W@GG@Z"68B6Z1=D M=[S'4CO>S2<'I6_V:L,K=5MS=J3K/FSMH2%F:!9[;"+1EC&SA#Q>%/N<,@T8 M9TV)4%QB%?YIFU'X5]]?R'B?SNX"#[Y!#V_B*1=LS'+&,$$]FANFR$G?Y:U: M,T#7ID B_@*N7L*; ,_R]&NV!BT80P(YH&H ;B"SF50=NZKTTG$A=9EPUS MIHLZEXWGW%-A,D< \-]3U=4Q&G2AM:"YF,;B'+C0]QWT(8-S31U;<&XBIO8W M<:+CN>:=%*^\+?C*BFCJZ[=GYT<4A\%E@A44)IR!2RUH"9KBLG7PV$T)C%_1 M+U]"WULZ 1O![3)5 8=80,T!B)N!)R16CEO;4.4Z3M=/3C '#+O:^F_&8=F5 M+8TO,6>651O[5QPYIC&D]%=CT*O7, 6-^F%GF$%#"+RO,(#+9,F$K_)W\P#D M]*L*8;T>>#6/Y[GT&LE4/[V4*1P],/!WDO^"N\R&+E,L: N@\#8;WD MS/VKG@2_) 25$P&//' &6 $9#HAP/TV'??FQ*?.8Q8%-9=P(&GB/OA/4!O;J MXE/&4:L>?LH-]KX4HWT58<5=W[A\%8&,V$:9_=37 M".(U(HZWCJC";F,.AE,+B/@SF1/;423L_ MB+/6?WZMJO:.CX?G9[WF1QNQ"_-7VRSJK E?U0Q W<44VQ:2:W83OZ*2[:6^ MVK9:SGK.AE9R%W10%,) ^_RQM1GB�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end